<SEC-DOCUMENT>0001564590-21-011767.txt : 20210309
<SEC-HEADER>0001564590-21-011767.hdr.sgml : 20210309
<ACCEPTANCE-DATETIME>20210309162625
ACCESSION NUMBER:		0001564590-21-011767
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		85
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210309
DATE AS OF CHANGE:		20210309

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lyra Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001327273
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39273
		FILM NUMBER:		21726156

	BUSINESS ADDRESS:	
		STREET 1:		480 ARSENAL STREET
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-373-4600

	MAIL ADDRESS:	
		STREET 1:		480 ARSENAL STREET
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	480 Biomedical, Inc.
		DATE OF NAME CHANGE:	20120927

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arsenal Vascular, Inc.
		DATE OF NAME CHANGE:	20110826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arsenal Medical, Inc.
		DATE OF NAME CHANGE:	20090414
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>lyra-10k_20201231.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
lyra-10k_20201231.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:6pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;"><a name="_cp_text_2_102"></a>&nbsp;</p>
<p style="text-align:center;border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 10-K<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark&#160;One) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4%;"></td>
<td style="width:96%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.7pt;padding-Right:0.7pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="padding-left:0.7pt;padding-Right:0.7pt;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended December 31, 2020</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OR </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4%;"></td>
<td style="width:96%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.7pt;padding-Right:0.7pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="padding-left:0.7pt;padding-Right:0.7pt;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number 001-39273</p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lyra Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its Charter) </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50.08%;"></td>
<td style="width:49.92%;"></td>
</tr>
<tr>
<td valign="bottom"  style="padding-Right:0.7pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="bottom"  style="padding-Right:0.7pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">84-1700838</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-Right:0.7pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom"  style="padding-Right:0.7pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-Right:0.7pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">480 Arsenal Way </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Watertown, MA</p></td>
<td valign="bottom"  style="padding-Right:0.7pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">02472</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-Right:0.7pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom"  style="padding-Right:0.7pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: (617) 393-4600</p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:20%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top"  style="width:38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common Stock, $0.001 par value per share</p></td>
<td valign="bottom"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:20%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LYRA</p></td>
<td valign="bottom"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nasdaq Global Market</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act: None</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. &#160; Yes&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> No&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act. &#160; Yes&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> No&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160; Yes&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font> No&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files). &#160; Yes&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font> No&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:20.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:20.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:20.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:20.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:20.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:20.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:20.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:20.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:20.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;">&nbsp;</p></td>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;">&nbsp;</p></td>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:20.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;">&nbsp;</p></td>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;">&nbsp;</p></td>
<td valign="top"  style="padding-Right:0pt;padding-Top:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_3"></a><a name="_cp_text_1_1"></a><a name="_cp_text_1_2"></a><a name="_cp_text_1_3"></a>Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&nbsp;&nbsp;<font style="font-family:Segoe UI Symbol;"><a name="_cp_text_1_1"></a><a name="_cp_text_1_2"></a>&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160; Yes&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> No&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_5"></a><a name="_cp_text_1_7"></a>The aggregate market value of outstanding shares of common stock held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on The Nasdaq<a name="_cp_text_1_5"></a> Global Market on June 30, 2020<a name="_cp_text_1_7"></a>, the last business day of the Registrant&#8217;s most recently completed second fiscal quarter, was $84,280,762. For purposes of this disclosure, shares of common stock held by officers and directors of the Registrant and by persons who hold more than 10% of the Registrant&#8217;s outstanding common shares have been excluded because such persons may be deemed to be affiliates.&nbsp;&nbsp;This determination of affiliate status is not necessarily conclusive.&nbsp;&nbsp;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_8"></a><a name="_cp_text_1_8"></a>The number of shares of Registrant&#8217;s Common Stock, $0.001 par value per share, outstanding as of March 1, 2021 was 12,947,572. </p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:center;border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;line-height:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;"><a name="_Hlk62410427"></a>&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I"><font style="text-decoration:underline;">PART I</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><font style="text-decoration:underline;">Business</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><font style="text-decoration:underline;">Risk Factors</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><font style="text-decoration:underline;">Unresolved Staff Comments</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><font style="text-decoration:underline;">Properties</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><font style="text-decoration:underline;">Legal Proceedings</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><font style="text-decoration:underline;">Mine Safety Disclosures</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II"><font style="text-decoration:underline;">PART&#160;II</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><font style="text-decoration:underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_SELECTED_CONSOLIDATED_FINANCIAL_D"><font style="text-decoration:underline;">Selected Financial Data</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><font style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><font style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><font style="text-decoration:underline;">Financial Statements and Supplementary Data</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><font style="text-decoration:underline;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><font style="text-decoration:underline;">Controls and Procedures</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><font style="text-decoration:underline;">Other Information</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_III"><font style="text-decoration:underline;">PART&#160;III</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><font style="text-decoration:underline;">Directors, Executive Officers and Corporate Governance</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><font style="text-decoration:underline;">Executive Compensation</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><font style="text-decoration:underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><font style="text-decoration:underline;">Certain Relationships and Related Transactions, and Director Independence</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTANT_FEES_SERVIC"><font style="text-decoration:underline;">Principal Accountant Fees and Services</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IV"><font style="text-decoration:underline;">PART&#160;IV</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><font style="text-decoration:underline;">Exhibits and Financial Statement Schedules</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_52"></a><a name="_cp_text_1_52"></a>Item&#160;16.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><font style="text-decoration:underline;">Form 10-K Summary</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this Annual Report on Form 10-K are forward-looking statements, including but not limited to statements regarding:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our plans to develop and commercialize our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_55"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="_cp_text_1_55"></a>the timing of our ongoing or planned clinical trials for LYR-210, LYR-220, and any future product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_56"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="_cp_text_1_56"></a>the timing of and our ability to obtain and maintain regulatory approvals for LYR-210, LYR-220, and any future product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the clinical utility of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_57"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="_cp_text_1_57"></a>our commercialization, marketing, and manufacturing capabilities and strategy; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_58"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="_cp_text_1_58"></a>our expectations about the willingness of healthcare professionals to use LYR-210, LYR-220, and any future product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our intellectual property position; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our competitive position and developments and projections relating to our competitors or our industry; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_59"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="_cp_text_1_59"></a>our ability to identify, recruit, and retain key personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the impact of laws and regulations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">risks associated with the COVID-19 pandemic, which may adversely impact our business and clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_61"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="_cp_text_1_61"></a>our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act, or the JOBS Act; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our plans to identify additional product candidates with significant commercial potential that are consistent with our commercial objectives; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_64"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="_cp_text_1_64"></a>our estimates and statements regarding our future revenue, future results of operations, and financial position; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our business strategy; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our research and development costs; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the plans and objectives of management for future operations.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_65"></a><a name="_cp_text_1_66"></a><a name="_cp_text_1_67"></a><a name="_cp_text_1_65"></a>These statements involve known and unknown risks, uncertainties, <a name="_cp_text_1_66"></a>and other important factors that may cause our actual results, performance, <a name="_cp_text_1_67"></a>or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_68"></a><a name="_cp_text_1_69"></a><a name="_cp_text_1_70"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_68"></a>In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;would</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_69"></a>&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. The forward-looking statements in this Annual Report on Form 10-K are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_70"></a>and results of operations. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K and are subject to a number of known and unknown risks, uncertainties</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and assumptions, including those described under the sections in this Annual Report on Form 10-K entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in this Annual Report on Form 10-K. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_71"></a><a name="_cp_text_1_71"></a>Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. You should read this Annual Report on Form 10-K and the documents that we reference in this Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances, or otherwise.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_72"></a><a name="_cp_text_1_73"></a><a name="_cp_text_1_74"></a><a name="_cp_text_1_72"></a><a name="_cp_text_1_73"></a><a name="_cp_text_1_74"></a>SUMMARY RISK FACTORS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_75"></a>Our business is subject to numerous risks and uncertainties, including those described in Part I, Item 1A. &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. You should carefully consider these risks and uncertainties when investing in our common stock. The principal risks and uncertainties affecting our business include the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_blt_1_76"></a><a name="_cp_text_1_77"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We have a limited operating history and a history of escalating operating losses, which may make it difficult to evaluate the prospects for our future viability.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_blt_1_78"></a><a name="_cp_text_1_79"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We have incurred significant losses since inception and expect to incur significant additional losses for the foreseeable future, and we may never achieve profitability.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_blt_1_80"></a><a name="_cp_text_1_81"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We will need significant additional funding in order to complete development of and obtain regulatory approval for our product candidates and commercialize our products, if approved.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_blt_1_82"></a><a name="_cp_text_1_83"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Our business is highly dependent on the success of our most advanced product candidate, LYR-210, which will require significant additional clinical testing before we can seek regulatory approval and potentially launch commercial sales, and if LYR-210 does not receive regulatory approval or is not successfully commercialized, or is significantly delayed in doing so, our business will be harmed.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_blt_1_84"></a><a name="_cp_text_1_85"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">clinical trials required for our product candidates are expensive and time-consuming, their outcome is uncertain, and if our clinical trials do not meet safety or efficacy endpoints in these evaluations, or if we experience significant delays in these trials, our ability to commercialize our product candidates and our financial position will be impaired;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_blt_1_86"></a><a name="_cp_text_1_87"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">developments by competitors may render our products or technologies obsolete or non-competitive or may reduce the size of our markets; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_blt_1_88"></a><a name="_cp_text_1_89"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and pricing policies, and the failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_blt_1_90"></a><a name="_cp_text_1_91"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">even if either LYR-210 or LYR-220 receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_blt_1_92"></a><a name="_cp_text_1_93"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we will rely on third parties for the manufacture of materials for our research programs, pre-clinical studies and clinical trials and we do not have long-term contracts with any of these parties, which increases the risk that we will not have sufficient quantities of such materials, product candidates, or any therapies that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_blt_1_94"></a><a name="_cp_text_1_95"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we rely on third parties to conduct our pre-clinical studies and clinical trials, and any failure by a third party to conduct the clinical trials according to GCPs and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_blt_1_96"></a><a name="_cp_text_1_97"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">if we are unable to obtain, maintain or adequately protect our intellectual property rights, we may not be able to compete effectively in our markets; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_blt_1_98"></a><a name="_cp_text_1_99"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">if we lose key management or scientific personnel, cannot recruit qualified employees, directors, officers or other significant personnel or experience increases in our compensation costs, our business may materially suffer; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_blt_1_100"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the pandemic caused by COVID-19 could adversely impact our business and operations, including our clinical trials.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_I"></a><a name="PART_I"></a>PART I</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Unless the context requires otherwise, we use the terms &#8220;Lyra,&#8221; &#8220;the Company&#8221;, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar designations in this Annual Report on Form 10-K to refer to Lyra Therapeutics, Inc. and its wholly-owned subsidiaries.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1_BUSINESS"></a><a name="ITEM_1_BUSINESS"></a>Item 1. Business. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_104"></a><a name="_cp_text_1_104"></a>We are a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat, or ENT, diseases. Our proprietary technology platform, XTreo&#8482;, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. Our initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS. The therapeutic embedded within LYR-210 and LYR-220 is mometasone furoate, or MF, which is the active ingredient in various U.S. Food and Drug Administration, or FDA, approved drugs and has a well-established efficacy and safety profile. CRS is an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities and affects approximately 14&#160;million people in the United States. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_105"></a><a name="_cp_text_1_106"></a><a name="_cp_text_1_105"></a>We have advanced LYR-210 as a potential preferred alternative to surgery through a Phase 2 randomized, controlled, patient blinded clinical trial, which we refer to as our Phase 2 LANTERN clinical trial, designed to evaluate safety and efficacy in CRS patients both with and without nasal polyps who have failed previous medical management but have not undergone endoscopic sinus surgery, who we refer to as surgically-na&#239;ve CRS patients. The trial was designed to enroll 99 evaluable patients with the potential to increase to up to 150 patients and was initiated in May 2019 at sites in Australia, Austria, Czech Republic, New Zealand, <a name="_cp_text_1_106"></a>and Poland. In December 2019, the FDA authorized our investigational new drug application, or IND, and, prior to the COVID-19 pandemic, we planned to enroll patients in the United States. However, in light of developments relating to the COVID-19 pandemic we discontinued enrollment at 67 patients in our Phase 2 LANTERN clinical trial and did not enroll any patients in the United States. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk60923980"></a><a name="_cp_text_1_108"></a><a name="_cp_text_1_108"></a>On December 7, 2020, we reported positive top-line results from our Phase 2 LANTERN clinical trial, including that the 7,500 &#181;g dose of LYR-210 achieved statistically significant improvement in the composite four cardinal symptoms score, or 4CSS, in favor of the treatment arm as measured by the change from baseline at weeks 16, 20, and 24. However, although a strong treatment effect was observed at week 4, LYR-210 did not achieve the primary endpoint of change from baseline in 4CSS at week 4 at either the 7,500 &#181;g dose or 2,500 &#181;g dose relative to the control group. We believe this was due primarily to the discontinuation of enrollment related to the COVID-19 pandemic. As a result of the decrease in the number of patients enrolled from planned (99 evaluable) to actually enrolled (67), a greater magnitude of change from baseline in 4CSS at week 4 and/or a smaller standard deviation associated with the change from baseline was required in order to achieve statistical significance for the primary endpoint at week 4. LYR-210 was observed to be safe and well-tolerated at all doses in the trial, and no treatment-related serious adverse events were reported. For more information on the top-line results from our Phase 2 LANTERN clinical trial, see &#8220;&#8212;LYR-210 for the Treatment of CRS&#8212;Overview of Clinical Development&#8212;Phase 2&#8221;.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, although we collected certain pharmacokinetic data from all patients in our Phase 2 LANTERN clinical trial starting at week 4, our protocol contemplated utilizing a subset of U.S. patients to collect certain additional pharmacokinetic data in order to support the NDA for LYR-210. However, because we were unable to enroll patients in the United States due to the COVID-19 pandemic, we were unable to collect these additional pharmacokinetic data as planned. As a result, in September 2020, we initiated a separate characterization study in the United States to collect these additional data. This study is fully enrolled and all 24 patients have completed the study-required visits. We expect data lock and analysis activities to be completed by the second quarter of 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In our Phase 1 clinical trial, LYR-210 met its primary safety endpoint, and we observed that patients generally experienced significant and rapid, clinically meaningful and durable improvement on a patient symptom severity scale through week 25, which was the end of the trial. Secondary findings from our Phase 1 clinical trial showed that LYR-210 demonstrated significant reduction of sinonasal Type 2 inflammation in surgically-na&#239;ve patients with CRS. We believe the reduction of Type 2 inflammation suggests a correlation with rhinologic symptom improvement in CRS and we believe the reduction could be a potential measure of LYR-210&#8217;s local anti-inflammatory effects at the site of inflammation in the sinonasal passages. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also developing LYR-220 for use in CRS patients who have an enlarged nasal cavity due to sinus surgery but continue to require treatment to manage CRS symptoms, and, subject to the impact of COVID-19 on our business, we intend to initiate a </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 2</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> clinical trial for LYR-220 by the end of 2021. Beyond CRS, we believe our XTreo platform has potential applications in other disease areas, which we are actively exploring to further broaden its therapeutic potential. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_110"></a><a name="_cp_text_1_110"></a>CRS has been described in the literature as an &#8220;unrecognized epidemic&#8221; due to its high prevalence, its substantial impact on patient quality of life, and the significant limitations of currently available treatment options. We estimate that sinusitis, which includes both CRS and acute rhinosinusitis, impacts approximately 12% of the adult population in the United States, or approximately 30&#160;million people, making it the fifth most common condition in people under the age of 65 and more prevalent than diabetes or heart disease. Of this population, we estimate that approximately 14&#160;million people are affected with CRS. Moreover, we estimate that approximately 8&#160;million people are treated for CRS by physicians annually, of which approximately 4&#160;million fail medical management every year. In the United States, over $60&#160;billion is spent annually in direct treatment costs for sinusitis, including approximately $5&#160;billion on sinus surgeries. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_111"></a><a name="_cp_text_1_111"></a>We believe LYR-210 and LYR-220, if successfully developed and approved, will be able to treat the entire spectrum of CRS patients that have failed medical management and present to an ENT physician, including pre- and post-surgical patients and those with and without nasal polyps, with up to six months of treatment in a single administration. Our most advanced product candidate, LYR-210, was evaluated in surgically-na&#239;ve CRS patients in our Phase 2 LANTERN clinical trial. On December 7, 2020, we reported positive top-line results from our Phase 2 LANTERN clinical trial, including that the 7,500 &#181;g dose of LYR-210 achieved statistically significant improvement in 4CSS in favor of the treatment arm as measured by the change from baseline at weeks 16, 20, and 24. While a strong treatment effect was observed at week 4, LYR-210 did not achieve the primary endpoint of change from baseline in 4CSS at week 4 at either the 7,500 &#181;g dose or 2,500 &#181;g dose. We believe this was due primarily to the discontinuation of enrollment related to the COVID-19 pandemic. For more information on the top-line results from our Phase 2 LANTERN clinical trial, see &#8220;&#8212;LYR-210 for the Treatment of CRS&#8212;Overview of Clinical Development&#8212;Phase 2&#8221;. In an open-label, multi-center Phase 1 clinical trial, we placed 40 LYR-210 matrices bilaterally in 20 patients at sites in New Zealand and Australia. LYR-210 met its primary safety endpoint in the Phase&#160;1 trial, and we observed significant and rapid, clinically meaningful and durable improvement through week 25 in SinoNasal Outcome Test scores, or SNOT-22 scores, an established patient symptom severity scale. At week 24, improvement versus baseline was observed in 90% of patients in this Phase 1 trial, with similar activity observed across both polyp and non-polyp patients. Additionally, subject to the impact of COVID-19 on our business, we intend to initiate a Phase 2 clinical trial for LYR-220 by the end of 2021, and ultimately plan to pursue a supplemental new drug application, or sNDA, to the FDA for a potentially faster path to approval of LYR-220 if a new drug application, or NDA, for LYR-210 is approved by the FDA. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our XTreo Platform </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XTreo, our innovative and proprietary drug delivery platform, is designed to locally and continuously deliver small molecule drugs to the affected tissue over a sustained period of time from a single administration. The platform is comprised of three interrelated technology components: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a biocompatible mesh scaffold, which is designed to maximize surface area for drug release while maintaining underlying tissue function; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">an engineered elastomeric matrix, which means a polymeric matrix composed of polymers having elastic characteristics, which has advanced physical properties resulting in implants with &#8220;shape memory&#8221; that dynamically adapt to nasal anatomy; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a versatile polymer-drug complex, which can be customized for the treatment of various chronic diseases treatable with ENT delivery to achieve the desired drug dose and drug elution rate. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chronic Rhinosinusitis: A Prevalent Disease with High Unmet Medical Needs </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_113"></a><a name="_cp_text_1_114"></a><a name="_cp_text_1_113"></a>CRS is an inflammatory disease of the paranasal sinuses causing the soft, moist layer of mucus-producing tissue, or mucosa, that lines the sinuses to become swollen and inflamed, leading to significant patient morbidities. The inflammation may be caused by infections, allergies, <a name="_cp_text_1_114"></a>or environmental factors, as well as structural issues such as blockages of an ostium. Patients with CRS on average experience a lower quality of life index than people suffering from congestive heart failure, angina, chronic obstructive pulmonary disease, or back pain. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CRS has two phenotypes: CRS with nasal polyps, which are teardrop-shaped benign masses arising from the mucosa lining, and CRS without nasal polyps. The non-polyp form of CRS represents approximately 70%-to-90% of CRS patients. We estimate that approximately 8&#160;million people are treated for CRS by physicians annually, of which approximately 4&#160;million fail medical management every year. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Current Treatments and Their Limitations </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The goals of therapy for CRS are to reduce mucosal swelling resulting from underlying inflammation, promote sinus drainage, and eradicate infections that may be present. The treatment of CRS is progressive in nature and typically begins with medical management, primarily with topical intranasal steroids and oral steroids. If this treatment is unsuccessful, an ENT physician may perform a sinus surgery. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gn15qjhcndsi000001.jpg" title="" alt="" style="width:610px;height:239px;"></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Figure 1. Current Primary Treatment Paradigm for CRS. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently, there are no FDA-approved drug therapies for CRS for non-polyp patients, although some drugs approved for nasal polyps are used off-label in this population. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Solution for CRS </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LYR-210 is an anti-inflammatory implantable drug matrix based on our XTreo platform that is designed to consistently and locally elute MF to the inflamed mucosal tissue for up to six months in surgically-na&#239;ve CRS patients who fail medical management. MF, the active ingredient in various FDA-approved drugs, has a well-established efficacy and safety profile, which we believe will support the development process for LYR-210. LYR-210 is designed to enable sustained drug delivery at difficult-to-access nasal inflammation sites without the need for patient compliance, while avoiding the systemic side effects associated with oral steroids. LYR-210 is designed to be administered in a brief, non-invasive, in-office procedure by an ENT physician under endoscopic visualization via a single-use applicator. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_115"></a><a name="_cp_text_1_116"></a><a name="_cp_text_1_117"></a><a name="_cp_text_1_115"></a>We have advanced LYR-210 as a potential preferred alternative to surgery through our Phase 2 LANTERN clinical trial, designed to evaluate the safety and efficacy in surgically-na&#239;ve CRS patients both with and without nasal polyps who have failed previous medical management at sites in Australia, Czech Republic, New Zealand, <a name="_cp_text_1_116"></a>and Poland. On December 7, 2020, we reported positive top-line results from our Phase 2 LANTERN clinical trial, including that the 7,500 &#181;g dose of LYR-210 achieved statistically significant improvement in 4CSS in favor of the treatment arm as measured by the change from baseline at week 16 (-1.47) (p=0.021), week 20 (-1.61) (p=0.012), <a name="_cp_text_1_117"></a>and week 24 (-1.64) (p=0.016). In addition, the 7,500 &#181;g dose of LYR-210 achieved statistically significant improvement in SNOT-22 score in favor of the treatment arm as measured by the change from baseline at week 8 (-12.2) (p=0.039), week 16 (-15.0) (p=0.008), week 20 (-18.4) (p=0.001), and week 24 (-19.0) (p=0.001). In particular, the improvement in SNOT-22 score of the 7,500 &#181;g dose of LYR-210 at week 24 over the control group (-19.0) was over two times the minimal clinically important difference of -8.9. However, although a strong treatment effect was observed at week 4, LYR-210 did not achieve the primary endpoint of change from baseline in 4CSS at week 4 at either the 7,500 &#181;g dose (-0.36) (p=0.306) or 2,500 &#181;g dose (0.04) (p=0.525) relative to the control group. We believe this was due primarily to the discontinuation of enrollment related to the COVID-19 pandemic. For more information on the top-line results from our Phase 2 LANTERN clinical trial, see &#8220;&#8212;LYR-210 for the Treatment of CRS&#8212;Overview of Clinical Development&#8212;Phase 2&#8221;. Subject to the impact of COVID-19 on our business, we expect to (i)&#160;report six-month post-treatment safety data and to hold an End of Phase 2 meeting with the FDA in mid-2021 and (ii)&#160;submit our Phase 3 protocol design for LYR-210 to the FDA in the second half of 2021. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LYR-210 was previously studied in an open-label, Phase&#160;1 clinical trial with 20 patients in New Zealand and Australia, and achieved its primary endpoint of safety at week&#160;4. In the Phase&#160;1 trial, we observed that patients generally experienced significant and rapid, clinically meaningful and durable improvement in SNOT-22 scores. Significant reduction in SNOT-22 scores was observed at week 1, and this reduction persisted through week&#160;25, which was the end of the trial. The changes from baseline, or CFBL, in SNOT-22 score were statistically significant (P &lt; 0.01) at all measured intervals. The average change from baseline in SNOT-22 score at week&#160;1 was -13.0 points (P=0.008 to pre-treatment), achieving the minimal clinically significant difference of -8.9 points. Further, symptom relief as measured by SNOT-22 score was observed through the entire duration of the trial, achieving an average change from baseline of -20.5 points at week 24, the end of the treatment period (</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">p &lt; </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.000</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to pre-treatment), and -20.0 points (p &lt; 0.0001) at week 25, one week after the removal of LYR-210. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing our second pipeline product candidate, LYR-220, for use in CRS patients who continue to require treatment to manage CRS symptoms despite having had sinus surgery. LYR-220 is also designed to utilize MF, but will employ an oversized matrix designed for patients whose nasal cavity is enlarged due to sinus surgery. LYR-220 is designed as a potential preferred alternative to revision sinus surgery and post-surgical medical management. Subject to the impact of COVID-19 on our business, we expect to initiate a Phase 2 clinical trial for LYR-220 by the end of 2021. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that the key potential benefits of our current investigational product portfolio, LYR-210 and LYR-220, include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">Clinical Activity</font>: We believe LYR-210 and LYR-220 have the potential to significantly improve symptoms by maintaining a steady, high dose of MF at the site of inflammation for up to six months with a single administration, without any dependence on patient compliance. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">Patient Compliance</font>: Because drug delivery for LYR-210 and LYR-220 is designed to be sustained for up to six months with a single administration, the efficacy of LYR-210 and LYR-220 will not depend on patient compliance within the treatment period, unlike other CRS treatment options that require repeated daily administrations, such as topical intranasal steroids and oral steroids. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">Patient Experience</font>: LYR-210 and LYR-220 are designed to be administered via a simple, in-office procedure every six months, which is intended to enhance convenience for patients, unlike the repeated daily medical management and/or time-consuming and painful surgery required by certain other CRS treatment options. Moreover, we believe patients may also benefit from the biocompatible, flexible structure of LYR-210 and LYR-220 that is designed to maximize comfort over the therapy period. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">Physician Experience</font>: LYR-210 and LYR-220 are designed to enable physicians to perform the placement of LYR-210 and LYR-220 in-office in conjunction with an endoscopy procedure, thereby making the placement aligned with the existing care continuum for CRS patients and eliminating the need for physicians to schedule separate surgical time. Moreover, the elastomeric matrix encapsulates the underlying mesh fibers to facilitate removal. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">Localized Delivery</font>: LYR-210 and LYR-220 are designed to benefit from our XTreo platform, which is intended to provide localized delivery to avoid systemic side effects that are common with certain other CRS treatment options, such as oral steroids. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">Patient Applicability</font>: LYR-210 and LYR-220 are designed to treat the entire spectrum of CRS patients who have failed medical management, including pre- and post-surgical patients and those with and without polyps. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">Pharmacoeconomic Impact</font>: LYR-210 and LYR-220 are designed as an alternative to surgery (initial or revision), and as such have the potential to provide significant savings to the healthcare industry by reducing the number and frequency of expensive surgical treatment options. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe LYR-210 and LYR-220, if approved, would be the only products able to deliver up to six months of continuous topical treatment in a single administration to treat the entire spectrum of CRS patients who fail medical management, including pre- and post-surgery patients and those with and without nasal polyps. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property and Barriers to Entry </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_119"></a>We own all the material intellectual property rights related to our platform and product candidate portfolio. As of December 31, 2020, our product and product candidate portfolio is protected by issued and pending patents in the U.S. and major foreign countries with claims directed to <a name="_cp_text_1_119"></a>devices, systems, and method of use, which, exclusive of possible patent term adjustments or extensions or other forms of exclusivity, are projected to expire between 2030 and 2037.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also rely upon know-how, continuing technological innovation, and technical barriers to entry, including manufacturing and drug delivery complexities, to develop and maintain our competitive intellectual property position. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Management Team and Investors </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_120"></a><a name="_cp_text_1_121"></a><a name="_cp_text_1_122"></a><a name="_cp_text_1_120"></a>Our management team has extensive drug development, manufacturing, <a name="_cp_text_1_121"></a>and commercialization experience across a broad spectrum of disease areas, for both drug and drug-device combination products, with a successful track record in large pharmaceutical, medical device, <a name="_cp_text_1_122"></a>and biotech companies. Additionally, our management team has been involved in the development of successfully approved and commercialized products such as Taxus (drug-eluting stent), AvoneX, Risperdal, Linzess, Vivitrol, XenMatrix, and Photrexa. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_123"></a><a name="_cp_text_1_123"></a>Further, we have been supported by a leading group of biotech investors including, among others, ArrowMark Partners, Intersouth Partners, North Bridge Venture Partners, Perceptive Advisors, Polaris Venture Partners, RA Capital, and Soleus Capital. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Pipeline </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current status of our product candidates is summarized below. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gn15qjhcndsi000002.jpg" title="" alt="" style="width:501px;height:284px;"></p>
<p style="margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-right:73.33%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Anticipated clinical milestones are subject to the impact of COVID-19 on our business. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Strategy </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our mission is to transform the ENT treatment paradigm by utilizing our proprietary drug delivery platform, XTreo, to develop safe and effective therapies for the treatment of debilitating diseases treatable with ENT delivery. We intend to achieve this through the following strategies: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">Complete the development and secure FDA approval of LYR-210 for the treatment of CRS.</font> We believe LYR-210, if approved, is well positioned in the CRS treatment paradigm to provide a preferred alternative to surgery. LYR-210, which has advanced through our randomized, sham procedure-controlled, patient-blinded Phase 2 LANTERN clinical trial, utilizes MF, the active ingredient in various FDA-approved drugs. Our goal is to advance LYR-210 into one or more pivotal Phase 3 clinical trials, followed by potential marketing approval through a 505(b)(2) NDA submitted to the FDA. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;">Advance our second product candidate, LYR-220, into the clinic to provide a comprehensive solution for CRS patients who have failed medical management and surgery. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing a larger version of LYR-210 designed for use in the enlarged nasal cavity of CRS patients who have had sinus surgery. We believe LYR-220, if successfully developed and approved, is well positioned to provide a preferred alternative to revision surgery and post-surgical medical management. LYR-220 is currently in product feasibility studies. We plan to advance LYR-220 into a </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 2</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> clinical trial by the end of 2021, subject to the impact of COVID-19 on our business, and </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ultimately </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">intend to seek approval through the sNDA pathway if an NDA for LYR-210 is approved by the FDA. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_125"></a><a name="_cp_text_1_127"></a><font style="font-weight:bold;">Build a commercialization infrastructure in the U.S. market for LYR-210 and LYR-220. </font><a name="_cp_text_1_125"></a>If any of our product candidates are approved, we plan to launch an efficient, go-to-market commercialization model focused on targeted outreach to our key physician, payor, <a name="_cp_text_1_127"></a>and patient audiences. We plan to build an in-house sales force that will target ENT physicians whose sub-specialty is general otolaryngology or rhinology, which together represent roughly 60% of the 12,000 ENT physicians in the United States. Ensuring physician and patient market access to our products will be critical to our success, and we plan to execute a holistic reimbursement strategy that will integrate payor coverage and physician practice management initiatives. In addition, we also plan to selectively use cost-effective, patient-directed marketing strategies to further increase awareness among the CRS patient community of our products with the goal of increasing ENT physician visits. Finally, we plan to leverage our commercial infrastructure in the subsequent launch of LYR-220 and any future product candidates. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_128"></a><font style="font-weight:bold;">Maximize the value of our XTreo platform and expand our product pipeline. </font><a name="_cp_text_1_128"></a>Our XTreo platform provides a versatile drug development engine that enables us to focus on indications where long-term delivery of existing treatments may provide improved local bioavailability and enhanced efficacy or safety. We plan to utilize our platform to identify additional product candidates, with an initial focus on conditions treatable with nasal delivery, potentially including allergic rhinitis, rare disorders where nasal disease contributes to the disease pathology, and central nervous system disorders. In addition, we believe we can adapt our platform to target conditions treatable with delivery to other tissues beyond the nasal cavities, such as the ear. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">Seek strategic collaborative relationships. </font>We intend to develop our product candidates on our own in the U.S. and retain all U.S. rights, but seek strategic collaborations ex-U.S. to facilitate the capital-efficient development of our product candidates. We may also enter into collaborative relationships within the U.S. for our future pipeline candidates. We believe these collaborations could potentially provide non-dilutive funding to advance our pipeline candidates while allowing us to benefit from the development expertise of our collaborators. </p></td></tr></table></div><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Technology Platform </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_130"></a><a name="_cp_text_1_131"></a><a name="_cp_text_1_130"></a>XTreo, our innovative and proprietary drug delivery platform is designed to locally and continuously deliver small molecule drugs to the affected tissue over a sustained period of time from a single administration. Our technology platform, developed over the past decade, was first patented in 2009 by members of our team who have extensive experience in drug formulation and delivery, materials <a name="_cp_text_1_131"></a>science, and biotechnology. This expertise has allowed us to significantly improve upon polymer drug delivery technology and add shape-memory properties to bioresorbable polymeric implants, one of our key innovations. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gn15qjhcndsi000003.jpg" title="" alt="" style="width:605px;height:340px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Figure 2. XTreo Proprietary Platform. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XTreo, our drug-eluting bioresorbable technology platform is comprised of three polymeric components, which are designed to work together to enable highly efficient, localized drug delivery (see Figure 2, above). This proprietary technology platform is designed to enable sustained delivery of medications for many months of therapy, targeting tissues deep in the ENT passages and potentially other diseased tissues that are not accessible with conventional therapeutic approaches. The components of our platform include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">Biocompatible Mesh Scaffold</font>&#8212;variants of poly(L-lactide-co-glycolide), or PLGA, braided to form an implantable mesh with a high surface area. Our biocompatible mesh scaffold is intended to provide the foundation for efficient drug delivery. We have designed the mesh scaffold to optimize surface area for drug release while maintaining underlying tissue function through an open-cell design. The mesh scaffold is comprised of bioresorbable polymers and is pliable to maximize patient comfort. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">Engineered Elastomeric Matrix</font>&#8212;overlying elastomer of poly(L-lactide-co-<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">e</font></font>-caprolactone), or PLCL, coating that constrains the intersection points of the braid. Over the last decade we have developed a highly sophisticated and proprietary engineered elastomeric matrix which has advanced physical properties to dynamically conform to nasal anatomy. Its adaptive elastic tension, which gives it shape-memory to resist deformation, is key to ensuring persistent positioning in the target location. The matrix works in conjunction with the underlying mesh to exert outward retention force, keeping it in place as tissue remodels. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;">Versatile Polymer-Drug Complex</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;active therapeutic embedded in a polymer designed to control its release. We have extensive drug-delivery know-how which has enabled us to design a versatile polymer-drug complex that can accommodate most small molecule drugs and achieve tunable elution profiles. We believe our versatile polymer-drug complex is potentially amenable to continuous, prolonged drug release across a wide range of drugs for different therapeutic applications. With proprietary bioresorbable polymer-drug formulations, we believe our platform can be used to customize controlled-release drugs for various chronic diseases treatable with ENT delivery and improve the efficacy of therapeutic properties of existing active</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> pharmaceutical ingredients, or APIs, through more prolonged delivery. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_133"></a><a name="_cp_text_1_133"></a>The three integrated components are fundamental to the successful function and versatility of the XTreo technology. For application to a targeted tissue, the implant is compressed into a narrow applicator, which allows non-invasive placement deep within cavities of the ear, nose, and throat. The shape-memory properties ensure the implant self-expands as it is administered through the applicator to comfortably fit within and adapt to the target anatomy. The implant is designed to be oversized for the target anatomy and therefore will push outwards to stay fixed at the target location. Over time, as inflammation recedes due to the local drug therapy, the shape-memory properties are intended to allow the implant to actively adapt to the anatomy and continue to stay in place to elute drug locally for a prolonged period. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In engineering the implant, we use polymers that are biocompatible and bioresorbable which, if left in place, would gradually dissolve over time. The polymers used in our formulations have established safety profiles as they have previously been used in FDA-approved therapeutics. The mesh scaffold and elastomeric matrix are composed of PLGA and PLCL elastomer, both of which are well-established biodegradable polymers commonly used in medical applications. The customizable polymer drug complex consists of the active therapeutic embedded in the inactive ingredients containing PLCL and poly(L-lactide), or PLA, to control the drug elution rate. The polymer composition and drug formulation are tailored to achieve the desired drug dose and dissolution rate. Our expertise allows us to balance polymer resorption with drug elution to achieve a sustained rate of drug release over months in addition to varying the dosing and release rates to provide chronic local treatment. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chronic Rhinosinusitis and the Treatment Landscape </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_134"></a><a name="_cp_text_1_134"></a>Sinuses are air-filled pockets within the bones of the face and skull. The four types of sinuses are frontal, ethmoid, sphenoid, and maxillary (see Figure 3, below). One of each type of sinus lies on either side of the face. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gn15qjhcndsi000004.jpg" title="" alt="" style="width:430px;height:205px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Figure 3. Illustration of Nasal Sinuses. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_136"></a><a name="_cp_text_1_137"></a><a name="_cp_text_1_136"></a>The sinuses are lined with a soft, moist layer of mucus-producing tissue, or mucosa. Mucus moistens the nasal lining and protects the body from inhaled impurities such as dust, pollutants, <a name="_cp_text_1_137"></a>and bacteria. Each of the maxillary, sphenoid, and frontal sinuses has a corresponding ostium, or opening, through which mucus drains. The ethmoid sinuses are a series of cells with multiple, often interconnected openings and drainage pathways. The surface tissues of the sinuses are covered with millions of cilia, which are small, hair-like structures that act in coordination to sweep the mucus through the ostium of each sinus cavity to the back of the throat. The drainage of mucus is a normal process that keeps the sinuses healthy. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_138"></a><a name="_cp_text_1_139"></a><a name="_cp_text_1_140"></a><a name="_cp_text_1_141"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_138"></a>CRS is an inflammatory disease of the paranasal sinus causing the mucosa lining to become swollen and inflamed, leading to significant patient morbidities. The inflammation may be caused by infections, allergies</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_139"></a>or environmental factors, as well as structural issues such as blockages of an ostium. If one or more sinus drainage pathways becomes blocked, normal mucus drainage is prevented and damage to ciliary function may occur. There are two categories of sinusitis: acute and chronic. Acute sinusitis is transient in nature and lasts less than four weeks. Chronic sinusitis is more severe and lasts 12 weeks or longer. The term &#8220;chronic sinusitis&#8221; is generally used interchangeably with &#8220;CRS&#8221; in the medical community, and we refer to the condition as CRS in this Annual Report on Form 10-K. The four cardinal symptoms of CRS are nasal obstruction and congestion, facial pain and pressure, nasal discharge</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_140"></a>and olfactory loss (loss of sense of smell). Other symptoms include chronic headaches, bodily pain, fatigue, sleep deprivation, depression</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_141"></a>and recurrent infections. CRS may be diagnosed when two of the four cardinal symptoms persist for 12 weeks or longer and when inflammation is confirmed via endoscopy or CT scan. Patients with CRS experience a lower quality of life index than people suffering from congestive heart failure, angina, chronic obstructive pulmonary disease</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or back pain. In addition, CRS symptoms are estimated to cause patients to miss over 11&#160;million workdays per year in the United States alone, resulting over $1&#160;billion in indirect economic costs. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_142"></a><a name="_cp_text_1_142"></a>We estimate that sinusitis impacts approximately 12% of the adult population in the United States, or approximately 30&#160;million people, making it the fifth most common condition in people under the age of 65, and more prevalent than diabetes or heart disease. Beyond the United States, sinusitis has a similarly high prevalence in Europe, with approximately 27&#160;million cases in the EU5 (France, Germany, Italy, Spain, and the United Kingdom), and in Asia, with approximately 104&#160;million cases in China alone. Of the approximately 30&#160;million people impacted by sinusitis in the United States, we estimate approximately 14&#160;million are affected with CRS. Of these, we estimate that approximately 8&#160;million people are treated for CRS by physicians annually, of which approximately 4&#160;million fail medical management every year. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CRS has two phenotypes: CRS with nasal polyps, which are teardrop-shaped benign masses arising from the mucosa, and CRS without nasal polyps, with the non-polyp form representing approximately 70%-to-90% of CRS patients. Patients with polyps develop non-cancerous polyps on the chronically inflamed surfaces, but both subgroups typically share the same symptoms. Currently, the majority of our competitors target CRS patients with polyps, and there are no approved treatments for CRS without polyps, creating a vast untapped market opportunity for a more effective treatment solution. Given no approved treatments for CRS without polyps exist, there is only off-label drug usage for this segment of the patient population. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_143"></a><a name="_cp_text_1_143"></a>Current treatments are directed towards managing the symptoms of CRS through a combination of medical management and surgical intervention techniques. The first line of therapy is medical management involving nasal saline irrigation, intranasal corticosteroidal sprays, oral steroids, and antibiotics for patients with an active sinus infection. CRS is the most common reason for adult outpatient antibiotic use in the United States. It has been estimated that antibiotic use to treat infections relating to CRS may cost more than $150&#160;million per year in the aggregate. Patients whose symptoms persist despite medical management are generally recommended to undergo functional endoscopic sinus surgery (or FESS) or balloon sinus dilation (or BSD), or both. FESS is a highly invasive surgery performed in the operating room, under full anesthesia, to open the blocked sinus pathways by removing inflamed tissue and bone using surgical tools. BSD is a less severe form of endoscopic sinus surgery, often used in combination with FESS, in which small balloon catheters are inserted and inflated to drain the large nasal sinuses. Although FESS and BSD can improve symptoms and quality of life, limitations remain. Neither correct the underlying cause of the inflammation and patients who undergo either or both procedures often experience significant pain and require continued post-operative medical therapy to maintain improvements, with a high incidence of repeat surgeries. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Medical Management </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The first-line of treatment for CRS is medical therapy, which typically includes nasal saline irrigation, corticosteroids, and antibiotics for patients with an active infection. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Steroids represent the current first-line standard of care for CRS patients, given they are generally pharmacologically effective at treating inflammation. Intranasal steroid sprays and aerosols, commonly indicated for rhinitis, or inflammation of the nasal passage, are routinely prescribed and used over-the-counter for the treatment of CRS symptoms. Physicians may also prescribe oral steroids on an episodic basis to patients who have not received sufficient symptomatic relief. They are generally prescribed for short-term use by patients with severe symptoms or exacerbations of CRS who are already on maintenance therapy, such as nasal irrigation or intranasal corticosteroid sprays. Finally, physicians may prescribe antibiotics for patients with an active infection. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_144"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_144"></a>Intranasal steroid sprays, oral steroids</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and antibiotics each have significant limitations: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">While intranasal steroid sprays avoid systemic exposure and thus lack such serious side effects, penetration of the spray beyond the nasal cavities into the paranasal sinuses&#8212;the site of inflammation&#8212;is limited, particularly in pre-operative patients, despite requiring multiple, inconvenient administrations per day. In a published study, a large fraction of the spray is deposited in the anterior nasal cavity without any significant penetration into the paranasal sinuses. Additionally, intranasal spray efficacy is also limited due to fast clearance rates, as it has been demonstrated that mucocilliary action removes approximately 50% of the spray from the nasal cavity within 10 to 15 minutes of dosing. Poor patient compliance further limits the effectiveness of intranasal steroid sprays. While a recently launched intranasal exhalation delivery product has been developed to enhance the delivery of steroid to areas of inflammation within the sinus, the product is still subject to the limitations resulting from fast clearance and poor patient compliance. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_145"></a><a name="_cp_text_1_145"></a>Oral steroid therapy is effective at reaching the sinus lining, but it does so by means of systemic exposure and therefore carries the risk of serious side effects associated with prolonged use, including glaucoma, bone loss, weight gain, psychosis, and difficulty in controlling blood glucose levels in patients with diabetes. Additionally, studies have shown that long-term benefits from their use are limited. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Although antibiotics are generally prescribed for patients with an active infection, their role for treatment of CRS is unclear, and there is limited evidence that supports their use for the treatment of CRS. In addition, their prolonged use can lead to antibiotic resistance, and CRS is identified as a major target in national efforts to reduce unnecessary antibiotic intervention. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medical management is used as a first-line of medical therapy for pre-operative patients and as maintenance therapy for post-operative patients. Therefore, patients in both stages of the condition are managed medically and hence are subject to the limitations described above. Based on published medical literature, we estimate that at least 50% of CRS patients who are seen by ENT physicians and receive medical management remain symptomatic. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sinus Surgery </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary alternative after medical management is FESS, an invasive surgery during which a physician enlarges the inflamed and obstructed sinus pathways by removing inflamed tissue and bone in order to facilitate normal sinus drainage and aeration as well as provide greater access for delivery of steroids. First introduced in the United States in the 1980s, FESS is considered the standard of care for surgical intervention to treat CRS. However, while approximately 400,000 FESS procedures are performed each year, many surgical candidates opt not to have surgery given that it does not correct the underlying inflammation or obviate the need for medical management. Approximately, 65% of patients have recurrent symptoms post-FESS and up to 20% require a revision surgery. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_146"></a><a name="_cp_text_1_146"></a>FESS is a highly invasive procedure, requiring general anesthesia and involving significant post-operative discomfort. During this procedure, a physician inserts an endoscope into the nasal cavity to provide visualization of the patient&#8217;s anatomy, the turbinate is identified with help of the endoscope and the uncinated process is removed exposing the ethmoid bulla. Surgical instruments, powered cutting tools, and balloon dilation devices are used to remove or dilate the obstructive tissue and bone. Given the essential role of the ethmoid bulla in sinus function, the ethmoid sinuses are then opened in 75%-to-85% of FESS procedures. The dependent sinuses each drain into the ethmoid sinuses through ostia, which may be enlarged by either surgically removing tissue or via balloon dilation. Following the surgical intervention, physicians often pack the newly opened ethmoid sinuses with gauze or other obstructive sinus packing materials to hold the sinus cavities open. A follow-up office visit is required several days after the procedure to remove the sinus packing materials and depending on the circumstances a patient may have to visit the surgeon two to three times a week for a period of time using nasal irrigation or will be allowed to carry out simple nasal douching several times a day. A typical FESS procedure costs approximately $14,000 on average. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_147"></a><a name="_cp_text_1_147"></a>Since the introduction of FESS, several new technologies, such as image-guided surgical navigation systems, powered surgical instruments, and BSD devices have expanded the addressable patient population who can benefit from FESS. For instance, BSD devices were developed to be used in combination with traditional surgical instruments during FESS to treat the dependent sinuses and have now allowed for treatment of some patients in the physician office setting as a standalone procedure. The cost of a BSD procedure can range from $3,000 to $7,000 per treatment. </p><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_148"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_148"></a>On an annual basis, approximately 4&#160;million CRS patients fail medical management, but ultimately only approximately 400,000 patients choose to undergo an endoscopic sinus surgery each year. Physicians report that many patients, when presented with sinus surgery as a treatment option, opt to forego the procedure. Some patients regard the often temporary benefits provided by surgery as not worth the expense, recovery time</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or use of general anesthesia. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While sinus surgery is the standard of care for treating CRS after the failure of medical management, it has several significant limitations: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_149"></a><a name="_cp_text_1_150"></a><font style="font-weight:bold;font-style:italic;">Invasive surgery with significant post-operative pain and nasal care.</font><a name="_cp_text_1_149"></a> FESS is an invasive surgery that results in irreversible changes to the anatomy and significant post-operative pain, discomfort, <a name="_cp_text_1_150"></a>and recovery time. As with any invasive surgery, a FESS entails the potential for bleeding, infection, and scar tissue. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-style:italic;">Requirement for post-operative maintenance.</font> As the underlying inflammation of CRS is still unaddressed by sinus surgery, patients are required to post-operatively maintain their treatment with medical management. Additionally, reports have shown nasal polyp regrowth following surgery in many cases and post-nasal discharge often times remains a challenge. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-style:italic;">Additional FESS procedures may be needed.</font> Approximately 65% of patients have recurring symptoms post-FESS, and approximately 20% of patients will require a revision of sinus surgery within five years, 43% of whom will within the first post-operative year. This is because sinus surgery does not cure the underlying cause of the inflammation of the sinus pathways, which can cause repeat flare ups. We believe the risk of potential revision surgery is a significant deterrent to some patients that would otherwise undergo sinus surgery. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_152"></a><a name="_cp_text_1_153"></a><font style="font-weight:bold;font-style:italic;">Potential for severe complications.</font><a name="_cp_text_1_152"></a> As a result of the use of surgical tools in close proximity to the brain, eyes, <a name="_cp_text_1_153"></a>and other critical anatomy, the potential for significant complications is a concern of physicians and patients alike. The risks of FESS, particularly in the frontal sinuses, cause some ENT physicians to avoid performing surgery in the frontal sinus drainage pathway. Major complications, such as cerebral spinal fluid leaks, swelling of the eye, or blindness, occur in approximately 0.3% of FESS procedures. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Drug Eluting Stents and Monoclonal Antibodies </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For patients with nasal polyps who remain symptomatic following surgery, who we refer to as refractory patients, certain non-surgical options are available. A steroid-eluting implant that continuously delivers three months of MF was approved to treat CRS in adults with nasal polyps. In addition, two subcutaneously-administered monoclonal antibodies, or mAbs, were recently approved as add-on maintenance therapy for uncontrolled disease in adults with nasal polyps. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">However, each of these treatments has limitations. The drug-eluting stent has only a short elution profile, presenting a more burdensome treatment regimen and requiring patient compliance. Meanwhile, the mAbs are generally reserved for the most refractory patients, given their systemic nature, unknown long-term safety and significant price premium even when compared to surgical options. In addition, both of these treatment modalities are only approved for the treatment of nasal polyps, leaving non-polyp patients (who represent approximately 70%-to-90% of all CRS patients) who are refractory with no approved treatment options. </p><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">LYR-210 for the Treatment of CRS </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_154"></a><a name="_cp_text_1_154"></a>We believe LYR-210, if successfully developed and approved, has the potential to become a preferred alternative to surgery for the treatment of CRS. It is the only product candidate that we are aware of that is designed to provide up to six months of local delivery of anti-inflammatory medication with a single administration. The brief, non-invasive, in-office procedure allows for its implantation without the need for surgery. Further, we believe our studies have shown that LYR-210 has the potential to be an effective treatment for both patients with and without polyps. We believe LYR-210 has the potential to be a safe, effective, and broadly applicable CRS treatment, designed to enhance patient comfort and physician experience and eliminate patient compliance issues associated with other CRS treatments, such as intranasal steroid sprays, while achieving reduced costs compared to other CRS treatments, such as sinus surgery. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_6_155"></a><img src="gn15qjhcndsi000005.jpg" title="" alt="" style="width:422px;height:320px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Figure 4. Illustration of Placement of LYR-210 in Middle Meatus. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LYR-210 is an investigational miniaturized local drug delivery system designed to fit within, and conform to, the confined space of a surgically-na&#239;ve patient&#8217;s middle meatus, an air-containing space that plays a fundamental role in drainage of the paranasal sinuses (see Figure 4, above). LYR-210 consists of MF, the active ingredient in various FDA-approved drugs, embedded in biocompatible polymers to aid in the controlled and sustained delivery of MF to the sinonasal mucosal tissue from a single drug administration. LYR-210 has a tubular braid configuration with a uniform diamond pattern throughout and is 13 mm in diameter and 10 mm in length in the unconstrained state. It has elastic properties to promote patient comfort and is designed to be self-retaining against the mucosal tissue to allow effective drug transfer. The matrix is comprised of a base structure and a drug formulation. The base structure is composed of PLGA and PLCL elastomer to provide a 3-dimensional structure and elasticity. The drug formulation matrix consists of the active ingredient, MF, embedded in the inactive ingredients containing PLCL and PLA to control the release rate of MF. The composition and mass of the drug formulation matrix is specified to achieve the drug dose over time. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LYR-210 is intended to be administered bilaterally into the non-operated middle meatus by an ENT physician under endoscopic visualization via a provided, single use applicator. It is designed for office-based administration performed with topical anesthesia. Once administered, LYR-210 is designed to gradually release MF to the inflamed mucosal tissue for up to six months from a single administration. LYR-210 can be removed at six months or earlier at the physician&#8217;s discretion using standard instruments and, if needed, replaced with a new LYR-210. LYR-210 is made with bioresorbable polymers that, if left in place, would gradually dissolve over time. Moreover, the elastomeric matrix encapsulates the underlying mesh fibers to facilitate removal. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Overview of Our Clinical Development </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below summarizes our completed and ongoing clinical trials for LYR-210 for CRS in patients who have failed medical management and have not undergone endoscopic sinus surgery. In addition, because we were unable to enroll patients in the United States from whom we intended to collect certain additional pharmacokinetic data due to the COVID-19 pandemic, we initiated a separate characterization study in September 2020, as a follow-on to our Phase 2 LANTERN clinical trial, with certain patients not limited to the foregoing eligibility conditions, in order to collect such data as further described below. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:15.26%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trial</p>
<p style="border-top:Solid 0.75pt;padding-top:1pt;text-align:center;margin-top:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:14.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Status</p>
<p style="margin-top:0pt;border-top:Solid 0.75pt;padding-top:1pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:17.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trial Design</p>
<p style="margin-top:0pt;border-top:Solid 0.75pt;padding-top:1pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:28.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trial Objectives</p>
<p style="margin-top:0pt;border-top:Solid 0.75pt;padding-top:1pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:23.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trial Results</p>
<p style="margin-top:0pt;border-top:Solid 0.75pt;padding-top:1pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Phase&#160;1</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:14.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Completed; Results presented in October 2018</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:17.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.85pt;;text-indent:-18pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Prospective, multi-center, non-randomized, single-arm, open-label clinical trial</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.85pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.85pt;;text-indent:-18pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;25 week trial, including 24 week treatment period, plus one week post-removal</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.85pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.85pt;;text-indent:-18pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Bilateral 2,500 &#181;g dose</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.85pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.85pt;;text-indent:-18pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;20&#160;patients</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.85pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:23.85pt;;text-indent:-18pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;5 study sites</p></td>
<td valign="top"  style="width:28.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.4pt;;text-indent:-18pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Study objective: Evaluate the safety and feasibility over 24 weeks of continuous anti-inflammatory treatment with a single administration of LYR-210</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.4pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.4pt;;text-indent:-18pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Primary endpoint: Product-related serious adverse events from baseline to 4 weeks post-procedure</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.4pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:23.4pt;;text-indent:-18pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Additional data collected: Morning serum cortisol, change in intraocular pressure, plasma pharmacokinetics, quality of life by SNOT-22 (secondary endpoint), endoscopy and MRI</p></td>
<td valign="top"  style="width:23.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-18pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Primary safety endpoint achieved / 2,500 &#181;g was well tolerated during entire duration of treatment</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-18pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Significant and rapid, clinically meaningful and durable improvement in SNOT-22 scores was observed from week 1 through week 25</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-18pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Average change in baseline SNOT-22 score at week 1 was -13.0 points (P= 0.008 to pre-treatment)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:24pt;;text-indent:-18pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Symptom relief, as measured by SNOT-22 score, was observed through the entire duration of study, achieving an average change from baseline of -20.5 points at week 24 (p &lt; 0.0001 to pre-treatment), which was the end of the treatment period, and -20.0 (p &lt; 0.0001) at week 25, which was the end of the study</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:15.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="width:14.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="width:17.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.85pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="width:28.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.4pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="width:23.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Phase&#160;2 (LANTERN)</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:14.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Completed December 2020 </p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:17.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.85pt;;text-indent:-18pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Randomized, blinded, sham-controlled, dose-ranging, parallel-group clinical trial</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.85pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.85pt;;text-indent:-18pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;24 week treatment period, plus 24 week safety follow up post-removal</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.85pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.85pt;;text-indent:-18pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Bilateral 2,500 &#181;g or 7,500&#160;&#181;g dose</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.85pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.85pt;;text-indent:-18pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;99 evaluable patients with the option to increase to up to 150 patients. Enrollment discontinued at 67 patients due to COVID-19 pandemic</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.85pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:23.85pt;;text-indent:-18pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Up to 50 study sites globally</p></td>
<td valign="top"  style="width:28.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.4pt;;text-indent:-18pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Primary endpoint: Change in composite score of 7-day average of 4 cardinal symptoms from baseline at week&#160;4</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.4pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:23.4pt;;text-indent:-18pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Secondary objectives: Symptom improvement at week 24, sinus imaging to assess reduction in inflammation, SNOT-22, time to treatment failure, reduction in inflammation, frequency of exacerbations, pharmacokinetics/pharmacodynamics</p></td>
<td valign="top"  style="width:23.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-18pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;At the 7,500 &#181;g dose, LYR-210 achieved statistically significant improvement in 4CSS in favor of the treatment arm as measured by the change from baseline at week 16 (-1.47) (p=0.021), week 20 (-1.61) (p=0.012) and week&#160;24 (-1.64) (p=0.016).</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:-18pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;At the 7,500 &#181;g dose, LYR-210 achieved statistically significant improvement in SNOT-22 score in favor of the treatment arm as measured by the change from baseline at week 8 (-12.2) (p=0.039), week 16 (-15.0) (p=0.008), week 20 (-18.4) (p=0.001) and week&#160;24 (-19.0) (p=0.001).</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:24pt;;text-indent:-18pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Although a strong treatment effect was observed at week 4, LYR-210 did not achieve the primary endpoint of change from baseline in 4CSS at week 4 at either the 7,500 &#181;g dose (-0.36) (p=0.306) or 2,500 &#181;g dose (0.04) (p=0.525). We believe this was due primarily to the discontinuation of enrollment related to the COVID-19 global pandemic.</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:15.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="width:14.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="width:17.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="width:28.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="width:23.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.26%;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PK Characterization Study</p></td>
<td valign="top"  style="width:14.88%;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initiated September 2020</p></td>
<td valign="top"  style="width:17.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.4pt;;text-indent:-18pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Up to 24 patients in the United States with bilateral 2,500 &#181;g or 7,500 &#181;g dose</p></td>
<td valign="top"  style="width:28.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.4pt;;text-indent:-18pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Certain additional pharmacokinetic timepoints, safety, SNOT-22</p></td>
<td valign="top"  style="width:23.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:25.35pt;;text-indent:-18pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Enrollment complete and all patients completed all study visits; study data lock and analysis expected in second quarter of 2021</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.06%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Phase 2 </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_157"></a><a name="_cp_text_1_157"></a>Our Phase&#160;2 LANTERN clinical trial for LYR-210 was initiated in May 2019. The clinical trial was designed as a multi-center, randomized, controlled, patient blinded trial. The study was designed to enroll 99 evaluable patients with the option to expand to up to 150 patients at up to 30 sites in the United States, Australia, Austria, Czech Republic, New Zealand, and Poland. Due to the COVID-19 pandemic, we discontinued enrollment at 67 patients and did not open any sites in the United States. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gn15qjhcndsi000006.jpg" title="" alt="" style="width:406px;height:220px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Figure 5. Design of Phase 2 LANTERN Clinical Trial for LYR-210. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trial consisted of three arms with a 1:1:1 randomization: (1)&#160;an experimental arm with bilateral placement of 2,500 &#181;g of LYR-210, with 23 patients; (2)&#160;an experimental arm with bilateral placement of 7,500 &#181;g of LYR-210, with 21 patients; and (3)&#160;a control arm with a bilateral sham procedure only, with 23 patients (see Figure 5, above). In addition, subjects were supplied with saline for daily nasal irrigation treatment during the course of the treatment period and were permitted to use rescue medication if deemed medically necessary by their physician. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62138122"></a><a name="_cp_text_1_158"></a><a name="_cp_text_1_158"></a>The primary endpoint of the trial was a change from baseline in the 7-day average scores of the 4CSS at week 4. Because the FDA prefers a composite score of the cardinal symptoms of CRS for patients with CRS, we utilized the 4CSS for the trial. The 4CSS is comprised of four domains that are scored 0-3 with a total score of 12. The four domains are: (1)&#160;nasal obstruction and congestion; (2)&#160;facial pain and pressure; (3)&#160;nasal discharge; and (4)&#160;olfactory loss (loss of sense of smell). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The key secondary endpoints for the trial were the change from baseline in 7-day average 4CSS at week 24, time to treatment failure, and percentage of subjects with at least 1-point decrease in the bilateral Zinreich score (a measure of inflammation) in at least 1 pair of the anterior ethmoid, maxillary, posterior ethmoid, frontal, or sphenoid sinuses at Week 24. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_160"></a><a name="_cp_text_1_160"></a>On December 7, 2020, we reported positive top-line results from our Phase 2 LANTERN clinical trial. In our readout of top-line results, we reported that, at the 7,500 &#181;g dose, LYR-210 achieved statistically significant improvement in 4CSS in favor of the treatment arm as measured by the change from baseline at week 16 (-1.47) (p=0.021), week 20 (-1.61) (p=0.012), and week 24 (-1.64) (p=0.016) (see Figure 6, below). However, although a strong treatment effect was observed at week 4, LYR-210 did not achieve the primary endpoint of change from baseline in 4CSS at week 4 at either the 7,500 &#181;g dose (-0.36) (p=0.306) or 2,500 &#181;g dose (0.04) (p=0.525). We believe this was due primarily to the discontinuation of enrollment related to the COVID-19 pandemic. As a result of the decrease in the number of patients enrolled from planned (99 evaluable) to actually enrolled (67), a greater magnitude of change from baseline in 4CSS at week 4 and/or a smaller standard deviation associated with the change from baseline at week 4 was required in order to achieve statistical significance for the primary endpoint. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gn15qjhcndsi000007.jpg" title="" alt="" style="width:605px;height:308px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Figure 6. Total Symptom Improvement by 4CSS for Phase 2 LANTERN Clinical Trial. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_162"></a><a name="_cp_text_1_162"></a>Furthermore, the 7,500 &#181;g dose of LYR-210 achieved statistically significant improvement in SNOT-22 score in favor of the treatment arm as measured by the change from baseline at week 8 (-12.2) (p=0.039), week 16 (-15.0) (p=0.008), week 20 (-18.4) (p=0.001), and week 24 (-19.0) (p=0.001) (see Figure 7, below). In particular, the improvement of the 7,500 &#181;g dose of LYR-210 at week 24 over the control group (-19.0) was over two times the minimal clinically important difference of -8.9. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gn15qjhcndsi000008.jpg" title="" alt="" style="width:595px;height:307px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Figure 7. Total Symptom Improvement by SNOT-22 for Phase 2 LANTERN Clinical Trial. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_163"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_163"></a>LYR-210 was observed to be safe and well-tolerated at all doses in the trial. There was one serious adverse event, which was deemed to be unrelated to LYR-210. No treatment-related serious adverse events were reported. Treatment-related adverse events included epistaxis, rhinitis, rhinorrhea</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and headache. All treatment-related adverse events were generally mild to moderate in nature, other than one incident of increased viscosity of upper respiratory secretion in the 2,500 &#181;g dose treatment arm, and in line with the known safety profile of MF. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to submit full results from our Phase 2 LANTERN study for future presentation at a scientific meeting. Given the comparable safety profile of LYR-210 at both 2,500 &#181;g and 7,500 &#181;g doses, we anticipate progressing the LYR-210 program at the 7,500 &#181;g dose level, and plan to initiate a pivotal Phase 3 study for LYR-210 in CRS for both non-polyp and polyp patients following an end of Phase 2 meeting with the FDA which we anticipate will take place in mid-2021. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, because of developments relating to the COVID-19 pandemic, we discontinued enrollment at 67 patients in our Phase 2 LANTERN clinical trial and did not enroll any patients in the United States as planned. Although we collected certain pharmacokinetic data from all patients starting at week 4, we had planned (consistent with the existing protocol for the Phase 2 LANTERN clinical trial) to utilize a subset of these U.S. patients to collect certain additional pharmacokinetic data in order to support the NDA for LYR-210. Our protocol contemplated obtaining these additional data in only a subset of the total patients both because of the additional burden required from patients in doing so, including requiring patients to make additional site visits for blood draws, and because only a subset of patients is required in order to measure these additional pharmacokinetic endpoints. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_165"></a><a name="_cp_text_1_165"></a>Because we were unable to enroll patients in the United States and collect these additional pharmacokinetic data in the Phase 2 LANTERN clinical trial, in September 2020, we initiated a separate characterization study in the United States to collect these additional data. The characterization study is designed as an open-label study with enrollment of up to 24 patients at multiple sites in the United States. The purpose of the study is to collect pharmacokinetic data for LYR-210 over a 56-day treatment period at several timepoints after dosing, including at one hour, day 2 or 3, day 7, day 14, day 21, day 28, day 42, and day 56. We will also monitor safety and collect SNOT-22 scores as secondary endpoints. Unlike our Phase 2 LANTERN clinical trial, patient eligibility is not limited to adult surgically-na&#239;ve CRS patients who have failed medical management and have moderate-to-severe CRS symptoms, and there is no overlap in patients between our Phase 2 LANTERN clinical trial and this characterization study. The study will consist of two arms: one arm with bilateral placement of 2,500 &#181;g of LYR-210 and one arm with bilateral placement of 7,500 &#181;g of LYR-210, which are the same dosages evaluated in the Phase 2 LANTERN clinical trial. This study is fully enrolled and all 24 patients have completed the study-required visits. We expect data lock and analysis activities to be completed by the second quarter of 2021. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:9.06%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Phase 1 </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Phase 1 clinical trial for LYR-210 was a prospective, multi-center, non-randomized, single-arm, open-label clinical trial with adult surgically-na&#239;ve CRS patients who have failed medical management. The objective of the trial was to evaluate safety and feasibility over 24 weeks of continuous anti-inflammatory treatment with a single administration of LYR-210 with an additional measurement taken one week post-removal. The trial was conducted across five sites in New Zealand and Australia. Forty LYR-210 matrices were placed bilaterally in 20 patients with and without nasal polyps. Each matrix contained 2,500 &#181;g of MF. LYR-210 met its primary safety endpoint, and significant and rapid, clinically meaningful and durable improvement on a patient symptom severity scale was observed through 25 weeks. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:93.33%;">
<tr>
<td style="width:16.68%;"></td>
<td style="width:38.13%;"></td>
<td style="width:38.53%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Study Design</p></td>
<td colspan="2" valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prospective, multi-center, non-randomized, single-arm, open-label clinical trial</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Study Objectives</p></td>
<td colspan="2" valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Safety and feasibility over 24 weeks of continuous anti-inflammatory treatment with a single administration of LYR-210 with an additional measurement taken one week post-removal</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patient Population</p></td>
<td colspan="2" valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adult CRS patients who have failed medical management and have not had surgery</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Number of Subjects</p></td>
<td colspan="2" valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20 patients with CRS (40 LYR-210 matrices placed)</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Number of Sites</p></td>
<td colspan="2" valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 study sites (New Zealand and Australia)</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dose</p></td>
<td colspan="2" valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,500 mcg bilaterally</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Primary Endpoint</p></td>
<td colspan="2" valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product-related serious adverse events from baseline to week 4</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional Data Collected</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Morning serum cortisol</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Intraocular pressure</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Plasma pharmacokinetics</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Quality of life by SNOT-22</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;Endoscopy and MRI</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Figure 8. Description of Phase 1 Clinical Trial for LYR-210. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Twenty patients were enrolled, 12 of whom exhibited no bilateral nasal polyps and eight of whom exhibited bilateral nasal polyps. All 20 patients received bilateral administration of LYR-210 at 2,500 &#181;g in an office setting. The study population was predominantly male with a mean age of 39.9 (range: 24-67) years old. All patients reported moderate-to-severe CRS symptoms with a mean SNOT-22 score of 50.9, of which nine patients reported severe symptoms (SNOT-22 score &gt; 50). All patients complained of nasal obstruction. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_167"></a><a name="_cp_text_1_167"></a>The Phase 1 trial achieved its primary safety endpoint at week 4. LYR-210 at 2,500 &#181;g was well tolerated by patients during the entire duration of treatment and also gave insight into the successful office-based placement of the matrix and clinical outcomes in non-polyp and polyp patients. There were no reports of unexpected adverse events, or AEs, or local nasal AEs, including epistaxis, nasal burning, nasal dryness, nasal irritation, and nasal septal perforation during the 24-week MF local dosing treatment duration. Additionally, no change in morning serum cortisol levels or intraocular pressures were noted. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gn15qjhcndsi000009.jpg" title="" alt="" style="width:522px;height:377px;"></p>
<p style="margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-right:73.33%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">AEs coded using the MedDRA dictionary, version 21.0. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">N=20 total patients. Patients experiencing the same AEs are counted only once. An additional 5 AEs occurred during the screening period, prior to treatment and are not included in this table. 25-week period includes one week post-removal. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Figure 9. Adverse Event Profile for Phase 1 Clinical Trial for LYR-210. </p><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The most common reported AEs were nasopharyngitis, upper respiratory tract infection, sinusitis, nasal odor, procedural headache, nasal discomfort, and facial pain. There was one serious adverse event, an acute myocardial infarction, which was deemed to be unrelated to LYR-210. LYR-210 was removed due to AEs before the end of the 24-week treatment period from two patients who dropped out of the trial prior to completion. One patient requested removal after 20 weeks of treatment due to complaints of memory loss, which was deemed to be unrelated to LYR-210. The other patient requested removal after 17 weeks of treatment due to a recurrence of a sinus infection that was non-serious and moderate in severity and the patient reported relief of AE symptoms within four days following removal and medical treatment. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gn15qjhcndsi000010.jpg" title="" alt="" style="width:385px;height:221px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_168"></a><a name="_cp_text_1_169"></a><a name="_cp_text_1_168"></a>Figure 10. Plasma Drug Concentration for the 50% of Patients with Levels Above LLQ. Note: at day 1, week 1, week 4, <a name="_cp_text_1_169"></a>and week 12, there were 11, 10, 16, and 10 patients, respectively, whose plasma drug concentration was below the lower limit of quantification, or LLQ. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trial results indicated low levels of systemically circulated steroid from LYR-210. MF plasma concentrations were unquantifiable in about 50% of patients and near the lower limit of quantification of 20 pg/ML in the other 50% of patients (see Figure 10, above). There were no AEs associated with systemic levels of MF. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of the matrices were successfully bilaterally placed in the sinonasal passages, in both non-polyp and polyp patients. In 7 out of the 40 matrices placed, the investigator felt that the initial placement was not ideal, and therefore the matrix was removed and a new matrix was placed. Patients did not report feeling the matrices post-administration. Further, LYR-210 had high levels of intranasal retention out to 24 weeks, with a retention rate of more than 80%. There were no AEs associated with the matrices that were dislodged. </p><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_170"></a><a name="_cp_text_1_171"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_170"></a>The Sino-Nasal Outcome Test, or SNOT-22, is a disease-specific questionnaire for sinus disease. A validated patient-reported outcome measure, the SNOT-22 is used widely by ENTs to assess disease status and treatment outcomes in CRS patients with and without polyps. It is comprised of 20 questions which address CRS-related symptoms and quality of life that can be grouped into 5 domains including rhinologic, extranasal rhinologic, ear/facial, psychological</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_171"></a>and sleep. Each question is scored on a scale from 0 to 5 for a total score ranging from 0 to 110 points. Mild disease is defined on the SNOT-22 as a score of 8 to 20, moderate as a score of 21 to 50</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and severe as greater than 50. If a patient has a SNOT-22 score of 7 or lower they are considered &#8220;normal&#8221; or absent of sino-nasal disease. The SNOT-22 minimal clinically important difference, or MCID, which is the smallest change in SNOT-22 score that can be detected by a patient, has been established as a change of 8.9 points. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_6_172"></a><img src="gn15qjhcndsi000011.jpg" title="" alt="" style="width:372px;height:270px;"></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#687F7F;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">* P&lt;0.05, **P&lt;0.01, *** P&lt;0.001, **** P&lt;0.0001 to baseline by paired two tailed t-test</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Figure 11. Total Symptom Improvement by SNOT-22 Score in Phase 1 Clinical Trial for LYR-210. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gn15qjhcndsi000012.jpg" title="" alt="" style="width:408px;height:229px;"></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:93.33%;">
<tr>
<td style="width:93.33%;"></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">** P&lt;0.01, ***P&lt;0.001, **** P&lt;0.0001 to baseline by paired two tailed t-test</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Figure 12. Symptom Improvement by Retrospective Analysis of the Scores Corresponding to the Composite 4CSS Extracted from the Corresponding Individual SNOT-22 Scores. This composite score produced as a result of the retrospective analysis was not an endpoint of our Phase 1 clinical trial or addressed in our statistical analysis plan and was done for illustrative purposes only. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients generally experienced significant and rapid, clinically meaningful and durable improvements in CRS symptoms in the Phase 1 trial, as measured by SNOT-22 score (see Figure 11, above). Significant reduction in SNOT-22 scores was observed at week 1 and this reduction persisted through week 25, the end of the trial (see Figure 11, above). Changes from baseline, or CFBL, in SNOT-22 score were statistically significant (P &lt; 0.01) at all measured intervals. The average change from baseline in SNOT-22 score at week 1 was -13.0 points (P=&#160;0.008 to pre-treatment), achieving the MCID of -8.9 points. Further, symptom relief was observed through the entire duration of study, and achieved -20.5 points at week </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24 (</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">p &lt; 0.0001</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to pre-treatment), the time LYR-210 was removed. Significant symptom improvement was achieved in all of the SNOT-22 subdomains at week 24. We also conducted a retrospective analysis of symptom improvement, as measured by CFBL, in the individual domain scores extracted from individual SNOT-22 scores that correspond to the cardinal symptoms comprising the 4CSS in order to retrospectively assess the improvement of these cardinal symptoms in these patients (see Figure 12, above). This retrospective analysis showed that the CFBL in the individual domain scores were generally consistent with the CFBL in the SNOT-22 scores. This composite score produced as a result of the retrospective analysis was not an endpoint of our Phase 1 clinical trial or addressed in our statistical analysis plan and was done for illustrative purposes only. Our Phase 2 LANTERN clinical trial used a composite score of 4CSS as its primary endpoint at week 4. However, there are differences related to how the endpoint was calculated compared to the retrospective analysis of the Phase 1 clinical trial data. For example, the wording of the questions in the SNOT-22 questionnaire relating to the four cardinal symptom domains was similar, but not identical, to the wording in the 4CSS questionnaire used in our Phase 2 LANTERN clinical trial. In addition, the SNOT-22 questions use a scale of 0 to 5 while the 4CSS questions in our Phase 2 LANTERN clinical trial used a scale of 0 to 3. Finally, the individual SNOT-22 domain scores used in the retrospective analysis were measured every two weeks and were not averaged, while the primary endpoint in our Phase 2 LANTERN clinical trial was the CFBL of the 7-day average scores of 4CSS at week 4. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gn15qjhcndsi000013.jpg" title="" alt="" style="width:462px;height:230px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Figure 13. Percent of Patients with Symptom Improvement by SNOT-22 Score, Showing Improvement with MCID and without MCID, in Phase 1 Clinical Trial for LYR-210. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At week 24, 90% of patients improved versus the baseline score, with clinically meaningful improvement observed in 70% of patients (see Figure 13, above). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_6_175"></a><img src="gn15qjhcndsi000014.jpg" title="" alt="" style="width:386px;height:252px;"></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#687F7F;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">* P&lt;0.05, **P&lt;0.01, ***P&lt;0.001, **** P&lt;0.0001 to baseline by paired two tailed t-test</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Figure 14. Symptom Improvement in Polyp and Non-Polyp Patients by Change from Baseline in SNOT-22 Score in Phase 1 Clinical Trial for LYR-210. </p><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar efficacy was observed in both polyp and non-polyp patients (see Figure&#160;14, above). Further, even though each of the clinical trial patients were surgery candidates at the trial entry and no topical intranasal spray was utilized in conjunction with LYR-210 during the 25-week trial, none of the patients underwent sinus surgery during the treatment period. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gn15qjhcndsi000015.jpg" title="" alt="" style="width:439px;height:268px;"></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Figure 15. Endoscopy Images Before and After Treatment with LYR-210 in Phase 1 Clinical Trial. For illustrative purposes only. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_176"></a><a name="_cp_text_1_176"></a>Figure 15, above, shows via nasal endoscopy images from our Phase 1 clinical trial the impact of LYR-210 observed in a patient without nasal polyps and a patient with nasal polyps at three time points: before LYR-210 placement, after LYR-210 placement, and at week 25, one week after LYR-210 was removed. The middle image for each patient shows the deployment of LYR-210 in the middle meatus of a non-polyp and a polyp patient, and how LYR-210 conformed to the walls of the obstructed nasal anatomy to maximize tissue contact. In the third image for each patient, the erythema and inflammation present before treatment was observed to be resolved and less evident after 24 weeks of treatment and one week post-removal. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">LYR-220 for the Treatment of CRS </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LYR-220 is a new investigative therapy for CRS patients with and without nasal polyps that have failed medical management and have had a prior endoscopic sinus surgery. In the treatment paradigm, LYR-220, if approved, is positioned for use for patients post-surgical intervention who continue to have recurrent CRS symptoms or relapse, as a potential preferred alternative to revision surgery. LYR-220 utilizes the same API as LYR-210, but with a larger matrix to treat larger nasal cavities consistent with those in post-surgical CRS patients. We estimate that 40% of patients that present to an ENT physician with CRS have had a prior surgery. These patients represent the addressable market for LYR-220. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No product is currently approved by the FDA to treat post-surgery CRS patients that do not have polyps, representing the vast majority of such CRS patients, and only a three-month steroid-eluting sinus implant was approved by the FDA to treat CRS in adults with nasal polyps and two subcutaneously-administered mAbs were recently approved as add-on maintenance therapy for uncontrolled disease in adults with nasal polyps. We believe LYR-220 is meaningfully differentiated from currently approved products because, if successfully developed and approved, it would be the only product able to deliver up to six months of topical treatment in a single administration to treat both polyp and non-polyp post-surgery CRS patients who fail medical management. Further, with respect to the mAb, LYR-220 is differentiated because it would provide localized delivery so as to avoid systemic side effects with the added benefit of being a significantly more economical treatment alternative. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the impact of COVID-19 on our business, we expect to initiate a Phase 2 clinical trial for LYR-220 by the end of 2021 and, if LYR-210 is approved by the FDA, to submit an sNDA for a potentially faster path to approval for LYR-220. We believe the clinical development of LYR-220 may require only a single Phase 3 study for registration. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Early Stage and Future Product Candidates </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our XTreo platform provides a versatile drug development engine that enables us to focus on indications where long-term delivery of existing treatments may provide improved local bioavailability and enhanced efficacy or safety. In addition to CRS, LYR-210 may have the potential to address the significant unmet need that exists for allergic rhinitis patients who have failed medical management. We believe an allergic rhinitis indication could provide meaningful differentiation in those CRS patients that have allergic rhinitis and additionally could expand the addressable pool of patients for LYR-210 to include allergic rhinitis patients that do not have co-morbid CRS. We are currently evaluating the development path for this additional indication. We may also pursue other nasal delivery applications of our platform, such as rare disorders where nasal disease contributes to the disease pathology and central nervous system disorders. Additionally, we believe our platform can be adapted to locally address conditions of the ear. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Post-Approval Commercialization Strategy </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_178"></a><a name="_cp_text_1_178"></a>If LYR-210 and LYR-220 are successfully developed and approved, we intend to engage in targeted outreach to our key physician, payor, and patient audiences. ENT physicians are the primary treaters of CRS patients who have failed medical management and thus represent our target physician base. Given the requirement for endoscopic placement of our products, we plan to build an in-house sales force, consisting of approximately 75-100 employees, that will target ENT physicians whose sub-specialty is general otolaryngology or rhinology, which together represent approximately 60% of the approximately 12,000 ENT physicians in the United States. Given that LYR-210 and LYR-220 can be administered in a brief, simple procedure requiring no additional equipment, we anticipate that our sales representatives&#8217; time will primarily be directed at educating the ENT physicians around product attributes and patient selection. We plan to supplement our direct physician outreach with appropriate medical education and marketing efforts to further penetrate our physician base and drive adoption of our products. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_180"></a><a name="_cp_text_1_182"></a><a name="_cp_text_1_184"></a><a name="_cp_text_1_186"></a><a name="_cp_text_1_188"></a><a name="_cp_text_1_180"></a>Ensuring physician and patient market access to our products will be critical to our success, and we plan to execute a holistic reimbursement strategy, consisting of a reimbursement support hub and approximately 15-20 field-based reimbursement experts, that will integrate payor <a name="_cp_text_1_182"></a>coverage and physician practice management initiatives. We believe that the primary decision makers from a payor <a name="_cp_text_1_184"></a>perspective are private payors<a name="_cp_text_1_186"></a>, which represent approximately 80% of the payor <a name="_cp_text_1_188"></a>mix for our products. We intend to deploy a market access team to educate payors on the clinical and pharmacoeconomic attributes of our products and to seek to secure favorable coverage policies and to maximize the covered lives that have reimbursement for our products. The team will also secure the necessary codes to facilitate physician and patient payment including a J-code, which is required for physician-administered products. In addition, we expect to be able to use existing current procedural terminology codes for procedures involving the placement and removal of our product candidates, if approved. To maximize access to LYR-210 and LYR-220, we plan to develop a reimbursement support model which aims to reduce physician financial risk associated with physician-administered products. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_190"></a><a name="_cp_text_1_190"></a>Subsequent to our initial ENT physician and payor efforts, we also plan to selectively use cost-effective, patient-directed marketing strategies to further increase awareness among the CRS patient community of our products with the goal of increasing ENT physician visits. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may also consider entering into collaborative relationships with established entities outside the U.S. for a potentially faster path to bringing our products to market. We may also enter into collaborative relationships within the U.S. for future pipeline product candidates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Competition </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_191"></a><a name="_cp_text_1_191"></a>Our industry is highly competitive and subject to rapid and significant technological change as research provides a deeper understanding of the pathology of diseases and new technologies and treatments are developed. We believe our scientific knowledge, technology, and development capabilities provide us with substantial competitive advantages, but we face potential competition from multiple sources, including large pharmaceutical, biotechnology, specialty pharmaceutical, and, to a lesser degree, medical device companies. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_192"></a><a name="_cp_text_1_193"></a><a name="_cp_text_1_194"></a><a name="_cp_text_1_192"></a>Our competitors may have significantly greater financial resources, robust drug pipelines, established presence in the market, <a name="_cp_text_1_193"></a>and expertise in research and development, manufacturing,&#160;pre-clinical&#160;and clinical testing, obtaining regulatory approvals and reimbursement, <a name="_cp_text_1_194"></a>and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified clinical, regulatory, scientific, sales, marketing, and management personnel, in establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_195"></a><a name="_cp_text_1_197"></a><a name="_cp_text_1_198"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_195"></a>LYR-210 and LYR-220 are positioned following the failure of medical management and therefore are not anticipated to compete directly with branded, generic</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_197"></a>or over-the-counter inhaled corticosteroids. LYR-210 is positioned for use in surgically-na&#239;ve CRS patients where the primary competitive treatment is surgical procedures, including FESS with and without BSD and BSD as a standalone procedure. In this space, LYR-210 would be the only product we are aware of that may deliver six months of local treatment with a single administration for both patients with and without polyps as a preferred alternative to surgical interventions. LYR-220 is positioned for use in patients that have had a prior FESS. Currently there are no competitive treatments for post-surgical patients without polyps. For patients with polyps, LYR-220 would compete against steroid-releasing sinus implants and mAbs. We believe LYR-220 has competitive advantages over these interventions, including a longer elution profile than the existing sinus implant and no systemic exposure relative to the mAb. Key competitive factors affecting the commercial success of both LYR-210 and LYR-220 and any other product candidates we may develop are likely to be efficacy, safety</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_198"></a>and tolerability profile, reliability, convenience of administration, price</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and reimbursement. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_199"></a><a name="_cp_text_1_199"></a>Several companies are also currently developing treatments for CRS patients with nasal polyps, including Hoffmann-La Roche, GlaxoSmithKline, AnaptysBio, Regeneron, OptiNose, and Intersect ENT. If these treatments are approved by the FDA, they could represent competition across the spectrum of CRS patients. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing and Supply </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently manufacture our drug delivery products at our facility in Watertown, Massachusetts with components supplied by external suppliers. We perform inspections of these components before use in our manufacturing operations. Using these components, we manufacture, assemble, inspect, and package our implants, and send them to a third-party sterilization vendor. After sterilization, we inspect the product and test via third-party laboratories to determine compliance with our specifications. Upon release of the lot to inventory, the product is labeled and distributed via a third-party vendor to clinical sites. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_200"></a><a name="_cp_text_1_201"></a><a name="_cp_text_1_202"></a><a name="_cp_text_1_203"></a><a name="_cp_text_1_200"></a>The API and a number of the components used in our implants are currently supplied to us from single source suppliers. We source our supplies from manufacturers with a track record of compliance with current good manufacturing practices, or <a name="_cp_text_1_201"></a>cGMP. We rely on single source suppliers for some of our polymer materials, some extrusions, <a name="_cp_text_1_202"></a>and molded components, and for finished goods testing, labeling, <a name="_cp_text_1_203"></a>and distribution. Our ability to supply our products and to develop our product candidates depends, in part, on our ability to obtain successfully the API and polymer materials used in these products in accordance with regulatory requirements and in sufficient quantities. We plan to enter into manufacturing, supply, and quality agreements with our single source suppliers. We generally acquire our single source components pursuant to purchase orders placed in the ordinary course of business. We currently maintain sufficient supplies of the API and components from our single source suppliers to support our ongoing development activities. In the future, we intend to maintain sufficient supplies such that our ability to supply the clinic or commercial market will not be compromised and so as to allow for sufficient time necessary to obtain another source of API or components. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_204"></a><a name="_cp_text_1_204"></a>We are currently improving our manufacturing capabilities and increasing capacity to better support further clinical studies and commercialization. We plan to use an outsourcing model and choose a contract manufacturer with the appropriate infrastructure, technical experience, and quality systems and a track record of FDA compliance. We plan to continue to use an outsourcing model for our operations until we reach a sufficient scale to justify investment in internal manufacturing capacity. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We actively seek to protect the intellectual property and proprietary technology platform that we believe is important to our business, which includes seeking and maintaining patents covering our technology platform and products, and any other inventions that are commercially or strategically important to the development of our business. We also rely upon trademarks to build and maintain the integrity of our brand, and we seek to protect the confidentiality of trade secrets that may be important to the development of our business. For more information, please see &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property&#8221;. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:9.06%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Patents and Patent Applications </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we own 23 issued U.S. patents, nine foreign issued patents, eight U.S. pending applications, and 22 foreign pending applications, out of which 16 issued U.S. patents, nine foreign issued patents, eight U.S. pending applications, and 22 foreign pending applications are directed to our XTreo platform, LYR-210, and LYR-220. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_205"></a><a name="_cp_text_1_207"></a><a name="_cp_text_1_208"></a><a name="_cp_text_1_209"></a><a name="_cp_text_1_210"></a><a name="_cp_text_1_211"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_205"></a>All technology material to our business has been developed in-house and is protected with patents and patent applications in two major lineages, along with the beginning of a third, more recent lineage of patent applications. The first lineage dates from 2009 and provides protection potentially until 2030, exclusive of possible patent term adjustments or extensions or other forms of exclusivity. This first lineage includes issued patents in the U.S., Europe, Japan, Canada</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_207"></a>and Great Britain that are not limited to any particular drug, site of delivery</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_208"></a>or patient condition, but specify features of the implant, system, method</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_209"></a>and polymers. The second lineage dates from 2015 and provides protection potentially until 2036, exclusive of possible patent term adjustments or extensions or other forms of exclusivity. This second lineage includes issued U.S. patents with ENT-specific method claims directed to the specific drug, site of delivery (i.e. middle meatus)</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_210"></a>and patient condition, along with numerous pending applications in the U.S., Europe, Japan, Canada, China</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_211"></a>and the Great Britain. The third, more recent lineage dates from 2017 with the prospect of patent protection potentially until 2037, exclusive of possible patent term adjustments or extensions or other forms of exclusivity. This third lineage attempts to capture the drug release features and patient results from the recent clinical trial. It includes pending applications in the U.S. and Great Britain, along with a patent application filed under the Patent Cooperation Treaty that entered the National Phase in October of 2019 in the following countries: the U.S., Canada, Australia, Europe, Korea, Singapore, China</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Japan.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:9.06%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Trademarks and Trade Secrets </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, our trademark portfolio contained eight foreign trademark registrations and one pending U.S. trademark application.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_212"></a><a name="_cp_text_1_213"></a><a name="_cp_text_1_214"></a><a name="_cp_text_1_212"></a>We also rely upon trade secrets, know-how, <a name="_cp_text_1_213"></a>and continuing technologies innovation, and may pursue licensing opportunities in the future, to develop and maintain our competitive position. We seek to protect our proprietary rights through a variety of methods, including confidentiality agreements, invention assignment agreements, and <a name="_cp_text_1_214"></a>non-solicitation and non-compete agreements with suppliers, employees, consultants, and others who may have access to proprietary information. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_215"></a><a name="_cp_text_1_215"></a>Government Regulation and Product Approval </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_216"></a><a name="_cp_text_1_218"></a><a name="_cp_text_1_219"></a><a name="_cp_text_1_220"></a><a name="_cp_text_1_216"></a>Government authorities in the United States, at the federal, state, <a name="_cp_text_1_218"></a>and local levels<a name="_cp_text_1_219"></a>, and in other countries extensively regulate, among other things, the research, development, testing, manufacturing, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import, and export of pharmaceutical products such as those we are developing. We will be required to navigate the various preclinical, clinical, <a name="_cp_text_1_220"></a>and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval of our product candidates. The processes for obtaining regulatory approvals in the United States and other countries, as appropriate, along with subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations, require the expenditure of substantial time and resources. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">U.S. Government Regulation </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_221"></a><a name="_cp_text_1_222"></a><a name="_cp_text_1_224"></a><a name="_cp_text_1_221"></a>In the United States, we are subject to extensive regulation by the FDA, which regulates drugs under the Federal Food, Drug, and Cosmetic Act, or the FDCA, and its implementing regulations, and other federal, state, and local regulatory authorities. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, <a name="_cp_text_1_222"></a>and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process, <a name="_cp_text_1_224"></a>or after approval may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process required by the FDA before a drug may be marketed in the United States generally involves the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_225"></a><a name="_cp_text_1_225"></a>completion of preclinical laboratory tests, animal studies, and formulation studies in compliance with the FDA&#8217;s Good Laboratory Practice regulations; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">submission to the FDA of an IND which must become effective before human clinical trials may begin; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_226"></a><a name="_cp_text_1_226"></a>approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_228"></a><a name="_cp_text_1_230"></a><a name="_cp_text_1_228"></a>performance of adequate and well-controlled human clinical trials in accordance with good clinical practice, or <a name="_cp_text_1_230"></a>GCP, requirements to establish the safety and efficacy of the proposed drug product for each indication; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">submission to the FDA of an NDA; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">satisfactory completion of an FDA advisory committee review, if applicable; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_233"></a><a name="_cp_text_1_234"></a><a name="_cp_text_1_233"></a>satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with cGMP requirements and to assure that the facilities, methods, <a name="_cp_text_1_234"></a>and controls are adequate to preserve the drug&#8217;s identity, strength, quality, and purity; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">satisfactory completion of an FDA inspection of selected clinical sites to assure compliance with GCPs and the integrity of the clinical data; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">payment of user fees; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">FDA review and approval of the NDA. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_235"></a><a name="_cp_text_1_236"></a><a name="_cp_text_1_237"></a><a name="_cp_text_1_239"></a><a name="_cp_text_1_235"></a>We are developing our product candidates using an innovative drug delivery platform comprised of a mesh scaffold, an elastomeric matrix, <a name="_cp_text_1_236"></a>and a polymer-drug complex delivered through a narrow applicator. In the United States, products composed of components that would normally be regulated by different centers at the FDA are known as combination products. Typically, the FDA&#8217;s Office of Combination Products assigns a combination product to a specific Agency Center as the lead reviewer. The FDA determines which Center will lead a product&#8217;s review based upon the product&#8217;s primary mode of action. Depending on the type of combination product, its approval, clearance, <a name="_cp_text_1_237"></a>or licensure may usually be obtained through the submission of a single marketing application. We anticipate that LYR-210 and LYR-220 will be regulated as drugs, and for each product candidate, the FDA will permit a single regulatory submission seeking approval. However, the FDA sometimes will require separate marketing applications for individual constituent parts of the combination product which may require additional time, effort, and information. Even when a single marketing application is required for a combination product, such as an NDA for a combination pharmaceutical and device product, both the FDA&#8217;s Center for Drug Evaluation and Research and the FDA&#8217;s Center for Devices and Radiological Health may participate in the review. An applicant will also need to discuss with the Agency how to apply certain premarket requirements and post-marketing regulatory requirements, including conduct of clinical trials, adverse event reporting, <a name="_cp_text_1_239"></a>and cGMPs, to their combination product. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Preclinical Studies </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_240"></a><a name="_cp_text_1_241"></a><a name="_cp_text_1_240"></a>Preclinical studies include laboratory evaluation of product chemistry, toxicity, <a name="_cp_text_1_241"></a>and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may continue even after the IND is submitted. An IND automatically becomes effective and a clinical trial proposed in the IND may begin 30 days after the FDA receives the IND, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical Trials </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. An IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must continue to oversee the clinical trial while it is being conducted. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on their www.clinicaltrials.gov website. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human clinical trials are typically conducted in three or four sequential phases, which may overlap or be combined: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_242"></a><a name="_cp_text_1_242"></a>Phase 1: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion, and, if possible, to gain an early indication of its effectiveness. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_243"></a><a name="_cp_text_1_243"></a>Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases, and to determine dosage tolerance and optimal dosage. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_245"></a><a name="_cp_text_1_245"></a>Phase 4: In some cases, the FDA may conditionally approve an NDA for a product candidate on the sponsor&#8217;s agreement to conduct additional clinical trials after NDA approval. In other cases, a sponsor may voluntarily conduct additional clinical trials post approval to gain more information about the drug. Such post-approval trials are typically referred to as Phase 4 clinical trials. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_246"></a><a name="_cp_text_1_246"></a>Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA, and more frequently if serious adverse events occur. Phase 1, Phase 2, and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_247"></a><a name="_cp_text_1_247"></a>Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Marketing Approval </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_248"></a><a name="_cp_text_1_250"></a><a name="_cp_text_1_252"></a><a name="_cp_text_1_254"></a><a name="_cp_text_1_256"></a><a name="_cp_text_1_248"></a>Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls, <a name="_cp_text_1_250"></a>and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act, or <a name="_cp_text_1_252"></a>PDUFA, <a name="_cp_text_1_254"></a>guidelines that are currently in effect, the FDA has a goal of 10 months to review and act on a standard NDA and 6 months to review and act on a priority NDA, measured from the &#8220;filing&#8221; date for an NDA for a new molecular entity, or <a name="_cp_text_1_256"></a>NME, or from the receipt date for an NDA for a non-NME product. Measuring from the &#8220;filing&#8221; date typically adds approximately two months to the timeline for review and decision because the FDA has sixty days from receipt to make a &#8220;filing&#8221; decision, as described below. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, under the Pediatric Research Equity Act of 2003 as amended and reauthorized, certain NDAs or supplements to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA also may require submission of a risk evaluation and mitigation strategy, or REMS, plan to ensure that the benefits of the drug outweigh its risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_258"></a><a name="_cp_text_1_259"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_258"></a>The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_259"></a>or held meets standards designed to assure the product&#8217;s continued safety, quality</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and purity. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_260"></a><a name="_cp_text_1_260"></a>The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates, and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA generally accepts data from foreign clinical trials in support of an NDA if the trials were conducted under an IND. If a foreign clinical trial is not conducted under an IND, the FDA nevertheless may accept the data in support of an NDA if the study was conducted in accordance with GCP requirements and the FDA is able to validate the data through an on-site inspection, if deemed necessary. Although the FDA generally requests that marketing applications be supported by some data from domestic clinical studies, the FDA may accept foreign data as the sole basis for marketing approval if (1)&#160;the foreign data are applicable to the U.S. population and U.S. medical practice, (2)&#160;the studies were performed by clinical investigators with recognized competence, and (3)&#160;the data may be considered valid without the need for an on-site inspection or, if the FDA considers the inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_261"></a><a name="_cp_text_1_262"></a><a name="_cp_text_1_261"></a>The testing and approval process for an NDA requires substantial time, effort, <a name="_cp_text_1_262"></a>and financial resources, and each may take several years to complete. Data obtained from preclinical and clinical testing are not always conclusive and may be susceptible to varying interpretations, which could delay, limit, or prevent regulatory approval. The FDA may not grant approval on a timely basis, or at all. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_263"></a><a name="_cp_text_1_263"></a>After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met to secure final approval of the NDA and may require additional clinical testing, preclinical testing, manufacturing, or formulation modifications or other changes in order for the FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_264"></a><a name="_cp_text_1_264"></a>Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings, or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval. </p><a name="_AEIOULastRenderedPageBreakAEIOU8"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The Hatch-Waxman Amendments </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_265"></a><a name="_cp_text_1_265"></a>Our current regulatory strategy is to pursue development of LYR-210 as a Section&#160;505(b)(2) NDA. As an alternative path to FDA approval for modifications to formulations or uses of drugs previously approved by the FDA, an applicant may submit an NDA under Section&#160;505(b)(2) of the FDCA. Section&#160;505(b)(2) was enacted as part of the Hatch-Waxman Amendments. A Section&#160;505(b)(2) NDA is an application that contains full reports of investigations of safety and effectiveness, but where at least some of the information required for approval comes from studies not conducted by, or for, the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. This type of application permits reliance for such approvals on literature or on an FDA finding of safety, effectiveness, or both for an approved drug product. As such, under Section&#160;505(b)(2), the FDA may rely, for approval of an NDA, on data not developed by the applicant. Therefore, if we can satisfy the conditions required for a Section&#160;505(b)(2) NDA submission, it may eliminate the need for us to conduct some of the preclinical studies or clinical trials for the new product candidate that might otherwise have been required, although the review time is not shortened. The FDA may then approve the new product candidate for the new indication sought by the 505(b)(2) applicant. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Orange Book Listing </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_266"></a><a name="_cp_text_1_267"></a><a name="_cp_text_1_266"></a>In seeking approval for a drug through an NDA, applicants are required to list with the FDA certain patents whose claims cover the applicant&#8217;s product. Upon approval of an NDA, each of the patents listed in the application for the drug is then published in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, known as the Orange Book. Any applicant who files an Abbreviated New Drug Application (ANDA) seeking approval of a generic equivalent version of a drug listed in the Orange Book or a 505(b)(2) NDA referencing a drug listed in the Orange Book must certify, for each patent listed in the Orange Book for the referenced drug, to the FDA that (1)&#160;no patent information on the drug product that is the subject of the application has been submitted to the FDA, (2)&#160;such patent has expired, (3)&#160;the date on which such patent expires, <a name="_cp_text_1_267"></a>or (4)&#160;such patent is invalid or will not be infringed upon by the manufacture, use, or sale of the drug product for which the application is submitted. The fourth certification described above is known as a paragraph IV certification. A notice of the paragraph IV certification must be provided to each owner of the patent that is the subject of the certification and to the holder of the approved NDA to which the ANDA refers. The applicant may also elect to submit a &#8220;section viii&#8221; statement certifying that its proposed label does not contain (or carves out) any language regarding the patented method-of-use rather than certify to a listed method-of-use patent. This section viii statement does not require notice to the patent holder or NDA owner. There might also be no relevant patent certification. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the reference NDA holder and patent owners assert a patent challenge directed to one of the Orange Book listed patents within 45 days of the receipt of the paragraph IV certification notice, the FDA is prohibited from approving the application until the earlier of 30 months from the receipt of the paragraph IV certification expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the applicant. Even if the 45 days expire, a patent infringement lawsuit can be brought and could delay market entry, but it would not extend the FDA-related 30-month stay of approval. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_268"></a><a name="_cp_text_1_268"></a>The ANDA or 505(b)(2) application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the branded reference drug has expired. Specifically, the holder of the NDA for the listed drug may be entitled to a period of non-patent exclusivity, during which the FDA cannot approve an ANDA or 505(b)(2) application that relies on the listed drug. For example, a pharmaceutical manufacturer may obtain five years of non-patent exclusivity upon NDA approval of an NCE, which is a drug that contains an active moiety that has not been approved by FDA in any other NDA. An &#8220;active moiety&#8221; is defined as the molecule or ion responsible for the drug substance&#8217;s physiological or pharmacologic action. During the five-year exclusivity period, the FDA cannot accept for filing any ANDA seeking approval of a generic version of that drug or any 505(b)(2) NDA for the same active moiety and that relies on the FDA&#8217;s findings regarding that drug, except that FDA may accept an application for filing after four years if the follow-on applicant makes a paragraph IV certification. This exclusivity period may be extended by an additional six months if certain requirements are met to qualify the product for pediatric exclusivity, including the receipt of a written request from the FDA that the NDA holder conduct certain pediatric studies, the submission of study reports from such studies to the FDA after receipt of the written request, and satisfaction of the conditions specified in the written request. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Expedited Review and Approval Programs </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has various programs, including Fast Track Designation, accelerated approval, priority review, and breakthrough therapy designation, which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To be eligible for a Fast Track Designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. The FDA may review sections of the NDA for a fast track product on a rolling basis before the complete application is submitted if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may give a priority review designation to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of ten months under current PDUFA guidelines. Under the new PDUFA agreement, these six and ten month review periods are measured from the &#8220;filing&#8221; date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review and decision from the date of submission. Most products that are eligible for Fast Track Designation are also likely to be considered appropriate to receive a priority review. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_270"></a><a name="_cp_text_1_270"></a>In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, under the provisions of the Food and Drug Administration Safety and Innovation Act, a sponsor can request designation of a product candidate as a &#8220;breakthrough therapy.&#8221; A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities for our product candidates as appropriate. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Post Approval Requirements </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_271"></a><a name="_cp_text_1_272"></a><a name="_cp_text_1_271"></a>Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA and other government authorities, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion, <a name="_cp_text_1_272"></a>and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications, manufacturing changes, or other labeling claims, are subject to prior FDA review and approval. There also are continuing annual program fee requirements for any marketed products. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state authorities, and are subject to periodic unannounced inspections by the FDA and these state authorities for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other potential consequences include, among other things: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_273"></a><a name="_cp_text_1_273"></a>restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market, or product recalls; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_274"></a><a name="_cp_text_1_274"></a>fines, warning letters, or holds on post-approval clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">product seizure or detention, or refusal to permit the import or export of products; or </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.19%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">injunctions or the imposition of civil or criminal penalties. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_275"></a><a name="_cp_text_1_275"></a>The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label, although physicians, in the practice of medicine, may prescribe approved drugs for unapproved indications. The FDA and other authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Healthcare and Data Privacy and Security Laws </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_276"></a><a name="_cp_text_1_277"></a><a name="_cp_text_1_278"></a><a name="_cp_text_1_279"></a><a name="_cp_text_1_280"></a><a name="_cp_text_1_276"></a>Pharmaceutical and medical device manufacturers are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation, U.S. federal anti-kickback, fraud and abuse, false claims, consumer fraud, pricing reporting, data privacy and security, and transparency laws and regulations, <a name="_cp_text_1_277"></a>as well as similar foreign laws in the jurisdictions outside the U.S. Similar state and local laws and regulations may also restrict business practices in the pharmaceutical industry, such as state anti-kickback and false claims laws, which may apply to business practices, including but not limited to, research, distribution, sales, <a name="_cp_text_1_278"></a>and marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, or by patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information or which require tracking gifts and other remuneration and items of value provided to physicians, other healthcare providers, <a name="_cp_text_1_279"></a>and entities; state and local laws that require the registration of pharmaceutical sales representatives; and state and local laws governing the privacy and security of health-related and other personal information in some circumstances, many of which differ from each other in significant ways and often are not preempted by the Health Insurance Portability and Accountability Act, or <a name="_cp_text_1_280"></a>HIPAA, thus complicating compliance efforts. Violation of any of such laws or any other governmental regulations that apply may result in penalties, including, without limitation, civil and criminal penalties, damages, fines, additional reporting obligation, the curtailment or restructuring of operations, exclusion from participation in governmental healthcare programs, and individual imprisonment. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Coverage and Reimbursement </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_281"></a><a name="_cp_text_1_282"></a><a name="_cp_text_1_281"></a>Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, <a name="_cp_text_1_282"></a>and foreign government healthcare programs, commercial insurance, and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any newly approved product. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. One third-party payor&#8217;s decision to cover a particular product does not ensure that other payors will also provide coverage for the product. As a result, the coverage determination process can require manufactures to provide scientific and clinical support for the use of a product to each payor separately and can be a time-consuming process, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_283"></a><a name="_cp_text_1_285"></a><a name="_cp_text_1_287"></a><a name="_cp_text_1_283"></a>In addition, third-party payors are increasingly reducing reimbursements for pharmaceutical products and services. The U.S. government and state legislatures have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement, <a name="_cp_text_1_285"></a>and requirements for substitution of generic products. Third-party payors are increasingly <a name="_cp_text_1_287"></a>challenging the prices charged and examining the medical necessity and reviewing the cost effectiveness of pharmaceutical products, in addition to questioning their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_288"></a><a name="_cp_text_1_288"></a>In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products and may also compete with imported foreign products. Furthermore, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication, will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is available, or that the third-party payors&#8217; reimbursement policies will not adversely affect the ability for manufacturers to sell products profitably. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Healthcare Reform </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_290"></a><a name="_cp_text_1_292"></a><a name="_cp_text_1_290"></a>In the United States and certain foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system. In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States. By way of example, the ACA increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%; required collection of rebates for drugs paid by Medicaid managed care organizations; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain &#8220;branded prescription drugs&#8221; to specified federal government programs; <a name="_cp_text_1_292"></a>implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expanded eligibility criteria for Medicaid programs; created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_293"></a><a name="_cp_text_1_293"></a>Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, in 2017, Congress enacted the Tax Cuts and Jobs Act, which eliminated the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; On December&#160;14, 2018, a U.S. District Court Judge in the Northern District of Texas, or the Texas District Court Judge, ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid as well. On March&#160;2, 2020, the U.S. Supreme Court granted the petitions for writs of certiorari to review this case, although it is unclear when or how the Supreme Court will rule. It is also unclear how other efforts to challenge, repeal, or replace the ACA will impact the ACA. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_294"></a><a name="_cp_text_1_295"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_294"></a>Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year and reduced payments to several types of Medicare providers, which will remain in effect through 2030, with the exception of a temporary suspension from May&#160;1, 2020 through December&#160;31, 2020, absent additional congressional action. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted legislation designed, among other things, to bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_295"></a>and reform government program reimbursement methodologies for pharmaceutical products. Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and marketing cost disclosure and transparency measures and, in some cases, mechanisms to encourage importation from other countries and bulk purchasing. Furthermore, there has been increased interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_296"></a><a name="_cp_text_1_296"></a>Employees </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had 38 full-time employees. None of our employees is represented by a labor union or covered by a collective bargaining agreement. Employee turnover has not had a material impact on our operations. We consider our relationship with our employees to be good. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Corporate Information </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated under the laws of the state of Delaware in November 2005 under the name WMR Biomedical, Inc. In July 2018, we changed our name to Lyra Therapeutics, Inc. Our principal executive offices are located at 480 Arsenal Way, Watertown, MA 02472 and our telephone number is (617) 393-4600. Our website address is <font style="font-style:italic;">www.lyratherapeutics.com</font>. The information contained in, or accessible through, our website does not constitute a part of this Annual Report on Form 10-K. We have included our website address in this Annual Report on Form 10-K solely as an inactive textual reference. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Available Information</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_301"></a><a name="_cp_text_1_303"></a><a name="_cp_text_1_304"></a>Our Internet address is <font style="font-style:italic;">www.lyratherapeutics.com</font><a name="_cp_text_1_301"></a>. Our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, proxy and information statements and amendments to those reports filed or furnished pursuant to Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended, are filed with the SEC and are <a name="_cp_text_1_303"></a>available through the &#8220;Investors&#8221; portion of our website free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Information on our website is not part of this Annual Report on Form 10-K or any of our other securities filings unless specifically incorporated herein by reference. Our filings with the SEC may be accessed through the SEC&#8217;s website <a name="_cp_text_1_304"></a>at http://www.sec.gov, which contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.</p><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1A_RISK_FACTORS"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1A_RISK_FACTORS"></a>Item 1A. Ris</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">k Factors. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">You should carefully consider the risks and uncertainties described below and the other information in this Annual Report on Form 10-K before making an investment in our common stock. Our business, financial condition, results of operations, or prospects could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our common stock could decline and you could lose all or part of your investment. This Annual Report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. See &#8220;Special Note Regarding Forward-Looking Statements.&#8221; Our actual results could differ materially and adversely from those anticipated in these forward-looking statements as a result of certain factors, including those set forth below. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Financial Position and Need for Additional Capital </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have a limited operating history and a history of escalating operating losses, which may make it difficult to evaluate the prospects for our future viability. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage therapeutics company established in November 2005. Our operations to date have been limited to financing and staffing our company, developing our technology, and identifying and developing our product candidates. Our prospects must be considered in light of the uncertainties, risks, expenses, and difficulties frequently encountered by companies in their early stages of operations. We have not yet demonstrated an ability to obtain marketing approval, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing, obtaining marketing approval for, and commercializing CRS treatments. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may encounter unforeseen expenses, difficulties, complications, delays, and other known and unknown obstacles. We will eventually need to transition from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we continue to build our business, we expect our financial condition and operating results may fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any particular quarterly or annual period as indications of future operating performance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have incurred significant losses since inception and expect to incur significant additional losses for the foreseeable future. We may never achieve or maintain profitability. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred significant operating losses in each year since our inception, including operating losses of approximately $22.1 million and $16.3&#160;million for the fiscal years ended December&#160;31, 2020 and December&#160;31, 2019, respectively. In addition, we have not commercialized any products and have never generated any revenue from product sales. We have devoted almost all of our financial resources to research and development, including our pre-clinical development activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we expect to continue to incur significant additional operating losses for the foreseeable future as we seek to advance product candidates through pre-clinical and clinical development, expand our research and development activities, develop new product candidates, complete pre-clinical studies and clinical trials, seek regulatory approval, and, if we receive FDA approval, commercialize our products. In order to obtain FDA approval of any product candidate, we must submit to the FDA an NDA demonstrating that the product candidate is safe for humans and effective for its intended use. This demonstration requires significant research and animal tests, which are referred to as non-clinical or pre-clinical studies, as well as human tests, which are referred to as clinical trials. Furthermore, the costs of advancing product candidates into each succeeding clinical phase tend to increase substantially over time. The total costs to advance any of our product candidates to marketing approval in even a single jurisdiction would be substantial. Because of the numerous risks and uncertainties associated with ENT disease treatment product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to begin generating revenue from the commercialization of products or achieve or maintain profitability. Our expenses will also increase substantially if and as we: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">continue additional clinical trials of our most advanced product candidate, LYR-210, including the characterization study for LYR-210 initiated in September 2020 to collect pharmacokinetic data and one or more planned pivotal Phase&#160;3 clinical trials of LYR-210; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">advance the development of LYR-220; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">continue to discover and develop additional product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">establish manufacturing and supply chain capacity sufficient to provide commercial quantities of any product candidates for which we may obtain marketing approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">seek regulatory and marketing approvals for product candidates that successfully complete clinical trials, if any; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain regulatory approval in geographies in which we plan to commercialize our products ourselves; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">maintain, expand, and protect our intellectual property portfolio; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">hire additional staff, including clinical, scientific, technical, regulatory, operational, financial, commercial, and support personnel, to execute our business plan; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">add clinical, scientific operational, financial, and management information systems and personnel to support our product development and potential future commercialization efforts, and as to enable us to operate as a public reporting company; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">utilize external vendors for support with respect to research, development, commercialization, regulatory, pharmacovigilance, and other functions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">acquire or in-license other commercial products, product candidates, and technologies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">expand internationally; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">make royalty, milestone, or other payments under any future in-license agreements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">implement additional internal systems and infrastructure; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">operate as a public company. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, our ability to successfully develop, commercialize, and license our products and generate product revenue is subject to substantial additional risks and uncertainties. Each of our product candidates will require additional pre-clinical and/or clinical development, potential regulatory approval in multiple jurisdictions, the securing of manufacturing supply, capacity, and expertise, the use of external vendors, the building of a commercial organization, substantial investment, and significant marketing efforts before we generate any revenue from product sales. As a result, we expect to continue to incur net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amount of future losses and when, if ever, we will achieve profitability are uncertain. We have no products that have generated any commercial revenue, do not expect to generate revenues from the commercial sale of products in the foreseeable future, and might never generate revenues from the sale of products. Our ability to generate revenue and achieve profitability will depend on, among other things, successful completion of the clinical development of our product candidates; obtaining necessary regulatory approvals from the FDA and international regulatory agencies; establishing manufacturing, sales, and market acceptance of our products and marketing infrastructure to commercialize our product candidates for which we obtain approval; and raising sufficient funds to finance our activities. We might not succeed at any of these undertakings. If we are unsuccessful at some or all of these undertakings, our business, prospects, and results of operations may be materially adversely affected. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will need significant additional funding in order to complete development of and obtain regulatory approval for our product candidates and commercialize our products, if approved. If we are unable to raise capital when needed, we could be forced to delay, reduce, or eliminate our product development programs or commercialization efforts. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will continue to need additional capital, which we may raise through equity offerings, debt financings, marketing, and distribution arrangements and other collaborations, strategic alliances, and licensing arrangements or other sources. Additional sources of financing might not be available on favorable terms, if at all. If we do not succeed in raising additional funds on acceptable terms, we might be unable to complete planned clinical trials or obtain approval of any of our product candidates from the FDA, or any foreign regulatory authorities, and could be forced to discontinue product development. In addition, attempting to secure additional financing may divert the time and attention of our management from day-to-day activities and harm our product candidate development efforts. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will require substantial funds to further develop, obtain approval for, and commercialize our product candidates, including LYR-210, for which we plan to commence one or more pivotal Phase 3 clinical trials. We will also require substantial funds to further develop, obtain approval for, and commercialize our other product candidate, LYR-220, which is in pre-clinical development. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on our current operating plan, we believe that our current cash and cash equivalents will be sufficient to enable us to fund our operating expenses and capital expenditure requirements into 2023. This estimate is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances could cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more than currently expected because of circumstances beyond our control. Because the length of time and activities associated with successful development of LYR-210 and LYR-220 is highly uncertain, we are unable to estimate the actual funds we will require for development, approval, and any approved marketing and commercialization activities. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the scope and results of our pre-clinical studies and clinical trials, including any unforeseen costs we may incur as a result of pre-clinical study or clinical trial delays due to the COVID-19 pandemic or other causes; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the timing of, and the costs involved in, obtaining regulatory approvals for LYR-210 and LYR-220; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the costs and timing of changes in the regulatory environment and enforcement rules; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the costs and timing in changes in pharmaceutical pricing and reimbursement infrastructure; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the costs involved in preparing, filing, prosecuting, maintaining, and enforcing patent claims and other patent-related costs, including any litigation costs and the results of such litigation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the effect of competing technological and market developments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the extent to which we in-license or acquire other products and technologies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the cost of establishing sales, marketing, and distribution capabilities for our product candidates in regions where we choose to commercialize our products; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the initiation, progress, timing, and results of our commercialization of LYR-210 and LYR-220, if approved for commercial sale. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending on our business performance, the economic climate, and market conditions, we may be unable to raise additional funds through any sources. Market volatility resulting from the COVID-19 pandemic or other causes could also adversely impact our ability to access capital as and when needed. If we are unable to obtain adequate funding on a timely basis, we may be required to curtail or discontinue one or more of our development programs for LYR-210 or LYR-220, or to reduce our operations. If we raise additional funds by issuing equity securities, our then-existing stockholders will experience dilution and the terms of any new equity securities may have preference over those of our existing common stock. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate substantial revenue, we may finance our cash needs through a combination of equity offerings, debt financings, marketing, and distribution arrangements and other collaborations, strategic alliances, and licensing arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our shareholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our operations and our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends, redeeming our stock, making certain investments, and engaging in certain merger, consolidation, or asset sale transactions, among other restrictions. If we raise additional funds through collaborations, strategic alliances, or marketing, distribution, or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams, or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have no approved products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have no approved product on the market and have generated no product revenues. Unless we receive approval from the FDA or other regulatory authorities for our product candidates, we will not have product revenues. Therefore, for the foreseeable future, we will have to fund all of our operations and capital expenditures from cash on hand and licensing fees and grants, if any. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our product candidates are in various stages of development. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a therapeutics company focused on the development and commercialization of novel integrated drug and drug delivery solutions for the localized treatment of patients with ENT diseases. Our product candidates are at stages of pre-clinical or clinical development, and favorable results in pre-clinical or early-stage clinical trials may not be predictive of success in later clinical trials and may not lead to commercially viable products for any of several reasons. For example, our product candidates may fail to be safe and effective in current or future clinical trials or pre-clinical studies, or we may have inadequate financial or other resources to pursue discovery and development efforts for new product candidates. Our product candidates will require significant additional development, clinical trials, regulatory authorizations, and additional investment by us before they can be commercialized. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our business is highly dependent on the success of our most advanced product candidate, LYR-210, which will require significant additional clinical testing before we can seek regulatory approval and potentially launch commercial sales. If LYR-210 does not receive regulatory approval or is not successfully commercialized, or is significantly delayed in doing so, our business will be harmed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A substantial portion of our business and future success depends on our ability to develop, obtain regulatory approval for, and successfully commercialize our most advanced product candidate, LYR-210. We currently have no products that are approved for commercial sale and have not completed the development of any product candidates, and may never be able to develop marketable products. We expect that a substantial portion of our efforts and expenditures over the next few years will be devoted to LYR-210, which will require additional clinical development and potential additional pre-clinical development, management of clinical and medical affairs and manufacturing activities, regulatory approval in multiple jurisdictions, the securing of manufacturing supply, the building of a commercial organization, substantial investment, and significant marketing efforts before we can generate any revenues from any commercial sales. We cannot be certain that LYR-210 will be successful in ongoing or future clinical trials, receive regulatory approval, or be successfully commercialized even if we receive regulatory approval. Even if we receive approval to market LYR-210 from the FDA or other regulatory bodies, we cannot be certain that our product candidates will be successfully commercialized, widely accepted in the marketplace, or more effective than other commercially available alternatives. Nor can we be certain that, if and when approved, the safety and efficacy profile of LYR-210 or our other product candidates will be consistent with the profiles observed in clinical trials. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We advanced LYR-210 through our Phase 2 randomized, controlled, patient blinded LANTERN clinical trial, evaluating the safety and efficacy in surgically-na&#239;ve CRS patients who have failed previous medical management. The trial was designed to enroll 99 evaluable patients with the potential to increase to up to 150 patients and was initiated in May 2019 at sites in Australia, Austria, Czech Republic, New Zealand, and Poland. In December 2019, the FDA authorized our investigational new drug application, and, prior to the COVID-19 pandemic, we planned to enroll patients in the United States. However, in light of developments relating to the COVID-19 global pandemic, as described below, we discontinued enrollment at 67&#160;patients in our Phase 2 LANTERN clinical trial and did not enroll any patients in the United States. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 7, 2020, we reported top-line results from our Phase 2 LANTERN clinical trial, including that LYR-210 failed to meet the primary endpoint of the trial. We believe this was primarily due to the discontinuation of enrollment related to the COVID-19 pandemic. As a result of the decrease in the number of patients enrolled from planned (99 evaluable)&#160;to actually enrolled (67)&#160;patients in our Phase 2 LANTERN clinical trial, a greater magnitude of change in composite score of the seven-day average of four cardinal symptoms from baseline at week 4 and/or a smaller standard deviation associated with the change from baseline at week 4 was required in order for the trial to achieve statistical significance for the primary endpoint. There can be no assurance that we will be able to design a Phase 3 clinical trial for LYR-210 with a primary endpoint we desire, and in any event there can be no assurance that we will achieve the primary endpoint or any other endpoints in any Phase 3 clinical trial we commence for LYR-210. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, while we leveraged remote electronic data collection to enable us to complete the clinical assessments and generate sufficient information in our Phase 2 LANTERN clinical trial to commence designing our Phase 3 clinical trial, there can be no assurance that the COVID-19 pandemic or other delays or disruptions will not hinder our electronic data collection or our ability to collect data or measurements requiring sinus imaging to assess reduction in inflammation and phlebotomy to assess pharmacokinetics/pharmacodynamics. For example, we were unable to enroll patients in our Phase 2 LANTERN clinical trial in the United States from whom we intended to collect certain additional pharmacokinetic data due to the COVID-19 pandemic, and as a result, we initiated a separate characterization study in September 2020, as a follow-on to our Phase 2 LANTERN clinical trial, in order to collect such data. There can be no assurance that this separate study or any future trial we may conduct will not be affected or further affected by the COVID-19 pandemic or other delays and disruptions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the required regulatory approvals for LYR-210 are not obtained or are significantly delayed, including as a result of the COVID-19 pandemic, or any approved products are not commercially successful, our business, financial condition, and results of operations may be materially harmed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LYR-210 is our most advanced product candidate, and if we experience regulatory or developmental issues with respect to LYR-210, our development plans and business could be significantly harmed. Moreover, if we experience similar regulatory or developmental issues with our other pipeline product candidates, our development plans and business could be significantly harmed. Further, our competitors may be developing products with similar mechanisms of action and may experience problems with their products that could identify problems that would potentially harm our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be successful in our efforts to identify and successfully commercialize additional product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Part of our strategy involves identifying novel product candidates. The process by which we identify product candidates may fail to yield product candidates for clinical development for a number of reasons, including those discussed in these risk factors and also: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we may not be able to assemble sufficient resources to acquire or discover additional product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">competitors may develop alternatives that render our potential product candidates obsolete or less attractive; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">potential product candidates we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">potential product candidates may, on further study, be shown to have harmful side effects, toxicities, or other characteristics that indicate that they are unlikely to be products that will receive marketing approval or achieve market acceptance; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">potential product candidates may not be effective in treating their targeted diseases or symptoms; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the market for a potential product candidate may change so that the continued development of that product candidate is no longer reasonable; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a potential product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the regulatory pathway for a potential product candidate is highly complex and difficult to navigate successfully or economically. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may choose to focus our efforts and resources on a potential product candidate that ultimately proves to be unsuccessful, or to license or purchase a marketed product that does not meet our financial expectations. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases that may later prove to have greater commercial potential, or relinquish valuable rights to such product candidates through collaboration, licensing, or other royalty arrangements in cases in which it would have been advantageous for us to retain sole development and commercialization rights. If we are unable to identify and successfully commercialize additional suitable product candidates, this would adversely impact our business strategy and our financial position. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to timely capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing, or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Discovery, Development, Clinical Testing, Manufacturing, and Regulatory Approval </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Clinical trials required for our product candidates are expensive and time-consuming, their outcome is uncertain, and if our clinical trials do not meet safety or efficacy endpoints in these evaluations, or if we experience significant delays in these trials, our ability to commercialize our product candidates and our financial position will be impaired. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to commence one or more pivotal Phase 3 clinical trials for our most advanced product candidate, LYR-210. Our other product candidate, LYR-220, is in pre-clinical development. It is impossible to predict when or if either of our product candidates will prove effective and safe in humans or if we will receive regulatory approval for any of our product candidates, and the risk of failure through the development process is high. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete pre-clinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical development is a long, expensive, and uncertain process that is subject to significant delays. Due to known or unknown circumstances beyond our control, it may take us several years to complete our testing, and failure can occur at any stage of testing. The outcome of pre-clinical testing and early clinical trials may not be predictive of the results of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. We cannot assure you that any clinical trial that we are conducting, or may conduct in the future, will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval to market our product candidates. Moreover, pre-clinical and clinical data are often susceptible to varying interpretations and analysis, and many companies that have believed their product candidates performed satisfactorily in pre-clinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delays associated with products for which we are directly conducting pre-clinical studies or clinical trials may cause us to incur additional operating expenses. The commencement and rate of completion of pre-clinical studies or clinical trials may be delayed by, or terminated because of, many factors, including: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our pre-clinical studies or clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">failure to obtain regulatory approval to commence a trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">failure to reach, or delays in reaching, an agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">slower than expected rates of recruitment of patients or failure to recruit a sufficient number of patients; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">modification of pre-clinical studies or clinical trial protocols; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">changes in regulatory requirements for pre-clinical studies or clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the impact of unusual placebo effects; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the lack of effectiveness during pre-clinical studies or clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the emergence of unforeseen safety issues or undesirable side effects; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">failure to obtain institutional review board, or the IRB, approval at each site; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">delays, suspension, or termination of clinical trials by the IRB responsible for overseeing the trial at a particular trial site; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">failure of patients in completing a trial or returning for post-treatment follow-up; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">clinical sites deviating from trial protocol, dropping out of a trial, or failing to comply with regulatory requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">failure to address patient safety concerns that arise during the course of a trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">failure to manufacture sufficient quantities of product candidate for use in clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">government, IRB, or other regulatory delays or &#8220;clinical holds&#8221; requiring suspension or termination of the trials; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">business interruptions resulting from the COVID-19 pandemic. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates or significantly increase the cost of such trials, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon development programs; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we may be unable to enroll a sufficient number of patients in our clinical trials to ensure adequate statistical power to detect any statistically significant treatment effects; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">regulators, IRBs, or independent ethics committees, or IECs, may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site or may require that we or our investigators suspend or terminate clinical trials of our product candidates for various reasons, including non-compliance with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics, or a finding that the participants are being exposed to unacceptable health risks; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we may experience delays in reaching or fail to reach agreement on acceptable pre-clinical study or clinical trial contracts or pre-clinical study or clinical trial protocols with prospective trial sites; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the cost of pre-clinical studies or clinical trials of our product candidates may be greater than we anticipate and we may not have funds to cover the costs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the supply or quality of our product candidates or other materials necessary to conduct pre-clinical studies or clinical trials of our product candidates may be insufficient or inadequate; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any current or future collaborators that conduct pre-clinical studies or clinical trials may face any of the above issues, and may conduct pre-clinical studies or clinical trials in ways they view as advantageous to them but that are suboptimal for us. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are required to extend the duration of current pre-clinical studies or clinical trials or to conduct additional pre-clinical studies or clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete pre-clinical studies or clinical trials of our product candidates or other testing, if the results of these trials, studies, or tests are not positive or are only modestly positive, if there are safety concerns, or if we determine that the observed safety or efficacy profile would not be competitive in the marketplace, we may: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">incur unplanned costs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">be delayed in obtaining marketing approval for our product candidates or not obtain marketing approval at all; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">obtain marketing approval in some countries and not in others; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">obtain marketing approval for indications or patient populations that are not as broad as intended or desired; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">obtain marketing approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">be subject to additional post-marketing testing requirements; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">have the product removed from the market after obtaining marketing approval. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We could encounter delays if a clinical trial is materially modified, suspended, or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the Data Safety Monitoring Board, or DSMB, for such trial, or by the FDA or other regulatory authorities. Such authorities may impose a material modification, suspension, or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects for our product candidates, or other products or product candidates in the same drug class, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions, or lack of adequate funding to continue the clinical trial. Furthermore, we may rely on CROs and clinical trial sites to ensure the proper and timely conduct of clinical trials and while we would have agreements governing their committed activities, we would have limited influence over their actual performance, as described in &#8220;&#8212;Risks Related to Our Dependence on Third Parties.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our most advanced product candidate, LYR-210, is in clinical development and will require the completion of clinical testing before we are prepared to submit an NDA for regulatory approval. Further, there can be no assurance that the separate clinical trial initiated in September 2020 to collect pharmacokinetic data will not experience delays that impact this timeline. We cannot predict if or when we might complete the development of LYR-210 and submit an NDA or whether any such NDA will be approved by the FDA. We may also seek feedback from the FDA or other regulatory authorities on our clinical development programs, and the FDA or such regulatory authorities may not provide such feedback on a timely basis, or such feedback may not be favorable, which could further delay our development programs. If the results of ongoing and future clinical trials for LYR-210 are positive, we plan to submit an NDA in the United States. However, no assurance can be given that we will be successful in the near term, obtain regulatory approval, or have any commercial sales of LYR-210. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any clinical test may fail to produce results satisfactory to the FDA or foreign regulatory authorities. For example, our Phase 2 LANTERN clinical study for LYR-210 did not meet its primary endpoint and the FDA may not find such result to be sufficient to advance to a Phase 3 pivotal study. Pre-clinical and clinical data can be interpreted in different ways by different reviewers and regulators, which could delay, limit, or prevent regulatory approval. Drug-related adverse events during a pre-clinical study or clinical trial could cause us to repeat a trial or study, perform an additional trial or study, expand the size and/or duration of a trial or study, terminate a trial or study, or even cancel a pre-clinical or clinical program. The failure of pre-clinical studies or clinical trials to demonstrate safety and effectiveness for the desired indications could harm the development of that product candidate and other product candidates. This failure could cause us to abandon a product candidate and could delay development of other product candidates. Any delay in, or termination of, our clinical trials would delay the filing of our NDAs with the FDA and, ultimately, our ability to commercialize our product candidates and generate product revenues. A number of companies in the biotechnology and pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Even if our future and ongoing pre-clinical studies and clinical trials are completed as planned, we cannot be certain that their results will support the safety and effectiveness of LYR-210, LYR-220, and/or any future product candidate. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we experience delays in the commencement or completion of, or have to extend or expand, our pre-clinical studies or clinical trials, or if we terminate a pre-clinical study or clinical trial prior to completion, the commercial prospects of LYR-210, LYR-220, or any future product candidate could be harmed, and our ability to generate revenues from LYR-210, LYR-220, or any future product candidate may be delayed. In addition, any delays in our pre-clinical studies or clinical trials could increase our costs, slow down the development and approval process, and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition, and results of operations. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of pre-clinical studies or clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our pre-clinical studies and clinical trials may fail to demonstrate adequately the safety and efficacy of any of our product candidates and the development of our product candidates may be delayed or unsuccessful, which could prevent or delay regulatory approval and commercialization. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Both of our current product candidates are in clinical or pre-clinical development stages. Notwithstanding the data obtained to date with respect to LYR-210 and LYR-220 in CRS, LYR-210 and LYR-220 will require additional clinical and non-clinical development, regulatory review and approval in multiple jurisdictions, substantial investment, access to sufficient commercial manufacturing capacity, and significant marketing efforts before we can generate any revenue from our product sales. In addition, if we encounter safety or efficacy problems, developmental delays or regulatory issues, delays caused by the COVID-19 pandemic, or other problems, our developmental plans and business could be significantly harmed. For example, our Phase 2 LANTERN clinical trial for LYR-210 failed to meet its primary endpoint which may delay our overall commercialization efforts. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the development of LYR-210, LYR-220, or any other future product candidate is unsuccessful, our ability to generate revenues will be adversely affected. Our development of current and future product candidates is subject to the risks of failure and delay inherent in the development of new products and product candidates, including: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">delays in product development, pre-clinical, or clinical testing or manufacturing; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">unplanned expenditures in product development, pre-clinical, or clinical testing or manufacturing; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">failure to receive regulatory approvals; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">failure to secure rights from third parties for new technology; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">failure to achieve market acceptance; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">emergence of superior or equivalent products. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, product candidates in later stages of clinical trials may fail to show the desired safety profiles and efficacy results despite having progressed through pre-clinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Based upon negative or inconclusive results, we may decide, or regulators may require us, to conduct additional clinical trials or pre-clinical studies. In addition, data obtained from trials and studies are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may delay, limit, or prevent regulatory approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we have not conducted, nor do we believe we are required to conduct, any head-to-head trials comparing LYR-210 to other approved or experimental treatments for CRS. Any such head-to-head trial, if conducted, may show that LYR-210 is not more effective than any of such other drugs. Material adverse differences in the relative efficacy of LYR-210 could significantly harm the adoption of LYR-210 and our business prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of these risks, our research and development efforts may not result in any commercially viable products. If a significant portion of these development efforts are not successfully completed, required regulatory approvals are not obtained, or any approved products are not commercially successful, our business, financial condition, and results of operations may be materially harmed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Success in pre-clinical or earlier clinical trials may not be indicative of results in future clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Success in pre-clinical studies and early clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate. Pre-clinical studies and Phase 1 and Phase 2 clinical trials are primarily designed to test safety, study pharmacokinetics and pharmacodynamics, and understand the side effects of product candidates at various doses and schedules. Success in pre-clinical studies and early clinical trials does not ensure that later, large-scale efficacy trials will be successful nor does it predict final results. Our product candidates may fail to show the desired safety and efficacy in clinical development despite positive results in pre-clinical studies or having successfully advanced through initial clinical trials. For example, our Phase 2 LANTERN clinical trial for LYR-210 failed to meet its primary endpoint and we may be required to conduct additional trials to evaluate the efficacy<font style="font-size:12pt;"> </font>of this product candidate beyond those trials we currently anticipate. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. As an organization, we have limited experience designing clinical trials and may be unable to design and execute a clinical trial to support regulatory approval. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in pre-clinical studies and earlier-stage clinical trials. Data obtained from pre-clinical and clinical activities are subject to varying interpretations, which may delay, limit, or prevent regulatory approval. In addition, we may experience regulatory delays or rejections as a result of many factors, including changes in regulatory policy during the period of our product candidate development. Any such delays could negatively impact our business, financial condition, results of operations, and prospects. </p><a name="_AEIOULastRenderedPageBreakAEIOU10"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If the FDA does not conclude that certain of our product candidates satisfy the requirements for the Section&#160;505(b)(2) regulatory approval pathway, or if the requirements for such product candidates under Section&#160;505(b)(2) are not as we expect, the approval pathway for those product candidates may likely take significantly longer, cost significantly more, and entail significantly greater complications and risks than anticipated, and in either case may not be successful. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to seek FDA approval for our current product candidates, LYR-210 and LYR-220, and we may seek FDA approval for future product candidates, through the Section&#160;505(b)(2) regulatory pathway. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Amendments, added Section&#160;505(b)(2) to the Federal Food, Drug and Cosmetic Act, or FDCA. Section&#160;505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from trials that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference. Section&#160;505(b)(2), if applicable to us under the FDCA, would allow an NDA we submit to the FDA to rely in part on data in the public domain or the FDA&#8217;s prior conclusions regarding the safety and effectiveness of approved drugs, which could expedite the development program for our product candidates by potentially decreasing the amount of clinical data that we would need to generate in order to obtain FDA approval. If the FDA does not allow us to pursue the Section&#160;505(b)(2) regulatory pathway as we anticipate, we may need to conduct additional clinical trials, provide additional data and information, and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required to obtain FDA approval for our product candidates, and complications and risks associated with the development of our product candidates, would likely substantially increase. Moreover, inability to pursue the Section&#160;505(b)(2) regulatory pathway could result in competitive products reaching the market before our product candidates, which could impact our competitive position and prospects. Even if we are allowed to pursue the Section&#160;505(b)(2) regulatory pathway, we cannot assure you that our product candidates will receive the requisite approvals for commercialization, or that a competitor would not obtain approval first along with subsequent market exclusivity from the FDA, thereby delaying potential approval of our product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the pharmaceutical industry is highly competitive, and Section&#160;505(b)(2) NDAs are subject to special requirements designed to protect the patent rights of sponsors of previously approved drugs that are referenced in a Section&#160;505(b)(2) NDA. These requirements may give rise to patent litigation and mandatory delays in approval of our NDAs for up to 30 months or longer depending on the outcome of any litigation. It is not uncommon for a manufacturer of an approved product to file a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements for, pending competing products. If successful, such petitions can significantly delay, or even prevent, the approval of the new product. However, even if the FDA ultimately denies such a petition, the FDA may substantially delay approval while it considers and responds to the petition. In addition, even if we are able to utilize the Section&#160;505(b)(2) regulatory pathway, there is no guarantee this would ultimately lead to accelerated product development or earlier approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, even if our product candidates are approved under Section&#160;505(b)(2), the approval may be subject to limitations on the indicated uses for which the products may be marketed or to other conditions of approval, or may contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have conducted, are conducting, and, in the future, may conduct clinical trials for our product candidates in sites outside the United States, and the FDA may not accept data from trials conducted in foreign locations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have conducted and are conducting clinical trials for LYR-210 outside the United States, specifically in Australia, Austria, Czech Republic, New Zealand, and Poland, and we may in the future choose to conduct other clinical trials outside the United States for LYR-210, LYR-220, or any of our other future product candidates. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with good clinical practice, or GCP, including review and approval by an IEC and receipt of informed consent from subjects. In general, the patient population for any clinical trials conducted outside of the United States must be representative of the population for which we intend to seek approval for the product in the United States. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will be dependent upon its determination that the trials also complied with all applicable U.S. laws and regulations. There can be no assurance the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept the data from our clinical trials of our product candidates, it would likely result in the need for additional trials, which would be costly and time-consuming and delay or permanently halt our development of our product candidates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, there are risks inherent in conducting clinical trials in multiple jurisdictions, inside and outside of the United States, such as: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">regulatory and administrative requirements of the jurisdiction where the trial is conducted that could burden or limit our ability to conduct our clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">foreign exchange fluctuations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">manufacturing, customs, shipment, and storage requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">cultural differences in medical practice and clinical research; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the risk that the patient populations in such trials are not considered representative as compared to the patient population in the target markets where approval is being sought. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interim and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may publish interim or preliminary data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Interim or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Differences between interim or preliminary data and final data could significantly harm our business prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">LYR-210 and LYR-220 are drug-device combinations, which may result in additional regulatory and other risks. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LYR-210 and LYR-220 are drug-device combination products. We may experience delays in obtaining regulatory approval of these product candidates given the increased complexity of the review process when approval of a drug and a delivery device is sought under a single marketing application. Both LYR-210 and LYR-220 will be regulated as drug-device combination products, which require coordination within the FDA and similar foreign regulatory agencies for review of the product candidates&#8217; device and drug components. The determination whether a combination product requires a single marketing application or two separate marketing applications for each component is made by the FDA on a case-by-case basis. Although we believe a single marketing application for the approval of a combination product would be successful, there can be no assurance that the FDA will not determine that separate marketing applications are necessary. This determination could significantly increase the resources and time required to bring a particular combination product to market. Although the FDA and similar foreign regulatory agencies have systems in place for the review and approval of combination products such as ours, we may experience delays in the development and commercialization of our product candidates due to regulatory timing constraints and uncertainties in the product development and approval process, as well as coordination between two different centers within FDA responsible for review of the different components of the combination product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to successfully develop or supply the device component, delays in or failure of the studies conducted by us, our collaborators, or third-party providers, or failure of our Company, our collaborators, or third-party providers to obtain or maintain regulatory approval or clearance of the device component of LYR-210 or LYR-220, as appropriate, could result in increased development costs, delays in or failure to obtain regulatory approval, and associated delays in these product candidates reaching the market. Further, failure to successfully develop or supply the device, or to gain or maintain its approval, could adversely affect sales of LYR-210 and LYR-220. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to obtain the necessary U.S. regulatory approvals to commercialize any product candidate, we will not be able to generate revenue in the U.S. market. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot assure you that we will receive the approvals necessary to commercialize our product candidates, or any product candidate we acquire or develop in the future. We will need FDA approval to commercialize our product candidates in the United States and approvals from equivalent regulatory authorities in foreign jurisdictions to commercialize our product candidates in those jurisdictions. Satisfaction of the FDA&#8217;s regulatory requirements typically takes many years, depends upon the type, complexity, and novelty of the product candidate, and requires substantial resources for research, development, and testing. We cannot predict whether our research and clinical efforts will result in drugs that the FDA will determine are safe for humans and effective for their intended uses. The FDA has substantial discretion in the drug approval process and may require us to conduct additional pre-clinical and clinical testing, perform post-marketing studies, address manufacturing concerns, or otherwise limit or impose conditions on any approval we obtain. The approval process may also be delayed by changes in government regulation, the impact of the COVID-19 pandemic, future legislation or administrative action, or changes in FDA policy that occur prior to or during our regulatory review. Delays in obtaining regulatory approvals may: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">delay commercialization of, and our ability to derive product revenues from, our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">impose costly procedures on us; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">diminish any competitive advantages that we may otherwise enjoy. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we receive approval of an NDA or comparable foreign regulatory filing for our product candidates, the FDA or the applicable foreign regulatory body may approve our product candidates for a more limited indication than we originally requested, and the FDA may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we comply with all FDA requests, the FDA may ultimately reject one or more of our NDAs. We cannot be sure that we will ever obtain regulatory clearance for our product candidates. Failure to obtain FDA approval of our product candidates will severely undermine our business by leaving us without a commercially available product, and therefore without any source of revenues, until another product candidate can be developed or obtained and ultimately approved. There is no guarantee that we will ever be able to develop or acquire another product candidate or that we will be able to obtain FDA approval to commercialize such product candidate. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we obtain FDA approval for our product candidates in the United States, we may never obtain approval for or commercialize them in any other jurisdiction, which would limit our ability to realize their full market potential. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend, either on our own or through collaborations or partnerships, to market our products in international markets. In order to market any products in the European Union and many other foreign jurisdictions, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy. Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional pre-clinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, costly, time-consuming, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. We cannot predict when or if, and in which territories, we, or any of our potential future collaborators, will obtain marketing approval to commercialize a product candidate. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including substantial discretion of regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that neither LYR-210, LYR-220, nor any future product candidates we may seek to develop in the future will ever obtain regulatory approval. Neither we nor any future collaborator is permitted to market any of our product candidates in the United States until we receive regulatory approval of an NDA from the FDA. It is possible that the FDA may refuse to accept for substantive review any NDAs that we submit for our product candidates or may conclude after review of our data that our application is insufficient to obtain marketing approval of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or foreign regulatory agencies, that such product candidates are safe and effective for their intended uses in patients. Results from non-clinical studies and clinical trials can be interpreted in different ways. Even if we believe the non-clinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. The FDA may also require us to conduct additional pre-clinical studies or clinical trials for our product candidates either prior to or post-approval, or it may object to elements of our clinical development program. Depending on the extent of these or any other FDA-required studies, approval of any NDA or other application that we submit may be delayed by several years, or may require us to expend significantly more resources than we have available. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the large number of potential products in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy and costly approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations, and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authorities may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authorities, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Separately, in response to the COVID-19 pandemic, on March&#160;10, 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities and products through April 2020, and on March&#160;18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July&#160;10, 2020, the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic, including providing guidance regarding the conduct of clinical trials. If global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we encounter delays or difficulties enrolling patients in our clinical trials, our clinical development activities and receipt of regulatory approvals could be delayed or otherwise adversely affected. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. For example, we were unable to enroll patients in our Phase 2 LANTERN clinical trial in the United States from whom we intended to collect certain additional pharmacokinetic data due to the COVID-19 pandemic, and, as a result, we initiated a separate characterization study in September 2020 as a follow-on to our Phase 2 LANTERN clinical trial in order to collect such data. Trials may be subject to delays as a result of patient enrollment taking longer than anticipated or patient withdrawal. We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled we may be unable to retain a sufficient number of patients to complete any of our trials. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. We cannot predict how successful we will be at enrolling subjects in future clinical trials. The enrollment of patients depends on many factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the patient eligibility criteria defined in the protocol; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the proximity of patients to trial sites; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the design of the trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the perceived risks and benefits of the product candidate in the trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the availability of alternative therapies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to obtain and maintain patient consents; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the risk that patients enrolled in clinical trials will drop out of the trials before completion; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the impact of the ongoing COVID-19 pandemic. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials in such clinical trial site. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delays or failures in planned patient enrollment or retention may result in increased costs, program delays, or both, which could have a harmful effect on our ability to develop LYR-210, LYR-220, and/or any other future product candidates, or could render further development impossible. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our product candidates may cause serious adverse events or undesirable side effects including injury and death or have other properties which may delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval. If any of our product candidates receives marketing approval and we, or others, later discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability, or that of any potential future collaborators, to market the drug could be compromised. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex, and expensive pre-clinical testing and clinical trials that our product candidates are both safe and effective for use in each target indication, and failures can occur at any stage of testing. Clinical trials often fail to demonstrate safety and efficacy of the product candidate studied for the target indication. Serious adverse events, or SAEs, or undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Results of our clinical trials or pre-clinical studies could reveal a high and unacceptable severity and prevalence of side effects, toxicities, or unexpected characteristics, including death. For example, in our Phase 1 clinical trial for our most advanced product candidate, LYR-210, there was one SAE in the active group (acute myocardial infarction), which was considered not related to LYR-210. For more information, see &#8220;Business&#8212;LYR-210 for the Treatment of CRS&#8212;Overview of Our Clinical Development.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, subjects treated with LYR-210 have experienced adverse events, including epistaxis, rhinitis, rhinorrhea, facial pain, nasopharyngitis, sinusitis, upper respiratory tract infection, procedural headache, nasal discomfort, and nasal odor, among others. In our Phase 2 LANTERN clinical trial, treatment-related adverse events were reported in 16 patients, and all treatment-related adverse events except one (increased viscosity of upper respiratory secretion) were mild or moderate in nature. In addition, there was one patient who had a serious adverse event of Acarodermatitis in our Phase 2 LANTERN clinical trial, which was deemed to be not related to treatment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If unacceptable side effects arise in the development of our product candidates, we, the FDA, the IRBs at the institutions in which our studies are conducted, or DSMB, could materially modify, suspend, or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease pre-clinical studies or clinical trials, require us to conduct additional animal or human studies regarding the safety and efficacy of our product candidates which we have not planned or anticipated, or deny approval of our product candidates for any or all targeted indications. Many product candidates that initially showed promise in early-stage testing have later been found to cause side effects that prevented further development of the product candidate. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We currently train and expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition, and prospects significantly. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by any such product, including during any long-term follow-up observation period recommended or required for patients who receive treatment using our products, a number of potentially significant negative consequences could result, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">regulatory authorities may withdraw approvals of such product; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we may be required to recall a product or change the way such product is administered to patients; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">regulatory authorities may require additional warnings on the label, such as a &#8220;black box&#8221; warning or contraindication; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">regulatory authorities may require long-term patient registries for the product; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for distribution to patients; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the product could become less competitive; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we could be sued and held liable for harm caused to patients; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our reputation may suffer. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There can be no assurance that we will resolve any issues related to any product-related adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or at all. Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations, and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As product candidates proceed through pre-clinical studies to late-stage clinical trials towards potential approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. Such changes may also require additional testing, FDA notification or FDA approval. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commence sales and generate revenue. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include general liability, employment practices liability, and property, auto, workers&#8217; compensation, umbrella, and directors&#8217; and officers&#8217; insurance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any additional product liability insurance coverage we acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If we obtain marketing approval for LYR-210 and/or LYR-220, we intend to acquire insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. A successful product liability claim or series of claims brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business, including preventing or limiting the development and commercialization of any product candidates we develop. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty, and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating as a public company has made it more difficult and more expensive for us to obtain director and officer liability insurance, and in the future we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our board of directors, our board committees, or as executive officers. We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our cash position and results of operations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties we may engage in connection with research, development, regulatory, manufacturing, quality assurance, and other pharmaceutical functions and commercialization may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Misconduct by our employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties we may engage in connection with research, development, regulatory, manufacturing, quality assurance, and other pharmaceutical functions and commercialization, could include intentional, reckless, or negligent conduct or unauthorized activities that violate: (i)&#160;the laws and regulations of the FDA, the European Medicines Agency, or the EMA, and other similar regulatory authorities, including those laws that require the reporting of true, complete, and accurate information to such authorities; (ii)&#160;manufacturing standards; (iii)&#160;data privacy, security, fraud and abuse, and other healthcare laws and regulations; or (iv)&#160;laws that require the reporting of true, complete, and accurate financial information and data. Specifically, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of pre-clinical studies or clinical trials, creation of fraudulent data in pre-clinical studies or clinical trials, or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal, and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our business and operations would suffer in the event of system failures. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our computer systems, as well as those of our CROs and other contractors, vendors, suppliers, and consultants, are vulnerable to damage from computer viruses, unauthorized access, natural disasters (including hurricanes), terrorism, war, and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product candidate development programs and our business. For example, the loss of pre-clinical studies or clinical trial data from completed, ongoing, or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential, or proprietary information, we could incur liability and the further development of LYR-210, LYR-220, or any other product candidate could be delayed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of our business, we directly or indirectly collect and store sensitive data, including intellectual property, confidential information, pre-clinical and clinical trial data, proprietary business information, personal data, and personally identifiable health information of our clinical trial subjects and employees, in our data centers and on our networks, or on those of third parties. The secure processing, maintenance, and transmission of this information is critical to our operations. Despite our security measures, our information technology and infrastructure has been and, from time to time, may be vulnerable to attacks by hackers or internal bad actors, or breached due to employee error, a technical vulnerability, malfeasance, or other disruptions. For example, companies have experienced an increase in phishing and social engineering attacks from third parties in connection with the COVID-19 pandemic. Although, to our knowledge, we have not experienced any material security breach to date, any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost, or stolen. Any such access, disclosure, or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, or significant regulatory penalties, and such an event could disrupt our operations, damage our reputation, and cause a loss of confidence in us and our ability to conduct clinical trials, which could adversely affect our business reputation and delay our clinical development of our product candidates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Healthcare Laws and Other Legal Compliance Matters </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will be subject to extensive and costly government regulation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product candidates employing our technology will be subject to extensive and rigorous domestic government regulation including regulation by the FDA, the Centers for Medicare and Medicaid Services, or CMS, other divisions of the United States Department of Health and Human Services, the United States Department of Justice, state and local governments, and their respective equivalents outside of the United States. The FDA regulates the research, development, pre-clinical and clinical testing, manufacture, safety, effectiveness, record-keeping, reporting, labeling, packaging, storage, approval, advertising, promotion, sale, distribution, import, and export of pharmaceutical products. If products employing our technologies are marketed abroad, they will also be subject to extensive regulation by foreign governments, whether or not they have obtained FDA approval for a given product and its uses. Such foreign regulation may be equally or more demanding than corresponding United States regulation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government regulation substantially increases the cost and risk of researching, developing, manufacturing, and selling our products. The regulatory review and approval process, which includes pre-clinical testing and clinical trials of each product candidate, is lengthy, expensive, and uncertain. We or our collaborators must obtain and maintain regulatory authorization to conduct pre-clinical studies and clinical trials. We or our collaborators must obtain regulatory approval for each product we intend to market, and the manufacturing facilities used for the products must be inspected and meet legal requirements. Securing regulatory approval requires the submission of extensive pre-clinical and clinical data and other supporting information for each proposed therapeutic indication in order to establish the product&#8217;s safety and efficacy, potency, and purity, for each intended use. The development and approval process takes many years, requires substantial resources, and may never lead to the approval of a product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we are able to obtain regulatory approval for a particular product, the approval may limit the indicated medical uses for the product, may otherwise limit our ability to promote, sell, and distribute the product, may require that we conduct costly post-marketing surveillance, and/or may require that we conduct ongoing post-marketing studies. Material changes to an approved product, such as, for example, manufacturing changes or revised labeling, may require further regulatory review and approval. Once obtained, any approvals may be withdrawn, including, for example, if there is a later discovery of previously unknown problems with the product, such as a previously unknown safety issue. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we, our collaborators, consultants, contract manufacturers, CROs, or other vendors fail to comply with applicable regulatory requirements at any stage during the regulatory process, such noncompliance could result in, among other things, delays in the approval of applications or supplements to approved applications; refusal of a regulatory authority, including the FDA, to review pending market approval applications or supplements to approved applications; warning letters; fines; import and/or export restrictions; product recalls or seizures; injunctions; total or partial suspension of production; civil penalties; withdrawals of previously approved marketing applications or licenses; recommendations by the FDA or other regulatory authorities against governmental contracts; and/or criminal prosecutions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and could adversely affect our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the EU, and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could prevent or delay marketing approval of our products in development, restrict or regulate post-approval activities involving any product candidates for which we obtain marketing approval, impact pricing and reimbursement, and impact our ability to sell any such products profitably. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. In addition, new regulations and interpretations of existing healthcare statutes and regulations are frequently adopted. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents (other than those designated as orphan drugs), which is apportioned among these entities according to their market share in certain government healthcare programs; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">new requirements to report certain financial arrangements with physicians and teaching hospitals, including reporting &#8220;transfers of value&#8221; made or distributed to prescribers and other healthcare providers and reporting investment interests held by physicians and their immediate family members; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">extension of a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">establishment of a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. On March&#160;2, 2020, the U.S. Supreme Court granted the petitions for writs of certiorari to review the constitutionality of the ACA, although it is unclear when or how the Supreme Court will rule. It is also unclear how other efforts to challenge, repeal, or replace the ACA will impact the law and may impact our business or financial condition. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011 resulted in aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the temporary suspension from May&#160;1, 2020 through December&#160;31, 2020, unless additional action is taken by Congress. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers, and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws or any other similar laws introduced in the future may result in additional reductions in Medicare and other healthcare funding, which could negatively affect our customers and accordingly, our financial operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and review the relationship between pricing and manufacturer patient programs. While any proposed measures will require authorization through additional legislation to become effective, Congress has indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally-mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition, and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the EU, similar political, economic, and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of healthcare and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU&#160;member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities, and affect our ability to commercialize our product candidates, if approved. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In markets outside of the United States and the EU, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA&#8217;s regulations, guidance, or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative action in the United States, the EU, or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, and advertising and promotional activities for such product, among other things, will be subject to extensive and ongoing requirements of and review by the FDA, the EMA, and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug listing requirements, continued compliance with current good manufacturing practice, or cGMP, requirements relating to manufacturing, quality control, quality assurance, and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians, and recordkeeping and GCP requirements for any clinical trials that we conduct post-approval. In addition, the sponsor of an approved NDA is subject to periodic inspections and other FDA monitoring and reporting obligations, including obligations to monitor and report adverse events and other information such as the failure of a product to meet the specifications in the NDA. NDA sponsors must submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling, or manufacturing process. Application holders must also submit advertising and other promotional material to the FDA and report on ongoing clinical trials. The FDA may require changes in the labeling of already approved drug products and require that sponsors conduct post-marketing studies. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including the requirement to implement a REMS, which could include requirements for a medication guide, physician communication plans, or additional elements to ensure safe use, such as restricted distribution methods, patient registries, and other risk mitigation tools. If any of our product candidates receives marketing approval, the accompanying label may limit the approved use of our product, which could limit sales of the product. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of our approved products. In addition, advertising and promotional materials must comply with FDA rules in addition to other potentially applicable federal and state laws. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use, and if we market our products outside of their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the FDA&#8217;s restrictions relating to the promotion of prescription products may also lead to investigations alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The distribution of product samples to physicians must comply with the requirements of the FDCA. NDA sponsors must obtain FDA approval for product, manufacturing, and labeling changes, depending on the nature of the change. Depending on the circumstances, failure to meet these post-approval requirements can result in criminal prosecution, fines, injunctions, consent decrees of permanent injunction, recall or seizure of products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals, or refusal to allow us to enter into supply contracts, including government contracts. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers, or manufacturing processes, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">restrictions on manufacturing such products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">restrictions on the labeling or marketing of a product; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">restrictions on product distribution or use; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">requirements to conduct post-marketing studies or clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">warning letters or holds on clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">withdrawal of the products from the market; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">refusal to approve pending applications or supplements to approved applications that we submit; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">recall of products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">fines, restitution, or disgorgement of profits or revenues; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">suspension or withdrawal of marketing approvals; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">refusal to permit the import or export of our products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">product seizure or detention; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">injunctions or the imposition of civil or criminal penalties. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenues. If regulatory sanctions are applied or if regulatory approval is withheld or withdrawn, the value of our company and our operating results will be adversely affected. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA&#8217;s policies may change and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of LYR-210, LYR-220, and/or any other future product candidate. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained which would adversely affect our business, prospects, and ability to achieve or sustain profitability. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in funding for the&#160;FDA&#160;and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of the&#160;FDA&#160;to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disruptions at the&#160;FDA&#160;and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business.&#160;For example, over the last several years, including for 35 days beginning on December&#160;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the&#160;FDA, have had to furlough critical&#160;employees and stop critical activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Separately, in response to the COVID-19 pandemic, on March&#160;10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities and products through April 2020, and on March&#160;18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July&#160;10, 2020, the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic, including providing guidance regarding the conduct of clinical trials. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns or delays could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell, and distribute our product candidates, if approved. Such laws include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving, or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order, or recommendation of, any good, facility, item, or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the U.S. federal civil and criminal false claims laws, including the civil False Claims Act, which, among other things, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using, or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease, or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the federal civil monetary penalties laws, which impose civil fines for, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items, or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics, and medical devices; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the U.S. Physician Payments Sunshine Act and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics, and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the government information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members. Beginning in 2022, such obligations will include payments and other transfers of value provided in the previous year to certain other healthcare professionals, including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse midwives; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales, and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws that require the registration of pharmaceutical sales representatives; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">similar healthcare laws and regulations in the EU and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including our relationships with physicians and other healthcare providers, some of whom are compensated in the form of stock options for consulting services provided, may not comply with current or future statutes, regulations, agency guidance, or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal, and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil, or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming, and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are subject to governmental regulation and other legal obligations, particularly related to privacy, data protection, and information security, and we are subject to consumer protection laws that regulate our marketing practices and prohibit unfair or deceptive acts or practices. Our actual or perceived failure to comply with such obligations could harm our business. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and our partners may be subject to diverse laws and regulations relating to data privacy and security, including, in the United States, HIPAA and, in the EU and the European Economic Area, or EEA, the General Data Protection Regulation, or the GDPR. New privacy rules are being enacted in the United States and globally, and existing ones are being updated and strengthened. For example, on June&#160;28, 2018, California enacted the California Consumer Privacy Act, or CCPA, which took effect on January&#160;1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Complying with these numerous, complex, and often changing regulations is expensive and difficult, and failure to comply with any privacy laws or data security laws or any security incident or breach involving the misappropriation, loss, or other unauthorized use or disclosure of sensitive or confidential patient or consumer information, whether by us or another third-party, could adversely affect our business, financial condition, and results of operations, including but not limited to: investigation costs, material fines and penalties; compensatory, special, punitive, and statutory damages; litigation; consent orders regarding our privacy and security practices; requirements that we provide notices, credit monitoring services, and/or credit restoration services or other relevant services to impacted individuals; adverse actions against our licenses to do business; and injunctive relief. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Europe, the GDPR went into effect on May&#160;25, 2018. The GDPR requires us, among other things, to make detailed disclosures to data subjects, to disclose the legal basis on which we can process personal data, to obtain valid consent for processing, to appoint data protection officers when sensitive personal data, such as health data, is processed on a large scale, and provides robust rights for data subjects, introduces mandatory data breach notification, imposes additional obligations on us when contracting with service providers, and requires us to adopt appropriate privacy governance including policies, procedures, training, and data audit. In addition, the GDPR increases the scrutiny of transfers of personal data from clinical trial sites located in the EEA to the United States and other jurisdictions that the European Commission does not recognize as having &#8220;adequate&#8221; data protection laws; in July 2020, the Court of Justice of the European Union limited how organizations could lawfully transfer personal data from the EEA to the United States by invalidating the EU-US Privacy Shield and imposing further restrictions on use of the standard contractual clauses, which could increase our costs and our ability to efficiently process personal data from the EEA. If we do not comply with our obligations under the GDPR, we could be exposed to fines of up to the greater of &#8364;20&#160;million or up to 4% of our total global annual revenue in the event of a significant breach. In addition, we may be the subject of litigation and/or adverse publicity, which could adversely affect our business, results of operations, and financial condition. Additionally, following the United Kingdom&#8217;s withdrawal from the EEA and the EU, and the expiry of the transition period, companies will have to comply with the GDPR and the GDPR as incorporated into United Kingdom national law, the latter regime having the ability to separately fine up to the greater of &#163;17.5&#160;million or 4% of global turnover. The relationship between the United Kingdom and the EU in relation to certain aspects of data protection law remains unclear, for example around how data can lawfully be transferred between each jurisdiction, which exposes us to further compliance risk. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot assure you that our third-party service providers with access to our or our customers&#8217;, suppliers&#8217;, trial patients&#8217;, and employees&#8217; personally identifiable and other sensitive or confidential information in relation to which we are responsible will not breach contractual obligations imposed by us, or that they will not experience data security breaches or attempts thereof, which could have a corresponding effect on our business, including putting us in breach of our obligations under privacy laws and regulations and/or which could in turn adversely affect our business, results of operations, and financial condition. We cannot assure you that our contractual measures and our own privacy and security-related safeguards will protect us from the risks associated with the third-party processing, storage, and transmission of such information. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We face potential liability related to the privacy of health information we obtain from clinical trials sponsored by us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or the HITECH Act. We are not currently classified as a covered entity or business associate under HIPAA and thus are not subject to its requirements or penalties. However, any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HIPAA&#8217;s requirements for disclosure of individually identifiable health information. In addition, we may maintain sensitive personally identifiable information, including health information, that we receive throughout the clinical trial process, in the course of our research collaborations, and directly from individuals (or their healthcare providers) who enroll in our patient assistance programs. As such, we may be subject to state laws requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA. Our clinical trial programs outside the United States may implicate international data protection laws, including the GDPR and legislation of the EU and EEA member states implementing it. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our activities outside the United States impose additional compliance requirements and generate additional risks of enforcement for noncompliance. Failure by our CROs and other third-party contractors to comply with the strict rules on the transfer of personal data outside of the European Union into the United States may result in the imposition of criminal and administrative sanctions on such collaborators, which could adversely affect our business. Furthermore, certain health privacy laws, data breach notification laws, consumer protection laws, and genetic testing laws may apply directly to our operations and/or those of our collaborators and may impose restrictions on our collection, use, and dissemination of individuals&#8217; health information. The GDPR provides that EU and EEA member states may establish their own laws and regulations limiting the processing of personal data, including genetic, biometric, or health data, which could limit our ability to use and share personal data or could cause our costs to increase. Moreover, patients about whom we or our collaborators obtain health information, as well as the providers who share this information with us, may have statutory or contractual rights that limit our ability to use and disclose the information. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws. Claims that we have violated individuals&#8217; privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or third-party CMOs, CROs, or other contractors or consultants fail to comply with applicable federal, state, or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our or our contractors&#8217; ability to develop and commercialize our product candidates and could harm or prevent sales of any affected products that we are able to commercialize, or could substantially increase the costs and expenses of developing, commercializing, and marketing our products. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business. Increasing use of social media could give rise to liability, breaches of data security, or reputational damage. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are subject to environmental, health, and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations, including our development, testing, and manufacturing activities, are subject to numerous environmental, health, and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release, and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds, and compounds that have a toxic effect on reproduction, laboratory procedures, and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health, and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, the production efforts of our third-party manufacturers or our development efforts may be interrupted or delayed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We and our employees are increasingly utilizing social media tools as a means of communication both internally and externally. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite our efforts to monitor evolving social media communication guidelines and comply with applicable rules, there is risk that the use of social media by us or our employees to communicate about our product candidates or business may cause us to be found in violation of applicable requirements. In addition, our employees may knowingly or inadvertently make use of social media in ways that may not comply with our policies and other legal or contractual requirements, which may give rise to liability, lead to the loss of trade secrets or other intellectual property, or result in public exposure of personal information of our employees, clinical trial patients, customers, and others. Furthermore, negative posts or comments about us or our product candidates in social media could seriously damage our reputation, brand image, and goodwill. Any of these events could have a material adverse effect on our business, prospects, operating results, and financial condition and could adversely affect the price of our common stock. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Commercialization </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Developments by competitors may render our products or technologies obsolete or non-competitive or may reduce the size of our markets. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our industry has been characterized by extensive research and development efforts, rapid developments in technologies, intense competition, and a strong emphasis on proprietary products. We face potential competition from many different sources, including pharmaceutical, biotechnology, and specialty pharmaceutical companies either marketing or developing therapeutics to treat CRS. Academic research institutions, governmental agencies, as well as public and private institutions are also potential sources of competitive products and technologies. Our competitors may have or may develop superior technologies or approaches, which may provide them with competitive advantages. Our potential products may not compete successfully. If these competitors access the marketplace before we do with better or less expensive therapeutics, our product candidates, if approved for commercialization, may not be profitable to sell or worthwhile to continue to develop. Technology in the pharmaceutical industry has undergone rapid and significant change, and we expect that it will continue to do so. Any compounds, products, or processes that we develop may become obsolete or uneconomical before we recover any expenses incurred in connection with their development. The success of our product candidates will depend upon factors such as product efficacy, safety, reliability, availability, timing, scope of regulatory approval, acceptance, and price, among other things. Other important factors to our success include speed in developing product candidates, completing clinical development and laboratory testing, obtaining regulatory approvals, and manufacturing and selling commercial quantities of potential products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates are intended to compete directly or indirectly with existing products and treatments. Even if approved and commercialized, our product candidates may fail to achieve market acceptance with hospitals, physicians, or patients. Hospitals, physicians, or patients may conclude that our potential products are less safe or effective or otherwise less attractive than these existing drugs. If our product candidates do not receive market acceptance for any reason, our revenue potential would be diminished, which would materially adversely affect our ability to become profitable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant competition exists in the treatment of CRS. We will need to compete with all currently available or future therapies within the indications where our development is focused. LYR-210, if approved and commercialized, will face significant competition. The main classes of marketed products that are available for the treatment of CRS include nasal saline irrigation, intranasal corticosteroidal sprays and antibiotics, as well as surgical intervention. In addition, one company is currently marketing, and several companies are also currently developing, biologic monoclonal antibodies, or mAbs, for the treatment of nasal polyps. If these biologic mAbs are successfully developed and approved for marketing, they could represent competition for LYR-220 for the segment of patients that have polyps. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are a number of companies developing or marketing therapies for the treatment and management of CRS that may compete with our current product candidates, including many major pharmaceutical and biotechnology companies. These companies include, among others: Hoffman-La Roche, GlaxoSmithKline, AnaptysBio, Regeneron, OptiNose, and Intersect ENT. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most of our competitors, including many of those listed above, have substantially greater capital resources, robust product candidate pipelines, established presence in the market, and expertise in research and development, manufacturing, pre-clinical and clinical testing, obtaining regulatory approvals and reimbursement, and marketing approved products than we do. As a result, our competitors may achieve product commercialization or patent protection earlier than we can. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified clinical, regulatory, scientific, sales, marketing, and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop or that would render any products that we may develop obsolete or noncompetitive. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels, and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The availability of coverage and adequacy of reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers, and other third-party payors are essential for most patients to be able to afford medical services and pharmaceutical products such as our product candidates, assuming FDA approval. Our ability to achieve acceptable levels of coverage and reimbursement for our products or procedures using our products by governmental authorities, private health insurers, and other organizations will have an effect on our ability to successfully commercialize our product candidates. Obtaining coverage and adequate reimbursement for our products may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. Separate reimbursement for the product itself or the treatment or procedure in which our product is used may not be available. A decision by a third-party payor not to cover or separately reimburse for our products or procedures using our products could reduce physician utilization of our products once approved. Assuming there is coverage for our product candidates or procedures using our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Similarly, our product candidates are physician-administered treatments and as such, separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used. To the extent separate coverage and reimbursement should become available for LYR-210, we anticipate that it will be sold to physicians on a &#8220;buy and bill&#8221; basis. Buy and bill products must be purchased by healthcare providers before they can be administered to patients. Healthcare providers subsequently must seek reimbursement for the product from the applicable third-party payor, such as Medicare or a health insurance company. Healthcare providers may be reluctant to administer our product candidates, if approved, because they would have to fund the purchase of the product and then seek reimbursement, which may be lower than their purchase price, or because they do not want the additional administrative burden required to obtain reimbursement for the product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, the status of reimbursement codes for any of our product candidates, if approved, could also affect reimbursement. J-Codes and Q-Codes are reimbursement codes maintained by the Centers for Medicare and Medicaid Services, or CMS, that are a component of the Healthcare Common Procedure Coding System and are typically used to report injectable drugs that ordinarily cannot be self-administered. We currently do not have a specific J-Code or Q-Code for any of our product candidates. If our product candidates are approved, we may apply for one but cannot guarantee that a J-Code or Q-Code will be granted. To the extent separate coverage or reimbursement is available for any product candidate, if approved, and a specific J-Code or Q-Code is not available, physicians would need to use a non-specific miscellaneous J-Code to bill third-party payors for these physician-administered drugs. Because miscellaneous J-Codes may be used for a wide variety of products, health plans may have more difficulty determining the actual product used and billed for the patient. These claims must often be submitted with additional information and manually processed, which can delay claims processing times as well as increase the likelihood for claim denials and claim errors. We cannot be sure that coverage and reimbursement in the United States, the EU, or elsewhere will be available for our product candidates or any product that we may develop, and any reimbursement that may become available may not be adequate or may be decreased or eliminated in the future. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs and biologics when an equivalent generic drug, biosimilar, or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing third-party therapeutics may limit the amount we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates, and may not be able to obtain a satisfactory financial return on our product candidates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is significant uncertainty related to the insurance coverage and reimbursement of newly-approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative drug therapies before they will reimburse healthcare providers who use such therapies. We cannot predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likely. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in the EU and other jurisdictions have and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially-reasonable revenue and profits. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our clinical studies were designed to demonstrate the safety and efficacy of LYR-210 based on FDA requirements and may not be seen as compelling to physicians or patients. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends on the medical community&#8217;s acceptance of LYR-210, if approved, as a treatment for CRS patients. LYR-210 was previously studied in an open-label, Phase 1 clinical trial with 20 patients in New Zealand and Australia, which achieved its primary endpoint of safety at week 4. In the Phase 1 trial, we also observed that patients generally experienced significant and rapid, clinically meaningful and durable improvement in SNOT-22 scores. Significant reduction in SNOT-22 scores was observed at week 1, and this reduction persisted through week 25, which was the end of the trial. In our Phase 2 LANTERN clinical trial, we reported positive top-line results but failed to achieve the primary endpoint. Although not statistically significant at week 4 (the primary endpoint), at the 7,500 &#181;g dose, LYR-210 achieved statistically significant improvement in 4CSS in favor of the treatment arm as measured by the change from baseline at weeks 16, 20, and 24. Furthermore, at the 7,500 &#181;g dose, LYR-210 achieved statistically significant improvement in SNOT-22 score in favor of the treatment arm at weeks 8, 16, 20, and 24. Even if the results of these clinical trials suggest a favorable safety and efficacy profile, the study designs and results, and the designs and results of future clinical trials we conduct, may not be viewed as compelling to our physician customers or patients. If physicians do not find our data compelling, even if LYR-210 receives marketing approval they may choose not to use our products or limit their use. We cannot assure you that any data that we or others generate, including from any pivotal Phase 3 clinical study we may pursue for LYR-210, will be consistent with that observed in the Phase 1 clinical trial of LYR-210 and Phase 2 LANTERN clinical trial, nor that results will be maintained beyond the time points studied. We also cannot assure you that any data that may be collected will be compelling to the medical community because the data may not be clinically meaningful and may not demonstrate that LYR-210 is an attractive procedure when compared against data from alternative treatments. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if either LYR-210 or LYR-220 receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors, or others in the medical community necessary for commercial success. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If either LYR-210 or LYR-220 receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors, and others in the medical community. If it does not achieve an adequate level of acceptance, we may not generate significant product revenues or become profitable. The degree of market acceptance of LYR-210 or LYR-220, if approved for commercial sale, will depend on a number of factors, including but not limited to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">perceptions by members of the healthcare community, including physicians, about the safety and effectiveness of our platform; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the perception by members of the healthcare community, including physicians, or patients that the process of administering LYR-210 or LYR-220 is not unduly cumbersome; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the efficacy and potential advantages compared to alternative treatments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">effectiveness of sales and marketing efforts; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the cost of treatment in relation to alternative treatments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to offer our products for sale at competitive prices; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the convenience and ease of administration compared to alternative treatments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the strength of marketing and distribution support; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the timing of market introduction of competitive products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the availability of third-party coverage and adequate reimbursement; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">product labeling or product insert requirements of the FDA, the EMA, or other regulatory authorities, including any limitations or warnings contained in a product&#8217;s approved labeling; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the prevalence and severity of any side effects; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any restrictions on the use of our product together with other medications. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our product candidates are approved, but do not achieve an adequate level of acceptance by physicians, healthcare payors, and patients, we may not generate sufficient revenue from these products, and we may not be able to achieve or sustain profitability. Our efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful. In addition, our ability to successfully commercialize our product candidates will depend on our ability to manufacture our products through third-party manufacturers, differentiate our products from competing products, and defend the intellectual property of our products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we expect sales of LYR-210, if approved, to generate substantially all of our product revenues for a substantial period, the failure of this product to find market acceptance would harm our business and could require us to seek additional financing. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If physicians or patients are not willing to change current practices and adopt our office-based administration procedure for LYR-210 and LYR-220, our products may fail to gain market acceptance, and our business will be harmed. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure by an ENT physician under endoscopic visualization via a single-use applicator. While we believe ENT physicians will be able to administer our product candidates, if successfully developed and approved, in conjunction with an endoscopy procedure, thereby making the placement aligned with the existing care continuum for CRS patients and eliminating the need for ENT physicians to schedule separate surgical time, ENT physicians may not adopt our in-office procedure for a number of reasons, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">lack of significant experience with the placement procedure via a single-use applicator; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">lack of availability of adequate insurance coverage or reimbursement for the placement procedure; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">perceived inadequacy of evidence supporting clinical benefits or cost-effectiveness of the placement procedure and/or our products in general over existing alternatives; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a perception that patients may be unable to tolerate the placement procedure in the physician office setting; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">liability risks generally associated with the use of new products and procedures. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If ENT physicians do not adopt the placement procedure for any reason, including those listed above, our ability to grow our business would be impaired, even if LYR-210 and LYR-220 receive marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe recommendations and support of our products by notable ENT physicians could influence market acceptance and adoption. If we do not receive support from influential ENT physicians, our ability to achieve broad market acceptance for our products may be impaired. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if patient receptivity toward treatment in an ENT physician office setting becomes less favorable in the future, this shift could negatively impact market acceptance of our products. Any negative change due to patient receptivity could also be compounded by patients reporting to physicians or other patients through word-of-mouth or social media. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, while it is currently more cost-effective to the healthcare system for providers to perform the placement procedure in an ENT physician&#8217;s office than a FESS procedure in an operating room, healthcare economics are subject to change. If the use of our products were to cease being more cost-effective than FESS due to changes in reimbursement economics, our products may fail to gain market acceptance, our future growth would be limited, and our business may be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to establish sales, marketing, and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing LYR-210 or LYR-220, if approved, and we may not be able to generate any revenue. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any infrastructure for the sales, marketing, or distribution of our products, and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to build our own focused sales, distribution, and marketing infrastructure to market LYR-210 and LYR-220 in the United States, if approved. There are significant expenses and risks involved with establishing our own sales, marketing, and distribution capabilities, including our ability to hire, retain, and appropriately incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing, and distribution capabilities could delay any product launch, which would adversely impact the commercialization of LYR-210. Additionally, if the commercial launch of LYR-210 or LYR-220 for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Factors that may inhibit our efforts to commercialize our product candidates on our own include: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our inability to recruit and retain adequate numbers of effective sales and marketing personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our inability to equip medical and sales personnel with effective materials, including medical and sales literature to help them educate physicians and other healthcare providers regarding applicable diseases and our future products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our inability to develop or obtain sufficient operational functions to support our commercial activities; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">unforeseen costs and expenses associated with creating an independent sales and marketing organization. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not anticipate having the resources in the foreseeable future to allocate to the sales and marketing of LYR-210, LYR-220, or any future product candidates in markets outside of the United States. Therefore, our future sales in these markets will largely depend on our ability to enter into and maintain collaborative relationships for such capabilities, the collaborator&#8217;s strategic interest in the product, and such collaborator&#8217;s ability to successfully market and sell the product. We intend to selectively pursue collaborative arrangements regarding the sale and marketing of LYR-210, if approved, for certain markets outside of the United States; however, we cannot assure that we will be able to establish or maintain such collaborative arrangements, or if able to do so, that they will have effective sales forces. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to build our own sales force or negotiate a collaborative relationship for the commercialization of LYR-210 or LYR-220, we may be forced to delay the potential commercialization of LYR-210 or LYR-220 or reduce the scope of our sales or marketing activities for LYR-210 or LYR-220. If we elect to increase our expenditures to fund commercialization activities ourselves, we will need to obtain additional capital, which may not be available to us on acceptable terms, or at all. We could enter into arrangements with collaborative partners at an earlier stage than otherwise would be ideal and we may be required to relinquish rights to LYR-210 or LYR-220 or otherwise agree to terms unfavorable to us, any of which may have an adverse effect on our business, operating results and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to establish adequate sales, marketing, and distribution capabilities, either on our own or in collaboration with third parties, we will not be successful in commercializing LYR-210 or LYR-220 and may not become profitable and may incur significant additional losses. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our future growth may depend, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future profitability may depend, in part, on our ability to commercialize our product candidates in foreign markets for which we may rely on collaboration with third parties. We are evaluating the opportunities for the development and commercialization of our product candidates in foreign markets. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the applicable regulatory authority in that foreign market, and we may never receive such regulatory approval for any of our product candidates. To obtain separate regulatory approvals in other countries we may be required to comply with numerous and varying regulatory requirements of such countries regarding the safety and efficacy of our product candidates and governing, among other things, clinical trials and commercial sales, pricing, and distribution of our product candidates, and we cannot predict success in these jurisdictions. If we obtain approval of our product candidates and ultimately commercialize our product candidates in foreign markets, we would be subject to additional risks and uncertainties, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our customers&#8217; ability to obtain reimbursement for our product candidates in foreign markets; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our inability to directly control commercial activities if we are relying on third parties; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the burden of complying with complex and changing foreign regulatory, tax, accounting, and legal requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">different medical practices and customs in foreign countries affecting acceptance in the marketplace; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">import or export licensing requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">longer accounts receivable collection times; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">longer lead times for shipping; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">language barriers for technical training and the need for language translations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">reduced protection of intellectual property rights in some foreign countries; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the existence of additional potentially relevant third-party intellectual property rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">foreign currency exchange rate fluctuations; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign sales of our product candidates could also be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions, and changes in tariffs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some countries, particularly the countries in Europe, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The sizes of the patient populations that our product candidates are intended to treat have not been established with precision. If the market opportunities for our product candidates are smaller than we estimate, or if any approval that we obtain is based on a narrower definition of the patient population than we anticipate, our revenue and ability to achieve profitability may be materially adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The precise incidence and prevalence of the conditions we aim to address with our programs is unknown and cannot be precisely determined. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations, or market research, and may prove to be incorrect. Further, new information may change the estimated incidence or prevalence of these diseases, and the incidence or prevalence of these diseases is subject to change. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total addressable market across all of our product candidates will ultimately depend upon, among other things, the indications and conditions of use for which the product candidates are approved and may be marketed, acceptance by the medical community, and patient access, drug pricing, and reimbursement. The sizes of the patient populations that our product candidates are intended to treat in the United States and other major markets and elsewhere may turn out to be smaller than expected, patients may not be otherwise amenable to treatment with our product candidates, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. Further, even if we obtain significant market share for our product candidates, we may never achieve profitability despite obtaining such significant market share. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we cannot compete for market share against other drug companies, we may not achieve sufficient product revenues and our business will suffer. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our product candidates receive FDA approval, they will compete with a number of existing and future drugs and therapies developed, manufactured, and marketed by other companies. Existing or future competing products may provide greater therapeutic convenience or clinical or other benefits for a specific indication than our products, or may offer comparable performance at a lower cost. If our products fail to capture and maintain market share, we may not achieve sufficient product revenues and our business will suffer. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will compete against fully integrated pharmaceutical companies and smaller companies that are collaborating with larger pharmaceutical companies, academic institutions, government agencies, and other public and private research organizations. Many of these competitors may have compounds already approved or in development in the therapeutic categories that we are targeting with our current and future product candidates. In addition, many of these competitors, either alone or together with their collaborative partners, may operate larger research and development programs or have substantially greater financial resources than we do, as well as greater experience in: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">developing product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">undertaking pre-clinical testing and clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">obtaining NDA approval by the FDA and comparable foreign regulatory approvals of product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">formulating and manufacturing products; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">launching, marketing, and selling products. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we obtain approval to commercialize any products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If either LYR-210 or LYR-220 is approved for commercialization, we intend to selectively partner with third parties to market it in certain jurisdictions outside the United States. We expect that we will be subject to additional risks related to international pharmaceutical operations, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">different regulatory requirements for drug approvals and rules governing drug commercialization in foreign countries; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">reduced protection for intellectual property rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">foreign reimbursement, pricing, and insurance regimes; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">potential noncompliance with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act 2010, and similar anti-bribery and anticorruption laws in other jurisdictions; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have no prior experience in these areas. In addition, there are complex regulatory, tax, labor, and other legal requirements imposed by both the European Union and many of the individual countries in Europe with which we will need to comply. Many U.S.-based biotechnology companies have found the process of marketing their own products in Europe to be very challenging. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain legal and political risks are also inherent in foreign operations. For example, it may be more difficult for us to enforce our agreements or collect receivables through foreign legal systems. There is a risk that foreign governments may nationalize private enterprises in certain countries where we may operate. In certain countries or regions, terrorist activities and the response to such activities may threaten our operations more than in the United States. Social and cultural norms in certain countries may not support compliance with our corporate policies including those that require compliance with substantive laws and regulations. Also, changes in general economic and political conditions in countries where we may </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operate are a risk to our financial performance and future growth. Additionally, the need to identify financially and commercially strong partners for commercialization outside the United States who will comply with the high manufacturing and legal and regulatory compliance standards we require is a risk to our financial performance. As we operate our business globally, our success will depend, in part, on our ability to anticipate and effectively manage these and other related risks. There can be no assurance that the consequences of these and other factors relating to our international operations will not have an adverse effect on our business, financial condition or results of operations. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The use of our product candidates, including LYR-210 and LYR-220, in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. For example, complications arising from the placement procedure for LYR-210 or LYR-220, or from the degradation or dislodgment of the LYR-210 or LYR-220 polymeric matrix within the sinuses after placement, or from foreign growth occurring in the sinus after placement, could give rise to product liability claims against us. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies, or others selling or otherwise coming into contact with our products. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated adverse effects. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs, which may not be covered by insurance. In addition, regardless of merit or eventual outcome, product liability claims may result in: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">impairment of our business reputation and significant negative media attention; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">withdrawal of participants from our clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">significant costs to defend the related litigation and related litigation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">distraction of management&#8217;s attention from our primary business; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">substantial monetary awards to patients or other claimants; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">inability to commercialize LYR-210 or LYR-220 or any other product candidate; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">product recalls, withdrawals or labeling, marketing, or promotional restrictions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">decreased demand for LYR-210 or LYR-220 or any other product candidate, if approved for commercial sale; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">loss of revenue. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Dependence on Third Parties </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will rely on third parties for the manufacture of materials for our research programs, pre-clinical studies, and clinical trials and we do not have long-term contracts with any of these parties. This reliance on third parties increases the risk that we will not have sufficient quantities of such materials, product candidates, or any therapies that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we currently conduct certain manufacturing operations internally, we currently have no plans to build our own clinical or commercial scale manufacturing capabilities. Instead, we expect to rely on third parties for the manufacture of our product candidates and related raw materials for future pre-clinical and clinical development, as well as for commercial manufacture if any of our product candidates receive marketing approval. We do not have a long-term agreement with any of the third-party manufacturers we currently use to provide pre-clinical and clinical drug supply, and purchase any required materials on a purchase order basis. Certain of these manufacturers are critical to our production and the loss of these manufacturers to one of our competitors or otherwise, or an inability to obtain quantities at an acceptable cost or quality, could delay, prevent, or impair our ability to timely conduct pre-clinical studies or clinical trials, and would materially and adversely affect our development and commercialization efforts. The facilities used by third-party </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will be conducted after we submit an NDA to the FDA. We do not control the manufacturing process of, and are completely dependent on, third-party manufacturers for compliance with cGMP requirements for manufacture of drug products and other laws and regulations. If these third-party manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. Some of our contract manufacturers may not have produced a commercially-approved product and therefore may not have obtained the requisite FDA approvals to do so. In addition, we have no control over the ability of third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for, or market our product candidates, if approved. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of product candidates or products, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. In addition, we may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">failure of third-party manufacturers to comply with regulatory requirements and maintain quality assurance; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">breach of the manufacturing agreement by the third party; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">failure to manufacture our product according to our specifications; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">failure to manufacture our product according to our schedule or at all; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">misappropriation of our proprietary information, including our trade secrets and know-how; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval, and any related remedial measures may be costly or time-consuming to implement. We do not currently have arrangements in place for redundant supply or a second source for all required raw materials used in the manufacture of our product candidates. The extent to which the COVID-19 pandemic impacts our ability to procure sufficient supplies for the development of our products and product candidates will depend on the severity and duration of the spread of the virus, and the actions undertaken to contain COVID-19 or treat its effects and may cause delays. If our current third-party manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace them on a timely basis or at all. Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We rely on third parties to conduct our pre-clinical studies and clinical trials. Any failure by a third party to conduct the clinical trials according to GCPs and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are dependent on third parties to conduct our pre-clinical studies and clinical trials, including our planned and ongoing clinical trials for LYR-210, and we expect to rely on third parties to conduct any future clinical trials and pre-clinical studies for our product candidates, including LYR-220. Specifically, we have used and relied on, and intend to continue to use and rely on, medical institutions, clinical investigators, CROs, and consultants to conduct our clinical trials in accordance with our clinical protocols and regulatory requirements. These CROs, investigators, and other third parties play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. While we have agreements governing the activities of our third-party contractors, we have limited influence over their actual performance. Nevertheless, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol and legal, regulatory, and scientific standards, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators, and trial sites. If we or any of our CROs or trial sites fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no guarantee that any such CROs, investigators, or other third parties will devote adequate time and resources to such trials or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols, or meet regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be extended, delayed, or terminated. In addition, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned, and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any NDA we submit to the FDA. Any such delay or rejection could prevent us from commercializing our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our relationships with these third-parties terminate, we may not be able to enter into arrangements with alternative third parties or do so on commercially reasonable terms. Switching or adding additional CROs, investigators, and other third parties involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. The COVID-19 pandemic and government measures taken in response have also had a significant impact on our CROs, and we expect that they will face further disruption which may affect our ability to initiate and complete our pre-clinical studies and clinical trials. Though we carefully manage our relationships with our CROs, investigators, and other third parties, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition, and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may collaborate with third parties for the development and commercialization of LYR-210, LYR-220, and any of our future product candidates. We may not succeed in establishing and maintaining collaborative relationships, which may significantly limit our ability to develop and commercialize LYR-210, LYR-220, or our future product candidates successfully, if at all. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek collaborative relationships for the development and commercialization of LYR-210, LYR-220, or any future product candidates. Failure to obtain a collaborative relationship for LYR-210, LYR-220, or any future product candidates may significantly impair the potential for these product candidates. We also may need to enter into collaborative relationships to provide funding to support our other research and development programs. The process of establishing and maintaining collaborative relationships is difficult, time-consuming, and involves significant uncertainty, such as: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a collaboration partner may shift its priorities and resources away from our product candidates due to a change in business strategies, or a merger, acquisition, sale, or downsizing; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a collaboration partner may seek to renegotiate or terminate their relationships with us due to unsatisfactory clinical results, manufacturing issues, a change in business strategy, a change of control, or other reasons; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a collaboration partner may cease development in therapeutic areas which are the subject of our strategic collaboration; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a collaboration partner may not devote sufficient capital or resources towards our product candidates; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a collaboration partner may change the success criteria for a product candidate, thereby delaying or ceasing development of such candidate; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a significant delay in initiation of certain development activities by a collaboration partner will also delay payment of milestones tied to such activities, thereby impacting our ability to fund our own activities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a collaboration partner could develop a product that competes, either directly or indirectly, with our product candidate; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a collaboration partner with commercialization obligations may not commit sufficient financial or human resources to the marketing, distribution, or sale of a product; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a collaboration partner with manufacturing responsibilities may encounter regulatory, resource, or quality issues and be unable to meet demand requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a collaboration partner may terminate a strategic alliance; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a dispute may arise between us and a partner concerning the research, development, or commercialization of a product candidate resulting in a delay in milestones, royalty payments, or termination of an alliance and possibly resulting in costly litigation or arbitration which may divert management attention and resources; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a partner may use our products or technology in such a way as to invite litigation from a third party. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any collaborator fails to fulfill its responsibilities in a timely manner, or at all, our research, clinical development, manufacturing, or commercialization efforts related to that collaboration could be delayed or terminated, or it may be necessary for us to assume responsibility for expenses or activities that would otherwise have been the responsibility of our collaborator. If we are unable to establish and maintain collaborative relationships on acceptable terms or to successfully transition terminated collaborative agreements, we may have to delay or discontinue further development of one or more of our product candidates, undertake development and commercialization activities at our own expense, or find alternative sources of capital. Moreover, any collaborative partners we enter into agreements with in the future may shift their priorities and resources away from our product candidates or seek to renegotiate or terminate their relationships with us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we seek, but are not able to establish, collaborations, we may have to alter our development and commercialization plans. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product development programs and the potential commercialization of our product candidates will require substantial additional capital. We may decide to collaborate with pharmaceutical and biotechnology companies for the development and potential commercialization of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or comparable regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate revenue. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Data provided by collaborators and others upon which we rely that has not been independently verified could turn out to be false, misleading, or incomplete. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on third-party vendors, such as CROs, scientists, and collaborators to provide us with significant data and other information related to our projects, pre-clinical studies, or clinical trials and our business. If such third parties provide inaccurate, misleading, or incomplete data, our business, prospects, and results of operations could be materially adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We do not have multiple sources of supply for some of the components used in LYR-210 or LYR-220, nor long-term supply contracts, and certain of our suppliers are critical to our production. If we were to lose a supplier, it could have a material adverse effect on our ability to complete the development of LYR-210 or LYR-220. If we obtain regulatory approval for LYR-210 or LYR-220, we would need to expand the supply of their components in order to commercialize them. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have multiple sources of supply for the components used in the manufacturing of LYR-210 or LYR-220. We also do not have long-term supply agreements with any of our component suppliers. We may not be able to establish additional sources of supply for our product candidates, or may be unable to do so on acceptable terms. Manufacturing suppliers are subject to cGMP quality and regulatory requirements covering manufacturing, testing, quality control, and record keeping relating to our product candidates and are subject to ongoing inspections by the regulatory agencies. Failure by any of our suppliers to comply with applicable regulations may result in long delays and interruptions in supply. Manufacturing suppliers are also subject to local, state, and federal regulations and licensing requirements. Failure by any of our suppliers to comply with all applicable regulations and requirements may result in long delays and interruptions in supply. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of suppliers of the raw material components of our product candidates is limited. In the event it is necessary or desirable to acquire supplies from alternative suppliers, we might not be able to obtain them on commercially reasonable terms, if at all. It could also require significant time and expense to redesign our manufacturing processes to work with another company. Additionally, certain of our suppliers are critical to our production and the loss of these suppliers to one of our competitors or otherwise would materially and adversely affect our development and commercialization efforts. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of any marketing approval, regulatory authorities conduct inspections that must be successful prior to the approval of the product. Failure of manufacturing suppliers to successfully complete these regulatory inspections will result in delays. If supply from the approved supplier is interrupted, there could be a significant disruption in commercial supply. An alternative vendor would need to be qualified through an NDA amendment or supplement which could result in further delay. The FDA or other regulatory agencies outside of the United States may also require additional studies if a new supplier is relied upon for commercial production. Switching vendors may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to obtain the supplies we need at a reasonable price or on a timely basis, it could have a material adverse effect on our ability to complete the development of LYR-210 or LYR-220 or, if we obtain regulatory approval for LYR-210 or LYR-220, to commercialize them. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may enter into collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships with third-parties that may not result in the development of commercially viable products or the generation of significant future revenues. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of our business, we may enter into collaborations, in-licensing arrangements, joint ventures, strategic alliances, partnerships, or other arrangements to develop new products and to pursue new markets. Proposing, negotiating, and implementing collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships may be a lengthy and complex process. Other companies, including those with substantially greater financial, marketing, sales, technology, or other business resources, may compete with us for these opportunities or arrangements. We may not identify, secure, or complete any such transactions or arrangements in a timely manner, on a cost-effective basis, on acceptable terms, or at all. We have limited institutional knowledge and experience with respect to these business development activities, and we may also not realize the anticipated benefits of any such transaction or arrangement. In particular, these collaborations may not result in the development of products that achieve commercial success or result in significant revenues and could be terminated prior to developing any products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we may not be in a position to exercise sole decision making authority regarding the transaction or arrangement, which could create the potential risk of creating impasses on decisions, and our future collaborators may have economic or business interests or goals that are, or that may become, inconsistent with our business interests or goals. It is possible that conflicts may arise with our collaborators, such as conflicts concerning the achievement of performance milestones, or the interpretation of significant terms under any agreement, such as those related to financial obligations or the ownership or control of intellectual property developed during the collaboration. If any conflicts arise with any current or future collaborators, they may act in their self-interest, which may be adverse to our best interest, and they may breach their obligations to us. In addition, we may have limited control over the amount and timing of resources that any current or future collaborators devote to our or their future products. Disputes between us and our collaborators may result in litigation or arbitration which would increase our expenses and divert the attention of our management. Further, these transactions and arrangements will be contractual in nature and will generally be terminable under the terms of the applicable agreements and, in such event, we may not continue to have rights to the products relating to such transaction or arrangement or may need to purchase such rights at a premium. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we enter into in-bound intellectual property license agreements, we may not be able to fully protect the licensed intellectual property rights or maintain those licenses. Future licensors could retain the right to prosecute and defend the intellectual property rights licensed to us, in which case we would depend on the ability of our licensors to obtain, maintain, and enforce such licensed intellectual property. These licensors may determine not to pursue litigation against other companies or may pursue such litigation less aggressively than we would. If our licensors do not adequately protect such licensed intellectual property, competitors may be able to use such intellectual property and erode or negate any competitive advantage we may have, which could materially harm our business, negatively affect our position in the marketplace, limit our ability to commercialize our products and product candidates, and delay or render impossible our achievement of profitability. Further, entering into such license agreements could impose various diligence, commercialization, royalty, or other obligations on us. Future licensors may allege that we have breached our license agreement with them, and accordingly seek to terminate our license, which could adversely affect our competitive business position and harm our business prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Intellectual Property </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to obtain, maintain, or adequately protect our intellectual property rights, we may not be able to compete effectively in our markets. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely upon a combination of patents, trade secret protection, and confidentiality agreements to protect our intellectual property and prevent others from duplicating LYR-210, LYR-220, and any future product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The strength of patents in the biotechnology and pharmaceutical field involves complex legal, factual, and scientific questions and can be uncertain. It is possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. The patent applications that we own may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover our product candidates, third parties may challenge the inventorship, ownership, validity, enforceability, or scope of such patents, which may result in such patents being narrowed or invalidated, or being held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates, or prevent others from designing around our claims. In addition, no assurances can be given that third parties will not create new products or methods that achieve similar results without infringing upon our patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the patent applications we hold with respect to our programs or product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our product candidates, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize future products. Several patent applications covering our product candidates have been filed recently. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patents, or whether any issued patents will be found invalid or unenforceable or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. Since patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we were the first to file any patent application related to a product candidate. Furthermore, if third parties have filed such patent applications before enactment of the Leahy-Smith Act on March&#160;16, 2013, an interference proceeding in the United States can be initiated by a third party to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. In addition, patents have a limited lifespan. In the United States, the expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for the patent covering a product, we may be open to competition from generic competing products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The issuance of a patent is not conclusive as to its inventorship, ownership, scope, validity, or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our product candidate, if approved, or practicing our own patented technology. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is either not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information, or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations, and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. Once disclosed, we are likely to lose trade secret protection. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we require all of our employees and consultants to assign their inventions to us, to the extent that employees or consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. Further, although we require that all of our employees, consultants, collaborators, advisors, and any third parties who have access to our proprietary know-how, information, or technology enter into confidentiality agreements, we cannot provide any assurances that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently discover our trade secrets or develop substantially equivalent information and techniques. Any of these parties may breach these agreements and we may not have adequate remedies for any specific breach. Misappropriation or unauthorized disclosure of our trade secrets or other confidential proprietary information could impair our competitive position and may have a material adverse effect on our business. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. Additionally, if the steps taken to maintain our trade secrets or other confidential proprietary information are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret or other confidential proprietary information. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on our avoiding infringement, or allegations of infringement, of the patents and other proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, reexamination, and inter partes review proceedings before the United States Patent and Trademark Office, or USPTO, and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. Many companies in intellectual property-dependent industries, including the biotechnology and pharmaceutical industries, have employed intellectual property litigation as a means to gain an advantage over their competitors. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility and market exposure as a public company, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to composition of matter, drug delivery, methods of manufacture, or methods for treatment related to the use or manufacture of our product candidates. We cannot guarantee that our technologies, products, compositions, and their uses do not or will not infringe third party patent or other intellectual property rights. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use of our product candidates. After issuance, the scope of patent claims remains subject to construction as determined by an interpretation of the law, the written disclosure in a patent, and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our product candidates. If any third-party patents were held by a court of competent jurisdiction to cover the composition of matter of any of our product candidates, the manufacturing process of any of our product candidates, or the method of use for any of our product candidates, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, which may not be available or may not be available on commercially reasonable terms, or until such patents expire. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates and/or harm our reputation and financial results. Defense of these claims, regardless of their merit, could involve substantial litigation expense and could be a substantial diversion of management and employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products, in the case of claims concerning registered trademarks, rename our product candidates, or obtain one or more licenses from third parties, which may require substantial time and monetary expenditure, and which might be impossible or technically infeasible. Furthermore, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us; alternatively or additionally it could include terms that impede or destroy our ability to compete successfully in the commercial marketplace. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may infringe our patents, trademarks, copyrights, or other intellectual property. It may be difficult to detect infringers who do not advertise the components that are used in their products. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product. To counter infringement or unauthorized use, we may be required to file infringement claims on a country-by-country basis, which can be expensive and time-consuming and divert the time and attention of our management and scientific personnel. There can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Any claims we assert against perceived infringers could also provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid, is unenforceable and/or is not infringed, or may construe the patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, interpreted narrowly, or held unenforceable, could put our patent applications at risk of not issuing, and could limit our ability to assert those patents against those parties or other competitors and curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks, which could materially harm our business and negatively affect our position in the marketplace. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent patent reform legislation has increased the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, and may diminish the value of patents in general. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is the case with other biopharmaceutical companies, our commercial success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming, and inherently uncertain. Recent wide-ranging patent reform legislation in the United States, including the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase those uncertainties and costs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Leahy-Smith Act includes a number of significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted and may also affect patent litigation. Under The Leahy-Smith Act, the United States transitioned from a &#8220;first-to-invent&#8221; to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. This will require us to be cognizant going forward of the time from invention to filing of a patent application and be diligent in filing patent applications, but circumstances could prevent us from promptly filing patent applications on our inventions. The Leahy-Smith Act also enlarged the scope of disclosures that qualify as prior art, and it expanded the scope of procedures that a third party may use to challenge a U.S. patent, including post grant review and inter partes review procedures. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, recent court rulings in cases such as <font style="font-style:italic;">Association for Molecular Pathology v. Myriad Genetics,&#160;Inc., BRCA1-</font>&#160;&amp;<font style="font-style:italic;"> BRCA2-Based Hereditary Cancer Test Patent Litigation,</font> and <font style="font-style:italic;">Promega Corp.&#160;v. Life Technologies Corp.</font> have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents once obtained. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO, and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employee&#8217;s former employers or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, or our ability to hire personnel, which, in any case of the foregoing, could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The USPTO, European, and other patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. Periodic maintenance fees, renewal fees, annuity fees, and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees due to non-U.S. patent agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. We employ law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market, which could have a material adverse effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we initiated legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Such mechanisms include re-examination, post grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our product candidates. Such a loss of patent protection could have a material adverse impact on our business. A defendant could also challenge our ownership of patents assigned to us. We cannot be certain that a third party would not challenge our rights to these patents and patent applications. Any legal proceeding or enforcement action can also be expensive and time-consuming. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of any individual patent depends on applicable law in the country where the patent is granted. In the United States, provided all maintenance fees are timely paid, a patent generally has a term of 20 years from its application filing date or earliest claimed non-provisional filing date. Extensions may be available under certain circumstances, but the life of a patent and, correspondingly, the protection it affords is limited. Given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. For patents that are eligible for extension of patent term, we expect to seek extensions of patent terms in the United States and, if available, in other countries. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, which is limited to the approved indication (or any additional indications approved during the period of extension). We might not be granted an extension because of, for example, failure to apply within applicable periods, failure to apply prior to the expiration of relevant patents or otherwise, or failure to satisfy any of the numerous applicable requirements. Moreover, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to obtain approval of competing products following our patent expiration by referencing our clinical and pre-clinical data and launch their product earlier than might otherwise be the case. If this were to occur, it could have a material adverse effect on our ability to generate revenue. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be able to protect our intellectual property rights throughout the world. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting, and defending our intellectual property in all countries throughout the world could be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. Therefore, we may choose not to pursue or maintain protection for certain intellectual property in certain jurisdictions. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent such competitors from competing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuit that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. In addition, many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties (for example, the patent owner has failed to &#8220;work&#8221; the invention in that country, or the third party has patented improvements) or limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our trademarks of interest and our business may be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we seek to protect the trademarks we use in the United States and in other countries, we may be unsuccessful in obtaining registrations and/or otherwise protecting these trademarks. If that were to happen, we may be prevented from using our names, brands, and trademarks unless we enter into appropriate royalty, license, or coexistence agreements, which may not be available or may not be available on commercially reasonable terms. Over the long term, if we are unable to establish name recognition based on our trademarks, trade names, service marks, and domain names, then we may not be able to compete effectively, resulting in a material adverse effect on our business. Our registered or unregistered trademarks or trade names may be challenged, infringed, diluted, or declared generic, or determined to be infringing on other marks. We rely on both registration and common law protection for our trademarks. We may not be able to protect our rights </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to these trademarks and trade names or may be forced to stop using these names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trademarks and trade names similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks. Over the long term, if we are unable to establish name recognition based on our trademarks, then we may not be able to compete effectively and our business may be adversely affected. During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Effective trademark protection may not be available or may not be sought in every country in which our products are made available. Any name we propose to use for our products in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA objects to any of our proposed product names, we may be required to expend significant additional resources in an effort to identify a usable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties, and be acceptable to the FDA. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our proprietary rights may not adequately protect our technologies and product candidates, and do not necessarily address all potential threats to our competitive advantage. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">others may be able to make products that are the same as or similar to our product candidates but that are not covered by the claims of the patents that we own; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">others, including inventors or developers of our patented technologies who may become involved with competitors, may independently develop similar technologies that function as alternatives or replacements for any of our technologies without infringing our intellectual property rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we might not have been the first to conceive and reduce to practice the inventions covered by our patents or patent applications; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we might not have been the first to file patent applications covering certain of our patents or patent applications; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">it is possible that our pending patent applications will not result in issued patents; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">it is possible that there are prior public disclosures that could invalidate our patents; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our issued patents may not provide us with any commercially viable products or competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the Supreme Court of the United States, other U.S. federal courts, Congress, the USPTO, or similar foreign authorities may change the standards of patentability and any such changes could narrow or invalidate, or change the scope of, our or our collaboration partners&#8217; patents; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our competitors might conduct research and development activities in countries where we do not have patent rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">ownership, validity, or enforceability of our patents or patent applications may be challenged by third parties; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on our business. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Employee Matters and Managing Growth </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of product candidate development, regulatory affairs, and sales, marketing, and distribution. As of December 31, 2020, we had 38 full-time employees. To manage our growth activities, we must continue to implement and improve our managerial, operational, and financial systems, expand our facilities, and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. As we expand our organization, we may have difficulty identifying, hiring, and integrating new personnel. Future growth would impose significant additional responsibilities on our management, including the need to identify, recruit, maintain, motivate, and integrate additional employees, consultants, and contractors. Also, our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees, and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize our product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of the biotechnology and pharmaceutical companies that we compete against for qualified personnel and consultants have greater financial and other resources, different risk profiles, and a longer history in the industry than we do. If we are unable to continue to attract and retain high-quality personnel and consultants, the rate and success at which we can discover and develop product candidates and operate our business will be limited. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we lose key management or scientific personnel, cannot recruit qualified employees, directors, officers, or other significant personnel, or experience increases in our compensation costs, our business may materially suffer. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are highly dependent on our management and directors, including our chief executive officer, Maria Palasis, Ph.D., among others. Due to the specialized knowledge each of our officers and key employees possesses with respect to our product candidates and our operations, the loss of service of any of our officers or directors could delay or prevent the successful enrollment and completion of our clinical trials. We do not carry key person life insurance on our officers or directors. Although we have formal employment agreements with our executive officers, these agreements do not prevent them from terminating their employment with us at any time. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our future success and growth will depend in part on the continued service of our directors, employees, and management personnel and our ability to identify, hire, and retain additional personnel. If we lose one or more of our executive officers or key employees, our ability to implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of, and commercialize product candidates successfully. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain, or motivate these additional key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be engaged by entities other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to develop and commercialize product candidates will be limited. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our employees have become or will soon become vested in a substantial amount of our common stock or a number of common stock options. Our employees may be more likely to leave us if the shares they own have significantly appreciated in value relative to the original purchase prices of the shares, or if the exercise prices of the options that they hold are significantly below the market price of our common stock. Our future success also depends on our ability to continue to attract and retain additional executive officers and other key employees. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may engage in acquisitions or strategic partnerships that could disrupt our business, cause dilution to our stockholders, reduce our financial resources, cause us to incur debt or assume contingent liabilities, and subject us to other risks. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the future, we may enter into transactions to acquire other businesses, products, or technologies or enter into strategic partnerships, including licensing. If we do identify suitable acquisition or partnership candidates, we may not be able to make such acquisitions or partnerships on favorable terms, or at all. Any acquisitions or partnerships we make may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business or partnership that are not covered by the indemnification we may obtain from the seller or our partner. In addition, we may not be able to successfully integrate any acquired personnel, technologies, and operations into our existing business in an effective, timely, and non-disruptive manner. Acquisitions or partnerships may also divert management attention from day-to-day responsibilities, lead to a loss of key personnel, increase our expenses, and reduce our cash available for operations and other uses. We cannot predict the number, timing, or size of future acquisitions or partnerships or the effect that any such transactions might have on our operating results. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We or the third parties upon whom we depend may be adversely affected by natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Natural disasters could severely disrupt our operations and have a material adverse effect on our business, results of operations, financial condition, and prospects. If a natural disaster, power outage, or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as the manufacturing facilities on which we rely, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. For example, following Hurricane Maria, shortages in production and delays in a number of medical supplies produced in Puerto Rico resulted, and any similar interruption due to a natural disaster affecting us or any of our third-party manufacturers could materially delay our operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The global pandemic caused by COVID-19 could adversely impact our business and operations, including our clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, a disease caused by a novel strain of the coronavirus, COVID-19, was identified in Wuhan, China, and on March&#160;11, 2020, the World Health Organization declared the outbreak of COVID-19 as a global pandemic. This virus has subsequently spread to a number of countries where we have planned or ongoing clinical trials and activities, including the United States, Australia, Austria, Czech Republic, New Zealand, and Poland, and continues to spread globally. The global pandemic and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In light of developments relating to the COVID-19 pandemic and the focus of healthcare providers and hospitals on fighting the virus, and consistent with the FDA&#8217;s updated industry guidance for conducting clinical trials issued on March&#160;18, 2020, we discontinued enrollment at 67 patients in our Phase&#160;2 LANTERN clinical trial and we did not open any sites in the United States. Ultimately, LYR-210 did not achieve the primary endpoint in our Phase 2 LANTERN clinical trial, we believe due primarily to the discontinuation of enrollment related to the COVID-19 pandemic. As a result of the decrease in the number of patients enrolled from planned (99 evaluable) to actually enrolled (67), a greater magnitude of change from baseline in 4CSS at week 4 and/or a smaller standard deviation associated with the change from baseline was required in order to achieve statistical significance for the primary endpoint at week 4. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, although we leveraged remote electronic data collection to enable us to complete certain clinical assessments and generate sufficient information to commence designing our Phase&#160;3 clinical trial, we were unable to enroll patients in our Phase 2 LANTERN clinical trial in the United States from whom we intended to collect certain additional pharmacokinetic data, and as a result, we initiated a separate characterization study in September 2020 as a follow-on to our Phase 2 LANTERN clinical trial in order to collect such data. Furthermore, in response to the spread of COVID-19, we have closed our executive offices with our administrative employees continuing their work outside of our offices. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the COVID-19 pandemic, we may experience further disruptions that could severely impact our business and clinical trials, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">delays or difficulties in enrolling patients in our planned clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">further delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by foreign, federal, or state governments, employers, and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical study endpoints; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages, and disruptions in delivery systems; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">interruptions in planned pre-clinical studies due to restricted or limited operations at our laboratory facility; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">limitations on employee resources that would otherwise be focused on the conduct of our pre-clinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">risk that participants enrolled in our clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">refusal of the FDA to accept data from clinical trials in these affected geographies; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">interruption or delays to our sourced discovery and clinical activities. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, certain third parties, including manufacturers, medical institutions, clinical investigators, CROs, and consultants with whom we conduct business are similarly adjusting their operations and assessing their capacity in light of the COVID-19 pandemic. If these third parties continue to experience shutdowns or business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively impacted. For example, as a result of the COVID-19 pandemic, there could be delays in the manufacturing supply chain for mometasone furoate, which could delay or otherwise impact the manufacturing of LYR-210. It is also likely that the disproportionate impact of COVID-19 on hospitals and clinical sites will have an impact on recruitment and retention for our planned clinical trials. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic continues to evolve. The extent to which the outbreak impacts our business and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of COVID-19, the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, and the effectiveness of actions taken and vaccines and other treatments developed in the United States and other countries to contain and treat COVID-19. The COVID-19 pandemic resulted in a widespread health crisis that adversely affected the economies and financial markets worldwide, resulting in an economic downturn that could continue to significantly impact our business, financial condition, and results of operations. To the extent the COVID-19 pandemic adversely affects our business, financial condition, and results of operations, it may also have the effect of heightening many of the other risks described in this &#8220;Risk Factors&#8221; section. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Litigation against us could be costly and time-consuming to defend and could result in additional liabilities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may from time to time be subject to legal proceedings and claims that arise in the ordinary course of business or otherwise, such as claims brought by our customers in connection with commercial disputes and employment claims made by our current or former employees. Claims may also be asserted by or on behalf of a variety of other parties, including government agencies, patients, or vendors of our customers, or stockholders. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any litigation involving us may result in substantial costs, operationally restrict our business, and may divert management&#8217;s attention and resources, which may seriously harm our business, overall financial condition, and results of operations. Insurance may not cover existing or future claims, be sufficient to fully compensate us for one or more of such claims, or continue to be available on terms acceptable to us. A claim brought against us that is uninsured or underinsured could result in unanticipated costs, thereby adversely impacting our results of operations and resulting in a reduction in the trading price of our stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Common Stock</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our stock price may be volatile. The stock market in general and the market for smaller biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock at or above the purchase price. The market price for our common stock may be influenced by many factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the success of competitive products or technologies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">actual or expected changes in our growth rate relative to our competitors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">results of clinical trials of our product candidates or those of our competitors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">developments related to our existing or any future collaborations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">regulatory actions with respect to our product candidates or our competitors&#8217; products and product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">regulatory or legal developments in the United States and other countries; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">development of new product candidates that may address our markets and make our product candidates less attractive; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">changes in physician, hospital, or healthcare provider practices that may make our product candidates less useful; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">announcements by us, our partners, or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations, or capital commitments; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">developments or disputes concerning patent applications, issued patents, or other proprietary rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the recruitment or departure of key personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the level of expenses related to any of our product candidates or clinical development programs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the results of our efforts to discover, develop, acquire, or in-license additional product candidates or products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">actual or expected changes in estimates as to financial results, development timelines, or recommendations by securities analysts; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">variations in our financial results or those of companies that are perceived to be similar to us; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">changes in the structure of healthcare payment systems; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">market conditions in the pharmaceutical and biotechnology sectors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">short selling activities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">general economic, industry, and market conditions; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the other factors described in this &#8220;Risk Factors&#8221; section and elsewhere in this Annual Report on Form 10-K. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the trading prices for common stock of other biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic. The COVID-19 outbreak continues to evolve. The extent to which the outbreak may impact our business, pre-clinical studies, and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our current executive officers, directors, and principal stockholders, if they choose to act together, will continue to have the ability to control or significantly influence all matters submitted to stockholders for approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the number of shares of common stock outstanding as of December 31, 2020, our current executive officers, directors, and stockholders who own more than 5% of our outstanding common stock and their respective affiliates will, in the aggregate, hold shares representing approximately 48.2% of our outstanding voting stock. As a result, if these stockholders choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors, the composition of our management, and approval of any merger, consolidation, or sale of all or substantially all of our assets.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">A significant portion of our total outstanding shares are eligible to be sold into the market in the near future, which could cause the market price of our common stock to drop significantly, even if our business is doing well. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Holders of approximately 5.4 million shares of our common stock have rights, subject to specified conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders, until such shares can otherwise be sold without restriction under Rule 144 or until the rights terminate pursuant to the terms of the stockholders&#8217; agreement between us and such holders. We have also registered all shares of common stock that we may issue under our equity compensation plans, which can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, and may remain an emerging growth company until December&#160;31, 2025. However, if certain events occur prior to such date, including if we become a &#8220;large accelerated filer,&#8221; our annual gross revenues exceed $1.07&#160;billion, or we issue more than $1.0&#160;billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to such date. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure in this Annual Report on Form 10-K; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">reduced disclosure obligations regarding executive compensation; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have taken advantage of reduced reporting burdens in this Annual Report on Form 10-K. In particular, in this Annual Report on Form 10-K, we have provided only two years of audited financial statements and have not included all of the executive compensation related information that would be required if we were not an emerging growth company. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline, even if our business is doing well. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property, or our stock performance, or if our target pre-clinical studies or clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are a &#8220;smaller reporting company&#8221; and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are considered a &#8220;smaller reporting company.&#8221; We are therefore entitled to rely on certain reduced disclosure requirements, such as an exemption from providing selected financial data and executive compensation information. We are also exempt from the requirement to obtain an external audit on the effectiveness of internal control over financial reporting provided in Section&#160;404(b) of the Sarbanes-Oxley Act. These exemptions and reduced disclosures in our SEC filings due to our status as a smaller reporting company may make it harder for investors to analyze our results of operations and financial prospects. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock prices may be more volatile. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Provisions in our restated certificate of incorporation and amended and restated bylaws and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions in our restated certificate of incorporation and our amended and restated bylaws may discourage, delay, or prevent a merger, acquisition, or other change in control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions include those establishing: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death, or removal of a director, which prevents stockholders from filling vacancies on our board of directors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the ability of our board of directors to alter our bylaws without obtaining stockholder approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the required approval of the holders of at least two-thirds of the shares entitled to vote at an election of directors to adopt, amend, or repeal our bylaws or repeal the provisions of our restated certificate of incorporation regarding the election and removal of directors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, the chief executive officer, the president, or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of us. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the General Corporation Law of the State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our restated certificate of incorporation designates specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our restated certificate of incorporation specifies that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving claims brought against us by stockholders; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Securities Act, the Exchange Act, the rules and regulations thereunder, or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our restated certificate of incorporation further provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our restated certificate of incorporation described above. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:10pt;">We believe these provisions benefit us by providing increased consistency in the application of Delaware law by chancellors particularly experienced in resolving corporate disputes and in the application of the Securities Act by federal judges, as applicable, efficient administration of cases on a more expedited schedule relative to other forums, and protection against the burdens of multi-forum litigation. However, the provision may have the effect of discouraging lawsuits against our directors, officers, employees, and agents as it may limit any stockholder&#8217;s ability to bring a claim in a judicial forum that such stockholder finds favorable for disputes with us or our directors, officers, employees, or agents. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our restated certificate of incorporation to be inapplicable or unenforceable in such action. If a court were to find the choice of forum provision contained in our restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business, financial condition, or results of operations. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">General Risk Factors </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have incurred and expect to continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company, we have incurred significant legal, accounting, and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Global Market, and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased our legal and financial compliance costs and made some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified members of our board of directors. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are evaluating these rules and regulations, and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;404 of the Sarbanes-Oxley Act of 2002, or Section&#160;404, we will be required to furnish a report by our management on our internal control over financial reporting. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&#160;404 within the prescribed period, we are engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, engage outside consultants, adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">improve control processes as appropriate, validate through testing whether such controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section&#160;404. We may discover significant deficiencies or material weaknesses, which we may not successfully remediate on a timely basis or at all. Any failure to remediate any significant deficiencies or material weaknesses identified by us or to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations or result in material misstatements in our financial statements. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Because we do not anticipate paying any cash dividends on our common shares in the foreseeable future, capital appreciation, if any, would be your sole source of gain. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 20, 2012, we declared and paid a special cash dividend of $0.2630467 per share of our common stock, par value $0.001, which we refer to as the Special Dividend, which totaled approximately $42,115 in the aggregate. Other than the Special Dividend, we have never declared or paid any cash dividends on our common shares. We currently anticipate that we will retain future earnings for the development, operation, and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. As a result, capital appreciation, if any, of our common shares would be your sole source of gain on an investment in our common shares for the foreseeable future.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We could be subject to securities class action litigation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our ability to use our net operating losses and research and development credits to offset future taxable income may be subject to certain limitations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we had net operating loss carryforwards, or NOLs, of $135.4&#160;million for federal income tax purposes and $116.0&#160;million for state income tax purposes, which may be available to offset our future taxable income, if any, and begin to expire at various dates through 2037. As of December&#160;31, 2020, we also had federal and state research and development credit carryforwards of $5.6&#160;million, which begin to expire at various dates through 2035. In general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change by value in its equity ownership over a three-year period, is subject to limitations on its ability to utilize its pre-change NOLs and its research and development credit carryforwards to offset future taxable income. Our existing NOLs and research and development credit carryforwards may be subject to limitations arising from previous ownership changes. Future changes in our stock ownership, some of which might be beyond our control, could result in an ownership change under Section&#160;382 of the Code. For these reasons, in the event we experience a change of control, we may not be able to utilize a material portion of the NOLs or research and development credit carryforwards even if we attain profitability. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The impact of the Tax Cuts and Jobs Act on our financial results is not entirely clear and could differ materially from the financial statements provided herein. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December&#160;22, 2017, the United States enacted the Tax Cuts and Jobs Act, or TCJA, that significantly reformed the Code. The TCJA, among other things, contained significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%; limitation of the tax deduction for interest expense; limitation of the deduction for NOLs and elimination of NOL carrybacks, in each case, for losses arising in taxable years beginning after December&#160;31, 2017 (though any such tax losses may be carried forward indefinitely); and modifying or repealing many business deductions and credits. The financial statements contained herein reflect the effects of the TCJA based on current guidance. However, there remain uncertainties and ambiguities in the application of certain provisions of the TCJA, and, as a result, we made certain judgments and assumptions in the interpretation thereof. The U.S. Treasury Department and the Internal Revenue Service may issue further guidance on how the provisions of the TCJA will be applied or otherwise administered that differs from our current interpretation. In addition, the TCJA could be subject to potential amendments and technical corrections, any of which could materially lessen or increase certain adverse impacts of the legislation on us. </p><a name="_AEIOULastRenderedPageBreakAEIOU11"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a>Item 1B. Unresolve</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">d Staff Comments. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_2_PROPERTIES"></a><a name="ITEM_2_PROPERTIES"></a>Item 2. Properties. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We occupy office and laboratory space in Watertown, Massachusetts under a lease agreement, as amended, that terminates on April 30, 2023. We do not own any real property. We believe that our facilities are sufficient to meet our current needs and that suitable additional space will be available as and when needed.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_3_LEGAL_PROCEEDINGS"></a><a name="ITEM_3_LEGAL_PROCEEDINGS"></a>Item 3. Legal Proceedings. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may become involved in litigation relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations or financial condition.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a>Item 4. Mine Safety Disclosures.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p><a name="_AEIOULastRenderedPageBreakAEIOU12"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_II"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_II"></a>PART</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> II</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a><a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a>Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Market Information</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock commenced trading under the symbol &#8220;LYRA&#8221; on The Nasdaq Global Market on May 1, 2020. Prior to that time, there was no public market for our common stock. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Holders</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 1, 2021, there were approximately 64 holders of record of our common stock. However, because many of our outstanding shares are held in accounts with brokers and other institutions, we believe we have more beneficial owners.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dividend Policy</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently intend to retain all available funds and future earnings, if any, for the operation and expansion of our business and do not anticipate declaring or paying any dividends in the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors after considering our financial condition, results of operations, capital requirements, contractual requirements, business prospects, and other factors the board of directors deems relevant, and subject to the restrictions contained in any future financing instruments. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 20, 2012, we declared and paid a special cash dividend of $0.2630467 per share of our common stock, par value $0.001, which we refer to as the Special Dividend, which totaled approximately $42,115 in the aggregate. Other than the Special Dividend, we have not declared or paid any cash dividends on our capital stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Sales of Unregistered Securities; Purchases of Equity Securities by the Issuer or Affiliated Purchaser</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the quarter ended December 31, 2020, we did not repurchase any of our equity securities or issue any securities that were not registered under the Securities Act.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Proceeds from Initial Public Offering of Common Stock</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 5, 2020, we completed the sale of 4,025,000 shares of our common stock, including 525,000 shares pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, at a public offering price of $16.00 per share. The offer and sale of the shares in our initial public offering, or IPO, was registered under the Securities Act pursuant to a registration statement on Form S-1 (File No. 333-236962), which was declared effective by the SEC on April 30, 2020 (the &#8220;Registration Statement&#8221;).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There has been no material change in the planned use of proceeds from our IPO as described in our final prospectus for our IPO dated April 30, 2020 and filed pursuant to Rule 424(b)(4) under the Securities Act on May 1, 2020. We invested the funds received in cash equivalents and other short-term investments in accordance with our investment policy.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_6_SELECTED_CONSOLIDATED_FINANCIAL_D"></a><a name="ITEM_6_SELECTED_CONSOLIDATED_FINANCIAL_D"></a>Item 6. Selected Financial Data. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this Item 6.</p><a name="_AEIOULastRenderedPageBreakAEIOU13"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a>Item 7. Management&#8217;s Discussion and Analysis of</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> Financial Condition and Results of Operations. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">You should read the following discussion and analysis of our financial condition and results of operations together with the &#8220;Selected Consolidated Financial Data&#8221; section of this Annual Report on Form 10-K and our consolidated financial statements and the related notes included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_798"></a><a name="_cp_text_1_799"></a><a name="_cp_text_1_798"></a>Our actual results and timing of certain events may differ materially from the results discussed, projected, anticipated, or indicated in any forward-looking statements. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition, <a name="_cp_text_1_799"></a>and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Annual Report on Form 10-K. In addition, even if our results of operations, financial condition, and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Annual Report on Form 10-K, they may not be predictive of results or developments in future periods.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The following information and any forward-looking statements should be considered in light of factors discussed elsewhere in this Annual Report on Form 10-K, including those risks identified under Part I, Item 1A. Risk Factors.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_800"></a><a name="_cp_text_1_800"></a>We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_801"></a><a name="_cp_text_1_801"></a>We are a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. Our proprietary technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. Our initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of CRS. The therapeutic embedded within LYR-210 and LYR-220 is mometasone furoate, which is the active ingredient in various FDA approved drugs and has a well-established efficacy and safety profile. CRS is an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities and affects approximately 14 million people in the United States. We are advancing LYR-210 as a potential preferred alternative to surgery in our Phase 2 randomized, sham procedure-controlled, patient blinded LANTERN clinical trial, evaluating the safety and efficacy in surgically-na&#239;ve CRS patients who have failed previous medical management. The trial was designed to enroll 99 evaluable patients with the potential to increase to up to 150 patients and was initiated in May 2019 at sites in Australia, Austria, Czech Republic, New Zealand, and Poland. In December 2019, the FDA cleared our investigational new drug application, and, prior to the COVID-19 pandemic, we planned to enroll patients in the United States. However, in light of developments relating to the COVID-19 global pandemic we discontinued enrollment at 67 patients in our Phase 2 LANTERN clinical trial and did not enroll patients in the United States.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_802"></a><a name="_cp_text_1_802"></a>On December 7, 2020, we reported positive top-line results from our Phase 2 LANTERN clinical trial, including that the 7,500 &#181;g dose of LYR-210 achieved statistically significant improvement in the composite four cardinal symptoms score, or 4CSS, in favor of the treatment arm as measured by the change from baseline at weeks 16, 20, and 24. However, although a strong treatment effect was observed at week 4, LYR-210 did not achieve the primary endpoint of change from baseline in 4CSS at week 4 at either the 7,500 &#181;g dose or 2,500 &#181;g dose. We believe this was due primarily to the discontinuation of enrollment related to the COVID-19 global pandemic. As a result of the decrease in the number of patients enrolled from planned (99 evaluable) to actually enrolled (67), a greater magnitude of change from baseline in 4CSS at week 4 and/or a smaller standard deviation associated with the change from baseline was required in order to achieve statistical significance for the primary endpoint at week 4. LYR-210 was observed to be safe and well-tolerated at all doses in the trial, and no treatment-related serious adverse events were reported. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, although we collected certain pharmacokinetic data from all patients in our Phase 2 LANTERN clinical trial starting at week 4, our protocol contemplated utilizing a subset of U.S. patients to collect certain additional pharmacokinetic data in order to support the NDA for LYR-210. However, because we were unable to enroll patients in the United States due to the COVID-19 pandemic, we were unable to collect these additional pharmacokinetic data as planned. As a result, in September 2020, we initiated a separate characterization study in the United States to collect these additional data. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This study is fully enrolled and all 24 patients have completed the study-required visits. We expect data lock and analysis activities to be completed by the second quarter of 2021.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_804"></a><a name="_cp_text_1_805"></a><a name="_cp_text_1_807"></a><a name="_cp_text_1_804"></a>In our Phase 1 clinical trial, LYR-210 met its primary safety endpoint, and we observed that patients generally experienced significant, <a name="_cp_text_1_805"></a>rapid, clinically meaningful, <a name="_cp_text_1_807"></a>and durable improvement in SNOT-22 scores, an established patient symptom severity scale, through week 25, which was the end of the trial. Secondary findings from our Phase 1 clinical trial showed that LYR-210 demonstrated significant reduction of sinonasal Type 2 inflammation in surgically-na&#239;ve patients with CRS. The reduction of Type 2 inflammation suggests a correlation with rhinologic symptom improvement in CRS and could be a potential measure of LYR-210&#8217;s local anti-inflammatory effects at the site of inflammation in the sinonasal passages.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also developing LYR-220 for use in CRS patients who have an enlarged nasal cavity due to sinus surgery but continue to require treatment to manage CRS symptoms and, subject to the impact of COVID-19 on our business, we intend to initiate a Phase 2 clinical trial for LYR-220 by the end of 2021. Beyond CRS, we believe our XTreo platform has potential applications in other disease areas, which we are actively exploring to further broaden its therapeutic potential.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_808"></a><a name="_cp_text_1_808"></a>We were incorporated as a Delaware corporation on November&#160;21, 2005, and our headquarters is located in Watertown, Massachusetts. On July&#160;16, 2018, we formally changed our name to Lyra Therapeutics, Inc. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing our technology, building our intellectual property portfolio, and conducting research and development activities for our product candidates. We do not have any products approved for sale and have not generated any revenue from product sales.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_811"></a><a name="_cp_text_1_813"></a><a name="_cp_text_1_815"></a><a name="_cp_text_1_811"></a>On May 5, 2020, we completed our IPO in which we issued and sold 4,025,000 shares of our common stock (including shares issued upon the underwriters&#8217; exercise in full of their option to purchase additional shares of our common stock) at a public offering price of $16.00 per share, par value $0.001, for aggregate gross proceeds of $64.4 million. We received approximately $57.3<a name="_cp_text_1_813"></a> million in net proceeds after deducting underwriting discounts and commissions and offering expenses paid by us. The shares began trading on The Nasdaq Global Market on May 1, 2020. Upon completion of our IPO<a name="_cp_text_1_815"></a>, all of our outstanding shares of convertible preferred stock converted into 8,335,248 shares of our common stock, par value $0.001.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_817"></a><a name="_cp_text_1_819"></a><a name="_cp_text_1_820"></a><a name="_cp_text_1_817"></a>Prior to our IPO, we funded our operations primarily through private placements of redeemable convertible preferred stock and funding from government contracts. From inception through December 31, 2020, we have raised an aggregate of $236.5 million to fund our operations, of which $162.1 million were gross proceeds from sales of our redeemable convertible preferred stock, $57.3<a name="_cp_text_1_819"></a> million were <a name="_cp_text_1_820"></a>net proceeds from our IPO (taking into account the issuance and sale of 4,025,000 shares of our common stock at a public offering price of $16.00 per share, par value $0.001, for aggregate gross proceeds of $64.4 million, after deducting $7.1 million of underwriting discounts and offering expenses paid by us), and $16.8 million were gross proceeds from government contracts.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred significant net operating losses in every year since our inception and expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. Our net losses may fluctuate significantly from quarter to quarter and year to year and could be substantial. Our net losses were $22.1 million and $16.3 million for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, we had an accumulated deficit of $149.9 million. We anticipate that our expenses will increase significantly as we: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">conduct additional clinical trials of our most advanced product candidate, LYR-210, including one or more planned pivotal Phase 3 clinical trials of LYR-210; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">advance the development of LYR-220; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">continue to discover and develop additional product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">establish manufacturing and supply chain capacity sufficient to provide commercial quantities of any product candidates for which we may obtain marketing approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">seek regulatory and marketing approvals for product candidates that successfully complete clinical trials, if any; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_821"></a><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;"><a name="_cp_text_1_821"></a>establish a sales, marketing</font><font style="color:#000000;">, </font><font style="color:#000000;">and distribution infrastructure to commercialize any products for which we may obtain regulatory approval in geographies in which we plan to commercialize our products ourselves; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_822"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="_cp_text_1_822"></a>maintain, expand, and protect our intellectual property portfolio; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_823"></a><a name="_cp_text_1_824"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="_cp_text_1_823"></a>hire additional staff, including clinical, scientific, technical, regulatory, operational, financial, <a name="_cp_text_1_824"></a>commercial, and support personnel, to execute our business plan; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_825"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="_cp_text_1_825"></a>add clinical, scientific, operational, financial, and management information systems and personnel to support our product development and potential future commercialization efforts, and to enable us to operate as a public company. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_826"></a><a name="_cp_text_1_826"></a>We do not expect to generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for a product candidate. Additionally, we currently use contract research organizations, or CROs, to carry out our clinical development activities. We do not yet have a sales organization. If we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution. Furthermore, we will continue to incur additional costs associated with operating as a public company. As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to fund our operations through public or private equity or debt financings or other sources, including strategic collaborations and licensing arrangements. We may, however, be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to develop our current product candidates, or any additional product candidates, if developed.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with therapeutics product development, we are unable to accurately predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_cp_text_1_827"></a><a name="_cp_text_1_827"></a>COVID-19 Pandemic and the CARES Act</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_828"></a><a name="_cp_text_1_829"></a><a name="_cp_text_1_830"></a><a name="_cp_text_1_831"></a><a name="_cp_text_1_828"></a>On January 30, 2020, the World Health Organization, or WHO, announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China, or <a name="_cp_text_1_829"></a>the COVID-19 outbreak, and the risks to the international community as the virus subsequently spread globally beyond its point of origin. On March 11, 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The COVID-19 pandemic is affecting the United States and global economies and may affect our operations and those of third parties on which we rely, including by causing disruptions in the supply of our product candidates and the conduct of current and future clinical trials. In addition, the COVID-19 pandemic may affect the operations of the FDA and other health authorities, which could result in delays of reviews and approvals, including with respect to our product candidates. Additionally, while the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce our ability to access capital, which could negatively impact our short-term and long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, financing, <a name="_cp_text_1_830"></a>or clinical trial activities, <a name="_cp_text_1_831"></a>or on healthcare systems or the global economy as a whole. However, these effects could have a material impact on our liquidity, capital resources, operations, and business and those of the third parties on which we rely.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_833"></a><a name="_cp_text_1_834"></a><a name="_cp_text_1_835"></a><a name="_cp_text_1_836"></a><a name="_cp_text_1_833"></a>On March 27, 2020, President Trump signed into law the &#8220;Coronavirus Aid, Relief, and Economic Security (CARES) Act.&#8221; The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property. We currently defer the employer side social security payments and also are evaluating whether we will take advantage of other provisions, if any. The CARES Act also appropriated funds for the Small Business Administration <a name="_cp_text_1_834"></a>Paycheck Protection Program loans that are forgivable in certain situations to promote continued employment, as well as Economic Injury Disaster Loans to provide liquidity to small businesses harmed by the <a name="_cp_text_1_835"></a>COVID-19 pandemic. On December 27, 2020, the Consolidated Appropriations Act, 2021 was signed into law in order to provide further stimulus and support to those affected by the COVID-19 pandemic. We have not and do not plan on obtaining funding from such loans. We do not believe the CARES Act or the Consolidated Appropriations Act, 2021 will have a material impact on our financial condition, results of operations, or liquidity.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_837"></a><a name="_cp_text_1_838"></a>As of December 31, 2020, we had cash and cash equivalents totaling $74.6 million. We believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into 2023<a name="_cp_text_1_837"></a>. We have based these estimates on assumptions that may prove to be imprecise or incorrect, and we may use our available capital resources sooner than we currently expect. See &#8220;&#8212;Liquidity and Capital Resources.&#8221; Because of the numerous risks and uncertainties associated with the development of our product candidates and any future product candidates, our platform, <a name="_cp_text_1_838"></a>and technology, and because the extent to which we may enter into collaborations with third parties for development of any of our product candidates is unknown, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the research and development of our product candidates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_839"></a><a name="_cp_text_1_839"></a>If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Operations Overview </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval and successful commercialization efforts, we may generate revenue in the future from product sales. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating Expenses </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operating expenses since inception have consisted solely of research and development costs and general and administrative costs. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:9.06%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist primarily of costs incurred for our research activities, including the development of and pursuit of regulatory approval of our most advanced product candidate, LYR-210, for the treatment of CRS, which include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_840"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="_cp_text_1_840"></a>employee-related expenses, including salaries, benefits, and stock-based compensation expense for personnel engaged in research and development functions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_841"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="_cp_text_1_841"></a>expenses incurred in connection with the preclinical and clinical development of our product candidates, including under agreements with CROs, investigative sites, and consultants; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">costs of manufacturing our product candidates for use in our preclinical studies and clinical trials as well as manufacturers that provide components of our product candidates for use in our preclinical and potential future clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">consulting and professional fees related to research and development activities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">costs related to compliance with clinical regulatory requirements; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_842"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="_cp_text_1_842"></a>facility costs and other allocated expenses, which include expenses for rent and maintenance of our facility, utilities, depreciation, and other supplies. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expense research and development costs as incurred. We recognize costs for certain development activities, such as clinical trials, based on an evaluation of the progress to completion of specific tasks using data such as clinical site activations, patient enrollment, or information provided to us by our vendors and our clinical investigative sites. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and may be reflected in our consolidated financial statements as prepaid or accrued research and development expenses. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_843"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_843"></a>Our research and development expenses consist primarily of costs such as employee compensation, consulting fees</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and CRO expenses in connection with our preclinical and clinical development activities. We typically use our employee and infrastructure resources across our development programs and we do not allocate personnel costs and other internal costs to specific product candidates or development programs with the exception of the costs to manufacture our product candidates. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_844"></a><a name="_cp_text_1_844"></a>Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will continue to increase for the foreseeable future as we initiate additional clinical trials, including one or more clinical trials for LYR-210 and LYR-220, scale our manufacturing processes, and continue to discover and develop additional product candidates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_845"></a><a name="_cp_text_1_846"></a><a name="_cp_text_1_847"></a><a name="_cp_text_1_848"></a><a name="_cp_text_1_845"></a>The successful development of LYR-210, LYR-220, <a name="_cp_text_1_846"></a>and other potential future product candidates is highly uncertain. Accordingly, at this time, we cannot reasonably estimate or know the nature, timing, <a name="_cp_text_1_847"></a>and costs of the efforts that will be necessary to complete the development of these product candidates. We are also unable to predict when, if ever, we will generate revenue and material net cash inflows from the commercialization and sale of any of our product candidates for which we may obtain marketing approval. We may never succeed in achieving regulatory approval for any of our product candidates. The duration, costs, <a name="_cp_text_1_848"></a>and timing of preclinical studies, clinical trials, and development of our product candidates will depend on a variety of factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_849"></a><a name="_cp_text_1_850"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="_cp_text_1_849"></a>successful completion of clinical trials with safety, tolerability, <a name="_cp_text_1_850"></a>and efficacy profiles for LYR-210, LYR-220, and any potential future product candidates that are satisfactory to the FDA or any comparable foreign regulatory authority; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">approval of an IND for LYR-220 and any potential future product candidate to commence planned or future clinical trials in the United States or foreign countries; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">significant and changing government regulation and regulatory guidance; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">timing and receipt of marketing approvals from applicable regulatory authorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">establishing arrangements with contract manufacturing organizations, or CMOs, for third-party clinical and commercial manufacturing to obtain sufficient supply of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">obtaining and maintaining patent and other intellectual property protection and regulatory exclusivity for our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">commercializing the product candidates, if and when approved, whether alone or in collaboration with others; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">competition with other therapies; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">business interruptions resulting from the COVID-19 pandemic. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_852"></a><a name="_cp_text_1_853"></a><a name="_cp_text_1_852"></a>A change in the outcome of any of these variables with respect to the development, manufacture, <a name="_cp_text_1_853"></a>or commercialization enabling activities of any of our product candidates would significantly change the costs, timing, and viability associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we may be required to expend significant additional financial resources and time on the completion of clinical development. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:9.06%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_854"></a><a name="_cp_text_1_855"></a><a name="_cp_text_1_856"></a><a name="_cp_text_1_854"></a>General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in executive, finance, <a name="_cp_text_1_855"></a>and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, patent, consulting, investor, <a name="_cp_text_1_856"></a>and public relations, accounting, auditing, tax services, and insurance costs. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_857"></a><a name="_cp_text_1_858"></a><a name="_cp_text_1_857"></a>We expect that our general and administrative expenses will increase in the future to support continued research and development activities and potential commercialization of our product candidates. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, attorneys, <a name="_cp_text_1_858"></a>and accountants, among other expenses. Additionally, we will continue to incur increased expenses associated with being a public company, including costs of additional personnel, accounting, audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance costs, and investor and public relations costs. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interest Income </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income consists of interest income earned on our cash and cash equivalents. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Use of Estimates </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_861"></a><a name="_cp_text_1_861"></a>Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements during the reporting periods. These items are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on historical experience, known trends and events, and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ materially from these estimates under different assumptions or conditions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_864"></a><a name="_cp_text_1_864"></a>While our significant accounting policies are described in more detail in the notes to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies used in the preparation of our consolidated financial statements require the most significant judgments and estimates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accrued Research and Development Expenses </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_865"></a><a name="_cp_text_1_866"></a><a name="_cp_text_1_865"></a>As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing purchase orders and open contracts, communicating with our personnel to identify services that have been performed on our behalf, <a name="_cp_text_1_866"></a>and estimating the level of service performed and the associated cost incurred for the services when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed, on a pre-determined schedule, or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant estimates in our accrued research and development expenses include the following costs incurred for services in connection with research and development activities for which we have not yet been invoiced: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">vendors in connection with preclinical development activities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">vendors in connection with the testing of preclinical and clinical trial materials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">CROs in connection with preclinical and clinical studies; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">investigative sites in connection with clinical trials. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_868"></a><a name="_cp_text_1_868"></a>We contract with CROs to conduct clinical and other research and development services on our behalf. We base our expenses related to CROs on our estimates of the services received and efforts expended pursuant to quotes and contracts with them. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to our CROs will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or amount of prepaid expense accordingly. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We apply the fair value recognition provisions of ASC 718, <font style="font-style:italic;">Compensation&#8212;Stock Compensation</font>, or ASC 718, for stock-based awards granted to employees and directors for their services on the board of directors. Determining the amount of stock-based compensation to be recorded requires us to develop estimates of the fair value of stock options as of their grant date. We estimate the fair value of each stock option grant using the Black-Scholes option-pricing model. Calculating the fair value of stock-based awards requires that we make subjective assumptions. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to ASC 718, we measure stock-based awards granted to employees and members of the board of directors at fair value on the date of grant and recognize the corresponding stock-based compensation expense of those awards on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. We have historically granted stock options with exercise prices equivalent to the fair value of our common stock as of the date of grant. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_870"></a><a name="_cp_text_1_872"></a><a name="_cp_text_1_874"></a><a name="_cp_text_1_876"></a>We account for stock-based awards to non-employees in accordance with ASU No. 2018-07, <font style="font-style:italic;">Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</font>, or ASU No. 2018-07, which simplifies the accounting for stock-based payments granted to non-employees for goods and services. Under ASU No. 2018-07, most of the guidance on such payments to non-employees would be aligned with the requirements for stock-based payments granted to employees. Prior to January 1, 2019, we accounted for stock-based payments to non-employees in accordance with ASC 505-50, <font style="font-style:italic;">Equity-Based Payments to Non-Employees</font><a name="_cp_text_1_870"></a>, or ASC 505-50. Pursuant to ASC 505-50, we measured stock-based awards granted to non-employees at fair value as the awards vested <a name="_cp_text_1_872"></a>and recognized <a name="_cp_text_1_874"></a>the resulting value as expense during the period the related services were <a name="_cp_text_1_876"></a>rendered, which was typically the vesting period. At the end of each financial reporting period prior to completion of the service, we re-measured the unvested portion of these awards using the then-current fair value of our common stock and updated assumption inputs in the Black-Scholes option-pricing model. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_877"></a><a name="_cp_text_1_879"></a><a name="_cp_text_1_880"></a><a name="_cp_text_1_881"></a><a name="_cp_text_1_877"></a>The Black-Scholes option-pricing model uses the following inputs: the fair value of our common stock, the expected volatility of our common stock, the expected term of our stock options, the risk-free interest rate for a period that approximates the expected term of our stock options, <a name="_cp_text_1_879"></a>and our expected dividend yield. Following the closing of our IPO<a name="_cp_text_1_880"></a>, the fair value of our common stock is determined based on the quoted market price of our common stock. We have historically been a private company and lack company-specific historical and implied volatility data. Therefore, we have based our computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to us, including stage of product development, life science industry focus, length of trading history, and similar vesting provisions. The historical volatility data is calculated based on a period of time commensurate with the expected term assumption. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available or until circumstances change, such that the identified entities are no longer representative companies. In the latter case, more suitable, similar entities whose share prices are publicly available would be utilized in the calculation. We use the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, <font style="font-style:italic;">Share-Based Payment</font><a name="_cp_text_1_881"></a>, to calculate the expected term for options granted to employees as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. Under this approach, the weighted-average expected option term is presumed to be the average of the contractual term (ten years) and the vesting term (generally four years) of our stock options. We utilize this method due to lack of historical exercise data and the &#8220;plain-vanilla&#8221; nature of our stock-based awards. The expected term is applied to the stock option grant group as a whole, as we do not expect substantially different exercise or post-vesting termination behavior among our employee population. For options granted to non-employees, we utilize the contractual term of the arrangement as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as we have never paid cash dividends, other than the Special Dividend, and have no current plans to pay any cash dividends on our common stock. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have reviewed all recently issued standards and have determined that, other than as disclosed in Note 2 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, such standards will not have a material impact on our consolidated financial statements or do not otherwise apply to our operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_882"></a><a name="_cp_text_1_882"></a>Results of Operations </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comparison of the Years Ended December&#160;31, 2020 and 2019 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our results of operations for the years ended December 31, 2020 and 2019 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dollar</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,522</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,032</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">490</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,687</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,487</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,200</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,209</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,519</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,690</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,209</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,519</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,690</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">213</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(131</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">213</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(131</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,127</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,306</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,821</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.06%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense increased by $0.5&#160;million to $12.5&#160;million for the year ended December&#160;31, 2020 from $12.0&#160;million for the year ended December&#160;31, 2019.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The increase in research and development expense was primarily attributable to an increase of $1.9 million in employee related costs as we increased research and development headcount and an increase of $0.4 million in facility costs and other allocated expenses. The increase was partially offset by decreases of $1.0 million for product development and manufacturing expenses, $0.6 million for consulting expenses, and $0.3 million for clinical and regulatory expenses related to our LANTERN trial. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:9.06%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expense increased by $5.2&#160;million to $9.7&#160;million for the year ended December&#160;31, 2020 from $4.5&#160;million for the year ended December&#160;31, 2019.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The increase in general and administrative expenses was primarily attributable to an increase in employee related costs of $2.3 million, including an increase of $1.4 million of stock-based compensation, an increase in costs associated with being a public company of $2.4 million, in particular an increase in the cost of directors and officers insurance of $2.2 million, an increase in professional and consulting expenses of $0.4 million, and a decrease in sublease income and expense reimbursements of $0.4 million related to the end of all subleases in June 2019. These increases were partially offset by a decrease of $0.2 million for a charge for uncollectible accounts in the year ended December 31, 2019 without a corresponding charge in the year ended December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:9.06%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Interest Income </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_885"></a>Interest income decreased $0.1&#160;million to $82,000 for the year ended December&#160;31, 2020 from $0.2&#160;million for the year ended December&#160;31, 2019. The de<a name="_cp_text_1_885"></a>crease in interest income was attributable to lower average interest rates for the year ended December 31, 2020 due to changes in market conditions as compared to the year ended December 31, 2019.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sources of Liquidity </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_887"></a>We have funded our operations from inception through December 31, 2020 primarily with gross proceeds of $162.1&#160;million from sales of our redeemable convertible preferred stock, net proceeds of $57.3<a name="_cp_text_1_887"></a>&#160;million from our IPO, and $16.8&#160;million from government contracts. The following table provides information regarding our total cash and cash equivalents at December 31, 2020 and 2019 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,593</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,808</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash Flows </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides information regarding our cash flows for the years ended December 31, 2020 and 2019 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,143</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,754</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,775</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(211</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,703</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(115</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,785</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,080</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.06%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Net Cash Used in Operating Activities </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cash used in operating activities resulted primarily from our net losses adjusted for non-cash charges and changes in components of working capital. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities was $21.1&#160;million for the year ended December 31, 2020 compared to $13.8 million for the year ended December 31, 2019. The increase in cash used in operating activities of $7.3 million was primarily attributable to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">$5.8 million increase in net loss; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">$1.6 million increase in stock-based compensation; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">$3.0 million decrease in changes in the components of working capital. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:9.06%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Net Cash Used in Investing Activities </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities was $1.8 million for the year ended December 31, 2020 compared to $0.2 million for the year ended December 31, 2019. The increase in cash used in investing activities of $1.6 million was attributable to an increase in cash used for the purchases of property and equipment as we invest in increasing our manufacturing capabilities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:9.06%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Net Cash Provided by (Used in) Financing Activities </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities was $87.7 million for the year ended December 31, 2020 compared to net cash used in financing activities of $0.1 for the year ended December 31, 2019. The increase in cash provided by financing activities of $87.8 million was attributable to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">net proceeds of $30.2&#160;million from the sale of our Series C redeemable convertible preferred stock in the year ended December 31, 2020; and </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_888"></a><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;"><a name="_cp_text_1_888"></a>completion of our IPO by issuing 4,025,000 shares of common stock, at an offering price of $16.00 per share, </font><font style="color:#000000;">par value $0.001, </font><font style="color:#000000;">for gross proceeds of $</font><font style="color:#000000;">64.4</font><font style="color:#000000;">&#160;million and after deducting $</font><font style="color:#000000;">6.9</font><font style="color:#000000;"> million of underwriting discounts and commissions and offering expenses paid by us in the year ended December 31, 2020. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Funding Requirements </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_889"></a><a name="_cp_text_1_890"></a><a name="_cp_text_1_889"></a>We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development for, begin the manufacturing scale up process for, initiate later stage clinical trials for, and seek marketing approval for, our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing, <a name="_cp_text_1_890"></a>and distribution. Furthermore, we will continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into 2023. We have based this estimate on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the costs of conducting future clinical trials of LYR-210; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the costs of manufacturing additional material for one or more pivotal Phase 3 clinical trials of LYR-210 and potential future clinical studies we might conduct for our other product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the costs of scaling up our manufacturing process and supply chain capacity to provide sufficient quantities of LYR-210 for the potential commercialization of LYR-210 if our clinical development program is successful and we obtain marketing approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the advancement of LYR-220; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_891"></a><a name="_cp_text_1_892"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="_cp_text_1_891"></a>the scope, progress, results, <a name="_cp_text_1_892"></a>and costs of discovery, preclinical development, laboratory testing, and clinical trials for other potential product candidates we may develop, if any; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_893"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="_cp_text_1_893"></a>the costs, timing, and outcome of regulatory review of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to establish and maintain collaborations on favorable terms, if at all; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements we might have at such time; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_894"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="_cp_text_1_894"></a>the costs and timing of future commercialization activities, including product sales, marketing, manufacturing, and distribution, for any of our product candidates for which we receive marketing approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_895"></a><a name="_cp_text_1_896"></a><a name="_cp_text_1_897"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="_cp_text_1_895"></a>the costs of preparing, filing, <a name="_cp_text_1_896"></a>and prosecuting patent applications, obtaining, maintaining, <a name="_cp_text_1_897"></a>and enforcing our intellectual property rights, and defending intellectual property-related claims; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_898"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="_cp_text_1_898"></a>our headcount growth and associated costs as we expand our business operations, our research and development activities, and our manufacturing scale up; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the costs of operating as a public company; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the cost of potential business interruptions resulting from the COVID-19 pandemic. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_900"></a><a name="_cp_text_1_901"></a><a name="_cp_text_1_900"></a>Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, <a name="_cp_text_1_901"></a>and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interests may be diluted, and the terms of these securities may include liquidation or other preferences that could adversely affect your rights as a common stockholder. Any debt financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends, that could adversely impact our ability to conduct our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_902"></a><a name="_cp_text_1_903"></a><a name="_cp_text_1_904"></a><a name="_cp_text_1_905"></a><a name="_cp_text_1_902"></a>If we raise funds through collaborations, strategic alliances, <a name="_cp_text_1_903"></a>or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, <a name="_cp_text_1_904"></a>or product candidates, <a name="_cp_text_1_905"></a>or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_911"></a>Off-Balance Sheet Arrangements </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_912"></a><a name="_cp_text_1_912"></a>We did not have, during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable SEC rules. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Emerging Growth Company Status </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_62"></a>The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, permits an &#8220;emerging growth company&#8221; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have elected to use this extended transition period under the JOBS Act. As a result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make comparison of our financials to those of other public companies more difficult.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will remain an emerging growth company until the earliest to occur of: (1)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the completion of our IPO, or December&#160;31, 2025, (b) in which we have total annual gross revenues of $1.07&#160;billion or more, or (c)&#160;in which we are deemed to be a large accelerated filer under the rules of the SEC, which means the market value of our outstanding common stock held by&#160;non-affiliates&#160;exceeds $700&#160;million as of last business day of our most recently completed second fiscal quarter, and (2)&#160;the date on which we have issued more than $1.0&#160;billion in nonconvertible debt during the previous three years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a>Item 7A. Quantitative and Qualitative Disclosures About Market Risk. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Quantitative and Qualitative Disclosures About Market Risk </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_919"></a>We are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this Item 7A. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a>Item 8. Financial Statements and Supplementary Data. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_921"></a><a name="_cp_text_1_923"></a>The consolidated <a name="_cp_text_1_923"></a>financial statements required to be filed pursuant to this Item 8 are appended to this report and are incorporated herein by reference.&nbsp;&nbsp;An index to those financial statements is found in Item 15 of Part IV of this Annual Report on Form 10-K.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a>Item 9. Changes in and Disagreements w<a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a>ith Accountants on Accounting and Financial Disclosure.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p><a name="_AEIOULastRenderedPageBreakAEIOU14"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9A_CONTROLS_PROCEDURES"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9A_CONTROLS_PROCEDURES"></a>Item 9A. Controls</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> and Procedures. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Management&#8217;s Evaluation of Disclosure Controls and Procedures</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Limitations on Effectiveness of Controls and Procedures</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this Annual Report on Form 10-K, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K does not include a report of management&#8217;s assessment regarding our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) or an attestation report of our independent registered accounting firm due to a transition period established by rules of the SEC for newly public companies. Additionally, our independent registered accounting firm will not be required to opine on the effectiveness of our internal control over financial reporting pursuant to Section 404 until we are no longer an &#8220;emerging growth company&#8221; as defined in the JOBS Act.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no changes in our internal control over financial reporting identified in management&#8217;s evaluation pursuant to Rules 13a-15(f) or 15d-15(f) of the Exchange Act during the quarter ended December 31, 2020 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9B_OR_INFORMATION"></a><a name="ITEM_9B_OR_INFORMATION"></a>Item 9B. Other Information. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p><a name="_AEIOULastRenderedPageBreakAEIOU15"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_III"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_III"></a>PART </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">III </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a><a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a>Item 10. Directors, Executive Officers and Corporate Governance. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Information about our Directors </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents information concerning our board of directors.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.72%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Age</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Position</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">In Current Position Since</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.72%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maria Palasis, Ph.D.</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.26%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer and Director</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.06%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 2015</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Altman</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 2018</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Edward Anderson</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 2019</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C. Ann Merrifield</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September 2019</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Konstantin Poukalov</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 2020</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">W. Bradford Smith</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 2019</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nancy Snyderman, M.D., FACS</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October 2020</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following are brief biographies describing the backgrounds of our directors.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.17%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="PALASIS_BIO"></a>Maria Palasis, Ph.D.<font style="font-style:normal;"> has served as our President and Chief Executive Officer and a member of our board of directors since January 2015. Prior to her role with us as President and Chief Executive Officer, Dr. Palasis held positions of increasing responsibility, the most recent of which was Executive Vice President and Chief Technology Officer from 2011 to 2015. Before that, in 2008, Dr. Palasis joined Arsenal Medical, Inc., a biotechnology company, as Executive Vice President and subsequently served as President and Chief Executive Officer and a member of the board of directors of Arsenal Medical from January 2015 to June 2018. Before that, from November 1995 to January 2008, Dr. Palasis was employed with the title of Director at Boston Scientific Corporation, a medical device company, where she managed a portfolio of external biotech and medical device investments and led the development of several combination therapies. Dr. Palasis holds a B.S. and Ph.D. in Chemical Engineering from the University of Cincinnati, and she held a postdoctoral fellowship in molecular biology at the University of Cincinnati School of Medicine. We believe that Dr. Palasis&#8217; experience in the industry and knowledge of our company qualifies her to serve on our board of directors.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.17%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Michael Altman<font style="font-style:normal;"> has served as a member of our board of directors since June 2018. Since 2007, Mr. Altman has been employed on the investment team at Perceptive Advisors, a life sciences focused investment firm, where he currently serves as Managing Director and focuses on medical devices, diagnostics, digital health and specialty pharmaceuticals investments. Since October 2018, Mr. Altman has also served as Chief Financial Officer and member of the board of directors of ARYA Sciences Acquisition Corp., a special purpose acquisition company. From October 2005 to October 2007, Mr. Altman served as a healthcare trader and analyst at First New York Securities. Mr. Altman has served on the board of directors of Vitruvius Therapeutics, Inc., a pharmaceutical company, since December 2017, and served on the board of directors of Vensun Pharmaceuticals, Inc., a pharmaceutical company, from November 2016 to January 2019. Mr. Altman holds a B.S. in Business Administration from the University of Vermont. We believe that Mr. Altman&#8217;s broad operational and transactional experience qualifies him to serve on our board of directors.</font></p>
<p style="margin-top:12pt;margin-bottom:6pt;text-indent:9.17%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Edward Anderson<font style="font-style:normal;"> has served as a member of our board of directors since February 2019. Since June 1994, Mr. Anderson has served as the Founder and a Managing Partner at North Bridge Venture Partners &amp; Growth Equity, a venture capital firm. Mr. Anderson holds a B.F.A. from the University of Denver and an M.B.A. from Columbia University Graduate School of Business. We believe that Mr. Anderson&#8217;s extensive experience in venture capital investments qualifies him to serve on our board of directors. </font></p>
<p style="margin-top:12pt;margin-bottom:6pt;text-indent:9.17%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">C. Ann Merrifield<font style="font-style:normal;"> has served as a member of our board of directors since September 2019. Ms. Merrifield has also served as a member of the boards of directors for a portfolio of public and private companies in the life sciences sector which include Flexion Therapeutics, Inc., since June 2014, InVivo Therapeutics Holdings Corp., since November 2014. From July 2015 to August 2018, she served as a director of Juniper Pharmaceuticals, Inc., a healthcare company, until it was acquired by Catalent, Inc. and from December 2016 to January 2019, she served as a director of Veritas Genetics, Inc. Ms. Merrifield also serves as a Trustee for MassMutual Premier, Select and MML Series Investment Funds, Partners Continuing Care (the post-acute care services division of Partners HealthCare), the Huntington Theatre Company and the YMCA of Greater Boston. From November 2012 to July 2014, Ms. Merrifield served as President, Chief Executive Officer and director of PathoGenetix Inc., a genomics company, which voluntarily filed for Chapter 7 bankruptcy in July 2014. Before that, Ms. Merrifield spent 18 years at Genzyme Corporation, serving in several leadership roles, including President of Genzyme Biosurgery, President of Genzyme Genetics and Senior Vice President, Business Excellence. Ms. Merrifield holds a B.A. in Zoology and a Master of Education from the University of Maine and an M.B.A. from the Tuck School of Business at Dartmouth College. We believe that Ms. Merrifield&#8217;s extensive industry experience qualifies her to serve on our board of directors. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:6pt;text-indent:9.06%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Konstantin Poukalov</font><font style="font-style:normal;"> has served as a member of our board of directors since January 2020. Since March 2019, Mr. Poukalov has served as Managing Director at Perceptive Advisors, a life sciences focused investment firm. Since August 2019, Mr. Poukalov has also served on the board of directors of Landos Biopharma, Inc., a biopharmaceutical company. From July 2012 to October 2018, Mr. Poukalov served in roles of increasing responsibility at Kadmon Holdings, Inc., a biopharmaceutical company, most recently serving as Executive Vice President and Chief Financial Officer from July 2014 to October 2018. Mr. Poukalov holds a B.S. in Electrical Engineering from Stony Brook University. We believe that Mr. Poukalov&#8217;s extensive financial and industry experience qualify him to serve on our board of directors. </font></p>
<p style="margin-top:12pt;margin-bottom:6pt;text-indent:9.06%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">W. Bradford Smith<font style="font-style:normal;"> has served a member of our board of directors since November 2019. Mr. Smith has served as Chief Financial Officer and Treasurer of Homology Medicines, Inc., a genetic medicines company, since April 2017 and as Secretary since July 2017. From March 2014 to April 2017, Mr. Smith was Chief Financial Officer of Ocular Therapeutix, Inc., a biopharmaceutical company. Prior to joining Ocular Therapeutix, Mr. Smith served as Chief Financial Officer of OmniGuide, Inc., a medical device company, from July 2008 to March 2014. Mr. Smith holds a B.S. in Biology from Tufts University and an M.B.A. from the Whittemore School of Business and Economics at the University of New Hampshire. We believe that Mr. Smith&#8217;s extensive financial and industry experience qualify him to serve on our board of directors. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Nancy Snyderman, M.D., FACS<font style="font-style:normal;"> has served as a member of our board of directors since October 2020.&nbsp;&nbsp;Dr. Snyderman has also served on the boards of directors of Axonics Modulation Technologies, Inc., a medical device company, since April 2019 and Alkermes plc, a biopharmaceutical company, since May 2016. From 2006 to 2018, Dr. Snyderman served as an advisory board member to GE's Healthymagination, General Electric Company&#8217;s healthcare initiative.&nbsp;&nbsp;From 2003 to 2008, Dr. Snyderman also served as a vice president for corporate communications at Johnson &amp; Johnson. Dr. Snyderman is a board-certified head and neck surgeon and has had academic appointments at the University of Pennsylvania and the University of California-San Francisco. From 2016 to 2018, she served as a professor at the Center for Innovation for Global Health at Stanford University. Dr. Snyderman is an Emmy award winning medical correspondent, having worked at ABC News from 1987 to 2003 and later as chief medical editor at NBC News from 2004 to 2015. Dr. Snyderman holds a B.A. in Microbiology from Indiana University and a M.D. from the University of Nebraska and has completed residencies in Pediatrics and Otolaryngology Head and Neck Surgery at the University of Pittsburgh. We believe that Dr. Snyderman's extensive experience as a veteran healthcare journalist, a practicing physician, and an executive at a pharmaceutical company, as well as her roles in academia and as advisor to policy organizations, qualify her to serve on our board of directors.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Information about our Executive Officers</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.14%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Age</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Position</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">In Current Position Since</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.14%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maria Palasis, Ph.D.</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> President and Chief Executive Officer and Director</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.16%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 2015</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R. Don Elsey</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer, Treasurer and Secretary</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 2019</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robert Richard, Ph.D.</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senior Vice President of Research and Development</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 2020</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pamela Nelson</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senior Vice President of Regulatory Affairs</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 2020</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corinne Noyes</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senior Vice President of Commercial Strategy and Market Development</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September 2018</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:6pt;text-indent:9.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following are brief biographies describing the backgrounds of our executive officers. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biography for Dr. Palasis appears above on page 102.</p>
<p style="margin-top:12pt;margin-bottom:6pt;text-indent:9.17%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">R. Don Elsey<font style="font-style:normal;"> has served as our Chief Financial Officer since August 2019 and as our Treasurer and Secretary since October 2019. Prior to joining our company, from February 2015 to February 2019, Mr. Elsey served as Chief Financial Officer at Senseonics, Inc., a medical device company. From May 2014 until February 2015, Mr. Elsey served as Chief Financial Officer of Regado Biosciences, Inc., a biopharmaceutical company. From December 2012 to February 2014, Mr. Elsey served as Chief Financial Officer of LifeCell Corporation, a privately held regenerative medicine company. Mr. Elsey holds a B.A. in economics and an M.B.A. in finance from Michigan State University. </font></p>
<p style="margin-top:12pt;margin-bottom:6pt;text-indent:9.17%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Robert Richard, Ph.D.<font style="font-style:normal;"> has served as our Senior Vice President of Research and Development since June 2020.&nbsp;&nbsp;Prior to joining our company, from February 2019 to May 2020 Dr. Richard served as Vice President of Research and Development at Anika Therapeutics, Inc., a therapeutics company. Prior to that, he held research and development leadership positions at Hyalex Orthopaedics, Inc., a medical device company, from November 2017 to February 2019, C.R. Bard, Inc., a medical device company, from June 2008 to November 2017, Boston Scientific Corporation, a global medical device company, from September 2000 to June 2008, and Johnson &amp; Johnson, a global medical device, pharmaceutical and consumer product company, from September 1991 to August 2000.&nbsp;&nbsp;Dr. Richard holds a B.S. in chemistry and a B.S. in biology from University of Massachusetts at Dartmouth and a Ph.D. in polymer chemistry and plastics engineering from the University of Massachusetts at Lowell. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:6pt;text-indent:9.06%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Pamela Nelson</font><font style="font-style:normal;"> has served as our Senior Vice President of Regulatory Affairs since August 2020. Prior to joining our company, from January 2011 to July 2020, Ms. Nelson served as Vice President, Regulatory Affairs at Avedro, Inc., a medical technology company. Prior to that, she held regulatory positions at Alnara Pharmaceuticals, Inc., a biotechnology company from June 2009 to December 2010, Altus Pharmaceuticals Inc., a biopharmaceutical company from February 2006 to May 2009, Alkermes PLC, a global biopharmaceutical company July 1998 to January 2006 and Genzyme Corporation, a global biotechnology company January 1995 to June 1998.&nbsp;&nbsp;Ms. Nelson holds a B.A. in English and an M.A. in education administration from the University of Massachusetts at Amherst.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Corinne Noyes<font style="font-style:normal;"> has served as our Senior Vice President of Commercial Strategy and Market Development since September 2018. Prior to joining our company, from January 2018 to August 2018, Ms. Noyes served as an independent contractor to our Company, providing biopharmaceutical consulting services. Before that, from January 2005 to August 2018, Ms. Noyes worked as a strategic advisor and independent biopharmaceutical consultant providing commercial leadership to emerging life sciences companies, including, among others, AMAG Pharmaceuticals, Inc., Avila Therapeutics, Inc. (Celgene Corporation), Adnexus Therapeutics Inc. (Bristol-Myers Squibb Company), Constellation Pharmaceuticals, Inc. and Editas Medicine, Inc. Before that, from 1997 to 2004, Ms. Noyes held various commercial leadership positions at Biogen Inc., a biotechnology company. Prior to joining Biogen Inc., from 1992 to 1996, Ms. Noyes worked as a health care strategy consultant at Deloitte &amp; Touche LLP. Ms. Noyes holds a B.A. in Humanities and a B.B.A. in Business from St. Mary&#8217;s College of Notre Dame and an M.B.A. in finance from University of Chicago Graduate School of Business.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Family Relationships</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are no family relationships among any of our executive officers or directors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Code of Business Conduct and Ethics</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board has adopted a written code of business conduct (the &#8220;Code of Business Conduct and Ethics&#8221;) that applies to all of our directors, officers and employees, including our principal executive officer, principal financial officer and principal accounting officer. A copy of the code is available on our website at www.lyratherapeutics.com in the &#8220;Governance&#8221; section of the &#8220;Investors &amp; News&#8221; page. In addition, we intend to post on our website all disclosures that are required by law or The Nasdaq Stock Market LLC concerning any amendments to, or waivers from, any provision of our Code of Business Conduct and Ethics.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Audit Committee and Audit Committee Financial Expert</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have a separately-designated standing audit committee (&#8220;Audit Committee&#8221;) that consists of Edward Anderson, C. Ann Merrifield and Bradford Smith. Mr. Smith serves as the Chair of the Audit Committee. Our board of directors has determined that all members of the audit committee (Edward Anderson, C. Ann Merrifield and Bradford Smith) are independent directors under the Nasdaq rules and the additional independence standards applicable to audit committee members established pursuant to Rule 10A-3 under the Exchange Act. Our board of directors has also determined that each of Edward Anderson, C. Ann Merrifield and Bradford Smith meets the &#8220;financial literacy&#8221; requirement for audit committee members under the Nasdaq Stock Market rules and Bradford Smith is an &#8220;audit committee financial expert&#8221; within the meaning of the SEC rules.&nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a>Item 11. Executive Compensation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This section discusses the material components of the executive compensation program for our executive officers who are named in the &#8220;2020 Summary Compensation Table&#8221; below. In 2020, our &#8220;named executive officers&#8221; and their positions were as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Maria Palasis, Ph.D., President and Chief Executive Officer; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">R. Don Elsey, Chief Financial Officer; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Robert Richard, Ph.D., Senior Vice President of Research and Development.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Richard commenced employment with us effective June 22, 2020.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020 Summary Compensation Table</font></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth information concerning the compensation of our named executive officers for the years shown.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.74%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name and Principal Position</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Salary</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Awards<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-Equity</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incentive Plan</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation<sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">All Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.74%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maria Palasis, Ph.D.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<font style="font-style:italic;">President and Chief Executive Officer</font></p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">470,520</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,547,671</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">275,000</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,550</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(3)</sup></p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,301,741</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">388,025</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">318,850</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135,809</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">842,684</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R. Don Elsey</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Financial Officer</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362,558</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224,350</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150,000</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,778</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(4)</sup></p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">760,686</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130,625</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">501,247</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,671</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,235</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&nbsp;</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">737,778</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robert Richard, Ph.D.<sup style="font-size:85%;line-height:120%;vertical-align:top">(5)</sup></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Senior Vice President of Research and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Development</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164,127</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300,043</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,000</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,428</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(3)</sup></p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">549,598</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:86.67%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">Amounts represent the full grant date fair value of stock options granted during 2020 computed in accordance with ASC Topic 718, rather than the amounts paid to or realized by the named individual. We provide information regarding the assumptions used to calculate the value of all option awards made to named executive officers in Note 8 to the consolidated financial statements included in this Annual Report on Form 10-K. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">Amounts represent performance-based annual cash bonuses made by our board of directors for the named executive officers for fiscal year 2020. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">Amounts represent company 401(k) matching contributions.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(4)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">The amount represents company 401(k) matching contributions and use of a corporate apartment, commuting expenses and related tax gross-ups.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(5)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">Dr. Richard commenced employment with us in June 2020.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Narrative to Summary Compensation Table </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2020 Salaries </p>
<p style="margin-top:12pt;margin-bottom:5pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The named executive officers receive a base salary to provide a fixed component of compensation reflecting the executive&#8217;s skill set, experience, role and responsibilities.&nbsp;&nbsp;For 2020, the initial base salaries for Dr. Palasis and Mr. Elsey were $401,606 and $329,740, respectively. In connection with our initial public offering, our board of directors approved increasing the base salaries of Dr. Palasis and Mr. Elsey to $500,000 and $375,000, respectively, effective upon the closing of the offering in May 2020. Dr. Richard&#8217;s base salary was set at $307,000 in connection with his commencement of employment with us in June 2020. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2020 Bonuses </p>
<p style="margin-top:12pt;margin-bottom:5pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We offer our named executive officers the opportunity to earn annual cash bonuses to compensate them for attaining short-term company goals as approved by our board of directors. For 2020, bonuses were based entirely on attaining clinical, research and development, strategic, capital raising and financial goals. The 2020 target bonuses for each of Dr. Palasis, Mr. Elsey and Dr. Richard were 55%, 40% and 35%, respectively, of his or her annual base salary. The target bonuses for Dr. Palasis and Mr. Elsey were increased from 35% and 30%, respectively, in connection with our initial public offering, and Dr. Richard&#8217;s target bonus was set in connection with his commencement of employment with us in June 2020. Dr. Richard&#8217;s bonus for 2020 was prorated to reflect his partial year of employment. The actual annual cash bonuses awarded to each named executive officer for 2020 performance are set forth above in the 2020 Summary Compensation Table in the column titled &#8220;Non-Equity Incentive Plan Compensation&#8221;. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Equity Compensation </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We offer stock options to our employees, including our named executive officers, as the long-term incentive component of our compensation program. Our stock options generally allow employees to purchase shares of our common stock at a price equal to the fair market value of our common stock on the date of grant. With respect to grants made in connection with the commencement of employment, our stock options typically vest as to 25% of the underlying shares on the first anniversary of the vesting commencement date and in equal monthly installments over the following three years, subject to the holder&#8217;s continued service with us. From time to time, our board of directors may also construct alternate vesting schedules as it determines are appropriate to motivate particular employees. Historically, our stock options have been intended to qualify as &#8220;incentive stock options&#8221; to the extent permitted under the Internal Revenue Code.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the stock options granted to our named executive officers in 2020.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.56%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Named Executive Officer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020 Stock Options Granted</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maria Palasis, Ph.D.</p></td>
<td valign="middle"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">326,303</p></td>
<td valign="middle"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R. Don Elsey</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,635</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robert Richard, Ph.D.</p></td>
<td valign="middle"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,000</p></td>
<td valign="middle"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The stock option awards to Dr. Palasis and Mr. Elsey were made in connection with the initial public offering effective April 2020 and vest in 48 equal monthly installments following the effective date of grant, subject to the continued service of the applicable named executive officer. The stock option award to Dr. Richard was made in June 2020 in connection with his commencement of employment with us and is subject to our standard vesting schedule for grants made in connection with the commencement of employment described above.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-weight:bold;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Elements of Compensation </p>
<p style="margin-top:12pt;margin-bottom:5pt;text-indent:9.06%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Retirement Plan </p>
<p style="margin-top:12pt;margin-bottom:5pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain a 401(k) retirement savings plan for our employees, including our named executive officers, who satisfy certain eligibility requirements. Our named executive officers are eligible to participate in the 401(k) plan on the same terms as other full-time employees. We believe that providing a vehicle for tax-deferred retirement savings though our 401(k) plan adds to the overall desirability of our executive compensation package and further incentivizes our employees, including our named executive officers, in accordance with our compensation policies. For 2020, we made matching contributions of 50% of the first 6% of eligible compensation contributed under our 401(k) plan.</p>
<p style="margin-top:12pt;margin-bottom:5pt;text-indent:9.06%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Employee Benefits and Perquisites </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of our full-time employees, including our named executive officers, are eligible to participate in our employee benefit plans and programs, including medical, dental, and vision benefits, health spending accounts, and short- and long-term disability, accidental death and dismemberment, and life insurance, to the same extent as our other full-time employees, subject to the terms and eligibility requirements of those plans.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Outstanding Equity Awards at 2020 Fiscal Year-End </font></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the number of shares of common stock underlying outstanding equity incentive plan awards for each named executive officer as of December&#160;31, 2020.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vesting</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commencement</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unexercised</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options (#)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercisable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unexercised</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options (#)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unexercisable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incentive Plan</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Awards:</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unexercised</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unearned</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options (#)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expiration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maria Palasis, Ph.D.</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/16/2011</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,793</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&nbsp;</sup></p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.63</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&nbsp;</sup></p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/16/2021</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/26/2013</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,358</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&nbsp;</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.73</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&nbsp;</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6/26/2023</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/1/2015</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,287</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&nbsp;</sup></p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.76</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&nbsp;</sup></p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/23/2025</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6/13/2017</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,429</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,429</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.73</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&nbsp;</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6/13/2027</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/6/2019</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,573</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95,882</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&nbsp;</sup></p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.76</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&nbsp;</sup></p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/6/2029</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/30/2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,383</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">271,920</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&nbsp;</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.00</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&nbsp;</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/29/2030</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R. Don Elsey</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7/29/2019</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,485</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,298</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(3)</sup></p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&nbsp;</sup></p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.49</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&nbsp;</sup></p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/24/2029</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/30/2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,439</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,196</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&nbsp;</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.00</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&nbsp;</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/29/2030</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robert Richard, Ph.D.</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6/24/2020</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,000</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(3)</sup></p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&nbsp;</sup></p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.33</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&nbsp;</sup></p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6/24/2030</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:86.67%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">Options vest and become exercisable in equal monthly installments over four years following the vesting commencement date, subject to the named executive officer&#8217;s continued service with us on each applicable vesting date. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">Options vest and become exercisable at the end of any given three-month period occurring prior to six years from the vesting commencement date in which we recognize revenue from the commercial sale of an FDA-approved product each month and in amounts, with respect to the second and third months of such period that increase from the revenue recognized from such product sales in the immediately preceding month, subject to Dr. Palasis&#8217; continued employment with us on each applicable vesting date. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">Options vest and become exercisable as to 25% of the underlying shares on the first anniversary of the vesting commencement date and in 36 equal monthly installments over the following three years, subject to the named executive officer&#8217;s continued service with us on each applicable vesting date.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Executive Employment Agreements </p>
<p style="margin-top:12pt;margin-bottom:5pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We entered into new employment agreements with Dr. Palasis and Mr. Elsey in connection with our initial public offering that superseded their prior employment arrangements with us, and we entered into an employment agreement with Dr. Richard in connection with his commencement of employment with us in June 2020. The employment agreements provide for the annual base salaries and annual target bonus opportunities described above under the headings &#8220;&#8212;Annual Base Salaries&#8221; and &#8220;&#8212;Target Bonuses&#8221;. Through December&#160;31, 2020, and subject to renewal by our board of directors thereafter, Mr. Elsey is also entitled to (i) reimbursement of reasonable travel expenses from his home to our offices in Massachusetts, (ii) use of a corporate apartment while working in Massachusetts and (iii) reimbursement for income and employment taxes incurred by Mr. Elsey as a result of these commuting payments and benefits. The total amount for (i) through (iii) may not exceed $75,000. </p>
<p style="margin-top:12pt;margin-bottom:5pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the employment agreements, if we terminate the employment of Dr. Palasis, Mr. Elsey or Dr. Richard without &#8220;cause&#8221; or the executive resigns for &#8220;good reason&#8221; (each as defined below), subject to the executive&#8217;s timely execution of a release of claims and continued compliance with a separate restrictive covenant agreement (described below), the executive is entitled to receive (i) base salary continuation for a period of 12 months for Dr. Palasis, 9 months for Mr. Elsey and 6 months for Dr. Richard; (ii) payment of any annual bonus for the prior year earned but unpaid as of the date of termination and (iii) direct payment of or reimbursement for continued medical, dental or vision coverage pursuant to COBRA for up to 12 months for Dr. Palasis, 9 months for Mr. Elsey and 6 months for Dr. Richard, less the amount each named executive officer would have had to pay to receive such coverage as an active employee based on the cost sharing levels in effect on the named executive officer&#8217;s termination date. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:5pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we terminate Dr. Palasis, Mr. Elsey or Dr. Richard without &#8220;cause&#8221; or the executive resigns for &#8220;good reason,&#8221; in either case, on or within three months prior to or 12 months following a change in control, then, in lieu of the severance benefits described above, subject to the executive&#8217;s timely execution of a release of claims, the executive is entitled to receive (i) an amount equal in cash equal to 1.5 times for Dr. Palasis, one times for Mr. Elsey and 0.75 times for Dr. Richard the sum of the named executive officer&#8217;s annual base salary plus target annual bonus for the year of termination, (ii) payment of any annual bonus for the prior year earned but unpaid as of the date of termination, (iii) direct payment of or reimbursement for continued medical, dental or vision coverage pursuant to COBRA for up to 18 months for Dr. Palasis, 12 months for Mr. Elsey and 9 months for Dr. Richard, less the amount each named executive officer would have had to pay to receive such coverage as an active employee based on the cost sharing levels in effect on the named executive officer&#8217;s termination date, and (iv) accelerated vesting of all unvested equity or equity-based awards held by the named executive officer that vest solely based on the passage of time, with any such awards that vest based on the attainment of performance-vesting conditions being governed by the terms of the applicable award agreement. </font></p>
<p style="margin-top:12pt;margin-bottom:5pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of our named executive officers has agreed to refrain from competing with us while employed and following his or her termination of employment for any reason for a period of one year and to refrain from soliciting our employees or customers while employed and following his or her termination of employment for any reason for a period of two years in the case of Dr. Palasis and Mr. Elsey and one year in the case of Dr. Richard. </p>
<p style="margin-top:12pt;margin-bottom:5pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of the employment agreements, &#8220;cause&#8221; generally means the named executive officer&#8217;s refusal to substantially perform the duties associated with his or her position with our company or to carry out the reasonable and lawful instructions of our board of directors concerning duties or actions consistent with his or her position, his or her breach of a material provision of the employment agreement which remains uncured (to the extent capable of cure) for a period of 30 days following written notice from our company, his or her conviction, plea of no contest or nolo contendere or imposition of unadjudicated probation for any felony or crime involving moral turpitude, his or her unlawful use (including being under the influence) or possession of illegal drugs on our premises or while performing his or her duties and responsibilities under the employment agreement, or his or her commission of any act of fraud, embezzlement, misappropriation, willful misconduct, or breach of fiduciary duty against us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of the employment agreements, &#8220;good reason&#8221; generally means, subject to certain cure rights, the named executive officer&#8217;s termination of employment due to a reduction in salary or target bonus (other than a reduction of 20% or less of the named executive officer&#8217;s base salary implemented as part of an across the board, proportionate reduction of base salaries for other members of our management team), a material decrease in authority or areas of responsibility, our company&#8217;s breach of any one or more of the material provisions of the employment agreement, or a relocation by our company of the named executive officer&#8217;s primary office to a location more than 50 miles from the named executive officer&#8217;s primary office on the date of the agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Director Compensation </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020 Director Compensation Table</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.4%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fees Earned or Paid in Cash</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Awards</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option Awards</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)<font style="font-family:Calibri;font-weight:normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.4%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robert Langer Sc.D.<sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="middle"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,355</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,355</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">George Whitesides Ph.D.<sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,355</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">314,576</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333,931</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Altman</p></td>
<td valign="middle"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,667</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">156,163</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">182,830</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C. Ann Merrifield</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,333</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,264</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,597</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Edward Anderson</p></td>
<td valign="middle"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,667</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">156,163</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">187,830</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">W. Bradford Smith</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,667</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,110</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128,777</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Konstantin Poukalov</p></td>
<td valign="middle"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,667</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">156,163</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">182,830</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nancy Snyderman, M.D.<sup style="font-size:85%;line-height:120%;vertical-align:top">(3)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,204</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,264</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,468</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:86.67%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">Amounts reflect the full grant-date fair value of stock awards and stock options granted during 2020 computed in accordance with ASC Topic 718, rather than the amounts paid to or realized by the named individual. We provide information regarding the assumptions used to calculate the value of all stock awards and option awards made to our directors in Note 8 to the consolidated financial statements included in this Annual Report on Form 10-K</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">Dr. Langer and Dr. Whitesides resigned from our board of directors on October 26, 2020. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">Dr. Snyderman was appointed to our board of directors on October 27, 2020.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below shows the aggregate numbers of option awards (exercisable and unexercisable) held as of December&#160;31, 2020 by each non-employee director. None of our non-employee directors held unvested stock awards as of December 31, 2020.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding at Fiscal Year End</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.88%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robert Langer Sc.D.</p></td>
<td valign="middle"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121,584</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">George Whitesides Ph.D.</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,085</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Altman</p></td>
<td valign="middle"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,500</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C. Ann Merrifield</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,288</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Edward Anderson</p></td>
<td valign="middle"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,500</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">W. Bradford Smith</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,289</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Konstantin Poukalov</p></td>
<td valign="middle"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,500</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nancy Snyderman, M.D.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,500</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:5pt;text-indent:9.06%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Non-Employee Director Compensation Program </p>
<p style="margin-top:12pt;margin-bottom:5pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with our initial public offering, we adopted, and our stockholders approved, a compensation program for our non-employee directors under which each non-employee director receives the following amounts for their services on our board of directors: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Upon the director&#8217;s initial election or appointment to our board of directors, an option to purchase 14,500 shares of our common stock; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">If the director has served on our board of directors for at least six months as of the date of an annual meeting of stockholders and will continue to serve as a director immediately following such meeting, an option to purchase 7,250 shares of our common stock on the date of the annual meeting; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">An annual director fee of $40,000; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">If the director serves as lead independent director or chair or on a committee of our board of directors, an additional annual fee as follows: </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:12.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Chair of the board or lead independent director: $25,000; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:12.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Chair of the audit committee: $20,000; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:12.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Audit committee member other than the chair, $7,500; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:12.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Chair of the compensation committee, $15,000; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:12.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Compensation committee member other than the chair, $5,000; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:12.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Chair of the nominating and corporate governance committee, $8,000; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:12.44%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Nominating and corporate governance committee member other than the chair, $4,000. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:5pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director fees under the program are payable in arrears in four equal quarterly installments not later than the fifteenth day following the final day of each calendar quarter, provided that the amount of each payment is prorated for any portion of a quarter that a director is not serving on our board of directors and no fee was payable in respect of any period prior to the effective date of the registration statement relating to our initial public offering. </p>
<p style="margin-top:12pt;margin-bottom:5pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options granted to our non-employee directors under the program have an exercise price equal to the fair market value of our common stock on the date of grant and expire not later than ten years after the date of grant. The stock options granted upon a director&#8217;s initial election or appointment vest in 36 substantially equal monthly installments following the date of grant. The stock options granted annually to directors vest in a single installment on the earlier of the day before the next annual meeting or the first anniversary of the date of grant. In addition, all unvested stock options vest in full upon the occurrence of a change in control. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:5pt;text-indent:9.06%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">IPO Grants to Non-Employee Directors under the 2020 Plan </font></p>
<p style="margin-top:12pt;margin-bottom:5pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with our initial public offering, our board of directors approved the grant to each of Michael Altman, Edward Anderson, Robert Langer, Sc.D., Konstantin Poukalov and George Whitesides, Ph.D. of an option to purchase 14,500 shares of our common stock at an exercise price per share equal to the initial public offering price per share of our common stock. Each option vests in 36 substantially equal monthly installments following the date of grant, subject to such director&#8217;s continued service through each applicable vesting date and accelerated vesting upon a change in control. </p>
<p style="margin-top:12pt;margin-bottom:5pt;text-indent:9.06%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Whitesides Stock Award </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with our initial public offering, our board of directors granted to Dr. Whitesides an award of 19,661 vested shares of our common stock, effective as of May 1, 2020, the date of effectiveness of the registration statement on Form S-8 registering the issuance of the shares subject to the award.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a>Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Securities Authorized for Issuance under Equity Compensation Plans (As of December 31, 2020)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Plan category:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities to</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">be Issued Upon</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Outstanding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants, and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rights</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants, and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rights</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available for</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Future</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issuance Under</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Plans</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(excludes</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reflected in</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">first column) <sup style="font-size:85%;line-height:120%;vertical-align:top">(4)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk64894222"></a>Equity compensation plans approved by</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; security holders<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,428,886</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.41</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(3)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,609,767</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity compensation plans not approved by</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; security holders</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,428,886</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.41</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,609,767</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:86.67%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">Consists of the Lyra Therapeutics, Inc. 2020 Stock Incentive Plan, as amended (the &#8220;2020 Plan&#8221;), 2016 Equity Incentive Plan, as amended (&#8220;2016 Plan&#8221;), 2005 Equity Incentive Plan, as amended (&#8220;2005 Plan&#8221;), and the 2020 Employee Stock Purchase Plan (&#8220;2020 ESPP&#8221;).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">Includes 219,460 shares of common stock issuable upon exercise of stock options under the 2005 Plan, 576,806 shares of common stock issuable upon exercise of stock options under the 2016 Plan, and 632,620 shares of common stock issuable upon exercise of stock options under the 2020 Plan. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">As of December 31, 2020, the weighted-average exercise price of outstanding options under the 2005 Plan was $16.60, the weighted-average exercise price of outstanding options under the 2016 Plan was $2.95, and the weighted-average exercise price of outstanding options under the 2020 Plan was $15.05. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(4)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">Includes 1,459,767 shares available for future issuance under the 2020 Plan and 150,000 shares available for issuance under the 2020 ESPP.&nbsp;&nbsp;We no longer make any grants under the 2016 Plan or the 2005 Plan, and we have not yet commenced offering periods under the 2020 ESPP. The 2020 Plan provides for an annual increase on the first day of each calendar year beginning January 1, 2021 and ending on and including January 1, 2030, equal to the lesser of (A) 4% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year, and (B) such smaller number of shares as is determined by the board of directors, provided that no more than 8,800,000 shares of our common stock may be issued pursuant to the exercise of incentive stock options. In addition, any shares that were subject to awards outstanding under the 2005 Plan and the 2016 Plan as of the effective date of the 2020 Plan which are forfeited, expire, lapse for any reason or are settled for cash without the issuance of shares will be added to the number of shares available for issuance under the 2020 Plan. The 2020 ESPP provides for an annual increase on the first day of each calendar year beginning January 1, 2021 and ending on and including January 1, 2030, equal to the lesser of (A) 0.5% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year, and (B) such smaller number of shares as is determined by the board of directors, provided that no more than 987,500 shares of our common stock may be issued under the 2020 ESPP.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Security Ownership of Certain Beneficial Owners and Management</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth information with respect to the beneficial ownership of our common stock by (i) each person or group of affiliated persons known by us to beneficially own more than 5% of our common stock and (ii) each of our named executive officers, each of our directors and all of our current executive officers and directors as a group as of March 1, 2021, unless otherwise indicated.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares beneficially owned by each stockholder is determined under rules issued by the SEC. Under these rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power. Applicable percentage ownership is based on 12,947,572 shares of common stock outstanding as of March 1, 2021. In computing the number of shares beneficially owned by an individual or entity and the percentage ownership of that person, shares of common stock subject to options held by such person that are currently exercisable or will become exercisable within 60 days of March 1, 2021 are considered outstanding, although these shares are not considered outstanding for purposes of computing the percentage ownership of any other person.&nbsp;&nbsp;Unless noted otherwise, the address of all listed stockholders is 480 Arsenal Way, Watertown, MA 02472.&nbsp;&nbsp;Each of the stockholders listed has sole voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of Beneficial Owner</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares&#160;of&#160;Common</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock&#160;Beneficially</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Owned</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percentage</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">5% or Greater Stockholders</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entities Affiliated with Perceptive Advisors, LLC<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,222,561</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.9</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entities Affiliated with North Bridge Venture Partners<sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,713,333</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entities Affiliated with Polaris Venture Partners<sup style="font-size:85%;line-height:120%;vertical-align:top">(3)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,423,772</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RA Capital Healthcare Fund, L.P.<sup style="font-size:85%;line-height:120%;vertical-align:top">(4)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">815,849</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ikarian Capital, LLC<sup style="font-size:85%;line-height:120%;vertical-align:top">(5)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">815,364</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intersouth Partners VII, L.P.<sup style="font-size:85%;line-height:120%;vertical-align:top">(6)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">738,203</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowmark Colorado Holdings, LLC<sup style="font-size:85%;line-height:120%;vertical-align:top">(7)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">648,321</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Named Executive Officers and Directors</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maria Palasis, Ph.D.<sup style="font-size:85%;line-height:120%;vertical-align:top">(8)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">348,220</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R. Don Elsey<sup style="font-size:85%;line-height:120%;vertical-align:top">(9)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,750</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robert Richard, Ph.D.<sup style="font-size:85%;line-height:120%;vertical-align:top">(10)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">750</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Edward Anderson<sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,718,166</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Altman<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,833</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C. Ann Merrifield<sup style="font-size:85%;line-height:120%;vertical-align:top">(11)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,110</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nancy Snyderman, M.D., FACS<sup style="font-size:85%;line-height:120%;vertical-align:top">(12)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,441</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">W. Bradford Smith<sup style="font-size:85%;line-height:120%;vertical-align:top">(13)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,275</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Konstantin Poukalov<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,833</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All current executive officers and directors as a group (11 persons)<sup style="font-size:85%;line-height:120%;vertical-align:top">(14)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,173,910</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">________</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Less than 1%. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">Pursuant to a Schedule 13D filed with the SEC on June 1, 2020, Perceptive Life Sciences Master Fund, Ltd. (&#8220;Perceptive Life&#8221;) reported shared voting power and shared dispositive power over 1,934,115 shares of common stock; Perceptive LS (A), LLC (&#8220;Perceptive LS&#8221;) reported shared voting power and shared dispositive power over 1,288,446 shares of common stock; Joseph Edelman reported shared voting power and shared dispositive power over 3,223,561 shares of common stock; and Perceptive Advisors LLC reported shared voting power and shared dispositive power over 3,223,561 shares of common stock. Perceptive Advisors LLC serves as the investment advisor to Perceptive Life. Perceptive LS GP, LLC is the manager of Perceptive LS. Joseph Edelman is the managing member of Perceptive Advisors LLC and the sole member of Perceptive LS GP, LLC. Michael Altman and Konstantin Poukalov, two of our directors, are Managing Directors at Perceptive Advisors LLC. Messrs. Altman and Poukalov each have sole voting power and sole dispositive power over 4,833 shares of common stock that are or will be immediately exercisable within 60 days of March 1, 2021. The address of the aforementioned individuals and entities is c/o Perceptive Advisors, LLC, 51 Astor Place, 10th Floor, New York, New York 10003.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">Pursuant to a Schedule 13D filed with the SEC on May 15, 2020, North Bridge Venture Partners V-A, L.P. (&#8220;NBVP V-A&#8221;) reported shared voting power and shared dispositive power over 778,592 shares of common stock; North Bridge Venture Partners V-B, L.P. (&#8220;NBVP V-B&#8221;) reported shared voting power and shared dispositive power over 381,618&nbsp;&nbsp;shares of common stock;&nbsp;&nbsp;and North Bridge Venture Partners VI, L.P. (&#8220;NBVP VI&#8221;) reported shared voting power and shared dispositive power over 553,123 shares of common stock. North Bridge Venture Management V, L.P. (&#8220;NBVM V&#8221;), is the sole General Partner of NBVP V-A and NBVP V-B and may be deemed to have voting and dispositive power with respect to the shares held by those entities. NBVM GP, LLC, the General Partner of NBVM V, may be deemed to have voting and dispositive power over the shares held of record by NBVP VA and NBVP V-B. Shared voting and dispositive power of such shares are vested in Edward T. Anderson and Richard A. D&#8217;Amore. North Bridge Venture Management VI, L.P. (&#8220;NBVM VI&#8221;), is the sole General Partner of NBVP VI. NBVM GP, LLC, the General Partner of NBVM VI, and may be deemed to have voting and dispositive power over the shares held of record by NBVP VI. Shared voting and dispositive power of such shares are vested in Edward T. Anderson and Richard A. D&#8217;Amore. Mr. Anderson, a member of our board of directors and a manager of NBVM GP, LLC, disclaims beneficial ownership over such shares, except to the extent of his pecuniary interest therein. Mr. Anderson has sole voting power and sole dispositive power over </font><font style="color:#000000;">4,833</font><font style="color:#000000;"> shares of common stock that are or will be immediately exercisable within 60 days of </font><font style="color:#000000;">March 1, 2021</font><font style="color:#000000;">. The address of all entities affiliated with North Bridge Venture Partners is 60 William Street, Suite 350, Wellesley, MA 02481. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.13%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">Pursuant to a Schedule 13G filed with the SEC on February 12, 2021, Polaris Venture Partners IV, L.P. (&#8220;PVP IV&#8221;) reported shared voting power and shared dispositive power over 316,980 shares of common stock; Polaris Venture Partners Entrepreneurs&#8217; Fund IV, L.P. (&#8220;PVPEF IV&#8221; and, together with PVP IV, the &#8220;Polaris IV Funds&#8221;) reported shared voting power and shared dispositive power over 5,940 shares of common stock; Polaris Venture Partners V, L.P. (&#8220;PVP V&#8221;) reported shared voting power and shared dispositive power over 1,062,259 shares of common stock; Polaris Venture Partners Entrepreneurs&#8217; Fund V, L.P. (&#8220;PVPEF V&#8221;) reported shared voting power and shared dispositive power over 20,701 shares of common stock; Polaris Venture Partners Founders&#8217; Fund V, L.P. (&#8220;PVPFF V&#8221;) reported shared voting power and shared dispositive power over 7,274 shares of common stock; Polaris Venture Partners Special Founders&#8217; Fund V, L.P. (&#8220;PVPSFF V,&#8221; and together with PVP V, PVPEF V and PVPFF V, the &#8220;Polaris V Funds&#8221; and the Polaris V Funds, together with the Polaris IV Funds, the &#8220;Polaris Funds&#8221;) reported shared voting power and shared dispositive power over 10,618 shares of common stock; Polaris Venture Management Co., IV, L.L.C. (&#8220;PVM IV&#8221;) reported shared voting power and shared dispositive power over 1,100,852 shares of common stock; and Polaris Venture Management Co. IV, L.L.C.. reported shared voting power and shared dispositive power over 322,920 shares of common stock.&nbsp;&nbsp;PVM IV is the sole general partner of each of the Polaris IV Funds and may be deemed to have sole voting and dispositive power with respect to the shares held by each of the Polaris IV Funds. Polaris Venture Management Co. V, L.L.C. (&#8220;PVM V&#8221;) is the sole general partner of each of the Polaris V Funds and may be deemed to have sole voting and dispositive power with respect to the shares held by each of the Polaris V Funds. Jonathan A. Flint and Terrance G. McGuire are the managing members of each of PVM V and PVM IV. Each of Messrs. Flint and McGuire, as managing members of each of PVM V and PVM IV, may be deemed to have shared voting and dispositive power with respect to the shares held by each of the Polaris Funds. Each of PVM IV, PVM V and Messrs. Flint and McGuire expressly disclaim beneficial ownership of the shares held by the each of the Polaris Funds, except to the extent of their respective pecuniary interests therein, if any. The mailing address of the aforementioned individuals and entities is One Marina Park Drive, 10th Floor, Boston, MA 02210. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(4)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">Pursuant to a Schedule 13G filed with the SEC on February 16, 2021, each of RA Capital Management, L.P., R.A. Capital Healthcare Fund, L.P. (&#8220;RA Capital&#8221;), Peter Kolchinsky and Rajeev Shah reported shared voting power and shared dispositive power over 815,849 shares of common stock.&nbsp;&nbsp;RA Capital Management, L.P., is the investment advisor (&#8220;Adviser&#8221;) of RA Capital and RA Capital Management GP, LLC (&#8220;Adviser GP&#8221;) is the general partner of the Adviser. Dr. Kolchinsky and Rajeev Shah are the controlling persons of the Adviser GP. The Adviser, Dr. Kolchinsky, and Mr. Shah may be deemed to beneficially own the shares held by RA Capital. The address of RA Capital is c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston, Massachusetts 02116. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(5)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">Pursuant to a Schedule 13G/A filed with the SEC on February 16, 2021, Ikarian Capital, LLC (&#8220;Ikarian Capital&#8221;) reported shared voting power and shared dispositive power over 815,364 shares of common stock; each of Ikarian Healthcare Master Fund, L.P. (the &#8220;Fund&#8221;) and Ikarian Healthcare Fund GP, L.P. (the &#8220;Ikarian GP&#8221;) reported shared voting power and shared dispositive power over 654,626 shares of common stock; and each of Chart Westcott and Neil Shahrestani reported shared voting power and shared dispositive power over 815,364 shares of common stock. Ikarian Capital is the investment manager of, and may be deemed to indirectly beneficially own securities owned by, the Fund. Ikarian GP is the general partner of, and may be deemed to indirectly beneficially own securities owned by, the Fund. Ikarian Capital is also the general partner of, and may be deemed to indirectly beneficially own, securities beneficially owned by Ikarian GP. Ikarian Capital is a sub-advisor for certain separate managed accounts (collectively, the &#8220;Managed Accounts&#8221;) and may be deemed to indirectly beneficially own securities owned by the Managed Accounts. Ikarian Capital is ultimately owned and controlled by Chart Westcott Living Trust, of which Mr. Westcott serves as the sole trustee (the &#8220;Trust&#8221;), and indirectly by Mr. Shahrestani. Accordingly, each of Mr. Westcott, as sole trustee of the Trust, and Mr. Shahrestani may be deemed to indirectly beneficially own securities beneficially owned by Ikarian Capital. The Fund disclaims beneficial ownership of the shares held by the Managed Accounts.&nbsp;&nbsp;The address of the principal business office of each of the aforementioned individuals and entities is c/o Ikarian Capital, LLC, 100 Crescent Court, Suite 1620, Dallas, Texas 75201.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(6)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">Pursuant to a Schedule 13G filed with the SEC on February 12, 2021, each of Intersouth Partners VII, L.P. (&#8220;ISP VII&#8221;), Intersouth Associates VII, LLC (&#8220;ISA VII, LLC&#8221;), Dennis Dougherty and Mitch Mumma reported shared voting power and shared dispositive power over 738,203 shares of common stock.&nbsp;&nbsp;ISA VII directly beneficially owns 738,203 shares of common stock.&nbsp;&nbsp;ISA VII, LLC, as the general partner of ISP VII, may be deemed to beneficially own the securities owned by ISP VII.&nbsp;&nbsp;Messrs. Dougherty and Mumma, as Member Managers of ISA VII, LLC, may be deemed to indirectly beneficially own the securities owned by ISP VII.&nbsp;&nbsp;Each of (i) ISP VII, (ii) ISP VII, LLC and (iii) Messrs. Dougherty and Mumma, may be deemed to share the power to vote or direct the voting of, and to dispose or direct the disposition of, the securities that are directly beneficially owned by ISP VII.&nbsp;&nbsp;Each of Messrs. Dougherty and Mumma disclaims beneficial ownership of all securities other than those he owns by virtue of his indirect pro rata interest as a member of ISA VII, LLC.&nbsp;&nbsp;The mailing address of the aforementioned individuals and entities is 4711 Hope Valley Road, Suite 4F-632, Durham NC 27707. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(7)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">Pursuant to a Schedule 13G filed with the SEC on February 16, 2021, ArrowMark Colorado Holdings, LLC reported sole voting power over 648,321 shares of common stock.&nbsp;&nbsp;The address of ArrowMark Colorado Holdings, LLC is 100 Fillmore Street, Suite 325, Denver, Colorado, 80206.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(8)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">Consists of options to purchase 348,220 shares of common stock that are or will be immediately exercisable within 60 days of March 1, 2021. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(9)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">Consists of options to purchase 39,750 shares of common stock that are or will be immediately exercisable within 60 days of March 1, 2021.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(10)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">Consists of options to purchase 750 shares of common stock that are or will be immediately exercisable within 60 days of March 1, 2021.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(11)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">Consists of options to purchase 7,110 shares of common stock that are or will be immediately exercisable within 60 days of March 1, 2021.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(12)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">Consists of 1,025 shares of common stock and 2,416 options to purchase shares of common stock that are or will be immediately exercisable within 60 days of March 1, 2021.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(13)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;"> Consists of options to purchase 6,275 shares of common stock that are or will be immediately exercisable within 60 days of March 1, 2021.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(14)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">Consists of 1,714,358 shares of common stock and 459,552 options to purchase shares of common stock that are or will be immediately exercisable within 60 days of March 1, 2021.</font></p></td></tr></table></div><a name="_AEIOULastRenderedPageBreakAEIOU16"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a>Item 13. Certain Relationships and Related</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> Transactions, and Director Independence. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Policies and Procedures for Approval of Related Person Transactions</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors recognizes the fact that transactions with related persons present a heightened risk of conflicts of interests (or the perception thereof) and has adopted a written related person transactions policy to comply with Section 404 of the Exchange Act. Under the policy, our finance team is primarily responsible for developing and implementing processes and procedures to obtain information regarding related persons with respect to potential related person transactions and then determining, based on the facts and circumstances, whether such potential related person transactions do, in fact, constitute related person transactions requiring compliance with the policy. In addition, any potential related person transaction that is proposed to be entered into by the Company must be reported to the Company&#8217;s Chief Financial Officer, by both the related person and the person at the Company responsible for such potential related person transaction.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our finance team determines that a transaction or relationship is a related person transaction requiring compliance with the policy, our Chief Financial Officer is required to present to the Audit Committee all relevant facts and circumstances relating to the related person transaction. Our Audit Committee must review the relevant facts and circumstances of each related person transaction, including if the transaction is on terms comparable to those that could be obtained in arm's length dealings with an unrelated third party and the extent of the related person's interest in the transaction, take into account the conflicts of interest and corporate opportunity provisions of our Code of Business Conduct and Ethics, and either approve or disapprove the related person transaction. If advance Audit Committee approval of a related person transaction requiring the Audit Committee's approval is not feasible, then the transaction may be preliminarily entered into by management upon prior approval of the transaction by the chair of the Audit Committee subject to ratification of the transaction by the Audit Committee at the Audit Committee's next regularly scheduled meeting; provided, that if ratification is not forthcoming, management will make all reasonable efforts to cancel or annul the transaction. If a transaction was not initially recognized as a related person transaction, then upon such recognition the transaction will be presented to the Audit Committee for ratification at the Audit Committee's next regularly scheduled meeting; provided, that if ratification is not forthcoming, management will make all reasonable efforts to cancel or annul the transaction.</p>
<p style="margin-top:12pt;margin-bottom:6pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management will update the Audit Committee as to any material changes to any approved or ratified related person transaction and will provide a status report at least annually of all then current related person transactions. No director may participate in approval of a related person transaction for which he or she is a related person.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following are certain transactions, arrangements and relationships with our directors, executive officers and stockholders owning 5% or more of our outstanding common stock, or any member of the immediate family of any of the foregoing persons, since January 1, 2019.&#8221;</p>
<p style="margin-top:12pt;margin-bottom:6pt;text-indent:9.06%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Series C Preferred Stock Financing.<font style="font-weight:normal;"> At various closings between January 10, 2020 and January 31, 2020, we issued and sold to investors an aggregate of 78,306,611 shares of our Series C preferred stock at a price per share of $0.38811, for aggregate consideration of approximately $30.4 million. We also issued to such investors warrants to purchase up to an aggregate of 681,256 shares of common stock, at an exercise price per share equal to the fair market value of our common stock following January 10, 2020 (as determined by our board of directors, in good faith, based on the most recent independent third party valuation of our company available following January 10, 2020 performed pursuant to Section 409A of the Internal Revenue Code, and taking into account any changes to our business between the date of such third party valuation and January 10, 2020). In accordance with such terms, on February 6, 2020, our board of directors determined such fair market value of our common stock to be $8.63 per share. Certain holders of 5% or more of our common stock at the time of the transactions, on an as-converted basis, including entities affiliated with Polaris Venture Partners, North Bridge Venture Partners, Intersouth Partners VII, L.P., Perceptive Advisors, LLC, RA Capital Healthcare Fund, L.P., ArrowMark Partners and Soleus Private Equity Fund I, L.P., participated in the Series C preferred stock financing, including the issuance of the warrants to purchase common stock. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the aggregate number of shares of our capital stock acquired by beneficial owners of more than 5% of our common stock at the time of the Series C preferred stock financing transaction described above. Each share of our Series C preferred stock identified in the following table converted into 0.0289998 shares of common stock immediately prior to the closing of our initial public offering.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:95%;">
<tr>
<td valign="bottom"  style="width:51%;white-space:nowrap;">
<p style="margin-bottom:5pt;margin-top:5pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Participants</p>
<p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:5pt;margin-top:5pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:20%;">
<p style="text-align:center;margin-bottom:5pt;margin-top:5pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series C<br />Preferred&#160;Stock</p>
<p style="margin-top:0pt;text-align:center;border-top:Solid 1pt;padding-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:5pt;margin-top:5pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:20%;">
<p style="text-align:center;margin-bottom:5pt;margin-top:5pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants&#160;to<br />Purchase<br />Common&#160;Stock</p>
<p style="margin-top:0pt;text-align:center;border-top:Solid 1pt;padding-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:51%;">
<p style="margin-bottom:5pt;margin-top:5pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5%&#160;or&#160;Greater&#160;Stockholders<font style="font-weight:normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></font></p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:2%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:2%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entities affiliated with Polaris Venture Partners<sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,061,271</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,932</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intersouth Partners VII, L.P.</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,030,635</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,966</p></td>
</tr>
<tr>
<td valign="top"  style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entities affiliated with North Bridge Venture Partners<sup style="font-size:85%;line-height:120%;vertical-align:top">(3)</sup></p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,153,178</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,831</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entities affiliated with Perceptive Advisors, LLC<sup style="font-size:85%;line-height:120%;vertical-align:top">(4)</sup></p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,267,836</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">480,825</p></td>
</tr>
<tr>
<td valign="top"  style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RA Capital Healthcare Fund, L.P.</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,288,294</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,208</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entities Affiliated with ArrowMark Partners<sup style="font-size:85%;line-height:120%;vertical-align:top">(5)</sup></p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,864,883</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,624</p></td>
</tr>
<tr>
<td valign="top"  style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soleus Private Equity Fund I, L.P.</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,607,224</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,382</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">________</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:3pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:3pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Additional details regarding certain of these stockholders and their equity holdings are provided in this Annual Report on Form 10-K under the caption &#8220;Security Ownership of Certain Beneficial Owners and Management.&#8221; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:3pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Represents securities acquired by (i)&#160;Polaris Venture Partners Entrepreneurs&#8217; Fund V, L.P., (ii) Polaris Venture Partners V, L.P., (iii) Polaris Venture Partners Founders&#8217; Fund V, L.P. and (iv)&#160;Polaris Venture Partners Special Founders&#8217; Fund V, L.P. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:3pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Represents securities acquired by (i)&#160;North Bridge Venture Partners V-A, L.P., (ii) North Bridge Venture Partners V-B, L.P. and (iii)&#160;North Bridge Venture Partners VI, L.P. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:3pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Represents securities acquired by (i) Perceptive Life Sciences Master Fund, Ltd. and (ii) Perceptive LS (A), LLC. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:3pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</font></p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Represents securities acquired by (i) ArrowMark Fundamental Opportunity Fund, L.P. and (ii) Meridian Small Cap Growth Fund. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of our directors are associated with our principal stockholders as indicated in the table below:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:95%;">
<tr>
<td valign="bottom"  style="width:40.5%;white-space:nowrap;">
<p style="margin-bottom:5pt;margin-top:5pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Director</p>
<p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40.5%;">
<p style="text-align:center;margin-bottom:5pt;margin-top:5pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Principal&#160;Stockholder</p>
<p style="margin-top:0pt;text-align:center;border-top:Solid 1pt;padding-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:40.5%;">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Altman</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:40.5%;">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entities affiliated with Perceptive Advisors, LLC</p></td>
</tr>
<tr>
<td valign="top"  style="width:40.5%;">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Edward Anderson</p></td>
<td valign="bottom"  style="width:40.5%;">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entities&#160;affiliated&#160;with&#160;North&#160;Bridge&#160;Venture&#160;Partners</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:40.5%;">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robert S. Langer Sc.D.<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:40.5%;">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entities affiliated with Polaris Venture Partners</p></td>
</tr>
<tr>
<td valign="top"  style="width:40.5%;">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Konstantin Poukalov</p></td>
<td valign="bottom"  style="width:40.5%;">
<p style="margin-bottom:3pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entities affiliated with Perceptive Advisors, LLC</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">________</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:3pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:3pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:3pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Robert S. Langer Sc.D. resigned as a director on October 26, 2020.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Agreements with Arsenal</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2011, we entered into a Collaboration Agreement, a Technology License Agreement, a Trademark Coexistence Agreement and a Transition Services Agreement with Arsenal Medical, Inc., or Arsenal, a company in which certain of our principal stockholders are stockholders. In October 2018, we entered an Acknowledgment and Release Agreement with Arsenal with respect to the expiration of the Collaboration Agreement and certain other intellectual property matters. In November 2019, we entered into an amendment to the Acknowledgement and Release Agreement, which clarifies our and Arsenal&#8217;s rights to each of our and Arsenal&#8217;s respective patents and patent applications, including patents and patent applications existing as of the effective date of the Collaboration Agreement, the Technology License Agreement, the Trademark Coexistence Agreement and the Transition Services Agreement. The amendment to the Acknowledgment and Release Agreement also provides for a mutual release of all claims arising under such patents and patent applications. The Technology License Agreement is a non-exclusive in-license agreement covering certain intellectual property regarding in situ forming foam and nanofiber, which is unrelated to our current and future expected product candidates. The Technology License Agreement provides for no future payments by us and remains in effect. In addition, the Trademark Coexistence Agreement relates to certain trademarks around our previous corporate name, which we no longer use. The Transition Services Agreement expired in June 2019.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consulting Agreement with George Whitesides, Ph.D.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2005, we entered into a consulting agreement with George Whitesides, Ph.D., who was one of our directors between October 2005 and October 2020, pursuant to which Dr. Whitesides agreed to provide us certain consulting and advisory services. The agreement was subsequently amended in March 2006, February 2012, January 2015 and January 2017. Pursuant to the terms of the agreement, as amended, the agreement expired on January 1, 2019. In lieu of all compensation payable by us under the agreement, upon consummation of our IPO on May 5, 2020, we granted to Dr. Whitesides an award of 19,661 fully vested shares of common stock under our 2020 Plan.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Investor Rights Agreement</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 10, 2020, we entered into an Eighth Amended and Restated Investor Rights Agreement with the holders of our then-outstanding preferred stock, including Perceptive Advisers, LLC, North Bridge Venture Partners, and Polaris Venture Partners, which are 5% or greater holders of our common stock and entities with which certain of our directors are related. The agreement provides for certain rights relating to the registration of such holders&#8217; common stock and a right of first refusal to purchase future securities sold by us.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Indemnification Agreements</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into indemnification agreements with each of our directors and executive officers. These agreements, among other things, require us to indemnify each director (and in certain cases their related venture capital funds) and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys&#8217; fees, judgments, fines and settlement amounts incurred by the director or executive officer in any action or proceeding, including any action or proceeding by or in right of us, arising out of the person&#8217;s services as a director or executive officer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Independence of the Board of Directors</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors has determined that each of Michael Altman, Edward Anderson, C. Ann Merrifield, Konstantin Poukalov, W. Bradford Smith and Nancy Snyderman, M.D., FACS qualify as &#8220;independent&#8221; in accordance with the listing requirements of Nasdaq.&nbsp;&nbsp;Our board of directors previously determined that Robert S. Langer, Sc.D. qualified as &#8220;independent&#8221; while he served on the board, in accordance with the listing requirements of Nasdaq.&nbsp;&nbsp;The Nasdaq independence definition includes a series of objective tests, including that the director is not, and has not been for at least three years, one of our employees and that neither the director nor any of his family members has engaged in various types of business dealings with us. In addition, as required by Nasdaq rules, our board of directors has made a subjective determination as to each independent director that no relationships exist, which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In making these determinations, our board of directors reviewed and discussed information provided by the directors and us with regard to each director&#8217;s business and personal activities and relationships as they may relate to us and our management, including that Mr. Altman, Mr. Anderson and Mr. Poukalov are affiliated with certain of our significant stockholders. Maria Palasis, Ph.D. is not independent and George Whitesides, Ph.D., who resigned from the board on October 26, 2020, was not independent while we served on the Board. There are no family relationships among any of our directors or executive officers.</p><a name="_AEIOULastRenderedPageBreakAEIOU17"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62417045"></a><a name="ITEM_14_PRINCIPAL_ACCOUNTANT_FEES_SERVIC"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_14_PRINCIPAL_ACCOUNTANT_FEES_SERVIC"></a>Item 14. Principal Accoun</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">tant Fees and Services. </font></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the fees of BDO USA, LLP, our independent registered public accounting firm, billed to us for each of the last two fiscal years.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fee Category</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audit Fees<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237,725</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audit-Related Fees<sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax Fees<sup style="font-size:85%;line-height:120%;vertical-align:top">(3)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,700</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,425</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All Other Fees<sup style="font-size:85%;line-height:120%;vertical-align:top">(4)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Fees</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">246,425</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">358,425</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">________</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Audit fees consist of fees for the audit of our financial statements, the review of the interim financial statements included in our quarterly reports on Form 10-Q, and other professional services provided in connection with statutory and regulatory filings or engagements. Audit fees also includes fees for services incurred in connection with our IPO.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Audit-related fees consist of fees that are reasonably related to the performance of the audit and the review of our financial statements and which are not reported under &#8220;Audit Fees.&#8221;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Tax fees consist of fees for tax-related services, including tax compliance and tax advice.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:3pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(4)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:3pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">All other fees consist of fees for all other services that are not reported above.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pre-Approval Policies and Procedures</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Audit Committee has adopted a policy (the &#8220;Pre-Approval Policy&#8221;) that sets forth the procedures and conditions pursuant to which audit and non-audit services proposed to be performed by the independent auditor may be pre-approved. The Pre-Approval Policy generally provides that we will not engage BDO USA, LLP to render any audit, audit-related, tax or permissible non-audit service unless the service is either (i) explicitly approved by the Audit Committee (&#8220;specific pre-approval&#8221;) or (ii) entered into pursuant to the pre-approval policies and procedures described in the Pre-Approval Policy (&#8220;general pre-approval&#8221;). Unless a type of service to be provided by BDO USA, LLP has received general pre-approval under the Pre-Approval Policy, it requires specific pre-approval by the Audit Committee or by a designated member of the Audit Committee to whom the committee has delegated the authority to grant pre-approvals. Any proposed services exceeding pre-approved cost levels or budgeted amounts will also require specific pre-approval. For both types of pre-approval, the Audit Committee will consider whether such services are consistent with the SEC's rules on auditor independence. The Audit Committee will also consider whether the independent auditor is best positioned to provide the most effective and efficient service, for reasons such as its familiarity with the Company's business, people, culture, accounting systems, risk profile and other factors, and whether the service might enhance the Company's ability to manage or control risk or improve audit quality. All such factors will be considered as a whole, and no one factor should necessarily be determinative. The Audit Committee periodically reviews and generally pre-approves any services (and related fee levels or budgeted amounts) that may be provided by BDO USA, LLP without first obtaining specific pre-approvals from the Audit Committee or the Chair of the Audit Committee. The Audit Committee may revise the list of general pre-approved services from time to time, based on subsequent determinations. </p><a name="_AEIOULastRenderedPageBreakAEIOU18"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_IV"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_IV"></a>PART</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> IV </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62416937"></a><a name="_cp_text_1_1019"></a><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a><a name="_cp_text_1_1019"></a>Item 15. Exhibits and <a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a>Financial Statement Schedules. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_blt_1_1020"></a><a name="_cp_text_1_1021"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="color:#000000;">Documents filed as part of this report:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="color:#000000;">Financial Statements.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1023"></a>The following documents are included on pages F-1 through F-22 attached hereto and are filed as part of this Annual Report on Form 10-K.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:93%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top"  style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><font style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm</font></a></p></td>
<td valign="bottom"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="top"  style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial Statements:</p></td>
<td valign="bottom"  style="width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><font style="text-decoration:underline;">Consolidated Balance Sheets</font></a></p></td>
<td valign="bottom"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
</tr>
<tr>
<td valign="top"  style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"><font style="text-decoration:underline;">Consolidated Statements of Operations and Comprehensive Loss</font></a></p></td>
<td valign="bottom"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="top"  style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_REDEEMABLE_CONVE"><font style="text-decoration:underline;">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</font></a></p></td>
<td valign="bottom"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="top"  style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><font style="text-decoration:underline;">Consolidated Statements of Cash Flows</font></a></p></td>
<td valign="bottom"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr>
<td valign="top"  style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><font style="text-decoration:underline;">Notes to Consolidated Financial Statements</font></a></p></td>
<td valign="bottom"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_table_9_1024"></a>F-7</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="color:#000000;">Financial Statement Schedules.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No financial statement schedules have been submitted because they are not required or are not applicable or because the information required is included in the financial statements or the notes thereto.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_1025"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="color:#000000;"><a name="_cp_text_1_1025"></a>List of Exhibits.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:45.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description&#160;of&#160;Exhibit</p></td>
<td valign="bottom"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form or</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Schedule</p></td>
<td valign="bottom"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="bottom"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:13.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">with SEC</p></td>
<td valign="bottom"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SEC File</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:45.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.1</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001327273/000119312520133819/d925971dex31.htm"><font style="text-decoration:underline;">Restated Certificate of Incorporation of the Registrant</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 5, 2020</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-39273</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.2</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001327273/000119312520133819/d925971dex32.htm"><font style="text-decoration:underline;">Amended and Restated Bylaws of the Registrant</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 5, 2020</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-39273</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.1</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001327273/000119312520065213/d805799dex41.htm"><font style="text-decoration:underline;">Eighth Amended and Restated Investor Rights Agreement, dated as of January&#160;10, 2020, as amended</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 6, 2020</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-236962</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.2</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001327273/000119312520120337/d805799dex42.htm"><font style="text-decoration:underline;">Specimen Stock Certificate evidencing the shares of Common Stock of the Registrant</font></a></p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1028"></a><a name="_cp_text_1_1028"></a>S-1/A</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 27, 2020</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-236962</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;4.3</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1327273/000119312520120337/d805799dex43.htm"><font style="text-decoration:underline;">Form of Warrants to Purchase Common Stock, dated various dates, issued by the Registrant to various investors, together with a schedule of warrants and warrantholders</font></a></p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 27, 2020</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-236962</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;4.4*</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="lyra-ex44_349.htm"><font style="text-decoration:underline;">Description of Securities</font></a></p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.1#</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001327273/000119312520065213/d805799dex101.htm"><font style="text-decoration:underline;">2005 Equity Incentive Plan, as amended, and form of agreements thereunder</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 6, 2020</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-236962</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.2#</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001327273/000119312520065213/d805799dex102.htm"><font style="text-decoration:underline;">2016 Equity Incentive Plan, as amended, and form of agreements thereunder</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 6, 2020</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-236962</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.3#</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001327273/000119312520120337/d805799dex103.htm"><font style="text-decoration:underline;">2020 Incentive Award Plan and form of agreements thereunder</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1029"></a><a name="_cp_text_1_1029"></a>S-1/A</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 27, 2020</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-236962</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.4#</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001327273/000119312520120337/d805799dex104.htm"><font style="text-decoration:underline;">Non-Employee Director Compensation Program</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1030"></a><a name="_cp_text_1_1030"></a>S-1/A</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 27, 2020</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-236962</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.5#</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001327273/000119312520120337/d805799dex105.htm"><font style="text-decoration:underline;">2020 Employee Stock Purchase Plan</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1031"></a><a name="_cp_text_1_1031"></a>S-1/A</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 27, 2020</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-236962</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.6#</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001327273/000119312520120337/d805799dex106.htm"><font style="text-decoration:underline;">Form of Indemnification Agreement for directors and officers of the Registrant</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1032"></a><a name="_cp_text_1_1032"></a>S-1/A</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 27, 2020</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-236962</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  style="width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:45.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description&#160;of&#160;Exhibit</p></td>
<td valign="bottom"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form or</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Schedule</p></td>
<td valign="bottom"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="bottom"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:13.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">with SEC</p></td>
<td valign="bottom"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SEC File</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.7</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001327273/000119312520065213/d805799dex107.htm"><font style="text-decoration:underline;">Lease Agreement between the Registrant and ARE-480 Arsenal St, LLC, dated August&#160;14, 2007, as amended</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1033"></a>S-1</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1034"></a>10.7</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1035"></a>March 6, 2020</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1036"></a>333-236962</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.8#</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001327273/000119312520120337/d805799dex108.htm"><font style="text-decoration:underline;">Employment Agreement between the Registrant and Maria Palasis, Ph.D., dated as of April 27, 2020</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1037"></a><a name="_cp_text_1_1037"></a>S-1/A</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 27, 2020</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-236962</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.9#</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1039"></a><a href="http://www.sec.gov/Archives/edgar/data/0001327273/000119312520120337/d805799dex109.htm"><font style="text-decoration:underline;">Offer Letter between the Registrant and R. Don Elsey, dated as of April 27, 2020</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1040"></a><a name="_cp_text_1_1040"></a>S-1/A</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 27, 2020</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-236962</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.10#</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1042"></a><a href="http://www.sec.gov/Archives/edgar/data/0001327273/000119312520120337/d805799dex1010.htm"><font style="text-decoration:underline;">Offer Letter between the Registrant and Laura Edgerly-Pflug, dated as of April 27, 2020</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1043"></a><a name="_cp_text_1_1043"></a>S-1/A</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 27, 2020</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-236962</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.11#</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001327273/000156459020036803/lyra-ex108_81.htm"><font style="text-decoration:underline;">Separation Agreement and Release between the Registrant and Laura Edgerly-Pflug, dated as of July 24, 2020</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 5, 2020</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-39273</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;21.1</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1044"></a><a href="http://www.sec.gov/Archives/edgar/data/0001327273/000119312520065213/d805799dex211.htm"><font style="text-decoration:underline;">Subsidiaries of the Registrant</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1044"></a> </font></p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1045"></a>S-1</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1046"></a>21.1</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1047"></a>March 6, 2020</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1048"></a>333-236962</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1049"></a><a name="_cp_text_1_1049"></a>&#160;&#160;23.1*</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="lyra-ex231_175.htm"><font style="text-decoration:underline;">Consent of BDO USA, LLP</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;31.1*</font></p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="lyra-ex311_9.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;31.2*</font></p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="lyra-ex312_8.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;32.1+</font></p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="lyra-ex321_6.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;&#160;32.2+</font></p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="lyra-ex322_7.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a></p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Instance Document</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Schema Document</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Definition Linkbase Document</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Label Linkbase Document</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</p></td>
<td valign="top"  style="width:1.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.4pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-right:66.67%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">#</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Indicates management contract or compensatory plan. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Filed herewith.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Furnished herewith.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16_FORM_10K_SUMMARY"></a><a name="ITEM_16_FORM_10K_SUMMARY"></a>Item 16. Form 10-K Summary</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p><a name="_AEIOULastRenderedPageBreakAEIOU19"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a>SIGNA</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TURES</font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized<font style="font-weight:bold;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:93.33%;">
<tr>
<td style="width:42.11%;"></td>
<td style="width:4.64%;"></td>
<td style="width:3.04%;"></td>
<td style="width:43.55%;"></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LYRA THERAPEUTICS, INC.</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 9, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Maria Palasis, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maria Palasis, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:6pt;">
<td valign="middle"  style="width:34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-weight:bold;font-size:8pt;">Signature</font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Maria Palasis, Ph.D.</p>
<p style="text-align:justify;border-top:Solid 0.75pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maria Palasis, Ph.D.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Director (principal executive officer)</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 9, 2021</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.75pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ R. Don Elsey</p>
<p style="text-align:justify;border-top:Solid 0.75pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R. Don Elsey</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer (principal financial officer and principal accounting officer)</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 9, 2021</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.75pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Michael Altman</p>
<p style="text-align:justify;border-top:Solid 0.75pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Altman</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.75pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 9, 2021</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.75pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Edward T. Anderson</p>
<p style="text-align:justify;border-top:Solid 0.75pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Edward T. Anderson</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.75pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 9, 2021</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.75pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ C. Ann Merrifield</p>
<p style="text-align:justify;border-top:Solid 0.75pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C. Ann Merrifield</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.75pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 9, 2021</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.75pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Konstantin Poukalov</p>
<p style="text-align:justify;border-top:Solid 0.75pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Konstantin Poukalov</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.75pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 9, 2021</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.75pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ W. Bradford Smith</p>
<p style="text-align:justify;border-top:Solid 0.75pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">W. Bradford Smith</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.75pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 9, 2021</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.75pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Nancy Snyderman, M.D., FACS</p>
<p style="text-align:justify;border-top:Solid 0.75pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nancy Snyderman, M.D., FACS</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.75pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 9, 2021</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><font style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><font style="text-decoration:underline;">Consolidated Balance Sheets</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"><font style="text-decoration:underline;">Consolidated Statements of Operations and Comprehensive Loss</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_REDEEMABLE_CONVE"><font style="text-decoration:underline;">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><font style="text-decoration:underline;">Consolidated Statements of Cash Flows</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:91.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><font style="text-decoration:underline;">Notes to Consolidated Financial Statements</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Board of Directors and Stockholders </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lyra Therapeutics, Inc. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Watertown, MA </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Opinion on the Consolidated Financial Statements </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of Lyra Therapeutics, Inc. (the &#8220;Company&#8221;) and subsidiary as of December&#160;31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, redeemable convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2020 and 2019, and the results of its operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:62.33%;text-indent:-2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ BDO USA, LLP </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2013. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, Massachusetts </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 9, 2021 </p><a name="_AEIOULastRenderedPageBreakAEIOU21"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LYRA THERAPEUTICS, INC. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_BALANCE_SHEETS"></a><a name="CONSOLIDATED_BALANCE_SHEETS"></a>CONSOLIDATED BALANCE SHEETS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share data) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,593</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,808</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,324</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">311</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,917</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,119</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,165</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,301</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,182</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">329</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">329</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,096</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,830</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,963</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">922</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,069</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,977</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,240</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">985</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">899</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,884</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,208</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, net of current portion</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,454</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,427</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,338</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,635</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 11)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A-1 redeemable convertible preferred stock, $0.001 par value; no shares issued, authorized or</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; outstanding at December 31, 2020; 34,017,033 shares authorized, issued and outstanding at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,742</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A-2 redeemable convertible preferred stock, $0.001 par value; no shares issued, authorized or</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; outstanding at December 31, 2020; 26,680,202 shares authorized, issued and outstanding at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,393</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A-3 redeemable convertible preferred stock, $0.001 par value; no shares issued, authorized or</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; outstanding at December 31, 2020; 30,070,487 shares authorized, issued and outstanding at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,114</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A-4 redeemable convertible preferred stock, $0.001 par value; no shares issued, authorized or</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; outstanding at December 31, 2020; 19,999,999 shares authorized, issued and outstanding at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B redeemable convertible preferred stock, $0.001 par value; no shares issued, authorized or</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; outstanding at December 31, 2020; 100,018,619 shares authorized and 98,351,953 shares issued and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; outstanding at December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,417</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series C redeemable convertible preferred stock, $0.001 par value; no shares authorized, issued or</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; outstanding at December 31, 2020 and 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total redeemable convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130,666</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity (deficit):</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $0.001 par value; 200,000,000 and 275,000,000 shares authorized at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2020 and 2019, respectively; 12,932,377 and 230,860 shares issued and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; outstanding at December 31, 2020 and 2019, respectively</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224,363</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,419</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(149,884</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(127,757</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity (deficit)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,492</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(123,338</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities, redeemable convertible preferred stock and stockholders&#8217; equity (deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,830</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,963</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes to consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LYRA THERAPEUTICS, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"></a><a name="CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"></a>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share data) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,522</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,032</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,687</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,487</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,209</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,519</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,209</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,519</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">213</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">213</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,127</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,306</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,127</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,306</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders&#8212;basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.59</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(82.23</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares outstanding&#8212;basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,590,205</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202,093</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes to consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU23"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">LYRA THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_REDEEMABLE_CONVE"></a><a name="CONSOLIDATED_STATEMENTS_REDEEMABLE_CONVE"></a>CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Redeemable Convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity (Deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance<font style="font-family:Calibri;">&#160;</font>at&#160;December&#160;31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">209,119,674</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130,353</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170,156</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,377</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(111,451</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(107,074</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of common stock options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,704</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accretion of convertible preferred stock to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; redemption value</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(313</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(313</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,306</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,306</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">209,119,674</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130,666</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,860</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,419</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(127,757</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(123,338</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series C redeemable convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stock, net of issuance costs</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; of $201</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,306,611</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,446</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accretion of convertible preferred stock to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; redemption value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(115</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(115</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock warrants in</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; conjunction with sale of Series C</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; redeemable convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">740</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">740</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of redeemable convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stock to common stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; upon closing of initial public offering</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(287,426,285</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(160,227</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,335,248</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,219</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,227</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock from initial</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; public offering, net of issuance</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; costs of $7,116</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,025,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,280</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,284</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of restricted common stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,661</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon exercise of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; warrants</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313,794</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of common stock options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,814</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,813</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,813</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,127</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,127</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-right:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-left:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,932,377</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224,363</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(149,884</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,492</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes to consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU24"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LYRA THERAPEUTICS, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a>CONSOLIDATED STATEMENTS OF CASH FLOWS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,127</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,306</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,813</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserve for uncollectible accounts</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain on disposal of assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in assets and liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,013</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">561</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">894</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">864</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(118</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">345</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(205</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(87</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,734</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(900</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(840</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,143</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,754</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,775</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(211</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,775</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(211</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from the sale of Series C redeemable convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,392</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of offering costs related to sale of Series C redeemable convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(206</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from initial public offering, net of underwriting discount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,892</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of initial public offering costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,383</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(226</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of stock options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,703</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(115</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,785</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,080</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents and restricted cash, beginning of period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,137</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,217</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents and restricted cash, end of period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,922</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,137</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of non-cash financing and investing activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment purchases included in accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">205</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of redeemable convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,227</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allocation of Series C redeemable convertible preferred stock to common stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; warrant</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">740</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accretion of redeemable convertible preferred stock to redemption value</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use asset obtained in exchange of operating lease obligation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,046</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred offering costs included in accounts payable and accrued expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">870</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes to consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU25"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LYRA THERAPEUTICS, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a><a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Organization and Basis of Presentation </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lyra Therapeutics, Inc. (the &#8220;Company&#8221;) is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (&#8220;ENT&#8221;) diseases. The Company&#8217;s proprietary technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. The Company&#8217;s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (&#8220;CRS&#8221;). The Company was incorporated as a Delaware corporation on November&#160;21, 2005 and is located in Watertown, Massachusetts. On July&#160;16, 2018, the Company formerly changed its name from 480 Biomedical, Inc. to Lyra Therapeutics, Inc. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks common to companies in the therapeutics and pharmaceutical industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations, reliance on third party manufacturers, ability to transition from pilot-scale manufacturing to large-scale production of products and the need to obtain adequate additional financing to fund the development of its product candidates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, the Company has funded its operations with proceeds from sales of redeemable convertible preferred stock and funding from government contracts. The Company has incurred recurring net losses since inception and had net losses of approximately $22.1 million and $16.3 million for the years ended December 31, 2020 and 2019, respectively. In addition, the Company has an accumulated deficit of approximately $149.9&#160;million at December 31, 2020. The Company expects to continue to generate operating losses for the foreseeable future. At December 31, 2020, the Company had approximately $74.6&#160;million of cash and cash equivalents.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk39757367"></a><a name="_Hlk39757367"></a>On May 5, 2020, the Company completed its initial public offering (&#8220;IPO&#8221;), in which the Company issued and sold 4,025,000 shares of its common stock, including 525,000 shares pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, at a public offering price of $16.00 per share, for aggregate gross proceeds of $64.4 million. The Company received approximately $57.3 million in net proceeds after deducting underwriting discounts and offering expenses paid by the Company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that its cash and cash equivalents as of December 31, 2020 will be sufficient to fund the Company&#8217;s operating plan for a period of at least one year from the issuance date of the consolidated financial statements. The Company will need additional financing to support its continuing operations and pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of equity or debt financings, collaboration agreements, strategic alliances and licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all.&nbsp;&nbsp;The inability to obtain funding as and when needed would have a negative impact on the Company&#8217;s financial condition and ability to pursue its business strategies. If the Company is unable to obtain funding when needed, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations.&nbsp;&nbsp;The Company will need to generate significant revenue to achieve profitability, and it may never do so.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the completion of the IPO of its common stock in May 2020, all outstanding redeemable convertible preferred stock of the Company converted into shares of common stock and all outstanding warrants to purchase common stock were automatically cashless exercised.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62404652"></a>LYRA THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU26"></a>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COVID-19 Pandemic and CARES Act</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 30, 2020, the World Health Organization (&#8220;WHO&#8221;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &#8220;COVID-19 outbreak&#8221;) and the risks to the international community as the virus subsequently spread globally beyond its point of origin. On March 11, 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The COVID-19 pandemic is affecting the United States and global economies and may affect the Company&#8217;s operations and those of third parties on which the Company relies, including by causing disruptions in the supply of the Company&#8217;s product candidates and the conduct of current and future clinical trials. In addition, the COVID-19 pandemic may affect the operations of the Food and Drug Administration and other health authorities, which could result in delays of reviews and approvals, including with respect to the Company&#8217;s product candidates. In light of developments relating to the COVID-19 pandemic, the Company discontinued enrollment at 67 patients in its Phase 2 LANTERN clinical trial and did not enroll patients in the United States. Additionally, while the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce the Company&#8217;s ability to access capital, which could negatively impact the Company&#8217;s short-term and long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, financing or clinical trial activities or on healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company&#8217;s liquidity, capital resources, operations and business and those of the third parties on which the Company relies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 27, 2020, President Trump signed into law the &#8220;Coronavirus Aid, Relief, and Economic Security (CARES) Act.&#8221; The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property. The Company currently defers the employer side social security payments and also is evaluating whether it will take advantage of other provisions, if any. The CARES Act also appropriated funds for the SBA Paycheck Protection Program loans that are forgivable in certain situations to promote continued employment, as well as Economic Injury Disaster Loans to provide liquidity to small businesses harmed by COVID-19. On December 27, 2020, the Consolidated Appropriations Act, 2021 was signed into law in order to provide further stimulus and support to those affected by the COVID-19 pandemic. The Company has not and does not plan on obtaining funding from such loans. The Company does not believe the CARES Act or the Consolidated Appropriations Act, 2021 will have a material impact on its financial condition, results of operations, or liquidity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of Significant Accounting Policies </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of Lyra Therapeutics, Inc. and its wholly owned subsidiary Lyra Therapeutics Security Corporation, which was incorporated in December 2018. All intercompany transactions and balances have been eliminated. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the accompanying consolidated financial statements and notes. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62404652"></a>LYRA THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&#8217;s management evaluates its estimates, which include but are not limited to management&#8217;s judgments of accrued expenses, fair value of common stock, valuation of share-based awards warrants to purchase common stock and deferred income taxes. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilizes significant estimates and assumptions in determining the fair value of its common stock. The Company has utilized various valuation methodologies to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&#8217;s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment Information </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision-maker, the Company&#8217;s chief executive officer, views the Company&#8217;s operations and manages its business as a single operating segment, which is the business of developing targeted medicines to address ENT diseases. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive Income (Loss) </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. As the Company did not have any element of other comprehensive income (loss), its comprehensive loss is equal to its net loss for all periods presented. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash held in banks and amounts held in money market funds. Cash equivalents are stated at cost, which approximates market value. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents consist of cash held in banks at December&#160;31, 2020 and 2019. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Cash </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had restricted cash of approximately $0.3&#160;million as of December&#160;31, 2020 and 2019, which was held in certificates of deposit at the Company&#8217;s financial institution to secure the Company&#8217;s letter of credit for its facility lease. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Off-Balance Sheet Risk </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains all its cash and cash equivalents at a single accredited financial institution, in amounts that exceed federally insured limits.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign exchange hedging arrangements. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62404652"></a>LYRA THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Significant Suppliers </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the drug product and associated applicator related to these programs. These programs could be adversely affected by a significant interruption in the supply of the materials required to manufacture the drug product and associated applicator. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at a measurement date. ASC Topic 820, <font style="font-style:italic;">Fair Value Measurements</font> (&#8220;ASC 820&#8221;), establishes a three-level valuation hierarchy for instruments measured at fair value that prioritizes the inputs used to measure fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported or disclosed fair value of the financial instruments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy established by ASC 820 in order of priority are as follows: </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;1&#160;-Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;2 -Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;3 -Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An entity may elect to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in net loss. The Company did not elect to measure any financial instruments or other items at fair value. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Derivative Liabilities </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with certain debt and equity financings, the Company may issue financial instruments in which a derivative instrument is &#8220;embedded.&#8221; Upon issuing the financial instrument, the Company assesses whether the economic characteristics of the embedded derivative are clearly and closely related to the economic characteristics of the remaining component of the financial instrument (i.e., the host contract) and whether a separate, non-embedded instrument with the same terms as the embedded instrument would meet the definition of a derivative instrument. When it is determined that (1)&#160;the embedded derivative possesses economic characteristics that are not clearly and closely related to the economic characteristics of the host contract, and (2)&#160;a separate, stand-alone instrument with the same terms would qualify as a derivative instrument, the embedded derivative is separated from the host contract and carried at fair value until the derivative is settled. Changes in the fair value of the derivative liabilities are recognized as other income (expense) in the consolidated statement of operations and comprehensive loss. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62404652"></a>LYRA THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Classification and Accretion of Redeemable Convertible Preferred Shares </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has classified the redeemable convertible preferred stock outside of stockholders&#8217; deficit in the accompanying consolidated balance sheets in accordance with authoritative guidance for the classification and measurement of redeemable securities as the redeemable convertible preferred stock is redeemable at a determinable price on a fixed date or upon the occurrence of a deemed liquidation event. The carrying values of the redeemable convertible preferred shares are accreted to their redemption values from the date of issuance through the earliest date of redemption. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimated Useful Life</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:49%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer software and equipment</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office furniture and fixtures</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7 years</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of useful life or remaining term of related lease</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs for capital assets not yet placed into service are capitalized as construction in progress and are depreciated in accordance with the above guidelines once placed into service. Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statement of operations and comprehensive loss. Repairs and maintenance that do not improve or extend the lives of the respective assets are expensed as incurred, while costs of major additions and betterments are capitalized. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets consist of property and equipment. The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company did not record any impairment losses on long-lived assets during the years ended December&#160;31, 2020 and 2019. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASU No. 2016-02, <font style="font-style:italic;">Leases (Topic 842)</font> (&#8220;ASU No. 2016-02&#8221;), became effective January 1, 2019. As of the effective date of ASU No. 2016-02, the Company determines at the inception of an arrangement whether the arrangement contains a lease. If a lease is identified in an arrangement, the Company recognizes a right-of-use asset and liability on its balance sheet and determines whether the lease should be classified as a finance or operating lease. The Company does not recognize assets or liabilities for leases with lease terms of less than 12&#160;months. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the rate implicit in the lease is not readily determinable, the Company utilizes its incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62404652"></a>LYRA THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company separates lease and non-lease components when determining which lease payments to include in the calculation of its lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably certain it will exercise the option. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases are recorded in &#8220;Operating lease right-of use assets,&#8221; &#8220;Operating lease liabilities&#8221; and &#8220;Operating lease liabilities, net of current portion&#8221; in the Company&#8217;s consolidated balance sheets. The Company did not have any finance leases recorded in its consolidated balance sheet as of December 31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Costs </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, manufacturing expenses, stock-based compensation expense, depreciation of equipment, contract services and other outside expenses. Costs of certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development contracts with companies both inside and outside of the United States. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patent Costs </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accounting for Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, <font style="font-style:italic;">Compensation&#8212;Stock Compensation</font> (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments to employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees. The Company believes the fair value of the stock options granted to non-employees is more reliably determinable than the fair value of the services provided. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Black-Scholes option-pricing model uses the following inputs: the fair value of the Company&#8217;s common stock, the expected volatility of the Company&#8217;s common stock, the expected term of the Company&#8217;s stock options, the risk-free interest rate for a period that approximates the expected term of the Company&#8217;s stock options, and the Company&#8217;s expected dividend yield. Following the closing of the Company&#8217;s IPO, the fair value of the Company&#8217;s common stock is determined based on the quoted market price of its common stock. The Company has historically been a private company and lacks company-specific historical and implied volatility data. Therefore, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to it, including stage of product development, life science industry focus, length of trading history, and similar vesting provisions. The historical volatility data is calculated based on a period of time commensurate with the expected term assumption. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available or until circumstances change, such that the identified entities are no longer representative companies. In the latter case, more suitable, similar entities whose share prices are publicly available would be utilized in the calculation. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, <font style="font-style:italic;">Share-Based Payment</font>, to calculate the expected term for options granted to employees as it does not have sufficient historical </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62404652"></a>LYRA THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid cash dividends and has no current plans to pay any cash dividends on its common stock. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has elected as a policy to recognize forfeitures as they occur as described in ASU No.&#160;2016-09, <font style="font-style:italic;">Compensation&#8212;Stock Compensation</font> (&#8220;ASU No.&#160;2016-09&#8221;). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expenses the fair value of its stock-based compensation awards to employees on a straight-line basis over the requisite service period, which is generally the vesting period. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company follows the provisions of ASU No.&#160;2018-07, <font style="font-style:italic;">Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</font> (&#8220;ASU No.&#160;2018-07&#8221;) which permits the Company to recognize non-employee stock-based compensation costs over the requisite period based on a measurement of fair value on the grant date for each stock-based award. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes using the liability method in accordance with ASC Topic 740, <font style="font-style:italic;">Income Taxes</font> (&#8220;ASC 740&#8221;). The difference between the financial statement and tax basis of the assets and liabilities is determined annually. Deferred income tax assets and liabilities are computed using the tax laws and rates that are expected to apply for periods in which such differences reverse. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will more likely than not be realized. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contingencies </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with ASC Topic 450, <font style="font-style:italic;">Contingencies</font>, the Company records accruals for contingencies and legal proceedings expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Guarantees </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has identified the guarantees described below as disclosable, in accordance with ASC Topic 460, <font style="font-style:italic;">Guarantees</font>. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company&#8217;s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#8217; and officers&#8217; insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62404652"></a>LYRA THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office space under a noncancelable operating lease. The Company has standard indemnification arrangements under the lease that requires it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the lease. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, the Company had not experienced any losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves have been established. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Deferred Offering Costs </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&#8217; deficit as a reduction of additional paid-in capital generated as a result of the offering. Should the planned equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statement of operations and comprehensive loss. Deferred offering costs of $0 and $1.1 million are included in other assets in the consolidated balance sheets at December 31, 2020 and 2019, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss per Share </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company has computed diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, warrants to purchase common stock and redeemable convertible preferred stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive and basic and diluted loss per share have been the same. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share data): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,127</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,306</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accretion of redeemable convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(115</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(313</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,242</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,619</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares&#8212;basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,590,205</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202,093</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders&#8212;basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.59</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(82.23</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62404652"></a>LYRA THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares retroactively adjusted): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A-1 redeemable convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">986,466</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A-2 redeemable convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">773,712</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A-3 redeemable convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">872,031</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A-4 redeemable convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">579,993</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B redeemable convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,852,177</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,428,886</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">792,439</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,428,886</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,856,818</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU No.&#160;2018-13, <font style="font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</font> (&#8220;ASU No.&#160;2018-13&#8221;), which modifies the disclosure requirements on fair value measurements. The Company adopted ASU No. 2018-13 on January&#160;1, 2020. The adoption of ASU 2018-13 did not have a material impact on the Company&#8217;s consolidated financial position, results of operations or cash flows.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU No.&#160;2018-15, <font style="font-style:italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</font> (&#8220;ASU No.&#160;2018-15&#8221;), which clarifies the accounting for implementation costs in cloud computing arrangements. The Company adopted ASU No. 2018-15 on January&#160;1, 2020 on a prospective basis. The adoption of ASU 2018-15 did not have a material impact on the Company&#8217;s consolidated financial position, results of operations or cash flows.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No. 2019-12, <font style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</font> (&#8220;ASU No. 2019-12&#8221;), which makes a number of changes meant to add or clarify guidance on accounting for income taxes. The new guidance will become effective for the Company on January 1, 2022. Early adoption is permitted. The Company currently is evaluating the impact the adoption of ASU 2019-12 will have on its consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. Fair Value Measurements </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not have financial assets and liabilities measured at fair value at December&#160;31, 2020 and 2019. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no changes to the valuation methods used during the years ended December 31, 2020 and 2019. There were no transfers within the fair value hierarchy during the years ended December 31, 2020 and 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying values of the Company&#8217;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Company&#8217;s sale of Series C redeemable convertible preferred stock (&#8220;Series C Preferred Stock&#8221;), the Company issued to investors warrants for the purchase of common stock (&#8220;Warrants&#8221;). The proceeds from the issuance of the Series C Preferred Stock were allocated between the Series C Preferred Stock and Warrants based on their relative fair values at the time of issuance.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62404652"></a>LYRA THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. Property and Equipment </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of the following at December&#160;31, 2020 and 2019 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62743141"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,277</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,715</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer software and equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">650</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">595</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office furniture and fixtures</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">317</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">317</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">498</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,043</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,066</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,878</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,829</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,165</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized approximately $0.1 million and $27,000 of depreciation expense for the years ended December 31, 2020 and 2019, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. Accrued Expenses and Other Current Liabilities </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities consist of the following at December&#160;31, 2020 and 2019 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62743197"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and employee related expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,892</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">885</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">381</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,344</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional and consulting fees</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">555</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">901</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses and other current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,977</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,240</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6. Redeemable Convertible Preferred Stock </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 10, 2020, the Company filed an amended and restated certificate of incorporation which authorized its Board of Directors to issue up to 299,300,288 shares of preferred stock, par value $0.001 per share. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, the Company issued 78,306,611 shares of Series C Preferred Stock for $0.38811 per share, in exchange for gross cash proceeds of approximately $30.4 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the completion of the IPO of its common stock in May 2020, all outstanding redeemable convertible preferred stock of the Company converted into shares of common stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7. Preferred and Common Stock </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 10, 2020, the Company filed an amended and restated certificate of incorporation which authorized its Board of Directors to issue up to 400,000,000 shares of common stock, par value $0.001 per share. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 5, 2020, the Company filed a restated certificate of incorporation which authorizes its Board of Directors to issue up to 200,000,000 shares of common stock, par value $0.001 per share and 10,000,000 shares of undesignated preferred stock, par value $0.001 per share.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of common stock are entitled to one vote for each share held. Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62404652"></a>LYRA THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s Board of Directors approved a </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one-for-34.483</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> reverse stock split of its issued and outstanding common stock and stock options and a proportional adjustment to the existing conversion ratios for the Company&#8217;s redeemable convertible preferred stock pursuant to an amendment to the Company&#8217;s amended and restated certificate of incorporation effective as of April 27, 2020. Accordingly, all common stock shares, per share amounts, and additional paid in capital amounts for all periods presented in the accompanying consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, the Company completed its IPO in which the Company issued and sold 4,025,000 shares of its common stock, including 525,000 shares pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, at a public offering price of $16.00 per share, for aggregate gross proceeds of $64.4 million. The Company received approximately $57.3 million in net proceeds after deducting underwriting discounts and offering expenses paid by the Company. In connection with this financing, all outstanding shares of redeemable convertible preferred stock converted into 8,335,248 shares of the Company&#8217;s common stock, all outstanding Warrants were automatically cashless exercised resulting in the issuance of 313,794 shares of the Company&#8217;s stock and the issuance to one of our directors, in lieu of compensation payable by the Company under a consulting agreement, of 19,661 fully vested shares of the Company&#8217;s common stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, the Company issued as non-employee compensation 5,000 fully vested shares of the Company&#8217;s common stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has reserved for future issuances the following shares of common stock as of December 31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,888,653</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock purchase plan</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,038,653</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Warrants</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In conjunction with the issuance of the Series C Preferred Stock, the Company issued Warrants to purchase 681,256 shares of common stock at an exercise price of $8.63 per share.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classified the Warrants as equity in the consolidated balance sheets in accordance with the guidance in ASC 815, <font style="font-style:italic;">Derivatives and Hedging</font>. The Company allocated the net proceeds from the issuance of the Series C Preferred Stock based on the relative fair values of the Series C Preferred Stock and Warrants, which resulted in approximately $0.7 million of the net proceeds being allocated to the Warrants.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the completion of the IPO of the Company&#8217;s common stock in May 2020, all outstanding Warrants were automatically cashless exercised resulting in the issuance of 313,794 shares of the Company&#8217;s common stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1051"></a><a name="_cp_text_1_1051"></a>8. Stock-Based Compensation Expense </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted the 2016 Equity Incentive Plan (&#8220;2016 Plan&#8221;) in February 2016 and amended it in June 2017 and June 2018. Upon adoption of the 2016 Plan, no further grants were made under the 2005 Equity Incentive Plan (&#8220;2005 Plan&#8221;).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2020, the Company&#8217;s Board of Directors adopted the Company&#8217;s 2020 Incentive Award Plan (&#8220;2020 Plan&#8221;, and together with the 2016 Plan and 2005 Plan, the &#8220;Plans&#8221;), and upon effectiveness of the 2020 Plan, the Company ceased granting equity-based awards under the 2016 Plan. The 2020 Plan provides for grant of incentive stock options and nonqualified stock options, stock appreciation rights, restricted stock, dividend equivalents, restricted stock units, performance awards and other share and cash-based awards to employees and consultants and members of the Board of Directors of the Company and its subsidiaries.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62404652"></a>LYRA THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initial number of shares of the Company&#8217;s common stock that may be issued under the 2020 Plan is </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,100,000</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares plus the number of shares of the Company&#8217;s common stock underlying outstanding awards under the 2005 Plan and 2016 Plan as of the effective date of the 2020 Plan that expire, lapse or are terminated, exchanged for cash, surrendered, repurchased, canceled or forfeited following the effective date of the 2020 Plan. The number of shares available under the 2020 Plan will automatically increase on January 1st of each year from 2021 to 2030 by the lesser of (i)</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 4</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of the number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) a smaller number of shares determined by the Company&#8217;s Board of Directors. However, no more than </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,800,000</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares may be issued under the 2020 Plan pursuant to the exercise of incentive stock options. As of December 31, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company had </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,459,767</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares available for issuance under the 2020 Plan.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All stock option grants are nonqualified stock options except option grants to employees and officers intended to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended. Stock options may not be granted at less than the fair market value of the Company&#8217;s common stock on the date of grant. Vesting periods of awards are determined by the Board of Directors or its compensation committee. Vesting periods of awards granted to date range from vesting upon grant to vesting over a four-year period. Vesting conditions are generally based on continued service. Additionally, the Company has granted certain awards which vest upon the achievement of certain financing and revenue milestones. Stock options granted under the Plans expire no more than 10 years from the date of grant. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense included in the Company&#8217;s consolidated statements of operations and comprehensive loss was as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">229</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,584</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">218</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,813</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not record any stock-based compensation associated with milestone-based awards in the years ended December&#160;31, 2020 and 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each stock option granted to employees, directors and non-employees was estimated on the date of grant using the Black-Scholes option-pricing model, with the following weighted-average assumptions: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62743649"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80.7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76.8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62404652"></a>LYRA THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the stock option activity under the Plans for the year ended December 31, 2020 was as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in&#160;thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">792,439</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.59</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,363</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">763,505</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.16</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,814</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.92</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(124,244</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.30</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,428,886</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.41</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,165</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">626,578</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.30</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,099</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:16.35pt;">
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,428,886</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.41</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,165</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average fair value of options granted to employees, directors and non-employees during the years ended December&#160;31, 2020 and 2019 was $9.66 and $3.45, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. The aggregate intrinsic value of stock options exercised during the years ended December&#160;31, 2020 and 2019 was approximately $27,000 and $0.2 million, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, total unrecognized stock-based compensation expense relating to unvested stock options was approximately $6.2&#160;million. This amount is expected to be recognized over a weighted-average period of 3.2 years. Additionally, as of December 31, 2020, there was approximately $36,000 of unrecognized stock-based compensation related to a stock option award related to the achievement of a revenue-based milestone. As the Company believes the achievement of the revenue-based milestone is currently not probable, it has not recorded any stock-based compensation related to this award. The Company will continue to assess the probability of achieving the revenue-based milestone at each reporting period. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020 Employee Stock Purchase Plan</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2020, the Company&#8217;s Board of Directors adopted the Company&#8217;s 2020 Employee Stock Purchase Plan (&#8220;2020 ESPP&#8221;). The 2020 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.&nbsp;&nbsp;The Company initially reserved 150,000 shares of common stock for issuance under the 2020 ESPP.&nbsp;&nbsp;In addition, the number of shares available for issuance under the 2020 ESPP will be annually increased on January 1st of each year from 2021 to 2030 by the lesser of (i) 0.5% of the number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by the Company&#8217;s Board of Directors, provided that no more than 987,500 shares of common stock may be issued under the 2020 ESPP. The 2020 ESPP permits eligible participants to purchase common stock through payroll deductions of up to a specified percentage of their eligible compensation. On the first trading day of each offering period, each participant will automatically be granted an option to purchase shares of the Company&#8217;s common stock. The option will expire at the end of the applicable offering period, and will be exercised at that time to the extent of the payroll deductions accumulated during the offering period, subject to the limits set forth in the 2020 ESPP. The purchase price of the shares, in the absence of a contrary designation, will be 85% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the purchase date. As of December 31, 2020, no shares have been issued under the 2020 ESPP. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9. Related Parties </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had consulting agreements that expired in January 2020 with two of its founders who resigned as directors of the Company in October 2020. Total consulting expense related to these consulting agreements was $0 and $50,000 for the years ended December 31, 2020 and 2019, respectively. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62404652"></a>LYRA THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2011, the Company entered into a Contribution Agreement, Transition Services Agreement (as amended), Collaboration Agreement, Technology License Agreement and Trademark Coexistence Agreement with Arsenal Medical, Inc. (&#8220;Arsenal&#8221;), a company which shares certain common owners with the Company. During the year ended December 31, 2019, the Company invoiced Arsenal for an aggregate of $</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, primarily for its share of rent and other overhead costs.&nbsp;&nbsp;The Transition Services Agreement expired in June 2019. All amounts receivable from Arsenal were collected as of December 31, 2019. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10. Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records a provision or benefit for income taxes on pre-tax income or loss based on its estimated effective tax rate for the year. During the years ended December&#160;31, 2020 and 2019, the Company recorded net losses of approximately $22.1 million and $16.3&#160;million, respectively, and, since it maintains a full valuation allowance on its deferred tax assets, the Company did not record an income tax benefit for the years ended December&#160;31, 2020 and 2019. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of income tax expense computed at the statutory federal income tax rate to income taxes reflected in the consolidated financial statements is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax computed at federal statutory tax rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes, net of federal benefit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development and other tax credits</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in deferred tax asset valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28.4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30.7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets as of December&#160;31, 2020 and 2019 consist of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,729</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,006</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,223</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,652</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">322</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">661</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">909</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">280</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total gross deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,075</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,451</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35,150</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">624</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">870</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(624</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(870</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(624</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(870</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred taxes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company had U.S. federal net operating loss carryforwards of approximately $91.4&#160;million which may be able to offset future income tax liabilities and expire at various dates through 2037 and approximately $44.0&#160;million of federal net operating loss carryforwards that may be carried forward indefinitely. As of December&#160;31, 2020, the Company also had state net operating loss carryforwards of approximately $116.0&#160;million which may be available to offset future income tax liabilities and expire at various dates through 2040. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62404652"></a>LYRA THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company had federal research and development tax credit carryforwards of approximately $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.6</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million and $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;million, respectively, available to reduce future tax liabilities which expire at various dates through </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2040</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. As of December&#160;31, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company had state research and development tax credit carryforwards of approximately $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million and $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;million, respectively, available to reduce future tax liabilities which expire at various dates through </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2035</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The Company has generated research credits but has not conducted a study to document the qualified activity. This study may result in an adjustment to the Company&#8217;s research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the research and development credit carryforwards and the valuation allowance.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the provisions of the Internal Revenue Code, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section&#160;382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section&#160;382, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed by the Company and any limitation is known, no amounts are being presented as an uncertain tax position. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at December&#160;31, 2020 and 2019 because the Company&#8217;s management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets primarily due to its history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and, as a result, a valuation allowance of approximately $41.5 million and $35.2&#160;million, respectively, has been established at December&#160;31, 2020 and 2019. Management reevaluates the positive and negative evidence at each reporting period. The valuation allowance increased by approximately $6.3 million and $5.1&#160;million, respectively, during the years ended December&#160;31, 2020 and 2019 due primarily to the generation of net operating losses. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has recorded adjustments to deferred tax assets for unrecognized tax benefits as of December&#160;31, 2020 and 2019. The Company&#8217;s policy is to record interest and penalties related to uncertain tax positions as part of its income tax provision. As of December&#160;31, 2020 and 2019, the Company had no accrued interest or penalties related to uncertain tax positions and no such amounts have been recognized in the Company&#8217;s statement of operations and comprehensive loss. In many cases, the Company&#8217;s uncertain tax positions are related to years that remain subject to examination by relevant tax authorities. The statute of limitations for federal and state tax authorities is closed for years prior to December&#160;31, 2017. However, since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11. Leases </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2007, the Company entered into an operating lease, as amended, for approximately 22,343 square feet of office and laboratory space in Watertown, Massachusetts. In November 2017, the Company amended its lease (&#8220;2017 Amendment&#8221;) and extended the lease term through April 2023. Initial base rent under the 2017 Amendment was approximately $1.0&#160;million per year. The 2017 Amendment includes annual rent escalations over the term of the operating lease. The Company maintains a letter of credit of approximately $0.3&#160;million securing its obligations under the operating lease which is secured by approximately $0.3&#160;million of certificate of deposits, which are included as restricted cash in the consolidated balance sheets. Rent expense is recognized on a straight-line basis over the terms of occupancy. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62404652"></a>LYRA THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the lease discussed above, the Company is party to an </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 2020</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> lease for office equipment that expires in </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 2024</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;The equipment lease is accounted for as an operating lease.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease cost recorded in the Company&#8217;s consolidated financial statements were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease Cost:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,055</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,053</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">726</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">727</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(368</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,781</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,412</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease payments include the Company&#8217;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. The Company&#8217;s sublease income during the year ended December 31, 2019 related to subleases for a portion of the Company&#8217;s office and lab space.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average remaining lease term and discount rate related to the Company&#8217;s operating leases were as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (in years)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturity of the Company&#8217;s operating lease liabilities in accordance with ASC 842 as of December 31, 2020 were as follows (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,095</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,127</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">382</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total maturities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,606</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Amount representing interest</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(167</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of operating lease liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,439</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Current portion of operating lease liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(985</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liability, net of current portion</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,454</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="FINAL_FPAGE"></a>12. Retirement Plan </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a defined-contribution plan under Section&#160;401(k) of the Internal Revenue Code (&#8220;401(k) Plan&#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. As currently established, the Company is not required to make any contributions to the 401(k) Plan. For the year ended December 31, 2020, the Company made a discretionary match that matches 50% of employee contributions up to a maximum of 3% of employees&#8217; salary. Matching contributions are fully vested at the time of contribution. During the year ended December 31, 2020, matching contribution costs incurred by the Company were $0.1 million. The Company did not make any matching contributions during the year ended December&#160;31, 2019. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-22</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>2
<FILENAME>lyra-ex44_349.htm
<DESCRIPTION>EX-4.4
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
lyra-ex44_349.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4.4</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="rom846749_15"></a>DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, Lyra Therapeutics, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). References herein to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and the &#8220;Company&#8221; refer to Lyra Therapeutics, Inc. and not to any of its subsidiaries.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">General </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following description summarizes some of the terms of our amended and restated certificate of incorporation and amended and restated bylaws. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description, you should refer to our amended and restated certificate of incorporation, amended and restated bylaws and investor rights agreement, copies of which have been filed with the Securities and Exchange Commission, as well as the relevant provisions of the General Corporation Law of the State of Delaware. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our authorized capital stock consists of 200,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Subject to the supermajority votes for some matters, other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter. Our amended and restated certificate of incorporation and amended and restated bylaws also provide that our directors may be removed only for cause and only by the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon. In addition, the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon is required to amend or repeal, or to adopt any provision inconsistent with, several of the provisions of our amended and restated certificate of incorporation. See below under &#8220;&#8212;Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws&#8212;Amendment of Charter Provisions.&#8221; Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any series of preferred stock that we may designate and issue in the future. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately our net assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion rights. Our outstanding shares of common stock are validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of our amended and restated certificate of incorporation, our board of directors is authorized to direct us to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have the effect of making it more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock.&nbsp;&nbsp;There are no shares of preferred stock outstanding, and we have no present plans to issue any shares of preferred stock. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registration Rights </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain holders of our common stock are entitled to certain rights with respect to the registration of such shares for public resale under the Securities Act, pursuant to the investor rights agreement, until the rights otherwise terminate pursuant to the terms of the investor rights agreement. The registration of shares of common stock as a result of the following rights being exercised would enable holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Form S-1 Registration Rights </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If at any time the holders of at least 30% of the registrable securities then outstanding request in writing that we effect a registration with respect to all or part of such registrable securities then outstanding having an anticipated aggregate offering price that would exceed $5,000,000, we may be required to register their shares. We are obligated to effect at most two registrations in response to these demand registration rights. If the holders requesting registration intend to distribute their shares by means of an underwriting, the managing underwriter of such offering will have the right to limit the numbers of shares to be underwritten for reasons related to the marketing of the shares. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Piggyback Registration Rights </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If at any time we propose to register any shares of our common stock under the Securities Act, subject to certain exceptions, the holders of registrable securities then outstanding will be entitled to notice of the registration and to include their shares of registrable securities in the registration. If our proposed registration involves an underwriting, the managing underwriter of such offering will have the right to limit the number of shares to be underwritten for reasons related to the marketing of the shares. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Form S-3 Registration Rights </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If, at any time after we become entitled under the Securities Act to register our shares on a registration statement on Form S-3, the holders of the registrable securities then outstanding request in writing that we effect a registration with respect to all or part of such registrable securities having an anticipated aggregate offering price to the public in the offering of at least $2,000,000, we will be required to effect such registration; provided, however, that we will not be required to effect such a registration if, within any twelve month period, we have already effected two registrations on Form S-3 for the holders of registrable securities. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Expenses and Indemnification </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ordinarily, other than underwriting discounts and commissions, we will be required to pay all expenses incurred by us related to any registration effected pursuant to the exercise of these registration rights. These expenses may include all registration and filing fees, printing expenses, fees and disbursements of our counsel, reasonable fees and disbursements of a counsel for the selling securityholders and blue sky fees and expenses. Additionally, we have agreed to indemnify selling stockholders for damages, and any legal or other expenses reasonably incurred, arising from or based upon any untrue statement of a material fact contained in any registration statement, an omission or alleged omission to state a material fact in any registration statement or necessary to make the statements therein not misleading, or any violation or alleged violation by the indemnifying party of securities laws, subject to certain exceptions. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Termination of Registration Rights </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The registration rights terminate upon the earlier of the date on which no stockholder holds any registrable securities, the closing of a company sale, as defined in the investor rights agreement, at such time as SEC Rule&#160;144 </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or another similar exemption under the Securities Act is available for the sale of all of a stockholder&#8217;s shares without limitation during a three-month period without registration or May 5, 2025. </font></p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some provisions of Delaware law, our restated certificate of incorporation and our restated bylaws could make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for payment of a premium over the market price for our shares. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Undesignated Preferred Stock </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of our board of directors, without action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stockholder Meetings </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our restated bylaws provide that a special meeting of stockholders may be called only by our chairman of the board, chief executive officer or president (in the absence of a chief executive officer), or by a resolution adopted by a majority of our board of directors. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Requirements for Advance Notification of Stockholder Nominations and Proposals </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our restated bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Elimination of Stockholder Action by Written Consent </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our restated certificate of incorporation eliminates the right of stockholders to act by written consent without a meeting. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Staggered Board </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors is divided into three classes. The directors in each class serve for a three-year term, one class being elected each year by our stockholders. This system of electing and removing directors may tend to discourage a third-party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Removal of Directors </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our restated certificate of incorporation provides that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the holders of at least two-thirds in voting power of the outstanding shares of stock entitled to vote in the election of directors. </font></p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stockholders Not Entitled to Cumulative Voting </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our restated certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock may be entitled to elect. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Delaware Anti-Takeover Statute </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to Section&#160;203 of the General Corporation Law of the State of Delaware, which prohibits persons deemed to be &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Choice of Forum </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for: (1)&#160;any derivative action or proceeding brought on our behalf; (2)&#160;any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (3)&#160;any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our certificate of incorporation or bylaws; (4)&#160;any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws; or (5)&#160;any action asserting a claim governed by the internal affairs doctrine. Under our amended and restated certificate of incorporation, this exclusive forum provision will not apply to claims which are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction. For instance, the provision would not apply to actions arising under federal securities laws, including suits brought to enforce any liability or duty created by the Securities Act, Exchange Act, or the rules and regulations thereunder. Our restated certificate of incorporation further provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Our restated certificate of incorporation also provides that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to these choice of forum provisions. It is possible that a court of law could rule that either or both of the choice of forum provisions contained in our restated certificate of incorporation is inapplicable or unenforceable if it is challenged in a proceeding or otherwise. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Amendment of Charter Provisions </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock and the provision prohibiting cumulative voting, would require approval by holders of at least two-thirds in voting power of the outstanding shares of stock entitled to vote thereon. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provisions of Delaware law, our restated certificate of incorporation and our restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Exchange Listing </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is listed on The Nasdaq Global Market under the symbol &#8220;LYRA.&#8221; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>lyra-ex231_175.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
lyra-ex231_175.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:12pt;font-weight:bold;color:#000000;font-size:10.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">Exhibit 23.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;"><font style="text-decoration:underline;">Consent of Independent Registered Public Accounting Firm</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;color:#000000;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lyra Therapeutics, Inc.</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;color:#000000;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Watertown, Massachusetts</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;margin-right:0.89%;text-indent:0%;color:#000000;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (333-237973) of Lyra Therapeutics, Inc. of our report dated March 9, 2021 relating to the consolidated financial statements, which appears in this Annual Report on Form 10-K.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;color:#000000;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ BDO USA, LLP</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;color:#000000;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, Massachusetts</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;color:#000000;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 9, 2021</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>lyra-ex311_9.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
lyra-ex311_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Maria Palasis, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of Lyra Therapeutics, Inc.;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_1052"></a>[Intentionally omitted];</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1054"></a>(</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_1054"></a>Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1056"></a>(</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_1056"></a>Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:45.06%;"></td>
<td style="width:4.93%;"></td>
<td style="width:3.46%;"></td>
<td style="width:46.55%;"></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 9, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Maria Palasis, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maria Palasis, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>lyra-ex312_8.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
lyra-ex312_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, R. Don Elsey, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of Lyra Therapeutics, Inc.;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_1057"></a>[Intentionally omitted];</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1059"></a>(</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_1059"></a>Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1061"></a>(</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_1061"></a>Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:45%;"></td>
<td style="width:4.91%;"></td>
<td style="width:3.46%;"></td>
<td style="width:46.62%;"></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 9, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;R. Don Elsey</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R. Don. Elsey</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>lyra-ex321_6.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
lyra-ex321_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Exhibit 32.1</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">CERTIFICATION PURSUANT TO</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report on Form 10-K of Lyra Therapeutics, Inc. (the &#8220;Company&#8221;) for the period ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 9, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Maria Palasis, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maria Palasis, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>lyra-ex322_7.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
lyra-ex322_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Exhibit 32.2</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">CERTIFICATION PURSUANT TO</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report on Form 10-K of Lyra Therapeutics, Inc. (the &#8220;Company&#8221;) for the period ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 9, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;R. Don Elsey</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R. Don. Elsey</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>gn15qjhcndsi000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gn15qjhcndsi000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -X!AX# 2(  A$! Q$!_\0
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MIZTE48A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !2K]X?6DI5^\/K0!T6N?\ (.L_]W_&N<KH]<_Y!UG_ +O^-<Y4
MQV-:_P 844451D%%%% !1110 4444 %%%% !1110 4444""BBB@84444@"BB
MBF(****0PHHHI@%%%% !1110 4444 %%%% !1110 5W/P[_UUY_NBN&KN?AW
M_KKS_=%1/8Z<'_&B<-1115G,%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!8L?\
MC^A_WA6GXG_Y"*_[M9EC_P ?T/\ O"M/Q/\ \A%?]VIZFT?X3]3$HHHJC$**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *D@_X^(_\ >'\ZCJ2#_CXC_P!X?SI MS<\4?ZRV_ZY
MC^5<_70>*/\ 66W_ %S'\JY^E'8UK_Q&%%%%49!1110 4444 %%%% !1110
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M=#%EJK6TK%8P0 QI\R,Y8><5=F)17=3>!H1IWVF"<O\ +FN?N])MK:T1S/\
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MG_WJO^&?^0JOTJAJ/_(1G_WJGJ;/^$O4JT4451B%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %='I?_(NW7UKG*Z/2
M_P#D7;KZU+-J'Q/T.=/6DI3UI*HQ"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "E7[P^M)2K]X?6@#HM<_Y!UG_N_X
MUSE='KG_ "#K/_=_QKG*F.QK7^,****HR"BBB@ HHHH **** "BBB@ HHHH
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M&ZNW>(@Y/44TO>9G5G&6'C%/5&+1116APA1110 4444 %%%% !1110 4444
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M@.>U5=V.6-&G*;47H<Q>>';JSA\QB&7&<K70?#>1CJTR$\",_P C74/;1?\
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M+6U2R#OY:HPZ=Z?,*.%34I/9'G=]I\UA+LD!Z9SBJE=MXHO=-N[0M!*K2!0
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M^IB44451B%%%% #XDWR*N<9->M>%IH;7PW]G>:/=_O"O(N1TJ07$RC FD ]
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M=A5JT:;G%;L[^RT:&WT&68%3,5RI!Z5LVKLWA9!)(&?:<\^U>:0^)KN&T:W
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M HHHI@%%%% !1110 4444 %%%% !1110 5)!_P ?$?\ O#^=1U)!_P ?$?\
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M2GK251B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2BBBJ,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ J2#_CXC_WA_.HZD@_X^(_]X?SI MS<\4?
MZRV_ZYC^5<_70>*/]9;?]<Q_*N?I1V-:_P#$844451D%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ;/AG_ )"J_2J&
MH_\ (1G_ -ZK_AG_ )"J_2J&H_\ (1G_ -ZIZFS_ (2]2K1115&(4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5T>E
M_P#(NW7UKG*Z/2_^1=NOK4LVH?$_0YT]:2E/6DJC$**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *5?O#ZTE*OWA]:
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M\F_*O=?^$3T_T_2C_A$]/]/TH]J@_LJ?<\*^RS_\\F_*C[+/_P \F_*O=?\
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MX1/3_3]*/:H/[*GW/"OLL_\ SR;\J/LL_P#SR;\J]U_X1/3_ $_2C_A$]/\
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MGV6?_GDWY5[K_P (GI_I^E'_  B>G^GZ4_:HC^RI]SPK[+/_ ,\F_*C[+/\
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M  5_R"'_ -\UH:C_ ,@Z?_<-9_@K_D$/_OFG]DPE_'CZ,Z6BBBI.@0D*,DX
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M"XOKAFX-N1\IHL.YT%%%%(84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!4HHHIB"BBB@ HHHH
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *E%%%,04444 %%%%
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M!U(H!!Z&@!:C,\2G!< U)7$>.;R;2K:.>W.&=L&FE=V,JU7V4'/L=E]HA/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %2BBBF(****
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MXOHLW')AX%=O6<M-#T<.^>//W*FI &PE!]*X76?#*WFC)<0*!)G)('-=UJ9
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MJE*2>AEH-0N?#$U]]ND4H<8S]:V/"&ISWUK/#)(S,B?>-4;/_D0[K_>_QI/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP4444BPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"I112$X&:8A:*Y_5O%^GZ,
MQ%SNX..*FTCQ-9:T";;=QZT6%=&U145Q.MO$9'S@#/%<LWQ#T=;S[,=X?..:
M+#O8ZZBJ]I>1WEL)X_N&LV[\2V5G>1VL@8N_3% 7-JBN8U#QSI>FR;)]X.<4
MY?&NFM;F8!]H&>E.S%='2T5B:5XHL-7DV0,0V,X)K;I#"B@G SZ5S>M^,].T
M1]EQN)(_AH"YTE%<WH?C/3=<D\NW)# 9YKH9)5CCWL>* N/HKGW\7Z<MX;7)
M\P''6MY'#QJXZ$9H =16)=>)[*WN'@))=.N*ETSQ!9ZIGR200<8- 7-:BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH JZC_R#KC_<-9_@K_D$/_OF
MM#4?^0=<?[AK/\%?\@A_]\T_LF$OX\?1G2T445)T!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9O$?_(4?ZFM(;')5_C1]&9WVRX_Y[/\ G1]LN/\ GL_YU!15%$_VRX_Y[/\
MG1]LN/\ GL_YU!10!/\ ;+C_ )[/^='VRX_Y[/\ G4%% $_VRX_Y[/\ G1]L
MN/\ GL_YU!10!/\ ;+C_ )[/^='VRX_Y[/\ G4%% $_VRX_Y[/\ G1]LN/\
MGL_YU!10!/\ ;+C_ )[/^='VRX_Y[/\ G4%% $_VRX_Y[/\ G1]LN/\ GL_Y
MU!10!/\ ;+C_ )[/^='VRX_Y[/\ G4%% $_VRX_Y[/\ G1]LN/\ GL_YU!10
M!/\ ;+C_ )[/^='VRX_Y[/\ G4%% $_VRX_Y[/\ G1]LN/\ GL_YU!10!/\
M;+C_ )[/^='VRX_Y[/\ G4%% $_VRX_Y[/\ G1]LN/\ GL_YU!10!/\ ;+C_
M )[/^='VRX_Y[/\ G4%% $_VRX_Y[/\ G1]LN/\ GL_YU!10!/\ ;+C_ )[/
M^='VRX_Y[/\ G4%% $_VRX_Y[/\ G1]LN/\ GL_YU!10!/\ ;+C_ )[/^='V
MRX_Y[/\ G4%% $_VRX_Y[/\ G1]LN/\ GL_YU!10!/\ ;+C_ )[/^='VRX_Y
M[/\ G4%% $_VRX_Y[/\ G1]LN/\ GL_YU!10!/\ ;+C_ )[/^='VRX_Y[/\
MG4%% $_VRX_Y[/\ G1]LN/\ GL_YU!10!/\ ;+C_ )[/^='VRX_Y[/\ G4%%
M $_VRX_Y[/\ G1]LN/\ GL_YU!10!/\ ;+C_ )[/^='VRX_Y[/\ G4%% $_V
MRX_Y[/\ G1]LN/\ GL_YU!10!/\ ;+C_ )[/^='VRX_Y[/\ G4%% $_VRX_Y
M[/\ G1]LN/\ GL_YU!10!/\ ;+C_ )[/^='VRX_Y[/\ G4%% $_VRX_Y[/\
MG1]LN/\ GL_YU!10!/\ ;+C_ )[/^='VRX_Y[/\ G4%% $_VRX_Y[/\ G1]L
MN/\ GL_YU!10!/\ ;+C_ )[/^='VRX_Y[/\ G4%% $_VRX_Y[/\ G1]LN/\
MGL_YU!10!/\ ;+C_ )[/^='VRX_Y[/\ G4%% $_VRX_Y[/\ G1]LN/\ GL_Y
MU!10!/\ ;+C_ )[/^='VRX_Y[/\ G4%% $_VRX_Y[/\ G1]LN/\ GL_YU!10
M!/\ ;+C_ )[/^='VRX_Y[/\ G4%% $_VRX_Y[/\ G1]LN/\ GL_YU!10!/\
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MLH_"O3+&8W%HDAZFAH$[EFBBBD,**** *E%%%,044TR(O5U'U-*&#="#]#0
MM%%% !1110 4444 %%%% !1110 4444 %%%% !1136=5^\P'U- #J*0$,,@@
MCU%+0 4444 %%%% !1110 4444 %%%% !1110 4444 5-4_Y!=S_ +AKYF\1
M_P#(4?ZFOIG5/^07<_[AKYF\1_\ (4?ZFM(;')6_C1]&8]%%%44%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !2@D'(.#244 =UX*\;7&
MC7:QR,6C.%PQX%>_:5JMOJEJLT$@?(&<=C7R0.#D=17<>"?&L^C7*0RR'R"?
MF J)1-(3MHSZ.HJAI6JV^JV:7$####IGFK]9FP4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!4U
M3_D&7'^Y7EN@SW$7B<F&,N<5ZAJI TNX_P!RO-_"]R(O$^YD8#'7%4MB9;G1
MW5QJ4NIVN865-WS4_P >QR#1 \<S1G=_":U[[5[>*(N58LHR,5SGB6_.H>%%
MG"MR_3'-"!E"ST>:[T*:5KR4,J9'-1:'K,NCZ:L4DADQQN8UMZ.^?#=QP?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(;')6_C1]&8]%%%44%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYBG!X-%F%T=712(V]%8=QFEI#"BBB@ HHHH J4444Q!143W,$9P\T:GW8"I
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M_*C:WH?RH 2BEVMZ'\J-K>A_*@!**7:WH?RHVMZ'\J $HI=K>A_*C:WH?RH
M2BEVMZ'\J-K>A_*@!**7:WH?RHVMZ'\J $HI=K>A_*C:WH?RH 2BEVMZ'\J-
MK>A_*@!**7:WH?RHVMZ'\J $HI=K>A_*C:WH?RH 2BEVMZ'\J-K>A_*@!**7
M:WH?RHVMZ'\J $HI=K>A_*C:WH?RH 2BEVMZ'\J-K>A_*@!**7:WH?RHVMZ'
M\J $HI=K>A_*C:WH?RH 2BEVMZ'\J-K>A_*@!**7:WH?RHVMZ'\J $HI=K>A
M_*C:WH?RH 2BEVMZ'\J-K>A_*@!**7:WH?RHVMZ'\J $HI=K>A_*C:WH?RH
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M[_K7HU%',PY4><_\*ATG_GN_ZT?\*ATG_GN_ZUZ-11S,.5'G/_"H=)_Y[O\
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MS_PJ'2?^>[_K1_PJ'2?^>[_K7HU%',PY4><_\*ATG_GN_P"M'_"H=)_Y[O\
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M[_K7HU%',PY4><_\*ATG_GN_ZT?\*ATG_GN_ZUZ-11S,.5'G/_"H=)_Y[O\
MK1_PJ'2?^>[_ *UZ-11S,.5'G/\ PJ'2?^>[_K1_PJ'2?^>[_K7HU%',PY4>
M<_\ "H=)_P">[_K1_P *ATG_ )[O^M>C44<S#E1YS_PJ'2?^>[_K1_PJ'2?^
M>[_K7HU%',PY4><_\*ATG_GN_P"M*/A%I(.?/>O1:*.9ARHR=%T"TT2U2&!5
M.T8W8YK6HHI%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ##%&>J*?PIP5
M5Z #Z"EHH 0@'J,TWR8O^>:_E3Z* &B-!T11^%.HHH 9Y<><[%S]*=CC%+10
M PQ1GJBG\*<%"C  'TH!!Z&EH 0JK?>4'ZBD"*O10/H*=FCK0 F!Z4TQH3DH
MI^HI]% "!% P% ^@IODQ$Y\M<^N*?10 =*88HV.6C4GW%/HH 0  8 Q2;$SG
M:,^N*=10 TQHQY13]11Y:8QM&/3%.HH :(T'1%'X52U*S$]JZHH#8.,"K]%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA;_D>K[_ '?\:[N[MY)K0Q1OM8C&:Y31O"%]INO3:@]T&608Q20/<[6BD&0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 5****8@HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M*NH_\@ZX_P!PUG^"O^00_P#OFM#4?^0=<?[AK/\ !7_((?\ WS3^R82_CQ]&
M=+1114G0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 5****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *NH_P#(.N/]PUG^"O\
MD$/_ +YK0U'_ )!UQ_N&L_P5_P @A_\ ?-/[)A+^/'T9TM%%%2= 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!4HHHIB"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH JZC_P @ZX_W#6?X*_Y!#_[YK0U'_D'7'^X:
MS_!7_((?_?-/[)A+^/'T9TM%%%2= 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!4HHHIB"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH JZC_R#KC_<-9_@K_D$/_OFM#4?^0=<?[AK/\%?\@A_]\T_LF$OX\?1G2T4
M45)T!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ_N&L_P5_P @A_\ ?-:&H_\ (.N/]PUG^"O^00_^^:?V3"7\>/HSI:***DZ
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*\X_X6G8_P#/9/TH_P"%IV/_ #V3]*.5AS(]'HKSC_A:=C_SV3]*/^%IV/\
MSV3]*.5AS(]'HKSC_A:=C_SV3]*/^%IV/_/9/THY6',CT>BO./\ A:=C_P ]
MD_2C_A:=C_SV3]*.5AS(]'HKSC_A:=C_ ,]D_2C_ (6E89_UR?I1RL.9'H]%
M<_H/BJQUQ6\F8,PZXKH*15PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M *E%%!.!DTQ!16?<:S96K[)9<&K-O>0W2[HFR* )Z*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBJMWJ%M8J6G?:!0!:HJ*VN([J!9H6W(W0U+0 4444
M %%%% !1110 4444 %%%% !1110 4444 5-4_P"09<_[AKYF\1_\A1_J:^F=
M4_Y!=S_N&OF;Q'_R%'^IK2&QR5OXT?1F/1115%!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ;7A_P 07.B7J21R,(PV64=Z^A/"GBRVUVRC8,%D
M;L3S7S#6SH'B"ZT.^6:%CC@$$\5,HW+C*Q]7=1FBN6\*>++77+-<2 R* & ]
M:ZFLC9.X4444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M** "BBB@ HHHH **** "BBB@ HHHH *BN!FWD_W3_*I:CN/^/>3_ '3_ "H
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M&X:)HEMH]FD4,:JVW#$=ZU:**R-PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*** "BBB@ HHHH 0@,I!&0:H2:'ILK[WM$+>M:%% %6WTZTM3F&%4^E6J**
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MPZKD5S-C8R:_H-O?@L9W;)P?I3L*YW2LKC*D$>U(\B1C+L%'O5#28KF&WV7
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M%V%D8'_"':)_SX0_E1_PAVB?\^$/Y5OT47861@?\(=HG_/A#^5'_  AVB?\
M/A#^5;]%%V%D8'_"':)_SX0_E1_PAVB?\^$/Y5OT478612L=*L].4BUMTCSU
MVU=HHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N?\
M&'_(&;ZUT%<_XP_Y Q^M-;B>QR'@K5I;1KL):M)SVKI=.UFXO]>:WDMGCCQW
MZ5G?#T*?MF0.O?\ "NHOYK73F^U/@,3CBF]Q+8Y7QG=W=CJ%HL,[*KGD"J&J
M0:J-+CU!+^106^X*M>,Y/.U#39!T;D?K5_5L?\(M'_O4"8D/B7;I/EN?WVS
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M=X'-;% PHHHH **** "BBB@ HHJ-ID60(3R>E $E%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!5U'_D'7'^X:S_!7_((?_?-
M:&H_\@ZX_P!PUG^"O^00_P#OFG]DPE_'CZ,Z6BBBI.@**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*F-T&>?:D.YT.G7T>H6:7$9!5O2K=9>AV$>F6$=K$,*@XK4I%!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% %74?^0=<?[AK/\ !7_((?\
MWS6AJ/\ R#KC_<-9_@K_ )!#_P"^:?V3"7\>/HSI:***DZ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!4H
MHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH JZC_R#KC_ '#6?X*_Y!#_ .^:
MT-1_Y!UQ_N&L_P %?\@A_P#?-/[)A+^/'T9TM%%%2= 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!4HHHIB"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH JZC_ ,@ZX_W#6?X*_P"00_\ OFM#4?\ D'7'^X:S_!7_
M ""'_P!\T_LF$OX\?1G2T445)T!1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% %2BBBF(**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"
MKJ/_ "#KC_<-9_@K_D$/_OFM#4?^0=<?[AK/\%?\@A_]\T_LF$OX\?1G2T44
M5)T!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %
M2BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@"KJ/_(.N/]PUG^"O^00_^^:T
M-1_Y!UQ_N&L_P5_R"'_WS3^R82_CQ]&=+1114G0%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M #XK1_;'B'_GQ6BBC0+2_F8?VQXA_P"?%:/[8\0_\^*T44:!:7\S#^V/$/\
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/", ?+[T44,N'-S:R9__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>gn15qjhcndsi000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gn15qjhcndsi000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +,!/L# 2(  A$! Q$!_\0
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M'_"'VW_/9_SKI** NSF_^$/MO^>S_G1_PA]M_P ]G_.NDHH"[.;_ .$/MO\
MGL_YT?\ "'VW_/9_SKI** N<W_PA]M_SV?\ .C_A#[;_ )[/^==)10%SF_\
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M_A#[;_GL_P"==)10%V<W_P (?;?\]G_.C_A#[;_GL_YUTE% 7.;_ .$/MO\
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M_/9_SH_X0^V_Y[/^==)10%V<W_PA]M_SV?\ .C_A#[;_ )[/^==)10%SF_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *NH_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!5U'_ )!UQ_N&LCX??\@ZY_ZZ_P"-:^H_
M\@ZX_P!PUD?#[_D'7/\ UU_QH*B=A11104%%%% !1110 4444 %%%% !1110
M 4444 (>AKA->_Y"UO\ []=V>AKA-=_Y"UO_ -=*!/8E\76_F:%N4?-Q5CPK
M<>98I$3]Q:N:K!]ITO9C/%<_X/GQ>W,).-O%6M8G!+W:WJ=I1114'6%%%% P
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* *NH_\ (.N/]PUD?#[_ )!US_UU_P :U]1_Y!UQ_N&LCX??\@ZY_P"NO^-!
M43L****"@HHHH **** "BBB@ HHHH **** "BBB@!#T-<)KO_(5M_P#KI7=G
M[IKA-=_Y"UO_ +] '4; UOC_ &:X/3&-CK\_;>]=\G^I7_=K@=>4V6M6[CC?
M)S5Q['!B%9J1Z O*BEJ*W<20J0>U2U!TQ=T%%%%!04444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %74?^0=<?[AK(^'W_
M "#KG_KK_C6OJ/\ R#KC_<-9'P^_Y!US_P!=?\:"HG84444%!1110 4444 %
M%%% !1110 44E+0 4444 (>AKA-=_P"0M;_]=*[L]#7":[_R%K?_ *Z4 SJH
M_P#5K]*Y'QE;[I;>4#[AS77Q_P"K7Z5C>([;SM/D?'*J2*J.YR5U>)+X?N/M
M&GJV<UK5R?@BYW:7Y;?>S764GN%!WB%%%%(V"BBB@84444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 5=1_Y!UQ_N&LCX??\@ZY_
MZZ_XUKZC_P @ZX_W#61\/O\ D'7/_77_ !H*B=A11104%%%% !1110 4444
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M>M "T4F1ZT9'K0 M%)D>M&1ZT +129'K1D>M "T4F1ZT9'K0 M%)D>M&1ZT
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M:$D9 ^Z#3;7X=7MM*C#6+C:ISMW<4 >A)M" +T I]5;*V:U@$;2%R!U-6:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** *NH_P#(.N/]PUC_  ^_Y!MU_P!=?\:V-1_Y!UQ_N&L?X??\
M@ZZ_ZZ_XT%1.QHHHH*"BBB@ HHHH **** "BBB@ HHHH **** $/0UPFN_\
M(6M_^NE=V>AKA-=_Y"UO_P!=* .KC_U:_2G4V/\ U:_2G4&8AZ5Y]JZ_8==A
M8<;W_K7H5<9XRM\W-K*!]TYJH[G+B5I<T;Q@UPI!["MVW_X]T^E<G:W'V@*^
M<]!766_^H3Z4,*+OJ2T445)U!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M17.Z3JVH7P#O!A#WKH5)*C/6FU8(34M4+1112+"BBB@ HHHH **** "BBB@
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M[V/>LN^_X_5_WJWX_P#5K]*I['/2C9O4=1114G2%%%% !1110 4444 %%%%
M!1110 4444 %%%% !111F@049K&U:_OK.,O!$&4=:IZ3K&HWZAWA 0^@IV,G
M42ERG2T4U"2H)ZTZD:A1110,**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M12TU!M4#T%.H$5KV<V]LTB@DCL*XF?QC<1793[-*0#7?%5888 CWJ V5L>3
MF?I0!Y-JGB*:YU]#/:RO:8^9,5GV_B*%=81([1U7>,"O8GTFT=LF!,_2N0?P
MHW]L><L V;L]* .TL+D7-LCA2O ZU:J.&,1Q*H&,"I* $/0UP7B#/]K6^/\
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MU08, 1T-*2U-*,U**L1[7_O4;7_O5+12-KD6U_[U&U_[U2T4!<BVO_>HVO\
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MM%(W(MK_ -ZC:_\ >J6B@+D6U_[U&U_[U2T4!<BVO_>HVO\ WJEHH"Y%M?\
MO4;7_O5+10%R+:_]ZC:_]ZI:* N1;7_O4;7_ +U2T4!<BVO_ 'J-K_WJEHH"
MY%M?^]1M?^]4M% 7(MK_ -ZC:_\ >J6B@+D6U_[U&U_[U2T4!<BVO_>HVO\
MWJEHH"Y%M?\ O4;7_O5+10%R+:_]ZC:_]ZI:* N1;7_O4;7_ +U2T4!<BVO_
M 'J-K_WJEHH"Y%M?^]1M?^]4M% 7(MK_ -ZC:_\ >J6B@+D6U_[U&U_[U2T4
M!<BVO_>HVO\ WJEJI=:E;68S-)MH$Y)*[)MK_P!ZC:_]ZJ4&N6%R<139-:*L
M&4$'@TVK"4U+8CVO_>HVO_>J6BD5<BVO_>HVO_>J6B@+D6U_[U&U_P"]4M%
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MS!\-:?;&T:0I\P8UTJ@*,#M6)X9_X\&_WC6Y3EN11240HHHI&P4444 %%%%
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M0NQ:***DZ@HHHH **** "BBB@ HHHH **** *NH_\@ZX_P!PUD?#[_D'7/\
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MDNU[=J#-*/F/O0!Z)'_JU^E+2CI10 4444 %%%% !1110 AZ&N$UW_D+6_\
MUTKNST-<)KO_ "%K?_KI0!U<?^K7Z4ZFQ_ZM?I3J#,**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH ****!!1110,**** "BBB@ HHHH **** "BBB@ HHHH
M **** "DI:2@1G:L[QVS.A/RC-<;8ZE=7&I;<,%]:] FA6>)D<?*>M48=%LX
M#N1.<U2:1SU*4I.Z,G7;F:&R4(26*U0\-7MS(1%+N!]#763Z?!<;?,'W>E-A
MTNV@G\Y%PU.ZL)TI<U[G*:]>W-I,NS<16MX=N)KF)9'R/8UJ7.E6UV<RKFIK
M6RBM(]D0P!0VK!"E)3OT+%%%%0=(4444#"BBB@ HHHH **** "BBB@ HHHH
M**** $K U'_C['^]6Y-,L$1=@2!Z5R5_K$#761&_7TJD85I)*S.NB_U2?2GU
M2T^]CO+<-&",#'-7:EFL=4%%)2T%!1110 4444 %%%% !1110 4444 %%%%
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M=38_]6OTIU!F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% @HHHH ****!A1110(**
M**!A1110 4444 %%%% !1110 4444 %%%% !1110 C*K@AAD'M5<Z?:$Y,"?
ME5FB@EI/<CBACA&(T"CT%2444:E6"BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*B6XC>4QJX+#J*@U)ITM': X8#@UPEM>ZDNKMAB&)P35*-S"K5Y&D>BLP1<L
M<"FI,DA^5LUSVKR:BECYBO\ +MR:R-#O-0N;@HC$8]:.4AU[2M8[J218TW.<
M =Z2.194#H<J>]<AXCN]0@C\O><$<XJ7PW-J$EL?,?Y,?**.70?M_?Y;'4M<
M1HX1F 8]JD!R,BO.]4O-2@U-2[$\\&NOT62ZFMEDG;((H<;(<*O-*UC5HHHJ
M3<****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 5=1_Y!UQ_N&LCX??\ (.N?^NO^-:^H_P#(
M.N/]PUD?#[_D'7/_ %U_QH*B=A11104%%%% !1110 4444 %%%% !1110 44
M44 (>AKA-=_Y"UO_ -=*[L]#7":[_P A:W_ZZ4 =7'_JU^E.IL?^K7Z4Z@S"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH CFB$T3(3C-46T>$JN  P.=P')K2HIW(E%/<K36
MBS1"-ONXQ4%KI45K)O08/M5^EHNQ<BW*-UIT=U,KOSCM3H+%(&8IP#VJY11<
M.17N9TVDPS [P"3W(JW;P"WA$8Z"IJ*+C4$G<****184444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!5U'_D'7'^X:R/A]_R#KG_ *Z_XUKZC_R#KC_<-9'P^_Y!US_UU_QH
M*B=A11104%%%% !1110 4444 %%%)0 45Q7B3Q!.FJC2+-BEPX^4UE'6-6T"
MZMQJ<WF+.P5<<T >E4M102B6%''< U+0 AZ&N$UW_D+6_P#UTKNS]TUPFN_\
MA:W_ .NE '5Q_P"K7Z4ZFQ_ZI?I3J#,**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *NH_\@ZX_P!PUD?#
M[_D'7/\ UU_QK7U'_D'3_P"X:Q_A_P#\@VY_ZZ_XT%1.QHHHH*"BBB@ HHHH
M **** (IIXX(R\C84=360?%>CB?R?M:;R<8S6K=6ZW,!B<94US3^"-.:X\\0
M+O!R#B@#EO%<RCQ/'>:>?.NP/EC'>LO4;O4]4O++^UK4VRI("I/?FM/4(?['
M\<07+Q,T:#J!Q4_BC6(=5DM(XH&+;QVZ4#/1;%T:TC\MMP"BK-9>AV\EO8(L
MAR<"M6@0AZ&N#U\XU:W_ .NE=X>AK@]? .K6_P#OT =1&_[I?I3O,HC0>4OT
MIVP4&8W?1O-.VBC8*8:#=YHWFG;!1M% :#=YHWFG;!1L% :#=YHWFG;!1M%
M:#=YHWFG;!1M% :#=YHWFG;!1L% :#=YHWFG;!1M% :#=YHWFG;11L% :#=Y
MHWFG;!1L% :#=YHWFG;11L% :#=YHWFG;!1L% :#=YHWFG;11L% :#=YHWFG
M;11L% :#=YHWFG;!1L% :#=YHWFG;11M% :#=YHWFG;!1L% :#=YHWFG;!1M
M% :#=YHWFG;!1L% :#=YHWFG;!1M% :#=YHWFG;!1M% :#=YHWFG;!1L% :#
M=YHWFG;!1M% :#=YHWFG;11L% :#=YHWFG;!1L% :#=YHWFG;11L% :#=YHW
MFG;!1L% :#=YHWFG;11L% :#=YHWFG;11L% :#=YHWFG;!1L% :#=YHWFG;1
M1M% :#=YHWFG;!1L% :#=YHWFG;!1M% :#=YHWFG;!1L% :#=YHWFG;!1M%
M:#=YHWFG;!1M% :#=YHWFG;!1L% :#=YHWFG;!1M% :#=YHWFG;11L% :#=Y
MHWFG;!1L% :#=YHWFG;11L% :#=YHWFG;!1L% :#=YHWFG;11L% :#=YHWFG
M;11L% :#=YHWFG;!1L% :#=YHWFG;11M% :#=YHWFG;!1L% :#=YHWFG;!1M
M% :#=YHWFG;!1L6@-!N\T;S3M@HVB@-!N\T;S3M@HV"@-!N\T;S3M@HV"@-!
MN\T;S3M@HV"@-!N\T;S3MHHV"@-!N\T;S3MBT;!0&@W>:-YIVT4;!0&@W>:-
MYIVQ:-@H#0;O-&\T[:*-@H#0;O-&\T[8*-@H#0;O-&\T[8*-@H#0;O-&\T[8
M*-HH#0;O-&\T[8*-BT!H-WFC>:=L%&T4!H-WFC>:=L%&Q: T&[S1O-.V"C:*
M T&[S1O-.V"C8* T&[S1O-.V"C8* T&[S1O-.V"C8* T&[S1O-.VBC8* T&[
MS1O-.V+1L% :#=YHWT[:*-@I 5-0?_B7S_[AK*^'O_(-N?\ KK_C6OJ*C^SY
M_P#<-9'P^_Y!MS_UU_QH*B=C11104%%%% !1110 4444 %%%% %.\TZ"\4B2
M-=W]['-5+30;6VDW%%;TR.E:]&* &@!0 !@4ZBB@!#T-<)KO_(6M_P#KI7=G
MH:X37?\ D+6__72@#JX_]6OTIU-C_P!6OTIU!F%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %74?^0=<?
M[AK(^'W_ "#KG_KK_C6OJ/\ R#KC_<-9'P^_Y!US_P!=?\:"HG84444%!111
M0 4444 %%%% !1110 4444 %%%% "'H:X37?^0M;_P#72N[/0UPFN_\ (6M_
M^NE '5Q_ZM?I3J;'_JU^E.H,PHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH JZC_R#KC_<-9'P^_Y!US_U
MU_QK7U'_ )!UQ_N&LCX??\@ZY_ZZ_P"-!43L****"@HHHH **** "BBB@ HH
MHH **** "BBB@!#T-<)KO_(6M_\ KI7=GH:X37?^0M;_ /72@#JX_P#5K]*=
M38_]6OTIU!F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% %74?^0=<?[AK(^'W_(.N?^NO^-:^H_\ (.N/
M]PUD?#[_ )!US_UU_P :"HG84444%!1110 4444 %%%% !1110 4444 %%%%
M "'H:X37?^0M;_\ 72N[/0UPFN_\A:W_ .NE '5Q_P"K7Z4ZFQ_ZM?I3J#,*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M (2C3_[QI?\ A*-/_O&K7_",6G_/-:/^$8M/^>:T!RE7_A*-/_O&C_A*-/\
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MSS6C_A&+3_GFM <I5_X2C3_[QH_X2C3_ .\:M?\ ",6G_/-:/^$8M/\ GFM
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M5_X2C3_[QH_X2C3_ .\:M?\ ",6G_/-:/^$8M/\ GFM <I5_X2C3_P"\:/\
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MK7_",6G_ #S6C_A&+3_GFM <I5_X2C3_ .\:/^$HT_\ O&K7_",6G_/-:/\
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MHHH **** "BBDH 6BH5N(6D\L2*7'45-0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !112$XY)XH 6DJJVHV:/L:X0-Z9JRKJXRI!'M0 ZDI:*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI"<"@ I:BCFCE)".&(Z
MX[42310KND<*/4T 2TE5XK^TF;;'.C'T!JQ0 M)2T4 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !24QIHT.&< ^].#*PR#D4 +15>6^M86VR3HA]":E
MCFCF7=&X93W% #Z6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI* %HJ
M&6YA@&99%0>]-AOK:<XBG1_H: +%%1R2QQ+N=@J]R:BBOK68[8YT8CL#0!9H
MI!2T %%%% !1110 4444 %%%% !1110 4444 %%%% "4M(3@9-56U*R1]C7,
M8;TS0!;HID<B2+N1@R^HH=UC4LQ 4=2: '44V.6.5=R,&'M3Z $-9>I?ZY:U
M:RM3_P!:M %VS_X]UJQ5>S_X]UJQ0 4444 %%%% !1110 4444 %%%% !125
M'+<0P#,L@0>YH EHJM%>VLYQ%.CGV-2R2)$A=W"KZF@"2BJJ:A:2MM2=&;T!
MJSD8H 6BBB@ HHHH **** "BBB@ HHI* %HHHH Y[Q?JLFEZ,TT)^?.*Y6+2
MKNZTDZLV?,V;QS6I\0,_V8<_=W"M33MO_"$IZ>30!5\%ZQ-?6!2Z/[T-@5UE
M>?>#\_;OE^[N->A4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5E:YJ8T^QD96_>8^45I3/Y<+O_=!->97>KPZQKJ^=<+%' ^&4GK0!7\%Z]>:
MEXWFCG;Y=IXS7K%>/>'KZPMOB1.T<B+$4P#GBO7XW$B!U.0>0: '4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !6%XNU&72_#\]U#]]:W:YKQK=Q
MVWAZX+H'']TT <K:6$VHZ4VJ2-^\V%QSZ5N> =7N-2L)/M!R5;:*Y&S\.ZG>
M:6U[%>/' 5)$0/&*Z+X?7*Q6SV[)M?=^= '?T444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7)^)O$,EHKVUF?](QG%=95"]T^VD625XE+[3\V/:@
M#B/AOJMWJ%U?"Z/S*Q[^]7=;_M+4-<:QC'^C^U9_PZ4+K6JA1@!SC\Z[>_N;
M/3PUS*55L=30!PFI65UX>NK=X"<'E\FN\T:]-]8+,W4UP4\EUXKUB-E1D@B;
M&>S"O1;&U6TMEB7H!0!9HHHH **** "BBB@ HHHH **** "BBB@ HHHH *KW
M=REK"TCG  JQ3)(DE7:XR* /)]7\4ZA=:_%';']P&PU=X-2^RZ&)6;#E>/K7
M,^*K*WMM7A\F,+GKBI]?+CPS#LZD4 9VFV]YKXGFO&P5<A.>V:WO#4>J6^I2
M03X^RJ/D.:Y#PYX=U#5;2:6*]>'#'C-;'A#4+BW\27.DW#F0PCECWH ]('2B
MD[4M !1110 4444 %%%% !1110 4444 %)2T4 %,<[4)]*?2$9'- '!ZI#J>
MJ:^+?!^R'K65JQN_"VH6:P'Y9G .3[UW>J:A9Z7&TK%!(.U</';W7BS5UDD1
MHXH7W*2.HH NZWK=Q>:K'I$+99T!(JI?V=_X?FM)8<_.?WN34=PGE_%*!.RQ
M ?I73^,=OV5,XSCB@#;TF]6_LUE4YX /UJ_7->"MW]C'=UW5TM !124M !11
M10 4444 %%%% !1110 4444 %%%% &)XENKJUT_=:C+DXKE#X?O);*2]GR)<
M;EYKT"=(G3]Z 5'K7&>)/$(D4Z=8+YA<;2R?PT +X1UBY>?[#<'E!47CWQ*^
MG63P6[?O'7C%,L+8^'=&%Y<<S-D$GK7/3W%G<Z3J$]U<(\AY0,>10,Z_X?WE
MS=Z)&]R?G)/>NQK@OAWJ%M)IJ0)*I<9XS7?4"$K+U/\ UJUJUE:G_K5H NV?
M_'NM6*KV?_'NM6* "BBB@ HHHH **** "BBB@ HHHH :QPI-<-K::GJ.MQV\
M8_T4CYC7=&LO4KVSTV)I7*AP.!0!P>M)=>%;BU:W)Q-)@Y-7O$&NW4D]O8QG
MB5 3S5-H[GQ=JR[T9((6W(QZ&D\7R*VJV^CPIMN&3"R#J,8H @U**YT.*SN;
M=OGE<!N:[BUU=WM8V;J5YKSC4_#NI:;%:2SW+S*'!*D]*[:R\068LX@8ER!B
M@#L**** "BBB@ HHHH **** "BBB@ HHHH Y[Q?I4FJZ.T,(R^<URT.IWMMI
M)THYWA-@&*])(!ZU6.G6C2>8;="WKB@#G?!>D3V-@6NQ^]+9%=9354(, 8'I
M3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 8Z"1&1NC#!KDY_
MAYHT]P\S(VYSD\UU]% 'D.E^ 8(O&\I9&^S*,K7K4,2P0K&OW5&!2"",2^8$
M 8]ZEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG/&&E2ZEH
MLT=N,RGI71TA&>#0!YO9:K=Z=I/]FRC$H4J.*T?!VCW46;B\7#ELBNM;3K-Y
M-[6Z%O4BK"1K&,( ![4 .I:** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ J*X!:!P.ZFI:0]* .$\$:;<6.JZE)*,*[DC\ZQ?&YU&]U=[7G[(#G@5Z
MBD,49)1 ">N*CDL;:5MTD*,?4T >?Z-J=Q8QQP(, #'2N_L)FGMU=^IH&G6:
MG(MT'X581%084 "@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
MQGBG3Y[K4X7C'RBM*32S=:&L+#YU7CZUO/$CG+*#2@ # '% 'F>DW6H^'TN+
M>X&&9SLP.U7?"VC79\17.K3K\DPX-=Q)8VLS;I($8^I%2QQ)$NV-0J^@H D'
M2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.9BD3,.H%24A (P: /(?$
MXU&_U_;)DVO?%;FDZO<VHAMHQA <=*[E["UD;+0(3[B@:=9J<BW0$=.* .)U
M[2KI-876H%^<*.:I7]UJ.O36D47.QOWO%>DO#'(FQT!7TJ*.QM86W1PHI]0*
M (=)LEL;-8P,9 )J]0*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y
MOQC<WEOI)-F?G/%>>:&MSI\\D\@)D=MW->Q2PQ3+ME0,/0U#_9EEVMT_*@#F
M[<#Q';BVO03'67KGPYTH:5<-;QMYN..:[R.UAA.8XU7Z5*RJZE6&0>U ' ^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8$XJGXD2_;QGIH##S#'Z_2H-1M)6^SRV4[!BXW1J>E:&JQ72>)--NI(V*I$
MS'\* ._MKX6ULB7+#S1UYK0AG2==R'(KF)] ;5\7273(&[ UN:5IS:=!Y;2%
M_<F@"_2TE+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/GUJOX;U/38?":Q32(LNS&TUC^'[!M0TW4XU7 >0X([T =M'X@A.BI>DX#G
MK,_X2:06TN0V\_=.*XNXNYG\G0HL[X9 QP>W^170ZY?KIL=K:&!<2)\S^E #
M9?$FHV!CGN)U,3L %'6FZQ>K>>(+"1">0">?:N=UZSM6M;>47Q)+@[/QJ\A'
M]L6.#G"C^5 'JUG_ ,>ZU/5>S_X]UJQ0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 53O
M;"*]0I*,@\5<HH IVNGPVUI]F1?W?I6+-X.L&D=DCP'.6YKIJ* ,6V\.65M!
MY:I4\6CV\5O)"J?+)UK3HH SK32+>SC*1KA2,&H+7P]96T,\2Q_+,26K8HH
MYAO!UAN^6/"^E;&GZ3;:;$4@3 /6K]% &$GA?3TU:34!'^^?J:GU+0;340#*
MF64<&M:B@#ESX+T^15$L>=IR*N+X:L4GCE$?S)TK<HH 9&@10HZ4^BB@ HHH
4H **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gn15qjhcndsi000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gn15qjhcndsi000014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,4!+<# 2(  A$! Q$!_\0
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M!:HJK_:%I_S\)^=']H6G_/PGYT 6J*J_VA:?\_"?G1_:%I_S\)^= %JBJO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM?\ ^1G@H Z6W_U(J6HK?_4BI:9F%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 444E "T57N[E+2W:9R J^
MM<K/\0-.@E*-*F1[T =E17$?\+&TW_GK'^=;ND>(+?5T#0NI!]#0%C:HHHH$
M%)D5%=2>5;N^,[5)KA]-\<+-J9M95VG>5Y-*^H[:'>T5 TZFW,B'( [5@^']
M>;5+ZZA*D>4V*86TN=,*2HI;F* 9ED51[TD5W;S_ .KE5OH: )^U%0M=0H=K
M2*#Z9IBWULTFP3*6],T 6:*0'(ZT9 H$+15?[9;@D&5?EZT17D$Q_=RJWT-
MRQ136=5&2<"JZZA:,^P3H6],T!8M45GZI>?9+3S1S]*SM#UQ;Z217.W;TS0%
MCH:*:KJRY4YJ/[3#N*^8,CK0!-15<WUL 29EP.M.BN89QF*16^E $U%%% !1
M110(R=>_X]%^M/\ "O\ J9:9KW_'HOUI_A7_ %,M!:.BHHHI%!1110 4444
M%%%% !1110 4444 %%%% "4F:4D 9KF]8\5VNFSQQ&1=S-MQ0!T?-%4GU"..
MP^U.0%VYS7*7'C*[^T?N+??#GAA1UL'F=SFEK)T?6(M4BRI!8?> [5JT/0+B
MUPVO_P#(SP5W%</K_P#R,\% '2V_^I%2U#;?ZD5-3,PHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:<XPX&"*8&AX%;;?WZCH)"!7H%<9X*TZ6W>XN)!@2MN%=GVILDI76HQ6N-Y
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M35#;?ZE:FIF84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 !HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,G7O^/1?K3_"
MO^IEIFO?\>B_6G^%?]3+04CHJ***104444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5PVO\ _(SP5W-<-K__ ",\% '2V_\ J14M16_^I%2T
MS,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH$9.O?\ 'HOUI_A7_4RTS7O^
M/1?K3_"O^IEH+1T5%%%(H**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *X;7_\ D9X*[FN&U_\ Y&>"@#I;?_4BI:BM_P#4BI:9F%%%% !1
M110 444FX"@!:*;N7UI0<T +1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444",G7O\ CT7ZT_PK_J9:9KW_
M !Z+]:?X5_U,M!:.BHHHI%!1110 4444 %%%% !1110 4444 %%%% !1110
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MB?5+[Q3!#<W<CQGL37F-;'AN>]@U:-[$XF'2D-H^O8FW1@^M/S7A"^(/&2*
M)#C_ ':FC\4>+(U)D=C_ ,!IDV/<<T9KP]?&?B0'YM__ 'S3_P#A.-?'4/\
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M3RT_NBGT4C<9Y:?W12^6G]T4ZB@!OEI_=%'EI_=%.HH ;Y:?W11Y:?W13J*
M&^6G]T4>6G]T4ZB@!OEI_=%'EI_=%.HH ;Y:?W11Y:?W13J* &^6G]T4>6G]
MT4ZB@!OEI_=%'EI_=%.HH ;Y:?W11Y:?W13J* &^6G]T4>6G]T4ZB@!OEI_=
M%'EI_=%.HH ;Y:?W11Y:?W13J* &^6G]T4>6G]T4ZB@!OEI_=%'EI_=%.HH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110(R=>_X]%^M/\ "O\ J9:9KW_'HOUI_A7_
M %,M!:.BHHHI%!1110 G:LS6A(=/E\O.=A_E6G5>[ECCMW,OW<'-)ZC6YX%I
M;6*?VF-07$F]MI;ZUI0:CIB^&1 S*W^R#S6W?>%-'\3W$ILYB&5CN"G'-0V'
MPCACE4R2R;1V+&F@;+WPR6;[3<MM(A)^3/IQ7J%9FD:/!I-LD4('RC&:TQUI
MLE"T444AA1110 4444 %%%% !1110 5PVO\ _(SP5W-<-K__ ",\% '2V_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M**** "BBB@ HI** "EHHH *X;7_^1G@KN:X;7_\ D9X* .EM_P#4BI:BM_\
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M7!GRQD]JKQ6")U%7%4+P*&*$.4=1124&@M%%% !1110 4444 %%%% !1110
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M/6@!:*3(]:,CUH 6BDR/6C(]: %HI,CUHR/6@!:*3(]:,CUH 6BDR/6C(]:
M%HI,CUHR/6@!:*3(]:,CUH 1Y%098XK/N=8M;5E$D@&XX%5_$)D_LU_)DVMV
M->0:O?ZD+A4=F8!N#2OJ.VA[I',DJAE(.14E<1X+ENY;<&XF+>@-=MD531(Z
MBDR/6C(]:0Q:*3(]:,CUH 6BDR/6C(]: %HI,CUHR/6@!:*3(]:,CUH 6BDR
M/6C(]: %HI,CUHR* %IKL$7)Z4;A3)B/+;C-#&D<]J_BNWL3LC8&0=13M,\5
M6]VZQR, [=!7%^+=-DN[I_LZ&)B?O4GA?39K*[C^TH923PWI1'4)*R/6 P8
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M6-A)Y,DBEB=N,UHZE.;:R>0=17B,%E)XB\:SK+,P1#N SZ4MW8?2YW/B?3-
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M=1SBJ>MD;X>1]X5KQ$>4G(Z"@;8^BBB@ HHHH$%%%% PHHHH **** "BBB@
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M@(V9_"KM)P>U '.-J$XO!;X;)K8M&D/W\UGR ?V\G%;?'I0,6BBDH),35_\
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M;Z+$J;D]C5HHHI&IAZO_ ,A"V_WJVU^X/I6)J_\ R$+;_>K;7[H^E "T444
M9.O?\>B_6G^%?]3+3->_X]%^M/\ "O\ J9:"D=%1112*"BBB@"O=%A;ML^]V
MKQ[Q!?\ BZ/59!:(#%VZU[,V /FZ5YCXI\>V^E7S6\-LLTBGFIZCZ')?VEXW
M_P">8_6JE])XQU"'R)4&T_6NL@^(UI)92-+:JDH'"^M8:_$2Z6<3/IN(2?O=
MJJPKG8_#;2;S3UD:Z3:S"O1ZP/#.KV^K6,<L2@,5R0.U;XJI>8D&:6BBI&%%
M%)0 M%1R2K$A9SA1WK*?Q+IL<OEM<+NH V:*J1:A;31&6.0%!U-4)?$VF12F
M-KE0U &S2U6MKR&[7="X858H 6N&U_\ Y&>"NYKAM?\ ^1G@H!G2V_\ J14M
M16_^I6I:9F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5RGCQF3
M0F*G'TKJZY/Q_P#\@%J 1\P:G/*]]*&D8_,>IJLMQ,BX61@/0&IM1'^GRG_:
M-5:1H>B?##51;:G(;B8XSW->^0>(;!T4"5<X]:^9_!FB3:S>/'%,8R.XKTG_
M (5YJT2ADU"0\>]!-CUI=3M7Z2K^=2K=P-TE7\Z\;;PMX@@X6ZE;'N:C;2?$
MT0^628_B:!6/;!/$>DB_G2^;'_?'YUX69_%MJ<""9_QIRZ[XJB^]9RG\:86/
M<_,4_P 0_.E!![UXBGC#Q)!R]A(<583XD:U$,-IK\4!8]GS17CR?%74U8!].
M8"KJ?%20CY[7!H%8Z7QMJUEIEL#=,02.*\G?QAIV]L.>M-^(7C#^WH(UV;=M
M>8'DT7,YT%/5GI__  F&G_WS6_X?\2K/(#9DGFO$:[#P=KHTEP?*\SGI3N1]
M62U1[]8>) ,+<\&N@@OX+A05<<UX=J'C*\NC^XTXCW%58/$WB%#F.TDQ05%3
M6C/H+S4_OBF&YA4<R+^=>"3>,/$)^4V\B_C4EO<^(]3Z-*N?>D:7/<)-4M8Q
MEI%_.JDGB73H_O2K^=>4IX8\077#W,JY]S5J+X:ZE.,R:C(,_6@H[Z;QOI$/
M67\C5.3XC:,G_+0US4/PHE_Y:W[-]:O1?"V!3\\V[ZT!H33?%/2AD(6S]*SY
MOBA&_P#J Q_"MF'X;:;'C<B-^%:,'@?2H?\ EV0_A2#0XB7XBZHX/DH3Z<50
M?QCXNN"?*B&#TZUZM'X9TM!_QZI^56DT>Q3[MNH_"F%T>.'4/&=YQY8&?K5/
M4]-\6MITTEP,1A?FY->ZK8VZ?=C456UBR%UI%Q;H.70B@+H^.Y01*X;J&.:9
M7J4_PJNGFD<;N6)Z52A^&5S+.T0W97VI%)G$Z3;R76H111\.3Q7J5GX*UZ2!
M6B9MO;FFZ'\,[FQU6&=MV%/I7MVG0&WM%C/:F)L\9D\*^+4QY><#W-(-!\9)
MQC]37N=-*@]J!7/#O[,\9KVZ>YH$/C.-L[!^9KV\Q(?X::;>(]4% 79XF=0\
M:1''ECCZTHU_QFO/E#CZU[0;*W8Y,8_*FG3;0]85_*D%SQK_ (2OQDA_U0_6
MG1^-O%JG]Y$,#ZU[#_95F>L"_E33HVGMUMT/X4!<\H7X@:XK8>/]*F7XB:G_
M !1G\J]-/A_3#UM$_*HCX9TL_P#+JGY4!='G:_$B\'WD/Y5-%\365LRJVWZ5
MW+>%-+8'_14_*H'\&:4PQ]FC_*@-#E%^*EIG#AORKR+Q[KJZUKQN868+BO?G
M\!:4V3]G3\J\'^)6EQ:5XD,$"87!X H&K''[W/\ $?SK:\*RO_;L&7.,]S6'
M@^AJWIWGB]0P ^8#QB@9]<:"ZMI<6&!X]:U:\%T?QAKNC0(LMH[QCN:[?1_B
M5;71"7>(6[YIDV/0Z*S+77=/O /)N%8GWK15U89!!% AU%%% !1110 4444
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MC1)%0^HKR^\9WNI&D^^3S7U=J/AJTDL6BBMT#8/(6O(=3^%UY+=33+$0I.:
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MO8;#X76*J#.&/XT$M(I7/Q59B5AM';T(%8\_CK6[QB(+*< ]PIKT2U\!Z5;
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M1110 4444 %%%% !1110 5PVO_\ (SP5W-<-K_\ R,\% '2V_P#J14M16_\
MJ14M,S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIK2(IPQQ2A@1D=*
M %H[4=J9YJ;]FX;J ,O5)[L1LD,1;(Q6987&HVL.S[.>OI74X]:,#T% $5L[
MR0JTB[6/45-110 4444 %%%% !FDS16%K&N+8JP/&.]%QI7-ZBN-T7Q4EQ(Z
MLVXYXKJ#=@6_F[30(L.NY2/6LFXT2.X;+'BL75O%:0W,:*VSGGFM33M?CNI%
MB'S$CJ*$R903W'QZ!'&5*G %:\2"- N>E5-0U%;"-6*YS7+7GBQ(]4A19!M;
MJ,T[W81@EJCN**S['4TO -HXQUJIJNN)9(P(P>QI;%6-NBN,LO%<;-RX;)Z9
MKK;6<7,"R 8W#- ,FHHHH **** "FLBL,,,TZB@5C*O=%@N@?D /K7/7.C75
ME)OMV8@=A7;4UD##D4&<J:9Q]KKUQ:MLN%(]S70VFK6]RHPXR>U-O-'M[E22
M@W&N;O-&NK#=+"Y"CFF1[T#?U/4Y;4'8NX8KB-(U:>VURYG\O[]0W&K7<N4>
M0G'%4EE=7W@X)IV,98C4]1TN]DO(BSKMK0KS_1O$#VQ"2G(S6\_B>+^%":31
MO"M&2N='17*/XG)^[$U0-X@N7^Y&P_"D/VJ.QR*0R*.IKB&U+49/N[QGVIJC
M5YO^6C ?2F+VIV;7D*=6 _&HFU6U7K(/SKEETK4Y>3,:E7PY=O\ >EHL'M'V
M-U]=LUZ2C\ZKOXCMEZ.*HIX7;^,YJS'X9@'WUS0%ZC(9/% 'W #5=O$EP_W(
MZV4T"R7K$*G72+1>D8% N6;.:.M:A+]V$_E49N-4E_Y9L!77K8P)T05*(8QT
M447'[.1Q1M=4E_OBL;5+"YA<M-N/N:]0"@=A6=JMC%<6[;E!)HN3.C=:'EF*
MGMHY))0(P=W:K>J6?V6=0!PS8%='H>EI&Z.RY)YS57.6-%\Q5M[K4K- IB8@
M>U6X_$DZ'$D>*ZEK:-A@J*K2:1:2#YHQ4W.M4Y+8H0>)(&'SL!5^+6+23I(/
MSK/G\-P/GRUQ6?)X:N(^8I,4#O-;G5)<Q2?=8&I=P]:X=[/5+7[LI('I2QZI
MJ%O_ *T.?PH#VO<[?-+7*1>)RO$D9K0@\16\G!X^II%JHF;?6BJD>HV\@XD7
M\ZG6>-NC@T%<R), U6GL;:X7$D*M]15C(/>EH'<Y#5? FGZAN*QHA/H*XK4O
MAQ>V+&2QN9>.< U[)2%0>HH*N?*7BB+5+6=H[TOD==U<OYCGJQKUKXO(!J,V
M!7D5(KH/$C@CYC7L'@_QY%I.E11$@LHQ7CJ]1]:]X^'WA'2M1TF&:Y@#,1F@
M'8FD^*5TQQ% #59_B-K$O$5IG\*]!C\%:+&/EM15F/PQI<1RMNHH)/+&\8>)
MIC\MDW/L:A.I^*[S_EVE7Z U[&FD6:?=B7\JG6S@0<1@?A0%SQ,V?BJ;^&89
M^M.C\)>(KLYEN)T_&O;Q$@Z*/RIVT>@H"YXU'\.]4E_UE[/^=78OA9(PS)>2
M?G7K&!2T!<\RA^%$(.7N6;ZFK\7PSLDZD&N^HH"YR-OX"TZ'K$C?45H1>$M*
M3K:1'_@-;U% KF8F@Z;&/EM(ORK \;:%'/H92UMEW\]!794UT6088<4PN?*-
MYX)UK[1(PM'VY]*K)X,UF3[MJY_"OJRXLX/)<^6.GI6=IMG"2?D'7TH*YCRO
MX4^'-2TO5Y)+J!D4KU(KW!?NBHX[:.,Y50/H*FZ4$MABDI:* "BBB@ HHHH
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MN14,N#TKS?Q9\/SJ$[W=K)Y<IYR*2=I7':\;'>VUY;20*R2)MQP,UQ_Q"O[
M:.ZN59\UY])HGBJU?RHYYBHX&,U<T_P/K.KSJ=0N9"F<D-0U?02=C=^%L$JS
M7$A!\M^5KU05E:)HT.D64<,:C*K@FM4538EH+1112&%%%% !1110 4444 %%
M%% !7#:__P C/!7<UPVO_P#(SP4 =+;_ .I%2U%;_P"I%2TS,**** "BBB@
MHHHH **** "BBB@ HHHH *KW4IBA=Q_"*L56O83-;21CJRX%)@CS[5O&"PSE
M6?!!K>\.Z^=0C55.1BN.UCP=,]RS;B<FNE\)^'9=/ D9S@CI302W-_5M4-@
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M)R:[#3;Y+RV5P<DU'JFGI>0-Q\V*Y&*]GT2[:-@2@Z4;BNZ;L:OB;_D(V?\
MO?XUT=E_Q[K]*\]UG77N[JWD$?W3FNHT367NV2(QX![T&BDFSHJ***1H9.O?
M\>B_6G^%?]3+3->_X]%^M/\ "O\ J9:"T=%1112*"BBB@ I-H(Z4M% #/*3^
MZ/RI0BCHH%.HH ,4444 %%%% !1110 4E+2$T %%%% !12T4 %<-K_\ R,\%
M=S7#:_\ \C/!0!TMO_J14M16_P#J14M,S"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@")[>.0Y8"GHBHN%&!3J* # [U"+6-9?-"C=ZU-10  "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@04444#"BBB@04444#"BBB@ HHHH ***
M* "BBB@ I*6B@!&^Z?I7(Z!_R,UY]/\ &NN;[I^E<CX?_P"1FO/H?ZU2.:K\
M2.OHHHJ3H04444 %%%% PHHHH **** "BBB@ HHHH ****!,Y+Q-_P ?-O\
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MV*J!@ U/X5'[F6F:_P#\>B_6G^%O]3+07%61T=%)2TB@HHHH **** "BBB@
MHHHH *2EI* %HI*#0 4A-!( R37#>+/$DUK)'%:DAM^#B@#N<TAD4'!-<I%K
M$T>@2W3M\ZKFN?B&OZE#]NM[HB$\XH ]-S17*>$=7FOQ+#.Y9XCM-=70 5P^
MO_\ (S05W%</K_\ R,T% ,Z6W_U*U+45O_J5J6F9A1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2?-G.T9J?%&* (MTGI29<\$5-BC% 7(!N7HH%.WOZ5+BC% $6Z2C=)4N*,4
M1;I*-TE2XHQ0!%NDHW25+BC% $6Z2C=)4N*,4 1;I*-TE2XHQ0!%NDHW25+B
MC% $6Z2C=)4N*,4 1;I*-TE2XHQ0!%NDHW25+BC% $6Z2C=)4N*,4 8FNL_V
M5<CO5CPIGR9<TS7O^/5?K4GA7_52T%(Z*BBBD4%%%% !1110 4444 %%%% !
M1110 4444 (:*6DH *-H]*6B@ HHI* %KAM?_P"1G@KN:X;7_P#D9X* .EM_
M]2*EJ*W_ -2*EIF84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110(R=>_X]%^
MM/\ "O\ J9:9KW_'HOUI_A7_ %,M!:.BHHHI%!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7#:_\ \C/!7<UPVO\ _(SP4 =+;_ZD5+45
MO_J14M,S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****!&3KW_'HOUI_A7_4R
MTS7O^/1?K3_"O^IEH+1T5%%%(H**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *X;7_^1G@KN:X;7_\ D9X* .EM_P#4BI:BM_\ 4BI:9F%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444",G7O\ CT7ZT_PK_J9:9KW_ !Z+
M]:?X5_U,M!:.BHHHI%!1110 4444 %%%% !1110 4444 %%%% "4M(2 ,FJ;
MZM91OL>= P[9H NT5##=0W"EHG##VJ-]0M8WV/,H;T)H M44U75U!4@@TN:
M"N'U_P#Y&>"NXKA]?_Y&>"@#I;?_ %(J6H;;_4BIJ9F%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444",G7O^/1?K3_"O^IEIFO?\>B_6G^%?]3+06CHJ***1
M04444 %%%% !1110 4444 %)2T4 )1165K-]=646ZVB\PXZ4@)]4G^SV329Q
M7F30&\U-Y))#M8\<UT9U.]U2U:&_B\B(G[PIB^%K46DD\5VS84D4;/4.A:4G
M1M FDBDRP7(.:P;>QU'5;7^T _7FJL4L[:%>HSLX&1DUU/A>:-/"RAF&=O2J
MMU"_0/!NKW%Z9X)VR8FVUV&:\_\  JG^T+\]O--=_P!J&P$9T7JP'U-<-KTB
M'Q+"0P(K?UBSN+@CRF8<]C7-3^%[JXN5G9WW#WH ZJWEC\D?./SJ;SH_[Z_G
M7,+H=\HQYC_G2_V)??\ /1Z".4Z;SH_[Z_G1YT?]]?SKF?[$OO\ GH_YT?V)
M??\ /1_SH#E.F\Z/^^OYT>='_?7\ZYG^Q+[_ )Z/^=']B7W_ #T?\Z!\ITWG
M1_WU_.CSH_[Z_G7,_P!B7W_/1Z/[$OO^>C_G0'*=-YT?]]?SH\Z/^^OYUS/]
MB7W_ #T>C^Q+[_GH_P"= <ITWG1_WU_.CSH_[Z_G7,_V)??\]'H_L2^_YZ/^
M= <ITWG1_P!]?SH\Z/\ OK^=<S_8E]_ST>C^Q+[_ )Z/^= <ITWG1_WU_.CS
MH_[Z_G7,_P!B7W_/1Z/[$OO^>C_G0'*=-YT?]]?SH\Z/^^OYUS/]B7W_ #T>
MC^Q+[_GH] <ITWG1_P!]?SH\Z/\ OK^=<S_8E]_ST>C^Q+[_ )Z/0'*=-YT?
M]]?SH\Z/^^OYUS/]B7W_ #T?\Z/[$OO^>CT!RG3>='_?7\Z/.C_OK^=<S_8E
M]_ST?\Z/[$OO^>CT!RG3>='_ 'U_.CSH_P"^OYUS/]B7W_/1_P Z/[$OO^>C
MT!RG3>='_?7\Z/.C_OK^=<S_ &)??\]'_.C^Q+[_ )Z/^= <ITWG1_WU_.CS
MH_[Z_G7,_P!B7W_/1Z/[$OO^>C_G0'*=-YT?]]?SH\Z/^^OYUS/]B7W_ #T>
MC^Q+[_GH_P"= <ITWG1_WU_.CSH_[Z_G7,_V)??\]'H_L2^_YZ/0'*=-YT?]
M]?SH\Z/^^OYUS/\ 8E]_ST>C^Q+[_GH_YT!RG3>='_?7\Z/.C_OK^=<S_8E]
M_P ]'H_L2^_YZ/\ G0'*=-YT?]]?SH\Z/^^OYUS/]B7W_/1_SH_L2^_YZ/\
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M,<&NF%9VDK;1VJ1VY4J/2M&FR4+1112&%%%% !1110 4444 %%%% "4&EHH
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M^G_\A1:Z"Y_X]W^E<_IW_(46@#I:*2B@!:*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** *6I:E#IL!FF)V@9-<>_P 5M C=
ME9FR#@\UU6LZ2NK6K0,Q4,,9KQSQA\,8-)TFXODN6+ YQ4W'T.X'Q8T G +?
M]]5LVGC33KNPDNX]QC09/->+^"O $6O/^]N67 S7I4OA^W\)>'[GY_-7;SNJ
MWHB>NAU6D>(;76(P]N" ?6MCO7GG@K68)M.26*-1\N>*K?\ "THQ?7-LRJ&B
M;:!ZTF,],I:\P@^*:"]$-RBQJ>^:FU#XFQP!6MU61.YH ])HKF?#/BNWU^V,
M@8 CJ!5'Q%XZMM'D:&-E>93]VAZ =I17FNF?$U;BZ6*ZC6+>>*]!M;J.[A$L
M394TP+%9FH:Y:Z:Q$QY],U>N)/)@DD_NC->/:EJ,FM>.((5<F(G! J>MA]+G
M?S^.-+MPAD) <X'-;B7\+V@N0W[LC=^%>1_$G2C86%K)%QAQG%:]GKX/@J8[
M_F2,#]*.C%U2.D;X@:.FH_8BQ\SZUT+:A"MB;LG]V%W=:^9IK*ZD*:R&;#2
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC&AQ7EE;B^F4^1NKV;1;F*XL(FCQDKT%/S%Y&I12"BD,6BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** $I:2EH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQX(;I5KP[X9U.TM+M;G!:4Y%"V N_:[_ /L?^T//;AL;:L3^()Y(+:)"RL^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MIJ* *$6CV,-TUS' HF;JV*DN=.MKQ=L\*N/<5;HH Q1X6T<=+*/\JM)HM@@
M6W0 =.*OTM $4,*0KMC4*M%2T4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !BBBB@ HHHH **** "F/$C_>4'ZT44 "QHGW5 H,
M:%LE1FBB@!##&6R5%*(D X4444= #8N,8HV+MQBBBA;!T$6&,=%'Y4K1(W50
M?PHHH /*CQ]T?E2A% X%%% "-$A/*@TJHHZ#%%%" 4J&&"*B-M#_ ,\U_*BB
MD [R(QT0#\*=L7&,444P (H& ,4WR8R<E1GZ444NH#BB^E*  .***8"T444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
;%%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gn15qjhcndsi000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gn15qjhcndsi000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" / !T0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **AFNH8/]:X7ZU#_:ME_SW6@ER2W8ZYOX;5MLC $^]0?VS:?W
MU_[ZKS3XBZDS:Q%]EN&V;.=I^E<9_:%Y_P _$GYUJJ=U<\JOF7LZC@EL>_\
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M@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"/:K.F6"6$!11C<<GZU>HH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *PFTJ6"_:XML*7/S>];M% "+G:,]<<TM%% !1110 4444
M %%%% !3)5+QLHZD4^B@#G[71IX=:%VQ&S%=!110!F:S8RWEJ5@($F>IK$-C
MX@\KR?M"[,8QC_Z]==28'I0!BZ/I#V<.Z?!GQU%%CI4OVN66ZPWS93VK;HH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 44A( )/05SVI^)X;.;RXF5F]* .BHK TOQ)!?2&-V4..U;X.1D=Z
M "BBLS4-;L].E$=Q,$8C.#0*4E%79IT5B)XFTYQD7"T/XGTY!EKA0*+"YU:Y
MMT5GZ?K%IJ3,MO*'(ZXK0H'&2DKH****!A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4?G1N7U'YU3^QG^^WYT?8S_?;\Z +FY?4?G1N7U'YU3^QG^^WYT?8S_?;\Z
M+FY?4?G1N7U'YU3^QG^^WYT?8S_?;\Z +FY?4?G1N7U'YU3^QG^^WYT?8S_?
M;\Z +FY?4?G1N7U'YU3^QG^^WYT?8S_?;\Z +FY?4?G1N7U'YU3^QG^^WYT?
M8S_?;\Z +FY?4?G1N7U'YUESQ-%(BAC\Q]:L?8S_ 'V_.@"YN7U'YT;E]1^=
M4_L9_OM^='V,_P!]OSH N;E]1^=&Y?4?G5/[&?[[?G1]C/\ ?;\Z +FY?4?G
M1N7U'YU3^QG^^WYT?8S_ 'V_.@"YN7U'YT;E]1^=4_L9_OM^='V,_P!]OSH
MN;E]1^=&Y?4?G5/[&?[[?G1]C/\ ?;\Z +FY?4?G1N7U'YU3^QG^^WYT?8S_
M 'V_.@"YN7U'YT;E]1^=4_L9_OM^='V,_P!]OSH N;E]1^=&Y?4?G5/[&?[[
M?G1]C/\ ?;\Z +FY?4?G1N7U'YU3^QG^^WYT?8S_ 'V_.@"YN7U'YT;E]1^=
M4_L9_OM^='V,_P!]OSH N;E]1^=&Y?4?G5/[&?[[?G1]C/\ ?;\Z +FY?4?G
M1N7U'YU3^QG^^WYT?8S_ 'V_.@"YN7U'YT;E]1^=4_L9_OM^='V,_P!]OSH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU_Y<R +BO0$)**3W% #J*** "BBB@ HHHH **** "BBB@ HHHH @N?N46O\
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MZA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&E)71S4ZDL-+V=3;HSU.BH;:X2YA62,Y5AD5-69Z:=]0HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@# \66#7^D^6HY!S7#>']>;0KB2"9&
M(+8KU=E#J01D&N2UGP;;7C&6,-OZ\4 78O%=I(F[*C\:R=;\90_9GAB7+,,
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJMNG_NT;I_[M %FBJVZ?^[1NG_NT 6:*K;I_[M&Z?^[0!9HJMNG_ +M&Z?\
MNT 6:*K;I_[M&Z?^[0!9HJMNG_NT;I_[M %FBJVZ?^[1NG_NT 6:*K;I_P"[
M1NG_ +M %FBJVZ?^[1NG_NT 6:*K;I_[M&Z?^[0!9HJMNG_NT;I_[M %FBJV
MZ?\ NT;I_P"[0!9HJMNG_NT;I_[M %FBJVZ?^[1NG_NT 6:*K;I_[M&Z?^[0
M!9HJMNG_ +M&Z?\ NT 6:*K;I_[M&Z?^[0!9HJMNG_NT;I_[M %FBJVZ?^[1
MNG_NT 6:*K;I_P"[1NG_ +M %FBJVZ?^[1NG_NT 6:*K;I_[M&Z?^[0!9HJM
MNG_NT;I_[M %FBJVZ?\ NT;I_P"[0!9HJMNG_NT;I_[M %FBJVZ?^[1NG_NT
M 6:*K;I_[M&Z?^[0!9HJMNG_ +M&Z?\ NT 6:*K;I_[M&Z?^[0!9HJMNG_NT
M;I_[M %FBJVZ?^[1NG_NT 6:*K;I_P"[1NG_ +M %FBJVZ?^[1NG_NT 6:*K
M;I_[M&Z?^[0!9HJMNG_NT;I_[M %FBJVZ?\ NT;I_P"[0!9HJMNG_NT;I_[M
M %FBJVZ?^[1NG_NT 6:*K;I_[M&Z?^[0!9HJMNG_ +M&Z?\ NT 6:*K;I_[M
M&Z?^[0!9HJMNG_NT;I_[M %FBJVZ?^[1NG_NT 6:*K;I_P"[1NG_ +M %FBJ
MVZ?^[1NG_NT 6:*K;I_[M&Z?^[0!9HJMNG_NT;I_[M %FBJVZ?\ NT;I_P"[
M0!9HJMNG_NT;I_[M %FBJVZ?^[1NG_NT 6:*K;I_[M&Z?^[0!9HJMNG_ +M&
MZ?\ NT 6:*K;I_[M&Z?^[0!9HJMNG_NT;I_[M %FBJVZ?^[1NG_NT 6:*K;I
M_P"[1NG_ +M %FBJVZ?^[1NG_NT 6:*K;I_[M&Z?^[0!9HJMNG_NT;I_[M %
MFBJVZ?\ NT;I_P"[0!9HJMNG_NT;I_[M %FBJVZ?^[1NG_NT 6:*K;I_[M&Z
M?^[0!9HJMNG_ +M&Z?\ NT 6:*K;I_[M&Z?^[0!9HJMNG_NT;I_[M %FBJVZ
M?^[1NG_NT 6:*K;I_P"[3E:;/S#B@">BBB@ HHHH H:OJ2:79F=QD=*\PUKQ
M;<7TA2%FC7H:]'\1::VJ:?Y"@DYSQ7&'P'*3GRS3 QM'M(9Y!<74R-GJ&-=U
M9ZKI5E&%B6-2!R0:Y\>!9QT5Q^)H_P"$&N/1_P S0!V=IKMM=R^6C*3[&M4'
M(!KBM$\*S:?>>:P;&.Y-=J@VH!Z"D M%%% #)8EE0JPR#61_PC5AYA?R$R3F
MMJB@"*"%+>%8T "CH!7">,H)9/$%LR1LRA>H%>@5!-:13R!W4$CVH I6$1?0
MQ&PP2A&/PK@HOM'A[5BWD/(A8MP/>O3T0(NT=*@N+&&Y^^H_*@#SF&*?7M;:
M9H7C0,&&17ID2[(8U]% J*WLX;8811^56* "BBB@""Y^[1:_ZL_6BY^Y1:_Z
ML_6@">BBB@ HHHH **** "BBB@ HHHH **** (IX5GB:-AD,,5YMK^F3:+J)
MO+;*H.RUZ=5+4]/BU&U:&0<?2MZ%7V<M=CDQ>'5:&FZV,?3M7CU/19$)&]4P
M:X'4$,=TRD8JVWVCPWJA1_E@E?N>U7]2TXZBIO;0;HSWJJ]+E?-'9D8/$>T7
M)/XD<W2KC>N?45.;.8/LV\UIVGAN]N8]XC^7%<YVG>Z%=QW%C&J$?*H!Q6K7
ME^G:K/H5RT).%+8.:[?3?$%K>J%$F7H8HNZ-FBD!!&1WI:104444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBBB@ HHHH YCQM:/=:/M0$D-GBN1T?Q)_95E<0/&=W05ZC-"LT91QD&N5O/
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MM9/)O3@"@#MZ*IV>HP7J;HFS5R@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *Q_$=R]OI4Y3(.WJ*V*R]>2)]*G
M$G3;0!YCIFD7FMD2&=P&[UK#P)<_\_;4S0?$=II,@AD;$2CBNG'CK1\?ZPTP
M,_0_"<^G7OFO<%ACI7;(-J >@K#L/%>FZA/Y4#DM6Z#N4$=Z0"T444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !5/4K+[?920!]N\8S6?XIU"YTW3!-;??SBL72]?U"YT>
M[GD/[R,?+0!2/PVR<F]_S^5'_"MO^GW_ #^58_\ PFFN>OZ&E_X337/7]#3
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV,V!DY]ZU8+Z"<91A^= %FBDW*>C#\Z6@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV)R2W+U%8TGB6QBZM^M4Y?&VF1]=Q^E6J4WLC&6)I1WD=+17%3^/;,_ZH/\
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MCQ9?UH XW46&K:]B#YU60'(^M>F6Z[;>(>B ?I61I7AJRTU]\<>'/6MP<#%
M!1110!!<_<IMJBF,\#K3KG[E):?ZL_6@";8O]T4;%_NBG44 -V+_ '11L7^Z
M*=10 W8O]T4;%_NBG44 -V+_ '11L7^Z*=10 W8O]T4;%_NBG44 -V+_ '11
ML7^Z*=10 W8O]T4;%_NBG44 -V+_ '11L7^Z*=10 W8O]T4;%_NBG44 -V+_
M '11L7^Z*=10 W8O]T4;%_NBG44 -V+_ '11L7^Z*=10 W8O]T4;%_NBG44
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MV+_=%&Q?[HIU% #=B_W11L7^Z*=10 W8O]T4;%_NBG44 -V+_=%&Q?[HIU%
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MB_W11L7^Z*=10 W8O]T4;%_NBG44 -V+_=%&Q?[HIU% #=B_W11L7^Z*=10
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M"1%\U %BWUVRE',Z@^E78[N"7[D@-<E<>$'!S;*!Z54-AK6G_=D&!Z"@#O\
MK17 Q^(=2MFVW#,0/0&M2V\86^ )@^?I0!U5(2!UK+B\06DJ[@<?4US>M^*9
M4E:.UD(Q0!VPFC)P&&:?7E"^(]05]WFUU_A[Q%]N(AF;,@'- '444@.1FEH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%% !1110 4444 %%%% !1110 4444 07/W*+7_5GZT7/W*+7_5GZT 3T444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_5GZT 3T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 >??$0G81G^&O+$GEC^Y(R_0UZE\1
M/NG_ ':\IKHI['S68O\ ?LG^V7/_ #V?\Z[3X=W$TFI2AY&88[FN$KH_".LP
MZ/?-+,K$-QQ526AAA:G+5BY/0]T7[H^E+7/6'B_3[T*$RI_VC6W'<PRJ&61.
M?]H5S--'U,*D)J\6344@(/0@TM(L**** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@""Y^Y1:_P"K/UHN?N46O^K/UH GHHHH **** "BBB@
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MD49'=A5P2QGHZGZ&O+<6MSWXRC)73'T49!Z44B@HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K!\4LRZ3-C^[6]5'5K/[;I\L(^\RX% ' :*T-GH2W6X>8P(/Y
M54\-VB7NHR3R %0Y)S4-UHNIP-]C#?NP> !73:9HD^F:#<M_RU9<KBF!E@)%
MXRF%O@+QP/J:](@SY"9]*X+PKHMT^H&^N^=P[BO0%&U0!VI +1110 4444 %
M%%% !1110 4444 %%%% $%S]RBU_U9^M%S]RBU_U9^M $]%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#1M3QM&?6QU=%5;>_M[A-RRISVW"K(96Z,#]#4G4FGL+1110,**** "BBB@
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M44 %%%% !1110 4444 %)@>E+10 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "8'I1M7T%+10 WRT_N
MC\J3RH_[B_E3Z* (S!$1CRU_*N(\3Z$[3M<0)GV%=W37C61=K#(H \::UF1M
MK(0:U-(T2>[N%WH0G7->A/HE@[[FBYJU!:PVR[8EP!3 +2 06T<8_A&*GHHI
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M445E7>NV]H^Q@6.>U &K15.RU&&^3='Q[&KE !16??:O!8MM<%CZ"DLM8@O=
MVP$8[&@#1HK*NM=@M9?+9&)]JB3Q+:O(J!6R3B@#:HJC<ZI#;1;W_*JMOXBM
MIY @5E)..: -BBD!##(I: "BBB@ J*XF2"!I'.%49-2UA>*)6CTF< ]5H R+
MWQ?:1SD(L;X[D"H/^$YC*[=J8],5S^DZ M_IXN#M+$$U/H'A^WU%;I&5=Z-@
M9-,#H])\5B]N_(CC0#V%=>AW(#ZBO-]#M(-+\32V\B@E1V_&O2$(**1TQQ2
M=1110 4444 %%%% !1110 4444 %%%% $%S]RBU_U9^M%S]RBU_U9^M $]%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>AK,VN+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!(,B:/\ [Z%2AT;HP/T-969T)I[#J***0PHHHH **** "BBB@ HHHH ****
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MVV.ZVB/J@_E0!+1110!!<_<HM?\ 5GZT7/W*;:L/+/(ZT 6:*3<OJ*-P]10
MM%)N7U%&Y?44 +12;E]11N7U% "T4FY?44;E]10 M%)N7U%&Y?44 +12;E]1
M1N7U% "T4FY?44;E]10 M%)N7U%&Y?44 +12;E]11N7U% "T4FY?44;E]10
MM%)N7U%&Y?44 +12;E]11N7U% "T4FY?44;E]10 M%)N7U%&Y?44 +12;E]1
M1N7U% "T4FY?44;E]10 M%)N7U%&Y?44 +12;E]11N7U% "T4FY?44;E]10
MM%)N7U%&Y?44 +12;E]11N7U% "T4FY?44;E]10 M%)N7U%&Y?44 +12;E]1
M1N7U% "T4FY?44;E]10 M%)N7U%&Y?44 +12;E]11N7U% "T4FY?44;E]10
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MEU.%LO#>HW$"SPQ,>^0:UXM2UK2@%D@.U?4UZ=;6L5K"(HEVJ.U1SZ=:W/\
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M^\:L44 5_LH_O&C[*/[QJQ10!7^RC^\:/LH_O&K%% %?[*/[QH^RC^\:L44
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M8RKLN4\XU)=4UB4SM&VT]@>*P9$:-RC###K7O2:59QIL6( 5QNO^"S<7*O;
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?[QOO#O[UEU;TZ<6]VCL,@$5;.*#M)'T-9?\>,/^X*GKG=%\26=W:Q)O5"%
MY-;Z31R?<=6^AKE:L?74YQE%<K'T444C0**** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC+'->M=L53NM,M+L$31!L^M2I]S:6!2UI.S.6TOQY:SX6[E5&]!756FI6MZ
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MP,9B#=2S ]_F-='9>%+*SP5^;']X9K?HK*>(J2W9TT\%1I[(ACM88UPL2?\
M?(J4 #H *6BL+G4DEL%%%% PHHHH **** "BBB@ HHHH **** "BBB@ K'\1
MVYGTF?;G.WBMBL[6HY)=-F2(D,5XH XSPH]C;*L5SM\T#D$ UUXGTS'W8_\
MO@5YHN@ZFLGF!V#'OBIAI>L_\]G_ "I@>EP2V+/B()N]E%7ATXKS[P]8ZE%?
M[IY&*X[BO0$SY:Y]*0#J*** "BBB@ HHHH **** "BBB@ HHHH @N?N46O\
MJS]:+G[E%K_JS]: )Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC=-.;B>,N<D(2/Y&MSP[X.L?#JJ+=F=A_$W6NDHH **** "BBFM(B#YF ^M
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ-.ILS4HIJNKC*L"/:G5)T!1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVR*J8/H:^@W\/:8[;FLXR?I3/^$;TK_GSC_*MO:H\.64S;OS(\!B0O*BX/+
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW5]XA4-ZU/T'% 'F'CC0+W4=9\V!<KBO0-%A:WT:UB?[RI@U<:&-SED!-.
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBF2S1P1EY7"*.Y
MH ?15-]5L8P"]S& >F34L=W;RQ^8DJLGJ* )Z*H-K6FHQ5KR,$=1FG1ZOI\K
M;8[J-F] : +N0.II 0>A%>;^,_',EA<P6ME"9FD.T[#TK/T#QS>PZZNG7]L\
M8(SN>@#U2Y0RV\B#JPQ7F.L^!M1O+]IHU7::]/AE$T*2#HPR*XOQQXP;0X&B
M@C\R8'[HZU2DUL<]?#0KJTSD_P#A7>J'HJTY?AWJH8$HO!J.S\>ZE8:A9K>6
M<BQW;<%^WZ^U=GXJ\9QZ1HGVN$"5R<;15>T9S?V70\S=T.R>PLTBDQN"X-:U
M>*P^.=5M+RWEGLY1#.<Y;H!^=>I6GB"UFT@:A+(D<9'4GBLSOC%15D:^0.I%
M+7D&I_$AIO%%G96Z?NVDVEE/6O6;9S)"&-!1-1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %8_B*Z:WTJ<J<-MXK8K%\2V[3Z3/M&3MZ4 >80:1>ZI#]KZ@C-.TW
MPY=:DDQBZQG!K?\ "-TY5M/DBPRH>OTJM8ZN_A^]N$DCRLCD\TP$\+6/V/7W
MMY_]8J\_K7J"<(H'I7E^G7KZEXIDN(DV[@.GXUZ?#GR4SUQ2 ?1110 4444
M%%%% !1110 4444 %%%% $%S]RBU_P!6?K1<_<HM?]6?K0!/1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5Q_Q+O);'P=<3PG#CH?PKL*X?XL?\B-=?Y[&@#A-#L]:UW2Y)YF#"--
MR5:\,:_?Q7PT:Z?DDG%4O"/BFYLM&G@^Q,08\*?6K'@_1KS5_$:ZE-"\*Y(Y
M^M RMJ,;G4)OF_B]:MZ!&PU)<GMZUUES\-C<7+R_;R-QSC_(J;3_ (>FPN1-
M]M+8'3_(H$>>6V9O%R"3G;/Q6EX[ B\5"1.&VBH?$VEWGA_7;:Z@MWF4R;F(
MIDC7WBOQ>KM:/'"5'S=J!GLFADMHEH3U,8KR/QLQ?QXT3?=X_G7;WOB6ZT%]
M-T^.Q:59/D9A_#UKE/'^G78OCJ\%NSMQ\HH$1_$*-5M]#8  JHQ^M<UK<SSZ
M7&DA^7>*NZOJ&H>)+G1K=;%U6$A7([=:V/&?A6XM?#R26T;22!@=JB@9;\71
M(OA+3V &5@&/UJYX0TI=?^'5O;S D;L_H*Y/4M9U#6+33],%@XV((V->K>"]
M,?2?#<5JX(*^OTH$>0>(]!M-#\9:.ELI4M)\WY&O>;+_ (]EKR/QU8W,WC71
MY(X695DY([<&O7;($6Z@B@"Q1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,D19(
MRC?=/6GUFZW>&STV:0?>"Y% $,&DZ?97S72;1(PP>16=J^@Z=J+AVVEA[BN!
M^U:QJLYD@,VT] IJ7^SM?];C\Z8'?Z)H-AITGF1 >9C!Y%=$.E><>&[+5XM1
MW7)FV8_B->C1Y\M<]<4@'4444 %%%% !1110 4444 %%%% !1110!!<_<HM?
M]6?K1<_<HM?]6?K0!/1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M '11L7^Z* (OM2>AH^U)Z&I=B_W11L7^Z* (OM2>AH^U)Z&I=B_W11L7^Z*
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M_=%&Q?[HH B^U)Z&C[4GH:EV+_=%&Q?[HH B^U)Z&C[4GH:EV+_=%&Q?[HH
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MJC?>'M/U%]UQ%N:M6B@#,L-"L=-;=;1;36G110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4C,$7<>E+5'5Y#'ITC#J* .3U;Q/<->/;63,&0\\9IVC>)I_MR6EZQ+MR
M.,5G^%(UNM?NS( WUIGBA%M?%,!C 7"=OPI@>DHP=0PZ&G53TMR^G0L>XJY2
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]/B0]0*MT@  P*6D,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH KWI<6KF,X;M7F=Q:ZA'JLUP
M"?F[XKU,@$8-1M;0MG,2\^U 'CMY<WK:M$\C'S5&%.*]/T"6>2QC,Q).*HWO
MAB&YU:.[Z;1T XKH8(5AB5% &* ):*** "BBB@ HHHH **** "BBB@ HHHH
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M2T4 >9:K_P CM)_GO77ZQ 9?#KX'(CJM=^&4N-<:^+G)[5T'V=6M! W(VXH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ I*6B@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@!K.J_>8#ZFA75QE6!^AK \4^:MDTD9(VKG@UE^#-4
M>YB6.1B2!W- '9M(B??=5^IH61'^ZZGZ&O/_ !SJ\D,\*0L??!J3P5JTES<"
M"1B2!W- '>,Z)]YE7ZFE5E895@1[&N(\;ZE);3PQ1,1N'8UN>%B[:+$\I);O
MDT ;E%0->0(VUGP:E1U==RG(H =12$A1DU!]M@W[=_- %BF&6-3@R*#Z$TX$
M$9%>:^(=1GA\0&-78+O'?WH ]+ZT57MI +*%V/5 34B31R'"MF@"2BHY)XXO
MOMBF1W<,IPCYH GHI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#/UJ
M$3:3<+CDI7GOA*4V>MO"YP AKTZ=/-@=/45Y'KKOI7B&4H,<8H EO0VL:UM'
M*J^*LZ?C1_%,L?W0%_QJQX'M3>3S7#C)#9J/QA$UIJTMVHQGBF!%K5Q_:6MV
MB]?FQ72ZMJ)T/1$2,[7SCBN/\.(U_JL,K<[&K<\>(X3/\.Z@"A:V^KZG%)<K
M>JH'(!-:'A[6[FWU1K*[F\S:*IZ1:7,UGNB#;0.<&EM-+7^U6<LWF8Y&: -G
MQ7K[VIC@@<JTB\$5B16&L2V2WGVY.><9YJMXJC=-0M0V>G%:5I8W3Z>K@-Y9
M![T :/A/7I;@O;W+EW#;0:YKQ2P3Q&['LX/ZUK>'=,CBU .CDG=S6+XP1GUZ
M55ZE@/UH$:NI>(YKG[/:63E24 _2NHT2VN[;3C-<R;F"$_I7G26-SHU[;W,J
M';C=\U>HZ9?Q7VE"0D ,ISCZ4#. GU6_U/53!'<^6NXK\W%6Y++5K*1'2_1@
M6&0IS_6FZIH5I<79-E,YE)/ ..:S)H]5T-E>:-C'G@L<T >H:8\CVJF0Y; J
M[6'X9U1M3L3(R@%>.*W*0!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7"
M^*/#,VI7[3QD#)KNJ0@'J : .>\*Z.VDV[JV,M47BS1'U.SQ%@.3UKI@ .@H
M(!ZC- '&>$O#DNG;VF()SQ6YK^CC5K/RQ@,#G)K7  Z "EH \T71]:L-\,-P
M0C'L*VO#^@WL-U]INY0^1TKKRB'JJ_E2@ =!B@#F_$?ATZFHDBP'08!KF5TS
M788Q;+<G8/:O2Z;L3^XOY4 <YX<T2XL$9[EP[,<YK(UKPW<7FM&X1OEW@_K7
M>4A4'L/RH P=7T5;_21'@>:$ !K/\.:7=V(>"=]T>P@#\*Z^D"@'( _*@#@;
M_P /:E;7GGVTVT9SQ5:;1]8U9DCGN"44YP17HY4'J ?J*0(HZ*!^% &=HNEC
M2[3RAC)ZXK3HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
B*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gn15qjhcndsi000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gn15qjhcndsi000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0G!V,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *DA_UHJ.I(?\ 6B@#ZC\(_P#(IZ;_ -<1
M_,T4>$?^13TW_KB/YFB@#YWN) K&LV:8N<9IUS*3(:J]Z=Q6%-)124ABT4E)
M0 N>:GC:J]2Q]: +B#=4YM\KTJ.#M6G&H*51)D-#M--;BKEU@$U0=^:5AHC=
MJB+4YSFHZ0Q<YI*** %I0:2DH D#5*#D56J1&I@34TQY-2*,U8BBR>:+"*)C
M(IF<&M2>$;.*RY!AJ0#Q)B@RU#10,D+DTPYI** $I0<444 2*]2=:K]*D1J
M)@N:=Y="BK")FF25RF!3,<U:D7%5F.*&-#2::6I"U,)S2&!?-(2:2B@ #&I
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@5G--4339[T7'8T_M(-.64&L@2FK$4IS0!I!LT[&:JI+5J-P:! 8\U&8*N*
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M0"[MA#,^7S@9->2!JT]%O9;348WB)R#TS7-BJ"JPMU(E&Z/3O%WAU=3MU:$
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M-5I;.:$_.N*2DF%RO12E2*3%, HI<&DQ0 4444 %%%% !1110 4444 %%%%
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MRMYJC&.XI,#YRU&P>SE*OUS6:1BNO\9E6U)]H&-W:N1?K6+*&T444@"BBB@
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M]JN3B(UY#K,*MJ,Q]6JZ>XF<X(-W&*T;*Q .2*FBML'IQ6C;0-N''%;$CTA
M7I65K]H)].E^7)"\5UD5JI3WJG>6&]&7'!%(9\X:A;M#.RD$51"G->H^*?"3
ML[S11DUR-IH$[7(62/ !K%QU'<RK2REG<!4/Y5Z3X3\.E&65B..:T_#_ (7@
M,:G;DX]*Z6RT[[(S#&!FK4;!<V[2Z2W0)MZ5H1:A&XP5K)2$$592  =33:$:
M1G0#(I/M"^E4-@Z9-3+%@<9HL!.TWI4?GFDVD"FT@)1.?6E^T5#LS2&/% 7)
M_-)/6E+<57''2GY(ZT ,QF3DU(\D:C!J&1CG(JI.)6/ IV OI*K'BJ&I7P@!
M ..*0L+:'<YP<5P?BGQ*+='C1@211L"+^J>(([=22X)^M<7?>,;AI^';:*Y>
MZU66YE)9C^=,(\Z$D_>J7(=CN=+\7 M\S'/UKHH]>BN4QY@&?>O&T65),#(_
M&M>V:10,.V?K34@L>C-JS6LFX2AE/8&JVH>(GDA/EL17'^;<QJ&Y(]S4D=RM
MPN"WS5386$O==NT)/G'FL2?5[AY-[.33]1M9]^2ORYX-4GC00GGFLVV!.^I3
M3J%WGBM_PYJ@M'42\\UR:<=*LQSF,]<4)V ]KM=4A^S;MP.X=,U@ZS=R7$3)
M'D UR.FZNBE5>0_G750W"7$65P:TO<1Q-QH\S3EL'YCZ5JZ5X>EDD"]ZZ8+"
MW&!N^E7-/66"Y5P@Q18#F)?#.H),-C':3V%=?H>BF&U"SC+^IKI;3S9E&8DY
M]JM26^Q>1@^U,#RWQ%X<ES)(CC'7%><7<#02%&[5]"7&E?:E<,#BO(?&FEI8
MZBX3H*B2&CBWI ,FGOUI(_O5BQD@B)'2HWC*FM.! 5ID\7M4\P&914CKM:FF
MJ ;1110 4444 %%%% !1110 4444 %%%% !2YI** %J1&*\@U%10!8^T2#C=
M33(S'DU#10!=M&"7"FN_T.==JG(KSA6QS6_IFJ>6H4MBL*]/F6@F>BW-TOE]
M1TKG9Y\RM@U4;4O,7AJ@:X7DDUQPI.)-B2\F_='FN/NVW3-]:W;NX#(1FN=E
MYD:NVC&R*2(Z*7%)6PPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "I(?]:*CJ2'_6B@#ZC\(_\ (IZ;_P!<1_,T4>$?^13T
MW_KB/YFB@#P01*JY.*I-*%W 5)?3F-RM9!FS)U[T[DI$TC'=DU&Z[AFK1V-
M#GFH!T(I%%,\&FU-*,'-0T +BDI:2@ HHI10!O>&KR:.^1 YVY Q7LER/^)4
M&'#;!S^%>*^'ESJ*8_O"O:KKC1A_N#^5>-F"2J1,:FYP(UFYMM5V-(2A8#%=
MO<Z9;ZG8#,8W,HY_"O.3;3W>M81<X<$UZ=YT>G:<KRG 51G\J6-M'DY-Q2\C
MQ?54?2];DBC.-K8XKT_P5*UUI3-(=Q!KR[Q%=I>:[-(ARI;@UZ9\/_\ D#/_
M +U:XZ_U=-[Z%3^$P_&U]<6K_N9"OS=JS?"FOW$NIQ6URY=6/>K7CW_6#_>K
M)\):7<3ZU#,$_=CJ:NG&'U6\AI+E/0]=T"TOM/>58E#*I.:\6N83#<.GHQKW
M?5;V'3]*D65L$H0*\4Q]OU0KV+'^=1ETI<LK["IMV.J\'^%OM;^?.N4ZC-:_
MB[48M%@:TLU\N3&0175Z' MMHD(4 $)7EOC^=I=<'/\ #6=*;Q&(][9"3YI&
M&=<O_-W^>V<UZ'X0U&/5[9;>]'FNQZFO+54L:['P+*8]>A3/%=V+HQ=)M="Y
M+0TO%OAG[&?.@7"L<X':N+6YEMV^1RI!KW/6+=+C3)BPSA#BO"+Y#%=,O^T:
MRP%=U8.,N@J;NCV[0&\[1H&?EBG6N#\6ZM=67B'9#*57'05W7AO_ ) =O_N5
MYOXXC>3Q,509.*X\&D\1)/S)C\1WVAM;ZQIZB:,,P7DFN&\9Z*FGWCRP (@[
M"NX\)6CV6G"248!7-<EX\U2*>X>"-@:K#-K$M0V"/Q:#OAY=2RR3+(Q(!X_2
MNH\<RO:Z TD+;&SU%<G\.AB>;Z_X5U'Q"_Y%MOK2KI?7$@?QGFVF>(K^.^C#
MSL4+<BO6+:TL]:TSS9(0V1WKQ?3+.:ZOHUC7/S5[;H\7]F:,J3_+@5IF"C&S
MCHQU--CR#Q+IG]FW[;>%9N!5OP;=S#5E3>=N.E-\8:A'>WY$9SL:HO!W_(97
MZ5V.[P_O;V+^SJ>QWORZ-(XX;9G->/ZCJ4PN&#.37K^H?\@&3_KG7B&H\W;9
MKCRQ)\Q%,[;P->RSNZNQ(S73^,9FM=($D1VMGK7&_#\_OF_WJ[+QK"\^C!4&
M3NK+$)+%H4OB/+AK6I%V*3O@&NBTGQ"UW;-:W#$N%))/TJEIN@W":9=SS1XV
M\@US1N&MYV9.I&*]!PIU;I+8NR9<TZ58?$BRM]T2$UH^)/$MTVH21VTQ6,'C
M%<UYC;]_?-12LSON;J:V=&+FI/H5;4]9^'-U->Z?.UPY<AN":/B%=366FH\#
ME&W]14/PN_Y!MQ_O4?$S_D%1_P"__45Y%E]=MYF7VSE- \2W2W:17$Q96/.:
MR?$4JS:U/(GW2:S$8HP8=10S-(Q8]37L1HQC/G1K;6XVNT\":-]MOF:1<J!D
M9KD8(&GE6-!EC7J'AB\@TN"*)B!*>",5CC)R5-J.[)F]-"EXYTGR95EB7"*F
M#CZ5Q43@"O:/$-DNH:-( ,LRC%>)WJ&SNW@/!4UEE];GI\KW0H.Z$>5E?<IP
M17I?@.>2X!61MP"UY;NS7IWP\ZM_NU68)>Q;'/8D\=74UHC&%RGR]JXS0_$M
MW'>QI/*SJ[ 8KK?B']QO]VN!T/3;B\U"$Q)D*X)K+"Q@\/>0HVY=3V2]T2TU
M33Q^Z7>R@Y_"O%M7MC8:K-$O&QN*]U:XCTW35DE;"JHS^5>'>(+I;K6+B1#E
M2V0:SRV4G*2Z"IW.J\#Z^WVJ.SG8D,>IKO\ 6[/[7ILC1$#"'I7A%I=/9W"S
M1GYA7M_AG5(]3TN.,MEPOS"IQ]'V<E5B$U9W/%+^*6&Z=9<[LGK6CH%O,;E9
M(V(5#EJZ;QUX?873742?(!UJC&%T33 ^/FG7O7=&NJE)-;LJ]T-\2ZQ++/Y,
M<AV;>0*YKS#G)/-$LI=RS'/-5G;FMZ=-0C9%)61*YW5"PI5;UI36@R(TE/84
MR@ HHHH **** "EI*>J\T *BU.HR*:!BE9]HH 4\5&>:0/FE- $;#%-J4C(J
M/'- "44[%)B@!*2G8IM "T44H% "4Y#S1BI88MS4 :%FF[DUIKM%4(R(T&*<
MLI+4Q&G@%:A=2*="V5YI\F-M,1G3$^M9\Y-:$N,FJ<RY%)C1G,2325)(N*9V
MI#$HHHH ***.U #EJ]9HSL,55AC+-6W9HL2@FF)ERVBV@9JZ%XJHLP[5:B?(
MIDC'XS6=>3;5-:LH^4UCWB%LTAF/+,68\U7))J:9-K5!FD4)1110 4444 %/
M6F4]>E $T9^85N:>N_&:PX1N8 5O6G[J,$]:9+->) F.15H $<5D+<$M6I:M
MN7F@3$;(%9M[*0E:UP %-8UTN]30".>N92S&J9Y-6;E2'-5J18444M "444M
M "T4F:6@!15NT#/(H'K55%W'%;NF6H3#L*8F=)IL 2 %B*T49,X&*Q6N]J[0
M:EMK@LW6F2;A7*Y%4KG(!J[ =R<U!=&,#K02<9K+OD]<5SS'<QKM-2MTEC;'
M6N1N(#'(U(T1#&,R 5]9?#6/9H-N?6.OE" 9E%?6_P /%QX>M?\ KG2&=1>G
M%NQKRNZC,NIS$G(#5ZCJ;;;-C7EC3I]NN>?XJUIB9,T: \8 JJVHI;DBH+N_
M6*,MNKFSJ27%P4W\DXK4D[2SUE6(!-:J7*2CJ*XNWMBN&R:U8+I(1\S8Q2L,
MW9;>&9<.H(K)N-%M=V8X@":DCUNSW;3+6C;3PW'*MFBP%6PM#; 8%6W0D9J]
ML4#-1G!4@4K@5(\BK )-)''SS4APM%P&'.<U8A?)YJLS9IT1YXI,#0(!%0,
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M.G4VI%4L<"@ 5"QJ]%$$&320Q;!DTYFSP*!"LV>!0H[FA5]:BGE"\"@8V>;
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M:.?-)3F'--K(84444 %%%% !1110 4444 %%%% !1110 4HY-)3X0#,@/3-
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M2?@JFJVB3QZBN&7.!_\ JK%UGX;6FCW;6\VIQ@J<'/\ ^JO8_AFQ.B+D_P
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8#IFJS)S6;&144[;1MI -HIV*;0 4444 %%%% !1110 4444 %%%% !1110
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MNU^*MVKYX- C"NK<QR&JV.:Z._M!(FX#M6-':2/.$ /7TH&F:_A[33<3JY'
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MG5V&F0VIVQHO'<"MD1@+7%>%O$4FH2%9&)YKNG'R4TQ'%^+E40=>U>,:B/\
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M&1ST/>LS4K@2S, W -:^I2-!;,ASDC-<NQW-FA@@[T444B@HHHH 6DI>U)0
MH.*F0YJ+&5J2$9.* +$?/RFM'2=+>XN=Q4[5.:KVEE+/* G6NQL(Q86K%P=Q
M6F3<S=<D6" P*HK"+_9X20<%A5W49_M-T6/2L2\FWG:.@H&BO*YD?).:9112
M&%+244 %%%% !4T3\XJ+%*.&% %W:.M)Y/FL *L6J+, ,<UT%AH3,I<@4Q-F
M)M%O !_%264&^7>PX!JYJ=FT=TR'H#3&=;:V8=R*+ 5M4N@"8D/ ]*QF.33Y
MY#(Y)-1TAA1110 4444 &:EBE9.A(J*E'2@#?L1]K4+U-:<6E%#\PQ6!H]X+
M:Y!)X-=UYRW4(9/2F(S18)G&ZKD%B(6#!JBVLKY-2-<D+@&F(EO[@" )G)KG
MI,(I<U9N)&9LDUDZC= *44]12N-&==S;Y"!TJI3SDG-)WI#&TAI32&@!****
M %[4E%+0!8M92DJ\XYKMM.2*>W$G#'TK@03FNB\/Z@T<RQ,?EIB9TDC!./+%
M$2JW) J:95= ^/>JGG!3BF269CLB(!QQ63Y?S&1S^=:$C;D!K&U.]$4113S0
M-&9J=WO;8IX'%91I6<N[$]S3:10AI*4TAI )2TE% "U>L+CRI!D\51I0Q7!H
M Z>1%DC#+Z5!'E6J31G^UXA)Y/ KJH_#!5-[@8IDF1 AD3E<UH:98P"\W.%_
M$5,;98#L%210GS 1ZTQ(Z>ZCC2P.P#&VN2D=$D+<'-;UQ<EK7R5/)&*YZ6SE
M4[GZ4%,K32J%+L ,5R>J79FE8 \5KZQ>!!Y:GM7+R,6<FD)$=%+24BA:2BEH
M <#BM;3;DJ^TFLBI89"C@^],5CK)+;S1O'I5>/\ =RX]ZL:9<_:$$>>36M#H
M,LKERO!]J9+*4T:W%J00,FLC3=(:YU,(0=H85U<NG- P!Q5K2=.D%SNB0Y)]
M*0T=5;Z3%8Z1A,= <BN;%E=7MZR1HS8/:O2=+TB6YL-MP1@^O%1W%SHOAQ'D
MV?O<=01UH&<_IW@Y25FOF\E>^ZI=5\2:%X;M]ELMO/*!C..:XGQ?\2;VZ=X+
M6<B(CH:\UN;J2ZE:21LLQR: .L\0>/;W5)&$3/"A[*:Y">XFG8M)(SD^IJ(T
ME(9+!(8Y P.#FOJCX9:J+_1HX]V3&F*^4QUKV[X*ZSLEN(7;KP/TH ]YF3?$
MP]J^7O'MS>6&N39=PID..:^I.J_45X'\9]%*/#.B]3D_K33L!P>B^))A<JK,
M<?6O3].U 20QL#U%>%V /V@8]:]:\-HSP+NYP*V@[DLZF2](7 JHTTCGO4KP
MC=C%-/R"KL*XZ. R\EC39("A^\33X)B#UJ2<Y7-,+D(0NN ,U?M+3=U6J]K+
M'&H+@UHQWT2CBD,=)IB,.M0/;(I&% (K0CN%>/<.]4GD+3 ^]3<#S7QOILIE
M><1GDUP\#?.58X(->[:Y9Q7MAL(!8UP,7@H-? LJ[2U2T!DZ19W4TJE$;9V(
MKTK2-$#PAI6VD>M6+.QT_2[%8B '0>HKF-;\9_9)?*MG('3B@#JM4O;;2+3"
M.K.>*Y+3PU_J EEZ;N,US%SK-SJ<WSOD$UU6C),B+N//:J2N!Z-8QQFW5,#
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M$H;>.*,D\9 KR_QGI$=G,S*1DGI7HD%P(+Q7W#DYZU@>-;%;V#SHQEB<DT-
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MG>L^_B"3-M&!F@I%.BBBD,**** %[44E% #Q]VG1'#CZTP?=J:UB,DR@#/-
M'7Z$R+&KE0<5N75W;FW(+*"16=I5K'$BQLN#5#48296"D#!ID&1J4JJS!36(
MQRV:TKZ"1268@UFD4%(3O2TE%(8M)110 4M%%  *4T@I>M &CIDA$H &:[.V
MU'R(/FP.*Y32(0&5V4XKIIK)9[7<N.!31#,Z]N%N;AGXQ6!?S[FV@]*WXH(@
MA5L9 ]:YF]3;.P]Z!HJD4444B@HHHH **** "G#I3:<#0 JG:^179^')C+!M
M)[UQ@!+<5UOAU&B(SW--"9NW$#=A445F\G8UTD5LDD&YAVJ"!%$N!TS3$<MJ
MEL]M"6V]:XN:0O(2?6O7M7LX[FR88Y ->3ZA:M;7#*1CDTAHJYII-%%(84E+
M24 )112T )1110 M7M-?;=*:HCDXK;T?2Y9W#A3CZ4"9VUNT4MFHW#.VJ$EH
M3-@5';I)$VT]JU82,AC5$D\>D&2S8\Y"\5Y_KEM-!=,KJ<>]>G+JD<4>S/;U
MKF?$,<5ZK.HRQH&F>?TM231F.1E/8U%FI*$I#2T4 -I:,48H *2EQ1B@"]I=
MZUG=I(.QS7J.GZQ_:=DJX"GVKR%3@UU_A*Z=K@19X IH3.GFMV\S/-6($P*T
M&LW>,,!VJ".V<2$$?I3,[E/=(LZD+D"JFM:D$MRI4*U:MXDEM"T@!X'I7GVM
MW[S2-D]Z"D8][.9I6.>]4Z<QR:;4EB4&EI* $I:,48H 6C-&*<L;.<*I/T%
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MTG2D,NVC _*:F*_O<=JSX6*R U?7)^;K3$)>6VU=P]*SC6R6,T)%9$JE9"*
M&T4&@4A@:5%R<>M*15W3[5II<X. ?2@&:.G0BW@\\_>%";KNZ .<9I]\WECR
MDX&*N:3:_NWF.!M&>:HDMW[1Z=I3(K8DZUQHG9YV8]S6AK-^US,1GCI60IVM
MFDQHO.K=<<5'(NY:>DI=,$TX $$4@,\C!HJ29-KTP#B@8W-%+BB@!*444Y%+
M, * +-G!YLH!Z5JW3H(U1,=,&F6\/D6PD(P:9 AFN!QP331+9I:?#'';^=(<
M<5S]].9)VPV0#Q6KJDWD1?9U/2L!CDYH&C2LKG:FT^E&<N3ZUGQ.5/%7%8G%
M(&0W*?,354]:TY8BT>:S7&&H!#:*7K1B@84@I:4=>* )8(FED55&<FO4_"6@
M);0":5>>O(KF?".AF[N!(ZY7J,BO2+R9+*S\M."%% &1KUS&OR)CK7/I<,H*
M@9!J:[+W#EBP-9TS_9XV8GI5$L+_ %3[/%QUJEI^J&YS&YZFL._NFGF;GBH+
M6<P3!O2BX6.DNE(8X'%10OSBK2$7-JK#DXYJKL*R9H BU&V\R+<!7/N"&(-=
MDD?FQ8/I7.:I:&";@<4F-&=112BD,,4M%%  !FNI\):(U]>HS*=M86G6C7=T
MD:@G+8Z5[1X>TA-(TU9'4!AS0!+>-%IVGK$N =N*XV6YWR$UI:U>-<3, > :
MP9'$,9=J:$RAJ^H&./:#U%<NERZS;\G-6-0N3-,W/ -43UH!':VMPM[9@9Y1
M:IRH5.:RM)O#!*$)X8XKII;?S8_,7[M-"95M),_*:HZQ8Y)E45<1#&^/>KK0
MB>#::!7.'88.*2K5[;M#.P(XS5;O4EB48IV** &XJ6")II BC)S30I)P*]#\
M">$VOIDN)5!C([T")O#&EFSMFE>/YNHR*V&NYYI3&B9([5V=_IMI8::V$ 8+
M7"P7JV]Z\O.TC%4B6C5L)'6)ED&UCVI;I]D!.><5DS:LB!I.F*PI/% ENVC)
M.T]*=Q6$N[A_M!^8]:3 N(R&/&*;<)OPZ]^:2W;!VFD".4U2S^SSGC@UGXKL
M]4L#=H6C0LP'89I^@?#[4-5F4G"+U.\8_G29:.1M;*>\D$<,99CT KT'PW\-
M;B\*RWR/%&.<UW5KH&@^$;43WJ123*,_(XKD/$GQ.E?=!ICO%'T YZ4AG8--
MX=\(6N(I(99E'1EKS[Q+\1[K4"T,"B)!T*'%<3?:C=7\IDGDW$U3- $EQ=SW
M,A:65VSZG-0CDX]:,5IZ)IS7^H1Q@9^89H Z/P;I!>YCN)$^4'O7=WE^8E,4
M:#'2NGT[PO;Z;H@)10Q4']*X^^EAAO2"N0#5(EE*UA:2_7S%QFNK$IM;8[?2
ML*2^M3<I/&NU5&#FL2[\7*UV8 QVYQ3(L/U>^=[@MDTVQF\WY6/!XJ*\5)DW
MKW%4[64QRXS0,@\3Z.BHTT?I7%LI!P>U>GW,;7=H58YS7 :G:-;W#9'&:EE)
MF=BDI^*0BD4-H-%% #H7:.164XP:^GOA;KXU'2Q S9,2 5\O]Z]E^#:78GF(
M)"$^GTH ][N8%GB9&&017S#\1]"?2M7:4*0)7)KZE4?*/I7F?Q5\/"_T[[0J
M9,2Y-- >!Z/K4MA<*0QP/>O6]'\4B:V3:^3CFO"I,QRD'C!K6T;59X+A$5S@
MFK4A6/?[6_EN6![5L12#;R:YCPQ)YFGI+)SFM.5IMQ*9 ^E:6$;L4REL9J=7
M# BN4^V3PG)W?E4\6JNGW@QS[4K :=Y#&Q8L!BN:FB21V  ZT:WKC);$IN!^
ME<QI_BF%Y720G.>YJEH!T,>FKNW; ??%:L5DL:CL:RHM?M@@&1^=2/X@@Z[A
M@>]%P-RS?;,48\5K1P@\UYI>^* DV86(YKL_"VN+J=N=V21QS4,"[JTGDVV?
M6N74EF/N:Z'Q0=MDI7UKF;.9) 1D9SZU4 9H1,JCFICTXK/FW C:1UJS&Y$?
MS&J$9.K7WV8<M@9KGYM>3L0:B\7WXY16Y!KBHYG;.3WJ;C.IGUX,0N1UILM[
M)(-V.,5S(4M,#@]:W&D M\8/2O.Q5G("Q:ZQ*DZJ.>:](TG546RS,0@[FO,_
M#EI]LU)@RY .:ZOQ*PL=.98^#M'\J[*2M! 5?%6OQ2-Y<3A\&N=@O//7)-8X
MW3R;G.<UHQ0B*+C%<N*47:P&E"&D< <X-:GEG;C;6;HLBR3.I/2N@$>1UKS*
MC:=B&M3DM2NC$64'%+H-RYE$>-V3WJKK^U+@]^:T_!\4<ETCLO?O7K86$>2Y
M21V]II4>Q)6&"W.*WK>$1H%453B#<#.5'2M>T4'!(KI5-1U&30PJ@W-WI[LK
M<<4UV).T=*0Q'U%,0 #UJO<$#L#4N".,U R,ST#*ESI$-_$1(H''I7.MX1A@
MN]RC(^E=INV1X]JJNY)S30%2T\/V]O%O!&2,]*MB%4CQTJ:-R5P:CGW <4P*
M<EP((WKBM=U#)8;JZ#5#+Y3E0>!Z5YCK5](L[*V1^%%P$N+O+=:W/"S^9>+S
MVKBUE>=P%SS7?>$=*G4K,1QCTI(#J/$,NS2V53U2O$-4BD-PSD'%>S:[;SR6
M^T9/'I7GE[8LJD21L?PI- <QI<S17\;>AKVGP_JQ:W0D\UY):V):]4*N/F]*
M]/T&P81H,=*<4#.S_M-E0<=JH7^MQ+$-S '-3FVS&![5R?C"U-MIWF)@'-,#
M=M=7M[UMJRC/2N@MITAC #9KYUM]?NK&[RLA !KU/PYK9O[.-Y) 6(YR:2:8
M'>&8-R:C,JL<9K&EU2.-,9Y^M5/[3.[()IV W9^>*H2VB2#D<TV.^\P YJRE
MQ&W ZTP,WS6T[[HJA?Z]++'Y8&,\<5L3HDT@5AG-0#2+;?N9 : .=LK>3?YA
M=LYSUKJK&/:@=V---C#&1M  I\BG8 K "@"S)=J@Q'@FJHD:9_G.!4<>P'G!
M-5;JX=6PF>OI36V@&C(8HQR14&U9&!6LV3SY%W%N*6WFEC)'/Y4 =%;S+&G)
MYJ.YU'MFLM'D;GFGF R=:5@+*ZALC)!YJI<:C.XPN?SIZV#FK*:=A<G%%@.9
MO;^Y4%<'\Z@6]9(M\KD#'<UOWE@G)<9KS?Q5J31$PQ9&.#0W9 0>)?$(DW11
M/D>QKAII3(Q)/6G3R.[$M58GFL92N4(>M)2TE0 4444 %%%% !1110 4444
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M5E-BH3GFL:W?#5?R>.>*9+(+V%OO@<&L\UNR_O(,>@K%D7:QH&F1TN**6D,
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MJO'%(Q( (_"G<9!/$9E*]ZYG4? W]H;I"&SUKLK?2KN2X#;QMK96V>"([F'
MI-@?-/B?PZVCW#(0>/6N5=.:]6^)TJMJ#@=<5YW8V37<V,< UE-I*[&9BP.W
M04YK611DK7<V^AQQJ,J,T^?28BGW17+]85R>='G^RDVUL:KIYMV)4<5EK!*W
M16/X5O&2:N4F1[:0C%6#:S 9*-^50,K \BF,;12XI* "BBB@ HHHH **** "
MBBB@ HHHH **** "I(?]:*CJ2'_6B@#ZC\(_\BGIO_7$?S-%'A'_ )%/3?\
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MP+@%>#BMV\*Z=9,YP'%<!>3FXN'<GJ:3*B52<G-%&*,4BPHHQ1B@ HZ44=J
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ML*RE8R.:H:S.1=,%/%8[.6J:5%6N)(=)(9&))J$]:4&D/6NDH2BBB@ HHHH
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MQ\#V\9\V4, #78+&%<Y%<WXKUTV"&*,D9':FP(;^?3=+AVJXW+ZBN6N/&%P
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M,C*1@U,HV I44N*2I **** "BBB@ HHHH **** "BBB@ J2'_6BHZDA_UHH
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M/HHHI#"EQ2"G"@ Q5S3K5KFY5 ,\U4 )/%=+H$'DR"5Q[TQ,WI;#[#8X<8)
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M&:L;;EQ[5EWD>R3CO6I&A5L]C45_$"NX#M3(V9C&FTYA3:18HI.]*#3HTWR
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MZ=ZPM0FEMYB1G%+;ZA*P^ZV.]:6 T]2*31,I]*\1\8VZ)='8._->H:KJ.U&
M;!K@-1@%X9"W)]:EK0#SAQAJ;6EJ-BT,[  G%4O(?^Z:QL4145)Y+_W332A'
M6D VBEQ24 %%%% !112[30 H7-=/X4\)W>OW:"&/<F<&F^%?"]UKM\B+&X0$
M$G%?3GA'PG:Z%8(HC4R$ YH =HN@26&C6MJRX,2;2**ZD#BB@#XAAC\R?%=+
M;,(8PH[BJ.FZ<['S2IVD5HK#NF5>F#31+9HJXCM/-;N*XJ_N&GN&)/ /%=!K
M5T8+7R%/(-<HS$DD]Z;!(2@4E**DH=2QMM<'TIM&* .AMI1+;J!U%+(!)$PJ
MAIDP#;2>U:3KM8>AJD2<_<+L<BH*TM0BP2WK6;BI*0E7]+BWSJ3T!JB 2P%;
MNFV^Q,T"9LB8(JH#Q4=_J2VUJT<1Y/-5+ARBYK"NKAI7Y-42E<BFE,LA<]33
M!3>]+FI+'4E%(>M #E.&!':MVRN2\6TFL"M'2I!]I56.!30FCIK*<!MK'@UG
M^(K,<SJ. *L%=K!E/>IKN-KK3V3J339*.)-(*EGC,<K*1T--B3>VT5)9O:!;
M[I"Q'TKJ78J,=JR]'188@2.HJY?3J(C\P6J1#W.>UJX^; -8).:L7DI>=^<\
MU5I,I(6D/6B@FD,*0=:** ->RE+KMK4@D9!L/I6/H\JQW"AP"">]='?%#\R*
M /:FB&<UJ4.V3<.]9W:N@O+8RQ%O05@E"'VTF4F7M,MS+.K8X!KII&\N/8.U
M9^C0^4A9A6@\BM*>.*:)>Y1N) L9/>N>G<O(6-:FJSC.U3U]*QC0RD+2$TE%
M(8444E !5NQDV3<U4I\;;7!]Z .G=EW(5Z8JKJ-N'A#*.:DM9A+!]W)%:,,(
MGBV,,51&S.6M8B\PR. :Z&,%8E"T'35MI1R"#S5B% \FT=!0-DUC$Q8.X^45
MF^(-0! A0]#6MJ%REG:D+C.*XFYF,TS,3UH$D0EN:;0:*DL2BBB@ I0<,**3
MO0!I6[Y&:U4B\^$CVK&LW&<&MFVEV\>M-$O<Q;FW,4I!%:FDV>]LXI]W:F;E
M1DUI6%NT,.2".*8-EBX=8(2K5R5[*#*V/6M/5KQMY&36 \A9C281&D\TTF@T
ME(H***6@!IYJQ:SF)Q]:@H'7- '1PS>8=QJ.^C\Q-RCI4&G/N4 UN1Q+-;NN
MT9Q3).0(P:*M7UOY$Q%5!DL*"BS;1[VK>LXPHYK/L+<D XK8B7:O--$-DUQ.
ML-MP>:Y*\F,LQ.>]:6J76,H#6(QR<T,:5A#UI**6I*#%%+0: )+>4PS*X/0B
MO3=!U%-2L_+8Y/2O+:W/#NI-:7L8+87/--">QW\D)LI]P& 34L\L=QM"GC'-
M5[VZ%Q;JZ\Y]*SXY74\YIF>QGS>'I;C5E9$RK.*]\\':-%I6GH-N&(!K@/#F
MVZF13#D@CFO2[F":'3]T;$$*.!2L%[LJ^+-82"UV*W/2O)+F9KBX//4FM;7Y
M[IYF61F//>N9NI_LEL\C?>% ]V8GB'4"!Y*GD'!KE2<G-6;ZX-S<NY/4U5H9
M:"@]*2@T@&TTTI--)H&=5X1UAK&\V%L!SBO0M4C:Z3SE'&*\9MI3#.C@]#FO
M7O#-VNJZ0$9QO/%4B)(RK=W65D/K5+7[(2VS-CYJTKI/LEXP(S\U6I(H[JQ+
M$C/I38)GE,B[)"I[&KNE:?+J-VL,:Y)-/U6S:*[; ^\W%>I?"KPL)VBO95X]
M"*D=ST3P3X<CT72%F*8=TR>*S_%.IM.SP*U=EJ4J66F,H( "<5XSK5^\ETS!
MC31+*<SE7;)[\UR'B3406:W5JW;VZ%O;.SGYB.,UP%Y<&YG,AI,<45VYYIAI
MU--(L;1124 '.<BNZ\%:L$E%O*WRA>*X:K=A=-:W*.I(Y%-"9ZCJ$+JXDQP>
M16II<4=[:K'_ !@9-5XY8]3TA)$(W(@SBLRQOGLKAL$CC%5:YFG9C?$FFK+$
MV!RHQ7 PV;&^2''\0'ZUZ?$ZZ@Q1C]XU/9^#81J N'D4#(.#18KF/0OA_H<>
MF:2KE<%@#TI?%>J'!AC;D'FM!-6M;+351'3**!P:X'6-0^U73R \&D2Y$8OY
M,^5QANM<KXJU5;: QJWS=#6Q-<):VDDSD9'(S7F&N:BU[>N<_*3Q3815S*GD
M,DC,>YJ&GGFF5!JA#3D.&S244 >@>"=9V8M9&^\:Z;4;<LYD4<=:\FT^Z>TN
M5D4D8KU.PO/[0TM,-\P7)JD926HZQE:=?+7ELU1\0:;Y]L05^91FK6@SK;:P
MGFC*Y.<UTNO00/;^;&5/F=A3!,\)EA,<Q3'>O0/ GA-[ZY2:6/*Y!%4&\/FX
MUA !\IKWGPAHL5EIT1"C.VD#=W8VK&UBTNP  P !7%^(-4\V9E5N%-=3XBO!
M;V3J&P<5Y7>7;&9R<D&A!)]".^U,JI&?W?>O,?$&I-=7#(&X4\5T7B/4A# \
M:GYC7 RN9'+$]:&RHHB[T4II*DL6I%-0U(O2@#K_  EJ_P!FNDB=OEKOKNPF
MN;<3HN5(SFO&;>9H)0R]17L_A77([O2'B< LJ8YIHSDC*MHF\W8.M-UFP-S9
MMN7E5XJP\H@U'>1@>E='/;Q7=@&0#[O.*9)X1<P&&4HPJ(+DX%=/XGTSR+IY
M%'RU4\-Z1)J>IQ($)7=@TK&E]#L/AOX3>_O([F2/*'VKW*]E&F:8(TXVIBH?
M"^B0Z/IB(% 8#K61XFOC+((T.1T.*$2SF+W4#<2LY;DUB7E]]GADD8].E3W:
MLLA SQ7%>*=4V 1(>HP<4R4M3G]<U-KZ\=LY4UD [3D'FFLQ)S14FJ/2/ /C
MV?1;F.">3$ P!DU]&:-J\&JVB2Q-G(R:^+U)4@@X(KTCP!X\FTFZCM[AV>-C
MU8\"@9])7MG%>0-'(H((/:O'?%?@66TNC<6D?R9W-7K6E:M;ZI:)-#(K;NP-
M6KBVBN8RLB!@?6FG8#R/P] \=N@D["MR9E"8K8U#0OL[&6'A3_"*Q7C/(-;Q
M=R3*N3\KGVKS370;S40%Y[5ZM<Q+Y)!QR*Y4:*ANO-.#S5-7 J^']'6")977
MJ*Z14Y'H*(U2*-5X&*F4BFM!,D0 #BI@S+4&X"GK(#P: +"R5-')54$8H$FT
MYI6&7R^!3!(3TJC+=#9][%9,NO):M@D&D!TI; YJ$[?O^E<M)XK4]$IJ^(O-
M&T+C- '4><IXJ-YU1>O-8T6HDKG;FAIWF;H0*!%U[YSD*:I2N\C9-6(HLCFI
M&MMW2F!0*ML)]*YS59SYA!KLQ9G8W/:N>U/1GF)8$T,9Q%W( <BJ:S$-FKNJ
M:9<02=&(S4=CI=Q<RA=C5F!Z%X"N3N8&O4U^8"N&\&Z&;./<YY([UW2J<X%#
M &3(%-\KBK&WB@"DQC1& M C!I6IRMQ2 8PVJ:H$%ILXK0DY%0[ .<4(!H!V
MU3NU"KEJO_I5*[B,BD U2$8\@WRJ!5W[&!#N[XI(+7#$L>E0WEQ)%N55)&.U
M,#C?$OB$6#&'=C-<#=:Z97)#9S78ZIX8NM:N]QW(,^E6],^':0,&E8./0BB[
M Y/PY//=:C$0/ES7LR7B66F*S'! -0Z7X?LK0 K;(".X%0^)K*26P*PY'7@4
M@//_ !/XP,KM'')QTZUY[=ZD\K$ELYK1U73;N.Y?=&[<GM52PT6>\N@C1LHR
M.U+5@4HK>XO6^09K>T[P;>W6#Y?%=[H_A:&"%<JI./2NIM+*.V  44U$#E-%
M\+OI4>]TP1S3M;NV2W8*>2*["Z(,1 %<CJEJTF[BK$>4ZHLAE9F]35>RL9;E
MUV@XS78W6C-.2-GZ5?TS0OLX!*U'*VQD>D:4+: ;@<]:WX8/E&*EBM< "KD4
M'2M%H!76';S6-JZ$*<=ZZW[+\F:P=1AW. 1T-#U YBPTTSW >0<9KK;**UBP
MC'I6/?3)86C.N 17"77B.X^U$K(P /8U%U$+'N-K#;,P*5K)F,#97E?A3Q,9
MF2.1^3ZFO2;6[61%((.:J]PL:/VC8=S4YTBND^8#GVJMQ(V#5J(Q0C+R  >M
M2T!AZEX;BD4E%K"E\/MO4%>%KMY=5LC\OGQD^F:J,T;_ #*00::8%72XOLEL
M(P,5;D_>$>U5I;A(AR0*JC58?,"AQR:8&_!:"6/YZL)8[3P.*J6%T& 7=FM1
M']ZB5[@ B6-.:P=>U*.PA+AL8&:U[N0X(SBO*O&^K881*^>QI),"1_$4FHMB
M,@Y-:L5W):V;-+@9'%>:6>H&W .*N7OB&26WVY(P*OFL@+^IZNLLY!:JP)\L
MLO0]:XNYOI'D)#&A=5G5=N]JGG'8WKB.*:YVMU-;-OX5AFC5BO49KFM$$EW?
M L2:]0@S'#& O:JBDQ',R>$;>-"2O:N'UG3UM)B%'&:]5O9'8E1D5P_B&R9_
MGP>*4H60(X=NM-J69=KD5%6+*"BBG*,G%(!HZUT_A?PS=:]>QQQQY0G!J3PO
MX2NM<O458W$>0=V.*^EO"7A"TT&R0>6AD(!W8Y% #/!WA&W\/6,?[O$V,'(K
MKE..O%-=TB0LQ  &>:\O\=_$./3F-M:L&8C[RGI0!ZKD45QGA_5YKO0+*X=F
M+21Y.:* /#X98[>Q6+^(4D-L?*DN,<+S5-09;C;4^JWXLK!H1U=:HSZG):Q=
M&:]?!XK-)ISL7;)ZTVI-!*6D[44 +FES3>U+0!)&^Q@1ZUM13M*H8GH*P16A
M9RX&#0)FE<6_G6^0*P'7:Y'O73VT@92F.U8M_;E)\ =>:8DR&S@,LF,5TD*"
M) *S].MBB!B.M7I'VH<TP>Y0U&X & :PV))S5J]EWR&JF:D:&]Z=2=Z6@8X4
M8H%+0 F*=&Y1LBFT4".LLI8YK=1U8"M2U&3CM7-Z%=+'(RO@YZ9KI,_O R=/
M:F2SF=>L6@F\S'#FH]&L//E5F'%=7JEHM];(,<J*HV%M]E3'?- [Z$I3ROE7
MM6+J]TPRA-;TSI'$S.1G'>N.U.?SKDD=*!1*6XDFDS1BEQ2+$HHI: $HHH-
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M%.%1#U]*0R'.*0R1J:644WD]Z3RR>] A=^:<,8I!'BEH :PIACSUJ8"GX&*
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MD$=ZEG1%Z"4"BEI#%%+24M !249I: $JS96KW=RL2#):JX'-==X/M$^V1SR
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M'K6;JT/RAP.IIL$9%%+12&+2BD%+0 &K5I'OD'UJMC)K6L(B.<4(3-NV55B
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M2Z9",50J34**** $Q2&G4V@8VI(4,DJJ.YIF,FNE\.Z'+=2><5.U#F@3/1_
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MLP\6:<1 ;A1U-<.W!Q7IMY*-2T_RL#C)KSB[C,5PZD=#29<2O11104%%%(*
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MQ3=H&KK;*PALTVQK@588K&,]!6+JOBG3M+B8R7*!@.AJ&VPL;CNJ+EF ^IK
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MXC%.5(I,(LAHHHI%@*U])@WRAL<5DJ,L*Z72DV0*>] F;=LI!'M537KK9:E
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M.PSAGMYUEPV3@^E7(5.1D5T[V\3_ ,(_*JSZ<N,BJYQ6,U1@4I -2R6LD9.
M34.UA]X8HN \8 I>M19.:D4XI@.-)VIK.H[THY% #Q2-@"EQQ43@YH "V[@4
MS[-SN-21KBIOPH$4C&<X[4[:B#D59P*AE7TIW&<CXMM!=VK>4OS 5X]<V=U:
MSG<K<>U?0KVJE3N4'/K6)J7A^VN(RVQ<GVH3$>5:->R0R#;D'/I7HNAZS<R2
M*DA8CZ53B\))%-Y@' .>E=)I\$%O@;5R/:J8'20$/$I/I3)F5>U1)+\HQ3P
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MGI^%;GI7E5_=-<3LQ.>:1<5<K.2S$FDINZES4F@Z@TTFDS0 &DHHH 2EHH%
M%W3KI[6X5U;'/->K:5G6=-WJ<MP*\=#8->A_#W7EM+J.WE(V$\YIW)EL=UH6
MC'SW5UY%=(EEY9VLO%6M!1+F[>50-K<C%;NI6R1Q[P.@JC*SM<X+6-#:5-T0
MKE'TN2W8EQ^E>Q6MJDR<C-<9X_GM=+L)2"HD X&*945='D?B/40@\I#R.#7'
MLV3FK&H737-U(Y/!-4\U#9HD+0PXI**0PHHHQ0 E*.M&* * .F\-:Q)8S>4'
MP)#BNSGAN+@>?&>*\L@D,4RN.QKW#P,UKJFCHDK#S/2J1$D9%I<71E5)GR <
M 5UD,'FVV5'-16_A\S7S;%)4-741:;]CB (_.J,T>8:M:3+,<@]?2J B\B#S
M&XX[UZU=:%'=QE]HX'I7D'CNX_L^:2S3@J:5RHZLXS6;XW$Y&>%.*QS3W8LQ
M)[U'FI9J+1WHH%(!*6BB@!*6BB@ !(->@^ =01[HP3,-H7C)KSWI5[3+B2&Z
M5HR0<CH::$]CVZ^TM6NXECP0PSQ77:1H;6]JC-CD5QWAFXDN($FE&2@'6NK_
M .$B9%\H <52,+V-&XT*.]A88&:X[6](CTF&1VVC@XYKK;+7L(2V!S7F/Q+\
M3&9##&1P>U%RD[GFVN7WVJ[;!X!(K'-*[EW)/<TRI9K86DI:*0PI*6B@!*<C
M%6!':DH% 'I7@?Q+Y2I:2L=I/2MW4'1K@3(.,YKR2QNGM9U=3C%>J:&K:O9K
MM^9E7FKN9S1N0^(8AI9MR#NJ-="M]4VRE 3UK)NM/DMWVD'-=;X<@;R_GR.*
M=B%H<]J6GK89C5<**P1$9)OQKT3Q%IQGB8(.:Y"6R-K$[N,;1FD.^ID:K?FP
ML6"M@UYS=SF>=W)SDYK7\0ZB9[IE4_+6 3DU+-$A*6BDI%"TE+10 HI]1TN:
M .Q\':\;"[",QV8QBNKU&=;G$BC.>:\I@E,4BL#WKU/PK'_;%MM'+*,4T1)&
MKX?NK:/"3*3Q6C=:/'J"-(H&T=JR[W2I=/DY!7!KH_#BFX'EL3SQ5&:.:EC^
MPP>2!@+6&299_P :]3UKPEYL;.FZN'DT@V,K%P1@]Z!N]RG-/%861=AS@BO,
M=4O#=W3L3G!.*Z7Q7JFYF@1NA[5QI^8YI,T2&T445)0HIV13** ),T4VES0
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M-_.9KEV)[UV'BS4,,\2GBN'<Y;/K4LVCL(*D IJBGBI+#%!I:* &XI<4HI:
M$'!S7>>#+PE3!N^\<5P=:_A^[:VU&(@]ZI$R5ST>Z@>&\;@XSV%:$=F9(=X0
M@@>E;&G6"ZG917##ECS6S>PVUE9;01NV^E,R3MH>.^+8W%O@]C7GK_>/UKUO
MQ-"MQ:LPZUY/<)MF<>YJ6:0V(>]+112+"BBB@ HHHQ0 44H%+B@!*T=&=EU"
M,KUK/QFNH\'Z2;W4XF(.W/--">Q]!>$IHH-(AD?[Q7FI-7UZ-R8U/ZUCQQM:
MV*1*3@#%8UQ#*[E@2?QJ[&70["'65@LV<-T7->&_$/Q'/J.J-'O.PC&#7?R3
MND!C)/(QUKRWQ99L+QI<'&*3*AV.5HHHJ#0**** %I:*7% "8HQ3J* $KM?!
M>HW-O<1I&Y"UQB*6<*.]>B^"=(9Y8V*TT1+8]RT98H;%9GQN9<GFHKN_2>8J
M#Q]:H2)*EDBKGA?6L4S.DG)-69G4W&IQV>GR,3T6OG/QSJ/V_7YI5/!KU?7+
M\M8/&K<LN*\/UJ-TOW#9S[TF5 S324M)4&H4M%+0 E+2XHH ;13J3% "8SQ7
M1>'-+:[NE&W/(K%M(#/,J@9S7JOA33$LHDF<8R.]-(F3.UTK2/LVGA5 !(%5
MYK0QREB.:U;"]WX Q@58N(O.R56K,FC">01PD=Z\G\:JYF9^Q:O2]7<PL1TK
MB_$M@UU8JZC)ZU+*@>:]Z6G2(4=E(Z&FU)J%+12XH 3%)3J,4 ,I:7%)0 ZO
M0? 'B*/3YW28DAN!7GM7-/WB[CV$Y+=C3$UH?02K#J]XKH!M([UT0LEM(%*%
M1@<\UQ?AMI8-.61@=PQUK4?67.Y6-68G10*ER/GP:\V^(FHQ6,?E0D MP<&N
MD&KM;6Y8'FO%?%6IRWVI2[R<!N.:3*BCGII#(Y)/.:92FDJ#4**7%)B@ HI<
M4E !1110 JGFNW\!:^-+OT5V.UFYKA^]3VLC1S*5)SF@3/HS4[NVUA-\0ZGU
MJ;2$%E<1YXYKD/!PN)K&.0@D$=S712SND@[$59CLSU"!X[FW!X(-><_$4V]A
M9R%<!RN1S6CI_B%K>WVL>@KRSXD>(6OYP@;C&.#2+YNAYK>W#7%PTC'.:K"G
M&@4F:#:2G$<TA%(!**** #-&:2B@ S2TE+0!UOA#6IK*\5 Y 8@5]&>%Y-]L
MDC'D@&OEO0H))]1B$8)PXKZ)TZXN+'3H_EQA1_*K6QE)6=SK=56.1.H_.LNV
M>*",NQ P?6N<NM>F9\&LO7-:>/1Y=A^;ZTT3NSB/B/XB>]O&MD?*HU><-R:O
M:G.]Q?2.Y))/K5$U#-4AM%+24BA0:7--HH 6EIM':@!2:DMXFEE" 9S46,UU
M_A#1#=7*3.IV4">AZ7\/]!CM+3S9%&7&178:A897<!D5GZ6CPP(B+PHQ7169
M:X 1A5F-[G*W+?9H6!XXKS+Q= ;F)Y0.:]<\4V BA#+Z5Y]-;"[@:,C- UN>
M1NFUR/2F]*U-:L'LKMLK@$\5EFH-A Q!X-6(KZ>$YC?%5J* ->'Q-JEO_J[@
MBM&W\?Z_">+UL5R]'>@#NX?BCK\9&;UOUK4M_B_J: >;<.WX&O,** /8H/C1
M*N-[R'\#71:-\6X;Z8(V_/OFOGL"MWPU%++J*A >HIH3/JC3/$,=Z@89 /K6
MI)J$:)NR/SKSO3FFM;%.,?**4ZO+OVD_K3L9N9V\FOPQJ2>U<CK?Q/LM*<AE
M8X/:LK4[X_9VPQR17D/BF5WD8DGKZT-#4M3U)_C98]HY?UJO)\;+?^%91^!K
MPHL:3)J30]HF^-.?N&0?@:SI_C'>N/W<T@_ UY1FDH ]#N/BOKDF=EVX'T-9
M<_Q&\03?\OK?K7(T4 ;DWB_6I_OW1.:HRZM>3_ZR4FJ-.% $ZSR;]V[FO:/!
M/B&WN-/CM90695Q7B0KL_ LC?VD%).W(IHF6Q]%>'H8S#N"XYJQ=PB.8D#J:
MI6M_#8VR;7'W144VM1S-PPJC)NZL7WM8Y(]S 5XG\2[R!6$47!!P>:]7O-7$
M-DS BOGGQE=M<ZG*Q8D%O6ACB<JYRQ--I2**@V$HHHH ***44 *!2XHQ2T "
MG!KT[X<7.ZY"N<@&O,@#7I7PWT^1YVD(( .:J),MCW0ZHEJNT< 5$-36=AS6
M1?PEH\J3FLJ.X>W8[B15&5[EWQEK;6.CLT;8/(XKYQU2\>[O)7<Y)8FO9?%,
M_P!NL60'->*7T1BN9 ?[U2RX%7-&:0&BI- I:*6@ I:,4N* &XI:7%*!S0!O
M>%[YK?44&>"0*^G?#<L?]G(XP/E!KYH\)Z4]]J2A0< @\5]$:7;/;:>B*2?E
M'>K6Q$C>NKE&XS69>ZLEC9R.>WI5":21)#NS^=9&JR?:(&C)QD4S.^IW.G:D
M+C3X9AGYUS15+1H FCVJ@GA**@U1\A/_ *PTTBG2?ZPTTFD4-Z5:L9?*ND;T
M-533TZYS0!]#^#?L>JZ'''(JLX4GK[5HV+VFE^=&R?*6KR[P!KCV<VS?QMQ@
MFNDU/5WD?([U:,&M31U*:![J25!A,9%>6^+-4-U=!0V0O%=1?ZD_V$@=<&O-
M[R1I+ABWK4LN*ZE;WI*=24BQIIII]-- QHHI:* "GQDJV:93A0![3\-)H+I#
M#*1]W')KT%;2#3-1C8* F,FOGWPAJS:?J2'>0"P[U[G?:I!?Z2)$D_>;1T^E
M4C!JS%\3-8S6^Y$&YN^:\MU1Q96LD@."#Q727%\S*48GCWK@O$]V[%D_A(H'
M%79RMW.T]PSDYR:@-*>M(:DV&TG>EHH **2EH ;WIPZ4E.% #EZUU_A379;&
M58PY KCQUK0TQ6>Z4"FB9*Z/80RW$8N'(8XS562^$K%1P*K6,JBR5-QSMQ56
MYBDCC+@51G:QR?BO43/*L8/W3BN5K4U5'-PY.>M99J6:H****0PHHHH ***4
M4 **GMF*S*1ZBH*N6$)DF IH3/9O!^J0QZ?LEZD#%4];N/,O)#&>#7-V4KQ*
MH!(P/6K\EQE,L>35&5C UVV,REQV%<=(NUR#7?R*)HW4]ZXW5+8PW#<<4F:1
M9G4M%)4E"TE%% "@4[%-'6GT (*6BB@"Q:$^>N.M>C^'M1FM$4;B PQ7GVEQ
M;[Q,]*[NS0'8J]CS5(SF=%?W$1&YERV.M<UJD7VR!@.@'%:NI20I;_?^;%9U
MO,K*0>XH)1YU>0&&8J1WJN.M=)XBLMLID4<8KF^]2:H#UIPIIZTX4#'T4@I:
M $HI:*!"5:L21.I'K56KVFQ[IA]: /4-&$<VCKN(W^YH3?&SINX/%9>F[HU
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MI*6DH&%%%)0 4444 )1112*"BBBF E%%% !24M)28PHHHI %-IU--,84444
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M)2TE PHHH[T )1110 E%%%(84444#$HHHI@%)2TE)C"BBBD 4VG4VF,****
M"FT[M24 )1110,2BBBF,2DI:2D,*0TM(: "BBBD,*0TM(: $HHHH&%%%% "&
MDIQI* "BDHH #24M)0 E)2]J2@84444 %':BD- PHHHH *.U%+0 E%%% PHH
MHH&!I*6BD E%%% !24M)04%%%% !24M% "4444@"FGK3J:>M !1113&%%%%
M!2]J2@T )2TE% PHHHH #24M)0 4444AB&BBBF(****3 *2CO10,**** "BB
MB@ HHHH 2BBB@ HHHH&%%%% !1110 4444 %%%% !24M!H 2BBB@ HHHH *2
MEI* "BBB@ HHHH 2DI:2@84444 %%%% !1110 4444 )1110 4444 %%%%(
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M8_ VL2C*Q UCW.E7-K?M9RKB5>HH I45TMOX(UFYB$D<(*XIC>"M7$FPQ#-
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MJ>5/M7!NAC=D88*G!H ;1110(2DKJ!X?B_L>.ZP<LN:YAAAV'H<5G"I&=[=
M3N)10!DXK<TWPGJ>JP^;:QAESBM!F'16YJ/A74]+3?<Q[0:R(+=[B81(,L:
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M!H/6BNXS/8/A3BY6Y$WSA5XSVK#\?W\^G^+0L#,J;?NK6[\(O^7K_=I/%O\
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MNM)\-Y';6]A8E>.*Y+4!C4;D)]WS&Q^==7\-_P#D/?E03U/3_B:?LFEJUO\
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MU--,84444 %!HI*$-!1113& Y(%>D>'E%M\/]0;^+.0?SKS8<$&O2?#S"Y\
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M#7B,?CO4[:;S867=G/2LG5_$-_K+;KI\\YX- )E;5+QKZ^DE8]6./SJC2TE
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M<]$8_A32K+U4CZB@!M%!IP1R,A&/T%(8VBE*L.JD?A2A'/16/X4A$=%.*/\
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M^R8@"?3_ .O6[\;;QW\6",'Y?+Z?E7EX5CT!/T% 'J]Q!I.I>#I=0C6&.<'
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M# 'KDCK^58\U_H-I"RVD3+*1U]Z8K')O&\;8<8/I3*EN)WN)2[G-14 %%%%
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MH **** "D-+2&@ HHHH ****!A1110 4444 %%%% !24M)0 4IHH- "4444
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ME3DF<N1S76:#8^18B_'WNF*SQ:VM[J$4$ " -ALGK6YK<$^DV7D6\\?ECLK
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M IM.IM,84444 %)2TE "44M(:!H2BBB@8E)2TE PI#2TAH ****0PI#2TAH
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M0 4AI:* $HHHH ****!A1110 4444 %%%% !24M)0 O:DHHH **** "BBB@
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M114@%)2TE PHHHI@%)2TE!04444 %%%)0 4444@"FGK3J:>M !1113&%%%%
M!110:!B4444 %%%% !24M)2 ****!B&BBBF(**** "@T4&D E%%% PHHHH *
M*** $HHHH ****!A1110 4444 %%%% !24M)0 M)2]Z2@ HHHH **** "DI:
M2@ HHHH **** $I*6DH&%%%% !1110 4444 %%%% "4444 %%%% !1110 4E
M+2&@ HI*6@ HHHH **** "BBB@ I#2TAH 2BBBD,*:>M.IIZT %%%% !1110
M 4444 %%%% !1110 4444 %%%% !2-2TC4 -HHHH&%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !4D/\ K14=20_ZT4 ?4?A'_D4]
M-_ZXC^9HH\(_\BGIO_7$?S-% 'BU)2TE;'SH4TT[M333 ****!A24M!H0T)1
M113&)2TE+4@)1110 4E+24#$/2DI324QA1110,#24II* $HI:* $HI:2D,0T
ME+24@%HHHI -/6B@]:*!B&DI324QH****0PHHH/2@!*2EI*8PHHHH 2DI:2@
M84444 )12TE "4444%!1112 2BBBF 4E+24F,****0!3:=3:8PHHHH *;3J;
M0,**** $H-%% Q*2EI*!A2&EI#0 4444AA1110 4VG4V@ HHHH&(:2E-)0(*
M***!@:2EI* "DHHH&)2TE% !1110,2BBB@ I:2EH 2BBB@84445(!24M)0,*
M***8!24M)04%%%% !1110 E%%%( IIZTZFGK0 4444QA1110 M(:** $HHHH
M&%%%%  :2E-)0 4444@$-%%%, HHHH *#10:0"4444#"BBB@ HHI#0 4444
M%%%% PHHHH **** "BBB@ I*6DH **** "BBB@ HHHH *2EI* "BBB@ HHHH
M 2DI:2@84444 %%%% !1110 4444 )1110 4E+10 4444 %)2TE( HHHI@%%
M%% !1110 4444 %(:6D- "4444AA33UIU-/6@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *1J6D:@!M%%% PHHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *DA_UHJ.I(?]:* /J/PC_R*>F_]<1_,T4>$?\
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MBBB@ I#2TAH 2BBBD,*:>M.IIZT %%%% !1110 4444 %%%% !1110 4444
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M110 4C4M(U #:***!A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%%% "4444@"FGK3J:>M !1113&%%%% "TE%% "4444#"BBB@ I*6DI %%%%
MQ#10:*8@HHHH *#10:0"4444#"BBB@ HHHH 2BBB@ HHHH&%%%% !1110 44
M44 %%%% !24M!H 2BBB@ HHHH *2EI* "BBB@ HHHH 2DI:2@84444 %%%%
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M444AA1VHH[4 )24M)0,****8"444E PHHHH 2BEI* $HHHH&%!HHH&)1110
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MB@T@$HHHH&%%%% !1124 %%%% !1110,**** "BBB@ HHHH **** "DI:2@
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MBBD 4VG4VF,**** "FTZFT#"BBBF E%%%(8E(:6DH&%(:6D- !1112&%%%%
M!3:=3: "BBB@8&FTII* "EI*6@!*2E-)0 E%+24#$HHHH ***.U Q**** "C
MM12T )1110,****D I*6DH&%%%%, I*6DH*"BBB@ HHHH 2BBBD 4T]:=33U
MH ****8PHHHH *#10:!B4444 %%%% !24II* "BBBD AHHHI@%%%% !0:*#2
M 2BBB@84444 %(:6D- !1110 4444#"BBB@ HHHH **** "BBB@ I*6DH **
M** "BBB@ I*6DH **** "BBB@!*2EI*!A1110 4444 %%%% !1110 E%%% !
M1110 4444 %)2TE( HHHI@%%%% !1110 4444 %(:6D- "4444AA33UIU-/6
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1J6D:@!M%%% PHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *DA_UHJ.I(?]:*
M /J/PC_R*>F_]<1_,T4>$?\ D4]-_P"N(_F:* /%J2EI*V/G0[4TT[M333 *
M***!A0:*#0AH2BBBF,2EI*6I 2BBB@84E+24 (>E)2GI24QA1110,0T4&B@
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M110 4E+24 %%%% !1110 E)2TE PHHHH **** "BBB@ HHHH 2BBB@ HHI*
M%HHHI %)2TAH ****8!1110 4444 %%%% !2&EI#0 E%%%(84T]:=33UH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "D:EI&H ;1110,**** "BBB@
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M6DH&+24M)2$!I*4TE PHHHH&)10:*8@HHHH *#10:0"4444#"BBB@ I#2T4
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MLHB?\*GU7^_#_P!]"C_A4VJ_WH?^^A_C113NQ^RB)_PJ;5?[T/\ WT/\:/\
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M\:/^%+:S_?@_[Z'^-%% !_PI;6?[\'_?0_QH_P"%+:S_ 'X/^^A_C110 ?\
M"EM9_OP?]]#_ !H_X4MK/]^#_OH?XT44 '_"EM9_OP?]]#_&C_A2VL_WX/\
MOH?XT44 '_"EM9_OP?\ ?0_QH_X4MK/]^#_OH?XT44 '_"EM9_OP?]]#_&C_
M (4MK/\ ?@_[Z'^-%% !_P *6UG^_!_WT/\ &C_A2VL_WX/^^A_C110 ?\*6
MUG^_!_WT/\:/^%+:S_?@_P"^A_C110 ?\*6UG^_!_P!]#_&C_A2VL_WX/^^A
M_C110 ?\*6UG^_!_WT/\:='\%]85P=\'_?0_QHHH ]JT'P_/8:%9VLA7=%'M
(.#1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gn15qjhcndsi000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gn15qjhcndsi000011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -,!(L# 2(  A$! Q$!_\0
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M_P"?X4!='99'K1D>M<;_ &5K7_/\*/[*UK_G^% 71V61ZT9'K7&_V5K7_/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8)G7)_$4 MSO[6Y2ZA61/ND9J:N9FUK^R--MRL61Y8)-4)_&TT,4<IM?ED(
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MF]&_Y!4/U;_T(T%1.]HI*"<<TBA:*B$\9X#@T\$'H: '4444 %%%% !1110
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MHHH 2EHI,T +5"]TBUOF5IER5.15^DS0 R&%($")T%244E !2TE&: %HHI*
M%HI,TN: "BBB@ HI.*6@ I*,TM !129I: "DI<T4 %%)FEH 2EHHS0 E+244
M +1249H *6BCB@!" 1@BF1PK'G;WJ2C- !129I<T %%)2T )2TE+0 44F:*
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MJ*:MG;QG*Q*#["@+G%^+;SQ!;01G3GPQ/-<SIVK>,I+M%EE.SO7KDD$4P^=
MV/44Q;*W4Y$*@_2@+G+:]<ZW'HT#V;?Z0?O&N'&L^-O,QYIQGWKV5H8W7:R
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M8N;:*PG51P"*ZWX=^%KVSN7OK[>))1DANU 'J(.0#2T@X %+0 4444 %%%%
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M\_,GYT?VE>?\_$GYTO9!_::['O/VN#_GM'_WT*/M<'_/:/\ [Z%>#?VE>?\
M/Q)^=']I7G_/Q)^='L@_M+R/>?M<'_/:/_OH4?:X/^>T?_?0KP;^TKS_ )^)
M/SH_M*\_Y^)/SI^R#^TO(]Y^UP?\]H_^^A1]K@_Y[1_]]"O!O[2O/^?B3\Z/
M[2O/^?B3\Z/9!_:?D>\_:X/^>T?_ 'T*/M<'_/:/_OH5X-_:5Y_S\R?G1_:5
MY_S\R?G1[(/[3\CWG[7!_P ]H_\ OH4?:X/^>T?_ 'T*\&_M*\_Y^)/SH_M*
M\_Y^)/SH]D']I^1[S]K@_P">T?\ WT*/M<'_ #VC_P"^A7@W]I7G_/Q)^=']
MI7G_ #\2?G1[(/[2\CWG[7!_SVC_ .^A1]K@_P">T?\ WT*\&_M*\_Y^)/SH
M_M*\_P"?B3\Z/9!_:7D>\_:X/^>L?_?0H^UP?\]8_P#OH5X-_:5Y_P _$GYT
M?VE>?\_,GYTO9!_:7D>\_:X/^>L?_?0H^V0?\]8_^^A7@W]I7O\ S\2?G1_:
M5[_S\2?G3]D']I>1[S]L@_Y[1_\ ?0H^V0?\]8_^^A7@W]I7O_/Q)^=']I7G
M_/Q)^='L@69>1[ZLB2<JP/T-/KD/!<TDUNOF.6X[UU]9-69Z=*ISQN%%%%(U
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"IJ7_(-G_W*YO1O^05#]6_]
M"-=)J7_(-G_W*YO1O^05#]6_]"-!43HO$5U/;:?(;=L2]A6?::A=VFD/=W\@
MQL)&34WB+?;G[7C<BCD=J\O\;>,I-0LXK"T'SEMI5>*113N?&&N>(->^SZ5(
M57=C.*],\(W^H!C!J+DR*,&N;^'/A^'2=/-[J"A),[LL*Z73=4M=6UB6*W*_
MNSU44 =F#D9I:11A0/:EH **** "BBB@ HHHH ****  ]*XO6O\ D*0?[]=H
M>E<7K7_(4@_WZ!,Z5?NCZ4M-3[H^E.ID"-]T_2O,/&L7V;4('Z9.:]0KS[XB
MP;O(8#H*N&YQ8Q7IW-SPI)YM@C5TM<CX').DKGUKKJ4MS7#N\$%%%%2= 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% $<W^J;Z5XGXJ_Y#\_UKVR;_5-]*\3\5?\A^?ZUK3W/*S+
MX3%HHHK8\(****!A13HT,KA%&2:V;[0S::7#=<[GZBBY<8.2;70Q**DAA>>4
M1H,L>U$T+P2%'&&%!-B.BBB@5@HHHP30%@HI2".M 4D9 H'9B45KZ1IT5W]]
ML-Z50O81!=R1KT4T7U*=-I7*]%%;&FV%G-C[1-LS0V*,;NQCT5T.J:'!;VQN
M+:3?&.]9>FV)OKI(\<$X-)-6*=-I\I2HK5U[34TN]6%#D%<UE4TR)1Y79A15
MS3+$W]T(O6M&/2;>1GC,F'7@"E<J--M7,*BMBWT5WO##*"JCO4HTB*59MC$F
M*CF12I.QA45T%MH2-8?:)&(YQ6=>Z>;:1 N3O/%%T)TFE=E"BKD]LD,'S-^\
M]*ITR'&P45=C2$VH)/S>E4R#N.* <6)29IQ4CJ*"I'44!9B44H4GM2$$=J L
MPHI0I]* I- 68E%!!!YHH%8***7:<9Q0&HE% &37066CQ3:+-=%L,G04-V+C
M!RV.?HHI*9 M%%%(%N>K^!_^/=?]VNSKC/ W_'LO^[79US2W/I\)_#04445)
MU!1110 4444 %%%% !1110 4444 %%%% !1110!4U+_D&S_[E<WHW_(*A^K?
M^A&NDU+_ )!L_P#N5S>C?\@J'ZM_Z$:"HG:W5K%=P-#,NY&ZBN>'@#0%NOM(
MLU\S.<XKHYYXK:$RRMA!U-9*>+=&>?R5NP9,XQ2*+LNE6DUMY#Q@IC&*JZ;X
M9TS2;EY[2 )(_P!XU>FOH8K8SE_DZYJKI^OZ?J4K0V\X>1/O#TH U:*** "B
MBB@ HHHH **** "BBB@ /2N+UK_D*0?[]=H>E<7K7_(4@_WZ!,Z1/NBG=Z1?
MNCZ4M,@*XKQP\3VX!8$@5U&J7@LK-I/:O%]:U.:]O9-SMM#<#-:0C=W//QU9
M0CRG<>"]5@ALA [ '-=TDBR*&4Y!]*^?(KB6)@4=A@YX->G>"=;DNX6CE/*C
M S3G"VIC@L5=\C.XHH!XHK(]9.X4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $<W^J;Z5XGXJ_Y#
M\_UKVR;_ %3?2O$_%7_(?G^M:TMSRLR^$Q:2EHK<\,2EI*<!D@4@-'2+<O<K
M)_"#S78QI_:<$L#N"L:_**YF!H+?2W"O\YZ4W1-1:&Y8.Y"MP3FH>NIV4I*.
MCZCM$C6+Q J.O )I/$K0?VA(L:X;/-:5P]E!KL$\4H*[?F^M9>O_ &:6Y::&
M3<6-"W%-)1:(] BMIM1CCN5RA-;4&F61U&=&B_=_P\5R<$Q@E$B\$5U4VJP1
MV=L\; RDC>*<KBI2C;4IW6FPV=UND3]WZ5-_9ENBK.5'EOR!1KFJ17<0"$9Q
MVJ>PN+34-/2WN9O*\L<$4M2_<YK(9)IMI=#$*C=38["T@/ERJ,]ZBWV^G70:
M*<N/>KMW!I]U;K<"Z(D/)4&C4?N[BV5M"FJQI  %(JIJMI!9S2/<1YW_ '33
MM,GMK>]5S,2!W-7KZ\LM621)I OECY2.]+J5[KCH<2Y4L=O I\8>9U2DF15E
M(4\9KHM(M=/\DM-/M8BK;.2,6V,EN3#IG]G[LDG/%3:?;/:SVIB&-Y^:HKZV
ML8(S/%<;Y > :;8>(2EQ"KQKM4]:FVAT)I27,2>,H7_M)7/38*YBNM\1:G!J
M-^L:XV%1EA6-J>GQ6D,;QN6W=:<695DG)M%KPM<Q6^JJTN-N*U(M,9M5>Z5P
M8RV<5R,6[>-A(/J*Z"VOTL;1@)2[L.<GI0UJ52FDK,Z2^,18R18SCM6%HN3-
M>9Z%N:J:9JNZ<I.V%/<U9M+F"T%XQ<?/RM38U=1/5%FYU2WBM_LA'(.:I-(+
MS:3U3[E8ZN+F[+.V!ZU8-ZHNX<<*AY]Z=C/VG,M2S)I%Q>2D[ANQ6++&896C
M;JIQ786FHVXO#.S@+MQBN4OG62\E=>06R*<=R*D8VN;MI96CZ,DK1_O#U-6;
M6SL!9R2-%DJ*@L;BW&C*C28?TJ6.>V6PG7S/F8<"I9K%QL6)K33!HB7?DC);
M%0O96-S;K+%%@*.:22YMF\,QV_F?O Y)%+:3VZ6$B>9\Y' H+]UNQ*UOI=OI
MZ3/#DEL&EN],L)I[=X(@$.-PI+Z%7T&,AN=X-5_[0AAFMT5\KP&]J ?*G9HF
MO(M+M9MAAY)Q574;*UTQXVDC^60;A4>MSP/,LD;[OFS5G4[FVU:VA+. T: 8
M%,E\KNAMUIEJ--AOU0;';%)JFF6KB!K./ *_/BH+_44_L**R5LE#FIM)U*%-
M+F$S#S!]T&C47N-V(K/3K>ZD:!4_>*,DU82SLEADC=07Z"J>CZFD&I22.0 X
MVYJWJ%G8*#/'=L6;G%&H1Y>6Z(GTJ&TA^T2(#&>E:%C+"_AF\\M<<FH[>[M+
MVP%K-+M"C@TMJ]C:Z'=0";YF)P/QI%*RU6QQM%*P ; Z4E:'"]PHHHH$MSU?
MP-_Q[+_NUV=<9X&_X]E_W:[.N:6Y]/A/X:"BBBI.H**** "BBB@ HHHH ***
M* "BBB@ HHHH **** *FI?\ (-G_ -RN;T;_ )!4/U;_ -"-=)J7_(-G_P!R
MN;T;_D%0_5O_ $(T%1%^)5_=6OA^<6Y(/KBO/?#?@36]2M4U);E0TG(R/_KU
M[3KNE0:MILEM/@*W4U0T)K33D%A'*"L? I%G(&;4](L&L=49IB>A4<"L7X93
MF3Q=J&,A<G /TKUO5+:SFM&:X"A?[Q%<EX6\/Z?8:Y<W5I-O,AY H [X=!11
MV%% A:*** "BBB@ HHHH ****  ]*XO6O^0I!_OUVAZ5Q>M?\A2#_?H$SI5^
MZ/I2TU?NCZ4ZF0S'\20-<:8R)UKQ2]C:*[D5@0=U?0+H)%*MR#7$^(/!T$JR
M7"'#=>E:0E8\S'8>535'EM=IX&D2*9@[!<GO2Z3X-6\;,A(7/I6IJ'@Y[)%E
MLW8LHS@5;DFK'%0P]2#Y[;'?HRLH*D'Z4ZO/M(\37%C*+6_&P#NU=Q:7L-Y&
M'B<-6+5CV*59219HHHI&ZL%%%% PHHHH **** "BBB@ HHHH **** "BBB@
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MBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH&%%(6 [TF\>M KCJ***!A1110(CF_U1KQ/
MQ5_R'Y_K7MD_^I:O$_%7_(?N/K6M+<\O,OA,6BBBMCPPHHHH 2EHHH ****
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MBB@BX4444 %%%% !1110 4444 %%%% 684444#LPHHH_"@:3N>J^!V_T9?\
M=KL]XKB_!$>ZV7_=KLO*'K7-+<^EPG\-#MPHWBF^4/6D\H>M2=0_>*-XJA=W
M<%H,RN152/7+&3[LI-&I#G%.QM;A1N%11!9HU=3D&G^4/6@O0=O%&\4WRAZF
MCRAZF@-!V\4;Q3?*'J:/*'J: T';Q1O%-\H>IH\H>IH#0=O%&\4WRAZFCRAZ
MF@-!V\4;A3?*'J:/*'J: T*^I,/[.G_W*YS1C_Q*H?JW_H1KH-2B']G3G/\
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M\16VH(H\P;^XI.)=.NF[2W-VL[6_^03-]*T <BL_7/\ D$S?2DC:>L2/0?\
MD&QUJUE:!_R#HZU:&%/8****1H%%%% !1110 4444 %%%% !1110 4444 %%
M%13SQVT1DD;"CO0+8DHK,.OZ>/\ EL*MVU[!=KNB;(IV8E--V+-%%%(H****
M "BBB@ HHHH **** "BBB@ HHHH **** *&L_P#(+F^E0^'O^03']34VL_\
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M ?=:/^$!]UK:TCQ9:7R*'E D/:NB5PZA@>#6+E);GK4Z%&:NC@_^$!]UI/\
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MC:M_Q_0?[]=#'_JU^E4]C"E%*3'4445)N%%%% PHHHH **** "BBB@ HHHH
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M^U62^N3*S#O3?"WA;3M!ME"@%\9)85TD-_;R2&)&Y7L* +HHI!TI: "BBB@
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M<]JW_']!_OUT,?\ JU^E-[&-/=CJ***1N%%%% !1110 4444 %%%% !1110
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@3.<UG_7Q_P"^/YUT$/\
MJ4^E<_K'^NC_ -\?SKH(?]0GTIO8QA\3'T44F0*1MLB*Z_X]9/\ =K%T'[K_
M .]3=;\2V=C$\32 .1C%<SH_BZVMY2)) %)]:M1=CCG7@II-GI%%5+'4(;Z$
M/$<@BK=0=49)K0****"PHHHH **** "BBB@ HHHH J:E_P @V?\ W*YO1O\
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M[8D[UC)7=T>SA:G)%0D=1134D6105((-/K,]!.X4444#"BBB@ HHHH ****
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M];/A7QW_ ,)+>20BU,6SO7#PZAX%$2AWGW8Y^6NF\#W'AZ;49O[(:0MWW#%
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M_P"K7Z"G4U/]6OT%.I%QV"BBB@H**** "BBB@ HHHH **** "BBB@ I*6DH
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M%KVM7'EJ!@YXK,G^&.B6YQ(Q!]WK<\(>#K;0;N2>U.5?_:S0!WPZ"EI!T%%
MA:*04M !1110 4444 %%%%  >E<7K7_(4@_WZ[0]*XO6O^0I!_OT"9TJ_='T
MI:1?NCZ4M,@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **2EH *#THI.U GL<[JW_ !_0?[]=
M#'_JU^E<[JW_ !^P?[]=%'_JU^E,QI_$QU%%%(W"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@"AK/_(+F^E0^'O\ D$1_4U-K/_(+F^E0^'O^01']31T,
M?MFK1110:K8****!A1110 4444 %':BB@-"K<V,%VA62-6)]17&ZKX5FMY#<
M6<C)SG:M=Y2$ CD9IIV,)T(R//\ 3/$MUIT@M[R)L9^\U=G9:I;7L8:.12?0
M&JNJ:!:Z@A+K\W;'%<=<:7J>A3F2V/[K/?GBJT9A>=+?5'I-%<AH_BV*7$-S
MN$GTQ75Q31S(&1@0?>I:L=$*L9;$E<[J?_'W'_O5T7:N<U/_ (_(_P#>H05'
MH=#'_JU_W13J;'_JE_W13J1I'8****"@HHHH$%%%% PHHHH **** "BBB@ H
MHHH *IZI_P @Z;_=JY5/5/\ D'3?[M!$]BCX:_Y!B5M5B^&O^08E;5 J?PA1
M110:!1110(*8\BQKN8X JO>ZA!8Q%Y6'X&N%U3Q'=:G/]FL,[3P<BJ4;F%2L
MHZ&YK7BJ*U5HX,2.>, US=KINH:]<>;,\D<9/0]*U=%\)EF6XO@2Y]Z[*"WC
M@0*B@ >U.Z1C&$ZKO(H:7HEMI\*@1J7'\5:HX&***FYU1@HJR"BBBD:!1110
M 44E+0)G.:S_ *^/_?'\ZZ"'_4)_NUS^L_Z^/_?'\ZZ"'_4I]*;V,8?$Q]%%
M%(W(KK_CUD_W:Q=!^Z_^]6S=?\>LG^[6+H'W7_WJ:,7\2.@HHI*1J+1110,*
M*** "BBB@ HHHH **** *FI?\@V?_<KF]&_Y!4/U;_T(UTFI?\@V?_<KF]&_
MY!4/U;_T(T%1-OQCJ<FF:!//"I>5>@'6O%(?$OBB*[-X]I<F%CD<\5Z]XWNH
M;32Y9IP3&O45Y^?B+H;:7]D:-N%('R4BC U.Y\1^)9UGM!<(BC!"FN^^&>HZ
MB]Q)97ZR Q#&7^E<WX>^(VD:1;/$4;YFS]RNC\$>(K37-;N7M@02<GC% SU
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M6!HNJ0Q!P0WWO2F<\I+F1U]%,BE$T8=>AI](W3"BBB@84444 %%%% !1110
M4444 5-2_P"0;/\ [E<WHW_(*A^K?^A&NDU+_D&S_P"Y7-Z-_P @J'ZM_P"A
M&@J)L^*;*VOK-XKJ18XCU)Z5RUE\.M(NXP8)8W'J*Z?Q3:I>VS02?=/6J-O:
M/H^CJ]BX4JN3S2**'_"K;#_8_*M'PYX+A\/WDDL1'S>E)X;UJ^U7=(\H\M6P
M<FNL2Y1CMW MWP: )ATI:** $H/ R>U+2,H8$'O0!2EU:RAD\N2=5;TJ"\MK
M2>U>5U60$9&:ANO#&G7=SY\L>7]:R=8U$V82VA#>6IP0* #1-.(N#/$-L?\
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MTM !1110,**** "BBB@"KJ7_ "#9_P#<KFM&_P"05#]6_P#0C72:E_R#9_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH BFA69"C=#6'/H2%\*./I70T4[V,Y4U+<I6>GQVJ
M#8 #WXI+C3HIR[,H)(J]11</9JUCGM*T)+=IO,&[<<C/:MZ*,11A5Z4^BANX
M0IJ.P4444C0**** "BBB@ HHHH **** "BBB@ HHHH *YW4_^/N/_>KHJYW4
M_P#C[C_WJ:,JAT"?ZM?H*=38_P#5K_NBG4BX[!11104%%%% !1110 4444 %
M%%% !1110(**** $(!X(K!UW1;:>SDE\M0P&<XK?JGJG_(.F_P!VFMS.K%-.
MYS7AK0+8VB3,BL?<5UT<21(%0  >E8_AK_D&)6W0V31A&,=$(:6DI:1N%%%%
M !1110 4444 %%%% !1110 4F!WHI:!!1110,,#-,D8HA;TI]1S\Q&@F2ML<
M[J6M8E$8Z@\U8L=8\R581@YKG=3L9EOFD.=K'BK6EV<T=_&Y!VU=E8XE.7-8
MZ?4+[[(BG'6L"76]NI1D']WWK2U^%YH$"=<UR4]E,+E;?!W-T-"2*JSDI:'=
MVU[]HC9P. ,BLG5]:,=FZIQ(.@JSI,#P6A1QR%KG=9M)D9KD@E!0DKCG.7+=
M&[8:SOMH5ZN>M:=[>?9H/,([5R>EV4RM'/SL?D"N@UJ%YK'8G7 I-*X4YR<&
MV9G]MDR[\\5NZ???;(M^*X<64WW<'-=7X>AD@M-K]<TVD*C.3EJ;E%'>BH.P
M****!A1110!4U+_D&S_[E<WHW_(*A^K?^A&NDU+_ )!L_P#N5S>C?\@J'ZM_
MZ$:"HG=N@=2K#(/:N1UWP#I^M$DJD;$\D"NPHI%'G%A\)=/LK@2F17QV(KO+
M&PAL(%BAC50!C@5;HH **** "BBB@ HHHH **** "BBB@ /2N+UK_D*0?[]=
MH>E<7K7_ "%(/]^@3.E7[H^E+2+]T?2EID!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1124 +3'D6,?,:?6%XB,XMT,+[2#S32N1.7*KE
MTZG$+I8-PR:O!U(X->:S37)F# XE'0UV.D&=K+,K@L5IN)A"NY.UC0O+Z*VM
MVE9A@4ZWNXY[=)0PPW2N*U=[KS&BD?,1/04_29+II$C5\1 \ T<NA/M_?L=R
MSJHR3BJ7]J0^:8]_(JGK9G6P)A<!L"N026XR<M^\[FA(JI7<78]'2177*G-1
MRW4<:,Q;[HYK)\/&<V1,SACFL759;M+F0!\H>PH2U'*M:*9U=EJ$5W%O5LBK
M8((R*\]TF2Y%T(XGVQ$\@UWUOGR%R<G%)JQ5&KSHEHHHI&X4444 %%%% !11
M10 4E+10 E5-4_Y!TW^[5RJ>J?\ (.F_W:$1/8H>&O\ D&)6U6+X:_Y!B5M4
M/<5+X1:***#0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M10 4444 %%%% !1110 4444 5-2_Y!L_^Y7-Z-_R"H?JW_H1KI-2_P"0;/\
M[E<WHW_(*A^K?^A&@J)WM%%%(H**** "BBB@ HHHH **** "BBB@ HHHH #T
MKB]:_P"0I!_OUVAZ5Q>M?\A2#_?H$SI5^Z/I2TB_='TI:9 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 G>D9 XPP!'O3J*!&5<:+!-+O''L*O
M6]M%;H%1 /?%3T47)4$M2&2VCD+;D!)'7%9^GZ)!92RO]_><\CI6M10)P3=Q
M@B0+M"C;Z8K-O-&AN9DDQMV^@K5HH*<$RM;VD4 ^5!GUQS3I[:*X7#H#[XJ>
MB@.56L95OHL$-SYA^;/8BM-45!A0!]*=10"BH[!11104%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!4
MU+_D&S_[E<WHW_(*A^K?^A&NDU+_ )!L_P#N5S>C?\@J'ZM_Z$:"HG>T444B
M@HHHH **** "BBB@ HHHH **** "BBB@ /2N+UK_ )"D'^_7:'I7%ZU_R%(/
M]^@3.E7[H^E+2+]T?2EID!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444""BBB@ HHHH **** "BBB@ HHHH&%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!4U
M+_D&S_[E<WHW_(*A^K?^A&NDU+_D&S_[E<WHW_(*A^K?^A&@J)WM%%%(H***
M* "BBB@ HHHH **** "BBB@ HHHH #TKB]:_Y"D'^_7:'I7%ZU_R%(/]^@3.
ME7[H^E+2+]T?2EID!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXHETW81L[T =-16-K=[- 5CB1B6'4#I61H/B62YUE]+EC;>@R6- '8T4E+0
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MKPTR%L+N('44 ;]+6?H]W]NTV.?^\*OT +1110 5D>)/^0/+6O61XD_Y \M
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ME "T444 %%%% !1110 4444 %%%% !1110 4444 %)@>@I:* #'M28'I2T4
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M;@<KVKO]*O%O].BN5Z.,T 7:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD/2N<OO$IM
M-:BL#%G?WH Z2BF1MO0-3Z "DI:* $Q10>* : %HI,BN?UK7FTV81B(D'O0!
MT-%5;"X^U64<V,;AFK5 !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;H^K26X%A-IF[R_EWD'FI=?@>XLRD=OLSV% %[1=4O+RU@BLV&U!\U=C%O\
M+&_[W>O+_#\=]X=N$<H\JW!Q@_PUZ?!)YL2MTR* ):2BEH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M2EHH :44]5'Y4H4+T 'TI:* $*@]5!I-HQC:,?2G44 -V+_='Y4!%'\(_*G4
M4 ,V+_='Y4I4$8(!'TIU% #0BCHH'T%+2T4 4M1TZ'4;5X9ER&[U7TJPDT_]
MPO\ J!TK5HH 0^]'TI:* $Q[44M% #2JMU4'ZB@*%Z #Z"G44 -**>J@_44!
M0.  *=10 W8O7:/RHV*>JC\J=10 S8O]T?E39$_=,$ #$<<5+10!@6N@1M?B
M_N5S.O2MX #@=*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH .U5I+**1MS+DU9I*
M$1 B!1T%+2T4 1"",,S!1ENO%.2)(_NJ!^%.I: ()[2&X_UB@X]J(;6*!=J*
M,?2IZ0D 9- %0Z=;F7S-@W9STJ26SBE^\H_*IP<]*6@"J;"!@ 4''3BIXXP@
MP.E/HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&SCCK2T4
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gn15qjhcndsi000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gn15qjhcndsi000010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *S!+0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WZ@D <G%1
M7$ZV\#2-T%>::_KVJ:I</:Z<LL6T_?VG!H ]#FU:S@.))0#4D%_;7/\ JI :
M\4;PCXLNB7?43SZ__KIT7AWQ;IK"07Y91U !Y_6@#W+(Q2UP7AGQ+="5+*]B
MDWG^-A@5W:L&&0<B@!U%%% !1110 4444 %)2TV0$H0#@F@#$U?7!8R>4A!D
M/:I-,U22XA>6<!549)KC_$VC:C%J8U'S#)$O&Q>M:5IK$5SH%W''&4D2$YS0
M!JRZ^7)>VPT(ZFM:QOXKR,;&RW>N,\"1B[\.S&;YCOH\%7DDOB'4("3L0\"@
M#OZ*** "BD)Q3/-7UH DHJ/S5]:/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7
MU% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7
MU% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7
MU% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7
MU% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7
MU% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7
MU% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7
MU% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7
MU% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7
MU% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7
MU% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7
MU% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7
MU% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7
MU% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7
MU% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7
MU% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7U% $E%1^:OJ*/-7
MU% $E)3/-7U%'G+ZB@"2BD!!&110!7O;5;RV:%C@-4=KIMO;1*BHIQW(JT[K
M&NYC@4J.'4,#D&@"*9 D1*(-WTKF;SQ39:=<+%>E4+-M -=8:Y+Q5HMI=&&1
MXE+!@<GZT ; L[34(EEC51N&00*T8(A#"L8.<51T50MFJCH!BM.@ HHHH **
M** "BBB@ IDL@BB9VZ*,FGTUU#H589!ZT 84GB+3)2T#2*6Z8-9=IHSB/494
M7Y9T(2NB_L2P\SS/LZ[O7%74C1$"*N%H X'P^_\ 8.CRVL_RREL@&M'PEI$E
MKJ%S>LI"S<@UTLNF6DS;GB4FK,<:1*$08 [4 /HHHH 9+]RJD4(=B235N7[E
M0V_4T +]E7U-'V5?6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*
M/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*
M/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*
M/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*
M/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*
M/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*
M/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*
M/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*
M/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*
M/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*
M/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*
M/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*
M/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*
M/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*
M/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*
M/6K%% %?[*/6C[*/6K%% %?[*/6C[*/6K%% %?[*/6C[*OJ:L44 5_LJ^M12
MP!,$&KM07/04 .A_U?XT40_<_&B@##\:WTNG>&+FYA_UB]*\5C^,6O6R>4L8
M(7_9KWS5]/34].DM9 "K]0:Q8/ OAZ*W'G:?$6'5B* /(/\ A=/B#_GDO_?%
M1'XJZUJEY;PRQ@*S@'Y?>O7V\->#D.&M;8'WJ";PYX2W*T,-LK@Y!!H&=!H+
M%].C<]2H-:M4=,C6*W"H05'3%7J!!1110 4444 %%%% !1110 4444 %%%%
M!1110 R7[E0V_4U-+]RH;?J: +-%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %07/05/4%ST% #H?N?C11#]S\:* ):YOQ??75EIQ^R@%V!%=)7/>++R&ST
MUWECWG:=OUH \6;2_&NI2-+%&I7/_/0TZW\-^,TO(6GC 0."?WAZ9IUMXZU2
MU:1(K*X9=W! JU%X^U:XNX8WLKA0S $E:!GM.B(Z6"+)]X*,UIUF:([26*,W
M4@&M.@04444 %%%% !1110 4444 %%%% !1110 4444 ,E^Y4-OU-32_<J&W
MZF@"S1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M10 4444 %%%% !1110 4444 %%%% #)?N5#;]34TOW*AM^IH LT444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %07/05/4%ST% #H?
MN?C11#]S\:* *^IRRP63R1??'2N>A\3:?=D6UUGSDZY-=8Z!UVL,BN+\2>!A
MJJE[6<VTG4E.] &_%<Z:RY5H_P 2*;-?Z9"N6,9P/:O'[OP%XAMY"L6J73+[
M'_ZU6--^'FN74J^?JMRJ@]"10!WTVN6&H7 L[5/WC=#BNJL8FALXT;J!6+X?
M\+0Z/"OF$32C^-NM='0 4444 %%%% !1110 57O4DDLYDB^^5PM6** /+-4L
M/$]M82@LOEELCBCP];ZK)I=\MT<YB..*]-N;=;F$QOT-06VGQ6ZLH4888(H
MXSP;)_9OAV99>&W=*E\&:?)#K=[=,,+*<BNAN-!263]V=B?W16E:VD=K&%10
M#W- %BBBB@".7[E5(HV9SBKDOW*AM_O&@"=%*KS3J** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *@N>@J>H+GH* '0_<_&BB'[GXT4 2T45F:UJJ:5:-,Y'
MR!ZT :.U3_"/RHVJ.@ KQJZ^,MW%,R1::TB@XR,?XU'%\8K^YN8H3ICKO8+G
MC_&@#VK@TM9^DW+75FDK=6 .*T* "BBB@ HHHH **** "BBB@ HHHH ****
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M% !1110 4444 ,E^Y4-OU-32_<J&WZF@"S1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !4%ST%3U!<]!0 Z'[GXT40_<_&B@"CKFKQ:-IDE[*I*)U KG;3X
M@6%[:O*(I JKDY%=/JVG1ZII\EK+@*WK7(WOANQTVV6(2* W'2@#D]1\?^%[
MR=OM%E,S X.%_P#K4_3OB%X>MIXX[*TF1G(7)7_ZU;5O\.=*N09/-7)]JAN_
M .DZ?+#(9E!W#'% ST/3+DW5JLGJ,BKM4M+A2&T54.0 ,5>H$%%%% !1110
M4444 %%%% !1110 4444 %%%% #)?N5#;]34TOW*AM^IH LT444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5!<]!4]07/04 .A^Y^-%$/W/QHH =(I*$+UKR
M+X@V?B*%Q-!*3&6^4#M7L%4-5DM(;9I+H(549^89H \!MK_QDB8CF< >U6K:
M/Q;J=[ MS,Q17&<_6NPN/B#HUK,T:) 0#C[HJLWQ,L?/B2"*'+,!PHH&>G:7
M#)!91K*<MM%7JHZ9>_;;1)<#D U=H$+1110 4444 %%%% !1110 4444 %%%
M% !1110 R7[E0V_4U-+]RH;?J: +-%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *@N>@J>H+GH* '0_<_&BB'[GXT4
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MS#VU/N;]%8'_  E^D?\ /Q2?\)AI'_/Q19A[:GW.@HK _P"$PTG_ )^!2?\
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M  @$?^S2_P#" Q>BUW=%',P^JTSA/^$ B]%H_P"$ B]$KNZ6CF8?5:9PG_"
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M\(1I_P#SP6C_ (0C3O\ G@M=911S,/J]/L<I_P (3IW_ #P7\J7_ (0G3O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2EH[T4 5+ZV-
MU:M$#C-<9<^ WGE+EQ7>XH[TT[&-2C&IN<CHWA)]-O$FWC"UT\_W14]0W'04
M-W*ITXP5HCH?N?C11#]S\:*1H2U!=+"T#+,1L(P<U/7,^,C=?V:RVW5@0>:
M.1UWPMX:N[AGCFMD)Z\TNBZ'X:TN979[:1\\8/>N)M_ FHZHTDQGDY;_ )ZG
M_&K4'PXU"VNX9?/D(5P<&4_XT >[VDJ20*8P N.,5/6;HL;16*(W4 "M.@ H
MHHH **** "BBB@ HHHH **** "BBB@ KG?%6F'4+!L#)5>*Z*F2#,;# --.S
M,ZD%./*SYRO+62VG9)%(.3U%0!2QPHR37>^,-#OKK5"\$(V8["L*Q\-:BMY&
MQAR W-="DK'S53"R4[)&[X,\,"Z9;BZBW)W5A7>'PII/_/HGY59T*!H+!5=
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M4 +1110 4444 %%%% !1110 4444 %%)2T %%%% !1244 +124M !12=Z6@
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M0 M)2YI* %HHS10 44E% "TE+24 +129I: "BBB@ HI*6@ HI,TN: "BBB@
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M+24O(P!0#D<TL_BNYCTB2Z%G(65<[=O)KJ6LX6B$91=HZ#%.-K"8S&47!]J
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MQ;=6UY9Q)92D3-@D#I4VH^*+BSU-+=+21U90<@<5U$EG#(RLR*2O3BAK2%Y
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M?8Y?+D&2^.!4=_XIN8]4^RBSD*[@-V.*[ V<)F678NX=#BH;FTA+!R@SGTH
MFM&+VZL1C/.**? ,1X%% &7XG)&AS;3AJSO"VD&.W6YE;?O'0]JL^,I&A\/3
MR+U!JIX2\06EUID4!D E4<@G% '5 8%<[XB2>-H9(79?F!;%;_GQ8_UB?]]"
MN/\ %GB:TM3' '!=V"\<]Z .JL+D7-LI'88-6JQO#L;I8@M_%R*VJ "BBB@
MHHHH **** "BBB@ I*6B@!,4M%% !1110!'+]RHK?J:FE^Y4-OU- %FBBB@
MHHHH ***2@!:*** "BBB@ HHHH **** $I:2EH **** "BBB@ HHHH ***2@
M I:2EH **** "BBB@!*6DI: "BBB@ HHHH 2BEI* %HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH 2BEHH 2EI*6@ I*6B@ HHHH **** "BBB@ I**6@
MHHHH **** "BBB@ HHHH *2EHH 2EI*6@!**6B@ HHHH ***2@!:*** "DI:
M2@!:*** "BBB@ HHHH **** $HHI: "BDI: "BBB@ HHHH **** "BBB@ HH
MHH **** $I:** "BBB@!*6BB@ HHHH **** $HI:* "BBB@ J"XZ"IZ@N.@H
M =#]S\:*(?N?C10!%?VB7UH]O( 5;UKPOQ=X7US1;V2YTN6;8Q^['VKWVF20
MQRJ0Z*<^HH ^6GU;QB1Y8^UY[5UW@SPGK&LWB7&JR2X4A@)*]H_L.R\W?Y2Y
M_P!T5?BACB&U$5<>@H 2"$00)&HQM %2T44 %%%% !1110 4444 %%%% !11
M10 4444 %%%% #)?N5#;]34TOW*AM^IH LT444 %%%% !1110 4444 %%%%
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M/=,V,]*R(]5O;Y?.L_\ 5>] '34M<_8>([>:;[/(Q$JG!!]:W@<B@!U%)10
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M@N(S@X/-4I?B78++&D;HQ=@.#7G.I^#=/CB><@ECR:I'0M(M'LI>0[.,\^]
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M2W+;QD@=JETOQ2-2TJ2\$>-AP17%6^H2"WDT:/K$N,4S1+IK")]&?(FF;(%
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M 7Q9:[>,MVKTH=!0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5!<]!4]07/04 .A^Y^-%$/W/QHH EJEJ5DM]:21-C)4@
M'TJ[7/>*]4FTS3V>#[Y! XH Y:Q\$&TU#S+F_,D>[.QCQ6+JGP]%QK"W*WY$
M8D!"9X'-<\VL>,KZ1WB==F>/E-+#<^+S=P^>PV;QGY30,]STBT6TLDB5]V%
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MHQP:[JB@#D!X4O!!Y8U"3ICK5NW\-R1:2]I)<,[M_&:Z2B@#D=-\'O8?:/\
M2"?.!&:-)\'OIMP9!<ELYXKKJ* ..@\%O#JTMZ+D_.V<4Z^\'-=ZU'J N"I5
M=N*Z^DH Y'6O!S:LUH3<$>0V:MZMX9.IZ$VG-*03CYJZ2B@##\/:))HUN(FG
M,B@8&35W5=,BU6S:WE4%3ZU?HH X^V\(SVPD07;>4W 7/ %:]AH:V5BT ;YC
MGYJV:* .-TKP6^G:M/>BY8^:V2*[%1@ >@I:* ,O5=&@U-/WB@N/NMZ5PVN+
MJWA^V86_F3@'M7IM1301SH4=00?:@#AO"]O!=D7%ZX>8\A6ZJ:VO$?AL:Y;;
M8I/+;^\*O0^'[."8RHI#$YZUJ(H1=HZ4 <))X#GEBA22]=O+&!DU+>>!GGT]
M8%NF5P<[J[>EH \]NOA]-<M:,]ZY,'3FKU_X)EOK187NVX(/)KM** .6O/"C
MW.GQ6OV@@(N,U'_PAX;01IKS$X[UUM% ')6OA.:"PEM6NV*N,#VJ30O"CZ1D
M>>6!KJ:* .-F\%O+JR7GVD_*V[%6_$7A9M=L4MS.5"L#^5=/10!SQ\-HVB_8
M)&W'9M#'M7.6/P_O;.?Y-2D$0.=H/%>B8HH Y36/"(U*.';+LDC&-W>LF\\
M7-YIZ6\E\Y*G.2:]!HH Y6?PF9]-CMFG.Y$VAJ8GA*9=*6S-TQP<YS76T4 <
MSH_A<:=;7$,DGF+-U!JI'X/DMKUIH+EHXV&-@Z5V-% '/V'AQ;:.3>^]WZ,>
MU4+3P:UKKDFH_:"2XQBNOHH X^7P:\FKQWQN3\ASBNN12J@$YIU% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %07/05/4
M%ST% #H?N?C11#]S\:* ):P/%,UO#IKO.%.%. :WZYCQE!%+I^9L[%!)H \G
MM/B0=-,D*:.LPW<-_DU<C^*+75U#$VAJFY@,_P"33M,N_""K()T8N#SQ5\7G
M@PSQ"-&W[AMX[T#/4-&E$UDD@7;N .*TJSM',9LU,?W<<5HT""BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@!DOW*AM^IJ:7[E0V_4T 6:*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H+GH*
MGJ"YZ"@!T/W/QHHA^Y^-% $M9NLZ8NIVC1%MIQP?2M*L'Q/JKZ98,T9(D8$*
M?>@#SG_A6/FZN);J]DD7/1SFNGO-%@AMK:UCG\I8R.5XS7F-_P"(?&/GNPN
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444E "T44F1ZT
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M@TOV<^M'V<GK0!)#_J_QHIZKM7%% #+B!+F$QN,J>H-,BLH(HPBQ+@>U6**
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MTF(0,YQ7?HP9 WJ*Y2TT\W7B!KYA^[(QBNL4 # Z"@!U%)2T %%%% !1110
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M@!5MR8KL:* &J,*%]*=110 4444 %%%% !1110 4444 %%%% !1110 4444
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MROX=@;) 4,>]/L?#]O:3"9E5I0>&Q0!KIDH-W6G4E+0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gn15qjhcndsi000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gn15qjhcndsi000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *P!/4# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KY=\??\ (SW?^_7U%VKY=\??\C/=_P"_5P.3%_"CEJ**
M*L\T****!A7HWPI_Y"3UYS7HWPI_Y"3TGL:T/C1]!I]Q?I3J:GW%^E.K(]<*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#B?B)_R"7_W37S8_P#K&^M?27Q%
M_P"02_\ NFOFU_\ 6-]:TCL>=B_B&T4451R!1110!);_ /'PGUKZ7^&__(K0
M_A7S3;_\?"?6OI7X;_\ (JP_A4R.O"?$=C11169Z(4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%1^:*/-% $G:OEWQ]_P C/=_[]?3WFBOF#QZ<^)KO_?JX
M')B_A1R]%%%6><)2T8(ZC%&#C- "5Z/\*?\ D)25YQ7HOPJ;&HO2>QK0^-'T
M*GW%^E.J%)1L7Z4[S161ZY)14?FBCS10!)14?FBCS10!)14?FBCS10!)14?F
MBCS10!)14?FBCS10!)14?FBCS10!)14?FBCS10!)14?FBCS10!)14?FBCS10
M!)14?FBCS10!)14?FBCS10!)14?FBCS10!)14?FBCS10!)14?FBCS10!)14?
MFBCS10!)14?FBCS10!)14?FBCS10!)14?FBCS10!)14?FBCS10!)14?FBCS1
M0!)14?FBCS10!)14?FBCS10!)14?FBCS10!)14?FBCS10!)14?FBCS10!)14
M?FBCS10!)14?FBCS10!)14?FBCS10!)14?FBCS10!QGQ%_Y!+_[IKYM?_6-]
M:^C_ (AR9TI_]TU\X/\ ZQOK6D=CSL7\0VBBBJ.0**** )+?_CX3ZU]+_#;_
M )%6'\*^:;?_ %Z?6OI/X<2 >%HA]*F1UX3XCLZ*C\T4>:*S/1)**:K;J=0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 444E "T5'+*(DW-TI(;B.8?(X;'7% $M%%%
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M%% !1110 4444 %%%% !1110!4HHHIB"OF;QU_R,MW_OU],U\S>.O^1EN_\
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M.-O_ *]/K7T=\.O^18BJ9'7A/B.NHHHJ#T":'O4O>HH>]2]Z0PHHHH ****
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M%J+3.?W;D#FO0KS M)/]TUY7IEE<S_VE+#,P59#E!WIH3.F\+7MPVH&W!)@
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M^=']KZA_S]R?G0![?]LA_O#\Z/MD/]X?G7B']KZA_P _<GYT?VOJ'_/W)^=
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MO^0B]-[&-.WM%8]\3[B_2G4U/N+]*=69ZH4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM35-.D@G"JAX%4OLD^,^6: (**>(G9MH4YH>-X_O#% #***EMD\RXC0]V H
M=#:R3_=%+/9RVXRZ\5W-SIR:=HN](@S8!S1+]FFT-&EB16V<$]Z //J*60#S
M6QTR:2@ J>&TDG^Z/THM(/M%PL?3-=MJEA]AT>%X(=S%>2!0!Q<ME+%U&?I4
M#(R=16]I>IQQW&VXA5O]ZJ>J;9[EFA4!2> * ,NBIS:3@9,9Q3%AD<D*I)%
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M-&:2B@!<T9I** %S1FDHH 7-&:2B@!<T9I** %S1FDHH 7-&:2B@!<T9I**
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MU]5U2UD02Q*@;;C %<G*_F2,Y[F@#1T6^BL+Q9G[5LZSXAM=26,$D[:Y&EH
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M'(I^EZ%/J&Z0?<4;CD56U5Q-<AAWYKT;28$A\-"11AC&<G\* .-31$O 4MP
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MX=L#%_I1&#(*Z*F11K$@51@"GTAH**** "BBB@ HHHH **** "BBB@ HHHH
M**** .+^('_(+?\ W37SJ_WV^M?17Q!_Y!;_ .Z:^='_ -8WUJXGG8OXBQI^
M/MT61D;NE=-<VKWVH"".%PNT'.TUS>F2K#J4,CXVJW.:]8@\9Z7;JO[J'<%
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MUC\L,0I[4T,5.0<&@#J/&&H"XOE"$;2O.*P(+^>W_P!6Y%5Y)&D.68DCUIM
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M@UY4U#3(G21.$Y&X5YH78MN).?6I?M=QMV^:^/3- #;A/+F*U%2DDG).:2@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*6BGQ1/-($09
M8]* "*)I9 B DDXX%>A^%O"VP+/<*">M'A;PL$"W$Z\GG!KNXXUC0*H QZ4
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MXH_,>+"^M5",'!H 2BBB@!*6BB@ HHHH **** $I:** "BBB@ HHHH ****
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MBB@"OY9H\LU8HH K^6:/+-6** *_EFCRS5BB@"OY9H\LU8HH K^6:/+-6**
M*_EFCRS5BB@"OY9H\LU8HH K^6:/+-6** *_EFCRS5BB@"OY9H\LU8HH K^6
M:/+-6** *_EFCRS5BB@"OY9H\LU8HH K^6:/+-6** *_EFCRS5BB@"OY9H\L
MU8HH K^6:/+-6** *_EFCRS5BB@"OY9H\LU8HH K^6:/+-6** *_EFCRS5BB
M@"OY9H\LU8HH K^6:/+-6** *_EFCRS5BB@"OY9H\LU8HH K^6:/+-6** *_
MEFCRS5BB@"OL-'EFIZ* .#^(2$:4_P#NFOG-_OM]:^DOB)_R"7_W37S8_P!]
MOK6D=CS<7\0E=!X7CF^WAHV[5S];7AN^EM-15HDWGTJF<\/B.JU:6_%Q!% '
M!<X)Q7(^(;>>WU';<-N?&<UZ@VK2_8_,%FC28R/:O+_$-W/=ZDTEQ'Y;^E)&
MU5*QFV_^O7ZU](?#E"?"\7X5\WV__'PGUKZ6^&W_ "*T/X4I%X3XCJ?+-)Y9
MJS169Z)'$I%244E "T444 <GXS_X]&_W:\GKUCQG_P >C?[M>3T %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #D8JP(ZUZ3X3'GV
M9\P9PM>:CK7I?@SFT;_=H Y[Q%J$]GJ86)]JUU.G6MKJFC;IH]TFPG-9&KZ'
M_:.K+C-;,\\?A[2!&6PQ7'- 'G.K6@M+QD'3-4T@D?HA/OBK[LVK:E@CJ:["
MYT_^S--MWBA#NPYS0!P+P21_>0BD6&1_N(6^@KO;G3UO-#>=XPL@[ 4SP7#'
M--<121J=@[B@#AUM9V; B;/TI'MIHSAHV'X5W^HWD5EKR6Z0(5(]*NZY#;BP
MBN1$H;&< 4 >:_8YPF[RVQ]*AP0<=_2O4M ,.KZ6P>%%.<9 KB)-/$OB!X%'
MRA\4 9"V\K#(0X]<4CPR1_>1@/4UWNM6\6CV'EHBL<9R14BZ=#JNB>84"LJ9
MX% 'GJ122?<0M]!0T4B??0CZUU7AJ:.#4_LLT:E<GDBM+QE8*%@>WB&">U '
M!^5)MW;#CUH6)WZ*3]*WGN4@TDP/&HD)_&MC28+!=.DD+ R%<@$4 <:;28+N
M\MB/I4FGEEOHQT^;I7H>@0+>VVV2!0/7%<?>6JVWB#"]/,H [/5H(SX<#XYK
MS&7B5OK7J6J_\BP*\MF_US?6@!E%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 444^*%YI B+ECT% !%$TSA$&237H7A;PL$"
MSW"@MU'%'A;PL$"SSKR><$5WD<:QH%4  "@ 1%B0*HP!3Z*2@!:*** "BBB@
M HHHH #TKY=\??\ (SW?^_7U#7R_X^_Y&>[_ -^KB<F+^%'*TY%+N%SU--J2
M!=\Z+ZFK/.1;GTN2%-P8-D9P.:I-$Z#+(R_45Z9HFA:7#$MSJ%SMP.C&L_7A
MI-[<I;V,B-EL#%*YK[+2YP->C?"G_D)25QNN:1)I-T(G!&1D9KLOA5_R$I*'
ML.BK31]!I]Q?I3J:GW%^E.K(]8**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDH
M XKXB?\ ()?_ '37S6_^L;ZU])_$3_D$O_NFOFQ_]8WUK2.QYV+^(=#&TTJQ
MJ.6.!7?>$M!-M>"6YB9EV^E<+:3FWNXY5&2ISBO2]+\2:O<0J8+ %0, @4V9
M4DKZFQ<7,*,ZK;O@=/E->7^*'#ZLQ"E>.AKNWU_7&D*'3ACUVUP7B62:75"T
M\>Q\=*2*JNZ,NW_X^$^M?2WPV_Y%6'\*^:;?_7I]:^EOAM_R*T/X42+PGQ'8
MT445F>B%%%% !1110!R?C/\ X]&_W:\GKUCQG_QZ-_NUY/0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4E+10 HZBO2_!H/V-N/X:\UC
MQO&>E=5IGB<Z;!Y: 'C% %S4=6DT_P 0HS$^6.HKI;ZUAU[21(N"P7/6O.M8
MU(:C+YQP&'I5W1?%,VG(4/*XZ&@"O8V[:?KBB48 />NV\0K-/I$+VYZ#/%<3
MJVL#4)?. "M[5J:;XO>*U$$JJ5 P,T 8QU+4_+:%F94SSD5TW@+<;BZ+<DBN
M?U365N 4CC4 ]P*DT/7CI&XH 2XYS0!IZ[G_ (2F/CM6WX@!_L.+CM7(7>MB
M[U-;M@-P&,5<O/%!N[00,!@"@#H_ X_XEQ^M<XDJQ>*I-W>3O3=(\4-I=N8D
M ()K%O;\S7QNE^\3GB@#M?&7SP!EY&.U7-%81:"Q?C]WWKDO^$@^V6GD7&/J
M:;>>(W^R+;18VJ,9% &?+>>7JAEC.,-_6O1XGAU+0UD?!:-,]:\F+$MN/<UM
M6&O2VMG+!GAEQ0!5U:427A"=,XKJ]"T=TTV2XD^9=N0!7"LY,A8G.3FNMTSQ
M:UK9&$JN N.: .F\-S^8<(C(OH17(ZNI'B <'_65;L_&#13Y\M57VK+O]9%W
M?+-@#:V: .WU4?\ %,CBO+9O]<WUKJ[GQ4;BQ^S$#;7*2MNE9O4T ,HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***?#$\T@1!EC
MTH 2*-Y7"*"23C@5Z)X6\+! L]PN3U&:3PMX6"!9YUY(SS7>1QK&H50 !0 1
MQK&H51@"GT44 %%%% !1110 4444 5M[>M&]O6FT4Q#M[>M?,OCO)\2W?^_7
MTQ7S-XZ_Y&6[_P!^JB<F+^%',5-:9%W&?]JH:DMW\NX1\=#5GGK<[75(KRXT
MW]U%(R[1T%<FEK>VDBS&*2-E.02,5Z9H?BR_AL1'#90RH,<M&#_2J7BK6+W4
M;,">RAA [H@'\JE;G1**:O<\^O\ 4KK490]S(78#&37;_"TD:B^*\^?[Q^M>
M@_"[_D(O3>Q%'6:/?D=MB\]J=O;UJ-/N+]*=69ZP[>WK1O;UIM% #M[>M&]O
M6FT4 .WMZT;V]:;10 [>WK1O;UIM% #M[>M&]O6FT4 .WMZT;V]:;10 [>WK
M1O;UIM% #M[>M&]O6FT4 .WMZT;V]:;10 [>WK1O;UIM% #M[>M&]O6FT4 .
MWMZT;V]:;10 [>WK1O;UIM% #M[>M&]O6FT4 .WMZT;V]:;10 [>WK1O;UIM
M% #M[>M&]O6FT4 .WMZT;V]:;10 [>WK1O;UIM% #M[>M&]O6FT4 .WMZT;V
M]:;10 [>WK1O;UIM% #M[>M&]O6FT4 .WMZT;V]:;10 [>WK1O;UIM% #M[>
MM&]O6FT4 .WMZT;V]:;10 [>WK1O;UIM% #M[>M&]O6FT4 <9\0F)TI^?X37
MSH_WV^M?17Q!_P"06_\ NFOG1_OM]:N)YV*^(09W#'6O1/!5Y=HH0Q2-'Z@<
M5PFGHKWL2O\ =+<UZ,/')\,0+:6EM X SEHP339E223NS0UG59K.-W%M)R.H
M4\5Y=JMZ]_>-,^<^]>@K\2Y]71K2YM+=1)\N1&O^%<)K\,4.H,(C\IYH155I
MJZ,^W_UZ?6OH_P"'+$>&(OPKYPM_^/A?K7T=\.O^18BI2-,)\1V&]O6DWMZT
ME%0>@31,3G-2U%#WJ6D,**** .3\9_\ 'HW^[7D]>L>,_P#CT;_=KR>@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $I:**
M $I:** "BBB@ HHHH **** "BBB@ HHHH 2BEHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI*DAA>:01H,L: "*)YI
MB*22<<5Z%X6\+! L\ZY/49%+X6\*B/;<3KR>QKNXXUC0*H  ]* ".-8D"J,
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M 4444 %%%% !1110 4444 %%%% !1110!Q?Q _Y!;_[IKYU?[[?6OHKX@_\
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MS2M1N[%7CU:&W&!\K-C^M8WBS3+VSLP;C4XKD'LC9Q5RS@T:]M5>YO7B? &
MV*RO$EGI=O:@VEV\K$<@G-3U.R7PGGC??/UKT+X7?\A%Z\];[Y^M>A?"[_D(
MO3>QA1^-'O:?<7Z4ZFI]Q?I3JS/6"BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*,4 5L'THP?2K.*,4 5L'THP?2K.*,4 5L'THP?2K.*,4 5L'THP?2K.*,4
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M>/$V.<BI;2.FC&<WN:OARTN[:Q0W4I=F7G-;= &.*6LST4K*PE+110,****
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ML*Q1(%51P!1;6T=K"L<:@ #' J>LF[GJ4Z:@M!*6BBD:!1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "8JGJ6FP:C;/
M%,@;(P,]JNT4 ]3S6U^&%O;ZTMTS*T><[,5Z%:VT=I"L42A548 %3T4[D1A&
M.P4M%%(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*/:2[A=D_P!LN?\ GL_YT?;+G_GL_P"=044>TEW"[)_MES_SV?\ .C[9<_\
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MQ_SV?\Z/MEQ_SV?\ZS8=0AFE\I3\U620HR:'*:>K"[+/VRX_Y[/^=)]MN/\
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M+:W4CG.1D5S]E=/#J/W"PK?TT'[)<18PP&*S;"S,5_OF4[?I6L7%<PS;N_\
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M@SZXK6_L6Y_NT?V+<^E'L:BZ"LS):&-_O*#1Y2$8*CBM;^Q;G^[^E']B7/\
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M_P"X/RI?)C_N#\J?11RH!GDQ_P!P?E1Y,?\ <'Y4^BCE0$?DQ_W!^5+Y,?\
M<'Y4^BCE0#/)C_N#\J3R8_[@_*I**.5 1^3'_<'Y4>3'_<%244<J C\F/^X/
MRI?)C_N#\J?11RH!GDQ_W!^5'DQ_W!^5/HHY4 SR8_[@_*CR8_[@_*GT4<J
M9Y,?]P?E1Y,?]P?E3Z*.5 ,\F/\ N#\J/)C_ +@_*GT4<J 9Y,?]P?E1Y,?]
MP?E3Z*.5 ,\F/^X/RH\F/^X/RI]%'*@&>3'_ '!^5'DQ_P!P?E3Z*.5 ,\F/
M^X/RH\F/^X/RI]%'*@&>3'_<'Y4>3'_<'Y4^BCE0#/)C_N#\J/)C_N#\J?11
MRH!GDQ_W!^5'DQ_W!^5/HHY4 SR8_P"X/RH\F/\ N#\J?11RH!GDQ_W!^5'D
MQ_W!^5/HHY4 SR8_[@_*CR8_[@_*GT4<J 9Y,?\ <'Y4>3'_ '!^5/HHY4 S
MR8_[@_*CR8_[@_*GT4<J 9Y,?]P?E1Y,?]P?E3Z*.5 ,\F/^X/RH\F/^X/RI
M]%'*@&>3'_<'Y4>3'_<'Y4^BCE0#/)C_ +@_*CR8_P"X/RI]%'*@&>3'_<'Y
M4>3'_<'Y4^BCE0#/)C_N#\J/)C_N#\J?11RH!GDQ_P!P?E1Y,?\ <'Y4^BCE
M0#/)C_N#\J/)C_N#\J?11RH!GDQ_W!^5'DQ_W!^5/HHY4 SR8_[@_*CR8_[@
M_*GT4<J 9Y,?]P?E1Y,?]P?E3Z*.5 ,\F/\ N#\J/)C_ +@_*GT4<J 9Y,?]
MP?E2>3'_ '!^524460$?DQ_W!^54-6NX=-M/.9%QG'(K2KSSX@:MLA-J&Y!S
M3C!-F&(JJE3<CM;&>"\MUD0*<C-6_*C_ +@_*N$^'NJ_:89(G;[HP*[ZAQ28
M8>JJL%(9Y,?]P?E1Y,?]P?E4E%+E1N1^3'_<'Y4>3'_<'Y5)11RH!GDQ_P!P
M?E2>3'_<'Y5)11RH"/R8_P"X/RI?)C_N#\J?11RH!GDQ_P!P?E1Y,?\ <'Y4
M^BCE0#/)C_N#\J/)C_N#\J?11RH!GDQ_W!^5'DQ_W!^5/HHY4 SR8_[@_*CR
M8_[@_*GT4<J 9Y,?]P?E1Y,?]P?E3Z*.5 ,\F/\ N#\J/)C_ +@_*GT4<J 9
MY,?]P?E1Y,?]P?E3Z*.5 ,\F/^X/RH\F/^X/RI]%'*@&>3'_ '!^5'DQ_P!P
M?E3Z*.5 ,\F/^X/RH\F/^X/RI]%'*@&>3'_<'Y4>3'_<'Y4^BCE0#/)C_N#\
MJ/)C_N#\J?11RH!GDQ_W!^5'DQ_W!^5/HHY4 SR8_P"X/RH\F/\ N#\J?11R
MH!GDQ_W!^5'DQ_W!^5/HHY4 SR8_[@_*CR8_[@_*GT4<J 9Y,?\ <'Y4>3'_
M '!^5/HHY4 SR8_[@_*CR8_[@_*GT4<J 9Y,?]P?E1Y,?]P?E3Z*.5 ,\F/^
MX/RI/)C_ +@_*I**.5 1^3'_ '!^5'DQ_P!P?E4E%'*@&>3'_<'Y4>3'_<'Y
M4^BCE0$?E1_W!^5'E1_W!^5/HHY4!1O[BWL(/-D50,XYJ>#R9XED5001GI7
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ZSA^Q(^WG K9OW3Q:=%K%'7#I2TE+6)[84444 %%%% !1110 4444 %%%%
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MZU?I&L9*2N@I:2EH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(:6D- 'E'Q%^^G
MUKS^O0/B+]]/K7G]=,-CY;&_QF'>BBE"EN%!)JCD#FDI_DR?W&_*FD%3@C!I
MA9H2BBB@09HS110,**** "BBBD(,T44JHS\*I8^U,>XE&:4AE/(Q3: %KT;X
M=?\ 'VOTKSBO1OAW_P ?2_2HGL=F!_C(]3HHHKF/J HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** &M]T_2O(O'TLBW2[7(^;UKUUONGZ5X_\0/\ CZ7_ 'JTI[GG
MYE?V6AQOGR_\]&_.CSY?^>C?G4=%;GSG,R3SY?\ GHWYT>?+_P ]&_.HJ6@.
M9DGGR_\ /1OSH\^7_GHWYU'10',R3SY?^>C?G1Y\O_/1_P ZBI: N^XXR.X^
M9F/U-*)I%& [#Z&F8SP*,8H%=DGGS?\ /1OSH\^;_GHWYU'10/F9)Y\W_/1O
MSH\^7_GHWYU'10',R3SY?^>C_G1Y\O\ ST?\ZCHIAS,D\^7_ )Z-^='GS?\
M/1OSJ.BD%V>K_#]V:%"S$\=Z] KSWX>_ZE/I7H=<T]SZC!?P4%)2T5)UA111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPG5@/XR/4J***YCZ@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1110 4444 %%%% !1110 C?</TKQ_P ?_P#'TO\ O5[ WW3]*\>^('_'TO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC?#K_CZ7Z5,]CHP'\9'J5%%%<Q]0%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C
M?=/TKQ[X@?\ 'TO^]7L+?=/TKQ[X@?\ 'TO^]6E/<\_,OX1Q-36T!N)1&O+,
M< 5#5[1SC5;;']\5NSYV"O)(EN=(EM)?+E&&]*JW-H]N 6'!Z5V/B6SDN=8R
M)@O'>N8>*XNKGR&<L$.,U*9M4I*+:1F5;LK![L,5&=O6M2+2DFG^R @2 9W5
M-I4#V<MQ$3T.*;8HTG?4S+?2GGNC"HY S5&>(PSO&>JG%=7I#'_A(&&?X#69
M+IKW=_=3#[L;$FE<<J2Y;HPZ*W(]+6]C_<X##M2PZ/O@E?C,?6G<CV4C"HK<
M;2/^)0MZ!P3C%4;BV$,2DCEAFFF)TVMRC15NPMQ<7&RKITP+>10'&9#@&BY,
M:;:NC'HKHX/#C2:HUJ7' S4@\/HZ3 2+N3C%+F-/83L<Q14MS;M;3&-^HJ*F
M8M-.S/5?A[_J4^E>AUYY\/?]2GTKT.N:>Y]1@?X*"BBBI.P**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /)_B-]]/K7G]>@?$;[Z?6O/ZZ8?"?+8W^,RQ8LB7
M<;2'"AN370ZY?64]N!!,2V!Q7+4535S"%1QBXEO39$34(9)6(56R:U_$-]:S
M:DL]L^X =:YVBBP*HU'E.KN[NSO;:W!DPR#FB'7DLIQ'$V8_6N5!(& :2ERE
M_6);HZR_BT>:/[0LY\YADC'>ET[4+.6U^Q7,NV+.<BN3R<=:3)%'*'UC6Z1T
M=R;"QNDDM9V< YYJY<W&G:A:K+++B;(XQ7(DDT9([T<H>W\CL=2U"P,MB8I<
MB+&>*DGN],GU(W1FY(KB<D]Z7<?6ERE?6'V.O-[IPG!$W&:HMJ4$&M--$V4(
MQFN=R:*?*2Z\F=??1Z/)$)TNF\UADC'>N6N2IF)4Y'K46XXI*:1%2IS= KT;
MX=?\?2_2O.:]&^'7_'TOTJ9['3@/XR/4J***YCZ<**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2O'_ !__ ,?2_P"]7L!^Z?I7E_C31[B\N5,:,1GL*NF]3@S"+E2LCSBBMO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD0_\\T_*CR(?^>:?E4E% 61'Y$/_ #S3\J/(A_YYI^5244!9$?D0_P#/-/\
MOFCR(O\ GFG_ 'R*DHH"R&JB+]U0/H*=110,**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
7!1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gn15qjhcndsi000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gn15qjhcndsi000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +/!:0# 2(  A$! Q$!_\0
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M^>%'_"*:5_SPK;HHNP]A3_E1B?\ "*:5_P \*/\ A%-*_P">%;=%%V'L*?\
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MFE?\\*/^$4TK_GA6W11=A["G_*C$_P"$4TK_ )X4?\(II7_/"MNBB[#V%/\
ME1B?\(II7_/"C_A%-*_YX5MT478>PI_RHQ/^$4TK_GA1_P (II7_ #PK;HHN
MP]A3_E1B?\(II7_/"C_A%-*_YX5MT478>PI_RHQ/^$4TK_GA1_PBFE?\\*VZ
M*+L/84_Y48G_  BFE?\ /"C_ (132O\ GA6W11=A["G_ "HQ/^$4TK_GA1_P
MBFE?\\*VZ*+L/84_Y48G_"*:5_SPH_X132O^>%;=%%V'L*?\J,3_ (132O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "J]]_QXS?[AJQ5>^_X\9O]PT"ELS"\/?\ (+'^^U%'A[_D%C_?:BJ>YRTO
M@19\)_\ ("AK<K#\)_\ ("AK<I/<VH?PX^@4444C4**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "J]]_QXS?[AJQ5>^_X\9O]PT"ELS"\/?\ (+'^^U%'A[_D%C_?
M:BJ>YRTO@19\)_\ ("AK<K#\)_\ ("AK<I/<VH?PX^@4444C4**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA_#CZ!1112-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "J]]_QXS?[AJQ5>^_X\9O]PT"ELS"\/?\ (+'^^U%'
MA[_D%C_?:BJ>YRTO@19\)_\ ("AK<K#\)_\ ("AK<I/<VH?PX^@4444C4***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M" \MV% &I158WB;%<<JW0U.CJXRI!^E #J*** "BBB@ HHHH **** "BBB@
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M[@JP/% $4&I6MO($E8B8\&MD$,H(Z$9KC;S3[A[\;8VP&!W5V$(*PH#U"BF
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M11Y:?W10!']HC]:/M$?K4GEI_=%'EI_=% $?VB/UH^T1^M2>6G]T4>6G]T4
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M>'O^06/]]J*I[G+2^!%GPG_R H:W*P_"?_("AK<I/<VH?PX^@4444C4****
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ML?[[453W.6E\"+/A/_D!0UN5A^$_^0%#6Y2>YM0_AQ] HHHI&H4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 5A>(?]4/I6[6%XA_U0^E
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M^!%GPG_R H:W*P_"?_("AK<I/<VH?PX^@4444C4**** "BBB@ HHHH ****
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MOJ/SKF=2U#5-[M9D;(N7SZ4 =/17/Z-KZ7=GOG/SYQ3$UBXF>=XC^[AY;Z4
M='1639ZF;^P\^$]\5;L[Z.ZW(I^=.&H MT444 %%%% !1110 5A>(?\ 5#Z5
MNUA>(?\ 5#Z4 <6ZEEQFJJ6"))O4 '.:N44AD-Q;K<1[' -0PV*Q]<$5<HH
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M^F::;F,/MW ^^: )J*C>9$7<6&#[TL<JR#*D'Z&@!]%-$BEBH/(IU !1110
M4444 %%%!('4XH **C\Y!U8#ZFG)(D@RCJP]CF@!U%-,B*<,ZCZFG=>E !11
M3'FCC&6=1]30 ^BHXYXI?N2(WT8&E:5$ZL,^F: 'T4Q9$895@<>AI5=6Z$4
M.HHHH **** "BBB@ IDKA$R:?5>\_P!0:!-V12.JQHQ  %)_;*>U<]-_KG^M
M1T['&Z\CI?[93VH_ME/:N:HHL'MY'2_VRGM1_;*>U<U118/;R.E_ME/:C^V4
M]JYJBBP>WD=*=80C! -7[699H0R@ 'TKBZZK1_\ CR2@UI5)2=F:-%%%(Z H
MHHH **** "J6I_\ 'L?H:NU2U/\ X]C]#0!P$O\ K7^M<U<_\A)OK72R_P"M
M?ZFN8NFQJ3?*>H[4AFAK1(T20CKMJ+01G2D8]2M7+V W.FF(?Q+5'36^SQM;
M$$;%- &?*-VMQ1C[IZUH&TDBN'VJ2K<5%86[7-Y]H((V,1S6U<3").AR>!0!
MF10_9HS;H>7.<U+%=+#F- &=?O5/:0$DR2\MG@UDVZ.FJWC,#M*G% &W:72W
M2%E(X.*])TC_ )!L/TKR/04<12'&!O/7ZUZYH_\ R#(?I0!>HHHIB"BBB@ H
MHHH *XK0[EM0\1WT,AR(FXS7:UQ>C6K:;XAO9I!@3-Q0!N:_;I<:>\;J"I'0
MUR-NEUX:N4E3=)#.>0>BBNNUB4F(H%8DCL*>]C'?Z6L<BY;9@9H RA=0WVLQ
MR1RC;MY(JU);1&1C_:!'MFLW1] FT_40LN#'G/%=(VD6;,28N30!0M;>)9@1
M?%_;-7KWR8K*1<#<ZX'O2KIEI;G>D>"*YB[U&4WC+(DC+&WRX4T 0W%G);:"
M\X!1]W05?TQ5_L6Z;NT?-3PE]6@\IE81GLPJO!%+:Q75JP)$@VI@=*0$?A-V
M\@I_!DTS1+AK?6;Q220\G'MTK6\.Z8VG:<5F(\S).:RM"MFN-9O'8'"OD9'T
MH&=GVHH%%,04444 %%%% !6+KR;XQ]*VJR=9^X/I03-VC='&_9S1]G-7:*=C
MD]O(I?9S1]G-7:*+![>12^SFC[.:NT46#V\BE]G-'V<U=HHL'MY%:"W/FK]1
M7H%OQ;QC_9%<7%_K5^HKM(/]0GTI&]&HY[DE%%%!L%%%% !1110 5SOB/[OX
M5T5<]XC^[^% '&7!;R7"C)(-8>D17$,K!XB 6)S^-=#12&4M1N9[:-6AB,A)
MY%5?M%S>PF*2 H#WK7HH @M81#"J]Q4-UYDDPA"G8PY:KM% %=K<+:-&.NW%
M8*6<ZZ;-;>6?G;.?SKIJ* #P_"84@0]017IL?^K7Z"O/+#_CZ3_>%>AQ_P"K
M7Z"F ZBBB@04444 %%%% !7*^)/]:WTKJJY7Q)_K6^E '-454N[^.T +*6SZ
M5%::O#=N$ *D_P!ZD,T**9)*L:;B155=2B8_=('J: +M%1-.BQ[R>,9JO#J,
M4TFP CW- %VBDW#;GM4:3J[[0#]: -/2_P#C]B_WJ] '05Y_I?\ Q^Q?[U>@
MCH*8@HHHH **** "BBB@ HHIK2*O4C/UH =148FB)P)$SZ;A3RP49) ^M "T
M4U75ONL#]#3J "BD)"C)( ]ZB%W!OV^:F?\ >% $U%(64+DL,>N:8)XR>'7\
MZ )**:)%)QD4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J]
M]_QXS?[AJQ5>^_X\9O\ <- I;,PO#W_(+'^^U%'A[_D%C_?:BJ>YRTO@19\)
M_P#("AK<K#\)_P#("AK<I/<VH?PX^@4444C4**** "BBB@ HHHH **** "N7
MU^YDM=6@E8D6ZCYCFNHKF]9B-SJD,,BDPL/F]* *]G=EKB>YC8F%U.TYJ*V:
M0Z->2ECN#''/UHM-/FCU&XB0_P"CJIV+VI8%<:)>1E2'+' ]>M(9%)///I,(
MR<^N:OZ)--;V,F[)?/&35O1[)1I<9F3) Z&E$'G$O$NQ5."OK3 GM)(Q*97<
M[VZK6GG(KBKQKE+Y1'NQO&<"NRASY*9Z[10(?03CK12,-PQ0 F]?6C>OK4?E
M'UH\H^M $F]?6L?6=36")H8V_>GH*U/*/K7&:XC_ /"4P@GY-O/Z4 ;,UI]K
MT9G,C+)L)X/>N6\,ZU<Z7=FSNR?)+DEF.3UKN/+ TT\@#;7.KHB:GI<QC($^
M[ ?TZT@+NM^7.UK+',P4MG@UK?VG9VR*DDN#@=:X*&[N5O(["=7_ '3;0Q'!
MKJ;KP])=LL@D ^44QFH-:L2<"852OK"/5I=PG=4(ZJ:I+X6E5P?-'%7IIHM*
MM2KRJ7';/- CF["&31]1F\F5Y5+<[F)Q5P7;:AXCC7>1&5YP:N6EK ZS3-.C
M&49"YY%9NG0&W\1I&_<9S2&6+&]-EJ<\+N2KM@9-7FU$VFLK"Q_<D9)-8H@:
M[UMMG.R3FK'B*,K=#8?GQ0!V23(Z!@>#3MZ^M4M.B8Z?"6/.VK7E'UIB'[U]
M:-Z^M1^4?6CRCZT 2;U]:-Z^M1^4?6E\H^M #]Z^M5[MU\@\U)Y1]:@NXB(3
MS0*6QRDW^N;ZTRGS?ZUOK3*H\U[A1110 4444 %%%% !74:0X%DF37+UTVDQ
MYLT-)F^'^(T]Z^M&]?6H_*/K1Y1]:1V$F]?6C>OK4?E'UH\H^M $F]?6C>OK
M4?E'UH\H^M $GF+ZU2U)U-L>>QJSY1]:K7T/[@Y]* ;LKG S<RO]:K&TC+[B
M.?I6S)"GF-QWIODI_=HL8?6(]C."@#%0R6J.<]#[5K^2GI1Y*>E%@^LQ[&:D
M:QC"@"DDC$F,]JT_)3TH\E/2BP?68]C. P,"HI+9)#G&#[5K>2G]VCR4]*+!
M]9CV,R.-8UPH KT+2' TV+GM7(>2GI77Z=#_ *%'CTHL7"JINR+WF+ZT;U]:
MC\D^M'E'UH-"3>OK1O7UJ/RCZT>4?6@"3>OK1O7UJ/RCZT>4?6@"3S%]:IW=
MG#<LKYVLISQWJQY)]:H:H9(8,HV#B@"\FQD^=1D<<BI R 8&!7 -JEWN/[X]
M:3^U+S_GL:!GH&Y,YXS2[U]:\^_M2\_Y[&C^U;O_ )[&@#T'>OK49CMR<F-"
M?]VN"_M2\_Y[&C^U+O\ Y[&@#OU\I/NJH^@H/E$YVK^5<!_:EY_SV-']J7?_
M #V- '=7($D6Q3CZ4VUMXK8$KC+=>*XJ/4[LN!YQKM+1&>UC8GDB@"UYB^M&
M]?6F>4?6D\H^M B3>OK1O7UIGE'UI/*/K0!)O7UHWKZU'Y1]:/*/K0!)O7UK
M*UA@4&#VK1\H^M9>KIM0?2A$5/A.>HHHJCSPHHHH **** "BBB@!\7^L7ZBN
MRA=?(3GM7&Q?ZQ?K77PQ'R4Y[4F=6&ZD^]?6C>OK4?E'UH\H^M(Z23>OK1O7
MUJ/RCZT>4?6@"3>OK1O7UJ/RCZT>4?6@"3>OK7/>(F!7CTK=\H^M8^LQ#'//
M% I245<XZBM#R4]*/)3THL8_68]C/HK0\E/2CR4]*+!]9CV,^BM#R4]*/)3T
MHL'UF/8SZ*T/)3TH\E/2BP?68]B&P_X^4_WA7H*.OEKSV%<99PIYZX'>NP2$
M[%Y[4&D*BGL2[U]:-Z^M1^4?6CRCZT%DF]?6C>OK4?E'UH\H^M $F]?6C>OK
M4?E'UI?*/K0 _>OK7+>)&!D./2NE\H^M<QXB7;(?I2&<E]C5I&9N<^M8MY;"
M/508B0V.@KH)I5B0DGGM5&"'SKC[2_&.,&@#.U>Z>-[*,'[QPWZU>U& +IN%
MX/7(K.U]"+ZR(Y&^M;5' T[.>U &1]HDF1$&<)UIS-NXB/S58T6WW"4N,ANE
M7I((;5=X0$T (\[""*(=6&#5JUA$,>WJ?4U0*F.WDE;GC*^U4/MLZ::+HR$_
M-C% '9:8<7L6?[U=^'7 YKSK0G,S6SGJW->A"(X'- B3>OK1O7UJ/RCZT>4?
M6F!)O7UHWKZU'Y1]:/*/K0!)O7UHWKZU'Y1]:/*/K0!%?7BVEE+/G[@S63I<
MW]J1?;2YVN.QXJ7Q)&PT.ZP?X*H^"HR?"T))[?TH&8.H_:]-U-;F!W>%6RY+
M<"NJ@U.'6=+619,,?[M0+:Q73R0R$,&."*YW4;6Y\-WS31[FM6.U8U'2D!TN
MD3PV8F\V8GGN:T?[;L/^>PK#TZQ?4K5G#;=PS@T[_A%9?^>PI@;$UU!J,+0Q
M2G:W!([5R/B#1!IL$,\-U,S&0 @L?45T=GIG]EQ,\LJX'-5)I+?4[CRWG3RP
M<C)I"*]_JTJ06]FQP9$'.>:K:HSZ7I5M*DC,[2 ')]Q2Z]:9U2TEC.8XQR1T
MI/%!$FBVAC^;,HX'U% S8N[L)IZ7P<YC0$CM6EI.H#4-/CN"1\WI6'J%LT7A
M*7<>L8-2^$(W.B0<\8IB.EWKZT;U]:9Y1]:3RCZT 2;U]:=40B(/6I1P* "B
MBB@ HHHH **** "BBB@ HHHH **** "J]]_QXS?[AJQ5>^_X\9O]PT"ELS"\
M/?\ (+'^^U%'A[_D%C_?:BJ>YRTO@19\)_\ ("AK<K#\)_\ ("AK<I/<VH?P
MX^@4444C4**** "BBB@ HHHH **** "H9K9)OO"IJ* (8K=(A\HIILXFDWX_
M"K%% #=H"[0,"D2-4! '6GT4 5S9Q-)O(Y^E6!P,444 %%%% !1110 5BZWI
MOGJ;B,9F48%;5-<@)\W2@#-MD^T6"P/G>%PU3Z=8)81&-,X)SS4)U.VAD*@J
M#1_;5O\ WUH 6[T6VNIDE9<,ISP*T5&U0/08K-_MJ#^^M']LV_\ >6@#3K"U
M/PY!J5UY\C/G&, \5:_MF#^^M']LP?WUH I6OABWMY%<,_!SR:N7.D1270NT
MSYJC I?[9M_[ZT?VS!_?6@866E06#R3C.Y^6S6?)9-?:X)L9@Q@FKYUFW(P6
M6K=I+%-'NB Q[4")XT$:!!T%.HHH **** "BBB@ JO>?Z@U8JO>?Z@T"EL<A
M-_KG^M1U)-_KG^M1U1YKW"BBB@ HHHH **** "NJT?\ X\DKE:ZK1_\ CR2D
MS?#_ !&C1112.P**** "BBB@ JK??Z@_2K55;[_4'Z4"EL<A)_K&^M-ITG^L
M;ZTVJ/-"BBB@ HHHH **** "NPTW_CQC^E<?78:;_P >,?TI,Z,/\3+=%%%(
MZPHHHH **** "LO6O^/;\*U*R]:_X]OPH X.7=\VWKFL6TU&XEOI8I,;5.!6
MXWWC]:YNS_Y"L_\ O4AF[<7"VT!D<X K.2\NI1)(H&P<BH_$SE-'<CBK&FJ/
M[(1NY3F@ MM3#6Y:4X8&JPU&Y:1B /+6J$:&34Q #A35D0S([Q>6V#QF@#9L
M[D7,'F U&MP\TQ6/D*>:IQ(T%M]F4_,>:L17$<0PN"W\9]* -2+[XKT2Q_X\
M8?\ =KS>UE28AD((SVKTBQ_X\8?]V@"Q1113$%%%% !1110 5DZS]P?2M:LG
M6?N#Z4(BI\+.:HHHJCSPHHHH **** "BBB@!\/\ K5^HKM(?]0GTKBX?]:OU
M%=I#_J$^E)G3A^I)1112.H**** "BBB@ K&UKI^%;-8VM=/PH1G5^$YVBBBJ
M. **** "BBB@ HHHH L6?_'POUKL4^XOTKCK/_CX7ZUV*?<7Z4F=6'V8ZBBB
MD=(4444 %%%% !7*^)/]:WTKJJY7Q)_K6^E 'GE_#J<LP,2@JIXI(UU=B%DC
M4)[5OT4AF?<V/VF&,N/WB#BJTMI=W%OY,J_+6S10!!:P""%5 Y J*2"26Y^8
M?NZN44 03P"2V:,>F!61_9<[6?V9E^3.:WJ* +.AQ^5-;Q_W3BO1AT%>?:7_
M ,?L7^]7H(Z"F(**** "BBB@ HHHH K:A;?:[&6 C[XQ65HT!TV$6!&%45O5
M1N;JWMY"7"[O4T 10Z6D<_FC/)S5F]L8;Z(1RC(!STJM_;-O_?6H+KQ%;VT6
M_<IH T+*RCLT*Q]#5JN,B\<^9<B/[+A2<;JT+OQ7!;0!P%9B?NYH U]0L4OK
M=H7)"L,'%847@VUB"A7DX/K4EEXM@N>) L9[ GK5^77K:)-S.OYT 2_V1!]E
M,)R01C)JLN@PE%B?)C0Y&:2U\0Q3ABP"X/'O5C^V8/[ZT 0ZL@N+0V"<AEQ5
MK1[+^S]-CMR,%:;#?6UQ*,;2W:M&@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "J]]_P >,W^X:L57OO\ CQF_W#0*6S,+P]_R"Q_OM11X>_Y!
M8_WVHJGN<M+X$6?"?_("AK<K#\)_\@*&MRD]S:A_#CZ!1112-0HIGFIOV9^8
M=J?0 44W>N<9YIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M0W/^H:IJAN?]0U 'G]__ ,?LGUJM5F__ ./V3ZU6I#"BBB@ S129%!8#J: %
MHH!R,BD)P.: %KL_#7_(/'UKC*[/PU_R#Q]: -RBBBF(**** "BBB@ JO>?Z
M@U8JO>?Z@T"EL<A-_KG^M1U)-_KG^M1U1YKW"BBB@ HHHH **** "NJT?_CR
M2N5KJM'_ ./)*3-\/\1HT444CL"BBB@ HHHH *JWW^H/TJU56^_U!^E I;'(
M2?ZQOK3:=)_K&^M-JCS0HHHH **** "BBB@ KL--_P"/&/Z5Q]=AIO\ QXQ_
M2DSHP_Q,MT444CK"BBB@ HHHH *R]:_X]OPK4K+UK_CV_"@#A6^\?K7-6AQJ
MDW^]722+N+#..:H+IJ+,9 W).:0R+7+8W6EM&HR33+&4)IIB/6-,5K;05P>1
M51M/4N2&(SVH RM*@:6[%SC@&MNXE$:?[1Z4Z&%84VJ!22PB5E)/2@"K;0EO
MWTG^L]:R++=OU'=^'Z5TH  Q51[!&<L#C/7'>@"OX:W?9!G^]7K=C_QXP_[M
M>;VD*P811QFO2+'_ (\H?]V@"Q1113$%%%% !1110 5DZS]P?2M:LG6?N#Z4
M(BI\+.:HHHJCSPHHHH **** "BBB@!\/^M7ZBNTA_P!0GTKBX?\ 6K]17:0_
MZA/I29TX?J24444CJ"BBB@ HHHH *QM:Z?A6S6-K73\*$9U?A.=HHHJC@"BB
MB@ HHHH **** +%G_P ?"_6NQ3[B_2N.L_\ CX7ZUV*?<7Z4F=6'V8ZBBBD=
M(4444 %%%% !7*^)/]:WTKJJY7Q)_K6^E '-4444AA1110 4444 %%%% %[2
M_P#C]B_WJ] '05Y_I?\ Q^Q?[U>@CH*8@HHHH **** "BBB@ KD?$?\ KFKK
MJY'Q'_KF^M '/5C:T;AH\1G@'-;-,(1C@@&D,P=-U&%I%BD#>9T&:DU-'2;>
M>5)[4:E:(+^%HP%([#O6LD0DA D4$^] &(H:6[AD3(5>N:T)7-S.8B?E7D4L
M^U#Y* ?-WJGJI:SL8MOWB^"?RH VD*A0H(X]ZDKG)97@OK50Y(< GFNA!R,T
M :^A_P#'ZGUKN:X;0_\ C\3ZUW-,04444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !5>^_X\9O]PU8JO??\>,W^X:!2V9A>'O^06/]]J*/#W_(+'^^
MU%4]SEI? BSX3_Y 4-;E8?A/_D!0UN4GN;4/X<?0*S-5UA-+3<T3N,9^45IU
M%<6\=Q$T<B@@^HI&IYQ_PGL,>L22O&XC(X4UICXEZ?C_ %+U6U'P);3:F\TA
M=83T(IR?#73)%R)9?\_C2&17OC^"Z,:6<3K(7 )]LUW]HYELX7/5D!-<AIW@
M/2[.[RLDC..Q_P#UUV<:".-47HHP*8AU%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5#<_ZAJFJ&Y_U#4 >?W_\ Q^2?6N9U*>YBO %DPF.E=-?_
M /'[)]:YC5_^/L?2D,V+9BULC,><5FZE<2--]GAF6-B."36C:C-H@]JS-0T&
M*ZD\X2.'] : %LK:_C)::Y61?:F2W$TNIK"K84CI4.FW$]O.]O.,(.%)[U;F
MLI5OEN(5S@4 &EWCS7<\+G_5G%69YFDF\B/J>]4XH!922.W#S=JDCF$#;/\
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MZL/LQU%%%(Z0HHHH **** "N?UO[Y^E=!7/ZW]\_2A&5;X#$HHHJCA"BBB@
MHHHH **** +5A_Q]1_6NQ'2N.L/^/J/ZUV(Z4F=>'V84444CH"BBB@ HHHH
M*YS6O]<U='7.:U_KFH1C6^$QZ***HX@HHHH **** "BBB@#0TK_CY7ZUU=<I
MI7_'ROUKJZ3.S#_"%%%%(W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M HHHH **** "NPTW_CQC^E<?78:;_P >,?TI,Z,/\3+=%%%(ZPHHHH ****
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MJCB"BBB@ HHHH **** -#2O^/E?K75URFE?\?*_6NKI,[,/\(4444C<****
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M>^*Z%&W(K>HS0 ZBBFL<#- #J*A\TT>:: )JBG_U1I/--1S2DQ&@3V.4NO\
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MI @PZXZ5$NE/%;2V8R5E.=WI70T4 4[*T%G8K #D@8S3(+/*MYARQ/!-7Z*
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MZ4;5]*6B@!-J^E&U?2EHH 3:OI5#5%'D].U:%4-4_P!3^%!,_A9R4CK&"SG
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MCH$VKZ4;5]*6B@!-J^E&U?2EHH 3:/2L#6@-Y^E=!7/ZW_K#0C*M\!S\UQ%
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M:* "BBB@ I, = *6B@#0TK_CY7ZUU=<II7_'ROUKJZ3.S#_"%%%%(W"BBB@
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MZ"@0^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CG_U1J2HY_\
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M3*H\U[A1110 4444 %%%% !75:/_ ,>25RM=-I,J+9H":3-\/\1JT5%Y\?\
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M3Z* &>4G]T57NXD$!^6K=5[S_4&@4MCCYO\ 7-]:94DW^N?ZU'5'FO<****
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M/_D!0UN5A^$_^0%#6Y2>YM0_AQ] HHHI&H4444 %%%% !1110 4444 %%%%
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MK#\)_P#("AK<I/<VH?PX^@4444C4**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "HI_P#5&I:CG_U1H$]CCKK_ (^7^M0U/=?\?+_6
MH*H\Z6X4444""BBB@ HHHH *Z;0_^/,?6N9KIM#_ ./,?6DS:A\9JT444CM"
MBBB@ HHHH *KWG^H-6*KWG^H- I;'(3?ZY_K4=23?ZY_K4=4>:]PHHHH ***
M* "BBB@ KJM'_P"/)*Y6NJT?_CR2DS?#_$:-%%%([ HHHH **** "JM]_J#]
M*M55OO\ 4'Z4"EL<A)_K&^M-IS_ZQOK3:H\T**** "BBB@ HHHH *[#3?^/&
M/Z5Q]=AIO_'C']*3.C#_ !,MT444CK"BBB@ HHHH *S]4_U/X5H5GZI_J?PH
M)G\+.5/WC]:2E/WC]:2J/."BBB@ HHHH **** '1_?%=G:_\>L?TKC(_OBNS
MM?\ CUC^E)G3A]V34444CJ"BBB@ HHHH *R=9^X/I6M63K/W!]*$14^%G-44
M451YX4444 %%%% !1110 ^'_ %J_45VD/^H3Z5Q</^M7ZBNT@_U"?2DSIP_4
MDHHHI'4%%%% !1110 5C:UT_"MFL;6NGX4(SJ_"<[1115' %%%% !1110 44
M44 6+/\ X^%^M=BGW%^E<=9_Z]?K78I]Q?I29U8?9CJ***1TA1110 4444 %
M<_K?WS]*Z"L#6_OFA&5;X##HHHJCA"BBB@ HHHH **** +5A_P ?4?UKL1TK
MCK#_ (^H_K78CI29UX?9A1112.@**** "BBB@ KG-:_US5T=<YK7^N:A&-;X
M3'HHHJCB"BBB@ HHHH **** -#2O^/E?K75URFE?\?*_6NKI,[,/\(4444C<
M**** "BBB@ HHHH **** "BBB@ HHHH **** "J]]_QXS?[AJQ5>^_X\9O\
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M% !1110 4444 %%%% #2Z*<%@,TZN<\07$MM<VNP\.^#70QG,:GV% #J***
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M?96^M=/X?D>32XV="I]#5^>UBN,>8N<4Z*)(8PB#"B@"2BBB@ HHHH ****
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M9O\ <-6*KWW_ !XS?[AH%+9F%X>_Y!8_WVHH\/?\@L?[[453W.6E\"+/A/\
MY 4-;E8?A/\ Y 4-;E)[FU#^''T"BBBD:A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 44F0.IHW#U% "T4F1ZT;E]10 M%)D'H:"0.IH 6BD!!Z&EH ****
M"BBB@ HHR!U-)N'J* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5"[U2*UD*,"2*OUS.
MM?\ 'VU!G5DXQNB^->@+ ;6YK1CF\^W+IQQ7&1_ZP?6NLL/^/'\*9G1J2D]3
M"M+Z_?475YOW8?&*WY-0AC;:2"WH#7-VG-_,/]NDBM]_B&52[8V=,U)T'2?V
MC#C((/KSTIYOH1 )=PVGOFN.L(-UKJ9,C':3CFF2;CX3MSYC9+CG/TI@=B-1
M@+JN0-W3FG/?PI*8]P+#T-<S=:>JQVDJROOV@@9ZU3TZ%[GQ%(LKL#MZ9^M
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M/_?5'*'UA?RLZFBN6\WQ'ZP_]]4>;XC]8?\ OJCE#ZPOY6=317+>;XC]8?\
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MN0TAZFL3S?$?K#_WU1YOB/UA_P"^J.4/K"_E9N7.FPW%S'.Z LG0TM_I\5]
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6.G7EMIBQS[/,W$G!HH>Y--/D6A__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gn15qjhcndsi000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gn15qjhcndsi000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 2;!F # 2(  A$! Q$!_\0
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M\>*-RH!KG/\ A8=Y_P ]C2?$/_D)R_6N$KHC%-'SN*Q56%5I,[S_ (6'>_\
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MX6'>_P#/8T?\+#O/^>QK@Z*.1!]=K?S'>?\ "P[W_GL:/^%AWG_/8UPBJ6;
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M!]=K?S'>?\+#O?\ GL:/^%AWO_/8UP=%'(@^NUOYCO/^%AWO_/8T?\+#O?\
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M(?7*ZZG>?\+#O/\ GL:/^%AWO_/8UP=%'(@^NUOYCO/^%AWO_/8T?\+#O/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KT7PC_R!17G5>B^$?^0**B>QUX+^(<-JO_(4
MN/\ ?JG5S5?^0I<?[]4ZI'+/XF%%%%,04444 %%%% !1110 5OS(W_"-1?*>
MOI6$C;'#8SBMQO$A;3%LOLZ;1WQ4LUI.*3YF4]'U273+R.16PH.2*]:CU:#6
M="\S.6*GJ?:O%&;<Y;IDUJ:7K4^G$@$LI7&">*4HW-\+BG2O%[,EL,+XH7T$
MIKT+QPID\,V^P%OWO;GTKRQ;IEO3<@?-NS76+XYD.FI;26Z.%.?FI23NF7AZ
MT%3G"3M<ZO28V3PM< @YV5QWAT'_ (21^#T']:E7X@3I:R0"U3:U8]EXB>RU
M-[U85)8?=I*+U-*E>DW"SV.Q\>@FXM< _<'\JUK<'_A"X>.Q_D*X75?&4NJ.
MC26ZC8,"K">/9TTU;,6R[0",TN5V2+6*I>TE*^YO>  ?,N./^6I_G7->*0?^
M$S?CCS5_G3='\93:09#';JV]MU9VJ:X^IZA]K:,*VX-Q[&J47S7,*E>FZ$8)
MZIGIGBD9\-+CG]RO\JQ?A^IB\Z1_E'E'KQVK&N?&TUW:K;/"NT*%S58^*GAM
M/(AB5>,9%)1=K&\\32=95$]CI++489O%40!Z.1U]Z=XW^W6LGVB!B5+<;1FO
M/;>_E@O1<@G<#GK77)X]9[,0S6L;X'5AFAQ:=T1#$PG3E&;LV<_>:IJE] 1<
MR94#&"*]/TW(\$P_]<S_ "KRN_U?[9="40J@'\('%;T'CZ>'3!9"V7:%QFG*
M+:T)PU>%.4G)[HY*Y_X^IL_WS_.HJEN)O/E:3&-Q)J*K/.>YZ-\.KJ- (F(#
M%O6LS5XG/B\L <>:.<5S.F:E+IMTL\9/R]LUNMXI\Q_.:!-^<YQ4.+O<[XUX
M2HJ$M+,Z_P <7,:Z0(<C>8U[^U/\)@_V%+P?]4:\YU;7)M4N%D?( &-N:V-.
M\<SZ?9?9DME(V[<TN5VL;1Q=-UW.6Q@:N"+^3(_B/\ZH5<U&^-_<&8H%)["J
MB-M8-C.*T1YDVG)V/6/AL"-*Y!^]7%>+9)!K%P.<;_2K>C>.IM'M?)CME(SU
MK'U?7&U69I&B523GBH2?-<[JU>G+#QIIZHR*]$\.Z&RZ9+=3@,NS<H%>=UV.
ME>-Y;"R^S^2K*%QS3E=K0QPDJ<9WJ';^#[CS;<A054,1@BO/;H$>-B2,?OZT
M;+Q[+;2Y2V11GH!7/ZAK37FI"[$85@^[BI46FSHKXBG*G%)ZIGHOCM2^BG:,
M_*.GTKG_ (<J1=39!ZU2F\<37&G_ &:2W5O<U2T;Q5)H\\LL<"MYASCTH47R
MV*GB*3Q$:M]#J=<D6'QZCO\ =VU?\9_:GT^SFLV^ZN3@9]:X+6O$LNKWGVEH
MQ&_M6U9>/)(K(6\MND@5< MS1RO0:Q-.3G%NR?4Q+C5M6GLO*GD/E9^Z0:[[
MPGG^P[K/_//_  KS[5M;_M!CM@2,'^Z*U-.\<3Z?9-;I;J05VDTY)M&5"O"G
M4O*5S:\+@_\ "7=#TJMXZ'_$SMO]_P#QK'LO%\MGJ/VQ+=2WI5?7?$LFMR([
MQ!"OI0D[W'*O3]@X)ZW/0(?F\& +SSV^E>>6OVJWU)YXCMV/D\5?TSQG-8:>
M+0PAU'<U0&O'[2TWDKR<XQ0DU<5:M3FHM/5'I&BZ_!KEO]BNT=I<9)->=^*;
M&*SOV\H !F[&K4'BLP7!N8X$5B,8 K!O[Y[ZX:5\\G.*(Q:8L1B(U*:3U94'
M!S7I7@'45DM+BWN&R&X S7FM7]-U.33WS'GK525T<^&K>RJ*1W%[JL6C^)&@
MB.%! X^M:?B^2W?2HI6Y=H\@YKS*_P!0>]OS<MPQ.:N:KKTVHP0Q-D"-=O6I
MY-CJ^N+EG'OL7/!A+:UD^E=%\1P<VG'\%<9HNLMH]UYZ1ASCH:T=<\72ZVBK
M) J[1@4-/FN13K06'=-O5G>^'N? \(')P>/P%>;6T;+XDY!'[P]JT-&\8SZ5
M9BV$0= ,<UG3:X9-26[$*J5;. .M"BTV56KTYPAKJCT7Q0#_ ,(K;\?Q_P"%
M)X:!_P"$?N^*Y*_\=3WUDMLULH53FDLO'4UE:O MLI#]:GE=CH^M4?:\U]+6
M,+6QC5):SJM:A>F_NWG*A2W855K5;'DS:<FT%%%%,D**** "BBB@ HHHH ?%
M_K5^M>U>!/\ D#M]:\5B_P!:OUKVKP)_R!V^M95-CT\K_BG&_$/_ )"<OUKA
M*[OXA_\ (3E^M<)50V.;&_QI!1115G*:N@?\A%/J*];UN..31460<&,5Y+X?
M4MJ2X'<5ZGXF20^'QLSGRATK*>Z/6P.E&9P^O6UM#X<A:$ '=V/TKE[.X,%T
MDAZ+5\?;+RUCM-C, ?6DU;2VTL1JX(+KGFK6FAQ5+R?/%62L>CP6D.K>&4FA
M \PJ2?RKA+17M8[ISP4<UT/@#5@TC6DK8C"'K]*SO&+PV=P8K8AEDY.*A:.Q
MV57&=*-9=!?"FEIK.IS33KN786'Y&M1$;^WH;5V M\X8$U%\.[J/[3)$2 ?+
M(_0U%XJL+^#4%>WC8@\Y%#^*P02C04TKZZE/Q%81V&NA[<KY;2*, Y[UV>N6
M]I9Z MP(\2>6#G\*\Q<W#7L G+%_,7()]Z].\5 _\(N/^N*_RI2Z%8>2E&I)
M(BTB&WU70"TJ;B(R1^5<9X5D>'Q6L"G"&1N/QKM?" /_  CK?]<F_E7$>'L)
MXT3/'[QOYT+J.K_RZD=5X]U&>SB7RGQ\W-<TE\+SPW<%FR^?7ZUO_$2VEFMU
M:-21NS7FT<\D!*Y.,\BG!:&.,J2A7=]C>\,:I;Z3).TZD[T(&*K^9'>ZTACX
M4DGFL9W+N6Z9IT4[1'(Z^M7;J<:K/E47LC>\0WZRV\=J#DQFN<I\DC2.68DD
MTRFE8BI-SE=A1113("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5P<YJA13L@E6G))-['17OBFZO;58I)"3WKGF8LQ)[TE%"20IU)3=Y,****9
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#5=]+TDOMBNBWI2YD;?5YI:G.T5NW.@_90&DR$;D&M*'PBD^E+>H6*D=:.9
ML/4;LD<A13YD\J9X_P"Z<4RF8A1113 **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW(PX./$'/]X_SKN_%*EM#L]H)^7M7G%W>*FH>?"<]ZZ[_A+(;C3(HIBFZ->
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MY/\ A*47<V/-Z9J?XB(,.V!G--2=Q3P]-TI2BM4>:UWW@/1$N)ENIE#)MS7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KT7PC_P @45YU7HOA'_D"BHGL=>"_
MB'#:K_R%+C_?JG5S5?\ D*7'^_5.J1RS^)A1113$%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%( HHHI@%%%%
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M$\P7 ED ]-QH<;A1Q/LI-VW.]\)I9KJ,[3LF[S#M)-;3)';>)Y;MKF)HFP
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M32444Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*QTU\NE4J.5SP7['<_\ /%_RH^QW/_/%_P J]Z_X1VR_NC_OFC_A'++^Z/\
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M_A'++^Z/^^:/^$<LO[H_[YH]J@_LF7<\%^QW/_/%_P J/L=S_P \7_*O>O\
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M_A'++^Z/^^:/^$<LO[H_[YH]J@_LF7<\%^QW/_/%_P J/L=S_P \7_*O>O\
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M_A'++^Z/^^:/:H/[)EW/!?L=S_SQ?\J/L=S_ ,\7_*O>O^$<LO[H_P"^:/\
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M]T?]\T>U0?V3+N>"_9+C_GB_Y4?8[C_GB_Y5[U_PCEE_='_?-'_".67]T?\
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M #Q?\J/L=S_SQ?\ *O>O^$<LO[H_[YH_X1RR_NC_ +YH]J@_LF7<\%^QW/\
MSQ?\J/L=S_SQ?\J]Z_X1RR_NC_OFC_A'++^Z/^^:/:H/[)EW/!?L=S_SQ?\
M*C['<_\ /%_RKWK_ (1RR_NC_OFC_A';+^Z/^^:/:H/[)EW/!X[2X\U?W+]?
M2O9O R,FD,&4@Y[UI#P[9 YVC_OFM"VM8[6/9&,#Z5$Y\R.O"8%T)\S8DUTL
M38(J+^T4]*JZC_K36?DUF>D;7]HIZ4?VBGI6+DT4 ;7]HIZ4?VBGI6(6V\DT
MN?>@#:_M%/2C^T4]*Q&<(,L:8LZ-T:@#>_M%/2C^T4]*P3<(K8+<U(&R,@T
M;7]HIZ4?VBGI6+DT9- &U_:*>E']HIZ5B!LG&>:7)H VO[13TH_M%/2L7)I&
M;:,D\4 ;?]HIZ4?VBGI6"+A&. U29]Z -K^T4]*/[13TK%R:,F@#:_M%/2C^
MT4]*Q<FC)H VO[13TH_M%/2L7)HR: -K^T4]*/[13TK%R:,F@#:_M%/2C^T4
M]*Q<FC)H VO[13TH_M%/2L7)H)P.30!M?VBGI1_:*>E8!N8P<%J/M4?]Z@#?
M_M%/2C^T4]*P1<(QP&J3- &U_:*>E']HIZ5BYHR: -K^T4]*/[13TK%R:,F@
M#:_M%/2C^T4]*Q<FC)H VO[13TH_M%/2L7)HR: -K^T4]*/[13TK%R:,F@#:
M_M%/2C^T4]*Q<FC)H VO[13TH_M%/2L7)HR: -K^T4]*/[13TK%R:,F@#:_M
M%/2C^T4]*Q<FC)H VO[13TH_M%/2L7)HR: -K^T4]*/[13TK%R:,F@#:_M%/
M2C^T4]*Q<FC)H VO[13TH_M%/2L7)HR: -K^T4]*/[13TK%R:,F@#:_M%/2C
M^T4]*Q<FC)H VO[13TH_M%/2L7)HR: -K^T4]*/[13TK%R:,F@#:_M%/2C^T
M4]*Q<FC)H VO[13TH_M%/2L7)HR: -K^T4]*/[13TK%R:,F@#:_M%/2C^T4]
M*Q<FC)H VO[13TH_M%/2L7)HR: -K^T4]*/[13TK%R:,F@#:_M%/2C^T4]*Q
M<FC)H VO[13TH_M%/2L7)HR: -K^T4]*/[13TK%R:,F@#:_M%/2C^T4]*Q<F
MC)H VO[13TH_M%/2L7)HR: -K^T4]*/[13TK%R:,F@#:_M%/2C^T4]*Q<FC)
MH VO[13TH_M%/2L7)HR: -K^T4]*/[13TK%R:,F@#:_M%/2C^T4]*Q<FC)H
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MT ;7]HIZ4?VBGI6+DT9- &U_:*>E']HIZ5BY-&30!M?VBGI1_:*>E8N31DT
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M4I 0S2#)_&O3/ .MC5=)R6R4PM '8'@9-4KNY@:%HQ.@<^]9?B[7#HFF^:"
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M?+)^0YZBM^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\?3L&!!D'/XU[-J%DNI:$+<X(:-?Y5QT7P^4:NUVRM]X'->@V\7E0JG]T 4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHK1_L_VH_L_VH SJ*T?[/]J/[/\ :@#.HK1_L_VH_L_VH SJ*T?[/]J/[/\
M:@#.HK1_L_VH_L_VH SJ*T?[/]J/[/\ :@#.HK1_L_VH_L_VH SJ*T?[/]J/
M[/\ :@#.HK1_L_VH_L_VH SJ*T?[/]J/[/\ :@#.HK1_L_VH_L_VH SJ*T?[
M/]J/[/\ :@#.HK1_L_VH_L_VH SJ*T?[/]J/[/\ :@#.HK1_L_VH_L_VH SJ
M*T?[/]J/[/\ :@#.HK1_L_VH_L_VH SJ*T?[/]J/[/\ :@#.HK1_L_VH_L_V
MH SJ*T?[/]J/[/\ :@#.HK1_L_VH_L_VH SJ*T?[/]J/[/\ :@#.HK1_L_VH
M_L_VH SJ*T?[/]J/[/\ :@#.HK1_L_VH_L_VH SJ*T?[/]J/[/\ :@#.HK1_
ML_VH_L_VH SJ*T?[/]J/[/\ :@#.HK1_L_VH_L_VH SJ*T?[/]J/[/\ :@#.
MHK1_L_VH_L_VH SJ*T?[/]J/[/\ :@#.HK1_L_VH_L_VH SJ*T?[/]J/[/\
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M45H_V?[4?V?[4 9U%:/]G^U']G^U &=16C_9_M1_9_M0!G45H_V?[4?V?[4
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M:* ';V]31O;U--HH =O;U-&]O4TVB@!V]O[QHWM_>--HH =O;UHWM_>--HH
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M_P"0:_\ NBO0J ,[6TW:5<$'#!.#Z5X39WE^_BQK4WDFSTS[U[SK'_()N/\
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MW4^$KJ(#@+BN)^%FHL^H26.[Y8TX'X4 >LT444 %%%% !1110 4444 %%%%
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MS%6/#D#W7P[O(HLEB1C'XUU.L^#X]:LHK>Y3*QG(K1\/^'H]%LFM47$;')%
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M].6*.UM'F\W@LO\ #7.P^&]4U>07$M_+"I_Y9G_]5=[;RI=6\<H (89&:F
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MBBB@ HHHH **** "BBB@ HHHH *L0_<JO5B'[E $+_?--IS_ 'S3: "BBB@
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M '^:_P#>-'FO_>-,HH ?YK_WC1YK_P!XTRB@!_FO_>-'FO\ WC3** '^:_\
M>-'FO_>-,HH ?YK_ -XT>:_]XTRB@!_FO_>-'FO_ 'C3** '^:_]XT>:_P#>
M-,HH ?YK_P!XT>:_]XTRB@!_FO\ WC1YK_WC3** '^:_]XT>:_\ >-,HH ?Y
MK_WC1YK_ -XTRB@!_FO_ 'C1YK_WC3** '^:_P#>-'FO_>-,HH ?YK_WC1YK
M_P!XTRB@!_FO_>-'FO\ WC3** '^:_\ >-'FO_>-,HH ?YK_ -XT>:_]XTRB
M@!_FO_>-'FO_ 'C3** '^:_]XT>:_P#>-,HH ?YK_P!XT>:_]XTRB@!_FO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3*6QVYI?$Z"WT^-&;GRE_E73VNBKYGG7"@R'G-1ZOH*ZFP$B@J!B@".P8?\
M"&'G_EBW\JYGX=SI#H]XS8.)VX_$UV":7)'IPLTP(]NW'M5'3?#$>FQO%"@6
M-V+,/>@#)U;P[:ZLLEQ:W/E3*-S!.M1^#+N[@E^QS%Y!N^^Q]ZWAHD]O*[6V
M%#\-]*O:=I$5G\Y7]YG.: -2BBB@ HHHH **** "BBB@ HHHH *TK/\ U%9M
M:5G_ *B@"A+_ *UOK3*?+_K6^M,H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO15C[))1]DDH KUI6?\ J*J_9)*O6T++#@T 9DO^M;ZTRK4EK(9&/O3?LDE
M%>BK'V22C[))0!7HJQ]DDH^R24 5Z*L?9)*/LDE %>BK'V22C[))0!7HJQ]D
MDH^R24 5Z*L?9)*/LDE %>BK'V22C[))0!7HJQ]DDH^R24 5Z*L?9)*/LDE
M%>BK'V22C[))0!7HJQ]DDH^R24 5Z*L?9)*/LDE %>BK'V22C[))0!7HJQ]D
MDH^R24 5Z*L?9)*/LDE %>BK'V22C[))0!7HJQ]DDH^R24 5Z*L?9)*/LDE
M%>BK'V22C[))0!7HJQ]DDH^R24 5Z*L?9)*/LDE %>BK'V22C[))0!7HJQ]D
MDH^R24 5Z*L?9)*/LDE %>BK'V22C[))0!7HJQ]DDH^R24 5Z*L?9)*/LDE
M%>BK'V22C[))0!7HJQ]DDH^R24 5Z*L?9)*/LDE %>BK'V22C[))0!7HJQ]D
MDH^R24 5Z*L?9)*/LDE %>BK'V22C[))0!7HJQ]DDH^R24 5Z*L?9)*/LDE
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M_P!D4>?_ +(J&B@";S_]D4>?_LBH:* )O/\ ]D4>?_LBH:* )O/_ -D4>?\
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MS_\ 9%'G_P"R*AHH F\__9%'G_[(J&B@";S_ /9%'G?[(J&B@";SO]D4>?\
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M&B@";S_]D4>?_LBH:* )O/\ ]D4>?_LBH:* )O/_ -D4>?\ [(J&B@";S_\
M9%'G_P"R*AHH F\__9%'G_[(J&B@";S_ /9%'G_[(J&B@";S_P#9%'G_ .R*
MAHH F\__ &11Y_\ LBH:* )O/_V11Y_^R*AHH F\_P#V15F)MRYQ5#O5Z#[E
M $-Q]XU7JQ<?>-5Z "BBB@ HHHH **** "BBB@ HHHH **** "N9\8W4VEZ1
M-J$1),8Z9KIJY?XA?\B;>_3_ !H QO#>H7NN6,=PP9=PS@&M$R:E:ZI&HB9H
M3U8FN=\":_#8Z+$KQ2':G8&NTTK6HM:RR(RJ#@AA0!M0,7A5CU-25R6J:Y+]
MJ^QV8='5L$X.*H2:_>Z7KUO9WDV\2+NX_"@#O**QM3UZ"QM(I&S^^X7ZUAZC
M>:O:Z<^H"4F)>=H'- '8S@F!PO4CBL#3+6[CO=TN_;D]33-,\0&]THR%'$BH
M220:H:!XDFU#4?)9CC<1@_6@#M:*Y/5->GDO/LMIO1U;!)!Q6?\ \)#>:;XA
MAL;R7>'7=Q^% &QXLNI[:SWQ \#M47@6_EU#1GEE)+!\<GZU)XGE$VCF1>C(
M:H_#;_D R_\ 70_UH [.BFN2$)'I7G^J^,)M/\3)8DN5(S@ T >A45YEJ/B/
M5K"6.Y>1S;N<X"G@5T]IXK@N/#YU)59E4X('6@#IJ.U<0=2U2>VGO8YMD*+N
MPPYQ5_PKXB&KZ=YC$EP<9- #[NTO&U&-TW[ ^3S72+]T?2N%N?%$\>M1VP=@
MK2;<8JSXS\0SZ)8&=&8#CH* .RHK@I=:U*]T6*^M)&14CW/D'FM7PAXA.KV"
MF4DR9ZF@#J**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ JQ#]RJ]6(?N4 0O]\TVG/\ ?--H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#)UO4)K.S?[*GF3]D]:X6^O\ Q!;C[8+1\#YF&>!7I36T3RB5E^8=ZJZS
ML&D7*L1S&0!F@#&\'>)CKUAOF 24-MVBNIKS_P"'FFF.W><+M42G@CW->@4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *L0_<JO5B'[E $+
M_?--IS_?--H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!LDBQ)N<X4=ZYB_>75
M[I8H\^6C<X[BG>+(M1N+1X;"38Y'!Q7(VFG>)[5<I=@,>IQ_]>@#TJRMHK*(
M0Q@#/. *MUR'AVVUL7*2W]P'4'D5U] !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 '>KT'W*H]ZO0?<H AN/O&J]6ID+-UJ'R3ZT 1T5+Y)]:3R3ZT 1T5)Y)]:
M/)/K0!'14GDGUH\D^M $=%2>2?6CR3ZT 1T5)Y)]:/)/K0!'14GDGUH\D^M
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M\D^M $=%2>2?6CR3ZT 1T5)Y)]:/)/K0!'14GDGUH\D^M $=%2>2?6CR3ZT
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M^WOZ4?;W]*J44 6_M[^E'V]_2JE% %O[>_I1]O?TJI10!;^WOZ4?;W]*J44
M6_M[^E'V]_2JE% %O[>_I1]O?TJI10!;^WOZ4?;W]*J44 6_M[^E'V]_2JE%
M %O[>_I1]O?TJI10!;^WOZ4?;W]*J44 6_M[^E'V]_2JE% %O[>_I1]O?TJI
M10!;^WOZ4?;W]*J44 6_M[^E'V]_2JE% %O[>_I1]O?TJI10!;^WOZ4?;W]*
MJ44 6_M[^E'V]_2JE% %O[>_I1]O?TJI10!;^WOZ4?;W]*J44 6_M[^E'V]_
M2JE% %O[>_I1]O?TJI10!;^WOZ4?;W]*J44 6_M[^E7;>X9XLD5CUI6?^HH
MBDOG$C#'0TW[>_I5>7_6M]:90!;^WOZ4?;W]*J44 6_M[^E'V]_2JE% %O[>
M_I1]O?TJI10!;^WOZ4?;W]*J44 6_M[^E'V]_2JE% %O[>_I1]O?TJI10!;^
MWOZ4?;W]*J44 6_M[^E'V]_2JE% %O[>_I1]O?TJI10!;^WOZ4?;W]*J44 6
M_M[^E'V]_2JE% %O[>_I1]O?TJI10!;^WOZ4?;W]*J44 6_M[^E'V]_2JE%
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M0M6EANBG/&: .OHKBM"\1R37]QIUP3YL7&X]S6=J.M:A9^,8+#SF*.N<#\*
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MIJA5_4?]::H4 %%%% !1110 4444 %<3X^_X]&_W:[8]*Y+Q/X;O=;4K#<!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO4 4<#THJ]_9S?WJ/[.;^]0!1HJ]_9S?WJ3^SF_O"@"E1@#H*N_V<W]X4O\
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M.B@"3S6H\UJCHH D\UJ/-:HZ* )/-:CS6J.B@"3S6H\UJCHH D\UJ/-:HZ*
M)/-:CS6J.B@"3S6H\UJCHH D\UJ/-:HZ* )/-:CS6J.B@"3S6H\UJCHH D\U
MJ/-:HZ* )/-:CS6J.B@"3S6H\UJCHH D\UJ/-:HZ* )/-:CS6J.B@"3S6H\U
MJCHH D\UJ/-:HZ* )/-:CS6J.B@"3S6J:)R4JK5B'[E #&E.XTGFM37^^:;0
M!)YK4>:U1T4 2>:U'FM4=% $GFM1YK5'10!)YK4>:U1T4 2>:U'FM4=% $GF
MM1YK5'10!)YK4>:U1T4 2>:U'FM4=% $GFM1YK5'10!)YK4>:U1T4 2>:U'F
MM4=% $GFM1YK5'10!)YK4>:U1T4 2>:U'FM4=% $GFM1YK5'10!)YK4>:U1T
M4 2>:U'FFHZ* )/-:CS6J%W6-=SL% [FH/[0M.]Q'_WU0!=\UJ/-:JL=W;RM
MB.5&/H#4U $GFM1YK5'10!)YK4>:U1T4 2>:U'FM4=% $GFM1YK5'10!)YK4
M>:U1T4 2>:U'FM4=% $GFM1YK5'10!)YK4>:U1T4 2>:U'FM4=% $GFM1YK5
M'10!)YK4>:U1T4 2>:U'FM4=% $GFM1YK5'10!)YK4>:U1T4 2>:U'FM4=%
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MBBB@ HHHH **** "BBB@ HHHH *L0_<JO5B'[E $+_?--IS_ 'S3: "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5B'[E5ZL0_<
MH A?[YIM.?[YIM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<=XPG9KBRCB.<
MR -78USXT)Y=1:>:3>N[*@]J -BRMTM[9%08R 35BD484#T%+0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !WJ]!]RJ/>KT'W* (;C[QJO5N9 S<MBHO)7^^*
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M-QZU.K!U#*<@]Z )OM#^M'VA_6HJ* )?M#^M'VA_6HJ* )?M#^M'VA_6HJ*
M)?M#^M+]H?UJ!F"J6)P!U-017UM,^R.96;T!H O?:']:3[0_K45->18DW.P
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M0SQ7"[HG#KZBI* )?M#^M'VA_6HJ* )?M#^M'VA_6HJ* )?M#^M'VA_6HJ*
M)?M#^M'VA_6HJ* )?M#^M'VA_6HJ* )?M#^M'VA_6HJ* )?M#^M'VA_6HJ*
M)?M#^M'VA_6HJ* )?M#^M'VA_6HJ* )?M#^M'VA_6HJ* )?M#^M'VA_6HJ*
M)?M#^M'VA_6HJ* )?M#^M'VA_6HJ* )?M#^M'VA_6HJ* )?M#^M'VA_6HJ*
M)?M#^M'VA_6HJ* )?M#^M+]H?UJ&B@"87#Y'-;%DQ:+)K"'45MV'^IH I:C_
M *TU0J_J/^M-4* "BBB@ HHHH **** "BBB@ HHHH **** "N5\6:LUFA@!P
M&&:ZJL#Q/H?]KV$BHVR0C ;N* *6E:%:7^F1W#,QD8>M1V=A/8:S%'SY9.:X
MNUU/5_"=SY,L,UQ"IP">E>@Z#XCL];59#L28<!<\T 6];T2UU@0BX)'EL&&#
M6G#&D$*HI^50!S7 ?$"2\T^6REANG59)E!4?6MO7?M'_  C'GQSLCB->1]*
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MK$_,H^>MW6M12SM6"L/-[+WKG+^.$:7+<-(I>1"2/2@"S\/)7ET)V<Y;S/\
M&NOKB_AS+'_8LB;AN,AX_$UVE !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 *.H
MK;L/]36(.HK;L/\ 4T 4M1_UIJA5_4?]::H4 %%%% !1110 4444 %%%% !1
M110 4444 %9%_JHL]1CA8X5AS6O6-J^A_P!IRB02[& QF@">]LK35;,B0*5(
M.*\UMM,.C>.[6WM,B%R6;]*[5?#%VJ;1J+@?Y]JLZ7X<6RE$T\GGR@Y#MU%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5I6?\ J*S:TK/_
M %% %"7_ %K?6F4^7_6M]:90 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '*^(-
M%O+V^$]L,X&*YK6=(UB*Q<R ;0IKT^J>H6(OK=HBV,C% 'G_ ,-[.^$?G'_4
M!^?SKTRLO0M'71;-K=7W9;.:U* "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 4=
M16W8?ZFL0=16W8?ZF@"EJ/\ K35"MNXM%F8DOBH/[-3_ )Z"@#+HK4_LU/\
MGH*/[-3_ )Z"@#+HK4_LU/\ GH*/[-3_ )Z"@#+HK4_LU/\ GH*/[-3_ )Z"
M@#+HK4_LU/\ GH*/[-3_ )Z"@#+HK4_LU/\ GH*/[-3_ )Z"@#+HK4_LU/\
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M4 .W&C<:;10 [<:-QIM% #MQHW&FT4 .W&C<:;10 [<:-QIM% #MQHW&FT4
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M:\;VVF23R2Q."Q+'W'^- 'KDLR0J68CCWJK!JEO/)L5L'W-<1<:W<:OJLMM
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MU)<7\-L/G.?H:YJ#_B3>#_M?F%F$(8"JGA,2>(;!=4DE8"08V=A0!V5O>17
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MDF@#TBUO8;M28V!P<=:YWQCJYL;9$1L;S@UR^BO<:5XLAL#.\B.23D^]:GQ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*L0_<JO5B'[E $+_ 'S3:<_WS3: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH H
MZO?KINGO<MG"^E>;Q6&C^(]0E>[7.XY&37I6I6"ZC9M;L<!J\_UOP#+;1F[M
M;UU,?S;5/6@#KM!\-V&C1 6B8'4<UO5Q/@/6+BZLO(N@1(&P-W6NVH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ [U>@^Y5'O5Z#[E $-Q]XU7JQ<?>-5Z "BB
MB@ HHHH **** "BBB@ HHHH **** "N:\=V;7GA6[BC&7(XKI:9)&DJ%'4,I
MZ@T <'\.[Y8K"/3Y#MDB7G/%=?J>I165D\Q8';V!K'N_!Z37+307!@+'HG%+
M!X3:.56EO'E4=58\&@!NAP-+-/J&,+*IQFN4DE5?B+9J3C@_TKTP0);VC(@
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M@#D^GX5W58FM^'DUJ-HY92$/:@"+PP/,\'V<8ZF'&*X>?43H'CI/M(;R0,G
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M **** "BBB@ JQ#]RJ]6(?N4 0O]\TVG/]\TV@ HHHH **** "BBB@ HHHH
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M 045/^X_YZ"C]Q_ST% $%%3_ +C_ )Z"C]Q_ST% $%%3_N/^>@H_<?\ /04
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M!'+KEM$^W!..I':KMO=Q7,(D1A@^]<;Y<%KI-\KS9E8<9ZBJ_@Z262$PM(Q
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M.?3]5U.VN;:Y&Y  57UH [*BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K2L_]16;6E9_ZB@"A+_K6^M,I\O^M;ZTR@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@!1U%;=A_J:Q!U%;=A_J: *6H_ZTU0J_J/^M-4* "BBB@ HHHH **** "N'
M\?-_HC <_+VKN,<5CZAH,.H-F1S]* */A%A_PA\0/!V'@_2N=T8_\3[I_P M
M#_.NSL]%CLX?*20[<8Q4$/AN""Y\]7.[.: .6^(1W?9 HSB=>G^\*W?$I!\#
M/C_GDO\ *K>HZ#;7#>;/(<*=W/:LC6[NRN/#%U;6D_FL!MQ0 [P8,^&E'K&?
MY5BZ3<"QUW9*I&YR<GZUU'@RT:#P_;[Q@E>14^H^&;>_NEGW&-A_=H XKQM?
MK<7=JJ(QQ,O('O6SXMG$OA0[0<^4O'X5N2^&;:6*-'.2ASDBI;S0(;R,1NQV
M@8Q0!#X-(_X1BT'?;TJSX@TX:GI,MMC):I;#38],CPKG8HZ>E5+[Q/IMJQB-
MPOG=E- '#:(MQ=:H=*YV6A&,CBO2KBY33['S9 2J  XK&T*Q3[=-J 08F'7%
M;.H01W-F\4C;5/4T 4]+UZWU65XX00R]<UK5R?AO16T_5;F4%C&WW2:ZR@#S
M;Q\X34-/)_Y[#^==?J-Y'%H(DR&P@X!YZ5QOC_9+?6*;L9E _6NMMM C:WB)
MF=E*#@GCI0!RVFZ'(\.H707 F0E>*D^'UT=.A?3[@%7:0D$\#J:[Z&WCAA$:
MJ, 8Z5EW?AV"YN/.5O*;_9XH YOQQ$=3OM.2$;O+D&['-6?&L'D>"I(P,G X
M'TKH[+1XK1LL?,/;=S2ZEI,>I1F.1CM/:@#&\-R+'X<1G'"Q<BLNZT+3-=LG
MNX(U2X!P"Q%=5::-%:V[PJY*L,543PQ%&"%G< G. : .0TF"^N;'4K28DK"A
M5./I5WX?71L+/^SYP5?>3D\5V]M80VT>Q5'(P3CK6?=>'8+BX\Y&,1_V>* .
M9\:PMJFK:8(1D1R?-CGUJ/QC#Y&G",#GC@5V5GH\5J22?,/8MSBHM0T&'4)-
MTC'Z4 5&(_X0@C//V?I^-8OP^.-+P>#D\&NI.CQFU^S^8=F,8J*Q\/PV!_=N
M<>@H XN8_P#%2)P?];5WQTV;< <\CI71'PU ;KS]YW9S3[SP[#>MF1R?K0!7
MN"/^$(89Y^S]/QK&^'Y T4!ACKD&NH;1HVM?LYD.S&,53CTJ+18&DB;( /%
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MUUUX3MKBY\Y',1]$XJ1/"]LK*Q;<RG.30!S?BQC^[N-K;5C&>/85?EU6(>%
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M%=4VNF[1GME=0G7CK1?>$K2\N3.&\LG^Z,5J66F0V</EJ W'4B@#B;+4#?\
MB2>&\R8@N0#QZUEW4\*>*;3RXF"J_I7<7/A6WN+YKH2%&/\ =I\OABVEN89B
M<-%[=: .7^(#E[*"548@RCH/<5TD-\DOAU% .1$ :T;[28+ZU6"0# .>E,AT
M:*&U: ,2K"@#C?#(W>([H=,QD?SJE+'+H_BN .K%)'+9 XKN+/P]!9W)F1SN
M-6K[28+Y,. & P&QR* ,WQ)>1MI:E?FWG&!S6#I^F/IWAB_WC_6G<!72V_AV
M*'&Z5I .S'-7KK3H[FW,).U2,<4 <IX,;]VV>/D/7Z5FW9SXULSCC/6NRLM
MAL2?+<\C%1_\(U!]K%P7.\'(H KW[6&IW4EG=Q[E7IGI7)7&COHOB.W&G$)"
MWS$+S7<W.@1SG=YC*V>HIUOH44,RRLY=EZ;N: +]FSO;*7^]WJ>@  8 Q10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5I6?^HK-K2L_
M]10!0E_UK?6F4^7_ %K?6F4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 *.HK;L/]36(.HK;L/]30!2U'
M_6GBJ&#Z5O30QNV6.*A^S0?WJ ,?!]*,'TK8^S0?WJ/LT']Z@#'P?2C!]*V/
MLT']ZC[-!_>H R,'TI,'TK8^RP?WJ/LL']Z@#(P?2DP?2MC[+!_>H^S0?WJ
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M*-4PIXH Q)0?-;CO4>#Z5LM;0EB2U)]F@_O4 8^#Z48/I6Q]E@_O4?9H/[U
M&/@^E&#Z5L?9H/[U'V:#^]0!CX/I1@^E;'V:#^]1]F@_O4 8^#Z48/I6Q]F@
M_O4?9H/[U &/@^E&#Z5L?9H/[U'V:#^]0!CX/I1@^E;'V:#^]1]F@_O4 8^#
MZ48/I6Q]F@_O4?9H/[U &/@^E&#Z5L?9H/[U'V:#^]0!CX/I1@^E;'V:#^]1
M]F@_O4 8^#Z48/I6Q]F@_O4?9H/[U &/@^E&#Z5L?9H/[U'V:#^]0!CX/I1@
M^E;'V:#^]1]F@_O4 8^#Z48/I6Q]F@_O4?9H/[U &/@^E&#Z5L?9H/[U'V:#
M^]0!CX/I1@^E;'V:#^]1]F@_O4 8^#Z48/I6Q]F@_O4?9H/[U &/@^E&#Z5L
M?9H/[U'V:#^]0!CX/I1@^E;'V:#^]1]F@_O4 8^#Z48/I6Q]F@_O4?9H/[U
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC*<<GK6E<74=M'O8C\Z\LUVV_LCQ5IJ02-B67YN?8UM:_J=Q-KITZ+G !X-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *L0_<JO5B'[E $+_ 'S3:<_WS3: "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH S-1TXZ@WER$& ]5-8NK^#])_LF=Q:J)$0D'WKK:P=>U B'[+%@F7Y6H Y
M7X;&YB@:%F)C$A_G7I%8/A?1ETBP:/'+-NYK>H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ [U>@^Y5'O5Z#[E $-Q]XU7JQ<?>-5Z "BBB@ HHHH **** "BB
MB@ HHHH **** "N5^(+9\(WD:\L1P!UKJJS[[28;_P#UI./3M0!R?PW;;H\*
M."K!>AKO*R[+1+>Q;,1(]JT\<8H \P\;L3J5J%4MB9<X'O7>7-L+_0T@4CYH
MU_E3+GP_:W4WFR$DYSTK0M;9;6/RU)(]Z /-/"DLNC>*;R*=&$?121Q6QXR
MU9/[/B7=YJYW#D"NGO\ 1;:_(+#8V<Y48-+9Z+!9D$$N1W;F@#SKQ1H-Q;>'
M]*$*DFV8,V!Z&MK1O':-IX$EM)O0!<$'/%=S-!'/$8W12",<BL6/PI8QW7GK
MU],<4 9>I17&L:;)<#< $+*I'-<WX1\7-I,+V5Y;RES(<,0>F:]22%$B\L*-
MN,=*Q[WPM97L_FL C?[(Q0!1CU=]?@N((8WB 4C+#K7$Z7/+X=\5QV\T;F,D
ML6QQUKU:SL8;*(1QJ.!C..M5=1T*UU(DR *W]X#F@#AO'>J"[-@T43-AL\"K
M.J&2_P# DJ)$P8XXQ[5U*^&+,*@)+;.F1FM)+*%(/)"KM],4 <'X?UI;?2)+
M9HFWI'CI67X?O&;Q>CF!POJ1[UWL?ABSCG>52<N<D8XJU#HEK!<"95&X>U '
MGOBB0R:_8%4)'FC/'3K7<:_=2P:#YEL27"C[O/:I)O#MK--YK$[LY''2K\=G
M&EOY)^9??F@#SG2+^*>"^-S"S2@<9'?BH/"]X4\0KF!U^HKNH_#%G'</,I.7
M.2,<5/#H-K#>_:D #8QC% 'G_CYFG\1Z&Z(2%ER<#IUKU&%@T*8.>!69/X>M
M;B82ODL#D9'2M*W@6WB$:DD#UH K:N<:3<_[E<+X.)&J_,I''>O0KBV6YC*,
M3@C%9]MH%M:R^9&3F@#@?&!:3Q9I)12P67D@=.#4OC**?3=2.L0JS@X&$&37
M;R>';66<2N26!R,CI5Q].@EMO(D4,O\ M#- ')V'CF.>PCC%O()=N.AZU7\6
MZK?)X2CN;<2+(9,$ <XXKHK?PK96]QYRYSG.,<5J75A!>6_D2(NSTQ0!Y_->
M6TGA&;%NQG>+YB!SFH/ KF;PZMFT3*P0]1[5V]OX;M+>.1 25DZ@BK-CHUMI
MYS$.WI0!YCX0OY?#FLWL%Q$^)Y3M..*M>/=1^TA%BB9AY@.0,]Z[[4/#]IJ#
MJ[@(P[J,4P>&K/R5C;Y@ISEAF@#BM;U>[CBTR*-)!"8P'&/:HO$%S;R>'H/(
MMFW[^P^E>AW.C6UU;B%U& , XJM%X:M([<0_>4>HH XVW#:CX2NX$B8.4P.*
MJ>#O$S:':II-S!(3$.I!P?\ .*])L=+@L49(P"&Z@BJ-YX7LKRX,S#:Q.?E&
M* (;#6GU:<21H\4:G!W#K7'6Y*_$N]<J=A48;MWKT>#3X;>W\I!@8QD"J9\.
MVIN#-D[SU/>@#FO&K$F+:"?D[5EZ]ITU_P"";'R0=\4@<@#GC!KO;K0[>[V^
M83\HP*L6^G0V\'D@!EQC!% '"Z!X[5+/R)[:7=$-G(/.*ZS1]1DU&8R[66-A
MP"*B?PG8M<^<.#G. .*V;>WCMH@B  #VH FHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ4F#Z5)]JM_[U'VJW_O4 ,P?2C!]*?\ :K?^]1]JM_[U #,'THP?2G_:K?\
MO4?:K?\ O4 ,P?2C!]*?]JM_[U'VJW_O4 ,P?2C!]*?]JM_[U'VJW_O4 ,P?
M2C!]*?\ :K?^]1]JM_[U #,'TI,'TJ3[5;_WJ/M5O_>H 9@^E)@^E2?:K?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M .FN_$(MW.R!I$_O*.*L6&M07\+2(0"O49KF]"_M.XT%-L*LK*1D]>E-\/\
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M]8TNROK.&YMX%2<C)QUS7:'3X3!Y6T;3[5731;:.3>,\'I0!Q]S9W;^!IH9
M[R;N!CGO5SPGJ,D, @>W8;1@DBNS,2-'L*C;Z8J"+3X82Y50-_7B@#SV[\P_
M$Z*X$;>5L^]VZBM3QLS2&Q,:%L'G';K74'2+8R;\?-ZXI\FF02A0XSCIF@#$
MM9"/#O*G/I7.^&#-$-:;8R,0=AQUZ5WPTZ$0^5_#38]+MXB2HQGKQ0!P6@ZA
M(DI%Y;/)+S\S"JFEW4L6O2L;9PKR<<5Z-_8]M]H\[;AOI3O[*MA('"C(.>E
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M0!C^6_\ =-'EO_=-;'[JC]U0!C^6_P#=-'EO_=-;'[JC]U0!C^6_]TT>6_\
M=-;'[JC]U0!C^6_]TT>6_P#=-;'[JC]U0!C^6_\ =-'EO_=-;'[JC]U0!C^6
M_P#=-'EO_=-;'[JC]U0!C^6_]TT>6_\ =-;'[JC]U0!C^6_]TT>6_P#=-;'[
MJC]U0!C^6_\ =-'EO_=-;'[JC]U0!C^6_P#=-:-HI$'(J?\ =5-'LV\4 8DJ
M-YK?*>M,\M_[IK9;R]QS2?NJ ,?RW_NFCRW_ +IK8_=4?NJ ,?RW_NFCRW_N
MFMC]U1^ZH Q_+?\ NFCRW_NFMC]U1^ZH Q_+?^Z:/+?^Z:V/W5'[J@#'\M_[
MIH\M_P"Z:V/W5'[J@#'\M_[IH\M_[IK8_=4?NJ ,?RW_ +IH\M_[IK8_=4?N
MJ ,?RW_NFCRW_NFMC]U1^ZH Q_+?^Z:/+?\ NFMC]U1^ZH Q_+?^Z:/+?^Z:
MV/W5'[J@#'\M_P"Z:/+?^Z:V/W5'[J@#'\M_[IH\M_[IK8_=4?NJ ,?RW_NF
MCRW_ +IK8_=4?NJ ,?RW_NFCRW_NFMC]U1^ZH Q_+?\ NFCRW_NFMC]U1^ZH
M Q_+?^Z:/+?^Z:V/W5'[J@#'\M_[IH\M_P"Z:V/W5'[J@#'\M_[IH\M_[IK8
M_=4?NJ ,?RW_ +IH\M_[IK8_=4?NJ ,?RW_NFCRW_NFMC]U1^ZH Q_+?^Z:/
M+?\ NFMC]U1^ZH Q_+?^Z:/+?^Z:V/W5'[J@#'\M_P"Z:/+?^Z:V/W5'[J@#
M'\M_[IH\M_[IK8_=4?NJ ,?RW_NFCRW_ +IK8_=4?NJ ,?RW_NFCRW_NFMC]
MU1^ZH Q_+?\ NFCRW_NFMC]U1^ZH Q_+?^Z:/+?^Z:V/W5'[J@#'\M_[IH\M
M_P"Z:V/W5'[J@#'\M_[IH\M_[IK8_=4?NJ ,?RW_ +IH\M_[IK8_=4?NJ ,?
MRW_NFCRW_NFMC]U1^ZH Q_+?^Z:/+?\ NFMC]U1^ZH Q_+?^Z:/+?^Z:V/W5
M'[J@#'\M_P"Z:/+?^Z:V/W5'[J@#'\M_[IH\M_[IK8_=4?NJ ,@1OD?*:VK$
M$0\BF?NLU9BQMXH @N/O&J]6+C[QJO0 4444 %%%% !1110 4444 %%%% !1
M110 44'.#BN9\0ZQ>Z/"UR<"%!R: .FHK!\.>)+;7+93$^9,9-:MXTR0,8?O
M=J +-%<SIFKWMWJ,ELV,IUKIAG SUH **** "BBB@ HHK)UZ]N+#3Y)X<96@
M#6HKF/"^NW&K2RI,1\H[5T] !116-XBO[C3M.>XAQE: -FBN9\.ZW<ZI'+YA
M!91Q3[>]U1M=6"0#[,>M '1T444 %%%% !1110 4444 %%%% !1163KVL1Z1
M9^:S8).!0!K45Q%UK&NQ203(%^SR<D^U=7IET;RS68]30!<HHHH ***C:=%;
M:3S0!)10#D9HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "K$/W*KU8A^Y0!"_WS3:<_P!\TV@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BJ&JZE'IMFTTAP%KB;GQE?V\@F8C[
M,3D'VH ]%HK&\/Z_;:]9>?;ON .#]:V: "BBB@ HHHH **** "BBB@ HHHH
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MS]%K&G\9/:O_ *19F./^^W2N>N;T7NO0I*WRQR?)7;ZOH%EK=B+>Y7Y#@\4
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MRE*Y81@]*X:%1_PM:\&!]T?S- 'I6GW+W, 9XRAQT-6Z9& (UQZ4^@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *L0_<JO5B'[E $+_ 'S3:<_WS3: "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH I7-@EU-F7#1]T/0U2UC2['^Q[@?9TXC.WVK:S7-:S?27D@M+,
MYYVR?2@#GOAS:2PPN5)$8E/';J:]&K-T72XM*L_)C&-QW'ZUI4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME5ZL0_<H A?[YIM.?[YIM !1110 4444 %%%% !1110 4444 %%%% !1110
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M&]#4?V]?6C[>OK0!)L;T-&QO0U']O7UH^WKZT 2;&]#1L;T-1_;U]:/MZ^M
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !6E:?ZBLVM*T_P!10!0E
M_P!:WUIE/E_UK?6F4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445C>(-;CT>
MUWL?F8<8H V:*P?"FKR:QIK7$C9(; K>H **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@!1U%;=A_J:Q!U%;=A_J: *6H_P"M-4*OZC_K35"@ HHHH **** "BBB@
M HHHH **** "BBB@ K'\41+-H-PK '(K8K*\1?\ (%G^E 'EL5G>>&_)U"#>
MZ2L 5'0"O4='U>'5; 21N"0 "!ZU4L].AU+PW'%*N?D.*X6)[OP;K MWR+5V
M+L /?- '9Z00NO7C'L,U)=>)7COUMK>'S0>XJCX=NHK_ %&ZG7_5NIIY;3X=
M1$5FI%RQR#VH FTWQ6]UJ4EI/!Y6S@$]ZT-1UQ;.Z2W10\C#(7UKAD6<>))#
M,03O%;7BC2;Y[F+4K%E$L<8 )^@_PH TW\17<<L:O9D!VQFK&I^(!8S)"B!Y
MF7(3O7*Z;XI62XCM=7W-*K  XXS6[JO]E)J<-Q(A-T$^0CTXH AN/&%Q:2P+
M<6GEK*P4$UKZ[()M"=QSD _I7#>-OM,CZ:[G]T91M'XUUU[_ ,BP?]T?RH S
M?!7_ !^7'TKMJXGP5_Q^7'TKMJ ,O5-8CT[8,@LQP!61=^*+VUB,KV+!!W-<
M[K=VT_B"&.8_*DHVUW.K6Z76C^6XRI4?RH =I^KP7UIYP=00N6'I5";Q$YNO
M*M8?.3^\M<-X>NYH3KD63MC4A?TK?^&[BYT=II3F3S#_ %H Y[Q)J,][K^G+
M- 8MLHQGOUKTJ^U*/3K!9&(R%'!^E</XW15UW2R.\H_K4GBN[?[<ENY_=;10
M!O3>);U(O-6Q9H\9W>U7-+\0)J-GY@ $O]RI[>-9/#:)_"8L5PN@;[7QA]E3
MB+!.* -EO'$PN9X1:Y:,X ]:T]#U^]U*8)<630@]S7)V-NDOB6<L.DM>E1P(
MA# <XH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "M*S_U%9M:5G_J* *$O^M;ZTRGR_ZUOK3* "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH ANKA+6 RN0 /6N(UB&2]@N)I<F/:2F>E6_%6IO!=?9Y QMR.0!6%
MJ?BB$Z4;=$D "8&10!N_#D8T*0>DA_K795YK\-]94P_8L-EWSTXZUZ50 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% "CJ*V[#_4UB#J*V[#_4T 4M1_UIJA5_4?
M]::H4 %%%% !1110 4444 %%%% !1110 4444 %8'B>6Z.FRPV\!D+#M6_10
M!B>&GN/[,BCGA,; =#1XCT.+5["1"H$A& V.16W10!Q?AO1I],2X@(8CRR Q
M[\5B6O\ :FE:QC[$\X+$[SVYKT_%-*@MD]: /+ITU0ZP+D6+X=QGVKHKZ]U%
M-3M]MHSP[!N].U=AM!H(!&* //M:TJ75KBU>*T\EDD#,5'7FJWB&SU&U\3VE
M[! \\4<0!7L>E>DJ@7I2E0PP: /,/$S:GJ\-BRZ>R^6P; K?:6^G\-.C6C"0
M  +^%=?M&,>E.H X?P=#>P7<YGMFC#=,UW%%% '#>+?#TLUS;W=L"6C;<0O>
MK)U34KC2_+:R97'&*["FA%#9[T <KIOAQ8K&[=AB2Y0Y'I7,:9'JOAC4?LUO
M:/-!DMN[5ZG32H;K0!Y;XA&JZIJ6GS"Q<".0$_K6]XCT6;5=*\]4*S@ 8'6N
MUVBEH XS3]2U%-+^QO9L/+3:">]2Z-I$B2?VC*A$W3::ZSRUSG%.H \SLK?4
MHO$$TALW\MI<YKTF)BT8+#!I]% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %:5G_J*S:TK/\ U% %"7_6M]:93Y?]:WUIE !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 02VEO.<RPHY]Q6+KVCV\E@ZPVB%BIQ@
M5T-% '(^!=)^PZ8_GVX2;><$CGO77444 %%%% !1110 4444 %%%% !1110
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MT?9IO[AK6\^CSZ ,G[--_<-'V:;^X:UO/H\^@#)^S3?W#1]FF_N&M;SZ//H
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M:/LTW]PUK>?1Y] &3]FF_N&C[--_<-:WGT>?0!D_9IO[AH^S3?W#6MY]'GT
M9/V:;^X:/LTW]PUK>?1Y] &3]FF_N&C[--_<-:WGT>?0!D_9IO[AH^S3?W#6
MMY]'GT 9/V:;^X:/LTW]PUK>?1Y] &3]FF_N&C[--_<-:WGT>?0!D_9IO[AH
M^S3?W#6MY]'GT 9/V:;^X:/LTW]PUK>?1Y] &3]FF_N&C[--_<-:WGT>?0!D
M_9IO[AH^S3?W#6MY]'GT 9/V:;^X:/LTW]PUK>?1Y] &3]FF_N&C[--_<-:W
MGT>?0!D_9IO[AH^S3?W#6MY]'GT 9/V:;^X:/LTW]PUK>?1Y] &3]FF_N&C[
M--_<-:WGT>?0!D_9IO[AH^S3?W#6MY]'GT 9/V:;^X:/LTW]PUK>?1Y] &3]
MFF_N&C[--_<-:WGT>?0!D_9IO[AH^S3?W#6MY]'GT 9/V:;^X:/LTW]PUK>?
M1Y] &3]FF_N&C[--_<-:WGT>?0!D_9IO[AH^S3?W#6MY]'GT 9/V:;^X:/LT
MW]PUK>?1Y] &3]FF_N&C[--_<-:WGT>?0!D_9IO[AH^S3?W#6MY]'GT 9/V:
M;^X:/LTW]PUK>=1Y] &4+:;(^0UL62LD6&&*9Y]68VW+F@"O<?>-5ZL7'WC5
M>@ HHHH **Y'Q5XNAT79&&(D+A3@^]=+87*W=E#,"#O0'K0!9HK-UJ6>&P:2
MW;:R@G-<!X9\:7FI:L]K)*6VR%: /4:*\N\6^+]0T75O*68B,R!<#ZUZ!HUV
MU[81RN<EE!H T:*9+((H7D/15)K@QXEO-;U$Q:7.(U1BK!O44 =_17%7UUK>
MD*LEU-O1C@!171:+=R7=KOD.30!IT49 ZFB@ HHHR/6@ HK@O'/B'4-)-O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %6(?N57JQ#]R@"%_OFFTY_O
MFFT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 '>KT'W*H]ZO0?<H AN/O&J]6+C[QJO0!',66-BHR<<5P
M\RZM>ZW&\MG^[C;@^U=Y10!2D@1K5OW";BI&,5XSK_@_5&UH7=I:-\K$C;7N
M=% '$Z?_ &K_ ,(TMO-;'S-I!SUZ5QWA?PUJVG:^UP]JP1I2V3]:]GHH \?\
M;>'=5U;5?,BM691(&R/K7HGAB*XATU([B/8RJ!BMRB@"KJ$;26DBH,L5('Y5
MP6@)K>C2W""U:1'D)RQ]Z]'HH X#7X=3UV*."6RPH<$G'O6I%X3AB\-S:>/^
M6PR>.E=710!X;9Z%K_A76Y)-/M'FB)P.>U>F:,^I7T:W-["89$X">M=-10!X
MEXD\*ZM?^*?M<=JQ02ALCZU[!I;3?88EF3:R(JX^@J[10!Y7X_T+4M8N(Q!;
M,RI(&!'UK;TC09[KPK+IUY$8R^/ZUW-% 'E>BZ+J?AZ]O$M[9GB=2JDU)X=\
M(7$VO)JM[&T<B,<*?K7J%% 'GWQ&\-3ZM9V_V2,NT;;L"N:M]/U^;PK/I<M@
MRAVZ_G7LU% 'DW@#P_J>B37AEMV4.N 36ZW]JQ,T)L1-&QR2XS7>44 >8^%/
M"=Q%K]W>7$)A5VR .E>FJ,*!Z"EHH XOQ2VK375LMM;%HU?YL>E=%IL(:T4S
M6R(V.1BM*B@#ROXC>&;O6##]DM/N'JHQ5OX?6>KZ3;K97-LPBSRS5Z310!X[
MXG\%WMOK<>I:?"TKF3>P%+XEM/$'B#1S%)8,K<# KV&B@#@OA[IE]I=NR74!
M3C'-:/CK03K6B/%&FZ0GL.:ZRB@#FO"&@#1+!5P=S+SFJGCGPR-<TMU0$R$]
MJ["B@#QGPTGBC0)WM4L'>%CMW$]!7H4D-X^CES&3,1]VNDHH \6T'PSJUEXD
MDNGM6"/+N)KV4%C <CYMM244 ><21ZN3?Q26'FI(2$+#--\'^$I;/4FOIXC&
MS*5*]J])HH \5\1>"]1T_7%U#3(7E8OO(%=AX?O-=U)4@U&T:W4<[J[JB@!L
M:[(U7.<"L;Q%]J>P>.WBWD@BMNB@#P72O"NMZ?X@^VK9,?WA:O1[S6=>$+&+
M30688SBNSHH XWP5:Z@!<RZC&R.SY4,:T_%>BKK>F" KD@YZ5OT4 <;X%\.'
M0X+A9%.6;(S5GQOX<'B#21 ,AE.X8KJ:* /%?#<'B;PW.]M#8/)"S?>)[5Z7
M;I>2:=)/*A$TD;*4].*W\44 >(Z)X5U:T\6K>/:,$$I;/XU:\8^&]5U761-'
M:L4$@;(^M>R44 <BVF7%]X1DL)HRCE N/PKCO"&A:OX=UR0I:L82-H8UZ_10
M!Q>O+J:ZQ;26]L98MH+ ],\5S,OA6\U?6Q<36GD*KA@5&.]>M44 1VZ>5;11
M_P!U /TJ2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *L
M0_<JO5B'[E $+_?--IS_ 'S3: "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** #O5Z#[E4>]7H/N4 1SQLS<
M"H?)?TIMY=-%(0#5;[?)_>H M^2_I1Y+^E5/M\G]ZC[?)_>H M^2_I1Y+^E5
M/M\G]ZC[?)_>H M^2_I1Y+^E5/M\G]ZC[?)_>H M^2_I1Y+_ -VJGV^3^]1]
MOD_O4 6_)?\ NT>2_I53[?)_>H^WR?WJ +?DOZ4>2_I53[?)_>H^WR?WJ +?
MDOZ4>2_I53[?)_>H^WR?WJ +?DOZ4>2_I53[?)_>H^WO_>H M^2_I1Y+^E5/
M[0?U-']H2>IH M^2_I1Y+^E5/M\G]ZC[?)_>H M^2_I1Y+^E5/M\G]ZC[?)_
M>H M^2_I1Y+^E5/M\G]ZC[?)_>H M^2_I1Y+^E5/M\G]ZC[?)_>H M^2_I1Y
M+^E5/M\G]ZC[?)_>H M^2_I1Y+^E5/M\G]ZC[?)_>H M^2_]VCR7]*J?;Y/[
MU'V^3^]0!;\E_2CR7]*J?;Y/[U'V]_[QH M^2_I1Y+^E5/M[_P!ZC[?)_>H
MM^2_I1Y+^E5/M\G]ZC[?)_>H M^2_I1Y+^E5/M\G]ZC[?)_>H M^2_I1Y+_W
M:J?;Y/[U'V^3^]0!;\E_[M'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/
MM\G]Z@"WY+_W:/)?TJI]OD_O4?;Y/[U %OR7]*/)?TJI]OD_O4?;Y/[U %OR
M7]*/)?TJI]OD_O4?;Y/[U %OR7]*/)?TJI]OD_O4?;Y/[U %OR7]*/)?TJI]
MOD_O4?;Y/[U %OR7]*/)?TJI]OD_O4?;Y/[U %OR7]*/)?\ NU4^WR?WJ/M\
MG]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E
M'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?
MWJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"
MWY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ5
M4^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\
MG]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E
M'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?
MWJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"
MWY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ5
M4^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\
MG]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E
M'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?
MWJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"
MWY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E3QHP7D5F_;Y/[U7+>X9XLDT #0N6/%
M)Y+^E5GOG#L,]#3?M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^
MWR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]
MZ@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'D
MOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ
M/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY
M+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^
MWR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]
MZ@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'D
MOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ
M/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY
M+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^
MWR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]
MZ@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'D
MOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ
M/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E'DOZ54^WR?WJ/M\G]Z@"WY
M+^E'DOZ54^WR?WJ/M\G]Z@"WY+^E6X5*KS62+]\_>-:=K(98\F@#.U'_ %IJ
MA5_4?]::H4 %%%% !1110 4444 %%%8^NZW%I4#;N7QD =: -BBN0T\:MJL2
MWD5P8XGZ*W44NJ1ZQ863W'VG<%'04 ==169H%S)=Z/#-+G>PYS6EN&<9% "T
M449 [T %%&14-R':$K&P5ST- $NX9QGF@L <$UY[X<U/4)?&%]:7$Y>./H*Z
M?5;'4;F[22UN!'&!R#0!N45!:))';(LK;G Y-3;ESC(S0 M%%!('4XH ** 0
M>E% !116=K!F%B_V>0))V- &@&!. >E)N&[;GFN(\%ZC>W>JWT-U,7\L\5L3
M:=JC>)8[I+D"S YCH Z&BD'"\FC(]10 M%%)N&<9% "T449'K0 449![U#<;
MC$VQ@K8H E+ '&:6O/-*U/46UR:*><M&),**]"'04 +12 @]"*6@ HI,CUI2
M0.IH **,CUHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "M*S_U%9M:5G_J
M* *$O^M;ZTRGR_ZUOK3* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** %'45MV'^IK$'45MV'^IH I:C_K3
M5"K^H_ZTU0H **** "BBB@ HHHH 1SM1CZ#->3^)+Q]0\;V-N2=A." >*]7<
M;D8>HQ7DGB.U?3O&]C<,#L!R3CB@#U6RMUMK98E& /:GW$"W$+1N/E/6H[&Z
M2[M5E1@0?0U.S!%R3@4 9=_<C1K!1$!Z 5S\^LZDNF37WDC=']T=C6YKE]9P
M6BM<H'4G"\]ZYO4A-=:!<RP/LA'\)H VM&UZXU#2?/*#S@A8J/I7.KXNUBXN
M6ACMU,@8A1ZU<\'_ "Z<X)S^[/\ *J.AJIU\$CGS#_.@#:LM<U*WWMJD(A&/
MD]S3[;4M2OX9)UA&5.% [BJ'Q)EDAL[,QYYE&<?45T'AJ2.33%*$=!G!H X3
MPC),_C;43,NV3'(KH]<\1W^GZI':I$IC9<DUC>'L#X@:G5WQ?_R&(O\ <_PH
M WKO6I+;2X)@!ODXQ61?:SJ=KI,NH^2-R=!VJY=7EG::):?:XP^[A?8UD>($
MN9O#%Q*DFV+^Z?QH Z?1]:-[HZW4N ^S<P%48=8N]5+&U0/"#M+"L72G=/#/
MRG_ED<XJY\.;N)])G7< WG'@GGJ: +&C:_?S:K/:7,2K'&<*?6NN'0&J!M[*
M*X\Q44R,>2#6@.@H R-<UF/2DC#, \G"@]S6+>76J2:8]P8/G[#VK$\?3N-3
MTT-G:)A_.NYF:-](4J01L'0^U '%> 7E;5-1=EQ)UQ[UH#Q1?KXTBTF6)5C8
M9SWJMX&Q_;^I8]:JZC_R5BW_ -S^HH ZG7M>;3GMXDP3,=IS437NI0.-L(,)
M&=QJ+Q5HCZK#"UO(L<D7()/>N:LM9O\ 1KQ;35&>9!WQQ0!V.J:^-/AMU)'F
MS< 'UJC>W^KVUH;I;<%^PKE_$=X9M4TJ1@?+:0%<]NM>F.L<]D Q!79_2@#$
MTCQ(=3M)MF#<0K\R^AK _P"$NU:36OL4=NIDQP*S_!B2KKVN!<A _'Y"KFF*
M/^$_4XYVT ;&E:UJL:7CZI;B'8,Q>]26NIW^J6S3I$"O/(J#QS+)"D 3.T_>
MK0\(/&V@#81CVH XSP_+/)X@N!.FW$O%=IJ6OFWO3918,@'2N5L<#Q!<;>OF
MT-*'^(+1RD+\O5N!0!<OO%5[IE];H8U\N5OF)[5=\0>*;NRT=;VTC5U+8R:U
M+G1+*Z"R3!'V\CFL/QK!#!X32.%0$$@X% #(M>U^\-K)!:*R,,N?3]*O#Q%<
MSZJVFN@611G K3\+HHTF$@=4%<]XE\/W<NJ27^GSK',?3K0!M0W^HI=QQ2P@
M(QQFNDKSK0?$4B7J6>HH[S;MJL1BO1: "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %:5G_J*S:TK3_44 4)?]:WUIE/E_UK?6F4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2_W:/L$O]VKGG-ZT><WK0!3^P2_W:/L$O]VKGG-ZT><WK0!3^P2_W:/L$O\
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M*BHX23!&3U*C^524 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M ,>T7^X/Y5)4=O\ \>T7^X/Y5)0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !W
MJ]!]RJ/>KT'W* (;C[QJO5BX^\:KT %%%% !1110 4444 %%%% !1110 444
M4 %<WKUE?WK[(4S&1S7244 9^D036MC'#*N-HJKXDL)M3TR6TC3<'%;5% '#
M>&?#]_HTC QD1D8YIGB7P6;V^34+56^T(O ' KO** .(T?P]?2.O]HJRJG*X
M)K5\3: NJZ8\: F3  Q]*Z*B@#A;#0=2?39+"ZC*Q*A5,$\U-X,\,3:#&Z.I
M4-(6Y^M=I10!P@\)SV>O3W]JA/GMES5_Q!X0AU6Q;[WG$=JZRB@#S?3/#.K0
M2+!(C"!3@')Z5WUA9)8VXB0GU.:M44 17'F>4WEC+8XKF(M-U'^VUO'CZ5UE
M% &%K>@Q:T+<SKS&<\"K5O8G3=/\FT7)]#6G10!YU!X4OXM:>]$7+ON->@0;
M_) E&& J6N/\3Z-JM]<%[*^>%?04 4=6T6VU77+>6WR6@DR^*[M4 B"8&,8K
M#\.Z)+ID):XE\V1QR36_0!Q-_P"%'M=0^V:<I,CMN>K;Z3?:QB+4X]L7M75T
M4 8FI^'K:^TH6A'W$VK@5QMAX3U;39!;P(QMP>I)KTVB@#GF\/(=&GM_F\R9
M,,/>N?T/PYJ>F0FP$9%H <'G->@T4 >>Z!X2O-'U"YG2,CS7W<U-/X;OF\2M
MJBQ_,W%=Y10!1DM/MFF-:W X=<&N'3PKJ.BZFTFE1EH^@SFO1J* /.[SPC>7
MVK6=[-&=\1R:UO$VAW>L:>EKLRJON%==10!RB:%//X?FL)T()3:H%96B^'=3
ML+4Z<8R+55(4]^E>@44 >?\ AOPG=Z+>3R!"!(Y;FI]1\.7MSK+7:QY!(Y_&
MNYHH @M%=+=$<8*J!27@E-NRPC+$$58HH \\M?"M_#K"WGE='+5K^)M(O=:L
MHHC'DHX;C\*ZRB@#F;/3KZ'2)+9H_F(P!5'0=!O=.U26[:/!=<5VE% '#:YX
M>O\ 4]8AO3'EHA@5JWNB2:CHZ6\ZD.G( ]:Z2B@#SW3_  [JL=K-92Q8@=NO
MM4VB^%[O3KZ<["(RI"FN\HH X.'PW?IKD=Z8ON'BNON[(7]BT4XY92*NT4 >
M8)X,U#2;IAIR.T3,6.2:[+1=%^R1-)-N\Z1<,#6[10!P^H>$Y3K\=Y;J2JCD
MU<US1KS4+*&)4R4-=910!SVBZ1+#IC6ERF%8\UD1^'+W1M2FNM,C+>:><]*[
MBB@#EX-#EO=3CU"_3$R#  Z56\4>'[K6'M@D>5@;*XKL:* .;DT^^ET-K5H_
MGX %5O#6BWFEW,KR1X#UUM% !VHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K$/W*KU8A^Y0!"_
MWS3:<_WS3: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :^[;\O6N&UKPW?:EJ4
M4YCR(WW"N[HH K60F%LJS##  59HHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ [U>@^Y5'O5Z#[E #98BYR*C^SGTJW10!4^SGTH^SGTJW10!4^SGTH^SGTJ
MW10!4^SGTH^SGTJW10!4^SGTH^SGTJW10!4^SGTH^SGTJW10!4^SGTH^SGTJ
MW10!4^SGTH^SGTJW10!3^SGTI?LY]*MT4 4_L[>E+]G/I5NB@"I]G/I1]G;T
MJW10!4^SGTH^SGTJW10!4^SGTH^SGTJW10!4^SGTH^SGTJW10!4^SGTH^SGT
MJW10!4^SGTH^SGTJW10!4^SGTI#;$]JN44 5/LY]*/LY]*MT4 5/LY]*/LY]
M*MT4 5/LY]*/LY]*MT4 5/LY]*/LY]*MT4 5/LY]*/LY]*MT4 5/LY]*/LY]
M*MT4 5/LY]*/LY]*MT4 5/LY]*/LY]*MT4 5/LY]*/LY]*MT4 5/LY]*/LY]
M*MT4 5/LY]*/LY]*MT4 5/LY]*/LY]*MT4 5/LY]*3[.WI5RB@"I]G/I1]G/
MI5NB@"I]G;TI/LY]*N44 4_L[>E+]G/I5NB@"I]G/I1]G;TJW10!4^SGTH^S
MGTJW10!4^SGTI/L[>E7** *GV<^E'V<^E6Z* *GV<^E'V<^E6Z* *GV<^E'V
M<^E6Z* *GV<^E'V<^E6Z* *GV<^E'V<^E6Z* *GV<^E'V<^E6Z* *GV<^E'V
M<^E6Z* *GV<^E'V<^E6Z* *GV<^E'V<^E6Z* *GV<^E'V<^E6Z* *GV<^E'V
M<^E6Z* *GV<^E'V<^E6Z* *GV<^E'V<^E6Z* *GV<^E'V<^E6Z* *GV<^E'V
M<^E6Z* *GV<^E'V<^E6Z* *GV<^E'V<^E6Z* *GV<^E'V<^E6Z* *GV<^E'V
M<^E6Z* *GV<^E'V<^E6Z* *GV<^E'V<^E6Z* *GV<^E'V<^E6Z* *GV<^E'V
M<^E6Z* *GV<^E'V<^E6Z* *GV<^E'V<^E6Z* *GV<^E'V<^E6Z* *GV<^E'V
M<^E6Z* *GV<^E2I$57%344 5#;DDG%'V<^E6Z* *GV<^E'V<^E6Z* *GV<^E
M'V<^E6Z* *GV<^E'V<^E6Z* *GV<^E'V<^E6Z* *GV<^E'V<^E6Z* *GV<^E
M'V<^E6Z* *GV<^E'V<^E6Z* *GV<^E'V<^E6Z* *GV<^E'V<^E6Z* *GV<^E
M'V<^E6Z* *GV<^E'V<^E6Z* *GV<^E'V<^E6Z* *GV<^E'V<^E6Z* *GV<^E
M'V<^E6Z* *GV<^E'V<^E6Z* *GV<^E'V<^E6Z* *GV<^E'V<^E6Z* *GV<^E
M'V<^E6Z* *GV<^E'V=O2K=% %3[.?2C[.?2K=% %3[.?2C[.?2K=% %3[.?2
MC[.?2K=% %3[.?2C[.?2K=% %3[.?2C[.?2K=% %3[.?2C[.?2K=% %3[.?2
MC[.?2K=% %3[.?2C[.?2K=% %3[.?2C[.?2K=% %3[.?2C[.?2K=% %3[.?2
MC[.?2K=% %3[.?2C[.?2K=% %3[.?2C[.?2K=% %3[.?2C[.?2K=% %3[.?2
LC[.?2K=% %3[.?2C[.?2K=% %3[.?2C[.?2K=% %3[.?2K$:[5Q3Z* /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gn15qjhcndsi000015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gn15qjhcndsi000015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -&!5P# 2(  A$! Q$!_\0
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M9S@)+ 3G<,"@#+TJT2ZO/*DZ5!?1I#<,BG@&M73;<V^KA3Z5FW\;F\DPIY-
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M61C*7,[A1115B"BBB@ KO?A__P ?BUP5=[\/O^/Q:B>QV8+^(CUD=*Y;Q?\
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M/\A0!ZO1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>_Z>11S(.1GB>#Z48/I7MG_"GA_S\C]*/^%/#_GY%'.@Y&>)X/I1@^E>V?\
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M #W_ $HYT'U"KV/+J*]1_P"%;#_GO1_PK8?\]_THYT'U"IV/+J*]1_X5L/\
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M1PE%=W_PA0_YZT?\(5_TUH X2BN[_P"$*_Z:T?\ "%?]-: .$HKN_P#A"O\
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M*.M6:X;XF3R0>&[EXV*L%ZB@#7_X3/2/^>WZT?\ "9Z3_P ]OUKY#_MO4?\
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MO_/5J^3/M<__ #T-'VN?_GH: LCZS_X6AX=_Y[-1_P +1\._\]FKY,^US_\
M/0TGVN?_ )Z&@#ZT_P"%H^'?^>S4?\+0\._\]FKY+^US_P#/0THNY_\ GH:
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M_P!8: /K'_A:'A[_ )[-1_PM#P]_SV:OD\W<_P#ST--^U3_\]#0!]9_\+/\
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M7_"T/#W_ #V:C_A:/AW_ )[-7R;]KGQ_K#2?:Y_^>AH ^L_^%H>'O^>S4?\
M"T/#W_/9J^3/M<__ #T-'VN?_GH: /K/_A:/AW_GLU'_  M'P[_SV:ODS[7/
M_P ]#2&[G_YZ&@#ZT_X6CX=_Y[-1_P +1\._\]FKY*^US_\ /0T?:Y_^>AH
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M%% !2&EHH 3%)3J;0 5V/A/_ )!4O_7<_P#H*UQU=CX3_P"05+_UW/\ Z"M
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M*9(VBBDI +1BBB@!,5V/A,?\2N7_ *[G_P!!6N/KL?"G_(+E_P"NY_\ 05H
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MD8S5]&<;XC\'":)I[9.>IKS*[LY+61D=2"#BOHL1AX]I&017%^+/"D=W ]Q
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M,4S1:$!CJO,F*NY&*JW!XI%HI,HJO)@5)(^#5=V)-)F\2&X?",:\^\37)+L
M:[C4)-D#?2O,=<G\R=AFI*>QS5QEF)I8.@%.E'6D@^]4LF&YH0UHQ#Y15"(8
M%:,!#*!63.V!MV*_**THE^:LZQ/&*UH5YJ#=(L@@"FD9I=O-2(G% <I"4XI
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M324;%FV5L@BM59-H&35"*4*N *BGG8'.<52!ZZ&C)<-MP#69=7.U3DU7DO\
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MZ-AZB@SFM#SZ5-DA!KK/"O\ R"Y?^NQ_]!6N>U2'R[LUT7A3_D%R_P#78_\
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ME)Y  XJVI!2HW?!ID-E5LQCB@.Q%22'<,8IB@J>15(SW#:33N@Q3MRD8%,?
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MDP:3S"%:HHVP!5CR]RU)UA 36A;@]356"+!K1C^5<4$,E5N:E5OF%0+R:&W
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MIYEW=*J["7J]!;T(4F"*35A4-/$6!TJ5!BF929&JD5H:6?\ 2Q5? Q5C3?\
MC[%,PJ;'2=J\W^)\GEZ<6_VA7I':O+OBX^S16;_:%4MSSS;\+3";0K?GH@K4
M?@UQ_P .+[[3I04G.U*ZR=L9J^I42*:8**SY9\YI;F6J#R<5)ND17$F<UAZA
M+B,\UHW$A -<]J,_!%)FI@7[;G-9;=:NW#98U1>D(B8U7>IFJ%NE,"K*QH@'
MS4V3.:DMADYJ)&D%J:UN.E:UL.E9=N.E;%L.E9,]&GL;FFKDBNGM> "*YG3R
M%(K?MY.0!4HUD]#84D@4_!VT^W3<@-$_R+6J.5N^A1G JH,[L5--,<&J\;EV
MQ0W8WBGRDT<9<T^10BU(I"+4,K!B>:-P3=RE/@\U"'!6GS,.1FJ7F;7(S4V.
MA;#G)-9MWT-77DP*S+R3Y30#V.*\0-F>N?;IFMC79,SUC Y%6CQ<2_?8S/-2
M)U%,(P:>AY%-G,C5L/\ 7+6^G2N?L?\ 6*:Z&$9%0=E,N6YQ4SG=@57CX:I<
M_-3-6.88XJM)G=4[GFF<$T(1 \?&:KO5J8@"J3')JB6QP/%*ARU,SQ4T2Y-4
M9LLQKQ4ZK21IQ4Z)00V+&IS5@)21I4V,4T9MG+>+I=E@5'K6=X5YTR7_ *['
M_P!!6G^,)LLT>:9X5_Y!<O\ UV/_ *"M,Y9/4^J:***DD**** "BBB@ HHHH
M **** "C%%% !1110 E%+10 4444 %%%% !1110 4444 %%%% !3X_OBF4^/
M[XH MUQ_Q _Y -Q_NUUYZ5R'Q _Y %Q_NTBX?$CYUW8&!4;$XIQX%1,]0ST$
M1ODTU5YS3LYIR@YZ4C4FB'K5@8Q4*X%.#"@BXYCQ48(]:&8X-5'?!ZTAD\E1
M\XIH;-2"@FXU5.X'WK>LS\HK%SR,5HVTW %#1I W4?C&:M0D^M94<IXJ]%+Q
M4'0GH:\+]J>^-U9\4QS5GS<\TBHLD*YIA3%+OXI?O#-(U4K%=XSFHVA+#K5E
MJA=@HH-%,K,@CZ=:1F Y[U%<7 7DFLVXU <A3S32*=6R)[JY$8/-8=U=%^,T
M7$K2')-4R,FK43DJX@B=B:@?)6K3)Q413UJEH<%2;D5%;#5H6%JUU<  506,
MO-M'<UV6B6'DQ*[#FB3,H1NS2LK411JH':M2- BU%& O)IWF9..U9,]"$="T
MK#;4+N :@>X X!J/S"W-)&ZV'NV02:JLV6J1Y.,5&J[C5 @";SP*T;6VVX)I
MMK"!R:T$&.E.(,>BE1@5=MH-W)%001LS9(XK33"+D5HD9MB" *PI9F$:]:52
M2:;-"7YJK&;*HD.<TS!9\FK(A%.\GBDQMD>S X-3!@JU&4*BHV? I(S8]I\9
M!-<MHEWYOC"6//W6%:]_/Y-J\I.,"N1\&3_:/&,S@YRPJT<6(9])6W_'O'_N
MUYQ\7G*:7#CUKTBW_P"/>/\ W:\R^,AQI,/UIG)%V9X8S[G./6D+&HD8')]Z
MD'-9L[8.Z) ?ER:3S.U+QBHGQVIC8,<FE7K40;GFIH^328XER,_)3N2:8BU9
M2,<5)TP)X$XR:OPR!:@BCPE-<E33-C82X&,9I))\+63%<;6P33Y+C/2J3!Q%
MN)BV3FJ+7!SBI))>*JY#&@N*T+"/NJPJ!ES5-#@\595SC% [#HGVR8S5B28\
M8-9TCE7XI&N30,N2OE>34=N,M54S%N*E6?REH%(LW<ZQ1$9KC[Z4R2GZUJ7U
MT9"1FL24GS*$>;B9$L<95-Y-7[&,2Q/ZUGN_[D+6CI(.QO2M$<1)!=&&5HI#
ME<<40<R$CN:ANHO]()%6K50,5#.S#KJ:,1/ K;LXL*#6(O#"NAT_YHN:@])$
MO2H2Y<\5::$L>*9Y0C!S2&B%>M3(H+5"W7(I\;U+W*+2C#XK5M(_EK,A1F8&
MMFW0A15(19B!WXK8M8@Q%9]M%N;FMJVAVC-7%&566A<12B#%2;\CFHRV!BF[
MOEJF<EKC9F"@UE329:K=Q(>E43&6>I-H*R%A7<U:T$? JO:6W(K56(*M",JD
MR$H*C; -2R,%-57DYID;DN[BK>EX-R#6;YF*FTJ[']J"$GG%4D9U'[IUW:O*
MOC$<:#)]17JHKRGXR?\ ( D^HH. YSX1:@#'-$S=%P,FO3[D\5\[_#_5S8:H
MD>[ =L5] 23"2(,IX(K1ZHJ.YFW350=\#K5JY-9<\FW/-2=,2M=2GGFN:U&;
MD\UKWDXVMS7+7T^YSS2995E?FJS&G.^:C)S2$,;I4#'(J9S5=S0!6?J:LVJ\
M"JK'YL5>M5^45#-J>YIVZ]*V+<<"LJ#@@5KVXSBLF>A$U+5MI%:]O+AQBL6#
M@@U=638^X5*-[71UUC,=HYJ6Y;Y2:Q[&[ (!-:4LH:/.:U1S.%I&3-(3)@5/
M H7YC5*67$X J4N^*=SHL[$TL^XX4U6ED9!]ZF%BG)JG+/N8\T7*4!TTA )S
M6<92TIYJ6>?Y#S52'ER:"K6+#,<=:S[MQY;'VJ[(PQ61J,NV)OI4F4W9'%:N
M^^X-9PXJY?'<Y/O5/.!6B/%K.\KBL<TB'FD[4+]ZFS%,VM.7+BNCA&%K!TI<
MD&M\<+6;.RFR1>N:E'6HH^!2R-@<4^AJ.=LFF]!48;=3G?"T(ELKS/FH1S1(
MV3Q0F!5$,>$S5R"+BH8EW-6A%'@4R6QZ+@58C3--5*N01$TT9MBQQ<42KM1F
M/:KRPX'2JFJ$0:?,QXPM6D92D>6^*;CS-190>*T/"G_(+D_Z['_T%:YO5)O.
MO&?/>NB\*'_B5R_]=C_Z"M)G.]6?5=%%%2(**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *?']\4RGQ_?% %NN/\?L!
MH-Q_NUV%<1\2&V^'K@_[-(J+LSYX>05!G)J)&W*#ZU(.M9L]".J#^*K"XXJ$
M#FIE(%!;>A+@8I#@4PR"F%LT,$+(W%5BN34C'-(,YI#$1#FI&! J1!DC%2S
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M>D\W%5S)Z5$TQS3+4BX9N,5"TE5_,-#.*"N8&))IH!)J1,;<FFF0#-!?,(S
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M3&>5I&.2:#DKU+Z%8CFN_P#A9_R'/Q%<#U-=_P#"W_D.?B*#E/JFV_X]H_\
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ME,DBJK$;%*-.>E8WBW68],TUE#89UXK<NI$L[=II#A17AWC+7WU*]:,/\J'
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M8'#/Z@UX;K.N7.J7#/+(Q!.0":I7^H37LS22,22?6J);-)LS).M,--W&C)J
M$HHHH **** "NQ\*?\@N7_KN?_05KCJ['PI_R"Y?^NY_]!6@#ZOHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*?']\4RGQ_?% %NN"^*7_(KW7^[7>UP7Q2_Y%>Z_W: /DRBBB@ HHHH *4&D
MIV10 N[%31R]C5?- /- 7L7PV:6JB2E:G20&D:*1+0.M)4BBD4A56I M(.*D
M4=Z#1#D6K,:5"G6I=^*0RTC8'%2!ZJQL2:M;>*JP[DB-N-3KUJ!!@5('% R;
M-&^H/-ZT@?BF!:!W&G9"FJRR8H,H)I@6FDR,5);D!LU35LU.F<\4(ALUXYL
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MZ78;L'%4+&U50"Q&/K5^;Q'8:;&5W?.!5)$2FD=)"L5LH+L% ]:@U+QA::9
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MOU%>M5Y5\8;>2XT"18T+'(Z"@#YDHS5[^R;O_GB__?)H_LF[_P">+_\ ?)H
MI9I:N?V3=_\ /%_^^32C2;S_ )XO_P!\F@"E15[^R;S_ )XO_P!\FC^R;S_G
MB_\ WR: *-%7O[)O/^>+_P#?)H_LF\_YXO\ ]\F@"C15[^R;S_GB_P#WR:/[
M)O/^>+_]\F@"ENI=U7/[(N_^>+_]\FC^R;S_ )XO_P!\F@"CDYIRN5[U<_LF
M\_YXO_WR:/[)N_\ GB__ 'R:!W(5N2*G6Y'>D_LJ\_YXO_WR:7^RKP?\LG_[
MY- U-HF$JMWI<CUJ)=,O1_RR?_ODU(+&]'_+%_\ ODT%J8OXTHIPLKSO$_\
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MA%_WR*\&_P"%U:K_ ,]_UH_X73JO_/;]: />?^$6T;_GPB_[Y%'_  BVC?\
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M_P"%TZK_ ,]_UI?^%TZK_P ]_P!: NSWW^P--_Y](_RIK>&]);[UG$?^ BO
M_P#A=6J_\]_UH_X75JO_ #W_ %H%<]Y_X1?1O^?&+_OD4G_"+Z-_SXQ?]\BO
M!_\ A=.J_P#/;]:/^%TZK_SV_6@#WG_A%M&_Y\(O^^11_P (OHW_ #X1?]\B
MO!O^%U:K_P ]_P!:/^%TZK_SV_6@#WG_ (1;1O\ GPB_[Y%'_"+:-_SXQ?\
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M6F_\+9U+_GK^M*X>S9[)_P (QHW_ #XQ?]\BC_A&='_Y\8O^^17C1^+6H_\
M/;]:3_A;6I?\]OUHN'(SV;_A&-&_Y\8O^^11_P (OHW_ #XQ?]\BO%_^%N:E
M_P ]OUH_X6[J7_/;]:+BY6>T?\(OHW_/C%_WR*7_ (1C1O\ GQA_[Y%>)GXO
M:I_SV_6HS\7]5'_+;]:8K,]O_P"$8T;_ )\8O^^11_PC&C?\^,7_ 'R*\-/Q
MCU4?\MOUI!\9=4_Y[?K0(]S_ .$7T;_GQB_[Y%'_  C&C?\ /C%_WR*\-_X7
M)JG_ #V_6D_X7)JG_/?]: /<_P#A%]&_Y\8O^^11_P (OHW_ #XQ?]\BO#/^
M%RZI_P ]OUH_X7+JG_/;]: /<_\ A%]&_P"?&+_OD4?\(OHW_/C%_P!\BO#/
M^%S:I_SV_6D_X7-JG_/;]: /=/\ A%]&_P"?"+_OD4?\(OHW_/A%_P!\BO"_
M^%S:I_SV_6E_X7+JG_/;]: /<_\ A%]&_P"?"+_OD4?\(OHW_/C%_P!\BO"_
M^%S:I_SV_6C_ (7-JG_/;]: /=/^$7T;_GQB_P"^11_PB^C?\^$7_?(KPO\
MX7-JG_/;]:/^%S:I_P ]OUH ]T_X1?1O^?"+_OD4?\(OHW_/C%_WR*\+_P"%
MRZI_SV_6E_X7-JG_ #V_6@#W/_A%]&_Y\8O^^14L?A_2XEVI9QJ"<X"UX.OQ
MEU0LH\[J?6O0='\:W=[8+,TF23CK["@#O**** "BBB@ HHHH **** "BBB@
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MWM7J6H>%K.X!9$Y-<?J'A>YMW)0?+]*9'*SG:*GFM986PZ'\J@(Q2$%%)2T
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M'K45>P:[X2M[M&>%,/7FVIZ'<:?(P=>!Z46.:4&C(HI6&*2D0%%%% !1110
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M "4X#)P*%&6Z5T>B:"]TX=U^7K1<N$')V*>F:+->2*2I"^M=S8Z1%:QJ-H)
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MF+_='\J -JN(^*7_ "*$WUKMZXCXI?\ (H3?6@#Y5N/]>WUJ*I;C_7M]:BH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDC.O@,<56BC95+8XJ:5]S\FG>;^Z(%(F^A0=M\O-7PJ>03W JJJ#=NIUR^P
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MH4KXC!K)(4H^3S6G=9;(JB8Q@^]49R94@'-7X;=I2-JYID4"C'>NGL+-!$'
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M#$*6&:^@],OX[ZT2=&R"*^7XW*L"#@BO5_A]XC!"64K_ (DU:U+@['J;R<5
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ME%+12 3%+110 Y/]8OU%>V^%O^0*G^]_05XDG^L7ZBO;?"W_ "!4_P![^@H
M]IHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6O\ UT'\Z^P_#/\ R"8O]T?RH VJXCXI?\BA-]:[>N(^*7_(H3?6@#Y5N/\
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M31TL6HQ2<9YJT'##((KD5=AT.*LQWLD?\1-#-%59T+FH36>FIG&&%2B]1NI
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M +^/_P#$4?\ "KM;_P"?K3_^_C__ !%%% !_PJ[6_P#GZT__ +^/_P#$4?\
M"KM;_P"?K3_^_C__ !%%% !_PJ[6_P#GZT__ +^/_P#$4?\ "KM;_P"?K3_^
M_C__ !%%% !_PJ[6_P#GZT__ +^/_P#$4?\ "KM;_P"?K3_^_C__ !%%% !_
MPJ[6_P#GZT__ +^/_P#$4?\ "KM;_P"?K3_^_C__ !%%% "?\*NUO_GZT_\
M[^/_ /$4O_"KM;_Y^M/_ ._C_P#Q%%% "_\ "K]<_P"?K3_^_C__ !%)_P *
MOUP?\O>G_P#?Q_\ XBBB@ _X5=KA_P"7K3_^_C__ !%'_"KM;_Y^M/\ ^_C_
M /Q%%% !_P *NUO_ )^M/_[^/_\ $4O_  J_6_\ GZT__OX__P 1110 X?##
M6_\ GZT__OX__P 12_\ "L-;_P"?K3_^_C__ !%%% "?\*PUO_GZT_\ [^/_
M /$4G_"L-<_Y^M/_ ._C_P#Q%%% Q/\ A6.N?\_6G_\ ?Q__ (BC_A5^N?\
M/UI__?Q__B*** $_X5=KG_/WI_\ W\?_ .(I/^%7:W_S]:?_ -_'_P#B***
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M_P _>G?]_'_^(HHH)%_X57KG_/WIW_?Q_P#XBC_A5>N?\_>G?]_'_P#B***
M#_A5>N?\_>G?]_'_ /B*/^%5ZY_S]Z=_W\?_ .(HHH 3_A5>N?\ /WIW_?Q_
M_B*7_A5>N?\ /UIW_?Q__B*** #_ (57KG_/WIW_ '\?_P"(H_X57KG_ #]Z
M=_W\?_XBBB@ _P"%5ZY_S]Z=_P!_'_\ B*/^%5ZY_P _>G?]_'_^(HHH /\
MA5>N?\_>G?\ ?Q__ (BC_A5>N?\ /WIW_?Q__B*** #_ (57KG_/WIW_ '\?
M_P"(H_X57KG_ #]Z=_W\?_XBBB@ _P"%5ZY_S]Z=_P!_'_\ B*/^%5ZY_P _
M>G?]_'_^(HHH NZ3\,=:M]4MY7NM/*JX)Q(^?_0*^E="MGM=.CC<J2 !\M%%
M &G7*^/],GU;PW);0-&KD]9"0/T!HHH ^?IOA?K;2L1=:?R?^>C_ /Q%1_\
M"KM;_P"?K3_^_C__ !%%% !_PJ[6_P#GZT__ +^/_P#$4?\ "KM;_P"?K3_^
M_C__ !%%% !_PJ[6_P#GZT__ +^/_P#$4?\ "KM;_P"?K3_^_C__ !%%% !_
MPJ[6_P#GZT__ +^/_P#$4?\ "KM;_P"?K3_^_C__ !%%% !_PJ[6_P#GZT__
M +^/_P#$4?\ "KM;_P"?K3_^_C__ !%%% !_PJ[6_P#GZT__ +^/_P#$4?\
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M_GZT_P#[^/\ _$4?\*NUS_GZT_\ [^/_ /$444@$_P"%6ZY_S]:?_P!_'_\
MB*7_ (5;K?\ S]:?_P!_'_\ B*** #_A5NM_\_6G_P#?Q_\ XBC_ (5;K?\
MS]:?_P!_'_\ B*** #_A5VM_\_6G_P#?Q_\ XBC_ (5=K?\ S]:?_P!_'_\
MB*** #_A5VM_\_6G_P#?Q_\ XBC_ (5=K?\ S]:?_P!_'_\ B*** #_A5VM_
M\_6G_P#?Q_\ XBC_ (5=K?\ S]:?_P!_'_\ B*** #_A5VM_\_6G_P#?Q_\
MXBC_ (5=K?\ S]:?_P!_'_\ B*** #_A5VM_\_6G_P#?Q_\ XBC_ (5=K?\
MS]:?_P!_'_\ B*** #_A5VM_\_6G_P#?Q_\ XBC_ (5=K?\ S]:?_P!_'_\
MB*** %3X7:V'4_:M/X/_ #T?_P"(KU/0/"M]::6L4DMN6!_A9L=![444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gn15qjhcndsi000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gn15qjhcndsi000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +K!W,# 2(  A$! Q$!_\0
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M5>B@/90[%C[9-_>H^V3?WJKT4![*'8L?;)O[U=!X0N9'U^V#'^*N7KHO!O\
MR,%M_O4$3IP2T1]-Z?\ \>:5:JKI_P#QYI5JL&=T?A04444%!67X@_Y T_TK
M4K+\0_\ (&G^E-;D5?@9X-J/_'])]:J5;U'_ (_I/K52NH^/E\3"BBBF(***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#W;0/
M^0#9_P#7.BCP_P#\@&S_ .N=%<KW/JZ?P+T/F*\_X^&JO5B\_P"/AJKUJ9TO
M@04444%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5T7@W_D/VW^]7.UT7@W_D/VW^]014^$^F]/_P"/-*M55T__ (\TJU6!UQ^%
M!11104%9?B'_ ) T_P!*U*R_$/\ R!I_I36Y%7X&>#:C_P ?TGUJI5O4?^/Z
M3ZU4KJ/CY?$PHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ]V\/_P#(!L_^N=%'A_\ Y -G_P!<Z*Y7N?5T_@7H?,5Y
M_P ?#57JQ>?\?#57K4SI? @HHHH+"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !71>#?^0_;?[U<[71>#?\ D/VW
M^]014^$^F]/_ ./-*M55T_\ X\TJU6!UQ^%!11104%9?B'_D#3_2M2LOQ#_R
M!I_I36Y%7X&>#:C_ ,?TGUJI5O4?^/Z3ZU4KJ/CY?$PHHHIB"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]V\/_ /(!L_\
MKG11X?\ ^0#9_P#7.BN5[GU=/X%Z'S%>?\?#57JQ>?\ 'PU5ZU,Z7P(****"
MPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z+P;_
M ,A^V_WJYVNB\&_\A^V_WJ"*GPGTWI__ !YI5JJNG_\ 'FE6JP.N/PH****"
M@K+\0_\ (&G^E:E9?B'_ ) T_P!*:W(J_ SP;4?^/Z3ZU4JWJ/\ Q_2?6JE=
M1\?+XF%%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'NWA__ ) -G_USHH\/_P#(!L_^N=%<KW/JZ?P+T/F*\_X^&JO5
MB\_X^&JO6IG2^!!11106%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[:F6VF0'68;,*/G.*EU6RM-+G,3Q!B#BIQ_R-UOC^]5[Q/!ISW9,\Q5BW.*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M';SKA8I"=JD$4S)-2ERV)WTM=.A5[C#;AD"EM]/BU8,+<!&4;JN>,F/F6H'
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M_$/_ "!I_I36Y%7X&>#:C_Q_2?6JE6]1_P"/Z3ZU4KJ/CY?$PHHHIB"BBB@
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MA\Y R^IKB*=YCXQO;'UH:'"LXWOK<V/['2,-*TZ, >F:V?#+0VLEVQD4!XR
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MGM6?I\SZ-J 2Y^52V34VK_V=<2O<K(V6JY1;J6>S0%C0DC-X0 "I8U/!(/\
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MGU=/X%Z'S%>?\?#57JQ>?\?#57K4SI? @HHHH+"BBB@ HHHH **** "BBB@
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MDHHL@%))ZT9)[TE% !1113 **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 >[>'_\ D V?_7.BCP__ ,@&S_ZYT5RO
M<^KI_ O0^8KS_CX:J]6+S_CX:J]:F=+X$%%%%!84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z+P;_R'[;_ 'JY
MVNB\&_\ (?MO]Z@BI\)]-Z?_ ,>:5:JKI_\ QYI5JL#KC\*"BBB@H*R_$/\
MR!I_I6I67XA_Y T_TIK<BK\#/!M1_P"/Z3ZU4JWJ/_'])]:J5U'Q\OB84444
MQ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M>[>'_P#D V?_ %SHH\/_ /(!L_\ KG17*]SZNG\"]#YBO/\ CX:J]6+S_CX:
MJ]:F=+X$%%%%!84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %=%X-_P"0_;?[U<[71>#?^0_;?[U!%3X3Z;T__CS2K55=/_X\TJU6
M!UQ^%!11104%9?B'_D#3_2M2LOQ#_P @:?Z4UN15^!G@VH_\?TGUJI5O4?\
MC^D^M5*ZCX^7Q,****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /=O#__ " ;/_KG11X?_P"0#9_]<Z*Y7N?5T_@7H?,5
MY_Q\-5>K%Y_Q\-5>M3.E\""BBB@L**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "NB\&_\A^V_WJYVNB\&_P#(?MO]Z@BI\)]-Z?\
M\>:5:JKI_P#QYI5JL#KC\*"BBB@H*R_$/_(&G^E:E9?B'_D#3_2FMR*OP,\&
MU'_C^D^M5*MZC_Q_2?6JE=1\?+XF%%%%,04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'NWA_P#Y -G_ -<Z*/#_ /R ;/\
MZYT5RO<^KI_ O0\DMOAO)J,(N 7PWI4O_"J)?5Z]>\+?\@.*MJFY.Y5&"]FC
MP?\ X51+ZO1_PJB7U>O>**7,S3D1X/\ \*HE]7H_X51+ZO7O%%',PY$>#_\
M"J)?5Z/^%42^KU[Q11S,.1'@_P#PJB7U>C_A5$OJ]>\44<S#D1X/_P *HE]7
MH_X51+ZO7O%%',PY$>#_ /"J)?5Z/^%42^KU[Q11S,.1'@__  JB7U>C_A5$
MOJ]>\44<S#D1X/\ \*HE]7H_X51+ZO7O%%',PY$>#_\ "J)?5Z/^%42^KU[Q
M11S,.1'@_P#PJB7U>C_A5$OJ]>\44<S#D1X/_P *HE]7H_X51+ZO7O%%',PY
M$>#_ /"J)?5Z/^%42^KU[Q11S,.1'@__  JB7U>C_A5$OJ]>\44<S#D1X/\
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M/^%>2>KUZW11[1A_9M$\D_X5Y)ZO1_PKR3U>O6Z*/:,/[-HGDG_"O)/5Z/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K)\1_\@::M:LGQ'_R!9J:W,ZOP,73/^0;!_NT4:9_R#8/]VB@4
M/A1%X6_Y <5;58OA;_D!Q5M4/<*/\.(4444C4**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "L+6O^/E/I6[6%K7_'RGTIK<RK? :>
MG_\ 'FE6JJZ?_P >:5:I%Q^%!11104%9FO\ _('F^E:=9FO_ /('F^E-;D5/
M@8F@?\@F'Z5J5EZ!_P @F'Z5J4/<*7P(****184444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %9/B/_D"S5K5D^(_^0+-36YG5^!BZ
M9_R#8/\ =HHTS_D&P?[M% H?"B+PM_R XJVJQ?"W_(#BK:H>X4?X<0HHHI&H
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %86M?\
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MZK]32I(D@RC!AZ@T .HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW:*-,_Y!L'^[10*'PHB\+?\ (#BK:K%\+?\ (#BK:H>X4?X<0HHHI&H4444
M%%%% !7)>.8I;O1I[:$;I'7 %=;44EO%*<N@-"$]3SGX;:?=:8JI=)L(7%=)
MXST1M8T:98E+2E<**Z!+2",Y2, U-@8Q3OK<26ECRN&SN[?PO;Z44_?)PR_E
M5FVT"30_!6HK(I4RG=S^->B&QMFDWF(;O6LSQ1 USH-Q;1J<LN!BG<.4\Q\#
MWDEO)< @ -$RK]<&M/PEX>O!J4FH74>W;*2"/3-7?!.AO:73?:HB5V]Q7HD=
MO%&FU$ 4]J&Q16AY(NBWO_"<WEV8OW$IP&_.G^*?#NHVFO6FIV$.]8D&2?7
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MI15;[?:<#[1'STYJ5YXHX][R*J^I-(9)14 O;8XQ.ASTYZTY[F&(_/*J_4T
M2T57CO;69BL<Z,1U -.>[MXWV/,BMZ$T 345#'=V\Q(CF1B.N#3)-0M(I-DE
MQ&K>A- %FD+!1DU6&I618*+J(L>@W5SOC1;B33"+:^%N^>N:!-G6 Y&:*Q]!
M\R'2XC<7(E(3ELU>_M&S R;F/_OJ@9:HI%974,I!!Z$4R6:*%=TLBHOJ30!)
M3=XSC/-1"\MF( G0YZ<UQ6K17C^*&:+4Q'%_SSS[TQ-G>452CO+>VMHEN+A
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.=WM756]E//X)N+<Q,LGDX (YKB]%6_L=(%@UC*2H/S;?:A#9L^ +FYET_6
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MOR #Z5Q'E^(SXCGS$OV,G"FNYI-HSG%.XFB"SMEMH@%&">3]:L444AA1110
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M,@Y%+5 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9/B/_D"
MS5K5D^(_^0+-36YG5^!BZ9_R#8/]VBC3/^0;!_NT4"A\*(O"W_(#BK:K%\+?
M\@.*MJA[A1_AQ"BBBD:A1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5A:U_Q\I]*W:PM:_P"/E/I36YE6^ T]/_X\TJU573_^/-*M
M4BX_"@HHHH*"LS7_ /D#S?2M.LS7_P#D#S?2FMR*GP,30/\ D$P_2M2LO0/^
M03#]*U*'N%+X$%%%%(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "LGQ'_R!9JUJR?$?_(%FIK<SJ_ Q=,_Y!L'^[11IG_(-@_W:
M*!0^%$7A;_D!Q5M5B^%O^0'%6U0]PH_PXA1112-0HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5D^(_^0+-6M63XC_Y LU-;F=7X
M&+IG_(-@_P!VBC3/^0;!_NT4"A\*(O"W_(#BK:K%\+?\@.*MJA[A1_AQ"BBB
MD:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1_\ (%FK6K)\1_\ (%FIK<SJ_ Q=,_Y!L'^[11IG_(-@_P!VB@4/A1%X6_Y
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MUK(N;Q[6/)'##K4=E>><H9&W&CV\>;E'<W,CUHK'U*YNHI(1%$6!ZUHVKN\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGP,30/\ D$P_2M2LO0/^03#]*U*'N%+X$%%%%(L**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "LXZ)8-=M<F']ZW4UHT4 ( %
M4 =!2T44 %%%% %:[L+>]0I.FY35&'PUI<#AX[?!%:]% 6$50BA5' XI:**
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MCR(O^>:?E1=![.I_,<__ &^W_/*3_ODT?V^W_/*3_ODUT'D1?\\T_*CR(O\
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M_;[?\\I/^^370>1%_P \T_*CR(O^>:?E1=![.I_,8']OM_SRD_[Y-)_;[?\
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M &^W_/*3_ODT?V^W_/*3_ODUT'D1?\\T_*CR(O\ GFGY470>SJ?S&!_;[?\
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MRD_[Y-)_;[?\\I/^^370>1%_SS3\J/(B_P">2?E1=![.I_,8']OM_P \I/\
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M,<__ &^W_/*3_ODT?V^W_/*3_ODUT'D1?\\T_*CR(O\ GFGY470>SJ?S'/\
M]OM_SRD_[Y-']OM_SRD_[Y-=!Y$7_/-/RH\B+_GFGY470>SJ?S'/_P!OM_SR
MD_[Y-']OM_SRD_[Y-=!Y$7_/-/RH\B+_ )YI^5%T'LZG\Q@#7F) \J3_ +Y-
M;5G<&XBW$$?45+Y$7_/-/RIX4*,  ?2ALN$9)ZL6BBBD:!1110 4444 %9/B
M/_D"S5K5D^(_^0+-36YG5^!BZ9_R#8/]VBC3/^0;!_NT4"A\*(O"W_(#BK:K
M%\+?\@.*MJA[A1_AQ"BBBD:A1110 4444 17! MI<G^ _P J\Y\.NJZS+E@/
MWIZGWKT:>$3Q%"2 1CBN<C\$V<=PTRS2!B<]333$T7]>U>&RT]\$.SJ5 4YZ
MUY[H^BW(\/:I,RG?(Y9..>37>#PK;^;O::1N<X8DBME;:)(?*"*%QC&.M%["
MM<Y#P=<JFEBVF($BH<YX[52L[5W\1QRPC$8<[L5T3>%+4WLERLKJ7'*J2!6C
MI^E0Z>K!/FR<Y-%PL6KG_CUE_P!P_P JX;PV5_M&3)&?,/\ .N[EC$L;(3PP
MQ6':>%K:SN#,DKY+9ZT(;.4T_P#Y'35\'DQ$#\C4O@R9K.YFAN3AGE8KNXXS
M730^%;6'4Y;Y9'\R3J*=>>&+6ZNTN-[(R#&%XIW1-F<SK=N;G5\V_P!X."2.
M>]1W_P"[\<:;OXQ&,Y^@KL['1(+*9I0Q<G^]S5?4O#-MJ6HQWKNRR1C VT7'
M8VU8,,@Y%</XH*_\)%!GIM_PKM+>$6\"Q D@=S63J7ANWU*[6XDD8,HP,&DA
MLR]<1SHMNT62J\G'I46AR:3J.F2+.B##8*LV":ZE-/B2R^RGYEVXR:YD_#VR
M^V?:%NIUY)VJQ _G1H*S(=<O-.TN*VCBMR [!5(Z"LO64D#I)).K@J",'I77
MW_ABUO[*&VD=L1=&[U0?P-9R0F-KB4@]RQ_QIIH&F<SK<[6UII;L"Z%QT[<U
MW(O+&:SCD+)(P0?*&R>E13>&+6;3H[-V)5!@$]:IZ5X)M=*NA,ES-)@YVNQ(
M_G1=!9F)XI:-[G3RHP/-''IS5GQ*5\Z+D?ZL?R%;M]X6M;^>.621@4;< *6^
M\,6U\ZM)(X(&.#1=!9E_2#G2X/\ =KFO&NW[,X)'2NLM+9;2W2%"2JC S6=J
MWA^#5F)ED9<CL:2W&]CF]6V_V'IO(Z56U\AO 4XSGG^AKJ+GPQ;7-K# TCA8
MN!S39_"MK<:6U@TC^6W?-.Z%9G+WIE_X1S3&B)VJGS8_&M*TO()_##X=0<]"
M>:WX-!MX=/-GDLFW:">U9$?@.SC4J+F;:3G&X_XT7"S,S2R#I>J[3G]V?Z4S
MP9,D7A*178!O,/RD\]ZZ:P\,VUA#-&DC,)1@Y-4X?!%G#(62>4 _P@G'\Z+H
M+,R?"_ES2ZLKXVMU_2LJ_LKW2HS>65RJV@;_ %2GFNUL?"MK8+<".5SYXPW)
MXJ-/"-JL'DF:1E)SR2:+BL[&CHETUUIL+,#NV<DURGB_S8;TS$$Q>F*[>VMT
MMH$B3HHP*KZGI<.J6Q@EX![@<TD]2FM#'OGAN?"3*&4R&'Y1GFL;PQ#):^"]
MD_#;CUXKH(?"UO"5Q-(0O8DXJ_<Z3#<6?V;.Q/\ 9XHN*QSG@DC[3>\]_P#"
MNMN@QMWV]=IK-TGP];Z2\C12,=_7)K7(R,>M#&MCSGP)=K!K.K+<'86E.-W&
M>E.B=#\4)F# C9US]:W[WP99WEVMQYLD3 Y.PXS^5%OX,M+?4C>B:0R$8Y)I
MW1-F8.M,#XDL<$']Y_C5[Q#I)O+YWLIDAN\9+DUK2>%+66\CN6E?=&<CFI;C
MPW!<7S71FD#$8P"<47'8XZQO[U-'U*VN&:5U&T$"KO@V6P?1X[:\"K,!SO.*
MZFRT&VLED"_-YG7<*Q[[P#97E\;K[1-$3_"C$#]#1=!9A(^F:?977V2WV;OO
M$=ZY?7&:X\,6TJRJ8S(,)GZ5WI\.VYTYK,NQ5EVEN]90\ V0LDM3<2E%.1DG
M_&A-":8T16]WHT$)*^8T8"L3TKGBNIZ!,PFN?/M2-JHG.#791^%K>.(1B:3
M&!R:?'X9MD(W.SX_O<T7'9G'Z1=PP7RK>H?WS94MQBNNBM-(6^::")&F/5E.
M:CUGPA9ZQY>^1HB@P"G'\JET3PS!HI!CFDEP,?.2?YTK@DS5N 3:,(^#CBN
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MY&&4YX%*X['.>,[9[3PNJ(I.'!PHJSI9TB[T:-9E0LL?S*6Y-=+=VD=Y 89
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -:-7^\,TH
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MN,,/N>OUKI+'PU;6%K+!'(Y63J2:AT_PE::=J#WD<DA=Q@@FE<+,YOQ*R_\
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M76-0#. <]S]*U])\(6NEONCD<\YP32VG@^TM+^>Z263=*<D9-%T"3.>D9?\
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MK9+6<[RDG.,4[4?$5PME_:,8<1YQMI=9"_V1IW ^YZ?6HK\+_P (9G ^]Z4
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ME43%(FDKY@^79\N:FV(?!L9VC[WI0*[+\GC$_8OM"VKD*N3@5:M/%:7&AIJ
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M;+O^X_Y4?;+O^X_Y5TFU?[H_*C:O]T?E1</92_F.;^V7?]Q_RH^V7?\ <?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.9&C:AN!^W/6Y8P201;9)"Y]35JBBY<*48NZ"BBBD:!1110 4444 %9/B/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !63XC_ .0+-6M63XC_ .0+-36YG5^!BZ9_R#8/]VBC3/\
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MZ[B3LC4M[UX[EHV)8= :KW^IRVNHQQ#+;AFKELMG,!(H.XUDZH,Z_#@<;?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9M[RW,OF*,'!K&\/F.X\-Y;F1HCNKGM,@:/4?LB?ZAF)/YT["N=@VO/YS)'
M74'[PK'\2^)Y[739&B@;C^(5D/-K&C7TC3E?L;GY<>E2:_=VUYX7FEML[>^?
M6BPKF[%?/J7A2:2:$J?))!-97@6[-EX5FE";\2GC\ZVX"/\ A!^,?Z@UE?#N
M%)_#4J/R#*?ZT=!]3H=+UU=2,H"@-'U%2Q:J9;\6XCX/\5<3;3OX>U2^\[A9
MVQ'76>'T\^W^TR#]YG@TF@3-N1Q'&SL<!1DU@7/B7RLM##YB#^(5LWQC%E,9
MO]7M^;Z5Q#F)]-?^S3^YSW]:$-LZ"\UX'2)IX5W,J9(':LWP;XAN=6M09(&
MW8W&LS1RW]D:L&.2(S_2M'X<8_X1_MG>:+$WU.Q9PJ%F. .M8=WXA\F8I#%Y
MH'<5L7106LAD^YCFN/)A=F^P'L>M"*;-^WUV*XMI95P3$,LOI5#_ (2O?;>9
M#!YC9^Z*YGPQDPZX'/S '^E7_"-K&86<]<&BPKLZ?1=;CU<2!0 T?WE]*U6(
M523VKS_P#\NLZP ?^6G^%=Y<,BQ,7^[BA[C3T,23Q* 9O+BWK$?F([59MM;6
MZTP7<2;L]A7*3>2;'5/[,.,@^;G\*M^ U+Z J,<D@_RIV%=W-W2=>75&F5$
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M17">+K6.3^QV8<R.-WYFK7C+P]::;X>.H6D>VX51@_A19!=FSXP82+:21O\
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M.T'2EIL8(C4'KBG4B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ K"UK_CY3Z5NUA:U_Q\I]*:W,JWP&GI_P#Q
MYI5JJNG_ /'FE6J1<?A04444%!69K_\ R!YOI6G69K__ "!YOI36Y%3X&)H'
M_()A^E:E9>@?\@F'Z5J4/<*7P(****184444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K"UK
M_CY3Z5NUA:U_Q\I]*:W,JWP&GI__ !YI5JJNG_\ 'FE6J1<?A04444%!69K_
M /R!YOI6G69K_P#R!YOI36Y%3X&)H'_()A^E:E9>@?\ ()A^E:E#W"E\""BB
MBD6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_95C_P ^T?Y4?V58_P#/M'^5%D'M*OD:W]NZ=_S\+1_;NG?\_"UD_P!E6/\
MS[1_E1_95C_S[1_E19![2KY&M_;NG?\ /PM']NZ=_P _"UD_V58_\^T?Y4?V
M58_\^T?Y460>TJ^1K?V[IW_/PM']NZ=_S\+63_95C_S[1_E1_95C_P ^T?Y4
M60>TJ^1K?V[IW_/PM']NZ=_S\+63_95C_P ^T?Y4?V58_P#/M'^5%D'M*OD:
MW]NZ=_S\+1_;NG?\_"UD_P!E6/\ S[1_E1_95C_S[1_E19![2KY&M_;NG?\
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M?(UO[=T[_GX6C^W=._Y^%K)_LJQ_Y]H_RH_LJQ_Y]H_RHL@]I5\C6_MW3O\
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7!X*45:M(8X[6-$0!0. **DZ(Q:BC_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gn15qjhcndsi000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gn15qjhcndsi000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /H!2<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@">S_P"/M/Q_E119_P#'VGX_RHJX[$2W/0****Z3 ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *2EI.U &#XINA;Z5.,_>0BOGP@SWK+ZM7LWQ$O!#8!0<;N*\BTB/S]3
M5?4UR5GK8Z:6B/1-*CV:?$/:KU0VR[+=%]!4U)#84444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"X]WKK?"\>W3A7"_B.S[)O44459(4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!/9_\?:?C_*BBS_X^T_'^5%7'8B6YZ!111728!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)0
M M9>O2B'2Y']*TZP/%\GEZ!*WO4R>@UN>#:DWFZ[(WJ]=]H<?EV(%>>L?,U8
M'U>O2M.39;*/:N);G6]BY10**M$A1113 ****0"4M%% !112$XH 6BFEP.]-
M\T>M $E%1^:OK1O![T 244T-FG9H **** "BBBF 4444@"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* )[/_C[3\?Y446?_'VGX_RHJX[$2W/0****Z3 **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 3V?\ Q]I^/\J*+/\ X^T_'^5%7'8B
M6YZ!111728!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 )2&G4QJ3 YCQEK T[3F ;!=2*\<GEFNM,FE9B5W5UGQ+OVD
M=(0?NFL*VM<^#II2.C?XUS5'=V.FFK1N8FBG%Y'_ +U>GI_JU^E>6:6<7T7^
M]7J<1_=+]*RB7(=5>[_U=6:K7G^JJV0+;_ZM:L54M6RN/2K0H0Q:***8!2&E
MJ&>38N:0%:ZF_A'6F6T&?F85&BF67/O6DB[5 I ."@"G444P"BDI: "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZG="YC4Y^;O6[X2E^ZGO7-U.A[':44459 4444P"BBB@04444#"D/ I:0]*
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ML<S';GJ:''L71Q;3Y9GKHIU9^G:G%?0AT8'-7LUDSU(24E="THHH%!0M%%%
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M-6)(@W:J$D#1ME:0&FIS3N]4()_X6JX#D<4P'T4F:6@ HHHH **** "BBB@
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M%%% !1110!/9_P#'VGX_RHHL_P#C[3\?Y45<=B);GH%%%%=)@%%%% !1124
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MF3%=D;!WA!60[L9Q5<HKG1K(KYVG-2"L/03-F5)<\=,UMBI8Q:***0PHHHH
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MBBB@ HHHH **** )[/\ X^T_'^5%%G_Q]I^/\J*N.Q$MST"BBBNDP"DI324
M-8X4FO*O'>K&:;[.K?<.#7I.IW MK)Y"<<5X;KDYN=4F<G(+5I!7/.Q]6T;%
M&(;I.:TTDVJ *S8F &:F$O/6O3I0LC#"PLKFB),]Z>)/>LX2^].$WO6ECM-(
M3>].$F1UK-$OO3Q-[TK 7_-]Z>)O>LXRTHF]Z+ :'FT"7WJAYPSC-*)J5@+_
M )M.$E4!,*7SJ+"N:'G\]:<)ZS1)3O-]Z.4+E\ST>?[U0\[)H\P8ZT6"Y?\
M/]Z:;K'>LY[C'>H'N#ZT<H7-1K[CK4$E_P#*>:R9)^.M5)9SC&:?+8"Y=Z@P
M'#5R&NW!D89K5FD..:YS4Y=\F*Y\1*T;&D%=F:*6D[TM><= 4444@"DQ2T4
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MIS4+)5YDYZ5"R>U,91:.H6CJ^R5 \9H'<SWC-/MKN:TE#1L1BIF3CI5=T]J
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M),7(BPLQ9=S&DC=F#;C]!43J5EVBIV4I-'QQGFI<WN'*A]ON#YD^Z1T-6[.
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MBMH;'BXW^(CW/PU_R!8:V:Q_#8QHT(]JV*REN>K1^!!2TE+2-0HHHH ****
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MBK3,90:V*E+05*TF:I$>HM%)FEI@%%%%( HHHH **** "BBB@ HHHH GL_\
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M3 **** "D(I:0T 5;NV6YA:-QD$5X]XLT-["Z:55^5C7M1K$UW1X]2M6RHW
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M'3&K&02.,51DD.:=)-@U5=RS5:+4T3 [J=BF(>*?D 9H;*3 X6LR_P!52!<
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MTXZUV/@Z?++%FA'-75XG67RY /I6;FM>Y7,;5D=ZUB>546HM+2"EJC,****
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M3T4[BY$1"!!V%." =J?12N/E0W;1BG44!9#:4444#"BEHH *2BB@ [4A-#'
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M#TIMO"9GX'%;EM;B)!Q6U.%SCQ%?E5D.MX5C0 "B>985R33Y'$2$FL+4+HR
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MXCIVV@5R$1T\1U)BB@0S93@M+2T )MH I:*!ABC%&:*!!BEQ249H 7%(:**
M"BBB@ (I*4TE "\48HHH&-* ]14;6\;=5J:C% 7,^XTV.1.!@UD(K65XJ'HQ
MKIF;:.:YG4)@]\A7M3&M3?C :/<*E"U!9-NA4>U6J0@ I:**!!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4F*6D[T (:A<5/4;B
M@95:J[BK#U ],95DJM+5F2JLE!2*TE6]"'_$Q6JDM6]"_P"0BM!,_A/4X?\
MCU7Z5FW'^NK1A_X]5^E9UQ_KC6D3QJVY%1115F(4444 %%%% $]G_P ?:?C_
M "HHL_\ C[3\?Y45<=B);GH%%%%=)@%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%)0 4QW"#)-*S!5)/:N'\6^*
MTL87BC<;B.QJ)-)7*C&['^*O%T6GPO'&P+CC@UX_J6J7&IW+$L3D\"HKR^N-
M3N2SEF+&MW1=!+$22CWKEE-R9T1@HD&BZ$TSB20''O7;V]LD$85% I88$AC"
MJ, 5:AC,C@8I)6'<DMX#(PK410JX]*9%&$7BHKR[2UB9V8# J6S:$"'4+]+.
M L3SBO.-6U.2_N&^8[<XJSKFKO>SE58[?:LE(\\U#/2I4;:BQQU;CCI(XZMQ
MI1<Z-@CCJU&E*B581*+DMB)'S5A4Q0J\U)BD2(.*6DI: $HHH/2@!*?%$9&P
M*2-"S8%;5E:B-0Q'-:TZ?,<U:LH*Q):VPB4<<U8=@B9/2E)"CFLF]NR244\5
MTMJ"/-C%U9$=Y=EVV@\5G2G*FG<DDFFO]RN24VV>O2IJ*5C$O!DFLAB8I=PZ
MYK<NAR:R9H\U!TI&_I]XLT*KGD5?[5QMM</:S<'C-=-:7B3J.:")1+HI:04M
M!(HJ15R:B!J>,B@EC_+I/+J91FI/+XH(N4VCII2K9CINPT#YBH4II6K13VII
MCH'S%;%&*E,?M2;/:@JY#2YIY3VII7VH"X9I*7;[4;: N)12[:-OM0%Q!0:7
M!HVF@+C:*=L-&PT#N-HIWEFC8: NAM%.V&C8: T&TM&"*.:!!^%+2<T&@8M)
M124 %(13J.U 7&;:-M.Q10,9MI=M.HH  *6BB@04444 %%&*7!H%<2C-+M-
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M!522K<G6JDE!2*LE7?#PSJ:U2DJ_X:&=744$U/A9ZA%Q;K]*S+G_ %IK37B
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M3<<URU)N3/3HTE!"TU^E.I#TK,Z$9=PO)K.E2M>=>35&5*#1,RY(Z;#/);R
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MU<7]HG_O&E%S..] O9G<K?@]ZF2\'K7!B^N%_B-2+JLZGDF@7LSO!=#UI1=
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M=S._>KT8U(MU,G<U;,'M36@H#0C74IEJ1=9E':FF#VIIMAZ4"Y2<:U)Z4O\
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MJV$QVIP2@5RJ(:D$53[:7% B,1TX+BGTM AN*=1TI* %HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "HY&VH33S4<_\ JC0,Y@YFOY,]C5P)VJM;
MKF]FSZUHA:+E]"LR<54GAR,@5ILE0.E(=QVD71W&-NU;H-<GDP7*L.,FNFMY
M1+$#3(D3T444$A1110 5&_2I*CDZ4 57JL]3O5=Z92*LAYJK)5J2JDIH*14D
MKLO!L?*M7%RFN^\')_H:O0C&N_<.DNO]6:R:T[PX%9M:P/'F+24M-8U1F4[[
MJ*FM?]4*IW3[W%7+88A%(98HH%%,">S_ ./M/Q_E119_\?:?C_*BKCL1+<]
MHHHKI, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,LC2/DFKJSMHC'#T7)W8,Q8Y-)0.E%<K=SU5&PM%%%(84444 %%%% !1110
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M53SQZTHG'K0%BUD4N:K><*<)AZT")J6HO-'K2^8* )**;N![TH- "TE&:6@
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MDI:* "BBB@ HHHH **** "BBB@ HHHH **** $I:** "BBB@ HHHH #24M%
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M87#4][L <&H7LV#<4BV;D]:HYB.25YC5BVM?XFJ6*U"<FK2# I@"J%I:6BF
M4G>EHH GL_\ C[3\?Y44MG_Q])^/\J*N.Q$MSOZ***Z3 **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1;IK.%ZFJ;7G' -19DF..0* L237!8[5J2V@Q\QZTZ&VQR:L@ 4P# I:6DH
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M_'VGX_RHJX[$2W/0****Z3 **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB);GH%%%%=)@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP:Z?P?)_I 7VH1E77NG:78^3-98K6N!F(_2LD5K$\>8M%%%49A1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:3BE)JC>70C4X-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYB44459D%%%% !1110!/9_\ 'VGX_P J*+/_ (^T_'^5%7'8B6YZ!111728
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MLQ'=;*?45FSC$IK0LSOLHO\ =%4KKB8UI$\6JB&BBBK,0HHHH **** )[/\
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M@ HHHH **** "BBB@ S@YK0M9]PP36?3HY/+8&DT5%V+.JV*7ELV1R!7G%S
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MXKQ?QAX8DTNZ,D2GR^><5SSIVV-H3ON=+87B7<(93U%717!>&M2\F;RY&X/
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MBB@ HHHH **** "BBB@ HHHS0!;T^/?<#-="B[1BN8MIS#,"*Z&WN%E0$=:
M+-%-S2T +1110 4E%,>0(,DT ,GF$49)-<W<2F24\]ZN:A>>82BGBLY%+OCU
MH O:9#OFSCBN@48 %4[&W\N('&#5V@!:*2EH **** "BBB@ HHHH **** $H
M%+10 4444 )1VI:* &XK \3Z4NHZ5*@4%STKH*9(H="#4R5QQ=F?--W VG:L
M8N1L:O0='NA<V@;/05@>/M/%KJ#S 8W-4WA*Y)M=A/-<=K.QU;QN=712"EJD
M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ')?K767O^IKE/ X_=2GWKK+O_5543RL1NS*HI325J<+"BBB@84444 3V?\
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M%% %J'2E4_,,U>AMHX_NKS110!.!3J** "BBB@ HHHH **** "BBB@ HHHH
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@W&_*CRY/[C?E1118+EBSC<72?(W?M[4445<5H3+<_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>gn15qjhcndsi000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gn15qjhcndsi000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *!!4 # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHI* %HI*6@ HI*6@ HI*6@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF@*_6M:#5[68#]ZH/IFJYD2XLT**C6>-_NN#]*?5$BT4F:,T +1110 4444
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M?J:L+ JCIFI:*0QNQ?[H_*EV+Z"EHI )M'I1@>E+10 4444 )@>E&!Z"EHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3Q0I$ %4"I*P<FS9)(0  <"EHHI#"BBBD 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !2$ ]12T4 5;BRCG7!X^E54ANK#YK7+?6M2C%-.P>HMC
MXF,9"7K!6Z=:Z:WN4N8P\9R#7(2V<4O)4;O6JL<MYITOF>8SQC^$5I&IW,Y0
M3V._I:QM,UN*[0!\(WH:UP0>E;)WV,FFMQU%%%,04444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[4444 %%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "D*@CD4M%,#.GLRDGG1$AAS@5L:1KK$B"Z.'Z"J^*IW5IN&^([
M7[$549-$R5SN58.H*]*6N8T35SN^S3GE> Q[UTX((R*Z$[F#5@I:**8@HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI#5&^U*
M*SC))#-_=H>@TKEB:=($W.<"N;O];DG?R[4Y7H:J7-U<:B^0S(F>E.C@2,#"
MC/K6$I]C6,+;D$5GND,LA.\]>:N!0!@ 4M)6;-!:***0!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !5:[LX[J/:X'Y59HH Y66TN=(N!-;9VCGDUU>@^*4N@(KAL2=ZB>)95(
M89!K U#27B?S[8E#G/%7&30.*EN>GJRN-P.0:=7!>'O$[1.+6[!SG&YJ[B*5
M)D#HV0?2MXRN<\HM$M%%%42%%%% !1110 4444 %%%% !1110 4444 %%%%
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M[LZ$M+!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H+J+S(<5/2'
MD&F!IZ!<AXO(S]P5N5QFCR-:W\FX\.<"NR4Y4&NB#NC":LQ:***L@**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *2@T4 075PL$+.QQQQ7$&5]0O6DDS\C<5J>);[>@MXF
M^<-R!52UB$<0..2.:PJ2-H+J3CBEI*6LC0**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH .U8NMV>]%E0?,IR:VJ
M9*@DC93W% $WA'51<6ACD;YP< 5U=>66LSZ3KD:](VR37IEK.+BW60=#713E
M=&-2-F3T4E+6AF%%%% !1110 4444 %8'B24I'$N?O'%;_:N4\42;W@4=FJ9
M/0J&Y7MTV1_7FI::GW%^E.KF.@****0!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1113 I7+F.Z@(_O<UVMO('A4CTKD+E 1O/5>:W= G,]ED]C6M-F=
M1&Q1116QB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4E+10 5!=3""W:1N@%35@^)+P1VK09^9
MQQ2;LAQ5V<[S=:P]QU0CBM,<"J.F1%+0;NN:NURMW.D6BBBD 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 8FN6NZ%IU'S+TKH?"6I"XM%MR?F0<U3N8A- R$=:Q_#UT=-UN57X5N!5P=
MF*2O$],HIB-O16]13ZZ3F"BBB@ HHHH **** $/2N,U=O-O=O7:U=FWW3]*X
MF?\ >:G,/1JSJ;&E/<L+]T?2EH'2BN<V"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH CF&87'M5SPU+LB\D]2:K$94BG:4WEZHB"KAN3/8ZV
MBBBN@YPHHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !24M)0 ,<*37#^(IC<:I"JG*CK79W#A(6)/
M:N MY#=W\S-_ ^!651Z6-*:UN:D:A$ %/H]**P-@HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #&
M:YK6HS;7,,R\9<9KI:R]9M_/MLXY7FF".PT>[%U9(P.<#%:5<=X(N]]F\;GD
M-@5V-=,7='/)6844451(4444 %%%)0 C?=/TKBC_ ,A:Y^M=J?NGZ5Q)_P"0
MO<_6LJFQK3W+5%%%8&H4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.>IA9+8Z*BHXIHYEW1L&%25HFF<<H.+U"BDI:9(4444 %%%% !1110 4444
M%%%% !5:\_U!^M6:K7O_ ![GZTT(ZO2_^/"+Z5<JEI7_ "#XOI5VNI;'.]PH
MHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI*6@ HI*6@ HHHH *
M*2B@!:*2B@!:*** "BDI: "BBB@ HHI* %HHHH **** "BBB@ HHHH ****
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M%F'/'N:5-D^X:S_[>T[_ )^4I'US3BA_TE*+,?/$XV?_ )&R:MBN>N-0M?\
MA)Y91*-OK6K_ &K9_P#/=:Y7%W-_:QL7*9O&<5GS:Q:CA9E-,BO[4L&:<?2I
M<64JL3!\4S;FV>AJKIX^04WQ%<Q2W)*.",TRRN8EC&7%8.+/9I5X*"U-1NE8
MVHJ0<CM76:9HK:C$)02$(X-9VM:0UHVUAG-#@TKEQQ$92LF:7ARY633HXL\B
MMNO/=,O'T^]P22I. *[^-P\2/ZC-5!]#BQ5.SN/HHHK4XPHHHI %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN'\Z/^$5LO[A_.N@HHYF'LHG/_\ "*V7]P_G1_PBME_</YUT%%',P]E$Y_\
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M:@N&SAZN!@>XJ-H5(X&*A,#)R"36YY3+=%5!-(I^9<5,LZ'C/- B6BD!S2T
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MH **** "BBB@!**6B@!#11BEH 2BEHH 2BEI,4 %%&*,4 %%+28H **,48H
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MV0_O&H6LV7D,: L:&0:6LY9I83AAQZU;BG60=>:!6)J*3-+3 ****0!1110
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M.U2G3(3;B)E! ]13YB'A9-G V <6#RLI^]DU;UJ83V6G;!DAN177#1X!:M
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MH **** #%&*** #'%%%% !2TE+0 4444 %%%% !1110 4444 %%%% !1110
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MPLOW#BD2<H=KCFK512Q!Q[T#)%8,,BEJBCM#)M/0U=4@C(H$+3)&PM/J"?G
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MP0@QJ,U;K,T:[$T"QD_.!S6G3@95_BU%HHHJS#0****!!1110 4444 %%%%
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M2?[U=$/NBKG$YZ%:2ZD$=G!%]Q,5/T'M2T5*BC:524MPHHHID!1110 4444
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MU_9L7I1_9L7I1[H6J%7^W$_YYFC^W$_YYFK7]FQ>E']FQ>@H]T5JA5_MM/\
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MHP-/KSS2-<GM)UB<Y4G'-=]!,L\2NISD5K&9YU>AR$M%)2UI<Y0HHHI 073
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MHHH$%%%% :!2'D4M(: L9UZHP:IZ(#_;L/UJW?M\IH\.0&34TE]#0A5/A9Z
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MQ]%)D49%:F0M%)D49% "T4F11D4 +129%&10 M%%)0 M%)2T %%%-8A1D]J
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MHS5Q&FP&2[GEDYRV1FLIOH:02W+6GV(@3<_+GO5^C'%)6)K<6BDI: N%%%%
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MTYL=$V4%251LIPZ 9J]4'78*0TM%,1K^&H(9[QA, 0!QFMKQ':VL6FO(B+O
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MVB,ZXD(YK9K6"/)Q53FEH%%%%:'(%%%% !1110 4444 %%%% !1110 4444
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M'K5:_3?8S#U4U9IDJ[XF7U%)C6YP.FCR6:(]S6I6?=J8-=6(< UH5RR6IT]
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "J]Y.+>V>4_PBK%8OB*1ET^11T(J6[#CN<?+,^HZJTO)
MC/05IHS(H&#QVJKHL8%BI[UI8%<[=V=*T(UE!Z\5)FHWB#5%F1/I4@6J*@6X
M7'-2+*K=* 'T49%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %5;J;"[5ZU/(VU">]5(H_-DWGI0"
M'VL&WYFZFK6*!@#%+0 4444 %%%% !1110 4444 %13_ .H?Z5+39!F-A[4
M9GA1PEZZGN]>A#I7F&FR&U\10QDX#-7IR$,@Q713>AE56HZBBBM#(**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@"K?6XN;=HR,@UQ-I(5OYH3P$.
M!7?FN&U:'^S]0\SIYC5E474UIOH7**13E0?:EK U"BBB@ HHHH **** "D/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "L[6;;[382J/O$<5HTA&12:T&G9GF]E.;!
MOLLPV[>YK66XB89$BFM35O#MM?[I""&]A7#ZA!<6=TL%OSGBN>46CHC),Z-K
MJ%/O2J/QJ!M2M>AE3\ZR(]*N9U_?@BIAX:MCU)S4%:&@+RS;_EHGYT[=$_W)
M5_.LT^'+=?N$YI!I4T7^KS0/0T6<(,F8?G5<ZIB98T&\'J14 TV>3B0<5=M-
M+BMCE>OO0+0NQMO0$C%/H' Q10(**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHI* %I#2TAH KRY=@H_&IT0*N!3(TVL2:
MEH ****8!1112 **** "BBB@ HHHH *0]*6BF!S6J*;;5(KE0<+7H6C7/VK3
M8Y<\D5R&LV_G63D#Y@.*N>#=1)_T-C]P5=-V=B:BNKG9TM)FEKH.<**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!*P/$EC]HB64#_5\UOFH+J+SK
M9X\?>&*35T.+L[G'6,_GP[O0XJW6:$.G7YM.@)S6E7*]#H\PHHHH&%%%%( H
MHHH **** "BBB@ ^M%(PR*CW%3S0!+12 @TN: "BBB@ HHHH **** "BD) I
M P- #J*2EH **** "BBB@ HHHH ****8!5*]8R+Y2?>/I5MVVJ2>U,TJW:\U
M!;@#* TXJ[$]$=%I%N(;&+*X;'-:-(H"C I:Z4K'.W=A1113$%%%% !1110
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MU'"N6/Y5G/<3W3XA^Y[T!8MSWRQ\(-QJJEO-=2>8S%5_NU9M[!$PS9W=\U=
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MKZFNTKB?%0_XF]K]:B>Q=/XB9.% IU-7[HIU<QN%%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *2EHH 9+&)(RI&17,MYFCZGYZ9",U=35'4;,74!!'('%.]@.K
MTG4$O[574@X'-:->8Z!JLNE7PM92=C'->DP3+/$'0\&NB$KHPG&S):*2EJR
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1S0K-&589R*DHH
MY.>.?1;T3PY,8Y(%=]H.MQ:C;+EAOQR*QKJV2YB*.,@US0-SH%]YL7$;'G%7
M&5A2CS'K(I:Q]%UJ'4K<,K<XYR:UZZ$[G.TT+1113$%%%% !1110 4444 %%
M%% !6)K\WEQ*G]ZMNN;\3!B]OCIFIEL5'<S;1-D6/4U8I$0A1]*=M-<QT"44
M[::-IH$-HIVTT;30 VBG;31M- #:*=M-&TT -HIVTT;30 VBG;31M- [C:*=
MM-&TT"&T4[::-IH ;13MIHVF@!M%.VFC:: &T4[::-IH ;13MIHVF@!M%.VF
MC:: &U0?Y=5C;VK1VFJ%Q&1=*_I30':6AW6R&IZJ:<<V49JU72CG8M%%%,04
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )12TE "T444 %%%%
M "44M% "44M% !1110 E%+10 E%+10 E%+10 E%+10 E9>JZ1#?PL-H#XZBM
M2BDU=#3L>:LMQH]VR2 F,G )K8AG2= R-FMW6=*CU"W(*Y8#C%<-!YVEWOV6
M5N">*PE&QO&7,=#12)ET##O3MIJ"A**=M-&TT"&T4[::-IH ;13MIHVF@!M%
M.VFC:: &T4[::-IH ;13MIHVF@!M%.VFC:: &T4[::-IH ;13MIHVF@!M%.V
MFC:: &T4[::-IH ;13MIHVF@!M%.VFC:: &T4[::-IH 92TNPT;#2 2JUW:)
M<Q%6 ]JM[31M- [G)1FZT.^#H6,><X[5Z%I&LPZA IWC?CD9K"N;-;F,JXZU
ME6-E=:=?@Q, C./YUI"33)DDSTFBBBN@YPHHHH **** "BBB@ HHHH *H:AU
MCHHI/8:W(ATI:**S+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ J&3[U%%" T[?_ %*U-116IF%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %)VHHH 3^&N>O?^/\ HHJ)%Q+T
M?W!3J**D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
D4 %%%% !1110 4444 %%%% !1110 4444 %1M]]?K110@/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>gn15qjhcndsi000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gn15qjhcndsi000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /#!V,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH 2EHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MF22I$I9VP!5(ZUIX;;]I3- &A14<4\<Z[HV##VJ2@ HHHH **** "BBD) ZT
M +1110 4444 %%(2!R:B2[ADD,:R L.HH FHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]JI^8UM^'[I9M.B3/SJO(JCK&B-?ZAYN3MQ0!<\.6:V^EPOCYF7FF:WJ5A:
MK=QLP[XK6M(?(M8XO[HQ6=KFC1ZM:-$QVD]Q0 P2Z=+IA=2H0IG!89KC-/C6
M3Q)_HPQ%@U*W@^\5S&MS-Y?3J:Z?0/#J:7"-S%W]3UH YOPO<KIVM7RS';YD
MG&>/2M3QIJ$3:6848,V>QS2:]X2^V3":"5HV!R=O&:H:?X-F:Z$ES/(R^C'-
M %HV3?\ "-M+C_EEFIO!.H1#1UB=@K#U.*Z8V*'3S:_PE=M<1>^#)H[DM;7$
MBJ>RF@"/7+A;[Q#9"+YMDG..?6E\1L(-2^;CD5K:#X4%E*9II&=LY&ZL?QE;
M&XU%D#$<]J .KNIH_P#A&2=Z_P"J]:Y#0LR1'9_=-6H]"O+BP2(R2;67'6M3
M0M!&DQ?O&) 7J: *?@9T2>_#D*=YZG%-\=2Q&!%!!;S!T/N*KM90O>R/9W)W
M!OF"FLC7K%]Z.\S,^\90GWH ]'T3_D&P_P"X*X^XPWC6<+UX_F:ZJSD%IH:2
M,<;8Q7/:+:F]\32WQ&8W7@_G0!VT'^H3Z5)2 8 'I2T %%%% !1110!S>N>'
MGU.8.N.!WK&_X0>3T6N]HK>.(G%61RU,'2J2YI(\\N/ \WDL5"YKB[_39K&X
M:)U/!QTKW<\UC:EX?M]0968!2#GI6]'&23]\X\3ED)1_=[GFNA^&KC4L.%PN
M>XKI1X'D Z+7:6=C%9Q!(U ^@JU45,9-RT-*66THQM+5G!KX(E!SA:WWLC9:
M-)&<<1D5NU6OH?M%K)'_ 'E(K&=:<U:1U4L-3I.\3C?!$B+%+N=1^]/4^YKM
M_/B_YZI_WT*\W_X1"\BE<Q32J"Q/!J>W\-ZBEQ&S7$Q ;)^:LCH/1."/6O--
M>MHO[=A;;R917HMJC1P*K$D@=ZYS4M :ZU".8$_*^: .EMT"01@=-HKF?&BA
MK:-3T-=2@VQJOH *R->TTZC&BC/% '-^'?"FEWVEF26#+YZUB:AH2>']3CE\
MO]TSY&/2O1-#L#I]CY1SUS3M7TN/4;9D8#..#0!5MKLWVD;M/8*_09K)^S>)
MO.S]I79GT_\ KU;\.Z1-I9\IF9DSGFNE905/% '*ZAKLNEV!CN),W'J#65IF
MER:K<B[OIHW3.Y!N'%2>(O#$^I7[2AW"GL*H)X5OXU"I/, /0T >C6T<,402
M$KM'H:;?_P#'C-_NUC^'M/N+*%5FD=B/[QK;N8_-MY$_O#% '#>'O^1D/TJY
MXUB)GMIL?+'R:NZ7HAM-5^T$GI6MJFG)J%J\3<$C&: ,_0]2@DT8.74<="WM
M7,6#?;]>9TY$<G6FR>"[J)_+BN9A'[&NG\.^'4TE&)8NS\DF@#H.U<)XK!_M
M^P/;=7>5R_BJQ,@6Z4<Q#- &]:NJV8;/ &:X[6O$,EY<_8[.4(2=IR:U](N&
MO]!10Q$A!SCZ5R<G@RY^UR2B23+-D<T =)H&A06S"YNGC:X(Y8,*T-8U&PLV
M2.Y1F!'!%<I#X:U%)%/VB; (_BKJ+O0Q?:<(I&.\+C/>@":&;3I]-+QE0A4X
M!8>E</:1I+J3BU4A-YS5@^#KR-O*2ZFV>Q-=/X?\-QZ5$=S;V;G+4 <]HMRM
MEXKN$E.T!<9/'K6MXMU"%M-DMU8,SKQ@YJ/7O"?VV=KB&5D=CSMK/L/!LQO(
MY;BXD8*>C&@!\%B[>$[<8Y7D\5>\'ZC#]FF1F"D/CDXKIA91K9FW &W:17#W
MO@N:.X9[:XD4,22%- $>OS+?ZLL,1W%) >.>]2>)&$6M6.[C$0_D*TM \*?8
MK@W$TC2,PZ-65XWMS/K5O$I*Y3 (_"@#JC<1G02=Z\QGO[5QGA[,FF7@3KYK
M?S-7(-"O)[!8O-DVXQG-:GA_01H]I()&)!;)S0!5\).B:K<*Y 8#G)H\:2PD
ME<@L5XP:JRV4+ZI,]K<GS">54]*R=9L7-PI>9B^.%)ZT >@^'_\ D!0?[M<G
MJ&&\<6VW^Z?Z5U.EM]G\.QEN"$-<]I-N=2UQ;[&0A*Y_'_ZU ';P_P"J6I*0
M# Q2T %%%% !1110!B:[HS:HBA<<>M<[_P (/)Z+7>T4 >2:_P"&YM.16V\'
MT%<P1@X->[7]A'?0M&X'(P#7$7O@5?-)C=B/:@#@D4NP4#K78:+X3FO;-92!
MSZUJ:;X'2*97D<\'.#7;6ULEM"(T  'I0!Q \$2>BU+JGAV2'0#  ,@YXKN*
M9+&LL91AD$4 >??#R]1)KRW<X9&P,G'I7H>X8SD5YGK/AJ\TN_\ MFGAW+-N
M95IO_"4>(S%Y/]EMZ9JFKDIVW.JUKQ5;Z7>P6Y)9I#CY37)^.;AKNQ27!\LR
M#J/<4[1_#-YJFH)>Z@'0HVX*U=9XC\/1ZGIGD+P5.1BC1"U:+WA\I_9%MM(_
MU8[UQ/Q)9#"H7E_,'3ZBHK/4->T0/;QV+RH.%)IMOI.H^(]4-Q?PO"AYP>E%
M@;NK&5>*6UC1=_\ ='\J];50NG.!_=/\JX75]!N3KFFM%$6CAX)%=[L/V)EQ
MR5/\J&-(\U\.\:_+_P!=32:KQXWG^H_F:TM$T>Z@UF25XF"F0G-5O%FDWT>K
MM?6D+2%F' ^M/J3;0T/&@#:,H_Z9BM/P0@3PK %_NG^58=W%J.K:.4EMF5U0
M "NG\*6DEGH,$,JE6 Y!I/8I;G#ZQD>-K+S?7BO3HROV4D$8P>]<?XN\.R75
MRE_; F6(< =ZR8]>\0P6GV7^SF/&-U&X;,S?$)#>+[;R>G?%6O".?^$TO,]=
MO^-7-#\,W,[M>WBLLH;(5JL>']'NK7Q;=7+Q%8V'!_.F3;4] 'W12T@Z"EJ#
M0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H
M+JV2Z@,3C*FIZ* ,/2M)GL+J9B1Y;'Y0*W*** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6O6O!+L^B@LQ)SWI65A1G/GY9(Z6BBBD;A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% $<_,$@_V37D=]_H_C2W9^!D]?PKU\C((]:\
M_P#&7AJ:XN1>6JL74<8H D\9743Z+!M=3D]C4GP[0II<A;@;^_U-<?%H^M7[
MQ07$+B-&'.:]"CTV72?#[QVRDR$ XH W+\J]C,%8'Y#T->4: 1!XLC#G'SGK
M]:Z_PVVI3W,Z7D15"N 2:P/$WAJ\@U(7=C&S$#/% $WQ GCE%JJ,"=XZ&NK\
M'H4TC!]17GMCH.JZG=QF\B<*C \FO6;"T6SM5C7T% %JL[6_^09)6C6?K(SI
MT@H%+8\6U#_C^E^M5JL:@3_:,P(_BJ#:?2FU8BG4C-70+]X5Z;X1BNFTD&*0
M!<]*\RP174^'/%#Z<JV[ "//4UI3I.:T,JV(A2:YMCT7[/??\]11]GOO^>HI
MVGZO;7\:E) 6QR*T:S::=F;QDI*\3,^SWW_/44?9[[_GJ*TZ*11F?9[[_GJ*
M/L]]_P ]16G10!F?9[[_ )ZBC[/??\]16G10!F?9[[_GJ*/L]]_SU%:=% &9
M]GOO^>HH^SWW_/45IT4 9GV>^_YZBC[/??\ /45IT4 9GV>^_P">HH^SWW_/
M45IT4 9GV>^_YZBC[/??\]16G10!F?9[[_GJ*/L]]_SU%:=% &9]GOO^>HH^
MSWW_ #U%:=% &9]GOO\ GJ*/L]]_SU%:=% &9]GOO^>HH^SWW_/45IT4 9GV
M>^_YZBC[/??\]16G10!F?9[[_GJ*/L]]_P ]16G10!F?9[[_ )ZBFO#?*A;S
M1P*U:9*,Q,!Z4 9%O]MG4D2]#BI_L]]_SU%2Z=&\<;!ACFKU &9]GOO^>HH^
MSWW_ #U%:=% &9]GOO\ GJ*/L]]_SU%:=% &9]GOO^>HH^SWW_/45IT4 9GV
M>^_YZBC[/??\]16G10!F?9[[_GJ*/L]]_P ]16G10!F?9[[_ )ZBC[/??\]1
M6G10!F?9[[_GJ*/L]]_SU%:=% &9]GOO^>HH^SWW_/45IT4 9GV>^_YZBC[/
M??\ /45IT4 9GV>^_P">HH^SWW_/45IT4 9GV>^_YZBC[/??\]16G10!F?9[
M[_GJ*/L]]_SU%:=% &9]GOO^>HH^SWW_ #U%:=% &9]GOO\ GJ*/L]]_SU%:
M=% &9]GOO^>HH^SWW_/45IT4 9GV>^_YZBC[/??\]16G10!D2QWT:Y,HIL"W
MLR%A*.#6E<J63 %,L49(B&&.: *WV>__ .>HH^SW_P#SU%:=% &9]GOO^>HH
M^SWW_/45IT4 9GV>^_YZBC[/??\ /45IT4 9GV>^_P">HH^SWW_/45IT4 9G
MV>^_YZBC[/??\]16G10!F?9[[_GJ*/L]]_SU%:=% &9]GOO^>HH^SWW_ #U%
M:=% &9]GOO\ GJ*/L]]_SU%:=% &9]GOO^>HH^SWW_/45IT4 9GV>^_YZBC[
M/??\]16G10!F?9[[_GJ*/L]]_P ]16G10!F?9[[_ )ZBC[/??\]16G10!F?9
M[[_GJ*/L]]_SU%:=% &9]GOO^>HH^SWW_/45IT4 9GV>^_YZBC[/??\ /45I
MT4 9GV>^_P">HH^SWW_/45IT4 9GV>^_YZBH+@7L 7,HY-;54[^-G";1G!H
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MYZBC[/??\]16G10!F?9[[_GJ*/L]]_SU%:=% &9]GOO^>HH^SWW_ #U%:=%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ K,;_D,+]*TZS&_P"0POTH TZ*** "FN@=<,,BG44
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)+N(QFM+Q3X571@DD&[A<DT >OV5Y'>VZRQD$-Z59KA_A_>M-I\43-G KN*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH^B::-/M O'(K4JO9S+/:QL.ZBK%>1)MN[/IJ<5&*4=@HHHJ2PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ H)P,FBJ>IS_9]/FE'51F@#!\1>++?2<QD!V!Q@
M&K?AG6$U>!Y%7&*\HN4FU_Q$ZY+9(. ?>O6?#6B1Z19!4SEQDYH O:M=+:69
MD<9'-<;H_C>U:^:W:+;E\9-=KJ5@FH6QAD)Q[5X_XI\./HMWYT ;!Y)S0![1
M!,D\0D0@@^E25QW@34FNM,BB<Y(%=C0 4444 %%%% !1110 44FX9Q2T %%%
M(2!UH 6BD# ]*6@ HHHH *S&_P"0POTK3K,;_D,+]* -.BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %9VMQF72IU7J5K1IKH)$*GH:
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M&X4 +12;A1N% "T4FX4;A0 M%)N%&X4 +12;A1N% "T4FX4;A0 M%)N%&X4
M+12;A1N% "T4FX4;A0 M%)N%&X4 +12;A1N% "T4FX4;A0 M%)N%&X4 +12;
MA1N% "T4FX4;A0 M%)N%&X4 +12;A1N% "T4FX4;A0 M%)N%&X4 +12;A1N%
M "T4FX4;A0 M%)N%&X4 +12;A1N% "T4FX4;A0 M%)N%&X4 +12;A1N% "T4
MFX4;A0 M%)N%&X4 +12;A1N% "T4FX4;A0 M%)N%&X4 +12;A1N% "T4FX4;
MA0 M%)N%&X4 +12;A1N% "T4FX4;A0 M%)N%&X4 +12;A1N% "T4FX4;A0 M
M%)N%&X4 +12;A1N% "T4FX4;A0 M%)N%&X4 +12;A1N% "T4FX4;A0 M%)N%
M&X4 +12;A1N% "T4FX4;A0 M%)N%&X4 +12;A1N% "T4FX4;A0 M%)N%&X4
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MVI]%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F-_R&%^E:=9C?\
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MJJTU(****R-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJ][/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8D0QS[4 =[I&IQZG9I,I'S=A6A7 ?#N=VMDC)^4+7?T %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7+.#@[,]&E5C5CS1%HHHJ#0**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAH^UQ^AH L457^UQ^AH^UQ^AH L457^UQ^AH^UQ^AH L457^UQ^AH^UQ^AH
ML457^UQ^AH^UQ^AH L457^UQ^AH^UQ^AH L457^UQ^AH^UQ^AH L457^UQ^A
MH^UQ^AH L457^UQ^AH^UQ^AH L457^UQ^AH^UQ^AH L457^UQ^AH^UQ^AH L
M457^UQ^AH^UQ^AH L457^UQ^AH^UQ^AH L457^UQ^AH^UQ^AH L457^UQ^AH
M^UQ^AH L457^UQ^AH^UQ^AH L457^UQ^AH^UQ^AH L457^UQ^AH^UQ^AH L4
M57^UQ^AH^UQ^AH L457^UQ^AH^UQ^AH L457^UQ^AH^UQ^AH L457^UQ^AH^
MUQ^AH L457^UQ^AH^UQ^AH L457^UQ^AH^UQ^AH L457^UQ^AH^UQ^AH L45
M7^UQ^AH^UQ^AH L457^UQ^AH^UQ^AH L457^UQ^AH^UQ^AH L457^UQ^AH^U
MQ^AH L457^UQ^AH^UQ^AH L457^UQ^AH^UQ^AH L457^UQ^AH^UQ^AH L457
M^UQ^AH^UQ^AH L457^UQ^AH^UQ^AH L457^UQ^AH^UQ^AH L457^UQ^AH^UQ
M^AH L457^UQ^AH^UQ^AH L457^UQ^AH^UQ^AH L457^UQ^AH^UQ^AH L457^
MUQ^AH^UQ^AH L457^UQ^AH^UQ^AH L457^UQ^AH^V1^AH L457^UQ^AI1=H3
MC!H GHI%8,,BEH **** "BBB@ HHJ"\G^SVLDO\ =&: )7&8V'J#7F6N^#KB
M_O&D#O@FMBV\9";4GM]S?*,U5U'QV+27;N:@#G!X!NAT=Q2_\('=_P#/22M3
M_A8X_O/1_P +'']YZ .K\+:5)IEFD<A)('>NDK#\/:S_ &M;)+D\CO6Y0 44
M44 %96L:,NK0M&TFW(Q6K10!PT/P]AMI!+]JSM.:R?&'B,VBBP@?@KC<#Z5Z
M:ZAT93T(Q7*W_@BPOY_-DA!- '&^']3L;0":=DDD/7=7H-GX@@GTUKE-NU..
M*Q?^%=Z7G_4"MBU\,VEKILEFD>(W.2* "UUN+5TG@C()"'I7G$[2:#XE29D.
MT$GGZUZ5I/ARUTJ=Y88]I8<TNK^&K+5CNGBW-C% 'FNMZP_B"XMXXDSM<=*]
M.\.VC6FFJC#!(!K/TWP7IMA+YB0X(KIE 50!T Q0 M%%% !64ZAM77/I6K66
MW_(87Z4 :/E)_=%'E)_=%/HH 9Y2?W11Y2?W13Z* &>4G]T4>4G]T4^B@!GE
M)_=%'E)_=%/HH 9Y2?W11Y2?W13Z* &>4G]T4>4G]T4^B@!GE)_=%'E)_=%/
MHH 9Y2?W11Y2?W13Z* &>4G]T4>4G]T4^B@!GE)_=%'E)_=%/HH 9Y2?W11Y
M2?W13Z* (F@C==I4$&O-_%^B/9W(O;<'EP2!]:]-JEJEI'=V4BR#("D_I51=
MF<^)HJK"W4Q/"NK1:A9[7VAU^7%=)Y$?=!7C%CJW]AZR0#B$.<@?6NX3X@Z:
M4&=V:J4'?0YL-C8.'+4=FCL/*3^Z*IWVE6]Y$59%R1UQ7._\+ TS_:KH=,U6
M#4X5DAS@C/-0XM'7"O3F[1=S@]3T6ZT:Y\ZWWN@YXZ5K:7J]MJ,'V:[5$8#'
MS5V,\"7$1CD&5-</KGA=X)#<V:A2#DT)V=S5I-69FZIILVD7@N;;+Q#GCI75
M>']:@OH5CDVJX'(KGK#6_,3[#J.3DXJE>6DNEW(N[0@1,V>/2NV,HUX\LMSR
MYPGA)\\/A>YZ@(T(^Z*/*3^Z*PM U^+4(0K-\_3DUT%<<X.#LST:=2-2/-$9
MY2?W11Y2?W13Z*DT&>4G]T4>4G]T4^B@!GE)_=%'E)_=%/HH 9Y2?W11Y2?W
M13Z* &>4G]T4>4G]T4^B@!GE)_=%'E)_=%/HH 9Y2?W11Y2?W13Z* &>4G]T
M4>4G]T4^B@!GE)_=%'E)_=%/HH 9Y2?W11Y2?W13Z* &>4G]T4>4G]T4^B@!
MGE)_=%'E)_=%/HH 9Y2?W11Y2?W13Z* &>4G]T4>4G]T4^B@!GE)_=%'E)_=
M%/HH 9Y2?W11Y2?W13Z* &>4G]T4>4G]T4^B@!GE)_=%'E)_=%/HH 9Y2?W1
M1Y2?W13Z* &>4G]T4>4G]T4^B@!GE)_=%'E)_=%/HH 9Y2?W11Y2?W13Z* &
M>4G]T4>4G]T4^B@!GE)_=%'E)_=%/HH 9Y2?W11Y2?W13Z* &>4G]T4>4G]T
M4^B@!GE)_=%'E)_=%/HH 9Y2?W11Y2?W13Z* &>4G]T4>4G]T4^B@!GE)_=%
M'E)_=%/HH 9Y2?W11Y2?W13Z* &>4G]T4>4G]T4^B@!GE)_=%'E)_=%/HH 9
MY2?W11Y2?W13Z* &>4G]T4>4G]T4^B@!GE)_=%'E)_=%/HH 9Y2?W11Y2?W1
M3Z* &>4G]T4>4G]T4^B@!GE)_=%'E)_=%/HH 9Y2?W11Y2?W13Z* &>4G]T4
M>4G]T4^B@!GE)_=%'E)_=%/HH 9Y2?W11Y2?W13Z* &>4G]T4>4G]T4^B@!G
ME)_=%'E)_=%/HH 9Y2?W11Y2?W13Z* &>4G]T4>4G]T4^B@!GE)_=%'E)_=%
M/HH 9Y2?W11Y2?W13Z* &>4G]T4>4G]T4^B@!GE)_=%'E)_=%/HH 9Y2?W11
MY2?W13Z* &>4G]T4>4G]T4^B@!GE)_=%'E)_=%/HH 9Y2?W11Y2?W13Z* &>
M4G]T4>4G]T4^B@!GE)_=%'E)_=%/HH 9Y2?W11Y2?W13Z* &>4G]T4>4G]T4
M^B@!GE)_=%'E)_=%/HH 9Y2?W11Y2?W13Z* &>4G]T4>4G]T4^B@!GE)_=%'
ME)_=%/HH 9Y2?W11Y2?W13Z* &>4G]T4>4G]T4^B@!GE)_=%'E)_=%/HH 9Y
M2?W11Y2?W13Z* &>4G]T4>4G]T4^B@!GE)_=%'E)_=%/HH 9Y2?W11Y2?W13
MZ* &>4G]T4>4G]T4^B@!GE)_=%'E)_=%/HH 9Y2?W11Y2?W13Z* &>4G]T4>
M4G]T4^B@!GE)_=%'E)_=%/HH 9Y2?W11Y2?W13Z* &>4G]T4>4G]T4^B@!GE
M)_=%'E)_=%/HH 9Y2?W11Y2?W13Z* &>4G]T4>4G]T4^B@!GE)_=%'E)_=%/
MHH 9Y2?W11Y2?W13Z* &>4G]T4>4G]T4^B@!GE)_=%'E)_=%/HH 9Y2?W11Y
M2?W13Z* &>4G]T4>4G]T4^B@!GE)_=%'EK_=%/HH  ,"BBB@ HHHH **** "
MH;J 7%N\1. PQ4U5=1E>&PEDC^\HXH YRW\'007SW(EY88Q5>]\"V]Y)O,V*
MX_4O&6O0WC)'(X4?[)JI_P )OXA_YZO_ -\F@#L?^%<6W_/?]*/^%<6W_/?]
M*X__ (3?Q#_SU?\ [Y-)_P )OXA_YZO_ -\F@#UG1=&32;=8D;< *UZY?PCJ
MEYJ-E')=,2Q'.1744 %%%% !1110 4444 %%%% !1110 4444 %%%% !68W_
M "&%^E:=9C?\AA?I0!IT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !4-W_QYS?[A_E4U0W?_ !YS?[C?RH$]CY^U4G^T)N?X
MS_.J6YO4U=U7_C_F_P!\_P ZHUUH^.G\3%WMZFO8? A)L(\G^&O':]B\!_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFLI4*D=T=$,71GM(W:*K17T$O*NO_?53B1#T93^-9M-'0I)[#J***0PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH 0G"D^@KAM?\ %[6FHQV\(#!C@UVT_P#J)/\ =/\
M*O&WC2?Q.HGQM$AZT =5K?B@VV@QRJ 96."/RKC+7Q5J$=SYQ5M@.3S3O%LR
M?VE]CA_U8<8 ^M;4^CVEMX;DD=5\PH".: .\\.ZN-5TZ.4XW-U%;->?_  \9
M_LZ+_#MXKT"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S&_Y#"_2M
M.LQO^0POTH TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M HHHH **** "BBDR!U(H 6BF--&O611^-5)]5MH!S(I^C"@"]17-77C"T@R
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS6Q;>';2VZ*K?45L44 0)9P1C B3_OFI0BKT4#\*=10 4444 %%%% !1110
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M>^M %NBJG[WUH_>^M %NBJG[WUH_>^M %NBJG[WUH_>^M %NBJG[WUH_>^M
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M_O4 6Z*I&1QUD J-[M4&3.G_ 'U0!HT5SESXAAMLY<-CT-94_C5!D)&Y^@-
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M8'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444
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M<#C KH:* /*9?!5VLN$B8KGK70:%X.2VD6:8$.IZ&NVHH ;&@C0*HX%.HHH
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M1110 4444 %%%% !1110 4444 %9C?\ (87Z5IUF-_R&%^E &G1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "L76M>ATR)OG'F8X!I=>UA-+M"YY)XXKR75-4FU"
MX9G<D9XS77AL,ZCN]CS<=CE17+'<]0T/Q-#J1".XWXZ"NB!R,BO![*^ELI@\
M;$<\XKU3PSKG]HVP#*<CC)JL3AN3WH[$X''^V]R>YTM%%%<1Z@4444 %%%%
M#9/]4WT->+^*;];?65FAQN1C7M+#<I'J,5R6I>$;2YE,LNP9.<DT <?:?$6[
MB@5"$XJ?_A9%SZ)5Z;PYI,+8,L!_X$*L0>$=,N!^[DA)/8-0!T7AO6GU>U25
M\?,.U;]9FD:3'ID"QH!@>E:= !1110 4444 %%%% !1110 4444 %%%% !11
M10 5F-_R&%^E:=9C?\AA?I0!IT444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 TJK#YE!^HK,U#0;2_0AU SZ+6K11<F4(R5FCS;5/!,UNQDL3(2#G&XB
ML^WU?6M#?9/& H[DUZSUJA=Z3:7BGS80Q/K6BGW.*>"2?-2=F8.E>-;*Y55G
MF <]A73074-RNZ)L@UQ.J^!\DR6C+&>O%8'G:SH<X#-+(@]!1RI[$+$UJ.E5
M77<]<HKA]*\<1R%8YXV5NA+<5>U;QC:V&-N'R,_*:GE=SI6+I./-<ZJBO//^
M%D0?\\6H_P"%D0?\\6I\DB/KU#^8]#HKCM'\;0ZE<>6L9'-=@IRH/J*EIK<Z
M*56%57@Q:***1H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% #'B1QAE!^HK&U'PU:7P)(VG_9%;E%5&<HNZ(G3C-6DCS:^\+WMC)Y
MEF'8#U8T6?B34--81W2A5'!R:](90PP1Q69>Z'9WBG="I8]ZZ8XE25JBN<$L
M#*#YJ,K%73_%%C=@*9AO/:MN.19%W*<@UP6H>$+BW8RVL@3'0"J$&K:GI,NV
M<2NH]J;H0GK38EC*E)VK1^9Z?17,:9XMM[K"R+L/^T:Z&*ZAF4%)%/T-<TJ<
MHO5'=3K0J*\63444UI$3[S ?6H-1U%(&##((-+0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*W*B&X<!R>!7:(P=0PZ&O [::6&8-$2&'3%=UI?C"6U@5)X78@=2*QQ&$UO
MZL%F*Y>6K]YZ)17+0^-+>3[T>WZUHP^(;2;_ ):(/QKB=&:W1ZD<32ELS8HJ
MHFI6K])D_.IA<PMTE4_C4.+1JI1>S):*:'5NC TZD4%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%,>6.,9=P/J:R[[Q!:V:D[U8CL#51BY;$
M3J1@KR9KU5N=0M[5297QBN(O_%\UT2EK#(,]P*I0:?JVK/EYG53V85T1PS2O
M-V.&>/3?+25V=#J/C*VBRMO(&;WKGI=3UC5V*Q1@J>X-=!IW@Z.'#7&V0UT=
MOIMK; >7$%QZ57M*5/X5<CV&(KZU'9=CA[#P?/.P>\,@/?DUU=AX>M+(#:-Q
M]Q6QC XHK&=><]V=5+!TJ6RU&+&B_=51]!3Z**Q.H**** "BBB@ HHHH ***
M* "BBB@!&&5(]1BO,_&GA>=YQ=6B$XY)KTN0[8V/H":\[N/%F-7%G+&65GQS
M0!QL.NZMIJ>1CIZFB.#5/$%VF]25)YP37K<.AZ;>Q"8VR<U?MM(LK4YB@53[
M4 4?#6D#2]-CC*X<#FMRBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *S&_P"0POTK3K,;_D,+]* -.BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3'ACD&&
M13^%/HH Q;[PS97H.\8SZ"N6U#P'Y>6L_,+=N37H=%4I-'/4PM*INCR;RO$&
MBMD1_*/4FM*P\=RQ,$OF5?6O09K6&<8DC#?6L6_\*V-V#LA16/>JYD]SF>%J
MT]:4AUAXJTZ] "39:MN.9)5RIR*\YO? ]Y:L9+:Y*]\+6:EYK6D2?O#-(H]J
M.5/8%BZE/2K$];HK@M/\>#(CGMV4],M746FO6=V 1,@)[9J7%HZJ>)IU-F:M
M%,26.091P?I3ZDW"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH 3 ]*0HIZJ/RIU% $+6T3=47\JK2:1;
M2]4'Y5?HIJ36Q+A%[HP9_"=A/][(^@K/F\#61^XTE==16BKU%LS&6$HRWB<!
M-X+D3_4F0_B:IMX=UB _ND8_4FO2Z0@&M%BI]3!Y=2>VAYICQ#9_\LNGJ33U
M\2:U;\2(HQ7HCV\3_>0&H7TRSD^] IJOK$7\42/J52/P39Q4/C:9?]>5%:,'
MCBR/^LF K9E\/6$G_+NE9UQX0M9/N(JT^:A+=6%[/&0VDF68?%NF2])JO1:S
M9R_<DS7+R^!I/^6<X6J4OA+4K?E+QOPH]G0>T@]OBH_%"YZ EQ')]TU)7F36
M.M6IXN)6QZ"A=2U>V^^)FQ[4OJM_AD-9A;XX-'IU%>=1>+[N'B2UE./:M"#Q
MTIX>U9?K4/"U%T-8X^B]W8[6BN<A\6VTO4!?J:OQ:[9R?\M4'XUFZ4UNC>.(
MIRV9J4562_M7Z3H?QJ43Q-TD4_C469JI)[,DHI P/0TR:9((R[L !ZT@NB2B
MN4E\8P1WQ@V@C.,YKI+:YCNH@\; @CM6DJ<HJ[1G3KTZC:B]B>BBBLS4****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1F"J2>@JJ^I6T8RS
MU)>$BTD(]*Y2QM);N_.Z7Y,=* .I@OH+C/EMG%1SZI:VTA21\,*YZYCETW4H
M$60[7/(%:-W]GDD+.%S[T 6QKMB3CS*BU+54AL5EB;.XX%40EGGHE1:X%_LV
M'9C;O'3\* &_9KN2!KH@[ARO-:FC7SSQB*7_ %@'(JQ$!_9:_P"X*RM(S_;$
M@'3% '0SRB&%G/05S&ZYU.]D0?ZH#*D&M[5<_P!G2X]*SM  V G[V.: *UI=
MSV%XMO-P&/&:2\OI[N^>UBY"TS7.-9M\5EVUO/=Z].D<A0XZT :<:W=I=QB(
M$QGELFM6XL6O8@Q)!/H:QI[2YT^Y1Y)RZCDBNEMYP^G^;T^4F@#E=0M#;2"&
M-F\UAP,UTND1RQV4?FCYL<UBV8.I:D)S]V-B*ZD *,"@!:*** "BBB@ HHHH
M **** "BBB@ HICR(@RS ?6LV]UVUM%)\Q&/IFJ47+8B4XQ5Y,U:KW%[#:KN
MD; KB;_QC+.3';0/GU6LZ*SU;5Y/FED13V(KHCAGO-V.*>/C?EI*[.DU'QE:
M0@K!*"_I7/2ZUJ^K-L@0%3Z&MO3O!JQ$-<,)#[UTEMI=K;*/+A4'VJN>C3^%
M7,_8XFM\;LCB;+PE=73A[T.,]<$UT]AX9L[( J"3[BML #I2UC/$3EU.JE@Z
M5/6UV,2)(QA5 _"GT45B=04444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5GZS&TNESJO4K6A2,H=2K#(- '@XU*YT'6964X;;CDU1.N7!U!
M;K<=P;/6O9=2\*6=Z[R>4FXCK7"OX(D_M1<+^[W>E $$?Q$OXT"@KQ3_ /A8
M]_ZK77Q>!K3RQF-,T_\ X0:S_P">:4 6_"^M2ZM:)++C)':NCK/TS2XM-A6.
M,  >E:% !1110 4444 %%%,ED6*,NQ  ]: 'T5YCKOC&2/5A;PL<!P,@UW^D
MSM<6:NQR2!0!?HI'8(A8]AFO/?%'BZ2WNOLMJK,Y'&V@#T.BO*=(\9W<-VJ7
M<<@#' W5ZA:W"W,"R*1@@&@":BBB@ K,;_D,+]*TZS&_Y#"_2@#3HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXHWBJ_V9_P"_1]F?^_0!8WBC>*K_ &9_[]'V9_[] %C>*-XJO]F?^_1]F?\
MOT 6-XHWBJ_V9_[]'V9_[] %C>*-XJO]F?\ OT?9G_OT 6-XHWBJ_P!F?^_1
M]F?^_0!8WBC>*K_9G_OT?9G_ +] %C>*-XJO]F?^_1]F?^_0!8WBC>*K_9G_
M +]'V9_[] %C>*-XJO\ 9G_OT?9G_OT 6-XHWBJ_V9_[]'V9_P"_0!8WBC>*
MK_9G_OT?9G_OT 6-XHWBJ_V9_P"_1]F?^_0!8WBC>*K_ &9_[]'V9_[] %C>
M*-XJO]F?^_1]F?\ OT 6-XHWBJ_V9_[]'V9_[] %C>*-XJO]F?\ OT?9G_OT
M 6-XHWBJ_P!F?^_1]F?^_0!8WBC>*K_9G_OT?9G_ +] %C>*-XJO]F?^_1]F
M?^_0!8WBC>*K_9G_ +]'V9_[] %C>*-XJO\ 9G_OT?9G_OT 6-XHWBJ_V9_[
M]'V9_P"_0!8WBC>*K_9G_OT?9G_OT 6-XHWBJ_V9_P"_1]F?^_0!8WBC>*K_
M &9_[]'V9_[] %C>*-XJO]F?^_1]F?\ OT 6-XHWBJ_V9_[]'V9_[] %C>*-
MXJO]F?\ OT?9G_OT 6-XHWBJ_P!F?^_1]F?^_0!8WBC>*K_9G_OT?9G_ +]
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MBB@!KG;&Q] 37D'B:]N=8UE+1#D;MN :]?D&8G'JIKQK78YM(UY+DQLRARU
M%*_T!]*,3."&W@'\ZV_$^FW+65M=IG$<8.<^U9&M^)4U)(SY>"'!_6K.J^*O
MMVGQV<47.P+Q0!V?@/4GN=/CB<Y(%=I7#^ +"2"QCE<$9'0UW% !1110 4F
M>U+10 THI&-H_*JS:=;N<E!^56Z* ."\0>$)KVZ1X(@5#@GBMLZ-(FAM;1KB
M0@=*Z*B@#D/#>AWMC=3-<@['&!S5/Q+X--_<>?;(?, XQ7=T4 >9:3X#N%NE
MDO$.%.17I%O"L$*HHX  J6B@ HHHH *S&_Y#"_2M.LQO^0POTH TZ*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFC16=_;=A_S\Q_G4]OJ%M=$B*57(]#19@IQ>B9:HHHI%!1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI\G6VC_*L^X\)64WW8T7Z"B\7T%['$QVE<KP^.--D_B-:4'B2PG^X_ZU@3^
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M* '455DU&TB^_.@^M9USXFL( <7$;$>].S(E4A'=FW29'K7$W?CQ$)6*(/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% %#6/^09-_NUS>D:REE;!)<XQ@8%=/JB-)82JHR2.E9VC:=&
M+-!/ -WN* ,^VC;5;Y9\'8IK6G\.V5Q*9'4[C6G'!%",1H%^E24 8J>&;!&#
M!3D56UFP,-O&81PK9-='3719!AU!'O0!R\^MQW-D;1-WF$8Z5HZ3']CL4>4?
M-CFM 6%J&W"! ?7%3^6FW;M&/2@#-NG34M/E6('/3FLBTU5--C-M-NRHP,"N
MH2)$!"J #Z5$]C;2-N:%"?4B@#F[.V?4I#.1T/%,@NAI.HRM.#L/ P*ZR.&.
M(8C0*/:HY+2WE.7B5C[B@#F))O[5U:*6 'RP,'(ILL#Z5>M<$?*QKJH[6"+_
M %<2K]!3I((I1B1 WUH Y:^U1-53[- #EACD5T6FPM!811MU IZ65M&VY84!
M]0*L 8Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 F!Z"FO$C]5'Y4^B@"E-I5M,/G3]*SIO"6F3?>C/-;U%.[,Y4H2W1
MR%QX"TQA^[C.:RI_  7)@2O1**?.S&6#HRZ'ES^$-6MSF' J,VGB:SZ$8'UK
MU0@'J*8T$3?>0&J]HS)X"*^%M'E$^M^((HGCF;Y<$'@UQ,[L\S,W4DDU[[J5
MA:FRE/D)G8>WM7@]^ MY* ,#>?YUI!IGEX^C*G;FE<K4445H><>K>$O$%E:Z
M?'%(Q# 5U<>OV4GW7_6O.M#\)/J%DDJ7)3(SQ5Z3P/>Q\I?2?A6$E&Y[U&MB
M(TU:-T>@QW\$G1Q^=3":,]'7\Z\M?PUJ\/W+N<_C47V/7;?HUP^/>ER+N;?7
M9KXH,]9WJ?XA^=+N'J*\F%_KL'6WG.*F3Q-J\/WK*4TO9L:Q\>J9ZGD>M+7F
MD?C>_3[]B_X__KJY'\09.CVF/K1R,M8ZB]V=_17&Q>.X6^^BK5V+QA9/]Z1!
M^-+E9HL52>S.EHK'C\1Z<X_X^HQ^-6$UFP;I=1_G2LS558/9FA154:A:-]V=
M#4HN86Z2 TBN9/J2T4T.IZ$4Z@84444 %%%% !1110 4R7_5/_NFGTC#<I'J
M,4 >,:IIUU=^(1):?ZY9#MKH;;PKK&IW(&M!6A4AACUKJ8_#<<=\+G>,[LXK
M>H @MK:.WMXXE481<"IMJ_W1^5+10!5OK*.]LY+=U^5Q@BN N?#&NV-PR:5M
M6 \8/I7I-% '*>%_#3:7$\EPO[YCN)]ZOV\6K?VQ,9B/LA&%%;E% '$>(O"U
MU/>I>::H$R#@GUJII?A34KJ\\W60&P<C'K7H5% #(T$<2H.B@ 5RD7AN=/$,
M]\5&USQ7744 <=XST34M7LS;V>-I4 _E7+Z;H'C/2X%AMS&%48%>LT4 <]X<
MCUN. C52I?/:NAHHH **** "BF-*B?>8"JTFJ6<7W[A!0)R2W+E%8-UXIL(
M=L\;8]ZQ+KQ\$RL4 ?Z52BV83Q5*.[.XR/44QIHT&2P_.O,I_%VIW9(BLI!G
MN/\ ]=5-NNZ@W(GC!JN3N8/'Q^PFSTFYURSML[WZ>AK&N_'.G1<*S9KF[;P=
MJ%U@S7DHSZUM6O@*-,&2??\ 6BT43[7%3^&-C.NO'KOD6Q;VXK/.O>(+\XA;
M@^H-=Y:>&;&WQNAC?'M6BFG6D?W+=!]!1S16R#ZM7G\<SS1=#\0:@<RD$&KU
MMX"D<@W*Y]:]$6-%^ZH%./ I<[+C@*>\M3E+7P+ID0!:,[JV+?0+*U_U:5SV
MM>.CI>LMIZ6WF,!FJEK\0;I[Q(KK3F@1VP&;O^M3S,Z8T*<=D=XD*1C"J/RI
M^!Z5S.L>)KFSMO.LK)KH=MM<_P#\+ UO_H 2_I_C2-3T8D*"3VKFM2\<:5I<
MWE3%BV<?+68?%=]=:;ON+![8L,<__KK/\(Z+'J37TMX!*6;*[^U '::3K]GK
M,2R6Q.#V-:M>8:?OTCQY-;QL?(5>%'3O7I8D_<!_49H S=7\066C1[[DG&>@
MJAIOC?2]4G$4!8,3CYJY*97UCQY<6DK$PJ,A3TZFK/B;1X]+N;:ZM0(Q&,L%
M[T >D;@!DD8K+E\064-]':,^9'.!@UBG4+J]\+Q3P(Q=\@X[=*X*VL+NS\7V
M9N+AWWOG#=J /9YIT@B,CG"@9KE[CXAZ-;7'DN7W XX%4_B1J;Z=HL#(Y3=(
M%)'U%<S'+8?V85:..1I%!,I_AH ]1TW5;;5(%FMSE6Z5>KA? ]JD4N^.[\Q2
MO">E=U0 4444 %%%% !1110 A. 3Z5Q?B3QG'ID@BB8AJ[&<X@D_W37BUY -
M0\2K%,V%,A'- %\_$2\SQ)^E,D^(5]MP)#FJVM:'#IU\""#&6 S^-:.L>&K6
M+2TO(Y%R$!P* .R\):I<:G9I+,<EA73UQW@2YCDTN&-5 8"NQH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "LQO^0POTK3K,;_D,+]* -.BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #K2  =*6B@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBF22)$A>1@JCJ30 ^BLU_$&E1C+
MWL8^IJ:VU6QO 3;W"2 =<4 7**S;CQ!I5K*8Y[V-''4$U$OB?16.!J$1/UH
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M6?GOTJWX&NH_+NU+ %#@Y-==+90/"T8C4 C'2N NO!EW9W,K6MW(!,V2%[4
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MKM:S-'O;>ZME-OMV]MM:= !1110 4444 %%%% !1110 4444 %%%% !1110
M5F-_R&%^E:=9C?\ (87Z4 :=%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%1S2B&)I&. !0
MLIQ$Y]%->*^)9;G5M9%LK<[BHS7H]SXML8V:)ID!QBO.]4U"UAUN&ZA=7 ;)
MQ0!)!\.-2DB#_)S4O_"M-2_V*ZZP\;V;6R[W13Z5;_X32P_Y[)0!+X6T2;2+
M-(IL94=JZ.J&G:E%J$0>)@P/I5^@ HHHH **** "J]S>16HS(0/QJQ7G'Q!O
M9%NU@CD*[E[&@#M!KMF3]\?G5VWN8[E-T9R*\@T[09KJ..3^T)-Q[9KTSP[8
M26%EY<DC.2>IH V:@N+N*V4F1@,>]/G?RX'?^ZN:\EU[4;O6-<6U@D=5.1\I
MH ]3M]2M[DX1US]:MUXIC4- O(6DEE*LX')KUS2;S[;9+)["@"_1110 5F-_
MR&%^E:=9C?\ (83Z4 :=%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6U(Z[Q_.NG\&DG1^?45YWJ^L2^(KFWC2/A7'2O4?#]H;/3E0CJ : -:BBB@
MK+FS'J2R$?*!6I32BDY*@T 5_MJ>AH^V)Z&I_+3^Z*/+3^Z/RH @^V)Z&C[8
MGH:G\M/[H_*CRT_NC\J (/MB>AH^V)Z&I_+3^Z/RH\M/[H_*@"#[8GH:/MB>
MAJ?RT_NC\J/+3^Z/RH @^V)Z&C[8GH:G\M/[H_*CRT_NC\J (/MB>AH^V)Z&
MI_+3^Z/RH\M/[H_*@"#[8GH:/MB>AJ?RT_NC\J/+3^Z/RH @^V)Z&C[8GH:G
M\M/[H_*CRT_NC\J (/MB>AH^V)Z&I_+3^Z/RH\M/[H_*@"#[8GH:/MB>AJ?R
MT_NC\J/+3^Z/RH @^V)Z&C[8GH:G\M/[H_*CRT_NC\J (/MB>AH^V)Z&I_+3
M^Z/RH\M/[H_*@"#[8GH:/MB>AJ?RT_NC\J/+3^Z/RH @^V)Z&C[8GH:G\M/[
MH_*CRT_NC\J (/MB>AH^V)Z&I_+3^Z/RH\M/[H_*@"#[8GH:/MB>AJ?RT_NC
M\J/+3^Z/RH @^V)Z&C[8GH:G\M/[H_*CRT_NC\J (/MB>AH^V)Z&I_+3^Z*/
M+3^Z/RH @^V)Z&C[8GH:G\M/[H_*CRT_NC\J (/MB>AH^V)Z&I_+3^Z/RH\M
M/[H_*@"#[8GH:/MB>AJ?RT_NC\J/+3^Z/RH @^V)Z&C[8GH:G\M/[H_*CRT_
MNC\J (/MB>AH^V)Z&I_+3^Z/RH\M/[H_*@"#[8GH:/MB>AJ?RT_NC\J/+3^Z
M/RH @^V)Z&C[8GH:G\M/[H_*CRT_NC\J (/MB>AH^V)Z&I_+3^Z/RH\M/[H_
M*@"#[8GH:/MB>AJ?RT_NC\J/+3^Z/RH @^V)Z&C[8GH:G\M/[H_*CRT_NC\J
M (/MB>AH^V)Z&I_+3^Z/RH\M/[H_*@"#[8GH:/MB>AJ?RT_NC\J/+3^Z/RH
M@^V)Z&C[8GH:G\M/[H_*CRT_NC\J (/MB>AH^V)Z&I_+3^Z/RH\M/[H_*@"#
M[8GH:/MB>AJ?RT_NC\J/+3^Z/RH @^V)Z&C[8GH:G\M/[H_*CRT_NC\J (/M
MB>AH^V)Z&I_+3^Z/RH\M/[H_*@"#[8GH:/MB>AJ?RT_NC\J/+3^Z/RH @^V)
MZ&C[8GH:G\M/[H_*CRT_NC\J (/MB>AH^V)Z&I_+3^Z/RH\M/[H_*@"#[8GH
M:/MB>AJ?RT_NC\J/+3^Z/RH @^V)Z&C[8GH:G\M/[H_*CRT_NC\J (/MB>AH
M^V)Z&I_+3^Z/RH\M/[H_*@"#[8GH:/MB>AJ?RT_NC\J/+3^Z/RH @^V)Z&C[
M8GH:G\M/[H_*CRT_NC\J (/MB>AH^V)Z&I_+3^Z/RH\M/[H_*@"#[8GH:/MB
M>AJ?RT_NC\J/+3^Z/RH @^V)Z&C[8GH:G\M/[H_*CRT_NC\J (/MB>AH^V)Z
M&I_+3^Z/RH\M/[H_*@"#[8GH:/MB>AJ?RT_NC\J/+3^Z/RH @^V)Z&C[8GH:
MG\M/[H_*CRT_NC\J (/MB>AH^V)Z&I_+3^Z/RH\M/[H_*@"#[8GH:/MB>AJ?
MRT_NC\J/+3^Z/RH @^V)Z&C[8GH:G\M/[HH\M/[HH @^V)Z&C[8GH:G\M/[H
MH\M/[H_*@"#[8GH:/MB>AJ?RT_NC\J/+3^Z/RH @^V)Z&C[8GH:G\M/[H_*C
MRT_NC\J (/MB>AH^V)Z&I_+3^Z/RH\M/[H_*@"#[8GH:/MB>AJ?RT_NC\J/+
M3^Z/RH @^V)Z&C[8GH:G\M/[H_*CRT_NC\J (/MB>AH^V)Z&I_+3^Z/RH\M/
M[H_*@"#[8GH:/MB>AJ?RT_NC\J/+3^Z/RH @^V)Z&C[8GH:G\M/[H_*CRT_N
MC\J (/MB>AH^V)Z&I_+3^Z/RH\M/[H_*@"#[8GH:/MB>AJ?RT_NC\J/+3^Z/
MRH @^V)Z&E^V)Z&IO+3^Z/RH\M/[H_*@"#[8GH:/MB>AJ?RT_NBCRT_NC\J
M(/MB>AH^V)Z&I_+3^Z/RH\M/[H_*@"#[8GH:/MB>AJ?RT_NC\J/+3^Z/RH @
M^V)Z&C[8GH:G\M/[H_*CRT_NB@"#[8GH:/MB>AJ?RT_NC\J/+3^Z/RH @^V)
MZ&C[8GH:G\M/[HH\M/[H_*@"#[8GH:/MB>AJ?RT_NC\J/+3^Z/RH @^V)Z&C
M[8GH:G\M/[H_*CRT_NC\J (/MB>AH^V)Z&I_+3^Z/RH\M/[H_*@"#[8GH:/M
MB>AJ?RT_NC\J/+3^Z/RH @^V)Z&C[8GH:G\M/[H_*CRT_NC\J (/MB>AH^V)
MZ&I_+3^Z/RH\M/[H_*@"#[8GH:/MB>AJ?RT_NC\J/+3^Z/RH @^V)Z&C[8GH
M:G\M/[H_*CRT_NC\J (/MB>AH^V)Z&I_+3^Z/RH\M/[H_*@"#[8GH:/MB>AJ
M?RT_NC\J/+3^Z/RH @^V)Z&C[8GH:G\M/[H_*CRT_NC\J (/MB>AH^V)Z&I_
M+3^Z/RH\M/[H_*@"#[8GH:/MB>AJ?RT_NC\J/+3^Z/RH @^V)Z&C[8GH:G\M
M/[H_*CRT_NC\J (/MB>AH^V)Z&I_+3^Z/RH\M/[H_*@"#[8GH:/MB>AJ?RT_
MNC\J/+3^Z* (/MB>AH^V)Z&I_+3^Z/RH\M/[H_*@"#[8GH:/MB>AJ?RT_NC\
MJ/+3^Z/RH @^V)Z&C[8GH:G\M/[H_*CRT_NC\J (/MB>AH^V)Z&I_+3^Z/RH
M\M/[H_*@"#[8GH:/MB>AJ?RT_NC\J/+3^Z/RH @^V)Z&C[8GH:G\M/[H_*CR
MT_NC\J (/MB>AH^V)Z&I_+3^Z/RH\M/[H_*@"#[8GH:/MB>AJ?RT_NC\J/+3
M^Z/RH @^V)Z&C[8GH:G\M/[H_*CRT_NC\J (/MB>AH^V)Z&I_+3^Z/RH\M/[
MH_*@"#[8GH:/MB>AJ?RT_NC\J/+3^Z/RH @^V)Z&C[8GH:G\M/[H_*CRT_NC
M\J (/MB>AH^V)Z&I_+3^Z/RH\M/[H_*@"#[8GH:/MB>AJ?RT_NC\J/+3^Z/R
MH @^V)Z&C[8GH:G\M/[H_*CRT_NC\J (/MB>AH^V)Z&I_+3^Z/RH\M/[H_*@
M"#[8GH:/MB>AJ?RT_NC\J/+3^Z/RH A^VIZ&@7:$XP:F\M/[HI?+3^Z* %5M
MRYI:.G2B@ HHHH **** "J6K3&#39I!P56KM9^LQ&;2YT7J5H \9\A]?\2.K
M<YP3GZUZ_H.CP:59JL2;2PYKR.QN/[&\2N91CH.:]?L-9LKFVC*S*3MYH MW
MUE%?0&*9=RUY)XQ\-II5P)K=0HZFO6FU&U0$M*!7FOC_ %J"Z=8H'#Y&#B@#
M?\ Z@]QIT43'.!7:UP?P]M'CL8Y6! *UWE !1110 4444 %9NI:)9ZFI%Q'N
MR*TJ* .8@\#Z1!*'6WP0<]JVYM-MYK,VS)F,C&*N44 9&F^'[+2YFDMXMK-U
MHU/P[8:H<W$6XXQ6O10!SUCX0TNQDWQ08:N@50J@#H*6B@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5'\J\O\ #_AJ\N]0^T7J.O.>:]3B3RXE0=@!0 ^BBB@ HHHH **** "BBB@
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M55"K@=*6B@",P1DY(YIX 48%+10 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3617^\,TZB@"'[+%_
M=I1;QJ<A:EHH *8T2.<L*?10 BJ%&!2T44 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
H@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>23
<FILENAME>lyra-20201231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Instance Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-09T01:56:07.7019343+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 5245d08838e248bbac25af17c6adc28d -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xbrli:xbrl xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:lyra="http://lyratherapeutics.com/20201231" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="lyra-20201231.xsd" />
  <xbrli:unit id="U_iso4217USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_xbrlishares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD_xbrlishares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U_lyraPatient">
    <xbrli:measure>lyra:Patient</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_lyraVote">
    <xbrli:measure>lyra:Vote</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_xbrlipure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_utrsqft">
    <xbrli:measure>utr:sqft</xbrli:measure>
  </xbrli:unit>
  <xbrli:context id="C_0001327273_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_20210301">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA1RedeemableConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyra:SeriesA1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA2RedeemableConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyra:SeriesA2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA3RedeemableConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyra:SeriesA3RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA4RedeemableConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyra:SeriesA4RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesBRedeemableConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyra:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA1RedeemableConvertiblePreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyra:SeriesA1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA2RedeemableConvertiblePreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyra:SeriesA2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA3RedeemableConvertiblePreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyra:SeriesA3RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA4RedeemableConvertiblePreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyra:SeriesA4RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesBRedeemableConvertiblePreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyra:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesCRedeemableConvertiblePreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyra:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesCRedeemableConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyra:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesCRedeemableConvertiblePreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyra:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200504_20200505">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-05-04</xbrli:startDate>
      <xbrli:endDate>2020-05-05</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200504_20200505">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-05-04</xbrli:startDate>
      <xbrli:endDate>2020-05-05</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200505">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-05-05</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200504_20200505">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-05-04</xbrli:startDate>
      <xbrli:endDate>2020-05-05</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_20200311_20200311">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-03-11</xbrli:startDate>
      <xbrli:endDate>2020-03-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lyraSeriesA1RedeemableConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lyra:SeriesA1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lyraSeriesA2RedeemableConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lyra:SeriesA2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lyraSeriesA3RedeemableConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lyra:SeriesA3RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lyraSeriesA4RedeemableConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lyra:SeriesA4RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lyraSeriesBRedeemableConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lyra:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_lyraComputerSoftwareAndEquipmentMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lyra:ComputerSoftwareAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_lyraComputerSoftwareAndEquipmentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lyra:ComputerSoftwareAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_srtRangeAxis_srtMaximumMember_20200110">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-10</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_20200110">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-10</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesCRedeemableConvertiblePreferredStockMember_20200131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyra:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesCRedeemableConvertiblePreferredStockMember_20200101_20200131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyra:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_20200505">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-05-05</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200505">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-05-05</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200504_20200505">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-05-04</xbrli:startDate>
      <xbrli:endDate>2020-05-05</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapSubsidiarySaleOfStockAxis_lyraNonEmployeeCompensationMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lyra:NonEmployeeCompensationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapOptionIndexedToIssuersEquityTypeAxis_us-gaapEmployeeStockOptionMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementClassOfStockAxis_us-gaapEmployeeStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesCRedeemableConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lyra:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200531">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapPlanNameAxis_lyraTwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember_20160201_20160229">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-02-01</xbrli:startDate>
      <xbrli:endDate>2016-02-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapPlanNameAxis_lyraTwentyThousandTwentyIncentiveAwardPlanMember_20200430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapPlanNameAxis_lyraTwentyThousandTwentyIncentiveAwardPlanMember_20200401_20200430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapPlanNameAxis_lyraTwentyThousandTwentyIncentiveAwardPlanMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyIncentiveAwardPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_srtRangeAxis_srtMinimumMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_srtRangeAxis_srtMaximumMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapAwardTypeAxis_lyraMilestoneBasedAwardsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lyra:MilestoneBasedAwardsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapAwardTypeAxis_lyraMilestoneBasedAwardsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lyra:MilestoneBasedAwardsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapAwardTypeAxis_lyraRevenueBasedMilestoneAwardsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lyra:RevenueBasedMilestoneAwardsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapPlanNameAxis_lyraTwentyThousandTwentyEmployeeStockPurchasePlanMember_20200430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapPlanNameAxis_lyraTwentyThousandTwentyEmployeeStockPurchasePlanMember_20200401_20200430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lyra:TwentyThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_lyraArsenalMedicalIncorporationMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">lyra:ArsenalMedicalIncorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapTaxCreditCarryforwardAxis_us-gaapDomesticCountryMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapTaxCreditCarryforwardAxis_us-gaapDomesticCountryMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_srtRangeAxis_srtMinimumMember_us-gaapTaxCreditCarryforwardAxis_us-gaapDomesticCountryMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapTaxCreditCarryforwardAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapTaxCreditCarryforwardAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapTaxCreditCarryforwardAxis_us-gaapDomesticCountryMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapTaxCreditCarryforwardAxis_us-gaapStateAndLocalJurisdictionMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_20171101_20171130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-11-01</xbrli:startDate>
      <xbrli:endDate>2017-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapShortTermDebtTypeAxis_us-gaapLetterOfCreditMember_20171130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapCertificatesOfDepositMember_20171130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_lyraOfficeAndLaboratoryMember_20070831">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lyra:OfficeAndLaboratoryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2007-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <dei:DocumentType id="F_000000" contextRef="C_0001327273_20200101_20201231">10-K</dei:DocumentType>
  <dei:DocumentAnnualReport id="F_000001" contextRef="C_0001327273_20200101_20201231">true</dei:DocumentAnnualReport>
  <dei:DocumentTransitionReport id="F_000002" contextRef="C_0001327273_20200101_20201231">false</dei:DocumentTransitionReport>
  <dei:DocumentPeriodEndDate id="F_000003" contextRef="C_0001327273_20200101_20201231">2020-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalYearFocus id="F_000004" contextRef="C_0001327273_20200101_20201231">2020</dei:DocumentFiscalYearFocus>
  <dei:EntityFileNumber id="F_000005" contextRef="C_0001327273_20200101_20201231">001-39273</dei:EntityFileNumber>
  <dei:EntityRegistrantName id="F_000006" contextRef="C_0001327273_20200101_20201231">Lyra Therapeutics, Inc.</dei:EntityRegistrantName>
  <dei:EntityIncorporationStateCountryCode id="F_000007" contextRef="C_0001327273_20200101_20201231">DE</dei:EntityIncorporationStateCountryCode>
  <dei:EntityTaxIdentificationNumber id="F_000008" contextRef="C_0001327273_20200101_20201231">84-1700838</dei:EntityTaxIdentificationNumber>
  <dei:EntityAddressAddressLine1 id="F_000009" contextRef="C_0001327273_20200101_20201231">480 Arsenal Way</dei:EntityAddressAddressLine1>
  <dei:EntityAddressCityOrTown id="F_000010" contextRef="C_0001327273_20200101_20201231">Watertown</dei:EntityAddressCityOrTown>
  <dei:EntityAddressStateOrProvince id="F_000011" contextRef="C_0001327273_20200101_20201231">MA</dei:EntityAddressStateOrProvince>
  <dei:EntityAddressPostalZipCode id="F_000012" contextRef="C_0001327273_20200101_20201231">02472</dei:EntityAddressPostalZipCode>
  <dei:CityAreaCode id="F_000013" contextRef="C_0001327273_20200101_20201231">617</dei:CityAreaCode>
  <dei:LocalPhoneNumber id="F_000014" contextRef="C_0001327273_20200101_20201231">393-4600</dei:LocalPhoneNumber>
  <dei:Security12bTitle id="F_000015" contextRef="C_0001327273_20200101_20201231">Common Stock, $0.001 par value per share</dei:Security12bTitle>
  <dei:TradingSymbol id="F_000016" contextRef="C_0001327273_20200101_20201231">LYRA</dei:TradingSymbol>
  <dei:SecurityExchangeName id="F_000017" contextRef="C_0001327273_20200101_20201231">NASDAQ</dei:SecurityExchangeName>
  <dei:EntityWellKnownSeasonedIssuer id="F_000018" contextRef="C_0001327273_20200101_20201231">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityVoluntaryFilers id="F_000019" contextRef="C_0001327273_20200101_20201231">No</dei:EntityVoluntaryFilers>
  <dei:EntityCurrentReportingStatus id="F_000020" contextRef="C_0001327273_20200101_20201231">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityInteractiveDataCurrent id="F_000021" contextRef="C_0001327273_20200101_20201231">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityFilerCategory id="F_000022" contextRef="C_0001327273_20200101_20201231">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntitySmallBusiness id="F_000023" contextRef="C_0001327273_20200101_20201231">true</dei:EntitySmallBusiness>
  <dei:EntityEmergingGrowthCompany id="F_000024" contextRef="C_0001327273_20200101_20201231">true</dei:EntityEmergingGrowthCompany>
  <dei:EntityExTransitionPeriod id="F_000025" contextRef="C_0001327273_20200101_20201231">false</dei:EntityExTransitionPeriod>
  <dei:IcfrAuditorAttestationFlag id="F_000026" contextRef="C_0001327273_20200101_20201231">false</dei:IcfrAuditorAttestationFlag>
  <dei:EntityShellCompany id="F_000027" contextRef="C_0001327273_20200101_20201231">false</dei:EntityShellCompany>
  <dei:EntityPublicFloat id="F_000028" contextRef="C_0001327273_20200630" decimals="-3" unitRef="U_iso4217USD">84280762000</dei:EntityPublicFloat>
  <dei:EntityCommonStockSharesOutstanding id="F_000029" contextRef="C_0001327273_20210301" decimals="INF" unitRef="U_xbrlishares">12947572</dei:EntityCommonStockSharesOutstanding>
  <dei:DocumentsIncorporatedByReferenceTextBlock id="F_000030" contextRef="C_0001327273_20200101_20201231">&lt;p&gt;None.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
  <dei:CurrentFiscalYearEndDate id="F_000031" contextRef="C_0001327273_20200101_20201231">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:AmendmentFlag id="F_000032" contextRef="C_0001327273_20200101_20201231">false</dei:AmendmentFlag>
  <dei:EntityCentralIndexKey id="F_000033" contextRef="C_0001327273_20200101_20201231">0001327273</dei:EntityCentralIndexKey>
  <dei:DocumentFiscalPeriodFocus id="F_000034" contextRef="C_0001327273_20200101_20201231">FY</dei:DocumentFiscalPeriodFocus>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000035" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">74593000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000036" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">9808000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000037" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">1324000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000038" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">311000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000039" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">75917000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000040" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">10119000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000041" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">2165000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000042" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">237000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:OperatingLeaseRightOfUseAsset id="F_000043" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">2301000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseRightOfUseAsset id="F_000044" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">3182000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:RestrictedCashNoncurrent id="F_000045" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">329000</us-gaap:RestrictedCashNoncurrent>
  <us-gaap:RestrictedCashNoncurrent id="F_000046" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">329000</us-gaap:RestrictedCashNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="F_000047" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">118000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="F_000048" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">1096000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets id="F_000049" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">80830000</us-gaap:Assets>
  <us-gaap:Assets id="F_000050" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">14963000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="F_000051" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">922000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="F_000052" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">1069000</us-gaap:AccountsPayableCurrent>
  <lyra:AccruedExpensesAndOtherLiabilitiesCurrent id="F_000053" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">2977000</lyra:AccruedExpensesAndOtherLiabilitiesCurrent>
  <lyra:AccruedExpensesAndOtherLiabilitiesCurrent id="F_000054" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">3240000</lyra:AccruedExpensesAndOtherLiabilitiesCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent id="F_000055" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">985000</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent id="F_000056" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">899000</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000057" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">4884000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000058" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">5208000</us-gaap:LiabilitiesCurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent id="F_000059" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">1454000</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent id="F_000060" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">2427000</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:Liabilities id="F_000061" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">6338000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="F_000062" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">7635000</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies id="F_000063" xsi:nil="true" contextRef="C_0001327273_20201231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="F_000064" xsi:nil="true" contextRef="C_0001327273_20191231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000065" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA1RedeemableConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">39742000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000066" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA2RedeemableConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">18393000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000067" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA3RedeemableConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">38114000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000068" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA4RedeemableConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">6000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000069" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesBRedeemableConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">28417000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000070" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">130666000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:CommonStockValue id="F_000071" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">13000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000072" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">224363000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000073" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">4419000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000074" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">-149884000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000075" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">-127757000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="F_000076" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">74492000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000077" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">-123338000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000078" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">80830000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000079" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">14963000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000080" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA1RedeemableConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000081" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA1RedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000082" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA2RedeemableConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000083" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA2RedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000084" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA3RedeemableConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000085" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA3RedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000086" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA4RedeemableConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000087" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA4RedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000088" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesBRedeemableConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000089" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesBRedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000090" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesCRedeemableConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000091" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesCRedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000092" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA1RedeemableConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000093" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA1RedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">34017033</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000094" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA2RedeemableConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000095" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA2RedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">26680202</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000096" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA3RedeemableConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000097" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA3RedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">30070487</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000098" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA4RedeemableConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000099" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA4RedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">19999999</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000100" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesBRedeemableConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000101" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesBRedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">100018619</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000102" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesCRedeemableConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000103" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesCRedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="F_000104" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA1RedeemableConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000105" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA1RedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">34017033</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000106" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA2RedeemableConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000107" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA2RedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">26680202</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000108" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA3RedeemableConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000109" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA3RedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">30070487</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000110" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA4RedeemableConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000111" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA4RedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">19999999</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000112" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesBRedeemableConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000113" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesBRedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">98351953</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000114" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesCRedeemableConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000115" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesCRedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000116" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA1RedeemableConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000117" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA1RedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">34017033</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000118" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA2RedeemableConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000119" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA2RedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">26680202</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000120" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA3RedeemableConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000121" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA3RedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">30070487</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000122" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA4RedeemableConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000123" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesA4RedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">19999999</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000124" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesBRedeemableConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000125" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesBRedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">98351953</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000126" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesCRedeemableConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000127" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesCRedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000128" contextRef="C_0001327273_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000129" contextRef="C_0001327273_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000130" contextRef="C_0001327273_20201231" decimals="INF" unitRef="U_xbrlishares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000131" contextRef="C_0001327273_20191231" decimals="INF" unitRef="U_xbrlishares">275000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="F_000132" contextRef="C_0001327273_20201231" decimals="INF" unitRef="U_xbrlishares">12932377</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000133" contextRef="C_0001327273_20191231" decimals="INF" unitRef="U_xbrlishares">230860</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="F_000134" contextRef="C_0001327273_20201231" decimals="INF" unitRef="U_xbrlishares">12932377</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000135" contextRef="C_0001327273_20191231" decimals="INF" unitRef="U_xbrlishares">230860</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000136" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">12522000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000137" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">12032000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000138" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">9687000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000139" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">4487000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="F_000140" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">22209000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000141" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">16519000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="F_000142" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-22209000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000143" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-16519000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InvestmentIncomeInterest id="F_000144" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">82000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest id="F_000145" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">213000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:NonoperatingIncomeExpense id="F_000146" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">82000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="F_000147" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">213000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss id="F_000148" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-22127000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000149" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-16306000</us-gaap:NetIncomeLoss>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000150" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-22127000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000151" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-16306000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000152" contextRef="C_0001327273_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-2.59</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000153" contextRef="C_0001327273_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-82.23</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000154" contextRef="C_0001327273_20200101_20201231" decimals="0" unitRef="U_xbrlishares">8590205</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000155" contextRef="C_0001327273_20190101_20191231" decimals="0" unitRef="U_xbrlishares">202093</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000156" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">209119674</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000157" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">130353000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:SharesOutstanding id="F_000158" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">170156</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000159" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" unitRef="U_iso4217USD">4377000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000160" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" unitRef="U_iso4217USD">-111451000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000161" contextRef="C_0001327273_20181231" decimals="-3" unitRef="U_iso4217USD">-107074000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000162" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">60704</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000163" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">111000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000164" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">111000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:TemporaryEquityAccretionToRedemptionValue id="F_000165" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">313000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock id="F_000166" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-313000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock id="F_000167" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-313000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000168" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">244000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000169" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">244000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="F_000170" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-16306000</us-gaap:NetIncomeLoss>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000171" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">209119674</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000172" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">130666000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:SharesOutstanding id="F_000173" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">230860</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000174" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" unitRef="U_iso4217USD">4419000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000175" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" unitRef="U_iso4217USD">-127757000</us-gaap:StockholdersEquity>
  <lyra:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues id="F_000176" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesCRedeemableConvertiblePreferredStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">78306611</lyra:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues id="F_000177" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesCRedeemableConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">29446000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
  <us-gaap:TemporaryEquityAccretionToRedemptionValue id="F_000178" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">115000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock id="F_000179" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-115000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock id="F_000180" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-115000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued id="F_000181" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">740000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued id="F_000182" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">740000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000183" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesCRedeemableConvertiblePreferredStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">-287426285</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000184" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesCRedeemableConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-160227000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000185" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">8335248</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000186" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">8000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000187" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">160219000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000188" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">160227000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000189" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">4025000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000190" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000191" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">57280000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000192" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">57284000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <lyra:VestingOfRestrictedCommonStockShares id="F_000193" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">24661</lyra:VestingOfRestrictedCommonStockShares>
  <lyra:IssuanceOfCommonStockSharesUponExerciseOfWarrants id="F_000194" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">313794</lyra:IssuanceOfCommonStockSharesUponExerciseOfWarrants>
  <lyra:IssuanceOfCommonStockValueUponExerciseOfWarrants id="F_000195" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1000</lyra:IssuanceOfCommonStockValueUponExerciseOfWarrants>
  <lyra:IssuanceOfCommonStockValueUponExerciseOfWarrants id="F_000196" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-1000</lyra:IssuanceOfCommonStockValueUponExerciseOfWarrants>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000197" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">2814</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000198" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">8000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000199" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">8000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000200" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1813000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000201" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1813000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="F_000202" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-22127000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding id="F_000203" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">12932377</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000204" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" unitRef="U_iso4217USD">13000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000205" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" unitRef="U_iso4217USD">224363000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000206" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" unitRef="U_iso4217USD">-149884000</us-gaap:StockholdersEquity>
  <lyra:TemporaryEquityStockIssuanceCosts id="F_000207" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesCRedeemableConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">201000</lyra:TemporaryEquityStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000208" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">7116000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ProfitLoss id="F_000209" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-22127000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="F_000210" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-16306000</us-gaap:ProfitLoss>
  <us-gaap:ShareBasedCompensation id="F_000211" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1813000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000212" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">244000</us-gaap:ShareBasedCompensation>
  <us-gaap:Depreciation id="F_000213" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">95000</us-gaap:Depreciation>
  <us-gaap:Depreciation id="F_000214" contextRef="C_0001327273_20190101_20191231" decimals="0" unitRef="U_iso4217USD">27000</us-gaap:Depreciation>
  <lyra:ReserveForUncollectibleAccounts id="F_000215" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-167000</lyra:ReserveForUncollectibleAccounts>
  <us-gaap:GainLossOnDispositionOfAssets1 id="F_000216" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">45000</us-gaap:GainLossOnDispositionOfAssets1>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000217" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1013000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000218" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-561000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <lyra:IncreaseDecreaseInOperatingLeaseRightOfUseAsset id="F_000219" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-894000</lyra:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
  <lyra:IncreaseDecreaseInOperatingLeaseRightOfUseAsset id="F_000220" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-864000</lyra:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets id="F_000221" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">118000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000222" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">345000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000223" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-205000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <lyra:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities id="F_000224" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-87000</lyra:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities>
  <lyra:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities id="F_000225" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1734000</lyra:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities>
  <lyra:IncreaseDecreaseInOperatingLeaseLiability id="F_000226" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-900000</lyra:IncreaseDecreaseInOperatingLeaseLiability>
  <lyra:IncreaseDecreaseInOperatingLeaseLiability id="F_000227" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-840000</lyra:IncreaseDecreaseInOperatingLeaseLiability>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000228" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-21143000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000229" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-13754000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000230" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1775000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000231" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">211000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000232" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-1775000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000233" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-211000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock id="F_000234" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">30392000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
  <us-gaap:PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock id="F_000235" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">206000</us-gaap:PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="F_000236" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">59892000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering id="F_000237" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2383000</us-gaap:PaymentsForRepurchaseOfInitialPublicOffering>
  <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering id="F_000238" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">226000</us-gaap:PaymentsForRepurchaseOfInitialPublicOffering>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_000239" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">8000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_000240" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">111000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000241" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">87703000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000242" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-115000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000243" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">64785000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000244" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-14080000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations id="F_000245" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">10137000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations id="F_000246" contextRef="C_0001327273_20181231" decimals="-3" unitRef="U_iso4217USD">24217000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations id="F_000247" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">74922000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="F_000248" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">205000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="F_000249" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:StockIssued1 id="F_000250" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">160227000</us-gaap:StockIssued1>
  <lyra:AllocationOfRedeemableConvertiblePreferredStockToCommonStockWarrant id="F_000251" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">740000</lyra:AllocationOfRedeemableConvertiblePreferredStockToCommonStockWarrant>
  <lyra:AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue id="F_000252" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">115000</lyra:AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue>
  <lyra:AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue id="F_000253" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">313000</lyra:AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue>
  <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability id="F_000254" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">13000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
  <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability id="F_000255" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">4046000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
  <lyra:DeferredOfferingCostsIncurredButNotYetPaid id="F_000256" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">870000</lyra:DeferredOfferingCostsIncurredButNotYetPaid>
  <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock id="F_000257" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1. Organization and Basis of Presentation &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lyra Therapeutics, Inc. (the &amp;#8220;Company&amp;#8221;) is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (&amp;#8220;ENT&amp;#8221;) diseases. The Company&amp;#8217;s proprietary technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. The Company&amp;#8217;s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (&amp;#8220;CRS&amp;#8221;). The Company was incorporated as a Delaware corporation on November&amp;#160;21, 2005 and is located in Watertown, Massachusetts. On July&amp;#160;16, 2018, the Company formerly changed its name from 480 Biomedical, Inc. to Lyra Therapeutics, Inc. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to risks common to companies in the therapeutics and pharmaceutical industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations, reliance on third party manufacturers, ability to transition from pilot-scale manufacturing to large-scale production of products and the need to obtain adequate additional financing to fund the development of its product candidates. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since inception, the Company has funded its operations with proceeds from sales of redeemable convertible preferred stock and funding from government contracts. The Company has incurred recurring net losses since inception and had net losses of approximately $22.1 million and $16.3 million for the years ended December 31, 2020 and 2019, respectively. In addition, the Company has an accumulated deficit of approximately $149.9&amp;#160;million at December 31, 2020. The Company expects to continue to generate operating losses for the foreseeable future. At December 31, 2020, the Company had approximately $74.6&amp;#160;million of cash and cash equivalents.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On May 5, 2020, the Company completed its initial public offering (&amp;#8220;IPO&amp;#8221;), in which the Company issued and sold 4,025,000 shares of its common stock, including 525,000 shares pursuant to the full exercise of the underwriters&amp;#8217; option to purchase additional shares, at a public offering price of $16.00 per share, for aggregate gross proceeds of $64.4 million. The Company received approximately $57.3 million in net proceeds after deducting underwriting discounts and offering expenses paid by the Company.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company believes that its cash and cash equivalents as of December 31, 2020 will be sufficient to fund the Company&amp;#8217;s operating plan for a period of at least one year from the issuance date of the consolidated financial statements. The Company will need additional financing to support its continuing operations and pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of equity or debt financings, collaboration agreements, strategic alliances and licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all.&amp;nbsp;&amp;nbsp;The inability to obtain funding as and when needed would have a negative impact on the Company&amp;#8217;s financial condition and ability to pursue its business strategies. If the Company is unable to obtain funding when needed, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations.&amp;nbsp;&amp;nbsp;The Company will need to generate significant revenue to achieve profitability, and it may never do so.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon the completion of the IPO of its common stock in May 2020, all outstanding redeemable convertible preferred stock of the Company converted into shares of common stock and all outstanding warrants to purchase common stock were automatically cashless exercised.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;COVID-19 Pandemic and CARES Act&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January 30, 2020, the World Health Organization (&amp;#8220;WHO&amp;#8221;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &amp;#8220;COVID-19 outbreak&amp;#8221;) and the risks to the international community as the virus subsequently spread globally beyond its point of origin. On March 11, 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The COVID-19 pandemic is affecting the United States and global economies and may affect the Company&amp;#8217;s operations and those of third parties on which the Company relies, including by causing disruptions in the supply of the Company&amp;#8217;s product candidates and the conduct of current and future clinical trials. In addition, the COVID-19 pandemic may affect the operations of the Food and Drug Administration and other health authorities, which could result in delays of reviews and approvals, including with respect to the Company&amp;#8217;s product candidates. In light of developments relating to the COVID-19 pandemic, the Company discontinued enrollment at 67 patients in its Phase 2 LANTERN clinical trial and did not enroll patients in the United States. Additionally, while the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce the Company&amp;#8217;s ability to access capital, which could negatively impact the Company&amp;#8217;s short-term and long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, financing or clinical trial activities or on healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company&amp;#8217;s liquidity, capital resources, operations and business and those of the third parties on which the Company relies.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 27, 2020, President Trump signed into law the &amp;#8220;Coronavirus Aid, Relief, and Economic Security (CARES) Act.&amp;#8221; The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property. The Company currently defers the employer side social security payments and also is evaluating whether it will take advantage of other provisions, if any. The CARES Act also appropriated funds for the SBA Paycheck Protection Program loans that are forgivable in certain situations to promote continued employment, as well as Economic Injury Disaster Loans to provide liquidity to small businesses harmed by COVID-19. On December 27, 2020, the Consolidated Appropriations Act, 2021 was signed into law in order to provide further stimulus and support to those affected by the COVID-19 pandemic. The Company has not and does not plan on obtaining funding from such loans. The Company does not believe the CARES Act or the Consolidated Appropriations Act, 2021 will have a material impact on its financial condition, results of operations, or liquidity.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification (&amp;#8220;ASC&amp;#8221;) and Accounting Standards Updates (&amp;#8220;ASU&amp;#8221;) of the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;). &lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="F_000258" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2. Summary of Significant Accounting Policies &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements include the accounts of Lyra Therapeutics, Inc. and its wholly owned subsidiary Lyra Therapeutics Security Corporation, which was incorporated in December 2018. All intercompany transactions and balances have been eliminated. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the accompanying consolidated financial statements and notes. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of the Company&amp;#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&amp;#8217;s management evaluates its estimates, which include but are not limited to management&amp;#8217;s judgments of accrued expenses, fair value of common stock, valuation of share-based awards warrants to purchase common stock and deferred income taxes. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company utilizes significant estimates and assumptions in determining the fair value of its common stock. The Company has utilized various valuation methodologies to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&amp;#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&amp;#8217;s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Segment Information &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&amp;#8217;s chief operating decision-maker, the Company&amp;#8217;s chief executive officer, views the Company&amp;#8217;s operations and manages its business as a single operating segment, which is the business of developing targeted medicines to address ENT diseases. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Comprehensive Income (Loss) &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. As the Company did not have any element of other comprehensive income (loss), its comprehensive loss is equal to its net loss for all periods presented. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash held in banks and amounts held in money market funds. Cash equivalents are stated at cost, which approximates market value. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents consist of cash held in banks at December&amp;#160;31, 2020 and 2019. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Restricted Cash &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had restricted cash of approximately $0.3&amp;#160;million as of December&amp;#160;31, 2020 and 2019, which was held in certificates of deposit at the Company&amp;#8217;s financial institution to secure the Company&amp;#8217;s letter of credit for its facility lease. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Concentrations of Credit Risk and Off-Balance Sheet Risk &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains all its cash and cash equivalents at a single accredited financial institution, in amounts that exceed federally insured limits.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign exchange hedging arrangements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Significant Suppliers &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the drug product and associated applicator related to these programs. These programs could be adversely affected by a significant interruption in the supply of the materials required to manufacture the drug product and associated applicator. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at a measurement date. ASC Topic 820, &lt;font style="font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt; (&amp;#8220;ASC 820&amp;#8221;), establishes a three-level valuation hierarchy for instruments measured at fair value that prioritizes the inputs used to measure fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&amp;#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported or disclosed fair value of the financial instruments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy established by ASC 820 in order of priority are as follows: &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;1&amp;#160;-Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;2 -Inputs other than quoted prices included within Level&amp;#160;1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;3 -Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&amp;#160;3. A financial instrument&amp;#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;An entity may elect to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in net loss. The Company did not elect to measure any financial instruments or other items at fair value. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Derivative Liabilities &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with certain debt and equity financings, the Company may issue financial instruments in which a derivative instrument is &amp;#8220;embedded.&amp;#8221; Upon issuing the financial instrument, the Company assesses whether the economic characteristics of the embedded derivative are clearly and closely related to the economic characteristics of the remaining component of the financial instrument (i.e., the host contract) and whether a separate, non-embedded instrument with the same terms as the embedded instrument would meet the definition of a derivative instrument. When it is determined that (1)&amp;#160;the embedded derivative possesses economic characteristics that are not clearly and closely related to the economic characteristics of the host contract, and (2)&amp;#160;a separate, stand-alone instrument with the same terms would qualify as a derivative instrument, the embedded derivative is separated from the host contract and carried at fair value until the derivative is settled. Changes in the fair value of the derivative liabilities are recognized as other income (expense) in the consolidated statement of operations and comprehensive loss. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Classification and Accretion of Redeemable Convertible Preferred Shares &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has classified the redeemable convertible preferred stock outside of stockholders&amp;#8217; deficit in the accompanying consolidated balance sheets in accordance with authoritative guidance for the classification and measurement of redeemable securities as the redeemable convertible preferred stock is redeemable at a determinable price on a fixed date or upon the occurrence of a deemed liquidation event. The carrying values of the redeemable convertible preferred shares are accreted to their redemption values from the date of issuance through the earliest date of redemption. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Property and Equipment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost, less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" style="width:49%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" style="width:50%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated Useful Life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:49%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:50%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:49%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer software and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:50%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:49%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:50%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:49%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:50%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shorter of useful life or remaining term of related lease&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs for capital assets not yet placed into service are capitalized as construction in progress and are depreciated in accordance with the above guidelines once placed into service. Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statement of operations and comprehensive loss. Repairs and maintenance that do not improve or extend the lives of the respective assets are expensed as incurred, while costs of major additions and betterments are capitalized. &lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-lived assets consist of property and equipment. The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company did not record any impairment losses on long-lived assets during the years ended December&amp;#160;31, 2020 and 2019. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Leases &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASU No. 2016-02, &lt;font style="font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt; (&amp;#8220;ASU No. 2016-02&amp;#8221;), became effective January 1, 2019. As of the effective date of ASU No. 2016-02, the Company determines at the inception of an arrangement whether the arrangement contains a lease. If a lease is identified in an arrangement, the Company recognizes a right-of-use asset and liability on its balance sheet and determines whether the lease should be classified as a finance or operating lease. The Company does not recognize assets or liabilities for leases with lease terms of less than 12&amp;#160;months. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the rate implicit in the lease is not readily determinable, the Company utilizes its incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company separates lease and non-lease components when determining which lease payments to include in the calculation of its lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably certain it will exercise the option. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating leases are recorded in &amp;#8220;Operating lease right-of use assets,&amp;#8221; &amp;#8220;Operating lease liabilities&amp;#8221; and &amp;#8220;Operating lease liabilities, net of current portion&amp;#8221; in the Company&amp;#8217;s consolidated balance sheets. The Company did not have any finance leases recorded in its consolidated balance sheet as of December 31, 2020. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and Development Costs &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred. Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, manufacturing expenses, stock-based compensation expense, depreciation of equipment, contract services and other outside expenses. Costs of certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into various research and development contracts with companies both inside and outside of the United States. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&amp;#8217;s estimates. The Company&amp;#8217;s historical accrual estimates have not been materially different from the actual costs. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Patent Costs &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Accounting for Stock-Based Compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718, &lt;font style="font-style:italic;"&gt;Compensation&amp;#8212;Stock Compensation&lt;/font&gt; (&amp;#8220;ASC 718&amp;#8221;). ASC 718 requires all stock-based payments to employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees. The Company believes the fair value of the stock options granted to non-employees is more reliably determinable than the fair value of the services provided. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Black-Scholes option-pricing model uses the following inputs: the fair value of the Company&amp;#8217;s common stock, the expected volatility of the Company&amp;#8217;s common stock, the expected term of the Company&amp;#8217;s stock options, the risk-free interest rate for a period that approximates the expected term of the Company&amp;#8217;s stock options, and the Company&amp;#8217;s expected dividend yield. Following the closing of the Company&amp;#8217;s IPO, the fair value of the Company&amp;#8217;s common stock is determined based on the quoted market price of its common stock. The Company has historically been a private company and lacks company-specific historical and implied volatility data. Therefore, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to it, including stage of product development, life science industry focus, length of trading history, and similar vesting provisions. The historical volatility data is calculated based on a period of time commensurate with the expected term assumption. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available or until circumstances change, such that the identified entities are no longer representative companies. In the latter case, more suitable, similar entities whose share prices are publicly available would be utilized in the calculation. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&amp;#160;107, &lt;font style="font-style:italic;"&gt;Share-Based Payment&lt;/font&gt;, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid cash dividends and has no current plans to pay any cash dividends on its common stock. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has elected as a policy to recognize forfeitures as they occur as described in ASU No.&amp;#160;2016-09, &lt;font style="font-style:italic;"&gt;Compensation&amp;#8212;Stock Compensation&lt;/font&gt; (&amp;#8220;ASU No.&amp;#160;2016-09&amp;#8221;). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company expenses the fair value of its stock-based compensation awards to employees on a straight-line basis over the requisite service period, which is generally the vesting period. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company follows the provisions of ASU No.&amp;#160;2018-07, &lt;font style="font-style:italic;"&gt;Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting&lt;/font&gt; (&amp;#8220;ASU No.&amp;#160;2018-07&amp;#8221;) which permits the Company to recognize non-employee stock-based compensation costs over the requisite period based on a measurement of fair value on the grant date for each stock-based award. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income Taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes using the liability method in accordance with ASC Topic 740, &lt;font style="font-style:italic;"&gt;Income Taxes&lt;/font&gt; (&amp;#8220;ASC 740&amp;#8221;). The difference between the financial statement and tax basis of the assets and liabilities is determined annually. Deferred income tax assets and liabilities are computed using the tax laws and rates that are expected to apply for periods in which such differences reverse. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will more likely than not be realized. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Contingencies &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In accordance with ASC Topic 450, &lt;font style="font-style:italic;"&gt;Contingencies&lt;/font&gt;, the Company records accruals for contingencies and legal proceedings expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If a loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Guarantees &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has identified the guarantees described below as disclosable, in accordance with ASC Topic 460, &lt;font style="font-style:italic;"&gt;Guarantees&lt;/font&gt;. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company&amp;#8217;s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&amp;#8217; and officers&amp;#8217; insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company leases office space under a noncancelable operating lease. The Company has standard indemnification arrangements under the lease that requires it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the lease. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020 and 2019, the Company had not experienced any losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves have been established. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Deferred Offering Costs &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&amp;#8217; deficit as a reduction of additional paid-in capital generated as a result of the offering. Should the planned equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statement of operations and comprehensive loss. Deferred offering costs of $0 and $1.1 million are included in other assets in the consolidated balance sheets at December 31, 2020 and 2019, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Net Loss per Share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company has computed diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, warrants to purchase common stock and redeemable convertible preferred stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive and basic and diluted loss per share have been the same. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share data): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22,127&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,306&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accretion of redeemable convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(115&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(313&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22,242&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,619&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average common shares&amp;#8212;basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,590,205&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;202,093&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributable to common stockholders&amp;#8212;basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.59&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(82.23&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares retroactively adjusted): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A-1 redeemable convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;986,466&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A-2 redeemable convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;773,712&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A-3 redeemable convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;872,031&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A-4 redeemable convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;579,993&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series B redeemable convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,852,177&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,428,886&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;792,439&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,428,886&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,856,818&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the FASB issued ASU No.&amp;#160;2018-13, &lt;font style="font-style:italic;"&gt;Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement&lt;/font&gt; (&amp;#8220;ASU No.&amp;#160;2018-13&amp;#8221;), which modifies the disclosure requirements on fair value measurements. The Company adopted ASU No. 2018-13 on January&amp;#160;1, 2020. The adoption of ASU 2018-13 did not have a material impact on the Company&amp;#8217;s consolidated financial position, results of operations or cash flows.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the FASB issued ASU No.&amp;#160;2018-15, &lt;font style="font-style:italic;"&gt;Intangibles&amp;#8212;Goodwill and Other&amp;#8212;Internal-Use Software (Subtopic 350-40): Customer&amp;#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/font&gt; (&amp;#8220;ASU No.&amp;#160;2018-15&amp;#8221;), which clarifies the accounting for implementation costs in cloud computing arrangements. The Company adopted ASU No. 2018-15 on January&amp;#160;1, 2020 on a prospective basis. The adoption of ASU 2018-15 did not have a material impact on the Company&amp;#8217;s consolidated financial position, results of operations or cash flows.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;font style="font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/font&gt; (&amp;#8220;ASU No. 2019-12&amp;#8221;), which makes a number of changes meant to add or clarify guidance on accounting for income taxes. The new guidance will become effective for the Company on January 1, 2022. Early adoption is permitted. The Company currently is evaluating the impact the adoption of ASU 2019-12 will have on its consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock id="F_000259" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3. Fair Value Measurements &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company did not have financial assets and liabilities measured at fair value at December&amp;#160;31, 2020 and 2019. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There have been no changes to the valuation methods used during the years ended December 31, 2020 and 2019. There were no transfers within the fair value hierarchy during the years ended December 31, 2020 and 2019.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying values of the Company&amp;#8217;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the Company&amp;#8217;s sale of Series C redeemable convertible preferred stock (&amp;#8220;Series C Preferred Stock&amp;#8221;), the Company issued to investors warrants for the purchase of common stock (&amp;#8220;Warrants&amp;#8221;). The proceeds from the issuance of the Series C Preferred Stock were allocated between the Series C Preferred Stock and Warrants based on their relative fair values at the time of issuance.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock id="F_000260" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4. Property and Equipment &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consist of the following at December&amp;#160;31, 2020 and 2019 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,277&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,715&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer software and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;650&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;595&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;301&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;301&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;317&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;317&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;498&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;138&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,043&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,066&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,878&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,829&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,165&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;237&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognized approximately $0.1 million and $27,000 of depreciation expense for the years ended December 31, 2020 and 2019, respectively.&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Property and Equipment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost, less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" style="width:49%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" style="width:50%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated Useful Life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:49%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:50%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:49%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer software and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:50%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:49%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:50%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:49%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:50%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shorter of useful life or remaining term of related lease&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs for capital assets not yet placed into service are capitalized as construction in progress and are depreciated in accordance with the above guidelines once placed into service. Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statement of operations and comprehensive loss. Repairs and maintenance that do not improve or extend the lives of the respective assets are expensed as incurred, while costs of major additions and betterments are capitalized. &lt;/p&gt;
</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <lyra:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock id="F_000261" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;5. Accrued Expenses and Other Current Liabilities &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses and other current liabilities consist of the following at December&amp;#160;31, 2020 and 2019 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payroll and employee related expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,892&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;885&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Third-party research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;381&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,344&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional and consulting fees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;555&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;901&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;149&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued expenses and other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,977&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,240&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</lyra:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock>
  <us-gaap:PreferredStockTextBlock id="F_000262" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6. Redeemable Convertible Preferred Stock &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January 10, 2020, the Company filed an amended and restated certificate of incorporation which authorized its Board of Directors to issue up to 299,300,288 shares of preferred stock, par value $0.001 per share. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2020, the Company issued 78,306,611 shares of Series C Preferred Stock for $0.38811 per share, in exchange for gross cash proceeds of approximately $30.4 million.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon the completion of the IPO of its common stock in May 2020, all outstanding redeemable convertible preferred stock of the Company converted into shares of common stock.&lt;/p&gt;</us-gaap:PreferredStockTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="F_000263" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7. Preferred and Common Stock &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January 10, 2020, the Company filed an amended and restated certificate of incorporation which authorized its Board of Directors to issue up to 400,000,000 shares of common stock, par value $0.001 per share. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On May 5, 2020, the Company filed a restated certificate of incorporation which authorizes its Board of Directors to issue up to 200,000,000 shares of common stock, par value $0.001 per share and 10,000,000 shares of undesignated preferred stock, par value $0.001 per share.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The holders of common stock are entitled to one vote for each share held. Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s Board of Directors approved a one-for-34.483 reverse stock split of its issued and outstanding common stock and stock options and a proportional adjustment to the existing conversion ratios for the Company&amp;#8217;s redeemable convertible preferred stock pursuant to an amendment to the Company&amp;#8217;s amended and restated certificate of incorporation effective as of April 27, 2020. Accordingly, all common stock shares, per share amounts, and additional paid in capital amounts for all periods presented in the accompanying consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2020, the Company completed its IPO in which the Company issued and sold 4,025,000 shares of its common stock, including 525,000 shares pursuant to the full exercise of the underwriters&amp;#8217; option to purchase additional shares, at a public offering price of $16.00 per share, for aggregate gross proceeds of $64.4 million. The Company received approximately $57.3 million in net proceeds after deducting underwriting discounts and offering expenses paid by the Company. In connection with this financing, all outstanding shares of redeemable convertible preferred stock converted into 8,335,248 shares of the Company&amp;#8217;s common stock, all outstanding Warrants were automatically cashless exercised resulting in the issuance of 313,794 shares of the Company&amp;#8217;s stock and the issuance to one of our directors, in lieu of compensation payable by the Company under a consulting agreement, of 19,661 fully vested shares of the Company&amp;#8217;s common stock.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2020, the Company issued as non-employee compensation 5,000 fully vested shares of the Company&amp;#8217;s common stock.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has reserved for future issuances the following shares of common stock as of December 31, 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,888,653&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee stock purchase plan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;150,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,038,653&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Warrants&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In conjunction with the issuance of the Series C Preferred Stock, the Company issued Warrants to purchase 681,256 shares of common stock at an exercise price of $8.63 per share.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classified the Warrants as equity in the consolidated balance sheets in accordance with the guidance in ASC 815, &lt;font style="font-style:italic;"&gt;Derivatives and Hedging&lt;/font&gt;. The Company allocated the net proceeds from the issuance of the Series C Preferred Stock based on the relative fair values of the Series C Preferred Stock and Warrants, which resulted in approximately $0.7 million of the net proceeds being allocated to the Warrants.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon the completion of the IPO of the Company&amp;#8217;s common stock in May 2020, all outstanding Warrants were automatically cashless exercised resulting in the issuance of 313,794 shares of the Company&amp;#8217;s common stock.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="F_000264" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;8. Stock-Based Compensation Expense &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company adopted the 2016 Equity Incentive Plan (&amp;#8220;2016 Plan&amp;#8221;) in February 2016 and amended it in June 2017 and June 2018. Upon adoption of the 2016 Plan, no further grants were made under the 2005 Equity Incentive Plan (&amp;#8220;2005 Plan&amp;#8221;).&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2020, the Company&amp;#8217;s Board of Directors adopted the Company&amp;#8217;s 2020 Incentive Award Plan (&amp;#8220;2020 Plan&amp;#8221;, and together with the 2016 Plan and 2005 Plan, the &amp;#8220;Plans&amp;#8221;), and upon effectiveness of the 2020 Plan, the Company ceased granting equity-based awards under the 2016 Plan. The 2020 Plan provides for grant of incentive stock options and nonqualified stock options, stock appreciation rights, restricted stock, dividend equivalents, restricted stock units, performance awards and other share and cash-based awards to employees and consultants and members of the Board of Directors of the Company and its subsidiaries.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The initial number of shares of the Company&amp;#8217;s common stock that may be issued under the 2020 Plan is 2,100,000 shares plus the number of shares of the Company&amp;#8217;s common stock underlying outstanding awards under the 2005 Plan and 2016 Plan as of the effective date of the 2020 Plan that expire, lapse or are terminated, exchanged for cash, surrendered, repurchased, canceled or forfeited following the effective date of the 2020 Plan. The number of shares available under the 2020 Plan will automatically increase on January 1st of each year from 2021 to 2030 by the lesser of (i) 4% of the number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) a smaller number of shares determined by the Company&amp;#8217;s Board of Directors. However, no more than 8,800,000 shares may be issued under the 2020 Plan pursuant to the exercise of incentive stock options. As of December 31, 2020, the Company had 1,459,767 shares available for issuance under the 2020 Plan.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All stock option grants are nonqualified stock options except option grants to employees and officers intended to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended. Stock options may not be granted at less than the fair market value of the Company&amp;#8217;s common stock on the date of grant. Vesting periods of awards are determined by the Board of Directors or its compensation committee. Vesting periods of awards granted to date range from vesting upon grant to vesting over a four-year period. Vesting conditions are generally based on continued service. Additionally, the Company has granted certain awards which vest upon the achievement of certain financing and revenue milestones. Stock options granted under the Plans expire no more than 10 years from the date of grant. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense included in the Company&amp;#8217;s consolidated statements of operations and comprehensive loss was as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;229&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,584&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;218&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,813&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;244&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company did not record any stock-based compensation associated with milestone-based awards in the years ended December&amp;#160;31, 2020 and 2019.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of each stock option granted to employees, directors and non-employees was estimated on the date of grant using the Black-Scholes option-pricing model, with the following weighted-average assumptions: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the stock option activity under the Plans for the year ended December 31, 2020 was as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in&amp;#160;thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;792,439&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.59&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,363&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;763,505&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.16&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,814&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.92&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(124,244&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.30&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,428,886&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.41&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,165&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;626,578&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.30&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,099&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:16.35pt;"&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and expected to vest at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,428,886&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.41&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,165&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average fair value of options granted to employees, directors and non-employees during the years ended December&amp;#160;31, 2020 and 2019 was $9.66 and $3.45, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&amp;#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&amp;#8217;s common stock. The aggregate intrinsic value of stock options exercised during the years ended December&amp;#160;31, 2020 and 2019 was approximately $27,000 and $0.2 million, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, total unrecognized stock-based compensation expense relating to unvested stock options was approximately $6.2&amp;#160;million. This amount is expected to be recognized over a weighted-average period of 3.2 years. Additionally, as of December 31, 2020, there was approximately $36,000 of unrecognized stock-based compensation related to a stock option award related to the achievement of a revenue-based milestone. As the Company believes the achievement of the revenue-based milestone is currently not probable, it has not recorded any stock-based compensation related to this award. The Company will continue to assess the probability of achieving the revenue-based milestone at each reporting period. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020 Employee Stock Purchase Plan&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2020, the Company&amp;#8217;s Board of Directors adopted the Company&amp;#8217;s 2020 Employee Stock Purchase Plan (&amp;#8220;2020 ESPP&amp;#8221;). The 2020 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.&amp;nbsp;&amp;nbsp;The Company initially reserved 150,000 shares of common stock for issuance under the 2020 ESPP.&amp;nbsp;&amp;nbsp;In addition, the number of shares available for issuance under the 2020 ESPP will be annually increased on January 1st of each year from 2021 to 2030 by the lesser of (i) 0.5% of the number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by the Company&amp;#8217;s Board of Directors, provided that no more than 987,500 shares of common stock may be issued under the 2020 ESPP. The 2020 ESPP permits eligible participants to purchase common stock through payroll deductions of up to a specified percentage of their eligible compensation. On the first trading day of each offering period, each participant will automatically be granted an option to purchase shares of the Company&amp;#8217;s common stock. The option will expire at the end of the applicable offering period, and will be exercised at that time to the extent of the payroll deductions accumulated during the offering period, subject to the limits set forth in the 2020 ESPP. The purchase price of the shares, in the absence of a contrary designation, will be 85% of the lower of the fair market value of the Company&amp;#8217;s common stock on the first trading day of the offering period or on the purchase date. As of December 31, 2020, no shares have been issued under the 2020 ESPP. &lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock id="F_000265" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;9. Related Parties &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had consulting agreements that expired in January 2020 with two of its founders who resigned as directors of the Company in October 2020. Total consulting expense related to these consulting agreements was $0 and $50,000 for the years ended December 31, 2020 and 2019, respectively. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2011, the Company entered into a Contribution Agreement, Transition Services Agreement (as amended), Collaboration Agreement, Technology License Agreement and Trademark Coexistence Agreement with Arsenal Medical, Inc. (&amp;#8220;Arsenal&amp;#8221;), a company which shares certain common owners with the Company. During the year ended December 31, 2019, the Company invoiced Arsenal for an aggregate of $0.3, primarily for its share of rent and other overhead costs.&amp;nbsp;&amp;nbsp;The Transition Services Agreement expired in June 2019. All amounts receivable from Arsenal were collected as of December 31, 2019. &lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="F_000266" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;10. Income Taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company records a provision or benefit for income taxes on pre-tax income or loss based on its estimated effective tax rate for the year. During the years ended December&amp;#160;31, 2020 and 2019, the Company recorded net losses of approximately $22.1 million and $16.3&amp;#160;million, respectively, and, since it maintains a full valuation allowance on its deferred tax assets, the Company did not record an income tax benefit for the years ended December&amp;#160;31, 2020 and 2019. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of income tax expense computed at the statutory federal income tax rate to income taxes reflected in the consolidated financial statements is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax computed at federal statutory tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development and other tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in deferred tax asset valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(28.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(30.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets as of December&amp;#160;31, 2020 and 2019 consist of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.9%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,729&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,006&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,223&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,652&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;322&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;173&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;661&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;909&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;140&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;280&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total gross deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,075&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41,451&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(35,150&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;624&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;870&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(624&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(870&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(624&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(870&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020, the Company had U.S. federal net operating loss carryforwards of approximately $91.4&amp;#160;million which may be able to offset future income tax liabilities and expire at various dates through 2037 and approximately $44.0&amp;#160;million of federal net operating loss carryforwards that may be carried forward indefinitely. As of December&amp;#160;31, 2020, the Company also had state net operating loss carryforwards of approximately $116.0&amp;#160;million which may be available to offset future income tax liabilities and expire at various dates through 2040. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020 and 2019, the Company had federal research and development tax credit carryforwards of approximately $3.6 million and $3.2&amp;#160;million, respectively, available to reduce future tax liabilities which expire at various dates through 2040. As of December&amp;#160;31, 2020 and 2019, the Company had state research and development tax credit carryforwards of approximately $2.0 million and $1.8&amp;#160;million, respectively, available to reduce future tax liabilities which expire at various dates through 2035. The Company has generated research credits but has not conducted a study to document the qualified activity. This study may result in an adjustment to the Company&amp;#8217;s research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&amp;#8217;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the research and development credit carryforwards and the valuation allowance. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the provisions of the Internal Revenue Code, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section&amp;#160;382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section&amp;#160;382, which is determined by first multiplying the value of the Company&amp;#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed by the Company and any limitation is known, no amounts are being presented as an uncertain tax position. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at December&amp;#160;31, 2020 and 2019 because the Company&amp;#8217;s management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets primarily due to its history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and, as a result, a valuation allowance of approximately $41.5 million and $35.2&amp;#160;million, respectively, has been established at December&amp;#160;31, 2020 and 2019. Management reevaluates the positive and negative evidence at each reporting period. The valuation allowance increased by approximately $6.3 million and $5.1&amp;#160;million, respectively, during the years ended December&amp;#160;31, 2020 and 2019 due primarily to the generation of net operating losses. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has recorded adjustments to deferred tax assets for unrecognized tax benefits as of December&amp;#160;31, 2020 and 2019. The Company&amp;#8217;s policy is to record interest and penalties related to uncertain tax positions as part of its income tax provision. As of December&amp;#160;31, 2020 and 2019, the Company had no accrued interest or penalties related to uncertain tax positions and no such amounts have been recognized in the Company&amp;#8217;s statement of operations and comprehensive loss. In many cases, the Company&amp;#8217;s uncertain tax positions are related to years that remain subject to examination by relevant tax authorities. The statute of limitations for federal and state tax authorities is closed for years prior to December&amp;#160;31, 2017. However, since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available. &lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income Taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes using the liability method in accordance with ASC Topic 740, &lt;font style="font-style:italic;"&gt;Income Taxes&lt;/font&gt; (&amp;#8220;ASC 740&amp;#8221;). The difference between the financial statement and tax basis of the assets and liabilities is determined annually. Deferred income tax assets and liabilities are computed using the tax laws and rates that are expected to apply for periods in which such differences reverse. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will more likely than not be realized. &lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. &lt;/p&gt;
</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:LesseeOperatingLeasesTextBlock id="F_000267" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;11. Leases &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2007, the Company entered into an operating lease, as amended, for approximately 22,343 square feet of office and laboratory space in Watertown, Massachusetts. In November 2017, the Company amended its lease (&amp;#8220;2017 Amendment&amp;#8221;) and extended the lease term through April 2023. Initial base rent under the 2017 Amendment was approximately $1.0&amp;#160;million per year. The 2017 Amendment includes annual rent escalations over the term of the operating lease. The Company maintains a letter of credit of approximately $0.3&amp;#160;million securing its obligations under the operating lease which is secured by approximately $0.3&amp;#160;million of certificate of deposits, which are included as restricted cash in the consolidated balance sheets. Rent expense is recognized on a straight-line basis over the terms of occupancy. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition to the lease discussed above, the Company is party to an April 2020 lease for office equipment that expires in June 2024.&amp;nbsp;&amp;nbsp;The equipment lease is accounted for as an operating lease.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of lease cost recorded in the Company&amp;#8217;s consolidated financial statements were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease Cost:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,055&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,053&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;726&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;727&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sublease income&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(368&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease cost, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,781&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,412&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Variable lease payments include the Company&amp;#8217;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. The Company&amp;#8217;s sublease income during the year ended December 31, 2019 related to subleases for a portion of the Company&amp;#8217;s office and lab space.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average remaining lease term and discount rate related to the Company&amp;#8217;s operating leases were as follows:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average remaining lease term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturity of the Company&amp;#8217;s operating lease liabilities in accordance with ASC 842 as of December 31, 2020 were as follows (in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,095&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,127&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;382&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total maturities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Amount representing interest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(167&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of operating lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,439&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Current portion of operating lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(985&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease liability, net of current portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,454&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
  <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock id="F_000268" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;12. Retirement Plan &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has a defined-contribution plan under Section&amp;#160;401(k) of the Internal Revenue Code (&amp;#8220;401(k) Plan&amp;#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. As currently established, the Company is not required to make any contributions to the 401(k) Plan. For the year ended December 31, 2020, the Company made a discretionary match that matches 50% of employee contributions up to a maximum of 3% of employees&amp;#8217; salary. Matching contributions are fully vested at the time of contribution. During the year ended December 31, 2020, matching contribution costs incurred by the Company were $0.1 million. The Company did not make any matching contributions during the year ended December&amp;#160;31, 2019. &lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
  <lyra:COVID19PandemicAndCARESActPolicyTextBlock id="F_000269" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;COVID-19 Pandemic and CARES Act&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January 30, 2020, the World Health Organization (&amp;#8220;WHO&amp;#8221;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &amp;#8220;COVID-19 outbreak&amp;#8221;) and the risks to the international community as the virus subsequently spread globally beyond its point of origin. On March 11, 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The COVID-19 pandemic is affecting the United States and global economies and may affect the Company&amp;#8217;s operations and those of third parties on which the Company relies, including by causing disruptions in the supply of the Company&amp;#8217;s product candidates and the conduct of current and future clinical trials. In addition, the COVID-19 pandemic may affect the operations of the Food and Drug Administration and other health authorities, which could result in delays of reviews and approvals, including with respect to the Company&amp;#8217;s product candidates. In light of developments relating to the COVID-19 pandemic, the Company discontinued enrollment at 67 patients in its Phase 2 LANTERN clinical trial and did not enroll patients in the United States. Additionally, while the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce the Company&amp;#8217;s ability to access capital, which could negatively impact the Company&amp;#8217;s short-term and long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, financing or clinical trial activities or on healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company&amp;#8217;s liquidity, capital resources, operations and business and those of the third parties on which the Company relies.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 27, 2020, President Trump signed into law the &amp;#8220;Coronavirus Aid, Relief, and Economic Security (CARES) Act.&amp;#8221; The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property. The Company currently defers the employer side social security payments and also is evaluating whether it will take advantage of other provisions, if any. The CARES Act also appropriated funds for the SBA Paycheck Protection Program loans that are forgivable in certain situations to promote continued employment, as well as Economic Injury Disaster Loans to provide liquidity to small businesses harmed by COVID-19. On December 27, 2020, the Consolidated Appropriations Act, 2021 was signed into law in order to provide further stimulus and support to those affected by the COVID-19 pandemic. The Company has not and does not plan on obtaining funding from such loans. The Company does not believe the CARES Act or the Consolidated Appropriations Act, 2021 will have a material impact on its financial condition, results of operations, or liquidity.&lt;/p&gt;</lyra:COVID19PandemicAndCARESActPolicyTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="F_000270" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification (&amp;#8220;ASC&amp;#8221;) and Accounting Standards Updates (&amp;#8220;ASU&amp;#8221;) of the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;). &lt;/p&gt;
</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:ConsolidationPolicyTextBlock id="F_000271" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements include the accounts of Lyra Therapeutics, Inc. and its wholly owned subsidiary Lyra Therapeutics Security Corporation, which was incorporated in December 2018. All intercompany transactions and balances have been eliminated. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the accompanying consolidated financial statements and notes. &lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:UseOfEstimates id="F_000272" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of the Company&amp;#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&amp;#8217;s management evaluates its estimates, which include but are not limited to management&amp;#8217;s judgments of accrued expenses, fair value of common stock, valuation of share-based awards warrants to purchase common stock and deferred income taxes. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company utilizes significant estimates and assumptions in determining the fair value of its common stock. The Company has utilized various valuation methodologies to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&amp;#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&amp;#8217;s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date. &lt;/p&gt;</us-gaap:UseOfEstimates>
  <lyra:SegmentInformationTextBlock id="F_000273" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Segment Information &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&amp;#8217;s chief operating decision-maker, the Company&amp;#8217;s chief executive officer, views the Company&amp;#8217;s operations and manages its business as a single operating segment, which is the business of developing targeted medicines to address ENT diseases. &lt;/p&gt;</lyra:SegmentInformationTextBlock>
  <us-gaap:ComprehensiveIncomeNoteTextBlock id="F_000274" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Comprehensive Income (Loss) &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. As the Company did not have any element of other comprehensive income (loss), its comprehensive loss is equal to its net loss for all periods presented. &lt;/p&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock id="F_000275" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash held in banks and amounts held in money market funds. Cash equivalents are stated at cost, which approximates market value. &lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents consist of cash held in banks at December&amp;#160;31, 2020 and 2019. &lt;/p&gt;
</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <lyra:RestrictedCashPolicyTextBlock id="F_000276" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Restricted Cash &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had restricted cash of approximately $0.3&amp;#160;million as of December&amp;#160;31, 2020 and 2019, which was held in certificates of deposit at the Company&amp;#8217;s financial institution to secure the Company&amp;#8217;s letter of credit for its facility lease. &lt;/p&gt;</lyra:RestrictedCashPolicyTextBlock>
  <lyra:ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock id="F_000277" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Concentrations of Credit Risk and Off-Balance Sheet Risk &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains all its cash and cash equivalents at a single accredited financial institution, in amounts that exceed federally insured limits.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign exchange hedging arrangements. &lt;/p&gt;</lyra:ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock>
  <lyra:SignificantSuppliersPolicyTextBlock id="F_000278" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Significant Suppliers &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the drug product and associated applicator related to these programs. These programs could be adversely affected by a significant interruption in the supply of the materials required to manufacture the drug product and associated applicator. &lt;/p&gt;</lyra:SignificantSuppliersPolicyTextBlock>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy id="F_000279" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at a measurement date. ASC Topic 820, &lt;font style="font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt; (&amp;#8220;ASC 820&amp;#8221;), establishes a three-level valuation hierarchy for instruments measured at fair value that prioritizes the inputs used to measure fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&amp;#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported or disclosed fair value of the financial instruments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy established by ASC 820 in order of priority are as follows: &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;1&amp;#160;-Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;2 -Inputs other than quoted prices included within Level&amp;#160;1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;3 -Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&amp;#160;3. A financial instrument&amp;#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;An entity may elect to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in net loss. The Company did not elect to measure any financial instruments or other items at fair value. &lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:DerivativesPolicyTextBlock id="F_000280" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Derivative Liabilities &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with certain debt and equity financings, the Company may issue financial instruments in which a derivative instrument is &amp;#8220;embedded.&amp;#8221; Upon issuing the financial instrument, the Company assesses whether the economic characteristics of the embedded derivative are clearly and closely related to the economic characteristics of the remaining component of the financial instrument (i.e., the host contract) and whether a separate, non-embedded instrument with the same terms as the embedded instrument would meet the definition of a derivative instrument. When it is determined that (1)&amp;#160;the embedded derivative possesses economic characteristics that are not clearly and closely related to the economic characteristics of the host contract, and (2)&amp;#160;a separate, stand-alone instrument with the same terms would qualify as a derivative instrument, the embedded derivative is separated from the host contract and carried at fair value until the derivative is settled. Changes in the fair value of the derivative liabilities are recognized as other income (expense) in the consolidated statement of operations and comprehensive loss. &lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
  <us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy id="F_000281" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Classification and Accretion of Redeemable Convertible Preferred Shares &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has classified the redeemable convertible preferred stock outside of stockholders&amp;#8217; deficit in the accompanying consolidated balance sheets in accordance with authoritative guidance for the classification and measurement of redeemable securities as the redeemable convertible preferred stock is redeemable at a determinable price on a fixed date or upon the occurrence of a deemed liquidation event. The carrying values of the redeemable convertible preferred shares are accreted to their redemption values from the date of issuance through the earliest date of redemption. &lt;/p&gt;</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock id="F_000282" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-lived assets consist of property and equipment. The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company did not record any impairment losses on long-lived assets during the years ended December&amp;#160;31, 2020 and 2019. &lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:LeasesOfLesseeDisclosureTextBlock id="F_000283" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Leases &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASU No. 2016-02, &lt;font style="font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt; (&amp;#8220;ASU No. 2016-02&amp;#8221;), became effective January 1, 2019. As of the effective date of ASU No. 2016-02, the Company determines at the inception of an arrangement whether the arrangement contains a lease. If a lease is identified in an arrangement, the Company recognizes a right-of-use asset and liability on its balance sheet and determines whether the lease should be classified as a finance or operating lease. The Company does not recognize assets or liabilities for leases with lease terms of less than 12&amp;#160;months. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the rate implicit in the lease is not readily determinable, the Company utilizes its incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company separates lease and non-lease components when determining which lease payments to include in the calculation of its lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably certain it will exercise the option. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating leases are recorded in &amp;#8220;Operating lease right-of use assets,&amp;#8221; &amp;#8220;Operating lease liabilities&amp;#8221; and &amp;#8220;Operating lease liabilities, net of current portion&amp;#8221; in the Company&amp;#8217;s consolidated balance sheets. The Company did not have any finance leases recorded in its consolidated balance sheet as of December 31, 2020. &lt;/p&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
  <lyra:ResearchAndDevelopmentCostsTextBlock id="F_000284" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and Development Costs &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred. Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, manufacturing expenses, stock-based compensation expense, depreciation of equipment, contract services and other outside expenses. Costs of certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into various research and development contracts with companies both inside and outside of the United States. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&amp;#8217;s estimates. The Company&amp;#8217;s historical accrual estimates have not been materially different from the actual costs. &lt;/p&gt;</lyra:ResearchAndDevelopmentCostsTextBlock>
  <lyra:PatentsCostsPolicyTextBlock id="F_000285" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Patent Costs &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss. &lt;/p&gt;</lyra:PatentsCostsPolicyTextBlock>
  <lyra:AccountingForStockBasedCompensationPolicy id="F_000286" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Accounting for Stock-Based Compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718, &lt;font style="font-style:italic;"&gt;Compensation&amp;#8212;Stock Compensation&lt;/font&gt; (&amp;#8220;ASC 718&amp;#8221;). ASC 718 requires all stock-based payments to employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees. The Company believes the fair value of the stock options granted to non-employees is more reliably determinable than the fair value of the services provided. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Black-Scholes option-pricing model uses the following inputs: the fair value of the Company&amp;#8217;s common stock, the expected volatility of the Company&amp;#8217;s common stock, the expected term of the Company&amp;#8217;s stock options, the risk-free interest rate for a period that approximates the expected term of the Company&amp;#8217;s stock options, and the Company&amp;#8217;s expected dividend yield. Following the closing of the Company&amp;#8217;s IPO, the fair value of the Company&amp;#8217;s common stock is determined based on the quoted market price of its common stock. The Company has historically been a private company and lacks company-specific historical and implied volatility data. Therefore, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to it, including stage of product development, life science industry focus, length of trading history, and similar vesting provisions. The historical volatility data is calculated based on a period of time commensurate with the expected term assumption. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available or until circumstances change, such that the identified entities are no longer representative companies. In the latter case, more suitable, similar entities whose share prices are publicly available would be utilized in the calculation. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&amp;#160;107, &lt;font style="font-style:italic;"&gt;Share-Based Payment&lt;/font&gt;, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid cash dividends and has no current plans to pay any cash dividends on its common stock. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has elected as a policy to recognize forfeitures as they occur as described in ASU No.&amp;#160;2016-09, &lt;font style="font-style:italic;"&gt;Compensation&amp;#8212;Stock Compensation&lt;/font&gt; (&amp;#8220;ASU No.&amp;#160;2016-09&amp;#8221;). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company expenses the fair value of its stock-based compensation awards to employees on a straight-line basis over the requisite service period, which is generally the vesting period. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company follows the provisions of ASU No.&amp;#160;2018-07, &lt;font style="font-style:italic;"&gt;Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting&lt;/font&gt; (&amp;#8220;ASU No.&amp;#160;2018-07&amp;#8221;) which permits the Company to recognize non-employee stock-based compensation costs over the requisite period based on a measurement of fair value on the grant date for each stock-based award. &lt;/p&gt;</lyra:AccountingForStockBasedCompensationPolicy>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="F_000287" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Contingencies &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In accordance with ASC Topic 450, &lt;font style="font-style:italic;"&gt;Contingencies&lt;/font&gt;, the Company records accruals for contingencies and legal proceedings expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If a loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. &lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:GuaranteesTextBlock id="F_000288" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Guarantees &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has identified the guarantees described below as disclosable, in accordance with ASC Topic 460, &lt;font style="font-style:italic;"&gt;Guarantees&lt;/font&gt;. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company&amp;#8217;s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&amp;#8217; and officers&amp;#8217; insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company leases office space under a noncancelable operating lease. The Company has standard indemnification arrangements under the lease that requires it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the lease. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020 and 2019, the Company had not experienced any losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves have been established. &lt;/p&gt;</us-gaap:GuaranteesTextBlock>
  <lyra:DeferredOfferingCostsTextBlock id="F_000289" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Deferred Offering Costs &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&amp;#8217; deficit as a reduction of additional paid-in capital generated as a result of the offering. Should the planned equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statement of operations and comprehensive loss. Deferred offering costs of $0 and $1.1 million are included in other assets in the consolidated balance sheets at December 31, 2020 and 2019, respectively.&lt;/p&gt;</lyra:DeferredOfferingCostsTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock id="F_000290" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Net Loss per Share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company has computed diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, warrants to purchase common stock and redeemable convertible preferred stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive and basic and diluted loss per share have been the same. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share data): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22,127&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,306&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accretion of redeemable convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(115&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(313&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22,242&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,619&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average common shares&amp;#8212;basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,590,205&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;202,093&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributable to common stockholders&amp;#8212;basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.59&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(82.23&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares retroactively adjusted): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A-1 redeemable convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;986,466&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A-2 redeemable convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;773,712&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A-3 redeemable convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;872,031&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A-4 redeemable convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;579,993&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series B redeemable convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,852,177&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,428,886&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;792,439&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,428,886&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,856,818&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="F_000291" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the FASB issued ASU No.&amp;#160;2018-13, &lt;font style="font-style:italic;"&gt;Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement&lt;/font&gt; (&amp;#8220;ASU No.&amp;#160;2018-13&amp;#8221;), which modifies the disclosure requirements on fair value measurements. The Company adopted ASU No. 2018-13 on January&amp;#160;1, 2020. The adoption of ASU 2018-13 did not have a material impact on the Company&amp;#8217;s consolidated financial position, results of operations or cash flows.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the FASB issued ASU No.&amp;#160;2018-15, &lt;font style="font-style:italic;"&gt;Intangibles&amp;#8212;Goodwill and Other&amp;#8212;Internal-Use Software (Subtopic 350-40): Customer&amp;#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/font&gt; (&amp;#8220;ASU No.&amp;#160;2018-15&amp;#8221;), which clarifies the accounting for implementation costs in cloud computing arrangements. The Company adopted ASU No. 2018-15 on January&amp;#160;1, 2020 on a prospective basis. The adoption of ASU 2018-15 did not have a material impact on the Company&amp;#8217;s consolidated financial position, results of operations or cash flows.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <lyra:RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock id="F_000292" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;font style="font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/font&gt; (&amp;#8220;ASU No. 2019-12&amp;#8221;), which makes a number of changes meant to add or clarify guidance on accounting for income taxes. The new guidance will become effective for the Company on January 1, 2022. Early adoption is permitted. The Company currently is evaluating the impact the adoption of ASU 2019-12 will have on its consolidated financial statements.&lt;/p&gt;</lyra:RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="F_000293" contextRef="C_0001327273_20200101_20201231">Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" style="width:49%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" style="width:50%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated Useful Life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:49%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:50%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:49%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer software and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:50%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:49%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:50%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:49%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:50%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shorter of useful life or remaining term of related lease&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consist of the following at December&amp;#160;31, 2020 and 2019 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,277&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,715&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer software and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;650&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;595&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;301&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;301&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;317&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;317&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;498&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;138&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,043&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,066&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,878&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,829&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,165&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;237&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock id="F_000294" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share data): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22,127&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,306&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accretion of redeemable convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(115&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(313&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22,242&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,619&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average common shares&amp;#8212;basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,590,205&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;202,093&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributable to common stockholders&amp;#8212;basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.59&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(82.23&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="F_000295" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares retroactively adjusted): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A-1 redeemable convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;986,466&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A-2 redeemable convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;773,712&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A-3 redeemable convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;872,031&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A-4 redeemable convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;579,993&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series B redeemable convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,852,177&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,428,886&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;792,439&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,428,886&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,856,818&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <lyra:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock id="F_000296" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses and other current liabilities consist of the following at December&amp;#160;31, 2020 and 2019 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payroll and employee related expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,892&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;885&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Third-party research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;381&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,344&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional and consulting fees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;555&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;901&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;149&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued expenses and other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,977&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,240&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</lyra:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock>
  <lyra:SharesOfCommonStockReservedForFutureIssuancesTableTextBlock id="F_000297" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has reserved for future issuances the following shares of common stock as of December 31, 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,888,653&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee stock purchase plan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;150,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,038,653&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</lyra:SharesOfCommonStockReservedForFutureIssuancesTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="F_000298" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense included in the Company&amp;#8217;s consolidated statements of operations and comprehensive loss was as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;229&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,584&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;218&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,813&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;244&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="F_000299" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of each stock option granted to employees, directors and non-employees was estimated on the date of grant using the Black-Scholes option-pricing model, with the following weighted-average assumptions: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="F_000300" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the stock option activity under the Plans for the year ended December 31, 2020 was as follows: &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in&amp;#160;thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;792,439&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.59&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,363&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;763,505&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.16&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,814&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.92&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(124,244&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.30&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,428,886&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.41&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,165&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;626,578&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.30&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,099&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:16.35pt;"&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and expected to vest at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,428,886&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.41&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,165&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock id="F_000301" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of income tax expense computed at the statutory federal income tax rate to income taxes reflected in the consolidated financial statements is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax computed at federal statutory tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development and other tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in deferred tax asset valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(28.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(30.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock id="F_000302" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets as of December&amp;#160;31, 2020 and 2019 consist of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.9%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,729&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,006&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,223&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,652&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;322&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;173&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;661&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;909&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;140&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;280&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total gross deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,075&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41,451&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(35,150&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;624&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;870&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(624&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(870&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(624&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(870&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:LeaseCostTableTextBlock id="F_000303" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of lease cost recorded in the Company&amp;#8217;s consolidated financial statements were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease Cost:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,055&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,053&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;726&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;727&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sublease income&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(368&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease cost, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,781&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,412&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
  <lyra:SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock id="F_000304" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average remaining lease term and discount rate related to the Company&amp;#8217;s operating leases were as follows:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average remaining lease term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;</lyra:SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock>
  <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock id="F_000305" contextRef="C_0001327273_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturity of the Company&amp;#8217;s operating lease liabilities in accordance with ASC 842 as of December 31, 2020 were as follows (in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,095&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,127&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;382&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total maturities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Amount representing interest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(167&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of operating lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,439&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Current portion of operating lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(985&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease liability, net of current portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,454&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
  <dei:EntityIncorporationDateOfIncorporation id="F_000306" contextRef="C_0001327273_20200101_20201231">2005-11-21</dei:EntityIncorporationDateOfIncorporation>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000307" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200504_20200505" decimals="INF" unitRef="U_xbrlishares">4025000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000308" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200504_20200505" decimals="INF" unitRef="U_xbrlishares">525000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharesIssuedPricePerShare id="F_000309" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200505" decimals="INF" unitRef="U_iso4217USD_xbrlishares">16.00</us-gaap:SharesIssuedPricePerShare>
  <lyra:GrossProceedsFromInitialPublicOffering id="F_000310" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200504_20200505" decimals="-5" unitRef="U_iso4217USD">64400000</lyra:GrossProceedsFromInitialPublicOffering>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="F_000311" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200504_20200505" decimals="-5" unitRef="U_iso4217USD">57300000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <lyra:NumberOfPatients id="F_000312" contextRef="C_0001327273_20200311_20200311" decimals="INF" unitRef="U_lyraPatient">67</lyra:NumberOfPatients>
  <us-gaap:RestrictedCash id="F_000313" contextRef="C_0001327273_20201231" decimals="-5" unitRef="U_iso4217USD">300000</us-gaap:RestrictedCash>
  <us-gaap:RestrictedCash id="F_000314" contextRef="C_0001327273_20191231" decimals="-5" unitRef="U_iso4217USD">300000</us-gaap:RestrictedCash>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000315" contextRef="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20200101_20201231">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000316" contextRef="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000317" contextRef="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20200101_20201231">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives id="F_000318" contextRef="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">Shorter of useful life or remaining term of related lease</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <lyra:LeaseLiabilities id="F_000319" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">0</lyra:LeaseLiabilities>
  <lyra:LeaseLiabilities id="F_000320" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">0</lyra:LeaseLiabilities>
  <us-gaap:FinanceLeaseLiability id="F_000321" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:FinanceLeaseLiability>
  <us-gaap:FinanceLeaseLiability id="F_000322" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:FinanceLeaseLiability>
  <us-gaap:DeferredOfferingCosts id="F_000323" contextRef="C_0001327273_20201231" decimals="-6" unitRef="U_iso4217USD">0</us-gaap:DeferredOfferingCosts>
  <us-gaap:DeferredOfferingCosts id="F_000324" contextRef="C_0001327273_20191231" decimals="-5" unitRef="U_iso4217USD">1100000</us-gaap:DeferredOfferingCosts>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment id="F_000325" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">115000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment id="F_000326" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">313000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000327" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-22242000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000328" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-16619000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000329" contextRef="C_0001327273_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lyraSeriesA1RedeemableConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">986466</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000330" contextRef="C_0001327273_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lyraSeriesA2RedeemableConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">773712</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000331" contextRef="C_0001327273_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lyraSeriesA3RedeemableConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">872031</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000332" contextRef="C_0001327273_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lyraSeriesA4RedeemableConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">579993</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000333" contextRef="C_0001327273_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lyraSeriesBRedeemableConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">2852177</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000334" contextRef="C_0001327273_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">1428886</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000335" contextRef="C_0001327273_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">792439</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000336" contextRef="C_0001327273_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">1428886</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000337" contextRef="C_0001327273_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">6856818</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AssetsFairValueDisclosure id="F_000338" contextRef="C_0001327273_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000339" contextRef="C_0001327273_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure id="F_000340" contextRef="C_0001327273_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure id="F_000341" contextRef="C_0001327273_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:AlternativeInvestmentChangeInValuationTechnique id="F_000342" contextRef="C_0001327273_20201231">false</us-gaap:AlternativeInvestmentChangeInValuationTechnique>
  <us-gaap:AlternativeInvestmentChangeInValuationTechnique id="F_000343" contextRef="C_0001327273_20191231">false</us-gaap:AlternativeInvestmentChangeInValuationTechnique>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000344" contextRef="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231" decimals="-3" unitRef="U_iso4217USD">3277000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000345" contextRef="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20191231" decimals="-3" unitRef="U_iso4217USD">1715000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000346" contextRef="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_lyraComputerSoftwareAndEquipmentMember_20201231" decimals="-3" unitRef="U_iso4217USD">650000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000347" contextRef="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_lyraComputerSoftwareAndEquipmentMember_20191231" decimals="-3" unitRef="U_iso4217USD">595000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000348" contextRef="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231" decimals="-3" unitRef="U_iso4217USD">301000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000349" contextRef="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231" decimals="-3" unitRef="U_iso4217USD">301000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000350" contextRef="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231" decimals="-3" unitRef="U_iso4217USD">317000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000351" contextRef="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231" decimals="-3" unitRef="U_iso4217USD">317000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000352" contextRef="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231" decimals="-3" unitRef="U_iso4217USD">498000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000353" contextRef="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231" decimals="-3" unitRef="U_iso4217USD">138000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000354" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">5043000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000355" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">3066000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000356" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">2878000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000357" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">2829000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000358" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">1892000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000359" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">885000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <lyra:ThirdPartyResearchAndDevelopmentExpensesCurrent id="F_000360" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">381000</lyra:ThirdPartyResearchAndDevelopmentExpensesCurrent>
  <lyra:ThirdPartyResearchAndDevelopmentExpensesCurrent id="F_000361" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">1344000</lyra:ThirdPartyResearchAndDevelopmentExpensesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000362" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">555000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000363" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">901000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:OtherLiabilitiesCurrent id="F_000364" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">149000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent id="F_000365" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">110000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000366" contextRef="C_0001327273_srtRangeAxis_srtMaximumMember_20200110" decimals="INF" unitRef="U_xbrlishares">299300288</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000367" contextRef="C_0001327273_20200110" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesIssued id="F_000368" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesCRedeemableConvertiblePreferredStockMember_20200131" decimals="INF" unitRef="U_xbrlishares">78306611</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:SharesIssuedPricePerShare id="F_000369" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesCRedeemableConvertiblePreferredStockMember_20200131" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.38811</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock id="F_000370" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesCRedeemableConvertiblePreferredStockMember_20200101_20200131" decimals="-5" unitRef="U_iso4217USD">30400000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
  <us-gaap:CommonStockSharesAuthorized id="F_000371" contextRef="C_0001327273_20200110" decimals="INF" unitRef="U_xbrlishares">400000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000372" contextRef="C_0001327273_20200110" decimals="3" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000373" contextRef="C_0001327273_20200505" decimals="INF" unitRef="U_xbrlishares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000374" contextRef="C_0001327273_20200505" decimals="3" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="F_000375" contextRef="C_0001327273_20200505" decimals="INF" unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000376" contextRef="C_0001327273_20200505" decimals="3" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:CommonStockVotingRights id="F_000377" contextRef="C_0001327273_20200101_20201231">The holders of common stock are entitled to one vote for each share held.</us-gaap:CommonStockVotingRights>
  <lyra:CommonStockVotingRightsNumberOfVotes id="F_000378" contextRef="C_0001327273_20200101_20201231" decimals="INF" unitRef="U_lyraVote">1</lyra:CommonStockVotingRightsNumberOfVotes>
  <us-gaap:StockholdersEquityReverseStockSplit id="F_000379" contextRef="C_0001327273_20200101_20201231">one-for-34.483</us-gaap:StockholdersEquityReverseStockSplit>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="F_000380" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200505" decimals="INF" unitRef="U_xbrlishares">8335248</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="F_000381" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200505" decimals="INF" unitRef="U_xbrlishares">313794</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices id="F_000382" contextRef="C_0001327273_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200504_20200505" decimals="INF" unitRef="U_xbrlishares">19661</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:CommonStockSharesIssued id="F_000383" contextRef="C_0001327273_us-gaapSubsidiarySaleOfStockAxis_lyraNonEmployeeCompensationMember_20201231" decimals="INF" unitRef="U_xbrlishares">5000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000384" contextRef="C_0001327273_us-gaapOptionIndexedToIssuersEquityTypeAxis_us-gaapEmployeeStockOptionMember_20201231" decimals="INF" unitRef="U_xbrlishares">2888653</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000385" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_us-gaapEmployeeStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">150000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000386" contextRef="C_0001327273_20201231" decimals="INF" unitRef="U_xbrlishares">3038653</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="F_000387" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">681256</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="F_000388" contextRef="C_0001327273_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">8.63</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="F_000389" contextRef="C_0001327273_us-gaapStatementClassOfStockAxis_lyraSeriesCRedeemableConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">700000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:CommonStockSharesIssued id="F_000390" contextRef="C_0001327273_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200531" decimals="INF" unitRef="U_xbrlishares">313794</us-gaap:CommonStockSharesIssued>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000391" contextRef="C_0001327273_us-gaapPlanNameAxis_lyraTwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember_20160201_20160229" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000392" contextRef="C_0001327273_us-gaapPlanNameAxis_lyraTwentyThousandTwentyIncentiveAwardPlanMember_20200430" decimals="INF" unitRef="U_xbrlishares">2100000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued id="F_000393" contextRef="C_0001327273_us-gaapPlanNameAxis_lyraTwentyThousandTwentyIncentiveAwardPlanMember_20200401_20200430" decimals="INF" unitRef="U_xbrlishares">8800000</lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued>
  <lyra:PercentageOfCommonSharesIncreaseAutomaticallyInEachYear id="F_000394" contextRef="C_0001327273_us-gaapPlanNameAxis_lyraTwentyThousandTwentyIncentiveAwardPlanMember_20200401_20200430" decimals="2" unitRef="U_xbrlipure">0.04</lyra:PercentageOfCommonSharesIncreaseAutomaticallyInEachYear>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="F_000395" contextRef="C_0001327273_us-gaapPlanNameAxis_lyraTwentyThousandTwentyIncentiveAwardPlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">1459767</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="F_000396" contextRef="C_0001327273_srtRangeAxis_srtMinimumMember_20200101_20201231">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="F_000397" contextRef="C_0001327273_srtRangeAxis_srtMaximumMember_20200101_20201231">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000398" contextRef="C_0001327273_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">229000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000399" contextRef="C_0001327273_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">26000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000400" contextRef="C_0001327273_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1584000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000401" contextRef="C_0001327273_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">218000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000402" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1813000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000403" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">244000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000404" contextRef="C_0001327273_us-gaapAwardTypeAxis_lyraMilestoneBasedAwardsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000405" contextRef="C_0001327273_us-gaapAwardTypeAxis_lyraMilestoneBasedAwardsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000406" contextRef="C_0001327273_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000407" contextRef="C_0001327273_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000408" contextRef="C_0001327273_20200101_20201231">P6Y0M0D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000409" contextRef="C_0001327273_20190101_20191231">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000410" contextRef="C_0001327273_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.807</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000411" contextRef="C_0001327273_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.768</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000412" contextRef="C_0001327273_20191231" decimals="INF" unitRef="U_xbrlishares">792439</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000413" contextRef="C_0001327273_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">763505</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000414" contextRef="C_0001327273_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">2814</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000415" contextRef="C_0001327273_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">124244</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000416" contextRef="C_0001327273_20201231" decimals="INF" unitRef="U_xbrlishares">1428886</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="F_000417" contextRef="C_0001327273_20201231" decimals="INF" unitRef="U_xbrlishares">626578</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber id="F_000418" contextRef="C_0001327273_20201231" decimals="INF" unitRef="U_xbrlishares">1428886</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000419" contextRef="C_0001327273_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">6.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000420" contextRef="C_0001327273_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">14.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000421" contextRef="C_0001327273_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">2.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000422" contextRef="C_0001327273_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">9.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000423" contextRef="C_0001327273_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">10.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="F_000424" contextRef="C_0001327273_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">9.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice id="F_000425" contextRef="C_0001327273_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">10.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000426" contextRef="C_0001327273_20190101_20191231">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000427" contextRef="C_0001327273_20200101_20201231">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="F_000428" contextRef="C_0001327273_20200101_20201231">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 id="F_000429" contextRef="C_0001327273_20200101_20201231">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000430" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">3363000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000431" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">5165000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="F_000432" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">3099000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue id="F_000433" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">5165000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000434" contextRef="C_0001327273_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">9.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000435" contextRef="C_0001327273_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">3.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="F_000436" contextRef="C_0001327273_20200101_20201231" decimals="0" unitRef="U_iso4217USD">27000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="F_000437" contextRef="C_0001327273_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="F_000438" contextRef="C_0001327273_20201231" decimals="-5" unitRef="U_iso4217USD">6200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="F_000439" contextRef="C_0001327273_us-gaapAwardTypeAxis_lyraRevenueBasedMilestoneAwardsMember_20201231" decimals="0" unitRef="U_iso4217USD">36000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000440" contextRef="C_0001327273_20200101_20201231">P3Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000441" contextRef="C_0001327273_us-gaapPlanNameAxis_lyraTwentyThousandTwentyEmployeeStockPurchasePlanMember_20200430" decimals="INF" unitRef="U_xbrlishares">150000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued id="F_000442" contextRef="C_0001327273_us-gaapPlanNameAxis_lyraTwentyThousandTwentyEmployeeStockPurchasePlanMember_20200401_20200430" decimals="INF" unitRef="U_xbrlishares">987500</lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued>
  <lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear id="F_000443" contextRef="C_0001327273_us-gaapPlanNameAxis_lyraTwentyThousandTwentyEmployeeStockPurchasePlanMember_20200401_20200430" decimals="3" unitRef="U_xbrlipure">0.005</lyra:AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear>
  <lyra:PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock id="F_000444" contextRef="C_0001327273_us-gaapPlanNameAxis_lyraTwentyThousandTwentyEmployeeStockPurchasePlanMember_20200401_20200430" decimals="2" unitRef="U_xbrlipure">0.85</lyra:PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty id="F_000445" contextRef="C_0001327273_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember_20200101_20201231" decimals="0" unitRef="U_iso4217USD">0</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty id="F_000446" contextRef="C_0001327273_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">50000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <lyra:DueFromRelatedPartiesDuringPeriod id="F_000447" contextRef="C_0001327273_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_lyraArsenalMedicalIncorporationMember_20190101_20191231" decimals="-2" unitRef="U_iso4217USD">300</lyra:DueFromRelatedPartiesDuringPeriod>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000448" contextRef="C_0001327273_20200101_20201231" decimals="0" unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000449" contextRef="C_0001327273_20190101_20191231" decimals="0" unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000450" contextRef="C_0001327273_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000451" contextRef="C_0001327273_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential id="F_000452" contextRef="C_0001327273_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.020</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential id="F_000453" contextRef="C_0001327273_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="F_000454" contextRef="C_0001327273_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.054</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="F_000455" contextRef="C_0001327273_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.062</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch id="F_000456" contextRef="C_0001327273_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.026</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch id="F_000457" contextRef="C_0001327273_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.038</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000458" contextRef="C_0001327273_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.284</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000459" contextRef="C_0001327273_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.307</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent id="F_000460" contextRef="C_0001327273_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent id="F_000461" contextRef="C_0001327273_20190101_20191231" decimals="3" unitRef="U_xbrlipure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000462" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">35729000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000463" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">30006000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment id="F_000464" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">5223000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment id="F_000465" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">4652000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="F_000466" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">322000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="F_000467" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">173000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <lyra:DeferredTaxAssetsOperatingLeaseLiabilities id="F_000468" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">661000</lyra:DeferredTaxAssetsOperatingLeaseLiabilities>
  <lyra:DeferredTaxAssetsOperatingLeaseLiabilities id="F_000469" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">909000</lyra:DeferredTaxAssetsOperatingLeaseLiabilities>
  <us-gaap:DeferredTaxAssetsOther id="F_000470" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">140000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsOther id="F_000471" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">280000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsGross id="F_000472" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">42075000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross id="F_000473" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">36020000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000474" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">41451000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000475" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">35150000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsNet id="F_000476" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">624000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsNet id="F_000477" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">870000</us-gaap:DeferredTaxAssetsNet>
  <lyra:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets id="F_000478" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">624000</lyra:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
  <lyra:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets id="F_000479" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">870000</lyra:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
  <us-gaap:DeferredIncomeTaxLiabilities id="F_000480" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">624000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:DeferredIncomeTaxLiabilities id="F_000481" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">870000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:OperatingLossCarryforwards id="F_000482" contextRef="C_0001327273_us-gaapTaxCreditCarryforwardAxis_us-gaapDomesticCountryMember_20201231" decimals="-5" unitRef="U_iso4217USD">91400000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwardsLimitationsOnUse id="F_000483" contextRef="C_0001327273_us-gaapTaxCreditCarryforwardAxis_us-gaapDomesticCountryMember_20200101_20201231">offset future income tax liabilities and expire at various dates through 2037</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
  <us-gaap:OperatingLossCarryforwards id="F_000484" contextRef="C_0001327273_srtRangeAxis_srtMinimumMember_us-gaapTaxCreditCarryforwardAxis_us-gaapDomesticCountryMember_20201231" decimals="-5" unitRef="U_iso4217USD">44000000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwardsLimitationsOnUse id="F_000485" contextRef="C_0001327273_us-gaapTaxCreditCarryforwardAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">offset future income tax liabilities and expire at various dates through 2040</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
  <us-gaap:OperatingLossCarryforwards id="F_000486" contextRef="C_0001327273_us-gaapTaxCreditCarryforwardAxis_us-gaapStateAndLocalJurisdictionMember_20201231" decimals="-5" unitRef="U_iso4217USD">116000000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="F_000487" contextRef="C_0001327273_us-gaapTaxCreditCarryforwardAxis_us-gaapDomesticCountryMember_20201231" decimals="-5" unitRef="U_iso4217USD">3600000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="F_000488" contextRef="C_0001327273_us-gaapTaxCreditCarryforwardAxis_us-gaapDomesticCountryMember_20191231" decimals="-5" unitRef="U_iso4217USD">3200000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="F_000489" contextRef="C_0001327273_us-gaapTaxCreditCarryforwardAxis_us-gaapStateAndLocalJurisdictionMember_20201231" decimals="-5" unitRef="U_iso4217USD">2000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="F_000490" contextRef="C_0001327273_us-gaapTaxCreditCarryforwardAxis_us-gaapStateAndLocalJurisdictionMember_20191231" decimals="-5" unitRef="U_iso4217USD">1800000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit id="F_000491" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="F_000492" contextRef="C_0001327273_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">6300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="F_000493" contextRef="C_0001327273_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">5100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued id="F_000494" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued id="F_000495" contextRef="C_0001327273_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued>
  <us-gaap:OperatingLeaseExpense id="F_000496" contextRef="C_0001327273_20171101_20171130" decimals="-5" unitRef="U_iso4217USD">1000000</us-gaap:OperatingLeaseExpense>
  <us-gaap:SecuredDebt id="F_000497" contextRef="C_0001327273_us-gaapShortTermDebtTypeAxis_us-gaapLetterOfCreditMember_20171130" decimals="-5" unitRef="U_iso4217USD">300000</us-gaap:SecuredDebt>
  <us-gaap:RestrictedCashNoncurrent id="F_000498" contextRef="C_0001327273_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapCertificatesOfDepositMember_20171130" decimals="-5" unitRef="U_iso4217USD">300000</us-gaap:RestrictedCashNoncurrent>
  <us-gaap:AreaOfRealEstateProperty id="F_000499" contextRef="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_lyraOfficeAndLaboratoryMember_20070831" decimals="INF" unitRef="U_utrsqft">22343</us-gaap:AreaOfRealEstateProperty>
  <lyra:LesseeOperatingLeaseExtendedLeaseTerm id="F_000500" contextRef="C_0001327273_20171101_20171130">2023-04</lyra:LesseeOperatingLeaseExtendedLeaseTerm>
  <lyra:LeaseInitiationDate id="F_000501" contextRef="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20200101_20201231">2020-04-30</lyra:LeaseInitiationDate>
  <us-gaap:LeaseExpirationDate1 id="F_000502" contextRef="C_0001327273_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20200101_20201231">2024-06-30</us-gaap:LeaseExpirationDate1>
  <us-gaap:OperatingLeaseCost id="F_000503" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1055000</us-gaap:OperatingLeaseCost>
  <us-gaap:OperatingLeaseCost id="F_000504" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1053000</us-gaap:OperatingLeaseCost>
  <us-gaap:VariableLeaseCost id="F_000505" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">726000</us-gaap:VariableLeaseCost>
  <us-gaap:VariableLeaseCost id="F_000506" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">727000</us-gaap:VariableLeaseCost>
  <us-gaap:SubleaseIncome id="F_000507" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">368000</us-gaap:SubleaseIncome>
  <us-gaap:LeaseCost id="F_000508" contextRef="C_0001327273_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1781000</us-gaap:LeaseCost>
  <us-gaap:LeaseCost id="F_000509" contextRef="C_0001327273_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1412000</us-gaap:LeaseCost>
  <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 id="F_000510" contextRef="C_0001327273_20201231">P2Y7M3D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
  <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent id="F_000511" contextRef="C_0001327273_20201231" decimals="3" unitRef="U_xbrlipure">0.055</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths id="F_000512" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">1095000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo id="F_000513" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">1127000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree id="F_000514" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">382000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour id="F_000515" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue id="F_000516" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">2606000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
  <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount id="F_000517" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">167000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
  <us-gaap:OperatingLeaseLiability id="F_000518" contextRef="C_0001327273_20201231" decimals="-3" unitRef="U_iso4217USD">2439000</us-gaap:OperatingLeaseLiability>
  <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent id="F_000519" contextRef="C_0001327273_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.03</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
  <us-gaap:DefinedContributionPlanCostRecognized id="F_000520" contextRef="C_0001327273_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:DefinedContributionPlanCostRecognized id="F_000521" contextRef="C_0001327273_20190101_20191231" decimals="-6" unitRef="U_iso4217USD">0</us-gaap:DefinedContributionPlanCostRecognized>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>24
<FILENAME>lyra-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-09T01:56:07.7019343+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 5245d08838e248bbac25af17c6adc28d -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:lyra="http://lyratherapeutics.com/20201231" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://lyratherapeutics.com/20201231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://lyratherapeutics.com/20201231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lyra-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lyra-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lyra-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lyra-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" id="Role_StatementCondensedConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="Role_StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAudited" id="Role_StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAudited">
        <link:definition>100040 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&apos; Equity (Deficit) (audited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalAudited" id="Role_StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalAudited">
        <link:definition>100050 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&apos; Equity (Deficit) (Parenthetical) (audited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" id="Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>100060 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentation" id="Role_DisclosureOrganizationAndBasisOfPresentation">
        <link:definition>100070 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100090 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>100100 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>100110 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStock" id="Role_DisclosureRedeemableConvertiblePreferredStock">
        <link:definition>100120 - Disclosure - Redeemable Convertible Preferred Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePreferredAndCommonStock" id="Role_DisclosurePreferredAndCommonStock">
        <link:definition>100130 - Disclosure - Preferred and Common Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpense" id="Role_DisclosureStockBasedCompensationExpense">
        <link:definition>100140 - Disclosure - Stock-Based Compensation Expense</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureRelatedParties" id="Role_DisclosureRelatedParties">
        <link:definition>100150 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100160 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100170 - Disclosure - Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureRetirementPlan" id="Role_DisclosureRetirementPlan">
        <link:definition>100180 - Disclosure - Retirement Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100190 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100200 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>100210 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>100220 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePreferredAndCommonStockTables" id="Role_DisclosurePreferredAndCommonStockTables">
        <link:definition>100230 - Disclosure - Preferred and Common Stock (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseTables" id="Role_DisclosureStockBasedCompensationExpenseTables">
        <link:definition>100240 - Disclosure - Stock-Based Compensation Expense (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100250 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100260 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" id="Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>100270 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100280 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
        <link:definition>100290 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100300 - Disclosure - Summary of Significant Accounting Policies - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>100310 - Disclosure - Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100320 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
        <link:definition>100330 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails">
        <link:definition>100340 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>100350 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" id="Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>100360 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails" id="Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails">
        <link:definition>100370 - Disclosure - Preferred and Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails" id="Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails">
        <link:definition>100380 - Disclosure - Preferred and Common Stock - Schedule of Common Stock Reserved for Future Issuances (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails">
        <link:definition>100390 - Disclosure - Stock-Based Compensation Expense - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails" id="Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails">
        <link:definition>100400 - Disclosure - Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails" id="Role_DisclosureStockBasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails">
        <link:definition>100410 - Disclosure - Stock-Based Compensation Expense - Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails" id="Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails">
        <link:definition>100420 - Disclosure - Stock-Based Compensation Expense - Summary of Stock Option Activity Under Plans (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" id="Role_DisclosureRelatedPartiesAdditionalInformationDetails">
        <link:definition>100430 - Disclosure - Related Parties - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100440 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>100450 - Disclosure - Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100460 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="Role_DisclosureLeasesAdditionalInformationDetails">
        <link:definition>100470 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails" id="Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails">
        <link:definition>100480 - Disclosure - Leases - Schedule of Components of Lease Cost (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToOperatingLeasesDetails" id="Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToOperatingLeasesDetails">
        <link:definition>100490 - Disclosure - Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails" id="Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails">
        <link:definition>100500 - Disclosure - Leases - Summary of Maturity of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails2" id="Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails2">
        <link:definition>100510 - Disclosure - Leases - Summary of Maturity of Operating Lease Liabilities (Details)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails" id="Role_DisclosureRetirementPlanAdditionalInformationDetails">
        <link:definition>100520 - Disclosure - Retirement Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="lyra_AccruedExpensesAndOtherLiabilitiesCurrent" name="AccruedExpensesAndOtherLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="lyra_SeriesA1RedeemableConvertiblePreferredStockMember" name="SeriesA1RedeemableConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="lyra_SeriesA2RedeemableConvertiblePreferredStockMember" name="SeriesA2RedeemableConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="lyra_SeriesA3RedeemableConvertiblePreferredStockMember" name="SeriesA3RedeemableConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="lyra_SeriesA4RedeemableConvertiblePreferredStockMember" name="SeriesA4RedeemableConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="lyra_SeriesBRedeemableConvertiblePreferredStockMember" name="SeriesBRedeemableConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="lyra_SeriesCRedeemableConvertiblePreferredStockMember" name="SeriesCRedeemableConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="lyra_VestingOfRestrictedCommonStockValue" name="VestingOfRestrictedCommonStockValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="lyra_VestingOfRestrictedCommonStockShares" name="VestingOfRestrictedCommonStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants" name="IssuanceOfCommonStockValueUponExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants" name="IssuanceOfCommonStockSharesUponExerciseOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="lyra_TemporaryEquityStockIssuanceCosts" name="TemporaryEquityStockIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="lyra_ReserveForUncollectibleAccounts" name="ReserveForUncollectibleAccounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" name="IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="lyra_IncreaseDecreaseInOperatingLeaseLiability" name="IncreaseDecreaseInOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="lyra_AllocationOfRedeemableConvertiblePreferredStockToCommonStockWarrant" name="AllocationOfRedeemableConvertiblePreferredStockToCommonStockWarrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="lyra_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue" name="AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="lyra_DeferredOfferingCostsIncurredButNotYetPaid" name="DeferredOfferingCostsIncurredButNotYetPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" name="AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="lyra_COVID19PandemicAndCARESActPolicyTextBlock" name="COVID19PandemicAndCARESActPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="lyra_SegmentInformationTextBlock" name="SegmentInformationTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="lyra_RestrictedCashPolicyTextBlock" name="RestrictedCashPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" name="ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="lyra_SignificantSuppliersPolicyTextBlock" name="SignificantSuppliersPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="lyra_ResearchAndDevelopmentCostsTextBlock" name="ResearchAndDevelopmentCostsTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="lyra_PatentsCostsPolicyTextBlock" name="PatentsCostsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="lyra_AccountingForStockBasedCompensationPolicy" name="AccountingForStockBasedCompensationPolicy" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="lyra_DeferredOfferingCostsTextBlock" name="DeferredOfferingCostsTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" name="RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" name="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock" name="SharesOfCommonStockReservedForFutureIssuancesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock" name="SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="lyra_OrganizationAndBasisOfPresentationLineItems" name="OrganizationAndBasisOfPresentationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="lyra_OrganizationAndBasisOfPresentationTable" name="OrganizationAndBasisOfPresentationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="lyra_GrossProceedsFromInitialPublicOffering" name="GrossProceedsFromInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="lyra_NumberOfPatients" name="NumberOfPatients" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="lyra_LeaseLiabilities" name="LeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="lyra_ComputerSoftwareAndEquipmentMember" name="ComputerSoftwareAndEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent" name="ThirdPartyResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="lyra_NonEmployeeCompensationMember" name="NonEmployeeCompensationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="lyra_CommonStockVotingRightsNumberOfVotes" name="CommonStockVotingRightsNumberOfVotes" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember" name="TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="lyra_TwentyThousandTwentyIncentiveAwardPlanMember" name="TwentyThousandTwentyIncentiveAwardPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="lyra_MilestoneBasedAwardsMember" name="MilestoneBasedAwardsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="lyra_RevenueBasedMilestoneAwardsMember" name="RevenueBasedMilestoneAwardsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember" name="TwentyThousandTwentyEmployeeStockPurchasePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" name="AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" name="PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" name="AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" name="PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="lyra_ArsenalMedicalIncorporationMember" name="ArsenalMedicalIncorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="lyra_DueFromRelatedPartiesDuringPeriod" name="DueFromRelatedPartiesDuringPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="lyra_DeferredTaxAssetsOperatingLeaseLiabilities" name="DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="lyra_LesseeOperatingLeaseExtendedLeaseTerm" name="LesseeOperatingLeaseExtendedLeaseTerm" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="lyra_LeaseInitiationDate" name="LeaseInitiationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="lyra_OfficeAndLaboratoryMember" name="OfficeAndLaboratoryMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>25
<FILENAME>lyra-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-09T01:56:07.7019343+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 5245d08838e248bbac25af17c6adc28d -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="lyra-20201231.xsd#TemplateLink" roleURI="http://lyratherapeutics.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" xlink:href="lyra-20201231.xsd#Role_StatementCondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:type="locator" xlink:label="lyra_AccruedExpensesAndOtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="lyra_AccruedExpensesAndOtherLiabilitiesCurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10190.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="lyra-20201231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="lyra-20201231.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
    <link:loc xlink:href="lyra-20201231.xsd#lyra_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator" xlink:label="lyra_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:type="locator" xlink:label="lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_ReserveForUncollectibleAccounts" xlink:type="locator" xlink:label="lyra_ReserveForUncollectibleAccounts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lyra_ReserveForUncollectibleAccounts" order="10130.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="10140.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10150.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" order="10160.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="10170.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lyra_IncreaseDecreaseInOperatingLeaseLiability" order="10200.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="lyra-20201231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:type="locator" xlink:label="lyra_AccruedExpensesAndOtherLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lyra_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lyra_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lyra_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lyra_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="locator" xlink:label="lyra_DeferredTaxAssetsOperatingLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:type="locator" xlink:label="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="lyra_DeferredTaxAssetsOperatingLeaseLiabilities" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10100.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_SubleaseIncome" order="10030.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails2" xlink:href="lyra-20201231.xsd#Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails2">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>26
<FILENAME>lyra-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-09T01:56:07.7029348+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 5245d08838e248bbac25af17c6adc28d -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="lyra-20201231.xsd#TemplateLink" roleURI="http://lyratherapeutics.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" xlink:href="lyra-20201231.xsd#Role_StatementCondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:type="locator" xlink:label="lyra_AccruedExpensesAndOtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesCRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesCRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesBRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesBRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesA4RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesA4RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesA3RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesA3RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesA2RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesA2RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesA1RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesA1RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10200.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesA1RedeemableConvertiblePreferredStockMember" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesA2RedeemableConvertiblePreferredStockMember" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesA3RedeemableConvertiblePreferredStockMember" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesA4RedeemableConvertiblePreferredStockMember" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesBRedeemableConvertiblePreferredStockMember" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesCRedeemableConvertiblePreferredStockMember" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="lyra_AccruedExpensesAndOtherLiabilitiesCurrent" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11850.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="lyra-20201231.xsd#Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesCRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesCRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesBRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesBRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesA4RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesA4RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesA3RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesA3RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesA2RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesA2RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesA1RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesA1RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesA1RedeemableConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesA2RedeemableConvertiblePreferredStockMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesA3RedeemableConvertiblePreferredStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesA4RedeemableConvertiblePreferredStockMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesBRedeemableConvertiblePreferredStockMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesCRedeemableConvertiblePreferredStockMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="11460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="11740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="12020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="12300.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAudited" xlink:href="lyra-20201231.xsd#Role_StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAudited" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants" xlink:type="locator" xlink:label="lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants" xlink:type="locator" xlink:label="lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_VestingOfRestrictedCommonStockShares" xlink:type="locator" xlink:label="lyra_VestingOfRestrictedCommonStockShares" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_VestingOfRestrictedCommonStockValue" xlink:type="locator" xlink:label="lyra_VestingOfRestrictedCommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesCRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesCRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesCRedeemableConvertiblePreferredStockMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" order="11680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue" order="11720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="11840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="12000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="12020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="12160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_VestingOfRestrictedCommonStockValue" order="12320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_VestingOfRestrictedCommonStockShares" order="12380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants" order="12480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants" order="12540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="12640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12800.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalAudited" xlink:href="lyra-20201231.xsd#Role_StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalAudited" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalAudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_TemporaryEquityStockIssuanceCosts" xlink:type="locator" xlink:label="lyra_TemporaryEquityStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesCRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesCRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesCRedeemableConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_TemporaryEquityStockIssuanceCosts" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10220.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="lyra-20201231.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
    <link:loc xlink:href="lyra-20201231.xsd#lyra_DeferredOfferingCostsIncurredButNotYetPaid" xlink:type="locator" xlink:label="lyra_DeferredOfferingCostsIncurredButNotYetPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue" xlink:type="locator" xlink:label="lyra_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_AllocationOfRedeemableConvertiblePreferredStockToCommonStockWarrant" xlink:type="locator" xlink:label="lyra_AllocationOfRedeemableConvertiblePreferredStockToCommonStockWarrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1" xlink:type="locator" xlink:label="us-gaap_StockIssued1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator" xlink:label="lyra_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:type="locator" xlink:label="lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_ReserveForUncollectibleAccounts" xlink:type="locator" xlink:label="lyra_ReserveForUncollectibleAccounts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10210.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lyra_ReserveForUncollectibleAccounts" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lyra_IncreaseDecreaseInOperatingLeaseLiability" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="11680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_StockIssued1" order="11800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lyra_AllocationOfRedeemableConvertiblePreferredStockToCommonStockWarrant" order="11840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lyra_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue" order="11880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="11920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lyra_DeferredOfferingCostsIncurredButNotYetPaid" order="11960.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:href="lyra-20201231.xsd#lyra_NumberOfPatients" xlink:type="locator" xlink:label="lyra_NumberOfPatients" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_GrossProceedsFromInitialPublicOffering" xlink:type="locator" xlink:label="lyra_GrossProceedsFromInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_OrganizationAndBasisOfPresentationTable" xlink:type="locator" xlink:label="lyra_OrganizationAndBasisOfPresentationTable" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_OrganizationAndBasisOfPresentationLineItems" xlink:type="locator" xlink:label="lyra_OrganizationAndBasisOfPresentationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="lyra_OrganizationAndBasisOfPresentationTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lyra_OrganizationAndBasisOfPresentationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lyra_OrganizationAndBasisOfPresentationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="lyra_GrossProceedsFromInitialPublicOffering" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="lyra_NumberOfPatients" order="10630.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesBRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesBRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesA4RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesA4RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesA3RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesA3RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesA2RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesA2RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesA1RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesA1RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lyra_SeriesA1RedeemableConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lyra_SeriesA2RedeemableConvertiblePreferredStockMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lyra_SeriesA3RedeemableConvertiblePreferredStockMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lyra_SeriesA4RedeemableConvertiblePreferredStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lyra_SeriesBRedeemableConvertiblePreferredStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10220.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="lyra-20201231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_ComputerSoftwareAndEquipmentMember" xlink:type="locator" xlink:label="lyra_ComputerSoftwareAndEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lyra_ComputerSoftwareAndEquipmentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10500.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesCRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesCRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesCRedeemableConvertiblePreferredStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="10310.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails" xlink:href="lyra-20201231.xsd#Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_GrossProceedsFromInitialPublicOffering" xlink:type="locator" xlink:label="lyra_GrossProceedsFromInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_CommonStockVotingRightsNumberOfVotes" xlink:type="locator" xlink:label="lyra_CommonStockVotingRightsNumberOfVotes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesCRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesCRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_NonEmployeeCompensationMember" xlink:type="locator" xlink:label="lyra_NonEmployeeCompensationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:type="locator" xlink:label="srt_DirectorMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_TitleOfIndividualAxis" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lyra_NonEmployeeCompensationMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesCRedeemableConvertiblePreferredStockMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_CommonStockVotingRightsNumberOfVotes" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_GrossProceedsFromInitialPublicOffering" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="11350.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails" xlink:href="lyra-20201231.xsd#Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_EmployeeStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseAdditionalInformationDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseAdditionalInformationDetails">
    <link:loc xlink:href="lyra-20201231.xsd#lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" xlink:type="locator" xlink:label="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" xlink:type="locator" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" xlink:type="locator" xlink:label="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" xlink:type="locator" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_RevenueBasedMilestoneAwardsMember" xlink:type="locator" xlink:label="lyra_RevenueBasedMilestoneAwardsMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_MilestoneBasedAwardsMember" xlink:type="locator" xlink:label="lyra_MilestoneBasedAwardsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_TwentyThousandTwentyIncentiveAwardPlanMember" xlink:type="locator" xlink:label="lyra_TwentyThousandTwentyIncentiveAwardPlanMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lyra_TwentyThousandTwentyIncentiveAwardPlanMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lyra_MilestoneBasedAwardsMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lyra_RevenueBasedMilestoneAwardsMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" order="11150.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureRelatedPartiesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails">
    <link:loc xlink:href="lyra-20201231.xsd#lyra_DueFromRelatedPartiesDuringPeriod" xlink:type="locator" xlink:label="lyra_DueFromRelatedPartiesDuringPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_ArsenalMedicalIncorporationMember" xlink:type="locator" xlink:label="lyra_ArsenalMedicalIncorporationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:type="locator" xlink:label="srt_DirectorMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_DirectorMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="lyra_ArsenalMedicalIncorporationMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="lyra_DueFromRelatedPartiesDuringPeriod" order="10250.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="lyra-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:type="locator" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_DomesticCountryMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="srt_RangeAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" order="10870.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_LeaseInitiationDate" xlink:type="locator" xlink:label="lyra_LeaseInitiationDate" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_LesseeOperatingLeaseExtendedLeaseTerm" xlink:type="locator" xlink:label="lyra_LesseeOperatingLeaseExtendedLeaseTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebt" xlink:type="locator" xlink:label="us-gaap_SecuredDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_OfficeAndLaboratoryMember" xlink:type="locator" xlink:label="lyra_OfficeAndLaboratoryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:type="locator" xlink:label="us-gaap_CertificatesOfDepositMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:type="locator" xlink:label="us-gaap_LetterOfCreditMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_LetterOfCreditMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lyra_OfficeAndLaboratoryMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecuredDebt" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lyra_LesseeOperatingLeaseExtendedLeaseTerm" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lyra_LeaseInitiationDate" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10640.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>27
<FILENAME>lyra-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-09T01:56:07.7029348+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 5245d08838e248bbac25af17c6adc28d -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:type="locator" xlink:label="lyra_AccruedExpensesAndOtherLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="lyra_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses and other liabilities current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="lyra_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesA1RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesA1RedeemableConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="lyra_SeriesA1RedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-1 redeemable convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_SeriesA1RedeemableConvertiblePreferredStockMember" xlink:to="lyra_SeriesA1RedeemableConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_SeriesA1RedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-1 Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_SeriesA1RedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A1 Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesA2RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesA2RedeemableConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="lyra_SeriesA2RedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-2 redeemable convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_SeriesA2RedeemableConvertiblePreferredStockMember" xlink:to="lyra_SeriesA2RedeemableConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_SeriesA2RedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-2 Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_SeriesA2RedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A2 Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesA3RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesA3RedeemableConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="lyra_SeriesA3RedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-3 redeemable convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_SeriesA3RedeemableConvertiblePreferredStockMember" xlink:to="lyra_SeriesA3RedeemableConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_SeriesA3RedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-3 Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_SeriesA3RedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A3 Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesA4RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesA4RedeemableConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="lyra_SeriesA4RedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-4 redeemable convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_SeriesA4RedeemableConvertiblePreferredStockMember" xlink:to="lyra_SeriesA4RedeemableConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_SeriesA4RedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-4 Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_SeriesA4RedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A4 Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesBRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesBRedeemableConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="lyra_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B redeemable convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_SeriesBRedeemableConvertiblePreferredStockMember" xlink:to="lyra_SeriesBRedeemableConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesCRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesCRedeemableConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="lyra_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C redeemable convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_SeriesCRedeemableConvertiblePreferredStockMember" xlink:to="lyra_SeriesCRedeemableConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series C Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Other Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 11)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total redeemable convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Attributable To Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity (deficit):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; 200,000,000 and 275,000,000 shares authorized at December 31, 2020 and 2019, respectively; 12,932,377 and 230,860 shares issued and outstanding at December 31, 2020 and 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, redeemable convertible preferred stock and stockholders&#8217; equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders&#8212;basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding&#8212;basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares new issues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_VestingOfRestrictedCommonStockValue" xlink:type="locator" xlink:label="lyra_VestingOfRestrictedCommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="lyra_VestingOfRestrictedCommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting of restricted common stock value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_VestingOfRestrictedCommonStockValue" xlink:to="lyra_VestingOfRestrictedCommonStockValue_lbl" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_VestingOfRestrictedCommonStockShares" xlink:type="locator" xlink:label="lyra_VestingOfRestrictedCommonStockShares" />
    <link:label xml:lang="en-US" xlink:label="lyra_VestingOfRestrictedCommonStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting of restricted common stock shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_VestingOfRestrictedCommonStockShares" xlink:to="lyra_VestingOfRestrictedCommonStockShares_lbl" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants" xlink:type="locator" xlink:label="lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants" />
    <link:label xml:lang="en-US" xlink:label="lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of exercise warrants common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants" xlink:to="lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants_lbl" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants" xlink:type="locator" xlink:label="lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants" />
    <link:label xml:lang="en-US" xlink:label="lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock shares upon exercise of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants" xlink:to="lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retained Earnings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity balance, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of common stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of common stock options, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series C redeemable convertiblepreferred stock, net of issuance costsof $201</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series C redeemable convertible preferred stock, net of issuance costs, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of convertible preferred stock to redemption value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, Accretion of convertible preferred stock to redemption value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Accretion To Redemption Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock warrants inconjunction with sale of Series Credeemable convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Warrant Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertiblepreferred stock to common stockupon closing of initial public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock to common stock upon closing of initial public offering, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from initialpublic offering, net of issuancecosts of $7,116</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from initial public offering, net of issuance costs, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_VestingOfRestrictedCommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_VestingOfRestrictedCommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting Of Restricted Common Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_VestingOfRestrictedCommonStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_VestingOfRestrictedCommonStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting Of Restricted Common Stock Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise ofwarrants</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Value Upon Exercise Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of warrants, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Shares Upon Exercise Of Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity balance, Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, Shares</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_TemporaryEquityStockIssuanceCosts" xlink:type="locator" xlink:label="lyra_TemporaryEquityStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="lyra_TemporaryEquityStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_TemporaryEquityStockIssuanceCosts" xlink:to="lyra_TemporaryEquityStockIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_TemporaryEquityStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_TemporaryEquityStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments Of Stock Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_ReserveForUncollectibleAccounts" xlink:type="locator" xlink:label="lyra_ReserveForUncollectibleAccounts" />
    <link:label xml:lang="en-US" xlink:label="lyra_ReserveForUncollectibleAccounts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of uncollectible accounts reserves.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ReserveForUncollectibleAccounts" xlink:to="lyra_ReserveForUncollectibleAccounts_lbl" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease right-of-use asset.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:type="locator" xlink:label="lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" />
    <link:label xml:lang="en-US" xlink:label="lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in accrued expenses and other current liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:to="lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator" xlink:label="lyra_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="lyra_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lyra_IncreaseDecreaseInOperatingLeaseLiability_lbl" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_AllocationOfRedeemableConvertiblePreferredStockToCommonStockWarrant" xlink:type="locator" xlink:label="lyra_AllocationOfRedeemableConvertiblePreferredStockToCommonStockWarrant" />
    <link:label xml:lang="en-US" xlink:label="lyra_AllocationOfRedeemableConvertiblePreferredStockToCommonStockWarrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Allocation of redeemable convertible preferred stock to common stock warrant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_AllocationOfRedeemableConvertiblePreferredStockToCommonStockWarrant" xlink:to="lyra_AllocationOfRedeemableConvertiblePreferredStockToCommonStockWarrant_lbl" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue" xlink:type="locator" xlink:label="lyra_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue" />
    <link:label xml:lang="en-US" xlink:label="lyra_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accretion of redeemable convertible preferred stock to redemption value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue" xlink:to="lyra_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue_lbl" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_DeferredOfferingCostsIncurredButNotYetPaid" xlink:type="locator" xlink:label="lyra_DeferredOfferingCostsIncurredButNotYetPaid" />
    <link:label xml:lang="en-US" xlink:label="lyra_DeferredOfferingCostsIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred offering costs incurred but not yet paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_DeferredOfferingCostsIncurredButNotYetPaid" xlink:to="lyra_DeferredOfferingCostsIncurredButNotYetPaid_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_ReserveForUncollectibleAccounts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reserve for uncollectible accounts</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_ReserveForUncollectibleAccounts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reserve For Uncollectible Accounts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on disposal of assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Disposition Of Assets1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Current Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Expenses And Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the sale of Series C redeemable convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Redeemable Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of offering costs related to sale of Series C redeemable convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Repurchase Of Redeemable Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial public offering, net of underwriting discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of initial public offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Repurchase Of Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents and restricted cash, beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents and restricted cash, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash financing and investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing And Financing Items [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment purchases included in accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1" xlink:type="locator" xlink:label="us-gaap_StockIssued1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued1</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_AllocationOfRedeemableConvertiblePreferredStockToCommonStockWarrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allocation of Series C redeemable convertible preferred stock to common stock warrant</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_AllocationOfRedeemableConvertiblePreferredStockToCommonStockWarrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocation Of Redeemable Convertible Preferred Stock To Common Stock Warrant</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of redeemable convertible preferred stock to redemption value</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Of Redeemable Convertible Preferred Stock To Redemption Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset obtained in exchange of operating lease obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Asset Obtained In Exchange For Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_DeferredOfferingCostsIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs included in accounts payable and accrued expense</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_DeferredOfferingCostsIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs Incurred But Not Yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Description And Basis Of Presentation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses and other current liabilities disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:to="lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Other Current Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:type="locator" xlink:label="us-gaap_PreferredStockTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PreferredStockTextBlock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred and Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Retirement Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_COVID19PandemicAndCARESActPolicyTextBlock" xlink:type="locator" xlink:label="lyra_COVID19PandemicAndCARESActPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="lyra_COVID19PandemicAndCARESActPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">COVID-19 Pandemic and CARES Act.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_COVID19PandemicAndCARESActPolicyTextBlock" xlink:to="lyra_COVID19PandemicAndCARESActPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_COVID19PandemicAndCARESActPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COVID-19 Pandemic and CARES Act</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_COVID19PandemicAndCARESActPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">C O V I D19 Pandemic And C A R E S Act Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SegmentInformationTextBlock" xlink:type="locator" xlink:label="lyra_SegmentInformationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="lyra_SegmentInformationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Segment information text block.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_SegmentInformationTextBlock" xlink:to="lyra_SegmentInformationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_SegmentInformationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_SegmentInformationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNoteTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNoteTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="us-gaap_ComprehensiveIncomeNoteTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNoteTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Note [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_RestrictedCashPolicyTextBlock" xlink:type="locator" xlink:label="lyra_RestrictedCashPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="lyra_RestrictedCashPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted cash.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_RestrictedCashPolicyTextBlock" xlink:to="lyra_RestrictedCashPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_RestrictedCashPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_RestrictedCashPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Policy [Text Block]</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" xlink:type="locator" xlink:label="lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Concentrations of credit risk and off-balance sheet risk.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" xlink:to="lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations Of Credit Risk And Off Balance Sheet Risk</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentrations Of Credit Risk And Off Balance Sheet Risk Policy [Text Block]</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SignificantSuppliersPolicyTextBlock" xlink:type="locator" xlink:label="lyra_SignificantSuppliersPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="lyra_SignificantSuppliersPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant suppliers policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_SignificantSuppliersPolicyTextBlock" xlink:to="lyra_SignificantSuppliersPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_SignificantSuppliersPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Suppliers</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_SignificantSuppliersPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Suppliers Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Financial Instruments Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivatives Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classification and Accretion of Redeemable Convertible Preferred Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Redeemable Preferred Stock Issue Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases Of Lessee Disclosure [Text Block]</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_ResearchAndDevelopmentCostsTextBlock" xlink:type="locator" xlink:label="lyra_ResearchAndDevelopmentCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="lyra_ResearchAndDevelopmentCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure for received credits as included in research and development costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ResearchAndDevelopmentCostsTextBlock" xlink:to="lyra_ResearchAndDevelopmentCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_ResearchAndDevelopmentCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research And Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_ResearchAndDevelopmentCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Costs [Text Block]</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_PatentsCostsPolicyTextBlock" xlink:type="locator" xlink:label="lyra_PatentsCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="lyra_PatentsCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the patents cost policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_PatentsCostsPolicyTextBlock" xlink:to="lyra_PatentsCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_PatentsCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patents Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_PatentsCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Patents Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_AccountingForStockBasedCompensationPolicy" xlink:type="locator" xlink:label="lyra_AccountingForStockBasedCompensationPolicy" />
    <link:label xml:lang="en-US" xlink:label="lyra_AccountingForStockBasedCompensationPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting for stock-based compensation policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_AccountingForStockBasedCompensationPolicy" xlink:to="lyra_AccountingForStockBasedCompensationPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_AccountingForStockBasedCompensationPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting for Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_AccountingForStockBasedCompensationPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting For Stock Based Compensation Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GuaranteesTextBlock" xlink:type="locator" xlink:label="us-gaap_GuaranteesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GuaranteesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Guarantees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteesTextBlock" xlink:to="us-gaap_GuaranteesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GuaranteesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Guarantees [Text Block]</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_DeferredOfferingCostsTextBlock" xlink:type="locator" xlink:label="lyra_DeferredOfferingCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="lyra_DeferredOfferingCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for deferred offering costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_DeferredOfferingCostsTextBlock" xlink:to="lyra_DeferredOfferingCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_DeferredOfferingCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_DeferredOfferingCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Recently issued accounting pronouncements policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Recently Issued Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of accrued expenses and other current liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock" xlink:type="locator" xlink:label="lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares of common stock reserved for future issuances.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock" xlink:to="lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Stock Reserved for Future Issuances</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Of Common Stock Reserved For Future Issuances Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity Under Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Lease Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost Table [Text Block]</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of weighted average remaining lease terms and discount rate related to operating leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock" xlink:to="lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Weighted Average Remaining Lease Terms And Discount Rate Related To Operating Leases Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Maturity of Operating Lease Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_OrganizationAndBasisOfPresentationLineItems" xlink:type="locator" xlink:label="lyra_OrganizationAndBasisOfPresentationLineItems" />
    <link:label xml:lang="en-US" xlink:label="lyra_OrganizationAndBasisOfPresentationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and basis of presentation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="lyra_OrganizationAndBasisOfPresentationLineItems_lbl" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_OrganizationAndBasisOfPresentationTable" xlink:type="locator" xlink:label="lyra_OrganizationAndBasisOfPresentationTable" />
    <link:label xml:lang="en-US" xlink:label="lyra_OrganizationAndBasisOfPresentationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and basis of presentation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_OrganizationAndBasisOfPresentationTable" xlink:to="lyra_OrganizationAndBasisOfPresentationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_OrganizationAndBasisOfPresentationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Basis Of Presentation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_OrganizationAndBasisOfPresentationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Basis Of Presentation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of Underwriters&apos; Option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Over Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_OrganizationAndBasisOfPresentationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Basis Of Presentation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_OrganizationAndBasisOfPresentationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Basis Of Presentation [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity incorporation, date of incorporation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation Date Of Incorporation</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_GrossProceedsFromInitialPublicOffering" xlink:type="locator" xlink:label="lyra_GrossProceedsFromInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="lyra_GrossProceedsFromInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from initial public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_GrossProceedsFromInitialPublicOffering" xlink:to="lyra_GrossProceedsFromInitialPublicOffering_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued and sold, public offering price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_GrossProceedsFromInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_GrossProceedsFromInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds From Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from initial public offering</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_NumberOfPatients" xlink:type="locator" xlink:label="lyra_NumberOfPatients" />
    <link:label xml:lang="en-US" xlink:label="lyra_NumberOfPatients_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of patients.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_NumberOfPatients" xlink:to="lyra_NumberOfPatients_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_NumberOfPatients_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of patients</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_NumberOfPatients_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Patients</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer software and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office furniture and fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_LeaseLiabilities" xlink:type="locator" xlink:label="lyra_LeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="lyra_LeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_LeaseLiabilities" xlink:to="lyra_LeaseLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_LeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_LeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion of redeemable convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Accretion To Redemption Value Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potentially dilutive securities excluded from calculation of diluted net loss per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets, fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities, fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AlternativeInvestmentChangeInValuationTechnique" xlink:type="locator" xlink:label="us-gaap_AlternativeInvestmentChangeInValuationTechnique" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AlternativeInvestmentChangeInValuationTechnique_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Alternative investment, change in valuation technique</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AlternativeInvestmentChangeInValuationTechnique" xlink:to="us-gaap_AlternativeInvestmentChangeInValuationTechnique_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AlternativeInvestmentChangeInValuationTechnique_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Alternative Investment Change In Valuation Technique</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_ComputerSoftwareAndEquipmentMember" xlink:type="locator" xlink:label="lyra_ComputerSoftwareAndEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="lyra_ComputerSoftwareAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer Software And Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ComputerSoftwareAndEquipmentMember" xlink:to="lyra_ComputerSoftwareAndEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_ComputerSoftwareAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Software and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_ComputerSoftwareAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Software And Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Furniture and Fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent" />
    <link:label xml:lang="en-US" xlink:label="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Third-party research and development expenses current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent" xlink:to="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll and employee related expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third-party research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Third Party Research And Development Expenses Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional and consulting fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:type="locator" xlink:label="srt_DirectorMember" />
    <link:label xml:lang="en-US" xlink:label="srt_DirectorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Director</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_DirectorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Director [Member]</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_NonEmployeeCompensationMember" xlink:type="locator" xlink:label="lyra_NonEmployeeCompensationMember" />
    <link:label xml:lang="en-US" xlink:label="lyra_NonEmployeeCompensationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Employee Compensation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_NonEmployeeCompensationMember" xlink:to="lyra_NonEmployeeCompensationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_NonEmployeeCompensationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non Employee Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_NonEmployeeCompensationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Employee Compensation [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_CommonStockVotingRightsNumberOfVotes" xlink:type="locator" xlink:label="lyra_CommonStockVotingRightsNumberOfVotes" />
    <link:label xml:lang="en-US" xlink:label="lyra_CommonStockVotingRightsNumberOfVotes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock voting rights, number of votes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_CommonStockVotingRightsNumberOfVotes" xlink:to="lyra_CommonStockVotingRightsNumberOfVotes_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, voting rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Voting Rights</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_CommonStockVotingRightsNumberOfVotes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock voting rights</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_CommonStockVotingRightsNumberOfVotes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Voting Rights Number Of Votes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split of issued and outstanding common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Reverse Stock Split</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock converted into common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Shares Issued Upon Conversion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants issued to purchase common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested share of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Issued For Services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee stock purchase plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option Indexed to Issuer&apos;s Equity, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Option Indexed To Issuers Equity Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option Indexed to Issuer&apos;s Equity, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Option Indexed To Issuers Equity Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of common stock reserved for future issuances</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercise price, per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance of preferred stock allocated to warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Preferred Stock And Preference Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand five and two thousand sixteen equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember" xlink:to="lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2005 and 2016 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Five And Two Thousand Sixteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_TwentyThousandTwentyIncentiveAwardPlanMember" xlink:type="locator" xlink:label="lyra_TwentyThousandTwentyIncentiveAwardPlanMember" />
    <link:label xml:lang="en-US" xlink:label="lyra_TwentyThousandTwentyIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Twenty thousand twenty incentive award plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_TwentyThousandTwentyIncentiveAwardPlanMember" xlink:to="lyra_TwentyThousandTwentyIncentiveAwardPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_TwentyThousandTwentyIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_TwentyThousandTwentyIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Twenty Thousand Twenty Incentive Award Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_MilestoneBasedAwardsMember" xlink:type="locator" xlink:label="lyra_MilestoneBasedAwardsMember" />
    <link:label xml:lang="en-US" xlink:label="lyra_MilestoneBasedAwardsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone-based awards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_MilestoneBasedAwardsMember" xlink:to="lyra_MilestoneBasedAwardsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_MilestoneBasedAwardsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone-based Awards</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_MilestoneBasedAwardsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Based Awards [Member]</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_RevenueBasedMilestoneAwardsMember" xlink:type="locator" xlink:label="lyra_RevenueBasedMilestoneAwardsMember" />
    <link:label xml:lang="en-US" xlink:label="lyra_RevenueBasedMilestoneAwardsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue-based milestone awards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_RevenueBasedMilestoneAwardsMember" xlink:to="lyra_RevenueBasedMilestoneAwardsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_RevenueBasedMilestoneAwardsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Based Milestone Awards [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_RevenueBasedMilestoneAwardsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Based Milestone Awards [Member]</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Twenty thousand twenty employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember" xlink:to="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 ESPP</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Twenty Thousand Twenty Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" xlink:type="locator" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" />
    <link:label xml:lang="en-US" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual increase in number of shares available for issuance maximum number of common stock issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" xlink:to="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued_lbl" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" xlink:type="locator" xlink:label="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" />
    <link:label xml:lang="en-US" xlink:label="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of common shares increase automatically in each year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" xlink:to="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of common shares issued</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual Increase In Number Of Shares Available For Issuance Maximum Number Of Common Stock Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of common shares increase automatically in each year</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Common Shares Increase Automatically In Each Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for future grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option expiration period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Shares, Outstanding December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares, Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares, Cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares, Outstanding December 31, 2020</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares, Exercisable at December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares, Vested and expected to vest at December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Outstanding December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Outstanding December 31, 2020</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercisable at December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price,Vested and expected to vest at December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding, Weighted Average Remaining Contractual Life (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable, Weighted Average Remaining Contractual Life (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest, Weighted Average Remaining Contractual Life (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value, Outstanding December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value, Outstanding December 31, 2020</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable at December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and expected to vest at December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average fair value of options granted to employees, directors and consultants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of stock options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense relating to unvested stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested stock options expected to be recognized over a weighted-average period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" xlink:type="locator" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" />
    <link:label xml:lang="en-US" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual increase in number of shares available for issuance as percentage on outstanding shares of common stock on final day of immediately preceding calendar year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" xlink:to="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear_lbl" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" xlink:type="locator" xlink:label="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase price of shares as percentage lower of fair market value of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" xlink:to="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual increase in number of shares available for issuance as percentage of outstanding shares common stock on final day of immediately preceding fiscal year</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual Increase In Number Of Shares Available For Issuance As Percentage On Outstanding Shares Of Common Stock On Final Day Of Immediately Preceding Calendar Year</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price of shares as percentage lower of fair market value of common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Price Of Shares As Percentage Lower Of Fair Market Value Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_ArsenalMedicalIncorporationMember" xlink:type="locator" xlink:label="lyra_ArsenalMedicalIncorporationMember" />
    <link:label xml:lang="en-US" xlink:label="lyra_ArsenalMedicalIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Arsenal Medical, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_ArsenalMedicalIncorporationMember" xlink:to="lyra_ArsenalMedicalIncorporationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_ArsenalMedicalIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Arsenal</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_ArsenalMedicalIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arsenal Medical Incorporation [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting expense related to consulting agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Expenses From Transactions With Related Party</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_DueFromRelatedPartiesDuringPeriod" xlink:type="locator" xlink:label="lyra_DueFromRelatedPartiesDuringPeriod" />
    <link:label xml:lang="en-US" xlink:label="lyra_DueFromRelatedPartiesDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Due from related parties during period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_DueFromRelatedPartiesDuringPeriod" xlink:to="lyra_DueFromRelatedPartiesDuringPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_DueFromRelatedPartiesDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_DueFromRelatedPartiesDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due From Related Parties During Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. federal jurisdiction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State jurisdiction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax computed at federal statutory tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Permanent differences</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes, net of federal benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development and other tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in deferred tax asset valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Other Reconciling Items Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="locator" xlink:label="lyra_DeferredTaxAssetsOperatingLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="lyra_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="lyra_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:type="locator" xlink:label="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" />
    <link:label xml:lang="en-US" xlink:label="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Liabilities Operating lease right-of-use assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:to="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets In Process Research And Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Lease Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total gross deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Operating Lease Right Of Use Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net deferred taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards limitations on use</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Limitations On Use</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:type="locator" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant change in unrecognized tax benefits is reasonably possible, amount of unrecorded benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:to="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits income tax penalties accrued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties Accrued</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_LesseeOperatingLeaseExtendedLeaseTerm" xlink:type="locator" xlink:label="lyra_LesseeOperatingLeaseExtendedLeaseTerm" />
    <link:label xml:lang="en-US" xlink:label="lyra_LesseeOperatingLeaseExtendedLeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease, extended lease term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_LesseeOperatingLeaseExtendedLeaseTerm" xlink:to="lyra_LesseeOperatingLeaseExtendedLeaseTerm_lbl" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_LeaseInitiationDate" xlink:type="locator" xlink:label="lyra_LeaseInitiationDate" />
    <link:label xml:lang="en-US" xlink:label="lyra_LeaseInitiationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease initiation date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_LeaseInitiationDate" xlink:to="lyra_LeaseInitiationDate_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Debt Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Debt Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:type="locator" xlink:label="us-gaap_LetterOfCreditMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of Credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Letter Of Credit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:type="locator" xlink:label="us-gaap_CertificatesOfDepositMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Certificate of Deposits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Certificates Of Deposit [Member]</link:label>
    <link:loc xlink:href="lyra-20201231.xsd#lyra_OfficeAndLaboratoryMember" xlink:type="locator" xlink:label="lyra_OfficeAndLaboratoryMember" />
    <link:label xml:lang="en-US" xlink:label="lyra_OfficeAndLaboratoryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Office and laboratory.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lyra_OfficeAndLaboratoryMember" xlink:to="lyra_OfficeAndLaboratoryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="lyra_OfficeAndLaboratoryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office and Laboratory</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_OfficeAndLaboratoryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office And Laboratory [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial base rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebt" xlink:type="locator" xlink:label="us-gaap_SecuredDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecuredDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Secured debt obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebt" xlink:to="us-gaap_SecuredDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecuredDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Secured Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of property</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Real Estate Property</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_LesseeOperatingLeaseExtendedLeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extended lease term</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_LesseeOperatingLeaseExtendedLeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Extended Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_LeaseInitiationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease initiation date</link:label>
    <link:label xml:lang="en-US" xlink:label="lyra_LeaseInitiationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Initiation Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Cost:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease cost, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total maturities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Amount representing interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Present value of operating lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Present value of operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Current portion of operating lease liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company match percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Maximum Annual Contributions Per Employee Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Matching contribution costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Cost Recognized</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>28
<FILENAME>lyra-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-09T01:56:07.7029348+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 5245d08838e248bbac25af17c6adc28d -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/role/TemplateLink" xlink:href="lyra-20201231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="lyra-20201231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" xlink:href="lyra-20201231.xsd#Role_StatementCondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:type="locator" xlink:label="lyra_AccruedExpensesAndOtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesCRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesCRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesBRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesBRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesA4RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesA4RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesA3RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesA3RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesA2RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesA2RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesA1RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesA1RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesA1RedeemableConvertiblePreferredStockMember" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesA2RedeemableConvertiblePreferredStockMember" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesA3RedeemableConvertiblePreferredStockMember" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesA4RedeemableConvertiblePreferredStockMember" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesBRedeemableConvertiblePreferredStockMember" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesCRedeemableConvertiblePreferredStockMember" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="lyra_AccruedExpensesAndOtherLiabilitiesCurrent" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="lyra-20201231.xsd#Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesCRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesCRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesBRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesBRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesA4RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesA4RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesA3RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesA3RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesA2RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesA2RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesA1RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesA1RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesA1RedeemableConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesA2RedeemableConvertiblePreferredStockMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesA3RedeemableConvertiblePreferredStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesA4RedeemableConvertiblePreferredStockMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesBRedeemableConvertiblePreferredStockMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesCRedeemableConvertiblePreferredStockMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="12290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="lyra-20201231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAudited" xlink:href="lyra-20201231.xsd#Role_StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants" xlink:type="locator" xlink:label="lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants" xlink:type="locator" xlink:label="lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_VestingOfRestrictedCommonStockShares" xlink:type="locator" xlink:label="lyra_VestingOfRestrictedCommonStockShares" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_VestingOfRestrictedCommonStockValue" xlink:type="locator" xlink:label="lyra_VestingOfRestrictedCommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesCRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesCRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesCRedeemableConvertiblePreferredStockMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="12150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_VestingOfRestrictedCommonStockValue" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_VestingOfRestrictedCommonStockShares" order="12370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants" order="12470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants" order="12530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="12630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="12950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_li0l2" order="12970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" order="12990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="13010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalAudited" xlink:href="lyra-20201231.xsd#Role_StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalAudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalAudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_TemporaryEquityStockIssuanceCosts" xlink:type="locator" xlink:label="lyra_TemporaryEquityStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesCRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesCRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesCRedeemableConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lyra_TemporaryEquityStockIssuanceCosts" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="lyra-20201231.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
    <link:loc xlink:href="lyra-20201231.xsd#lyra_DeferredOfferingCostsIncurredButNotYetPaid" xlink:type="locator" xlink:label="lyra_DeferredOfferingCostsIncurredButNotYetPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue" xlink:type="locator" xlink:label="lyra_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_AllocationOfRedeemableConvertiblePreferredStockToCommonStockWarrant" xlink:type="locator" xlink:label="lyra_AllocationOfRedeemableConvertiblePreferredStockToCommonStockWarrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1" xlink:type="locator" xlink:label="us-gaap_StockIssued1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator" xlink:label="lyra_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:type="locator" xlink:label="lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_ReserveForUncollectibleAccounts" xlink:type="locator" xlink:label="lyra_ReserveForUncollectibleAccounts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lyra_ReserveForUncollectibleAccounts" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lyra_IncreaseDecreaseInOperatingLeaseLiability" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_StockIssued1" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lyra_AllocationOfRedeemableConvertiblePreferredStockToCommonStockWarrant" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lyra_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lyra_DeferredOfferingCostsIncurredButNotYetPaid" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentation" xlink:href="lyra-20201231.xsd#Role_DisclosureOrganizationAndBasisOfPresentation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="lyra-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="lyra-20201231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment" xlink:href="lyra-20201231.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="lyra-20201231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities">
    <link:loc xlink:href="lyra-20201231.xsd#lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStock" xlink:href="lyra-20201231.xsd#Role_DisclosureRedeemableConvertiblePreferredStock" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStock">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:type="locator" xlink:label="us-gaap_PreferredStockTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePreferredAndCommonStock" xlink:href="lyra-20201231.xsd#Role_DisclosurePreferredAndCommonStock" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePreferredAndCommonStock">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpense" xlink:href="lyra-20201231.xsd#Role_DisclosureStockBasedCompensationExpense" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpense">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureRelatedParties" xlink:href="lyra-20201231.xsd#Role_DisclosureRelatedParties" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureRelatedParties">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="lyra-20201231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeases" xlink:href="lyra-20201231.xsd#Role_DisclosureLeases" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeases">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureRetirementPlan" xlink:href="lyra-20201231.xsd#Role_DisclosureRetirementPlan" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureRetirementPlan">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lyra-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="lyra-20201231.xsd#lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_DeferredOfferingCostsTextBlock" xlink:type="locator" xlink:label="lyra_DeferredOfferingCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GuaranteesTextBlock" xlink:type="locator" xlink:label="us-gaap_GuaranteesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_AccountingForStockBasedCompensationPolicy" xlink:type="locator" xlink:label="lyra_AccountingForStockBasedCompensationPolicy" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_PatentsCostsPolicyTextBlock" xlink:type="locator" xlink:label="lyra_PatentsCostsPolicyTextBlock" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_ResearchAndDevelopmentCostsTextBlock" xlink:type="locator" xlink:label="lyra_ResearchAndDevelopmentCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SignificantSuppliersPolicyTextBlock" xlink:type="locator" xlink:label="lyra_SignificantSuppliersPolicyTextBlock" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" xlink:type="locator" xlink:label="lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_RestrictedCashPolicyTextBlock" xlink:type="locator" xlink:label="lyra_RestrictedCashPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNoteTextBlock" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SegmentInformationTextBlock" xlink:type="locator" xlink:label="lyra_SegmentInformationTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_COVID19PandemicAndCARESActPolicyTextBlock" xlink:type="locator" xlink:label="lyra_COVID19PandemicAndCARESActPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lyra_COVID19PandemicAndCARESActPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lyra_SegmentInformationTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomeNoteTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lyra_RestrictedCashPolicyTextBlock" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lyra_SignificantSuppliersPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lyra_ResearchAndDevelopmentCostsTextBlock" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lyra_PatentsCostsPolicyTextBlock" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lyra_AccountingForStockBasedCompensationPolicy" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GuaranteesTextBlock" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lyra_DeferredOfferingCostsTextBlock" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="lyra-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:href="lyra-20201231.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="lyra-20201231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
    <link:loc xlink:href="lyra-20201231.xsd#lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePreferredAndCommonStockTables" xlink:href="lyra-20201231.xsd#Role_DisclosurePreferredAndCommonStockTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePreferredAndCommonStockTables">
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock" xlink:type="locator" xlink:label="lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseTables" xlink:href="lyra-20201231.xsd#Role_DisclosureStockBasedCompensationExpenseTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="lyra-20201231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesTables" xlink:href="lyra-20201231.xsd#Role_DisclosureLeasesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:href="lyra-20201231.xsd#lyra_NumberOfPatients" xlink:type="locator" xlink:label="lyra_NumberOfPatients" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_GrossProceedsFromInitialPublicOffering" xlink:type="locator" xlink:label="lyra_GrossProceedsFromInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_OrganizationAndBasisOfPresentationLineItems" xlink:type="locator" xlink:label="lyra_OrganizationAndBasisOfPresentationLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_OrganizationAndBasisOfPresentationTable" xlink:type="locator" xlink:label="lyra_OrganizationAndBasisOfPresentationTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lyra_OrganizationAndBasisOfPresentationTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationTable" xlink:to="lyra_OrganizationAndBasisOfPresentationLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="lyra_GrossProceedsFromInitialPublicOffering" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lyra_OrganizationAndBasisOfPresentationLineItems" xlink:to="lyra_NumberOfPatients" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_LeaseLiabilities" xlink:type="locator" xlink:label="lyra_LeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCash" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lyra_LeaseLiabilities" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FinanceLeaseLiability" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredOfferingCosts" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesBRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesBRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesA4RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesA4RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesA3RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesA3RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesA2RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesA2RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesA1RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesA1RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lyra_SeriesA1RedeemableConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lyra_SeriesA2RedeemableConvertiblePreferredStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lyra_SeriesA3RedeemableConvertiblePreferredStockMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lyra_SeriesA4RedeemableConvertiblePreferredStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lyra_SeriesBRedeemableConvertiblePreferredStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AlternativeInvestmentChangeInValuationTechnique" xlink:type="locator" xlink:label="us-gaap_AlternativeInvestmentChangeInValuationTechnique" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_AlternativeInvestmentChangeInValuationTechnique" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="lyra-20201231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_ComputerSoftwareAndEquipmentMember" xlink:type="locator" xlink:label="lyra_ComputerSoftwareAndEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lyra_ComputerSoftwareAndEquipmentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:href="lyra-20201231.xsd#Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
    <link:loc xlink:href="lyra-20201231.xsd#lyra_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:type="locator" xlink:label="lyra_AccruedExpensesAndOtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="lyra_AccruedExpensesAndOtherLiabilitiesCurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesCRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesCRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesCRedeemableConvertiblePreferredStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails" xlink:href="lyra-20201231.xsd#Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_GrossProceedsFromInitialPublicOffering" xlink:type="locator" xlink:label="lyra_GrossProceedsFromInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_CommonStockVotingRightsNumberOfVotes" xlink:type="locator" xlink:label="lyra_CommonStockVotingRightsNumberOfVotes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_SeriesCRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="lyra_SeriesCRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_NonEmployeeCompensationMember" xlink:type="locator" xlink:label="lyra_NonEmployeeCompensationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:type="locator" xlink:label="srt_DirectorMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lyra_NonEmployeeCompensationMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lyra_SeriesCRedeemableConvertiblePreferredStockMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_CommonStockVotingRightsNumberOfVotes" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lyra_GrossProceedsFromInitialPublicOffering" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails" xlink:href="lyra-20201231.xsd#Role_DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_EmployeeStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseAdditionalInformationDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureStockBasedCompensationExpenseAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseAdditionalInformationDetails">
    <link:loc xlink:href="lyra-20201231.xsd#lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" xlink:type="locator" xlink:label="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" xlink:type="locator" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" xlink:type="locator" xlink:label="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" xlink:type="locator" xlink:label="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_RevenueBasedMilestoneAwardsMember" xlink:type="locator" xlink:label="lyra_RevenueBasedMilestoneAwardsMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_MilestoneBasedAwardsMember" xlink:type="locator" xlink:label="lyra_MilestoneBasedAwardsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_TwentyThousandTwentyIncentiveAwardPlanMember" xlink:type="locator" xlink:label="lyra_TwentyThousandTwentyIncentiveAwardPlanMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lyra_TwentyThousandTwentyIncentiveAwardPlanMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lyra_MilestoneBasedAwardsMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lyra_RevenueBasedMilestoneAwardsMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureStockBasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_li0l2" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureRelatedPartiesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails">
    <link:loc xlink:href="lyra-20201231.xsd#lyra_DueFromRelatedPartiesDuringPeriod" xlink:type="locator" xlink:label="lyra_DueFromRelatedPartiesDuringPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_ArsenalMedicalIncorporationMember" xlink:type="locator" xlink:label="lyra_ArsenalMedicalIncorporationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:type="locator" xlink:label="srt_DirectorMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_DirectorMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="lyra_ArsenalMedicalIncorporationMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="lyra_DueFromRelatedPartiesDuringPeriod" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="lyra-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:type="locator" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_DomesticCountryMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:type="locator" xlink:label="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="locator" xlink:label="lyra_DeferredTaxAssetsOperatingLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lyra_DeferredTaxAssetsOperatingLeaseLiabilities" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_LeaseInitiationDate" xlink:type="locator" xlink:label="lyra_LeaseInitiationDate" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_LesseeOperatingLeaseExtendedLeaseTerm" xlink:type="locator" xlink:label="lyra_LesseeOperatingLeaseExtendedLeaseTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebt" xlink:type="locator" xlink:label="us-gaap_SecuredDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:href="lyra-20201231.xsd#lyra_OfficeAndLaboratoryMember" xlink:type="locator" xlink:label="lyra_OfficeAndLaboratoryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:type="locator" xlink:label="us-gaap_CertificatesOfDepositMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:type="locator" xlink:label="us-gaap_LetterOfCreditMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_LetterOfCreditMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lyra_OfficeAndLaboratoryMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecuredDebt" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lyra_LesseeOperatingLeaseExtendedLeaseTerm" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lyra_LeaseInitiationDate" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostAbstract" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_SubleaseIncome" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToOperatingLeasesDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToOperatingLeasesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToOperatingLeasesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability_li0l2" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails" xlink:href="lyra-20201231.xsd#Role_DisclosureRetirementPlanAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688554520264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 01, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lyra Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-1700838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">480 Arsenal Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">393-4600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LYRA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,280,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,947,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p>None.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001327273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688552080760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 74,593<span></span>
</td>
<td class="nump">$ 9,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,324<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">75,917<span></span>
</td>
<td class="nump">10,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,165<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,301<span></span>
</td>
<td class="nump">3,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">329<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">1,096<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">80,830<span></span>
</td>
<td class="nump">14,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">922<span></span>
</td>
<td class="nump">1,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_AccruedExpensesAndOtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">2,977<span></span>
</td>
<td class="nump">3,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">985<span></span>
</td>
<td class="nump">899<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,884<span></span>
</td>
<td class="nump">5,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">1,454<span></span>
</td>
<td class="nump">2,427<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">6,338<span></span>
</td>
<td class="nump">7,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200,000,000 and 275,000,000 shares authorized at December 31, 2020 and 2019, respectively; 12,932,377 and 230,860 shares issued and outstanding at December 31, 2020 and 2019, respectively</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">224,363<span></span>
</td>
<td class="nump">4,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(149,884)<span></span>
</td>
<td class="num">(127,757)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">74,492<span></span>
</td>
<td class="num">(123,338)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, redeemable convertible preferred stock and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">$ 80,830<span></span>
</td>
<td class="nump">14,963<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lyra_SeriesA1RedeemableConvertiblePreferredStockMember', window );">Series A-1 Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lyra_SeriesA2RedeemableConvertiblePreferredStockMember', window );">Series A-2 Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lyra_SeriesA3RedeemableConvertiblePreferredStockMember', window );">Series A-3 Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lyra_SeriesA4RedeemableConvertiblePreferredStockMember', window );">Series A-4 Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lyra_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,417<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_AccruedExpensesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_AccruedExpensesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lyra_SeriesA1RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lyra_SeriesA1RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lyra_SeriesA2RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lyra_SeriesA2RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lyra_SeriesA3RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lyra_SeriesA3RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lyra_SeriesA4RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lyra_SeriesA4RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lyra_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lyra_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688552177848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">12,932,377<span></span>
</td>
<td class="nump">230,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="nump">12,932,377<span></span>
</td>
<td class="nump">230,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lyra_SeriesA1RedeemableConvertiblePreferredStockMember', window );">Series A-1 Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">34,017,033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">34,017,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">34,017,033<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lyra_SeriesA2RedeemableConvertiblePreferredStockMember', window );">Series A-2 Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,680,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,680,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,680,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lyra_SeriesA3RedeemableConvertiblePreferredStockMember', window );">Series A-3 Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,070,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,070,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,070,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lyra_SeriesA4RedeemableConvertiblePreferredStockMember', window );">Series A-4 Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,999,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,999,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,999,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lyra_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,018,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">98,351,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">98,351,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lyra_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lyra_SeriesA1RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lyra_SeriesA1RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lyra_SeriesA2RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lyra_SeriesA2RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lyra_SeriesA3RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lyra_SeriesA3RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lyra_SeriesA4RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lyra_SeriesA4RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lyra_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lyra_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lyra_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lyra_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688554475192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 12,522<span></span>
</td>
<td class="nump">$ 12,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">9,687<span></span>
</td>
<td class="nump">4,487<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">22,209<span></span>
</td>
<td class="nump">16,519<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(22,209)<span></span>
</td>
<td class="num">(16,519)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(22,127)<span></span>
</td>
<td class="num">(16,306)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (22,127)<span></span>
</td>
<td class="num">$ (16,306)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders&#8212;basic and diluted</a></td>
<td class="num">$ (2.59)<span></span>
</td>
<td class="num">$ (82.23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding&#8212;basic and diluted</a></td>
<td class="nump">8,590,205<span></span>
</td>
<td class="nump">202,093<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688549659992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (audited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Redeemable Convertible Preferred Stock</div></th>
<th class="th"><div>Series C Redeemable Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="num">$ (107,074)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,377<span></span>
</td>
<td class="num">$ (111,451)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity balance, Shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,119,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity balance, Value at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock', window );">Accretion of convertible preferred stock to redemption value</a></td>
<td class="num">(313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Temporary equity, Accretion of convertible preferred stock to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(16,306)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,306)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="num">(123,338)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,419<span></span>
</td>
<td class="num">(127,757)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,119,674<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity balance, Value at Dec. 31, 2019</a></td>
<td class="nump">130,666<span></span>
</td>
<td class="nump">$ 130,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, Shares</a></td>
<td class="nump">2,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series C redeemable convertiblepreferred stock, net of issuance costsof $201</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series C redeemable convertible preferred stock, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,306,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock', window );">Accretion of convertible preferred stock to redemption value</a></td>
<td class="num">$ (115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Temporary equity, Accretion of convertible preferred stock to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of common stock warrants inconjunction with sale of Series Credeemable convertible preferred stock</a></td>
<td class="nump">740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of redeemable convertiblepreferred stock to common stockupon closing of initial public offering</a></td>
<td class="nump">160,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (160,227)<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">160,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock to common stock upon closing of initial public offering, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(287,426,285)<span></span>
</td>
<td class="nump">8,335,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from initialpublic offering, net of issuancecosts of $7,116</a></td>
<td class="nump">57,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">57,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from initial public offering, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_VestingOfRestrictedCommonStockShares', window );">Vesting of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants', window );">Issuance of common stock upon exercise ofwarrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants', window );">Issuance of common stock upon exercise of warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(22,127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,127)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 74,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 224,363<span></span>
</td>
<td class="num">$ (149,884)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,932,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock shares upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_IssuanceOfCommonStockSharesUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of exercise warrants common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_IssuanceOfCommonStockValueUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_VestingOfRestrictedCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting of restricted common stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_VestingOfRestrictedCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease (increase) in additional paid in capital (APIC) for the increase in carrying amount of redeemable preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 3.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177168-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688555934776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) (audited)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments Of Stock Issuance Costs</a></td>
<td class="nump">$ 7,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lyra_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_TemporaryEquityStockIssuanceCosts', window );">Temporary equity, issuance costs</a></td>
<td class="nump">$ 201<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_TemporaryEquityStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_TemporaryEquityStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lyra_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lyra_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688559450856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (22,127,000)<span></span>
</td>
<td class="num">$ (16,306,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,813,000<span></span>
</td>
<td class="nump">244,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">95,000<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_ReserveForUncollectibleAccounts', window );">Reserve for uncollectible accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain on disposal of assets</a></td>
<td class="num">(45,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,013,000)<span></span>
</td>
<td class="nump">561,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">894,000<span></span>
</td>
<td class="nump">864,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other assets</a></td>
<td class="num">(118,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">345,000<span></span>
</td>
<td class="num">(205,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(87,000)<span></span>
</td>
<td class="nump">1,734,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(900,000)<span></span>
</td>
<td class="num">(840,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(21,143,000)<span></span>
</td>
<td class="num">(13,754,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,775,000)<span></span>
</td>
<td class="num">(211,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,775,000)<span></span>
</td>
<td class="num">(211,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of underwriting discount</a></td>
<td class="nump">59,892,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering', window );">Payment of initial public offering costs</a></td>
<td class="num">(2,383,000)<span></span>
</td>
<td class="num">(226,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">111,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">87,703,000<span></span>
</td>
<td class="num">(115,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">64,785,000<span></span>
</td>
<td class="num">(14,080,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">10,137,000<span></span>
</td>
<td class="nump">24,217,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents and restricted cash, end of period</a></td>
<td class="nump">74,922,000<span></span>
</td>
<td class="nump">10,137,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash financing and investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases included in accounts payable</a></td>
<td class="nump">205,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Conversion of redeemable convertible preferred stock</a></td>
<td class="nump">160,227,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue', window );">Accretion of redeemable convertible preferred stock to redemption value</a></td>
<td class="nump">115,000<span></span>
</td>
<td class="nump">313,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange of operating lease obligation</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="nump">4,046,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_DeferredOfferingCostsIncurredButNotYetPaid', window );">Deferred offering costs included in accounts payable and accrued expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 870,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from the sale of Series C redeemable convertible preferred stock</a></td>
<td class="nump">30,392,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock', window );">Payment of offering costs related to sale of Series C redeemable convertible preferred stock</a></td>
<td class="num">(206,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash financing and investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_AllocationOfRedeemableConvertiblePreferredStockToCommonStockWarrant', window );">Allocation of Series C redeemable convertible preferred stock to common stock warrant</a></td>
<td class="nump">$ 740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion of redeemable convertible preferred stock to redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_AllocationOfRedeemableConvertiblePreferredStockToCommonStockWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allocation of redeemable convertible preferred stock to common stock warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_AllocationOfRedeemableConvertiblePreferredStockToCommonStockWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_DeferredOfferingCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_DeferredOfferingCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ReserveForUncollectibleAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of uncollectible accounts reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ReserveForUncollectibleAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire callable preferred stock which is identified as being convertible to another type of financial security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688632538632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Organization and Basis of Presentation </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lyra Therapeutics, Inc. (the &#8220;Company&#8221;) is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (&#8220;ENT&#8221;) diseases. The Company&#8217;s proprietary technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. The Company&#8217;s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (&#8220;CRS&#8221;). The Company was incorporated as a Delaware corporation on November&#160;21, 2005 and is located in Watertown, Massachusetts. On July&#160;16, 2018, the Company formerly changed its name from 480 Biomedical, Inc. to Lyra Therapeutics, Inc. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks common to companies in the therapeutics and pharmaceutical industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations, reliance on third party manufacturers, ability to transition from pilot-scale manufacturing to large-scale production of products and the need to obtain adequate additional financing to fund the development of its product candidates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, the Company has funded its operations with proceeds from sales of redeemable convertible preferred stock and funding from government contracts. The Company has incurred recurring net losses since inception and had net losses of approximately $22.1 million and $16.3 million for the years ended December 31, 2020 and 2019, respectively. In addition, the Company has an accumulated deficit of approximately $149.9&#160;million at December 31, 2020. The Company expects to continue to generate operating losses for the foreseeable future. At December 31, 2020, the Company had approximately $74.6&#160;million of cash and cash equivalents.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 5, 2020, the Company completed its initial public offering (&#8220;IPO&#8221;), in which the Company issued and sold 4,025,000 shares of its common stock, including 525,000 shares pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, at a public offering price of $16.00 per share, for aggregate gross proceeds of $64.4 million. The Company received approximately $57.3 million in net proceeds after deducting underwriting discounts and offering expenses paid by the Company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that its cash and cash equivalents as of December 31, 2020 will be sufficient to fund the Company&#8217;s operating plan for a period of at least one year from the issuance date of the consolidated financial statements. The Company will need additional financing to support its continuing operations and pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of equity or debt financings, collaboration agreements, strategic alliances and licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all.&nbsp;&nbsp;The inability to obtain funding as and when needed would have a negative impact on the Company&#8217;s financial condition and ability to pursue its business strategies. If the Company is unable to obtain funding when needed, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations.&nbsp;&nbsp;The Company will need to generate significant revenue to achieve profitability, and it may never do so.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the completion of the IPO of its common stock in May 2020, all outstanding redeemable convertible preferred stock of the Company converted into shares of common stock and all outstanding warrants to purchase common stock were automatically cashless exercised.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COVID-19 Pandemic and CARES Act</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 30, 2020, the World Health Organization (&#8220;WHO&#8221;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &#8220;COVID-19 outbreak&#8221;) and the risks to the international community as the virus subsequently spread globally beyond its point of origin. On March 11, 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The COVID-19 pandemic is affecting the United States and global economies and may affect the Company&#8217;s operations and those of third parties on which the Company relies, including by causing disruptions in the supply of the Company&#8217;s product candidates and the conduct of current and future clinical trials. In addition, the COVID-19 pandemic may affect the operations of the Food and Drug Administration and other health authorities, which could result in delays of reviews and approvals, including with respect to the Company&#8217;s product candidates. In light of developments relating to the COVID-19 pandemic, the Company discontinued enrollment at 67 patients in its Phase 2 LANTERN clinical trial and did not enroll patients in the United States. Additionally, while the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce the Company&#8217;s ability to access capital, which could negatively impact the Company&#8217;s short-term and long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, financing or clinical trial activities or on healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company&#8217;s liquidity, capital resources, operations and business and those of the third parties on which the Company relies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 27, 2020, President Trump signed into law the &#8220;Coronavirus Aid, Relief, and Economic Security (CARES) Act.&#8221; The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property. The Company currently defers the employer side social security payments and also is evaluating whether it will take advantage of other provisions, if any. The CARES Act also appropriated funds for the SBA Paycheck Protection Program loans that are forgivable in certain situations to promote continued employment, as well as Economic Injury Disaster Loans to provide liquidity to small businesses harmed by COVID-19. On December 27, 2020, the Consolidated Appropriations Act, 2021 was signed into law in order to provide further stimulus and support to those affected by the COVID-19 pandemic. The Company has not and does not plan on obtaining funding from such loans. The Company does not believe the CARES Act or the Consolidated Appropriations Act, 2021 will have a material impact on its financial condition, results of operations, or liquidity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688632626904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of Significant Accounting Policies </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of Lyra Therapeutics, Inc. and its wholly owned subsidiary Lyra Therapeutics Security Corporation, which was incorporated in December 2018. All intercompany transactions and balances have been eliminated. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the accompanying consolidated financial statements and notes. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&#8217;s management evaluates its estimates, which include but are not limited to management&#8217;s judgments of accrued expenses, fair value of common stock, valuation of share-based awards warrants to purchase common stock and deferred income taxes. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilizes significant estimates and assumptions in determining the fair value of its common stock. The Company has utilized various valuation methodologies to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&#8217;s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment Information </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision-maker, the Company&#8217;s chief executive officer, views the Company&#8217;s operations and manages its business as a single operating segment, which is the business of developing targeted medicines to address ENT diseases. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive Income (Loss) </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. As the Company did not have any element of other comprehensive income (loss), its comprehensive loss is equal to its net loss for all periods presented. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash held in banks and amounts held in money market funds. Cash equivalents are stated at cost, which approximates market value. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents consist of cash held in banks at December&#160;31, 2020 and 2019. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Cash </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had restricted cash of approximately $0.3&#160;million as of December&#160;31, 2020 and 2019, which was held in certificates of deposit at the Company&#8217;s financial institution to secure the Company&#8217;s letter of credit for its facility lease. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Off-Balance Sheet Risk </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains all its cash and cash equivalents at a single accredited financial institution, in amounts that exceed federally insured limits.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign exchange hedging arrangements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Significant Suppliers </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the drug product and associated applicator related to these programs. These programs could be adversely affected by a significant interruption in the supply of the materials required to manufacture the drug product and associated applicator. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at a measurement date. ASC Topic 820, <font style="font-style:italic;">Fair Value Measurements</font> (&#8220;ASC 820&#8221;), establishes a three-level valuation hierarchy for instruments measured at fair value that prioritizes the inputs used to measure fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported or disclosed fair value of the financial instruments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy established by ASC 820 in order of priority are as follows: </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;1&#160;-Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;2 -Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;3 -Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An entity may elect to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in net loss. The Company did not elect to measure any financial instruments or other items at fair value. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Derivative Liabilities </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with certain debt and equity financings, the Company may issue financial instruments in which a derivative instrument is &#8220;embedded.&#8221; Upon issuing the financial instrument, the Company assesses whether the economic characteristics of the embedded derivative are clearly and closely related to the economic characteristics of the remaining component of the financial instrument (i.e., the host contract) and whether a separate, non-embedded instrument with the same terms as the embedded instrument would meet the definition of a derivative instrument. When it is determined that (1)&#160;the embedded derivative possesses economic characteristics that are not clearly and closely related to the economic characteristics of the host contract, and (2)&#160;a separate, stand-alone instrument with the same terms would qualify as a derivative instrument, the embedded derivative is separated from the host contract and carried at fair value until the derivative is settled. Changes in the fair value of the derivative liabilities are recognized as other income (expense) in the consolidated statement of operations and comprehensive loss. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Classification and Accretion of Redeemable Convertible Preferred Shares </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has classified the redeemable convertible preferred stock outside of stockholders&#8217; deficit in the accompanying consolidated balance sheets in accordance with authoritative guidance for the classification and measurement of redeemable securities as the redeemable convertible preferred stock is redeemable at a determinable price on a fixed date or upon the occurrence of a deemed liquidation event. The carrying values of the redeemable convertible preferred shares are accreted to their redemption values from the date of issuance through the earliest date of redemption. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle" style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimated Useful Life</p></td>
</tr>
<tr>
<td valign="bottom" style="width:49%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td valign="bottom" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer software and equipment</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="bottom" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office furniture and fixtures</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7 years</p></td>
</tr>
<tr>
<td valign="bottom" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of useful life or remaining term of related lease</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs for capital assets not yet placed into service are capitalized as construction in progress and are depreciated in accordance with the above guidelines once placed into service. Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statement of operations and comprehensive loss. Repairs and maintenance that do not improve or extend the lives of the respective assets are expensed as incurred, while costs of major additions and betterments are capitalized. </p></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets consist of property and equipment. The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company did not record any impairment losses on long-lived assets during the years ended December&#160;31, 2020 and 2019. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASU No. 2016-02, <font style="font-style:italic;">Leases (Topic 842)</font> (&#8220;ASU No. 2016-02&#8221;), became effective January 1, 2019. As of the effective date of ASU No. 2016-02, the Company determines at the inception of an arrangement whether the arrangement contains a lease. If a lease is identified in an arrangement, the Company recognizes a right-of-use asset and liability on its balance sheet and determines whether the lease should be classified as a finance or operating lease. The Company does not recognize assets or liabilities for leases with lease terms of less than 12&#160;months. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the rate implicit in the lease is not readily determinable, the Company utilizes its incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company separates lease and non-lease components when determining which lease payments to include in the calculation of its lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably certain it will exercise the option. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases are recorded in &#8220;Operating lease right-of use assets,&#8221; &#8220;Operating lease liabilities&#8221; and &#8220;Operating lease liabilities, net of current portion&#8221; in the Company&#8217;s consolidated balance sheets. The Company did not have any finance leases recorded in its consolidated balance sheet as of December 31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Costs </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, manufacturing expenses, stock-based compensation expense, depreciation of equipment, contract services and other outside expenses. Costs of certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development contracts with companies both inside and outside of the United States. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patent Costs </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accounting for Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, <font style="font-style:italic;">Compensation&#8212;Stock Compensation</font> (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments to employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees. The Company believes the fair value of the stock options granted to non-employees is more reliably determinable than the fair value of the services provided. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Black-Scholes option-pricing model uses the following inputs: the fair value of the Company&#8217;s common stock, the expected volatility of the Company&#8217;s common stock, the expected term of the Company&#8217;s stock options, the risk-free interest rate for a period that approximates the expected term of the Company&#8217;s stock options, and the Company&#8217;s expected dividend yield. Following the closing of the Company&#8217;s IPO, the fair value of the Company&#8217;s common stock is determined based on the quoted market price of its common stock. The Company has historically been a private company and lacks company-specific historical and implied volatility data. Therefore, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to it, including stage of product development, life science industry focus, length of trading history, and similar vesting provisions. The historical volatility data is calculated based on a period of time commensurate with the expected term assumption. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available or until circumstances change, such that the identified entities are no longer representative companies. In the latter case, more suitable, similar entities whose share prices are publicly available would be utilized in the calculation. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, <font style="font-style:italic;">Share-Based Payment</font>, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid cash dividends and has no current plans to pay any cash dividends on its common stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has elected as a policy to recognize forfeitures as they occur as described in ASU No.&#160;2016-09, <font style="font-style:italic;">Compensation&#8212;Stock Compensation</font> (&#8220;ASU No.&#160;2016-09&#8221;). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expenses the fair value of its stock-based compensation awards to employees on a straight-line basis over the requisite service period, which is generally the vesting period. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company follows the provisions of ASU No.&#160;2018-07, <font style="font-style:italic;">Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</font> (&#8220;ASU No.&#160;2018-07&#8221;) which permits the Company to recognize non-employee stock-based compensation costs over the requisite period based on a measurement of fair value on the grant date for each stock-based award. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes using the liability method in accordance with ASC Topic 740, <font style="font-style:italic;">Income Taxes</font> (&#8220;ASC 740&#8221;). The difference between the financial statement and tax basis of the assets and liabilities is determined annually. Deferred income tax assets and liabilities are computed using the tax laws and rates that are expected to apply for periods in which such differences reverse. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will more likely than not be realized. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contingencies </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with ASC Topic 450, <font style="font-style:italic;">Contingencies</font>, the Company records accruals for contingencies and legal proceedings expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Guarantees </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has identified the guarantees described below as disclosable, in accordance with ASC Topic 460, <font style="font-style:italic;">Guarantees</font>. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company&#8217;s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#8217; and officers&#8217; insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office space under a noncancelable operating lease. The Company has standard indemnification arrangements under the lease that requires it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the lease. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, the Company had not experienced any losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves have been established. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Deferred Offering Costs </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&#8217; deficit as a reduction of additional paid-in capital generated as a result of the offering. Should the planned equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statement of operations and comprehensive loss. Deferred offering costs of $0 and $1.1 million are included in other assets in the consolidated balance sheets at December 31, 2020 and 2019, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss per Share </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company has computed diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, warrants to purchase common stock and redeemable convertible preferred stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive and basic and diluted loss per share have been the same. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share data): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,127</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,306</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accretion of redeemable convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(115</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(313</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,242</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,619</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares&#8212;basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,590,205</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202,093</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders&#8212;basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.59</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(82.23</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares retroactively adjusted): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A-1 redeemable convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">986,466</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A-2 redeemable convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">773,712</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A-3 redeemable convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">872,031</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A-4 redeemable convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">579,993</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B redeemable convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,852,177</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,428,886</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">792,439</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,428,886</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,856,818</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:12pt;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU No.&#160;2018-13, <font style="font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</font> (&#8220;ASU No.&#160;2018-13&#8221;), which modifies the disclosure requirements on fair value measurements. The Company adopted ASU No. 2018-13 on January&#160;1, 2020. The adoption of ASU 2018-13 did not have a material impact on the Company&#8217;s consolidated financial position, results of operations or cash flows.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU No.&#160;2018-15, <font style="font-style:italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</font> (&#8220;ASU No.&#160;2018-15&#8221;), which clarifies the accounting for implementation costs in cloud computing arrangements. The Company adopted ASU No. 2018-15 on January&#160;1, 2020 on a prospective basis. The adoption of ASU 2018-15 did not have a material impact on the Company&#8217;s consolidated financial position, results of operations or cash flows.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No. 2019-12, <font style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</font> (&#8220;ASU No. 2019-12&#8221;), which makes a number of changes meant to add or clarify guidance on accounting for income taxes. The new guidance will become effective for the Company on January 1, 2022. Early adoption is permitted. The Company currently is evaluating the impact the adoption of ASU 2019-12 will have on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688556005160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. Fair Value Measurements </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not have financial assets and liabilities measured at fair value at December&#160;31, 2020 and 2019. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no changes to the valuation methods used during the years ended December 31, 2020 and 2019. There were no transfers within the fair value hierarchy during the years ended December 31, 2020 and 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying values of the Company&#8217;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Company&#8217;s sale of Series C redeemable convertible preferred stock (&#8220;Series C Preferred Stock&#8221;), the Company issued to investors warrants for the purchase of common stock (&#8220;Warrants&#8221;). The proceeds from the issuance of the Series C Preferred Stock were allocated between the Series C Preferred Stock and Warrants based on their relative fair values at the time of issuance.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688560140152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. Property and Equipment </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of the following at December&#160;31, 2020 and 2019 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,277</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,715</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer software and equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">650</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">595</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office furniture and fixtures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">317</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">317</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">498</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,043</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,066</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,878</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,829</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,165</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized approximately $0.1 million and $27,000 of depreciation expense for the years ended December 31, 2020 and 2019, respectively.</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle" style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimated Useful Life</p></td>
</tr>
<tr>
<td valign="bottom" style="width:49%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td valign="bottom" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer software and equipment</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="bottom" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office furniture and fixtures</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7 years</p></td>
</tr>
<tr>
<td valign="bottom" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of useful life or remaining term of related lease</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs for capital assets not yet placed into service are capitalized as construction in progress and are depreciated in accordance with the above guidelines once placed into service. Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statement of operations and comprehensive loss. Repairs and maintenance that do not improve or extend the lives of the respective assets are expensed as incurred, while costs of major additions and betterments are capitalized. </p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688632471048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. Accrued Expenses and Other Current Liabilities </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities consist of the following at December&#160;31, 2020 and 2019 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and employee related expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,892</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">885</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party research and development expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">381</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,344</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional and consulting fees</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">555</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">901</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses and other current liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,977</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,240</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688556218568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">PreferredStockTextBlock</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6. Redeemable Convertible Preferred Stock </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 10, 2020, the Company filed an amended and restated certificate of incorporation which authorized its Board of Directors to issue up to 299,300,288 shares of preferred stock, par value $0.001 per share. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, the Company issued 78,306,611 shares of Series C Preferred Stock for $0.38811 per share, in exchange for gross cash proceeds of approximately $30.4 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the completion of the IPO of its common stock in May 2020, all outstanding redeemable convertible preferred stock of the Company converted into shares of common stock.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688632512456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Preferred and Common Stock</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7. Preferred and Common Stock </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 10, 2020, the Company filed an amended and restated certificate of incorporation which authorized its Board of Directors to issue up to 400,000,000 shares of common stock, par value $0.001 per share. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 5, 2020, the Company filed a restated certificate of incorporation which authorizes its Board of Directors to issue up to 200,000,000 shares of common stock, par value $0.001 per share and 10,000,000 shares of undesignated preferred stock, par value $0.001 per share.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of common stock are entitled to one vote for each share held. Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s Board of Directors approved a one-for-34.483 reverse stock split of its issued and outstanding common stock and stock options and a proportional adjustment to the existing conversion ratios for the Company&#8217;s redeemable convertible preferred stock pursuant to an amendment to the Company&#8217;s amended and restated certificate of incorporation effective as of April 27, 2020. Accordingly, all common stock shares, per share amounts, and additional paid in capital amounts for all periods presented in the accompanying consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, the Company completed its IPO in which the Company issued and sold 4,025,000 shares of its common stock, including 525,000 shares pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, at a public offering price of $16.00 per share, for aggregate gross proceeds of $64.4 million. The Company received approximately $57.3 million in net proceeds after deducting underwriting discounts and offering expenses paid by the Company. In connection with this financing, all outstanding shares of redeemable convertible preferred stock converted into 8,335,248 shares of the Company&#8217;s common stock, all outstanding Warrants were automatically cashless exercised resulting in the issuance of 313,794 shares of the Company&#8217;s stock and the issuance to one of our directors, in lieu of compensation payable by the Company under a consulting agreement, of 19,661 fully vested shares of the Company&#8217;s common stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, the Company issued as non-employee compensation 5,000 fully vested shares of the Company&#8217;s common stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has reserved for future issuances the following shares of common stock as of December 31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,888,653</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock purchase plan</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,038,653</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Warrants</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In conjunction with the issuance of the Series C Preferred Stock, the Company issued Warrants to purchase 681,256 shares of common stock at an exercise price of $8.63 per share.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classified the Warrants as equity in the consolidated balance sheets in accordance with the guidance in ASC 815, <font style="font-style:italic;">Derivatives and Hedging</font>. The Company allocated the net proceeds from the issuance of the Series C Preferred Stock based on the relative fair values of the Series C Preferred Stock and Warrants, which resulted in approximately $0.7 million of the net proceeds being allocated to the Warrants.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the completion of the IPO of the Company&#8217;s common stock in May 2020, all outstanding Warrants were automatically cashless exercised resulting in the issuance of 313,794 shares of the Company&#8217;s common stock.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688556008040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8. Stock-Based Compensation Expense </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted the 2016 Equity Incentive Plan (&#8220;2016 Plan&#8221;) in February 2016 and amended it in June 2017 and June 2018. Upon adoption of the 2016 Plan, no further grants were made under the 2005 Equity Incentive Plan (&#8220;2005 Plan&#8221;).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2020, the Company&#8217;s Board of Directors adopted the Company&#8217;s 2020 Incentive Award Plan (&#8220;2020 Plan&#8221;, and together with the 2016 Plan and 2005 Plan, the &#8220;Plans&#8221;), and upon effectiveness of the 2020 Plan, the Company ceased granting equity-based awards under the 2016 Plan. The 2020 Plan provides for grant of incentive stock options and nonqualified stock options, stock appreciation rights, restricted stock, dividend equivalents, restricted stock units, performance awards and other share and cash-based awards to employees and consultants and members of the Board of Directors of the Company and its subsidiaries.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initial number of shares of the Company&#8217;s common stock that may be issued under the 2020 Plan is 2,100,000 shares plus the number of shares of the Company&#8217;s common stock underlying outstanding awards under the 2005 Plan and 2016 Plan as of the effective date of the 2020 Plan that expire, lapse or are terminated, exchanged for cash, surrendered, repurchased, canceled or forfeited following the effective date of the 2020 Plan. The number of shares available under the 2020 Plan will automatically increase on January 1st of each year from 2021 to 2030 by the lesser of (i) 4% of the number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) a smaller number of shares determined by the Company&#8217;s Board of Directors. However, no more than 8,800,000 shares may be issued under the 2020 Plan pursuant to the exercise of incentive stock options. As of December 31, 2020, the Company had 1,459,767 shares available for issuance under the 2020 Plan.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All stock option grants are nonqualified stock options except option grants to employees and officers intended to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended. Stock options may not be granted at less than the fair market value of the Company&#8217;s common stock on the date of grant. Vesting periods of awards are determined by the Board of Directors or its compensation committee. Vesting periods of awards granted to date range from vesting upon grant to vesting over a four-year period. Vesting conditions are generally based on continued service. Additionally, the Company has granted certain awards which vest upon the achievement of certain financing and revenue milestones. Stock options granted under the Plans expire no more than 10 years from the date of grant. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense included in the Company&#8217;s consolidated statements of operations and comprehensive loss was as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">229</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,584</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">218</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,813</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not record any stock-based compensation associated with milestone-based awards in the years ended December&#160;31, 2020 and 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each stock option granted to employees, directors and non-employees was estimated on the date of grant using the Black-Scholes option-pricing model, with the following weighted-average assumptions: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80.7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76.8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the stock option activity under the Plans for the year ended December 31, 2020 was as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in&#160;thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">792,439</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.59</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,363</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">763,505</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.16</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,814</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.92</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(124,244</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.30</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,428,886</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.41</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.7</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,165</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">626,578</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.30</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,099</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:16.35pt;">
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,428,886</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.41</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.7</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,165</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average fair value of options granted to employees, directors and non-employees during the years ended December&#160;31, 2020 and 2019 was $9.66 and $3.45, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. The aggregate intrinsic value of stock options exercised during the years ended December&#160;31, 2020 and 2019 was approximately $27,000 and $0.2 million, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, total unrecognized stock-based compensation expense relating to unvested stock options was approximately $6.2&#160;million. This amount is expected to be recognized over a weighted-average period of 3.2 years. Additionally, as of December 31, 2020, there was approximately $36,000 of unrecognized stock-based compensation related to a stock option award related to the achievement of a revenue-based milestone. As the Company believes the achievement of the revenue-based milestone is currently not probable, it has not recorded any stock-based compensation related to this award. The Company will continue to assess the probability of achieving the revenue-based milestone at each reporting period. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020 Employee Stock Purchase Plan</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2020, the Company&#8217;s Board of Directors adopted the Company&#8217;s 2020 Employee Stock Purchase Plan (&#8220;2020 ESPP&#8221;). The 2020 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.&nbsp;&nbsp;The Company initially reserved 150,000 shares of common stock for issuance under the 2020 ESPP.&nbsp;&nbsp;In addition, the number of shares available for issuance under the 2020 ESPP will be annually increased on January 1st of each year from 2021 to 2030 by the lesser of (i) 0.5% of the number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by the Company&#8217;s Board of Directors, provided that no more than 987,500 shares of common stock may be issued under the 2020 ESPP. The 2020 ESPP permits eligible participants to purchase common stock through payroll deductions of up to a specified percentage of their eligible compensation. On the first trading day of each offering period, each participant will automatically be granted an option to purchase shares of the Company&#8217;s common stock. The option will expire at the end of the applicable offering period, and will be exercised at that time to the extent of the payroll deductions accumulated during the offering period, subject to the limits set forth in the 2020 ESPP. The purchase price of the shares, in the absence of a contrary designation, will be 85% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the purchase date. As of December 31, 2020, no shares have been issued under the 2020 ESPP. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688632446968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9. Related Parties </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had consulting agreements that expired in January 2020 with two of its founders who resigned as directors of the Company in October 2020. Total consulting expense related to these consulting agreements was $0 and $50,000 for the years ended December 31, 2020 and 2019, respectively. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2011, the Company entered into a Contribution Agreement, Transition Services Agreement (as amended), Collaboration Agreement, Technology License Agreement and Trademark Coexistence Agreement with Arsenal Medical, Inc. (&#8220;Arsenal&#8221;), a company which shares certain common owners with the Company. During the year ended December 31, 2019, the Company invoiced Arsenal for an aggregate of $0.3, primarily for its share of rent and other overhead costs.&nbsp;&nbsp;The Transition Services Agreement expired in June 2019. All amounts receivable from Arsenal were collected as of December 31, 2019. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688556212904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10. Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records a provision or benefit for income taxes on pre-tax income or loss based on its estimated effective tax rate for the year. During the years ended December&#160;31, 2020 and 2019, the Company recorded net losses of approximately $22.1 million and $16.3&#160;million, respectively, and, since it maintains a full valuation allowance on its deferred tax assets, the Company did not record an income tax benefit for the years ended December&#160;31, 2020 and 2019. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of income tax expense computed at the statutory federal income tax rate to income taxes reflected in the consolidated financial statements is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax computed at federal statutory tax rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes, net of federal benefit</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development and other tax credits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in deferred tax asset valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28.4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30.7</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets as of December&#160;31, 2020 and 2019 consist of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,729</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,006</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,223</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,652</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">322</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">661</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">909</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">280</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total gross deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,075</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,451</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35,150</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">624</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">870</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(624</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(870</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(624</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(870</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred taxes</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company had U.S. federal net operating loss carryforwards of approximately $91.4&#160;million which may be able to offset future income tax liabilities and expire at various dates through 2037 and approximately $44.0&#160;million of federal net operating loss carryforwards that may be carried forward indefinitely. As of December&#160;31, 2020, the Company also had state net operating loss carryforwards of approximately $116.0&#160;million which may be available to offset future income tax liabilities and expire at various dates through 2040. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, the Company had federal research and development tax credit carryforwards of approximately $3.6 million and $3.2&#160;million, respectively, available to reduce future tax liabilities which expire at various dates through 2040. As of December&#160;31, 2020 and 2019, the Company had state research and development tax credit carryforwards of approximately $2.0 million and $1.8&#160;million, respectively, available to reduce future tax liabilities which expire at various dates through 2035. The Company has generated research credits but has not conducted a study to document the qualified activity. This study may result in an adjustment to the Company&#8217;s research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the research and development credit carryforwards and the valuation allowance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the provisions of the Internal Revenue Code, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section&#160;382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section&#160;382, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed by the Company and any limitation is known, no amounts are being presented as an uncertain tax position. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at December&#160;31, 2020 and 2019 because the Company&#8217;s management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets primarily due to its history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and, as a result, a valuation allowance of approximately $41.5 million and $35.2&#160;million, respectively, has been established at December&#160;31, 2020 and 2019. Management reevaluates the positive and negative evidence at each reporting period. The valuation allowance increased by approximately $6.3 million and $5.1&#160;million, respectively, during the years ended December&#160;31, 2020 and 2019 due primarily to the generation of net operating losses. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has recorded adjustments to deferred tax assets for unrecognized tax benefits as of December&#160;31, 2020 and 2019. The Company&#8217;s policy is to record interest and penalties related to uncertain tax positions as part of its income tax provision. As of December&#160;31, 2020 and 2019, the Company had no accrued interest or penalties related to uncertain tax positions and no such amounts have been recognized in the Company&#8217;s statement of operations and comprehensive loss. In many cases, the Company&#8217;s uncertain tax positions are related to years that remain subject to examination by relevant tax authorities. The statute of limitations for federal and state tax authorities is closed for years prior to December&#160;31, 2017. However, since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available. </p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes using the liability method in accordance with ASC Topic 740, <font style="font-style:italic;">Income Taxes</font> (&#8220;ASC 740&#8221;). The difference between the financial statement and tax basis of the assets and liabilities is determined annually. Deferred income tax assets and liabilities are computed using the tax laws and rates that are expected to apply for periods in which such differences reverse. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will more likely than not be realized. </p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. </p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688556249496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11. Leases </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2007, the Company entered into an operating lease, as amended, for approximately 22,343 square feet of office and laboratory space in Watertown, Massachusetts. In November 2017, the Company amended its lease (&#8220;2017 Amendment&#8221;) and extended the lease term through April 2023. Initial base rent under the 2017 Amendment was approximately $1.0&#160;million per year. The 2017 Amendment includes annual rent escalations over the term of the operating lease. The Company maintains a letter of credit of approximately $0.3&#160;million securing its obligations under the operating lease which is secured by approximately $0.3&#160;million of certificate of deposits, which are included as restricted cash in the consolidated balance sheets. Rent expense is recognized on a straight-line basis over the terms of occupancy. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the lease discussed above, the Company is party to an April 2020 lease for office equipment that expires in June 2024.&nbsp;&nbsp;The equipment lease is accounted for as an operating lease.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease cost recorded in the Company&#8217;s consolidated financial statements were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease Cost:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,055</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,053</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">726</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">727</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(368</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,781</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,412</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease payments include the Company&#8217;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. The Company&#8217;s sublease income during the year ended December 31, 2019 related to subleases for a portion of the Company&#8217;s office and lab space.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average remaining lease term and discount rate related to the Company&#8217;s operating leases were as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (in years)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturity of the Company&#8217;s operating lease liabilities in accordance with ASC 842 as of December 31, 2020 were as follows (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,095</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,127</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">382</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total maturities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,606</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Amount representing interest</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(167</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of operating lease liability</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,439</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Current portion of operating lease liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(985</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liability, net of current portion</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,454</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688556238424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Retirement Plan</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12. Retirement Plan </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a defined-contribution plan under Section&#160;401(k) of the Internal Revenue Code (&#8220;401(k) Plan&#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. As currently established, the Company is not required to make any contributions to the 401(k) Plan. For the year ended December 31, 2020, the Company made a discretionary match that matches 50% of employee contributions up to a maximum of 3% of employees&#8217; salary. Matching contributions are fully vested at the time of contribution. During the year ended December 31, 2020, matching contribution costs incurred by the Company were $0.1 million. The Company did not make any matching contributions during the year ended December&#160;31, 2019. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688549542504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_COVID19PandemicAndCARESActPolicyTextBlock', window );">COVID-19 Pandemic and CARES Act</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COVID-19 Pandemic and CARES Act</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 30, 2020, the World Health Organization (&#8220;WHO&#8221;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &#8220;COVID-19 outbreak&#8221;) and the risks to the international community as the virus subsequently spread globally beyond its point of origin. On March 11, 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The COVID-19 pandemic is affecting the United States and global economies and may affect the Company&#8217;s operations and those of third parties on which the Company relies, including by causing disruptions in the supply of the Company&#8217;s product candidates and the conduct of current and future clinical trials. In addition, the COVID-19 pandemic may affect the operations of the Food and Drug Administration and other health authorities, which could result in delays of reviews and approvals, including with respect to the Company&#8217;s product candidates. In light of developments relating to the COVID-19 pandemic, the Company discontinued enrollment at 67 patients in its Phase 2 LANTERN clinical trial and did not enroll patients in the United States. Additionally, while the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce the Company&#8217;s ability to access capital, which could negatively impact the Company&#8217;s short-term and long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, financing or clinical trial activities or on healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company&#8217;s liquidity, capital resources, operations and business and those of the third parties on which the Company relies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 27, 2020, President Trump signed into law the &#8220;Coronavirus Aid, Relief, and Economic Security (CARES) Act.&#8221; The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property. The Company currently defers the employer side social security payments and also is evaluating whether it will take advantage of other provisions, if any. The CARES Act also appropriated funds for the SBA Paycheck Protection Program loans that are forgivable in certain situations to promote continued employment, as well as Economic Injury Disaster Loans to provide liquidity to small businesses harmed by COVID-19. On December 27, 2020, the Consolidated Appropriations Act, 2021 was signed into law in order to provide further stimulus and support to those affected by the COVID-19 pandemic. The Company has not and does not plan on obtaining funding from such loans. The Company does not believe the CARES Act or the Consolidated Appropriations Act, 2021 will have a material impact on its financial condition, results of operations, or liquidity.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation </p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of Lyra Therapeutics, Inc. and its wholly owned subsidiary Lyra Therapeutics Security Corporation, which was incorporated in December 2018. All intercompany transactions and balances have been eliminated. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the accompanying consolidated financial statements and notes. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&#8217;s management evaluates its estimates, which include but are not limited to management&#8217;s judgments of accrued expenses, fair value of common stock, valuation of share-based awards warrants to purchase common stock and deferred income taxes. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilizes significant estimates and assumptions in determining the fair value of its common stock. The Company has utilized various valuation methodologies to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&#8217;s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_SegmentInformationTextBlock', window );">Segment Information</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment Information </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision-maker, the Company&#8217;s chief executive officer, views the Company&#8217;s operations and manages its business as a single operating segment, which is the business of developing targeted medicines to address ENT diseases. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive Income (Loss) </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. As the Company did not have any element of other comprehensive income (loss), its comprehensive loss is equal to its net loss for all periods presented. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash held in banks and amounts held in money market funds. Cash equivalents are stated at cost, which approximates market value. </p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents consist of cash held in banks at December&#160;31, 2020 and 2019. </p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_RestrictedCashPolicyTextBlock', window );">Restricted Cash</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Cash </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had restricted cash of approximately $0.3&#160;million as of December&#160;31, 2020 and 2019, which was held in certificates of deposit at the Company&#8217;s financial institution to secure the Company&#8217;s letter of credit for its facility lease. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock', window );">Concentrations Of Credit Risk And Off Balance Sheet Risk</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Off-Balance Sheet Risk </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains all its cash and cash equivalents at a single accredited financial institution, in amounts that exceed federally insured limits.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign exchange hedging arrangements. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_SignificantSuppliersPolicyTextBlock', window );">Significant Suppliers</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Significant Suppliers </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the drug product and associated applicator related to these programs. These programs could be adversely affected by a significant interruption in the supply of the materials required to manufacture the drug product and associated applicator. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at a measurement date. ASC Topic 820, <font style="font-style:italic;">Fair Value Measurements</font> (&#8220;ASC 820&#8221;), establishes a three-level valuation hierarchy for instruments measured at fair value that prioritizes the inputs used to measure fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported or disclosed fair value of the financial instruments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy established by ASC 820 in order of priority are as follows: </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;1&#160;-Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;2 -Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;3 -Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An entity may elect to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in net loss. The Company did not elect to measure any financial instruments or other items at fair value. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Derivative Liabilities </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with certain debt and equity financings, the Company may issue financial instruments in which a derivative instrument is &#8220;embedded.&#8221; Upon issuing the financial instrument, the Company assesses whether the economic characteristics of the embedded derivative are clearly and closely related to the economic characteristics of the remaining component of the financial instrument (i.e., the host contract) and whether a separate, non-embedded instrument with the same terms as the embedded instrument would meet the definition of a derivative instrument. When it is determined that (1)&#160;the embedded derivative possesses economic characteristics that are not clearly and closely related to the economic characteristics of the host contract, and (2)&#160;a separate, stand-alone instrument with the same terms would qualify as a derivative instrument, the embedded derivative is separated from the host contract and carried at fair value until the derivative is settled. Changes in the fair value of the derivative liabilities are recognized as other income (expense) in the consolidated statement of operations and comprehensive loss. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy', window );">Classification and Accretion of Redeemable Convertible Preferred Shares</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Classification and Accretion of Redeemable Convertible Preferred Shares </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has classified the redeemable convertible preferred stock outside of stockholders&#8217; deficit in the accompanying consolidated balance sheets in accordance with authoritative guidance for the classification and measurement of redeemable securities as the redeemable convertible preferred stock is redeemable at a determinable price on a fixed date or upon the occurrence of a deemed liquidation event. The carrying values of the redeemable convertible preferred shares are accreted to their redemption values from the date of issuance through the earliest date of redemption. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. Property and Equipment </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of the following at December&#160;31, 2020 and 2019 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,277</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,715</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer software and equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">650</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">595</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office furniture and fixtures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">317</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">317</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">498</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,043</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,066</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,878</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,829</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,165</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized approximately $0.1 million and $27,000 of depreciation expense for the years ended December 31, 2020 and 2019, respectively.</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle" style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimated Useful Life</p></td>
</tr>
<tr>
<td valign="bottom" style="width:49%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td valign="bottom" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer software and equipment</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="bottom" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office furniture and fixtures</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7 years</p></td>
</tr>
<tr>
<td valign="bottom" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of useful life or remaining term of related lease</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs for capital assets not yet placed into service are capitalized as construction in progress and are depreciated in accordance with the above guidelines once placed into service. Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statement of operations and comprehensive loss. Repairs and maintenance that do not improve or extend the lives of the respective assets are expensed as incurred, while costs of major additions and betterments are capitalized. </p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets consist of property and equipment. The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company did not record any impairment losses on long-lived assets during the years ended December&#160;31, 2020 and 2019. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASU No. 2016-02, <font style="font-style:italic;">Leases (Topic 842)</font> (&#8220;ASU No. 2016-02&#8221;), became effective January 1, 2019. As of the effective date of ASU No. 2016-02, the Company determines at the inception of an arrangement whether the arrangement contains a lease. If a lease is identified in an arrangement, the Company recognizes a right-of-use asset and liability on its balance sheet and determines whether the lease should be classified as a finance or operating lease. The Company does not recognize assets or liabilities for leases with lease terms of less than 12&#160;months. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the rate implicit in the lease is not readily determinable, the Company utilizes its incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company separates lease and non-lease components when determining which lease payments to include in the calculation of its lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably certain it will exercise the option. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases are recorded in &#8220;Operating lease right-of use assets,&#8221; &#8220;Operating lease liabilities&#8221; and &#8220;Operating lease liabilities, net of current portion&#8221; in the Company&#8217;s consolidated balance sheets. The Company did not have any finance leases recorded in its consolidated balance sheet as of December 31, 2020. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_ResearchAndDevelopmentCostsTextBlock', window );">Research And Development Costs</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Costs </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, manufacturing expenses, stock-based compensation expense, depreciation of equipment, contract services and other outside expenses. Costs of certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development contracts with companies both inside and outside of the United States. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_PatentsCostsPolicyTextBlock', window );">Patents Costs</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patent Costs </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_AccountingForStockBasedCompensationPolicy', window );">Accounting for Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accounting for Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, <font style="font-style:italic;">Compensation&#8212;Stock Compensation</font> (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments to employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees. The Company believes the fair value of the stock options granted to non-employees is more reliably determinable than the fair value of the services provided. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Black-Scholes option-pricing model uses the following inputs: the fair value of the Company&#8217;s common stock, the expected volatility of the Company&#8217;s common stock, the expected term of the Company&#8217;s stock options, the risk-free interest rate for a period that approximates the expected term of the Company&#8217;s stock options, and the Company&#8217;s expected dividend yield. Following the closing of the Company&#8217;s IPO, the fair value of the Company&#8217;s common stock is determined based on the quoted market price of its common stock. The Company has historically been a private company and lacks company-specific historical and implied volatility data. Therefore, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to it, including stage of product development, life science industry focus, length of trading history, and similar vesting provisions. The historical volatility data is calculated based on a period of time commensurate with the expected term assumption. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available or until circumstances change, such that the identified entities are no longer representative companies. In the latter case, more suitable, similar entities whose share prices are publicly available would be utilized in the calculation. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, <font style="font-style:italic;">Share-Based Payment</font>, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid cash dividends and has no current plans to pay any cash dividends on its common stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has elected as a policy to recognize forfeitures as they occur as described in ASU No.&#160;2016-09, <font style="font-style:italic;">Compensation&#8212;Stock Compensation</font> (&#8220;ASU No.&#160;2016-09&#8221;). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expenses the fair value of its stock-based compensation awards to employees on a straight-line basis over the requisite service period, which is generally the vesting period. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company follows the provisions of ASU No.&#160;2018-07, <font style="font-style:italic;">Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</font> (&#8220;ASU No.&#160;2018-07&#8221;) which permits the Company to recognize non-employee stock-based compensation costs over the requisite period based on a measurement of fair value on the grant date for each stock-based award. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10. Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records a provision or benefit for income taxes on pre-tax income or loss based on its estimated effective tax rate for the year. During the years ended December&#160;31, 2020 and 2019, the Company recorded net losses of approximately $22.1 million and $16.3&#160;million, respectively, and, since it maintains a full valuation allowance on its deferred tax assets, the Company did not record an income tax benefit for the years ended December&#160;31, 2020 and 2019. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of income tax expense computed at the statutory federal income tax rate to income taxes reflected in the consolidated financial statements is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax computed at federal statutory tax rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes, net of federal benefit</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development and other tax credits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in deferred tax asset valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28.4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30.7</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets as of December&#160;31, 2020 and 2019 consist of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,729</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,006</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,223</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,652</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">322</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">661</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">909</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">280</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total gross deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,075</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,451</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35,150</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">624</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">870</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(624</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(870</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(624</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(870</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred taxes</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company had U.S. federal net operating loss carryforwards of approximately $91.4&#160;million which may be able to offset future income tax liabilities and expire at various dates through 2037 and approximately $44.0&#160;million of federal net operating loss carryforwards that may be carried forward indefinitely. As of December&#160;31, 2020, the Company also had state net operating loss carryforwards of approximately $116.0&#160;million which may be available to offset future income tax liabilities and expire at various dates through 2040. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, the Company had federal research and development tax credit carryforwards of approximately $3.6 million and $3.2&#160;million, respectively, available to reduce future tax liabilities which expire at various dates through 2040. As of December&#160;31, 2020 and 2019, the Company had state research and development tax credit carryforwards of approximately $2.0 million and $1.8&#160;million, respectively, available to reduce future tax liabilities which expire at various dates through 2035. The Company has generated research credits but has not conducted a study to document the qualified activity. This study may result in an adjustment to the Company&#8217;s research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the research and development credit carryforwards and the valuation allowance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the provisions of the Internal Revenue Code, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section&#160;382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section&#160;382, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed by the Company and any limitation is known, no amounts are being presented as an uncertain tax position. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at December&#160;31, 2020 and 2019 because the Company&#8217;s management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets primarily due to its history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and, as a result, a valuation allowance of approximately $41.5 million and $35.2&#160;million, respectively, has been established at December&#160;31, 2020 and 2019. Management reevaluates the positive and negative evidence at each reporting period. The valuation allowance increased by approximately $6.3 million and $5.1&#160;million, respectively, during the years ended December&#160;31, 2020 and 2019 due primarily to the generation of net operating losses. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has recorded adjustments to deferred tax assets for unrecognized tax benefits as of December&#160;31, 2020 and 2019. The Company&#8217;s policy is to record interest and penalties related to uncertain tax positions as part of its income tax provision. As of December&#160;31, 2020 and 2019, the Company had no accrued interest or penalties related to uncertain tax positions and no such amounts have been recognized in the Company&#8217;s statement of operations and comprehensive loss. In many cases, the Company&#8217;s uncertain tax positions are related to years that remain subject to examination by relevant tax authorities. The statute of limitations for federal and state tax authorities is closed for years prior to December&#160;31, 2017. However, since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available. </p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes using the liability method in accordance with ASC Topic 740, <font style="font-style:italic;">Income Taxes</font> (&#8220;ASC 740&#8221;). The difference between the financial statement and tax basis of the assets and liabilities is determined annually. Deferred income tax assets and liabilities are computed using the tax laws and rates that are expected to apply for periods in which such differences reverse. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will more likely than not be realized. </p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. </p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contingencies </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with ASC Topic 450, <font style="font-style:italic;">Contingencies</font>, the Company records accruals for contingencies and legal proceedings expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteesTextBlock', window );">Guarantees</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Guarantees </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has identified the guarantees described below as disclosable, in accordance with ASC Topic 460, <font style="font-style:italic;">Guarantees</font>. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company&#8217;s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#8217; and officers&#8217; insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office space under a noncancelable operating lease. The Company has standard indemnification arrangements under the lease that requires it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the lease. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, the Company had not experienced any losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves have been established. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_DeferredOfferingCostsTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Deferred Offering Costs </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&#8217; deficit as a reduction of additional paid-in capital generated as a result of the offering. Should the planned equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statement of operations and comprehensive loss. Deferred offering costs of $0 and $1.1 million are included in other assets in the consolidated balance sheets at December 31, 2020 and 2019, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss per Share </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company has computed diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, warrants to purchase common stock and redeemable convertible preferred stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive and basic and diluted loss per share have been the same. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share data): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,127</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,306</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accretion of redeemable convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(115</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(313</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,242</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,619</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares&#8212;basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,590,205</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202,093</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders&#8212;basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.59</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(82.23</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares retroactively adjusted): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A-1 redeemable convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">986,466</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A-2 redeemable convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">773,712</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A-3 redeemable convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">872,031</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A-4 redeemable convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">579,993</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B redeemable convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,852,177</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,428,886</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">792,439</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,428,886</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,856,818</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:12pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU No.&#160;2018-13, <font style="font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</font> (&#8220;ASU No.&#160;2018-13&#8221;), which modifies the disclosure requirements on fair value measurements. The Company adopted ASU No. 2018-13 on January&#160;1, 2020. The adoption of ASU 2018-13 did not have a material impact on the Company&#8217;s consolidated financial position, results of operations or cash flows.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU No.&#160;2018-15, <font style="font-style:italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</font> (&#8220;ASU No.&#160;2018-15&#8221;), which clarifies the accounting for implementation costs in cloud computing arrangements. The Company adopted ASU No. 2018-15 on January&#160;1, 2020 on a prospective basis. The adoption of ASU 2018-15 did not have a material impact on the Company&#8217;s consolidated financial position, results of operations or cash flows.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No. 2019-12, <font style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</font> (&#8220;ASU No. 2019-12&#8221;), which makes a number of changes meant to add or clarify guidance on accounting for income taxes. The new guidance will become effective for the Company on January 1, 2022. Early adoption is permitted. The Company currently is evaluating the impact the adoption of ASU 2019-12 will have on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_AccountingForStockBasedCompensationPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounting for stock-based compensation policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_AccountingForStockBasedCompensationPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_COVID19PandemicAndCARESActPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>COVID-19 Pandemic and CARES Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_COVID19PandemicAndCARESActPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentrations of credit risk and off-balance sheet risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_DeferredOfferingCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_DeferredOfferingCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_PatentsCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the patents cost policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_PatentsCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recently issued accounting pronouncements policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ResearchAndDevelopmentCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure for received credits as included in research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ResearchAndDevelopmentCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_RestrictedCashPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_RestrictedCashPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_SegmentInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Segment information text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_SegmentInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_SignificantSuppliersPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant suppliers policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_SignificantSuppliersPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for each guarantee obligation, or each group of similar guarantee obligations, including (a) the nature of the guarantee, including its term, how it arose, and the events or circumstances that would require the guarantor to perform under the guarantee; (b) the maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee; (c) the current carrying amount of the liability, if any, for the guarantor's obligations under the guarantee; and (d) the nature of any recourse provisions under the guarantee, and any assets held either as collateral or by third parties, and any relevant related party disclosure. Excludes disclosures about product warranties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -URI http://asc.fasb.org/topic&amp;trid=2155896<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116854557&amp;loc=d3e20905-112640<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688559364232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property Plant And Equipment</a></td>
<td class="text">Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle" style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimated Useful Life</p></td>
</tr>
<tr>
<td valign="bottom" style="width:49%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td valign="bottom" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer software and equipment</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="bottom" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office furniture and fixtures</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7 years</p></td>
</tr>
<tr>
<td valign="bottom" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of useful life or remaining term of related lease</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of the following at December&#160;31, 2020 and 2019 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,277</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,715</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer software and equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">650</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">595</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office furniture and fixtures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">317</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">317</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">498</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,043</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,066</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,878</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,829</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,165</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share data): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,127</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,306</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accretion of redeemable convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(115</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(313</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,242</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,619</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares&#8212;basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,590,205</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202,093</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders&#8212;basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.59</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(82.23</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares retroactively adjusted): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A-1 redeemable convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">986,466</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A-2 redeemable convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">773,712</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A-3 redeemable convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">872,031</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A-4 redeemable convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">579,993</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B redeemable convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,852,177</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,428,886</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">792,439</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,428,886</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,856,818</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688556187384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property Plant And Equipment</a></td>
<td class="text">Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle" style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimated Useful Life</p></td>
</tr>
<tr>
<td valign="bottom" style="width:49%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td valign="bottom" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer software and equipment</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="bottom" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office furniture and fixtures</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7 years</p></td>
</tr>
<tr>
<td valign="bottom" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of useful life or remaining term of related lease</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of the following at December&#160;31, 2020 and 2019 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,277</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,715</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer software and equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">650</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">595</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office furniture and fixtures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">317</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">317</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">498</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,043</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,066</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,878</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,829</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,165</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688556281480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities consist of the following at December&#160;31, 2020 and 2019 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and employee related expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,892</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">885</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party research and development expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">381</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,344</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional and consulting fees</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">555</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">901</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses and other current liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,977</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,240</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688632426216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock', window );">Schedule of Common Stock Reserved for Future Issuances</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has reserved for future issuances the following shares of common stock as of December 31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,888,653</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock purchase plan</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,038,653</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of common stock reserved for future issuances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_SharesOfCommonStockReservedForFutureIssuancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688556232616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense included in the Company&#8217;s consolidated statements of operations and comprehensive loss was as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">229</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,584</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">218</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,813</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each stock option granted to employees, directors and non-employees was estimated on the date of grant using the Black-Scholes option-pricing model, with the following weighted-average assumptions: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80.7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76.8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity Under Plans</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the stock option activity under the Plans for the year ended December 31, 2020 was as follows: </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in&#160;thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">792,439</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.59</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,363</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">763,505</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.16</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,814</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.92</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(124,244</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.30</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,428,886</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.41</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.7</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,165</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">626,578</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.30</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,099</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:16.35pt;">
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,428,886</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.41</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.7</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,165</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688634224360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of income tax expense computed at the statutory federal income tax rate to income taxes reflected in the consolidated financial statements is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax computed at federal statutory tax rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes, net of federal benefit</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development and other tax credits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in deferred tax asset valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28.4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30.7</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets as of December&#160;31, 2020 and 2019 consist of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,729</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,006</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,223</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,652</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">322</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">661</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">909</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">280</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total gross deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,075</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,451</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35,150</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">624</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">870</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(624</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(870</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(624</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(870</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred taxes</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688559327304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Cost</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease cost recorded in the Company&#8217;s consolidated financial statements were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease Cost:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,055</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,053</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">726</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">727</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(368</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,781</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,412</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock', window );">Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average remaining lease term and discount rate related to the Company&#8217;s operating leases were as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (in years)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Maturity of Operating Lease Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturity of the Company&#8217;s operating lease liabilities in accordance with ASC 842 as of December 31, 2020 were as follows (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,095</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,127</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">382</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total maturities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,606</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Amount representing interest</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(167</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of operating lease liability</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,439</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Current portion of operating lease liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(985</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liability, net of current portion</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,454</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of weighted average remaining lease terms and discount rate related to operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_SummaryOfWeightedAverageRemainingLeaseTermsAndDiscountRateRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688552369368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 05, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 11, 2020 </div>
<div>Patient</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Entity incorporation, date of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 21,  2005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (22,127)<span></span>
</td>
<td class="num">$ (16,306)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(149,884)<span></span>
</td>
<td class="num">(127,757)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,593<span></span>
</td>
<td class="nump">$ 9,808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_NumberOfPatients', window );">Number of patients | Patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from initial public offering, net of issuance costs, Shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_GrossProceedsFromInitialPublicOffering', window );">Gross proceeds from initial public offering</a></td>
<td class="nump">$ 64,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from initial public offering</a></td>
<td class="nump">$ 57,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from initial public offering, net of issuance costs, Shares | shares</a></td>
<td class="nump">4,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued and sold, public offering price | $ / shares</a></td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Exercise of Underwriters' Option | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from initial public offering, net of issuance costs, Shares | shares</a></td>
<td class="nump">525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_GrossProceedsFromInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_GrossProceedsFromInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_NumberOfPatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of patients.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_NumberOfPatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_OrganizationAndBasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_OrganizationAndBasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688555951848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688554451448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, gross</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer software and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, gross</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, gross</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and equipment, gross</a></td>
<td class="text">Shorter of useful life or remaining term of related lease<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688633800824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (22,127)<span></span>
</td>
<td class="num">$ (16,306)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of redeemable convertible preferred stock</a></td>
<td class="num">(115)<span></span>
</td>
<td class="num">(313)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (22,242)<span></span>
</td>
<td class="num">$ (16,619)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding&#8212;basic and diluted</a></td>
<td class="nump">8,590,205<span></span>
</td>
<td class="nump">202,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders&#8212;basic and diluted</a></td>
<td class="num">$ (2.59)<span></span>
</td>
<td class="num">$ (82.23)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688549618936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="nump">1,428,886<span></span>
</td>
<td class="nump">6,856,818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lyra_SeriesA1RedeemableConvertiblePreferredStockMember', window );">Series A-1 Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">986,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lyra_SeriesA2RedeemableConvertiblePreferredStockMember', window );">Series A-2 Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">773,712<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lyra_SeriesA3RedeemableConvertiblePreferredStockMember', window );">Series A-3 Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">872,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lyra_SeriesA4RedeemableConvertiblePreferredStockMember', window );">Series A-4 Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">579,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lyra_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,852,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="nump">1,428,886<span></span>
</td>
<td class="nump">792,439<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lyra_SeriesA1RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lyra_SeriesA1RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lyra_SeriesA2RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lyra_SeriesA2RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lyra_SeriesA3RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lyra_SeriesA3RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lyra_SeriesA4RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lyra_SeriesA4RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lyra_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lyra_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688559320920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets, fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities, fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentChangeInValuationTechnique', window );">Alternative investment, change in valuation technique</a></td>
<td class="text">false<span></span>
</td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentChangeInValuationTechnique">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether valuation technique or approach changed for measuring alternative investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentChangeInValuationTechnique</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688549964792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 5,043<span></span>
</td>
<td class="nump">$ 3,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(2,878)<span></span>
</td>
<td class="num">(2,829)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,165<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">3,277<span></span>
</td>
<td class="nump">1,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lyra_ComputerSoftwareAndEquipmentMember', window );">Computer Software and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">650<span></span>
</td>
<td class="nump">595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 498<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lyra_ComputerSoftwareAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=lyra_ComputerSoftwareAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688654615400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 95,000<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688554717224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee related expenses</a></td>
<td class="nump">$ 1,892<span></span>
</td>
<td class="nump">$ 885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent', window );">Third-party research and development expenses</a></td>
<td class="nump">381<span></span>
</td>
<td class="nump">1,344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional and consulting fees</a></td>
<td class="nump">555<span></span>
</td>
<td class="nump">901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_AccruedExpensesAndOtherLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 2,977<span></span>
</td>
<td class="nump">$ 3,240<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_AccruedExpensesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_AccruedExpensesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Third-party research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_ThirdPartyResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688554557688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 10, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lyra_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">78,306,611<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued and sold, public offering price</a></td>
<td class="nump">$ 0.38811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from the sale of Series C redeemable convertible preferred stock</a></td>
<td class="nump">$ 30.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299,300,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lyra_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lyra_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688548688856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stock - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 05, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 10, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The holders of common stock are entitled to one vote for each share held.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_CommonStockVotingRightsNumberOfVotes', window );">Number of common stock voting rights | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split of issued and outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-34.483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from initial public offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,932,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lyra_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued and sold, public offering price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.38811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lyra_NonEmployeeCompensationMember', window );">Non Employee Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from initial public offering, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_GrossProceedsFromInitialPublicOffering', window );">Gross proceeds from initial public offering | $</a></td>
<td class="nump">$ 64,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from initial public offering | $</a></td>
<td class="nump">$ 57,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Preferred stock converted into common stock</a></td>
<td class="nump">8,335,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued to purchase common stock</a></td>
<td class="nump">313,794<span></span>
</td>
<td class="nump">681,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price, per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Vested share of common stock</a></td>
<td class="nump">19,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Exercise of Underwriters' Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from initial public offering, net of issuance costs, Shares</a></td>
<td class="nump">525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from initial public offering, net of issuance costs, Shares</a></td>
<td class="nump">4,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued and sold, public offering price | $ / shares</a></td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants | Series C Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Net proceeds from issuance of preferred stock allocated to warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_CommonStockVotingRightsNumberOfVotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock voting rights, number of votes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_CommonStockVotingRightsNumberOfVotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_GrossProceedsFromInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_GrossProceedsFromInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lyra_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lyra_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lyra_NonEmployeeCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lyra_NonEmployeeCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688549539288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Preferred and Common Stock - Schedule of Common Stock Reserved for Future Issuances (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuances</a></td>
<td class="nump">3,038,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuances</a></td>
<td class="nump">2,888,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuances</a></td>
<td class="nump">150,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688549352248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Feb. 29, 2016</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">763,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,038,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,813,000<span></span>
</td>
<td class="nump">$ 244,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of options granted to employees, directors and consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.66<span></span>
</td>
<td class="nump">$ 3.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense relating to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unvested stock options expected to be recognized over a weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lyra_MilestoneBasedAwardsMember', window );">Milestone-based Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lyra_RevenueBasedMilestoneAwardsMember', window );">Revenue Based Milestone Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense relating to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember', window );">2005 and 2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyra_TwentyThousandTwentyIncentiveAwardPlanMember', window );">2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuances</a></td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued', window );">Maximum number of common shares issued</a></td>
<td class="nump">8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear', window );">Percentage of common shares increase automatically in each year</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,459,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuances</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued', window );">Maximum number of common shares issued</a></td>
<td class="nump">987,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear', window );">Annual increase in number of shares available for issuance as percentage of outstanding shares common stock on final day of immediately preceding fiscal year</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock', window );">Purchase price of shares as percentage lower of fair market value of common stock</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual increase in number of shares available for issuance as percentage on outstanding shares of common stock on final day of immediately preceding calendar year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceAsPercentageOnOutstandingSharesOfCommonStockOnFinalDayOfImmediatelyPrecedingCalendarYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual increase in number of shares available for issuance maximum number of common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_AnnualIncreaseInNumberOfSharesAvailableForIssuanceMaximumNumberOfCommonStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of common shares increase automatically in each year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_PercentageOfCommonSharesIncreaseAutomaticallyInEachYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of shares as percentage lower of fair market value of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_PurchasePriceOfSharesAsPercentageLowerOfFairMarketValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lyra_MilestoneBasedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lyra_MilestoneBasedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lyra_RevenueBasedMilestoneAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lyra_RevenueBasedMilestoneAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lyra_TwoThousandFiveAndTwoThousandSixteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lyra_TwentyThousandTwentyIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lyra_TwentyThousandTwentyIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lyra_TwentyThousandTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688552020936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,813<span></span>
</td>
<td class="nump">$ 244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,584<span></span>
</td>
<td class="nump">$ 218<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688554810552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense - Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">80.70%<span></span>
</td>
<td class="nump">76.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688554600072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense - Summary of Stock Option Activity Under Plans (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding December 31, 2019</a></td>
<td class="nump">792,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="nump">763,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised</a></td>
<td class="num">(2,814)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Cancelled</a></td>
<td class="num">(124,244)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding December 31, 2020</a></td>
<td class="nump">1,428,886<span></span>
</td>
<td class="nump">792,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares, Exercisable at December 31, 2020</a></td>
<td class="nump">626,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Shares, Vested and expected to vest at December 31, 2020</a></td>
<td class="nump">1,428,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding December 31, 2019</a></td>
<td class="nump">$ 6.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">14.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">2.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled</a></td>
<td class="nump">9.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding December 31, 2020</a></td>
<td class="nump">10.41<span></span>
</td>
<td class="nump">$ 6.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable at December 31, 2020</a></td>
<td class="nump">9.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price,Vested and expected to vest at December 31, 2020</a></td>
<td class="nump">$ 10.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted Average Remaining Contractual Life (in years)</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Weighted Average Remaining Contractual Life (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, Weighted Average Remaining Contractual Life (in years)</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding December 31, 2019</a></td>
<td class="nump">$ 3,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding December 31, 2020</a></td>
<td class="nump">5,165<span></span>
</td>
<td class="nump">$ 3,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable at December 31, 2020</a></td>
<td class="nump">3,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest at December 31, 2020</a></td>
<td class="nump">$ 5,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688556362824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Consulting expense related to consulting agreement</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=lyra_ArsenalMedicalIncorporationMember', window );">Arsenal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_DueFromRelatedPartiesDuringPeriod', window );">Amounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_DueFromRelatedPartiesDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Due from related parties during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_DueFromRelatedPartiesDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=lyra_ArsenalMedicalIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=lyra_ArsenalMedicalIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688548660600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (22,127,000)<span></span>
</td>
<td class="num">$ (16,306,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit', window );">Significant change in unrecognized tax benefits is reasonably possible, amount of unrecorded benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">41,451,000<span></span>
</td>
<td class="nump">35,150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">6,300,000<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued', window );">Unrecognized tax benefits income tax penalties accrued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_DomesticCountryMember', window );">U.S. federal jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 91,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Operating loss carryforwards limitations on use</a></td>
<td class="text">offset future income tax liabilities and expire at various dates through 2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred Tax Assets, Tax Credit Carryforwards, Research</a></td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_DomesticCountryMember', window );">U.S. federal jurisdiction | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">44,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 116,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Operating loss carryforwards limitations on use</a></td>
<td class="text">offset future income tax liabilities and expire at various dates through 2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred Tax Assets, Tax Credit Carryforwards, Research</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of statutory penalties accrued for a tax position claimed or expected to be claimed by the entity, in its tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688549915832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax computed at federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Permanent differences</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">5.40%<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development and other tax credits</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in deferred tax asset valuation allowance</a></td>
<td class="num">(28.40%)<span></span>
</td>
<td class="num">(30.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688549876984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 35,729<span></span>
</td>
<td class="nump">$ 30,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">5,223<span></span>
</td>
<td class="nump">4,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">322<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">661<span></span>
</td>
<td class="nump">909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">42,075<span></span>
</td>
<td class="nump">36,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(41,451)<span></span>
</td>
<td class="num">(35,150)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">624<span></span>
</td>
<td class="nump">870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="num">(624)<span></span>
</td>
<td class="num">(870)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">$ (624)<span></span>
</td>
<td class="num">$ (870)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities Operating lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688549891256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2007 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Initial base rent</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 329<span></span>
</td>
<td class="nump">$ 329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_LesseeOperatingLeaseExtendedLeaseTerm', window );">Extended lease term</a></td>
<td class="text">2023-04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lyra_OfficeAndLaboratoryMember', window );">Office and Laboratory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lyra_LeaseInitiationDate', window );">Lease initiation date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificate of Deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured debt obligations</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_LeaseInitiationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease initiation date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_LeaseInitiationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lyra_LesseeOperatingLeaseExtendedLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, operating lease, extended lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lyra_LesseeOperatingLeaseExtendedLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lyra_OfficeAndLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=lyra_OfficeAndLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688549571592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Components of Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,055<span></span>
</td>
<td class="nump">$ 1,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">726<span></span>
</td>
<td class="nump">727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost, net</a></td>
<td class="nump">$ 1,781<span></span>
</td>
<td class="nump">$ 1,412<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688560192024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">2 years 7 months 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">5.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688549324040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Maturity of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 1,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">1,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total maturities</a></td>
<td class="nump">2,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Amount representing interest</a></td>
<td class="num">(167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liability</a></td>
<td class="nump">2,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liability</a></td>
<td class="nump">2,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion of operating lease liability</a></td>
<td class="num">(985)<span></span>
</td>
<td class="num">$ (899)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">$ 1,454<span></span>
</td>
<td class="nump">$ 2,427<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140688559268136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Company match percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Matching contribution costs</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>81
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( $F#:5('04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !)@VE2'82Q?.X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)VVA8NCFLN))07!!\1:2V=U@TX1DI-VWMXV[740?P&-F_GSS
M#4RG@] ^XG/T 2-93#>3ZX<D=-BP(U$0 $D?T:E4SHEA;NY]=(KF9SQ 4/I#
M'1!JSEMP2,HH4K  B[ 2F>R,%CJB(A_/>*-7?/B,?889#=BCPX$25&4%3"X3
MPVGJ.[@"%AAA=.F[@&8EYNJ?V-P!=DY.R:ZI<1S+L<FY>8<*WIX>7_*ZA1T2
MJ4'C_"M90:> &W:9_-IL[W</3-:\K@K>%/QN5[6B;@6_?5]<?_A=A9TW=F__
ML?%%4';PZR[D%U!+ P04    " !)@VE2F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M $F#:5*#7(\K 08  ',9   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MI9E14^,V$,>?KY]"D[F'NQE";#F0< /,A 2NZ0&7$NX8VNF#8BN)!UM*)1G(
MM^_*=N) E;4[?8'8\?[]LU;^K[0Y?9'J22\Y-^0U380^:RV-67WI='2XY"G3
MAW+%!7PSERIE!@[5HJ-7BK,H#TJ3#O6\XT[*8M$Z/\W/3=3YJ<Q,$@L^441G
M:<K4^H(G\N6LY;<V)^[BQ=+8$YWSTQ5;\"DW/U83!4>=K4H4IUSH6 JB^/RL
M-?"_C(*^#<BO^!GS%[WSF=A'F4GY9 _&T5G+LT0\X:&Q$@S^/?,A3Q*K!!Q_
MEZ*M[3UMX.[GC?I5_O#P,#.F^5 F#W%DEF>M?HM$?,ZRQ-S)EU]Y^4!'5B^4
MB<[_DI?BVJ->BX29-C(M@X$@C47QG[V6 [$3T/7W!- R@+X+\+M[ H(R(&@:
MT"T#NOG(%(^2C\.(&79^JN0+4?9J4+,?\L',H^'Q8V'S/C4*OHTASIR/9)A!
M&@T9B(A<"A.;-1F+8C[9O+3)C^F(?/KXF7PDL2#W2YEI)B)]VC%P=ZO1"<L[
M711WHGONY%-R(X59:KA-Q*.W AW WK+3#?L%115'/#PD@7] J$<]!] 0#[]A
MZI!X1;CO"!_AX;]E N[NN>[^YFF";2:"7"_8HS>4SUR1/P<S;12\#7\ADMVM
M9#>7[-8E]WZ]XJZ,X>&^U_Z&4!QM*8Z:40R$R%A"[OA**N/"P76,RCB"<[S%
M.6XX*(J!?>6S?#\2KC5GB<:8>ENF7C.F"5>QM"]B1.!U=N:L1JE\)W[Y\*%F
M7O:W;/UF;%>Q#B%]CYPI<@4GG1Z :]4@G6R13E"9TJ>NXH23VRR=<>5"P34\
MSV\')[07(#R^5[FHUX3HCB]B^_K":-VRU)F^&J'KM6+@LERQ%<],'.H#L./P
M$(/<L7J_"23H207S/3?X S(U,-&(5&0H,V'4&OY';G)<?72)0=(*DC:!O&>O
M9!S!M(OG<5B4HOV9KI'L=]M^S_/Z01\CK'S:#YH0#J)(<0WY*3^0:[B.?!?N
ML<,ENWV/#)3F MZO![;&,"OO]W'W?H\YM$>0YGOY(IR(N-P#S!)E_A7[%JXJ
M"3[NY>_AMI-PHN1S+$+W(.*:-P,,K2H//N[I[]$F4AM(RQ_Q:O^;@2MZM-NC
M&%M5)GS<W?,<#F!]OQ\%%SCV>QA(51-\W,BOI2T%DZ44F /7B 0G0;M[[&$5
MP:]*@H_[^7ULH!K(.?'II]EG,N5AIF"TG%BXTE"F*=C-U,CPZ8!\] ZA5) 5
M%+UGEF2<K&"5II=,876?5H6#XGX/BY H%@LR7:<SF;AH:P2N'^^P>4^KZD!Q
M_]Z,&+E\#9=,+/C>$E8C=#N8C@:_8TQ5,:"-BL$#; O;3P+,!_+*-$RZB(RU
MSMRSKD;S5F)H516@C:K 3YE U80=<[X:4<XU48T2#E3Y/6WD]\-,*;M:*Y:T
M^=0";W4OUFH4'[G&R"JSIXW,?BR@@A3[?+NX91M4)QFN6$-6>3UMY/5YZL@0
M2M!"*J=EU.C<2M%F8<A!!D2B0A CK!R?XH9=$DY3EB3D(M/PM7;G$M>IV3S1
MRODI;MHET&7*U<+.KJ^@8)90C](5$^ZQPP7KR*H*0!OM"BY?=W=VQ8;*B86K
MU6WM@LKB ]RAQ\.K.S+(HMC ^F9@#(?U1,YVE;"%BZQ&KY:LLOR@T89@N@1_
MQ3)8(U,+5/E]T,CO)]DLB4,8'\E<[C J58YR%=O9?(8U/NU[O6-89CV["'::
M,(UL_>T:8&K+O2;?,P.I$[9>N[I-I?+Q#I5/3[J]H]X^JLK;@V:-'+VS>0.;
MF=D=YYR#B;H7S#6JX%H<VUD&E<,'N!]OBLYNBP#K8=3(M=L^;0<^AE99?(!;
M\P#&+2KZ%_M>M__7XPDJ+P\:>?D08!2,TEA$_)5\X^Y7#I?R8$T:T![>O@@J
M4P_^6X^G;$/M[?+4R%T]NJ@Z.UUJ6SWR;K\FH6T[% WK[=GM+PJ#O(_>J2XO
M?HZX8;;X:)+P.81ZASV83ZKH\!<'1J[RGO=,&B/3_..2LX@K>P%\/Y?2; [L
M#;:_LYS_ U!+ P04    " !)@VE2<.KA]P$&  "G&@  &    'AL+W=O<FMS
M:&5E=',O<VAE970R+GAM;*U976_;-A3]*X17#"W@Q"(IZR--##0IANUA6Y"T
MVS,CT;%0271)*FGVZW<INZ(L48S;Y*&-9%]>GGM$GL-KG3\*^45M.-?H6U76
MZF*VT7I[MEBH;,,KID[%EM?PS5K(BFFXE?<+M96<Y>V@JER0((@6%2OJV>J\
M_>Q:KLY%H\NBYM<2J::JF'RZY*5XO)CAV?</;HK[C38?+%;G6W;/;[G^O+V6
M<+?HLN1%Q6M5B!I)OKZ8?<!G5V%@!K01_Q3\4?6ND2GE3H@OYN:/_&(6&$2\
MY)DV*1C\>>!7O"Q-)L#Q=9]TULUI!O:OOV?_K2T>BKECBE^)\M\BUYN+63)#
M.5^SIM0WXO%WOB]H:?)EHE3M_^AQ'QO,4-8H+:K]8$!0%?7N+_NV)Z(W (<3
M \A^ #EV -T/H&VA.V1M61^99JMS*1Z1--&0S5RTW+2CH9JB-H_Q5DOXMH!Q
M>G4EZAP>"L\17"E1%CG3<'/)2E9G'-V:Q J=H,^W']';-^_0&U34Z--&-(K5
MN3I?:,!@,BVR_7R7N_G(Q'P?>7:**)XC$I# ,?SJZ.$X/1R^@,J[\DE7/FGS
MT:GR&REYK1%3"NH\\V2D74;:9@RG,C*U0< -RLP%_]H4#ZR$*9Q<[5(MVU1F
MPSVLXG"9TO/%0Y^2<52:!$D7=  S[&"&7IC7DF]9D2/^;6L>OVHA"[WA$E9=
MGQ,7[%WJJ <(4Q(.4(^#*,9NT,L.]-(+^I/0K#P"WW(T=;Q,<3P .([" 3:K
MR@4QZB!&S_ *"BOU4\NG>?I;T#P]1S77+J31" /!T7( U!%$8S?,N(,9>V'^
M#2"9+NI[5'(0022-VIV(]4D#-]/$Q@XD 1[ '0=1G! WWJ3#FWCQWG"E99$9
M:3+[RH4M&4]+T@$T?\P!LK1#EOJ9;/?,-&7I>)7A9 #+$1.DD1L7#JRR!T?L
MEFED^^']:4%6:#  YPC#81K1"7@]X\%'26]9L+NB+'3!O?J+K:1CXJW[0Y:)
M!@07;=D3NRNYLW8R*BHE9%CY. @'T<1ZP=8@L-\A )]LN%=Z>YPXT=/Q/DSC
MH;XYHD"E@PGXUCBPWSF&TO$<UK$/I,E0X1Q!23I%M'4+_"-V\1S.L1V$23(T
M-4?4DDQY,;:F@?VNX>&TM0XDUET=6R'- =A9P]@I<+@<U>#PDY!,& JVCH+]
MEK)C^SF6Q^8043K40T=4'-'E!$+K(=AO(E>BJ@IM_'BWYS)1&\YYG0%:]/8O
MH3G"^)T3MS>SZ;7.U)9E_&(&S93B\H'/5LAYO'UYHL/JK4]AOU'MGH_D.8=&
M$&31E/\ 1Y7"7,-D:P[K*T?0<61?G,@=+D6#*)KP*6)]B@1>([@U,VY$F7.I
M?OTE(3A^WYZ<X!#U%AJR(BOT.Y\S$&LY!#^[ *!U;$N<HS?!:1!@< F)X(C>
M\/?05 3S8/>O72 D7G;W:L.DT>I&;X0L_@.FF$;0CO#J#H3[>T>S&P:]R1R8
M5EO>-JGETWN$R3RE9$[C>!="@WD2=5D+I8PCM$;0:*7APHC!#\S@6K1[-@Z?
MV,33ZC5,S[AKGA=&?V MF0;B!-K!C&T+6%M."&,+)22DT;#%<<2%X=19G%BK
M)<]:;5,U9=O2[I>2$^78*4_@C#.6?V<@B>/EA'H2ZZK$[ZJ[W:F.V K. L;^
M&8=A.CS0.,( /NT+\"%\:[7D&*L]L*WCE*9=SC]=]G+4&;M.L,31Z4V?8(EU
M;>)W[5LNC7%\.,'HQA9[U2OVNBOV=BRKA[-:GR7Q:YZ;B;5'XK?'EQH$<717
M:1Q.='[$&A?Q&U=',WDYS=2Z$O6[T@_23*T)4;\)O91FZE#UA*83JYE:8:=^
M8>]HIJ] <^_7,OJJ-%M!I<<(Z@MH=OQ^E6 <3M!LE9+ZE;*C.7P%FJU4T>A5
M:;9J1(\Y];^ 9D=# ,>M"9:MEE&_ENU9OGP%CJU.T?0U.0ZM%(7'_)#S\QSO
MT_=MDB0A'IY9%KVW".85SI],WA>U@I9T#>."TQ@2R-U;D=V-%MOVQ<*=T%I4
M[>6&,S!Q$P#?KP5T5/L;\ZZB>S>U^A]02P,$%     @ 28-I4EKVU^<S!
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MSWEJ[!0,_I[YG.>YG0EP?-]/.FC6M ./KP^S?W+*@S(KIOE<YG^*S&QN!LD
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M:_GY^&,*Z1\M"#RS"=21)RHLG!29O6[384X,VNMRSH-<>=DFBP90,S?\\$H
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M965T<R]S:&5E=#$R+GAM;+5576_3,!1]SZ^P(AY *LUG:3NUE=IMB$E,5-N
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M$12X9(UT]WK]!;?UG'@\KJ4-3UBWOOWS"'ACG:ZVP91!)53[9INM#GL!P_1
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M+A*R_;/2+[QIXRA?&8^'(7Z&$K$-!CA?&^,/BQ!@>-L7_P!02P,$%     @
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M J*0>R2FD,N<8<FL5I0^J\I3">[A5D])#B* G\8*2:EF-0)9$%@YB&Q-M=Y
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M\PI9RC4?Y[$<O4QFBSUET;X>K;E(&0#M;X%C?>+&&$U_FDFPZW^&-$(1*S"
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M58](WWB."L=4I#2?OE9#X,5MB4=%3!*V4:P-AU/$O.ZRF@#@LB90S=LBC9=
M[[MX3ZRBB;\&"1)C ^^#W@VH+,BCMKN\W,/HN,>@+HGD:KU">)]87PATTVB
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M,!#-#QCM\R"-E >8/+J ?@'%[ZBO0"U$S"4ZL/%A#BH\(L3#DJGV_*OL",7
M3:Z<!<D1&9''XYN7;)R!.'-<K15*ORTZS_$) EF:5OCLF]\_X4&A#VQ<A;LT
M:'LY'@F%759J@[D" (8;EFA'[\JZ/U0].E@_^H[,$/B_B3P]RNDWC"M8=&9,
M0TY!X3[@/<V>8Z8&C@Z"BQ83B^8BXK2K_[/7C-@7?Y%D5=)N05TB;DHO%8!'
M:*L YV)4!</"PP\3EF%/"'RA<J7=JSQ#,KS+4(M#YP'RKJ('$-V.>/CX"'I'
MZ0<D0O1XB=,UV+$' @V6$728SVQ2PVP<(>)ZP]%P_/ &  T4CQ#JS5P8'6L
M'X8F\-VH<$A9BOY3W*P$3UCF  3O0(8SUV/_"/J?V%8D3;A2*MARS@1ZE1 Y
MP&@JC$Y'JN42$ I7H.P*IH%97/<GHQO0#QN5DU!:QL4785ZB2^M?8'H09*('
MD)-5!G?'I,A*0]IZC-I";7@$^6B_BIHBHY!,&ULBP:SF &_/*AMK(>OD#QH'
MS.7+<>1Q,F+FH\CS$<X%=!S<$"ZS%V5&1^A'F<ZP'<V4U #].VT<^8(%("#.
M#[/I(MAF>4YQ9V*YP[!P?0P:A*C/L[=)"</>E776:,6I*RNL[945H&TV%((@
M;S6J9_UJ:JZ:AE5."9<@I9,3-4XXMIDCVQ\_J<B>5/0 WP<>5S1:HKU?!=<\
MZ\>L_A)< 2C>KU;!*_:0!+>4Y88_]1[IZ%1#4L&;O_3GCWG^X\/Y'<\<@K9J
MF0V0$6 BH7#BE!#B 9J"K >SZM 4#JWI!V0(D%S&21;)$+GYR@EF\:'%Q_R*
MF/H@G:+70&L):,#B"CR#W4&:D/S!PEQHE^IKHO!IE8HO%9YN*QT2J_MB!YZ-
M"*K.L7B^ LY>I,UK]1VP3L'3. V+6XJB83090ZZ$Q^XWE<BX@]<V*EV3#$:3
MFDWX<8UE;M/-YHMQ5=O9S2UFPV0@)WH1<W2< 6V[;W /IJ28[%1!06$*76=5
M>HSQ942#HD7#$ ZD(L5-LG4DT83%-\Y%46;V)I@4$S<"+VDA.PZ\<5H*A;"3
M-H]]I5:BU^P?_+JC<#OC.@7<V$./R%P@VE&XS)JW0PNF6".(UHR\FF1<,Z7I
M4&&*&3TZ?T;4=XQKDC 3UR?ME;U;;-W5RMG1)^]OL>B6%-F$M>"*W4!9["$Q
M.78E,ZH_,4I'I,SRM3]);_<)NQC'6YO%.!_/.GR+END_M!_$,K(;R\AZL7AT
MU'XL?L14P5OKECG4M<E5P0SG7A],!2(3%-0T:'=H4<>Y$M.2/)24\1-G?-2H
M:J,?*S8N2\P4;.[1QR[J#&-SMHL-2]R"?&L9S\0NO[J]#CZ!790$%QBP=7;U
MFWVV#MXA#07SX/@_VQ)/3OPLF<Y<-DE$)%*1;BD%0!RK%'BT?E7:<]/AH>1J
M/T@QD@</U\T+BH+CFV+7XA22P1%CIH*_1-(J4R(V6*_>B0FQJXQ>33-,5D#L
M1HO:_K7$\T;CW/I?9 (-99HGM)D5E?%\[3-4;D ?N4.KAF=>!,>?"SLJO$;K
M-\N16#:3)$"C01RH4,3(?,+"M+6N7W-(%\ W[HDD6/<=C>MJPWWAO]LR59CW
M1]EV;6%4P%4.U.F[)<E_!S(2^*?D@?S5DE>5'4^2466.WSHZ@#I,^BG/Q\?@
M@X;,# =T\$CK@U+X$L*)&;B&@_%).X"P(0F0K(X/\XIBPZ@\[/4@:[1WX&W]
M$/HUJB2KG0P#+;I\+_#*XP P#.*&*)X.HT"M=UU6Y/LU.+J I714%G[>46CQ
M.4'LSC%O0*JB"-Q[P"678WF/:^"7B;WL&=0,Z:SN(E-G9(<8,;*-7H&,!#,9
MYIQK)\^@--CW[D'< 1*R*R7[!A/@8M?!B']A?BGG!IER"4DDO35ITX ( %MV
MGJ]92:2T0LI7H50)'!K!;OW"+DVPF$,^)$%*EHJ4@+%TXDZP5NTGZ*1]Z-31
M+@2& 6 TNYY]C\M#FZ Q'\_0> T"^H[S!-Y9*N\5@=^0H]$_.NI1H!D5<E2D
MX^AS3M62E0!Q+YED23_*1;B4U36<3#_H,IUB&,.09A'V"41B21U $S0%_F\2
M #_OB.'4K>&-/5/XRV&_J:I-GAAQ,YU-A?EPP)1A'35%U87!ZHG=%<:4!@ZJ
M:<[L&\.1J(;Y.MR#0P/Q24J2\4'KG_HV$QQE4S7E+6W*NC'F!6=PZ$W%QE,=
MDE/.;, 9B4Z35,$8XW+ YVJMS_0^3HK-%DT@9J0K"EPP*QXXNVGP!WJ2LH9U
M)N:E2D3=T?SY('!WI3ZF0?@948*D^AT.PH,F!W6.HN<>)-'7F1['.9S20X!D
M:'$JI*3\]D(H' 0!\FZ9.3413G^58C!75<8^,8<+8J)$+@?E#XE:2#H-KB60
M="AM!![.>UX@O2+5M@2I\D]6@(7QB:-68LO/]<!>E-W$UOUT-M['@5MWG'':
M]*#Y>'[0M13/)+:0X@K]"!IW/ZI4 1&BUG%=%G?HN\+/'TQ,\9;BC+V<]AN2
MB;[3<@X<%YT:H<H.DSC#="*E6$%$6;88#,4O-F6.?F112XC*DZQY.'_&\Y'4
MO6EY7JJ;28W3%G)R"!;74J :%K,C)VXK'.N1V\UJ]TFRHXQ:R<^C(4>V_RK[
MB@1)"2,5&W$X49EPSG*B--]36W(GH;.=UTXQ$E8I*.T;@65#K(];+9\Q$AOY
MO"P?RRIZFP.^>EC#'G1^"\I$ F^SH3H5YC+ (C/*%Y>G[$#CI&8SG.;C*4X?
M),F;<_@!(N2IZ:6<;\AT.ID&_1/X7ROSM>/B)QY7YJ ODYMMS+L/(A:/NFQK
M^*9^_G+B/CK!1R?XV*1_TI>3=_$2T^S*:F^_G?PP6831^3G\.P_/YZ<3I-RV
MH4#9JKFG<W9'F9R=SB:GEZ>3]Q1JQ51I$+:M/ :HB9_KR6(VI__>H:\;2==-
MN8>?Y^?T'V8L@KQ)M/^'O$@@7B<GEQ>3^>("5G4:SDX6M,K9V=D$&%*[;273
MRLGSGQQ%X<7YQ>0Y?8@NX4,_%*@& H:+POG9*?Z[.)^X#,N5(-W8P]S&'F#(
M'Z+S<#:;21C!5AR(G#'\8P_8C5%-E*)CT0JI<:.JIJ?B4U\$B@S9> !>4UA*
MSYJ)"QD <.TBZ0]8S+K>-,=(#F*/!W":HJ1*)@Z^H59M#CQG161,21KL52*7
M-&)Y_7+RQCS_F9]_!\_W8^<I@^]!K%S(<^-8>2Y/#6#E+=:+L3_5VTCEZ,)4
M/T8<BH%*P1S GEK<4KK"23P?NNIKE\>)KCI IH&+)#V=']<:2S) #^S3I,P0
M.;7^#'/V;Y4BQE1.>0<8+.E;P)2M%!3P6I9Q8D\H^I%E4+*;-*LQ').R0:_%
M.0-B"-/8_67R<:U$\(,7;@HEV];H-&+3FC6[E9C+WT-]^PCZ:U;I#!!TJA4B
ME(!\TI*.35 #UT$^)9U*=>=*2TVR)KL3-\O$1 <*RB<*Y527;B:$*.2P_Q,S
M *2Z4Q*9*71HTX <Y!@7@S:Y:3Z>W72SQ7UK0+W#@LAWY J^HN7WRL-O2'5Z
M8!K^)J=O!&Z.0-SULKAI-ZT @R(<(C29J?G!L$B1MK RL\NB/ ))&4&JM3:'
MGSR"3MI$)T#Z.E.'-M";P!4YQ$*!-Z(6A:@F?[#7F0LN.-*'!>*X(9.JBZT[
M.@J9C*Y-18H+*5/MC6XBK!<Z=)HZ#O .:B:BLG$5![JY;U;:ZVP>U'D;)L>"
M88>(C$,ZD.2?':G1V2&M@ *?^)=UC WO52*CK%*ZWJH^5QA.7*7L7K2+LCZY
M0YQP4J,?)YK':<]F:,W'4[1(Z/23V#>D8_%HP=7MY^#W<HKK/#N>16$@WQ])
MN.4D>AY<B9#2Y8^2W\9.'"4_<J'AH4*:@#6# 3C"BJTRJ1+ V-3.S>*G85Z"
MBDJ^DXITB=A&D) O8_Y5O<EVWBMR+IW\5HTYR';=ITG^AC +3V/M3!#FE+,J
M3E8W\_MP*O) -ZSMQ'6)%M;>N \Q[5D<[S21S&2GQ_<H?4N8.$; #IUFQJNC
ME:'N,G#PN^<2I:/D+Y^OU"TI&CROJ2VE;+*:A1*2";?U &XE"1,8%M:'>. Y
MZ4POLQ=Q(]4*!Y!"OPPZQD5#D3/B!B$.%%VVHFLH>:RZYK"26U*,;5($BWJ/
MEVM^V'F3,SIKWTZ5BF?'UC!+#N5;P69*"/1_':R\Z#B,&F<=F&Z,IK0)!OK1
MC=X#ZYR448\=S+$:M>;9%,A#UI6[[@Q)$;H1I!I\)."B(D3C-*-:9>LR\+W+
MILX@XR0XUOA *(+273&ITS3C4)@Z&<L^;"M;-1NG?[8U"2EN'D'19*07*?+P
MX70XI*VC=I6I!XR16*A?#Z4MFIY3L,ARL 405%6C4;W7JGNL351;6P+_[!A&
MGN*LH^[CJ_2@LLP V(E8 ;!4Y+IQ0'4^A*%QHTTY33$9V4^I#2#K#9$[.3M\
MGYMTU(Z_7SE) $Y^A3$\!&E=*:W]Q+4&-=6M%<<&O71N.^EC;DR3%87.UC&)
M5O(WM140YYA)HP41(O<8S4^#?X"V1>ZM,5QS%'<BPEA3FRYC\02-6 =X@A(&
M=F1.-\6'K!B&:NFEO;CR934LG73S "VBG)$.**G#-^%M"5=U*8[J4([9[-6E
M;CJ2-?"* U3]),+ZX:>E"85M7B18IT?)^IN(C/AT^Q5#D\?MZ3FU!XZL&1MX
M*,-T5!^,;(9V-)ZA_5&GCV&6YFLG?8R<"7UZXOB @SFW-DGM8);@XU .&QNJ
MPU0Q^*(I0=246@-,*YVXL02C8T7]2VQBEVZNP/VSD.?JAC8<-/.ZV]@*09L#
MYO#[.F1_NA0$(H>!KST6'OJ,'=U4UCEH ECB(W$K#'1$0D\U%1@Z5<']68 V
MJ:?3G2OLZB!&R<!"'Z_,D;4.\0916B#H R8T(]D+2=#$]1=8V ?-UL0)B61M
MDQ))@KCJ#$<&918T>4&#PZ(%-^E3IU/W5#=B#RM4[[A.JVY<MX=V7(W[;_J+
M7.L^[6$PZY)FGH(U5#BM<ZB]2N+P>03(NL2*"W1VZ4,V1BPGQNG0(QO9^$K+
M_>D>D_(I!5P<+N$XJ./&X=B+X_23G. NI;D: J^7QT53%@<6?<&B*?PJ)5=Z
M&C<&1T4U6EO0A9\CH)3,8$FLH(%P;\L2<TG)-<"$88-TN)I.[[)/C'B8UV2%
MK&T>D>#)Y*RJNNX_3R:[.LS@>FTAMLNBNFY]+ TF+$*F0T5PQ@^M:Z'-#(),
M?[";R+3P(2]%BC988FQEH]:Z,LX5^G$1Y_M_JMK2K[;PFC:5-EV:']C,.*(K
MLE_+JD/M[+?"A^]*.GR#N.SOY,,C]D>[<'.A;=DUN==L#2WE4;%BU<WKTSLT
MC19\ZXWAVRTRO_*+HCDMN,LXNE*^OTC:_+S)@+E7+!KX()T=D,!G#QQEI[)X
MR?=N3:F>5RJV!3YCXMS6S$3C-3,?XH; .BR]OZ%BA@<5.>/BL\'X'3_A=JEP
M:2E7:[U/ESA$LDI<OF;Y9)X2$F7>[31[O%.N='\@[NXP\G\YI2*R]3#1>#V,
MT^8%*?R6=(%7).NN'5V@]WR^R\A^J:MNJ*)K@ 9UDYY8CDV:/I]?A-XD1!#1
MC[2&P]E?Y3%,<IM@([]:;(-C+]$6Q5G=<?1Q'NS+ <_16-EYZ+NF[TJTQW)3
MQ?>DEW5XK>\UR0O9.97X6/)RO,*\62\Q6MQS4C7*^5AN)=ZW3CE4NFS&(LU)
MZ:1L,.$->#F3I"3OP<!D-Q_>A]\ _DX&FZ?8]221/ZY)A.6TU!M88=[)CM*N
M5) 8N0;\!5"MUM\<&S749=1%RKXK'S6 2<0T+2AK9=4QDRE%EO:ARVK;QFKK
M?8C&VW6F];$P1@%E>GQA>+0J6_)#2V\#J^(0[>G\\H/4/JSB=:5TK5OWZ>(3
M1RT)V=U3)YDTY$I;X*-@D)9)BZUD5+%NJ,@1F"O7U=/RI6VK7@+6R'*FO.X*
MR*?5OU<$*R*$]HMX-H4F")P26T2P>Z]NB62,&\<G#-O#P4<2<D*XM4DQ5>U0
MFR-8*M55<*I?#-(%H_(9R2F.!,$*G/6[G0HJ$%B548#\4T1D*.\UVC,V+Q5F
M][GM#2AA'R?V(WD<XA-3S,3&N(J$\[XQPUPK\$5)D2-5=1''( J5<I'CAHP?
MC+RID+/\ZY8[5X;F$,W8]]0YD)*H3!L1_$A8B.Y[LPU3KF/ZM1RZO#JM9#13
MKXG>:%/6.XJ[D'94$ENY?7.-JOIJY39'>]7FJ&@6%%6:S\Y#SNH322=VY:%Y
M(;8==_O&'EA[KE<3RQ89\DI11H9.C-MSPMI!HRP_HG7Y%,%WH!P=,M-1(2SM
M@]"EQXT^.808=UR]2^X:J#V]5.%1@^%C$CN8S)P^$=;F(:36%"V:<I^=H@E1
M)Q(]M&:G ['3>$-> !R$*3$W6$]-[E:GNY.1'SI[F3K$F(P*7(T=A"E\R>'M
MW_I:1-'PK!YZX\2CBW/&]:68X4BXYWK%O1^,4\2.Z#3J$=\=GX\V33B"X8);
M4I*T=T7WX<56BQ8-+XZ1#%QL.^Y!P".CJSU_&=PX:45X)K_#_@2E>NG)$N"8
M%FPK:Z/QREKISO$).UKUJKK?4% [GTT#=]Q^\]I"$?FP>/ND$LEVV<*#A9&/
ML5NO?"_9/O;@W39CJ?2?1@:,[Q@=KY$@/K;M>F)4O^N8%S>#+KSAK(1."F 4
M=7, YV>V(X&?PD=2'"4 R?[&K2SGUM_6O8>-=.X)@67?QGV$F]6MY]SE'F0_
M..#UH/YX>& =& Y78)<"&U"QPVIVQ.J8#9BBH==2VI[4LKLOT4EQV,:>_C?X
M K/:RR#\+]@2WZ,2#.3 WM@UN O62[2+UJN<1//I;/(W_<\'A3R%>*.X#T!6
M3XXB^/'YWR9'LVF$_Y*GBW=EXAIZ"CF&R>GT!,8[@Q?^-AGTFELOL]/D>Q)-
MS^"EQ?0"_G]MNN8<8D<?+L%:+V!F7.QB-CW'#^]Q@LF<U@,[F.-W(E$GSJ?@
M=]7TH>"#'3>&TYH?F;C\^G#2EY/?!WJ6 WJ3[,/<X-/P/+K$#[-P-CL;!K,&
M[&D818O)27AV&DUN!T3K9!%%D_GY8C(2S)J<G<TGE[-+#=H3V,C%;/*IQ,@Z
MV!AU+RU/3J)P=GXZ69R%N/5WH"N_I'KH@R,\F8<GIW/,:H8MSD\!]V3LOE'/
MHI/)Q?G,AZ*SV)<'.]%QOV,;]YL<X3 P(8[4.YN[??_A+MXH/!N-5O;353\:
M=4W -/@\O9T:<AIJ7:_1H(==7P*J&W9MHQ?8FP!U#&!+Y6I54V,?<O0[?,O+
M$^&&#-B7,&Z,\SP53P)7,42SQ3G[R_PEG)Q,9V8)#G-X<#>DALEJ=2&5_(B6
M)->X4:;XH\!)'>,1IL13OP68<Q!ULP%H&J/E^X+T9#:XNP$QCCO4(!Z,%CA7
M&3RTZ<7TS)?WBVDT*.Y=*,@5)P*%[O89>O]7 . C_A[;CYP39W5G>O'_N/W%
MZ:%C2F>M.H% 8>K4>U8WV9=+DE#H4YB%S-&T3+@NDEUC^C((W>L )\.$-WJ<
M[ZG1;2FQ.09E->F4USZGW' XK0?:/V(71;YAQ;A):.*LUM$><=,3^=K)X7>\
M0J8(*:W.B1XN%;N)I(^<9$39BVKP%*C;%3D.KH:54%.@+JE\,!1EY/?WR'I@
MUS6KP=FJ \/,-G0)V6OD_&A\'\),L&],WPGT:$)@,@ 29O5&\L_8 GS"P1@G
M;P]HIL'G(A6SWS<7\9N;0MK&?L0 78N@2L6QV<-O:9HA4N0>'<:DYTNRZ!6L
M/\XXLFV@(?Z<@_EO=:%)H9D"P<E>SS4->I2KT84QQR>>[JP/#Z? ='SG/A>M
MVU.PTLV1D#(1<J;YI;XV0=AX\S&WP8E>DN-,*D'9 Q,'U"?P&(T<[=^DB^02
M";2>SOX6LI.)&^.T=(*W^LZ8Q45$.UY<+!XXQPZ[LS>>:"<?@]CWTV8Z\DF
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M*GKM([[-'FI\]S >&7LI#JYM&$'X4!M%YA)P!A +"C&1V3\.P]VCFQS+__!
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M^,UT._Q;4,+Y,['.\KNY,##QAS06:\Q)7/MG-+'.8%;]NP=)MT;2]4BZ[]&
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M86'G,^6;JYPXO?#OG(EV^&KRPSD^4\&0 .Y/M7:;"3FH'[YG_P%02P,$%
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MKAT>TWZXQ/\B,!2 [PNM7?M !-L_K=D_4$L#!!0    ( $F#:5+%UA6(T@,
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M*$26MS-D6=Y33>=3*79$&FE$,P/KJM5&<HR;I*RTQ%V&>GK^"= E1:Z>Z;H
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M3X#G&\[5RX4^'I4'[LEW4$L#!!0    ( $F#:5(JWO<);@(  &4&   9
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M!T"[ -POE++[B;MJVC]+]@]02P,$%     @ 28-I4CG BB?) @  40D  !D
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MNV%M[CP@;8!Y7PJA-Q-+X&]1B_]02P,$%     @ 28-I4I*,$WY$ P  [@@
M !D   !X;"]W;W)K<VAE971S+W-H965T,S$N>&ULE59M;]HP$/XKIVR:6FDE
M)($4.D JL&F3UJH:Z_;9) >QZMC,=LKV[W=V:$998-T7\,O=XWON-:.MT@^F
M0+3PLQ32C(/"VLU5&)JLP)*9CMJ@I)N5TB6SM-7KT&PTLMPKE2*,N]TT+!F7
MP63DS^[T9*0J*[C$.PVF*DNF?TU1J.TXB(*G@R]\75AW$$Y&&[;&!=K[S9VF
M7=B@Y+Q$:;B2H'$U#JZCJ]G0R7N!;QRW9F\-CLE2J0>W^92/@ZXS" 5FUB$P
M^GO$&0KA@,B,'SO,H'G2*>ZOG] _>.[$9<D,SI3XSG-;C(-! #FN6"7L%[7]
MB#L^?8>7*6'\+VQWLMT LLI85>Z4R8*2R_J?_=SY84\A2H\HQ#N%^%"A=T0A
MV2DDGFAMF:<U9Y9-1EIM03MI0G,+[QNO36RX=%%<6$VWG/3L9%%'#]0*%GPM
M^8IG3%JXSC)52<OE&NZ4X!E' Q>P)SQEAF? 9 YS+BJ+.=Q2RGU6QL &-2P*
MIA&NK=5\65FV% A6P4R5)85N857V4"B1HS9P-D?+N##GA'^_F,/9ZW-X#2$8
MAV" 2[B7W)JW=$CKKX6J#+UJ1J$E]HY#F.V83FNF\1&F40PW2MK"P'N98_X<
M("2W-;Z+GWPWC4\BSC'K0!*]A;@;=UL,FKU8/1J>,"=I0IEXO.0(WFU5HF96
MZ:L38+T&K.?!>L? *)J"HMGFYUJS[S5=EWB<7,1Q%%^.PL=]]BUB49ITTT;L
MF6']QK#^2<,H,S7Z#D!9J#%'ZFHNO3(E'U%;[M;4SU:HZ1*,2[4V#O4CZ3/C
MHOX!@Q:A)$K:[4\;^],7.1;807%D=7&8O>)H,SQM<W[<BP],;Q&+TM3E69OQ
MEXWQER=3;(Y241/Z5Y(-&KC!25]\]TT6\PM&H:.9T?B@KGT:.L92L5,7>O-J
M0!GV;METG;SN.FT>&OP5M4%_2!5Z&-V_Y5P=#X_$=]AP&KXLOJX->B(OB?3_
M\*O?'SS+@$Y_>,"N16H0=^)#=N'>Z*#VL?83U8#O_G4G;$Z;H7WM9]7!^92&
M>3U[_\#47P(W3*^Y-"!P19#=SB5EI:ZG:[VQ:N,'U%)9&G=^6= '"6HG0/<K
MI>S3QCW0?.),?@-02P,$%     @ 28-I4LY@W\*B P  X1   !D   !X;"]W
M;W)K<VAE971S+W-H965T,S(N>&ULS9C?;]LV$,?_%4)/&[!&(F7K1V$;L)T6
M*]"N1HQM#\,>&.EL$Z%$CZ3B]+\O22F2$MM:@/9!+[9(\8[?NP_!\WEV$O)!
M'0 T>BIXJ>;>0>OC>]]7V0$*JF[$$4KS9B=D0;49RKVOCA)H[HP*[I,@B/R"
MLM);S-S<1BYFHM*<E;"12%5%0>6W%7!QFGO8>YZX8_N#MA/^8G:D>]B"_O.X
MD6;DMUYR5D"IF"B1A-W<6^+W:T*L@5OQ%X.3ZCTC&\J]$ ]V\"F?>X%5!!PR
M;5U0\_4(:^#<>C(Z_FN<>NV>UK#__.S]HPO>!'-/%:P%_YOE^C#W$@_EL*,5
MUW?B]#LT 4VMOTQPY3[1J5D;>"BKE!9%8VP4%*RLO^E3DXB> 8ZN&)#&@+PV
MF%PQ"!N#T 5:*W-AW5)-%S,I3DC:U<:;?7"Y<=8F&E9:C%LMS5MF[/1B6^-#
M8H>V;%^R'<MHJ=$RRT15:E;NT49PEC%0Z!WJ+=X(#>8]Y?P;NF6\LC#0%K)*
M,FT7?WC*>)5#CG92%&A->59QZL 98V=@WOUACNEGH10Z@D3; Y6 ?KD%31E7
MOYKME)U1,U^;.*U:/VMB6M4QD2LQ88*^B%(?C(K22'CIP#<):K-$GK.T(H,>
M;R&[02'^#9& !!<$K=]LCM,!.6$++73^PBO^EB;S^5#2/[JDB^)8Z3KI7W?H
M Y6EX:G0IDWV/Y^-8_1)0Z'^'9 U:65-G*S)%5G],]'*4YT\>'$FLI=G(F_.
M1&G.!'\^$^X$7#H M9#(";$WU>,"3TB2)-',?^QS.5\7)=,HP4F[[D6DTS;2
MZ6"D6Y VH.4[C.X@!W.SWG,P"2\?06IFGS?F-@(I34!;+;*'@>Q&[9[1F*#'
MK:QX)-#7\1G,-(DF47299=(&D+R-)?EQEFF[9SHFECCHJD$P%IJ-DC[.. YC
M3"[CQ+V*AM\&-/QQH)ATNY)1(>UJ!0Y'@S0\0YK$) CQ%:1=8<'#E:5%.OD)
M2+M+'D]'A;2K!#@:#=+H#.DT3M,TO(*T*QMXN&XT2%<_ 6AWT^-D5$"[<H#3
MT0!-SX"29$IP'%\F2KK:089KA^.$OAZM+C7TH[N[R0D>$R_27?:$C(37JE'R
M_S]U+RR,4S()TU=<_5ZS6(#<NQY:(=?OU1U1.]OVZ4O7G;Z:7YG^O>ZV.S=U
M\_^%RCTK%>*P,RZ#F]C<L[+NI^N!%D?7DMX+;1I<]W@ FH.T"\S[G3 );@9V
M@_9?C<5W4$L#!!0    ( $F#:5)(!RI:4 (   8&   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,S+GAM;)5436^C,!#]*Q;:0RME X&DNZT(4IJHVAXJ18W:
M/:SVX, 0K!J;VD/H_OO:AJ!4RM=>P!_SWKQYMB=NI'K3!0"2CY(+/?4*Q.K.
M]W5:0$GU4%8@S$XN54G13-7&UY4"FCE0R?TP"&[\DC+A);%;6ZHDEC5R)F"I
MB*[+DJI_]\!E,_5&WF[AF6T*M M^$E=T RO EVJIS,SO63)6@M!,"J(@GWJS
MT=U\8N-=P"N#1N^-B:UD+>6;G3QF4R^P@H!#BI:!FM\6YL"Y)3(RWCM.KT]I
M@?OC'?N#J]W4LJ8:YI+_9AD64^^G1S+(:<WQ63:_H*O'"4PEU^Y+FC;VYM8C
M::U1EAW8*"B9:/_TH_-A#S :'P&$'2"\%!!U@,@5VBIS92THTB16LB'*1ALV
M.W#>.+2IA@E[BBM49I<9'"8/E"GR2GD-Y FHKA68(T)-OI-9EC'K-.7D4;37
MQ?I^M0"DC.MK$_*R6I"K;]>QCT:)Y?/3+NM]FS4\DG4!Z9!$HP$)@S X )]?
M#!_=?H7[IO[>A+ W(71\T7D3%DRG7%H?-/DS6VM4YJ+]/9$CZG-$+L?X6 XF
MJ$B9<9-J#:@')+=9MS;K(0-;MHECLT]QFQBCMOL>G8KX(G'<2QQ?*)$SNF;<
M'#^<U3D^J_-4Q!>=DU[GY*3.&4=0@MKW3YC8@D9[9P<D+:C8V"6GMKVN"&DA
MV/MA[:?3Y)3K0[#Y?\/:*OV]5VH[Y!-5&R8TX9 ;HF#XP_"JMNNT$Y25>[AK
MB:8-N&%A&C4H&V#V<REQ-[&]H&_]R2=02P,$%     @ 28-I4DFZFQ90 P
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M'*:F+T9I \S[M1#Z=6(7:#KMZ7]02P,$%     @ 28-I4LS#(\<>!@  UQL
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M!D(S*8B"9=\;AM?C,+  %_&-P5;OC8E-92'E@YW<)GTOL(J 0VPL!<7'!L;
MN65"';]*4J_:TP+WQSOV#RYY3&9!-8PE_\X2D_:]CD<26-(U-S.Y_01E0BW+
M%TNNW2_9EK&!1^*U-C(KP:@@8Z)XTL>R$'N L'T"$)6 Z!#0/ %HE("&2[10
MYM*:4$,'/26W1-EH9+,#5QN'QFR8L#;.C<*W#'%F,#<R?K@882$2,I89G@Y-
M77UO'NT8R 69X]%)UAR(7))_AI]-P%#&]3D"[^<3<O;NG+PC3)"OJ5QK*A+=
M\PWJMKO[<:EQ5&B,3F@,(W(GA4DUN1$))"\)?$RXRCK:93V*:ADG$%^21OB>
M1$$4'!$T_F]XV*V1TZA,:#B^Q@F^FRSG\@F S$%M6(S/E"H@1\H\Y%S&Q?#+
MDLP@EBO!?F/4%!23-E@;37Y\Q@W(K8%,_ZR1UZSD-9V\9NT963@U\;X:*$P_
MYFC!V'*,]BK9#,).V.CYF_TJ_QT4-9M5S NMK4IKJU;K##10%:<$CQJ9P ;O
MJ1QO'5-3AG9%W7Z++EU5\JY>W:6"L;UO0-0],.E(3/NX1YU*::=6Z4<0H"AW
M%@T3O-28-HK:Z[RF#-V*O/L670J#YPLW>'6?2LH7?Z=6IWG@U)&H*.P<>.7O
M]8H,U,JU4(U*UL(4%VBU6K7IH6M.!^LCV[Y=#WJF*7K_'54K)C3AL$3*X/(*
M%:FBG183(W/7D1;28']SPQ0_04#9 'R_E-+L)G:#ZJ-F\ =02P,$%     @
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M$R4IH KHJIE7AE4;WP^7RE)W]<."WC_4;@'-YTK9@^$V:%[4\3]02P,$%
M  @ 28-I4ND/:D&<!   (Q,  !D   !X;"]W;W)K<VAE971S+W-H965T-#,N
M>&ULK5C?4ZLX%/Y7,IW[H#-:2"B4.K4S;75W[\S>M6-7[\/./J20MHQ NDEH
M];_?)"!0"Y&K^F!#R#GG.S]ROI#Q@;(GOB5$@.<D3OEU;RO$[LJR>+ E">9]
MNB.I?+.F+,%"/K*-Q7>,X% +);&%;-NS$AREO<E8SRW89$PS$4<I63# LR3!
M[&5&8GJX[L'>Z\1]M-D*-6%-QCN\(4LB'G8+)I^L4DL8)23E$4T!(^OKWA1>
MS=% ">@5CQ$Y\-H8*%=6E#ZIA^_A=<]6B$A, J%48/FS)W,2QTJ3Q/%?H;17
MVE2"]?&K]M^T\]*9%>9D3N.?42BVUSV_!T*RQEDL[NGA#U(XY"I] 8VY_@\.
MQ5J[!X*,"YH4PA)!$J7Y+WXN E$30&Z+ "H$4%<!IQ!PM*,Y,NW6#19X,F;T
M )A:+;6I@8Z-EI;>1*E*XU(P^3:2<F*R%#1XNIS)0(1@3A-9'1SK^-X^JS$!
MEV"99QC0-="KP=U.KYBJ#$3B!3RD(6%@$>.4@[,;(G 4\W,I^+"\ 6??SL$W
M8 &^Q8QP$*5R=23XA9R4X[^W-.,X#?G8$M(9!<D*"N"S'#AJ 0X1^$%3L>7@
M5IH/CQ58,@IE*-!K*&;(J/&&!'W@P N ;&0W )IW%H<C QRGS(RC]3EM^B(>
MQ)1GC("[]7%N[DF,A4X8%QPL56A7.H,+_"*WF)S[9[KB@LD]\J\!R:!$,M!(
M!FTUHG-W >XRP87,5I1N@/26)"N9]F:/\WCG:CVM5O63_60X0@-'KMTWP'%+
M.*X1SE^9-BS+L2BJ#<.I>%L".0+W%('GN+;;C, K$7B= G+[3%@0\6;3WHGI
M2^3#0;/E86EYV,GR'*>!;'W-EH>GEB$:H$&+;;^T[7^V#!KWS<P_P0,'R/=]
MK\23[Z_3=:9R&96P1[^2++R*"<"B&_+1"2(/>>[0;T8$[:KIVITP/1*N]K$,
M)B"RWP;J05"PE].=,1:F3.$]1EFC!FA$^5-SH(0TW1,F.;VL=[!@44 ^T! *
M@WX]H'VW)<$054#1YX#^WMXA"M40'L6O#]NB5[5OZ'P.E+%[%,J/8*'^"+6@
MJEHY-/?R=U$9.TNA_ C5J._8]3_8 K%J[]#<WS]3=BU;Q&W(L=T?P#<-J%C7
ML3PKMH!FNNA:";_4F@J;'TI%Q3;03#?O(?^2_C4\"?IQ;HZQ5VP%S715JY(+
M<.+(/5'?.*J"YO(4J4Y*&8[!G]&:@#-Y,'TAF/'S1KAFJ\-<%/@@R4^G\IP:
MXI>F ^Z\HRJG5.4WJ#J.3D6*T,R*M9+[TNB8K7JYJ.FP7G$H,G.HH?:^TJ-W
M4'3+][&+%0$C,P%/-QM&-O*H#[Y+S)'\=@[ (XZSCU!O8<JM;3/'\9SF788J
MZD5FZOT8Q.9.4)BJGV1<Z+EOFG2QJJ,C%5TC,UT;'/E(>RZLU7UQ[%$+E:"*
MOI&9O@THOZ(7%];=M@SDJ*W:=4-"V$;?PG 0T"P5^>=V.5O>]$SU_<:;^1F\
MFN?W-96:_/KH!V8;Z1V(R5JJM/M#"8GE-S+Y@Z [?:FQHD+01 ^W!(>$J07R
M_9I2\?J@#)3W8I/_ 5!+ P04    " !)@VE2,;P^?84"  "K!@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970T-"YX;6RU54MOVS ,_BN"L4,+;+5C)VE6) ;R
MV+ "*Q"TZW88=E!LQA8J2YFD//KO1TF.FS:)T<M\L$6)_/CQ(7JXE>I)EP"&
M["HN]"@HC5G=A*'.2JBHOI(K$'BRE*JB!D55A'JE@.;.J.)A'$7]L*),!.G0
M[<U5.I1KPYF N2)Z7554/4^ R^THZ 3[C7M6E,9NA.EP10MX /.XFBN4P@8E
M9Q4(S:0@"I:C8-RYF0ZLOE/XR6"K#];$1K*0\LD*M_DHB"PAX) 9BT#QLX$I
M<&Z!D,;?&C-H7%K#P_4>_:N+'6-94 U3R7^QW)2C8!"0')9TS<V]W'Z#.IZ>
MQ<LDU^Y-MEZWCQZSM3:RJHU1KICP7[JK\W!@T.F?,8AK@_BM0?>,05(;)"Y0
MS\R%-:.&ID,EMT19;42S"Y<;9XW1,&&K^& 4GC*T,^D]<&H@)W.J# --/I%Q
MGC.;8<K)K?!M8O-],0-#&=>7J/+X,",7'RZ'H4$&%B?,:F\3[RT^XZT3DSLI
M3*G)%Y%#_AH@1.H-_WC/?Q*W(LX@NR))YR.)HS@Z06CZ;O/.YQ8Z29/.Q.%U
MS^$QA?TI50M4MX'J.JCD'95Y)C\4%9KZUO_]'57)K8%*_VEQU&L<]5HY3Z70
MV/1,% 1V.!TTX/7TOHTDV<LI+10 WF!SJO#>1\_YL*-CDV(Y-H>5.-;H1?@T
M6J_(]QOR_5;R8Z4!6[4E#=<-TO7_S?>@<31HIUS)M3 :DYP!V] %AU-].SC*
M5G*4J_#@WE>@"C<.-98,\?T5:G:;B3MV@^;-_@0GL1^<+S!^C-]153"A"8<E
M0D97U\A(^='H!2-7;KHLI,%9Y98E_DU 604\7TII]H)UT/R?TG]02P,$%
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M/ZSHD@3&&=#W4FL\3)R#[MHU_P502P,$%     @ 28-I4M@71-]3 P  B@H
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M($R WM]QKHZ&2=#]N]*_4$L#!!0    ( $F#:5)?@/#<'P(  -8$   9
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MZ?]I+T]==2W$UY1>YYN-9LF;UW3%9]?4O_BOS.RYLJY"E2-*1G>S"$SWBKJ
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M<':ZYAJN-U39"?!]*:5YZ]@#M+XP#?\ 4$L#!!0    ( $F#:5*IG=LJ;P(
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M.$455:L^&,+!_HX34K'KOM>]68BVUV!_,]/SEDW"X;\C^@-02P,$%     @
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M57MISX67_UC3[I3>A&K@+B;H-KHX['_[()[8_Q-&4U6JD.>F:!NI?1]'*^L
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M#Y^%I=NJK>LS*+O47XPH]U]M[+\X^?@34$L#!!0    ( $F#:5**,79?SP$
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MIY4NZF,^:W^%3S\!4$L! A0#%     @ 28-I4@=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !)@VE2
M'82Q?.X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " !)@VE2F5R<(Q &  "<)P  $P              @ ',
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( $F#:5*#7(\K 08
M ',9   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    " !)@VE2<.KA]P$&  "G&@  &               @(%$
M#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 28-I4EKV
MU^<S!   :QD  !@              ("!>Q0  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    ( $F#:5(G!%R+HP,  )\+   8
M  " @>08  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !)
M@VE2<HL10& &   K'@  &               @(&]'   >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ 28-I4LZZ[?IY @  N 4  !@
M         ("!4R,  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   ( $F#:5+G(V!JYP8   (=   8              " @0(F  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !)@VE2.IKMPS\/  "G)@
M&               @($?+0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ 28-I4BQ\R%?,'P  ]&   !@              ("!E#P  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( $F#:5+H:)FD;P,
M /X'   9              " @99<  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ 28-I4D4V_LRF!   S@H  !D              ("!
M/&   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !)@VE2
M.IW_7[$"   D!@  &0              @($990  >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    ( $F#:5+QOK#*&P,  +\&   9
M      " @0%H  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ 28-I4I8H<%YA!@  ]!   !D              ("!4VL  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !)@VE2#/;]PY0+  "+(0
M&0              @('K<0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    ( $F#:5)JF2]?E@,  .<'   9              " @;9]  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ 28-I4N,S (.Z
M"P  4B,  !D              ("!@X$  'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    " !)@VE2$_16!*8%  !)#0  &0
M@(%TC0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( $F#
M:5+,-$S<<@,  ,P'   9              " @5&3  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ 28-I4KCB\:B[+@  UI\  !D
M         ("!^I8  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    " !)@VE22;32A6(%  "_#0  &0              @('LQ0  >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( $F#:5(0_OH"2 ,  %4'
M   9              " @87+  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ 28-I4@-]Z7N\ @  !P8  !D              ("!!,\
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !)@VE2=)Z[
MM7$"   \!0  &0              @('WT0  >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    ( $F#:5*0BW$%P00   0+   9
M  " @9_4  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
M28-I4A42!2<@!   =0D  !D              ("!E]D  'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    " !)@VE2Q=85B-(#  "E"0  &0
M            @('NW0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    ( $F#:5( (25V)P0  'P/   9              " @??A  !X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ 28-I4BK>]PEN @
M908  !D              ("!5>8  'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    " !)@VE2.<"*)\D"  !1"0  &0              @('Z
MZ   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( $F#:5*2
MC!-^1 ,  .X(   9              " @?KK  !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ 28-I4LY@W\*B P  X1   !D
M     ("!=>\  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M" !)@VE22 <J6E "   &!@  &0              @(%.\P  >&PO=V]R:W-H
M965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( $F#:5))NIL64 ,  #8-   9
M              " @=7U  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L!
M A0#%     @ 28-I4C-K1K<[ @  (@4  !D              ("!7/D  'AL
M+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " !)@VE2]]5;QLP"
M  "$!P  &0              @('.^P  >&PO=V]R:W-H965T<R]S:&5E=#,V
M+GAM;%!+ 0(4 Q0    ( $F#:5(>#C$I<@,  '4+   9              "
M@='^  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ 28-I
M4LS#(\<>!@  UQL  !D              ("!>@(! 'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    " !)@VE2I(";_6$"  #%!@  &0
M        @('/" $ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   ( $F#:5(8(E&_\ 4  !<:   9              " @6<+ 0!X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ 28-I4I:RZ&+? @  X @
M !D              ("!CA$! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q0
M2P$"% ,4    " !)@VE2RJFO],D"  !=!P  &0              @(&D% $
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( $F#:5+I#VI!
MG 0  ",3   9              " @:07 0!X;"]W;W)K<VAE971S+W-H965T
M-#,N>&UL4$L! A0#%     @ 28-I4C&\/GV% @  JP8  !D
M ("!=QP! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " !)
M@VE2+K9Z7%($   O$   &0              @($S'P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( $F#:5)?A8-E%P,  (()   9
M          " @;PC 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#
M%     @ 28-I4M@71-]3 P  B@H  !D              ("!"B<! 'AL+W=O
M<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " !)@VE2K3CEKZH#   "
M#0  &0              @(&4*@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM
M;%!+ 0(4 Q0    ( $F#:5(^14U+BP(  ,<&   9              " @74N
M 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ 28-I4E^
M\-P? @  U@0  !D              ("!-S$! 'AL+W=O<FMS:&5E=',O<VAE
M970U,"YX;6Q02P$"% ,4    " !)@VE2@)K(H>\"   \"0  &0
M    @(&-,P$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (
M $F#:5*IG=LJ;P(  ,<%   9              " @;,V 0!X;"]W;W)K<VAE
M971S+W-H965T-3(N>&UL4$L! A0#%     @ 28-I4K/>I!M3 @  A P   T
M             ( !63D! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !)@VE2
MEXJ[',     3 @  "P              @ '7.P$ 7W)E;',O+G)E;'-02P$"
M% ,4    " !)@VE2'A[//%($  #U(@  #P              @ ' / $ >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ 28-I4HHQ=E_/ 0  ,Q\  !H
M         ( !/T$! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ 28-I4C+A@>'' 0  $A\  !,              ( !1D,! %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     #P / !;$   /D4!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>107</ContextCount>
  <ElementCount>344</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>47</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (audited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAudited</Role>
      <ShortName>Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (audited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) (audited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParentheticalAudited</Role>
      <ShortName>Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) (audited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Redeemable Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStock</Role>
      <ShortName>Redeemable Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Preferred and Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePreferredAndCommonStock</Role>
      <ShortName>Preferred and Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Stock-Based Compensation Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpense</Role>
      <ShortName>Stock-Based Compensation Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureRelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureRetirementPlan</Role>
      <ShortName>Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Preferred and Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePreferredAndCommonStockTables</Role>
      <ShortName>Preferred and Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePreferredAndCommonStock</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Stock-Based Compensation Expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseTables</Role>
      <ShortName>Stock-Based Compensation Expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpense</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Organization and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Summary of Significant Accounting Policies - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Property and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Preferred and Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails</Role>
      <ShortName>Preferred and Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Preferred and Common Stock - Schedule of Common Stock Reserved for Future Issuances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosurePreferredAndCommonStockScheduleOfCommonStockReservedForFutureIssuancesDetails</Role>
      <ShortName>Preferred and Common Stock - Schedule of Common Stock Reserved for Future Issuances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Stock-Based Compensation Expense - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation Expense - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseScheduleOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Stock-Based Compensation Expense - Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseScheduleOfFairValueOfStockOptionEstimatedOnDateOfGrantUsingBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Stock-Based Compensation Expense - Schedule of Fair Value of Stock Option Estimated on Date of Grant Using Black-Scholes Option-Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Stock-Based Compensation Expense - Summary of Stock Option Activity Under Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationExpenseSummaryOfStockOptionActivityUnderPlansDetails</Role>
      <ShortName>Stock-Based Compensation Expense - Summary of Stock Option Activity Under Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Related Parties - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails</Role>
      <ShortName>Related Parties - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Leases - Schedule of Components of Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails</Role>
      <ShortName>Leases - Schedule of Components of Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToOperatingLeasesDetails</Role>
      <ShortName>Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Related to Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Leases - Summary of Maturity of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Summary of Maturity of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="lyra-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Retirement Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com/20201231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails</Role>
      <ShortName>Retirement Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>lyra-20201231.xml</File>
    <File>lyra-20201231.xsd</File>
    <File>lyra-20201231_cal.xml</File>
    <File>lyra-20201231_def.xml</File>
    <File>lyra-20201231_lab.xml</File>
    <File>lyra-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>86
<FILENAME>0001564590-21-011767-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-011767-xbrl.zip
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M+UN>1M. IE? >720 "/OWHFPA<='SW8>'#MFKK)JWSD!MR(_R'4Y:9I-'(2
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M)5^6%<1<&3>ALFX^.6SDN$Z$@Q&6=UREZK@>"$U7;C?[GJ!*94*6[HXG*%9
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MZF"-"U<(O6-DP>Z8VG'=[Z^5B%N=?7^7=6W3_4,HCAUSO<S+=<"JC<NZ=AA
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ME>PB<N/97Z(I#\0B^H'6UZWL&EU;ZAVSRS:K/NKZ>[<=B>[RRJSLJ"+<MK1
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MNTA7,:]P%7/8H@/>)OP9 *J M(2*A$6!5SPV Z(*_)G1'W:,MXY/I,A<*2
M?*MDQ_E(1QV! /,P'OV.\4,X>^"$?Y" FZ%0\Z6HHWBV$'(908@XFT\9+&S1
M;QA*-AN8-5@@@4M_WQC%$7P^,EQGYA!G@\@0'P("'#/'1=I'>0:20(I=@"V\
MR\4GDE\"PX%A(9#L<<$C/IE"P(W!'QR-'X/-@:$>X&FD=SPAL<<2R\,B(!^=
M"-Y$<PY0XXP74A"3',]^)HPMX/5P'+M(3YID%UP[2?=@,'AR'N&%(AX*::Y(
MWM@<W6Q.3WG&'WR!LBWT/8\#*<(+$::L"YU1+(9;A!S7H0^1/)P =P4><7;
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MCJ*N,W39E3@#ML#$ TZ1>*5<R.).0M IBPN1ID6!;Q+(T.Z)!>%1D])9\@(
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M>5,38[\3T&7_%MHZ3_NPIT)-G(OMHF$K)=%*M:I#FM*%_$?<D'B97(&%@+L
MNQ/F622WLJ8/SNE:Z(9249Q(-*OBKJQ]5[;.C#I9K[2-5"ZX+PM'L2 ]ZT3
M3]C[092UTO(JLRG$ A+5V@3H&TA&I/)-1+R4ROQ%BU5/+HW4E&:HZ3)+Q Y0
MJ<L\?A%J4.W_$BM0MF+$A7,5BZJE0QX"JP&0Q 8+SGTF089W/' >1*G9)\V:
M.A_R_TC17D^2)07)%$U3 T(*PXE$#[T7H2X(J8.W&!902"9)4U4&2R;@3)]
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MF#>(Z>O29Y,X$J,V-2CJEH<:TB/6"D-1G*//K")Y$JU&KVA>+Y(+)?NJW,/
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M$9#=-P3X#,C779'>XB=SH[W%+],.2WC[H!]'CQ)Q4$W^@DNC7_1$\X-P.<>
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M>1#*2I_4Z8GSB?4X#<"A "\:&V'V48"=U"$)S 1E9.O8DB]&*6)0CTU$0:K
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M'RFB1MBY9"+5ERS+IZ^)RXSO( %5%T,NI)X3J:C" PV?465V,KE3GE(E76-
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M8B7777C%9B7SB E&(G&315'@C&(QT4I48R>Y6)+E,<>2<K:0:),EMGP1Z53
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MV@99,P*,<#"-HL57%XT/SW[_K]B9H\Y,7RVR*JXZS\:JZ+<-!23"6@*A,Y(
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M)J,+ED>.UX/WFE%3-4N 7\EK4JN=?[+0G1Z#JFWB$"FM\T?&>23F/<NDNQ-
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MRP(!+ I5JA#JXRR9JNV94?YD N\":LHU*<"7L-(JC$>A8SL,+:4SXCHD$ >
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MAU6,!=?9H+WK'A.L8K;=[N3"DUM3^%)DQ03&.,.2A5AYL%82T?/S\ :<25'
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MMT -(<9J'-U!NX_D/EJ&+A\0?4XL_R&S7 ;"BP,AOT^ECW_DB;B!K_G :%-
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M0:8H.8!P5RL!AE!D1O&9<,I,3"2L#Q(/>%\:D,XEWQW-]*_)-/316&\1L7
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M6X-45@VIL0]VDA4@C\RXM"PRCS4/0A7BC4:H?K7,^0/F"T^^RKU<*AVG$9/
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M:8$M_;%B9+ F4Q5N4". 809X\ @H0.^=2."* !L I=;3@0N!ZBI< Y]@YD;
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M+]-PGK*^Z% +++>MZA:3E69S)6E)?20-24]9ZC#V#\:NT@01%D7V2/B66;/
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M5"77E=.RQZP&E(U-AHUE@I-+K6(F9#O.=?Q;45"R'.Z*/=L1'6FB94#VM!J
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MX+W3ID#C-B>QMG$%">815Y%A;5/!=7IVT;K8>5\(YB+>.VT2/-H[?<,[IXV
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M' _5H:Q0@1))BPP8&EF0 !V1%!DP-*]H:>9 LV0%"E1(6F3 S,B"!.B(I,B
MF>D26J!'TB(#MD86)$!')$4&;$V7T (]$IA#@VMXHN!9M%QKFD6#"AQ9=C"H
M N@M,N )4/?U]6-;,V5%JJ\Z)/$L=S ODB#14]60'QDP+Z]HZ8.Q+BM.H$'2
M(@-61A8D0$<D10:L3)?0 CV2%AFP-;(@ 3HB*3)@:[J$%NB1P-29;.,P#PRS
M4R<@TT[W?BM-GAEQ,J'3B3(!EO[CL!]*B=Z8N8$\^!YILD[3S6/=;)JN._QN
MVC*!)4G/<S!I<FZ*H$0=A*O>8/$C=NA&:SPP5"G  UWKE*Z!Y9(;'M"F+L$%
MEJOS$(+&=0LNL%]2PP/:U"6XP'YU'D+0N Y?_:O*7[KA_-9'BC[HGU&CQ_(Y
MR>ID/KUIX$,L:AL]D1Z#UHD2CMI&T%5X0MY3:G@96WV+0_C0/1WMV-3M8]MN
MVJ9-\'[+OMF"@DH %YA'J>$!;9)ZH$7%^7Q+H [>:JD#4Y,"/="Q;FV)8+&D
MA@>TJ4MP@>GBAW T&$F!':A:IU0-#)?<\( VP5'K(.W5\%BSFHX* AV3;4N4
M\A9GC\U8WA75(?P+S(*V4(_58]"DJ0YAS8)NS']!%K2S\*YG07>,\*$[.99N
M'0]'MAR[+;@YW5!/,(Y=@ >T:2<'\Q9JE.%@WM7;H:!B,N^(8+"DA@>TJ4MP
M@>5J<-H:@.'J DZ2J1H8+KGA 6V"D]9!VBOC6!V/I4 /=$QT"G0AB/N,#LT:
M&$3<1YO0A0NB;6+Y!XH3Y"I.X"KH^1%-R3^24'G"'\.%T:Z *$V9%J1*^PDO
MI$KAPB@X1/M74#"/78 'M FJF _3:L&%T8X@)=N6"!9+:GA F[H$%Y@NN# *
MJ@:&"^ !;8*CUF':*[@PRHE4AL8"C"K<]ILL?9N0:XK+;[G>4P,)%03RAA:
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M RU*EMKYK47)>?%L.!Y9(P$[8HT8! D[_<\?*$Z69W3:-QQS9:&]8"T+7>P
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M'HN*O1YK4M;.IR'>+J +_.(S?[Z,[$PB;_)_R-P+!M8MKZ!/">;*LH[J1.Y
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M)(L:"%@:I0(JER'&K:*UP+7_+)M+;I]V@X,_B8@W?],:(27R3G0UL)&& 2>
M\@U ZB@N^8%<QI@?J5<0;&(7<!X2F=K(;G&EKS]/GTB8!7^D1$ANRY6-+Z"N
M/Y*I4J(I\U"[AM!<*%V@6=0D%F6;TCA5)NG7!(PF68\N8%K&7.*FZ?!5%JJ2
ML.[_5/8.-SX3L]</===1+RESG%*;W TSDU];OZ3[X<*9U_=@-)E ]R,W3\*/
M,O;ZP3(;I$L$7C,X1V_=<F=&YOCG_P%02P,$%     @ 28-I4EI$IUUJ#0
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MOSD^&*'0Q9X?/GT]6))#A[B^?_#WO_WG?_SUOPX/1^??+J]'$S?VG]&Y3]P
MDV6$_GSW_2^C?YS>7HVN_/"/!X>@T3EVEW,4QJ/#T2R.%U^.CG[^_/G&>_1#
M@H-E3 <C;UP\/QH='F:DSR+DL#^,SIT8C9+_OHQ.CD_&A\=O#X\_WQ^/O[S_
M\.7XXYN/QR>?W[[[]-_'QU^.CPL$?DU1C K_?1F]?W/\9OSF_<=QX8LWCON'
M\X1&E^?%+YZ\>^\=?_KT]A,Z>??IX<%Q3]X[C^./[@?'<T\^>45.\6(5^4^S
M>/1G]R\)BQ1O&*(@0*O1-S]T0M=W@M%=AO1_1I>A^V8T"8+1+7N,C&X10=$S
M\MZLJ094;E^"3'CTE80D^?7K04%Z+P]1\ 9'3T<GQ\=OC[)O'ZR_SO[JQ?D#
MQ2^_/TK_F']UA_3/M\EWQY\_?SY*_II_E?AE7Z1$QT?_^'YUY\[0W#FD;S6F
MH!DOQ/]"D@^OL)N\3@$(H\IOL-\.LZ\=LH\.QR>';\=O7HAW0 4W&J6B<R(W
MP@&Z18^CA/TO\6J!OAX0?[X(&%?)9[,(/59RD\F(#?*>D?^3$P0'HS7A'[>7
MNY+UP_C(\^='Z^\<)0\<]<P5'1"%;)H?>NC1608QC,>2QQ5RC.>.'THSO'ZZ
M=WZ3<0[G:/Z (B"SFX_VS>F,DHC<Y0,ZS*4$X[>40)%K49:#5>10ODZ.QR?I
MXOS3/:+?HHK\*E$FVQRQ[\<S%#D+1%6DF^X%V?-'"6^;!,J8@A&-G1<<XODJ
MI7X74])L@SK#H4>1(X_^0+<FWZ.?>Z=.P-39W0RAF#0AO:7T?I>@MRG-(D"Z
M-/W09\J3@=_X.GJ)$1W RX@P,+T+(&$M8R[ ;MEL3>;8HT,>DHE&#8<GQUDD
M@Q^A(";9)XGH#H_':QW^I_7'OU_YSH,?4,R(3$+O+L;N'S,<>'1'O_C7TH]7
MFT(+V-Z"H^S#P'E 06*M"-(Z4H"H'09=7-^BF&HPY%TX44A-0#)QJ1VW9.O0
M.Z>STO5C" H1:BI033PO64Y.<./XWF5XYBS\V G.\'R.PT34$%0BU%2@*@SX
MJQ,L$03#[K-ZUL3D@<21XX)F51T5%2C8SH0C)UJE@Y\Y4;2BLWLRQ\LPGL1Q
MY#\L8^<A0/?XQHFHBH6 DR"N:J[Y,=LOF$ZE6T5,F:('1:ICH=.NDHP*'(6]
M07)+4</GE!IF#A/.%:(GGVSXU34.W64$G5,"Q!3+_@P.HNQIC6]" D$3I7HT
MNX8G^^1WNJ5&2[K#OBR8$<=6U929@'*RAE)4LG>[+E-]Y,99,;4G(?<J"GKF
MO,R.5T=%,8I2B[HEI@::2F89(3M'LX99M7Y"B0YB"S =4'('*">@YD1!WZ/O
M4I/_S"$S.?:K::C? 1(/[O3Q!T&)/.4W@!U"*K#<1)@R$:]NZ/D^INN.K;4%
ML\>N85#JZ:A;L3+;P>:#:J2.%O2HN-Y2LQU5&H$0.26G KH:F1U/_V$3X-D)
M$LL^SDXM\&.I&$'E\TMF@ZL@H(YW>:9%N:VP2>]0Q"R56^0A-$],+AP^4VWA
MTQ_IW'U$5"3ICO]][2D7-$WAA%OP?]H7_Q#"+?B?O.L+ (AR&P1O>T, H=P&
MP4EO"""4VR 8]X8 0EG);A8XA$P?DW'/U\%&P-95\K2-7/]^HLH7G 6@"BQ,
M7GS0(:R&B%(,]VP22S&^?E(IMU=^B"[ICW*B+CR]R34/6TXB=X.R$[D9U77H
M63";(GWF,<+S>D;6@^%J >/(0]'7@S$5S?&;X^.#T2+R<>3'JZ\'=,(O">4(
M+]*H#B67!-J_N#B,T4M\$22$OAX0]#1/3?7UWP-,D/?U((YVC=)NA5$:J*\5
MSN:,+!/,[I+A,GK;+*,^X99DJ=2"K50AN$G3<<COC(&\H<0[15S$^T$SWLU4
MF3*P-3L;EK<DN 0^#4@"$&LPE\!; 55HC00@%CV7P,F )  YE7$)Z-9['4H
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M<<Y$5\36 QKV@=-5<1&"@Q(BU#2@VCT8P;%<:0X]-$+"L-?P2DH; /,;[RQ
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MHO[O(FE%E*)Z=&U25IHH*9YK7;PH(7):;'6Y5U1+9I]1M,\H4I91!,:P/F7
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MJ\C7-)PN8Q([H>>'3^DC&TQ-PV\^?2?GSFKZ>#F?(\^GYEZPNHF0B]@C9TY
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M<+N7:ZT!.S U(ND__G.Z\W2T]583E>0;9_2_,:)LF/R3._\E1BA, XCYP%)
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M6O '%G155D2%>FYX/PVK]]2M-/T]J^;L0,4/<(:AV/P 3%A5=:%"@BS1<)G
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M=;;8K1)BSHNB@'G!'EM<H>A1U>3[*)AIO)NB>[._/K^Z X(9D+@!RFYZPU>
M!ZLI+4PHA/E3-@8H.%S!/T&$C%8\]6]:K2@E2OZ6[Y1):*N:5NWC?MV$I6ED
MHF1WYGN[>T!)?(5PI'F:6/NBC4HE0MYLE_, C$DHIMNF>=RKF*"TC P4[/""
M"&\V]+TUCO_^Z2DB\B]W!6L?0);]FM=$O92L;B9Z*/N[,F), >-Z CA?(#$.
MQ?J5 ,1ZZ@P;+-2)DQ9,+FMOY8=B G#U87\'US"#!+Q[^%)\()S^KNI*&@3M
M"D0-,O!7L2L',F_P0 N9".[3.Y4^HMA(L;- #_4"]T$"#OQ*60/&NZ=TM9/W
M0?QN[%#A3+.68_?W#5^Y=-#S\(9(W)O+==?"J>HXB M6T5>(&" ;];LP^07Q
MOA4KZZ=Q*-3XDIEB:T3<6W1%/I"SGG9%XTY=!*-4I*_/:7M?-!9Q4+GMA?N2
MJ?R,UZ)H:HV B[J=$D'_A5-%L=H@2Z>V0=-://5(8T'"@&P0:!@^VF<1L^VS
M]\*RZ2=_6\1QMH.KRY<M3'.8+]+5LGB"V4T2/20H*1*8:Z2\Z5+45[H>!S<H
MK(3ZV?$VB9F<.X""/2 ;1X"I   =)  Q%^'-M"YBB#$VT_1P1Y<R\O8WK**?
M-..P^/AOK,(&A6.YKGHOWF)^_:;3XD>/GKZEZM!W^URH9 B6:ZD]9<DSF)9!
M1H!B$\6.:I;WT8/:*^JN;SHP-4;)PZN_RK)^91Q",Z"ZZMM,15),6&H^\MU!
M#?NUXG,4Y?ERS4Y)%R^)TD)7@8@#I3>)>C@VH1QHP0#&(S ;[P2FS=S;=14L
M"$=.P)%8"B3(S$58C>T2\E O\"9*E*HK]GW;7/_'U+X.Z^_!  ]K)SQ](UG5
M!_/F+-0-O&-+]XEL#\E:_>P.KB#<T&GD'*?/,"L2\N-M1H_@,[AB/'^"JB6*
M3"D;;O&T.7G9ZG$IP.+T#&25(" ^2 *VI2@@I[*$L-LSAQ_;*7]>4-?+650X
M'Z0 DAB@DD,E+ 8\:E0?L.IXP:]<"%>QZ;VWV*1#V<Y@U3GYC4WOYQ>;#.#'
M=LJ?%]2ML>G]V+%I[%$W8I/J>%W'IN^\Q28=RG8&J\[);VSZ;GZQR0!^;*?\
M>4'=&IN^&SLVC3WJ1FQ2':_KV/1;;[%)A[*=P:IS\AN;?CN_V&0 /[93_KR@
M;HU-OQT[-HT]ZD9L4AVOX]CTP5=HTB%L9:[JC'P&I@^S"TL&R&,KQ<\*Y9:8
M]&'DB#3VD)'1:!W'HW-?\4B'L)6EJC/R&8_.9Q>/#)#'5HJ?%<HM\>A\Y'@T
M]I"1T6CUXY'C'(R;)(77Y$>SY OIVPXN_"MJ7K.**!? V(266G2,15N^14-+
MX>G].,U(2>5>['R1Y[#(35(VF]\TUW.=DH?W*HQ^&+;<H6_<KXVP=(MDM2IE
MLGHT79'Z;&[!1P1LE=T@Z.]%8<38_1"287>A<63?K4H*4O-U:R]U/YG5GT?Y
MTR)=T?]<_F.7/$>(OO%=%.=1ENV3]/'G".VT,I\5"5KD;ZDP\. EA!][%1+3
M'^"!<QC^HH<C-E+G+#!#$ER$)6 _2$S!H@ E6\#XCNQQ9$>RC9+R^4WY^J86
M<73\38F<.7(*Y-W[FF#:]AHKKDU68?B>#J+80+4S0 _5@1,,F0,REJ ^WTVY
MM#->TCE;4#AR&%Q$2#C,/?TY2-\8] *G]N[/LB>UW]L,;V%6[&^)!@KB4W0Z
MV]*M_D>H.5?TT;$),]UT?<P.G!N;%6#)Z@2D<.)J=%IP81WUA0P-:J#".+'(
M7_$"'_N@\>(R2R),1-O*W, HAW?)XU.Q7'\F<R#U8QV?&2!DCDPO8?=>4[$#
MB/(#&65XBM>G._*/D&8,->2PEB*#1@DU 6*L .-%'Q)]I@LIRFYD%[J#>9$E
M<0'9ONTC04Y_ =5-PQR2+IKN?>; B>WZP_"/05BPJJI"A0 =:9]MX@]LQIY+
M#ILF,R_H(& 1E=H(>I@SV-8MJ,FA%PJLI*$@U8YDC8O-QF0&S_GK;Y3MMVZ^
MML8AV7!#NT=[83>;8 ^[WY&M4"I(1'83+'WC":,5B4]T8U'L3>[HU&F:ZU^5
MA_MX+7$^44V(H9MH6<;_^+<_OC_[PY\ EQ5\>P'729P4OPG#=[1M IOB,A?\
MT1'T;.\MLRVQG.R2\;BTF*7O.KQD[Z;J[Z9=*BD7R'6[ D+MGN3XXMTW&BW>
M,OD5_"*.\2XM\MMHS[(G#:XI.BA8K"%:*7K(I1)\P)8S"L,;!A#!:GH*4_NH
MH7C!0ZWW<X"%/!O6U%7%,SX.O;,;*JJ/LF0KW;*VQ+5)S]U+>?8&06V(DJLS
MW29E_T?ORC8XS9%[)VB=9^[M*@P;H(Y3]XK91/YC5J.Y[]LN%V.^,Q>"\XS^
M<LI#B@I/]=WKWS#F"</S]6%BSH.1UW/W[@F#I3G02HZERVQQ1I_VA>$NZJ@.
MSR4.C^W'07!P1IGL/%]R=\/9Q%$L\S5_A#QO#$P8#F<*7U/$V$\2\&:3%*S7
M&,T9QREU)IC&FM;;2\8BE;V;K(<#PP,S_O9 9@>^_8@+",[. CF;5\$-:R@R
M8(S0,3SLK8',:62ON8<;VI,OV_/#_O*)PV)#CWD619$E#[N"GO3<X]M(=X%E
M0-P</6UF[OV.SRIJ-1+"<#YS^+&UYF<'M7#?BGMY05:]"^(" %D"<(\!EV'T
MT@$N+K[]7'6/>;G==DD-Q27U2EQ2!W*;IG<O[>\F>J2[YZ#NFJ76T_IO5X^^
M:[<&D6GY61SBE$]")^#?W[UY]^X,;*,,/%-^?P+D6R?O^/^SQ>/[/_RN^G?.
M>V1'N^()9\D_R5P6%> "QJPX"OCN[ 10]?*OO3O[_H3,A?D6QD7R#-'^3^#L
M_<GWW[T_^>X/?^!_\MV[DS_^OJ*:Y#F]GV"7+X<FW#H<PG#C3E/"0S"'9C:H
M9C$\\6>*MZ^+U8JU\HK0;92LKM/S:)N0E98T:*UK;P5J%I>P@]0]7&!6/ %]
M1WF:I"#F;,/P" W\L+XFP\<*'<%$^8'K% B.0':QT=]K%%&2PM5EE*4DWN:+
M.-YM=HBV:1=)?#K.I4+-Y@'!$'4OV0$E#R 6C&%XE09P6%^%X8,DO*ID!TI^
M0$;L8@BQD39?=ILNMZMY7\?IN<)6*PS7Z<&G=X?E?F?E>T<56/*]X3U2!RU_
MR=8CW#B=*!X4LKW.?%Q+V0(T4NQ]I]:/G5(_[1G_;90M,U;V<<4V<[<P^T1W
MX!8G^]TDG1WR=K'P<(I?G>\*#ZL.1\+P,%TXNT_J^W4Z$^BZ3N4)5[#, .?+
MCRT X0P8ZVD]D(F0+ZI3- O/.R;E#+8FZ1$\[>A\,4B/ZX2OV]/:=1DX5%V>
MQ;F!A0)*XWG3-3L]MO:DDHQC:#C9\3R(GZ4'[#T-N(8\1]9?P- ,>,SU "KC
M><OR<,%B[3(U6H[!D6B/YSS2[5/ 'M0&X9 ;':DS=+@&'&JI@I3O^V(7^RDE
M<DZN!\?;1\D7S:'MH73@:[^V];5W&@VJMLO=D/9,DB)L]DN]9)S Y'^?5/.D
M0/=(*G"U>Y+KO9%W:-H\9^H]T=&@]?=#G20<0N%K']3F(2'M@8;@Z?,,-WL?
MKU#T>,0D>YZCP1KN=_KI. 3#ZSZGS3F"V^,H0=;G)@[W-O[AZ7&8Z?8TUVF,
M-[!J"&:2+]Y)PAR,#I).<> \@-0+32$/>4SO&((&*^KK[0AF5+UDK0J<&!A2
M#Q$'+WJ;1'V^Q2ZKR@3RR& 8G;8WUNT*"Q8)U 2A*GHSV0.#.YA# A/M9W0!
MGR'"K,2]D$O',P8(655G[B;LI4HV8\?R6U8'AF&XB1I<6$M[04.#&JC0U!6)
M5^E!(WO-CS E+HR(,(O5)DD3ZKOTK8>!WPR2,H=G@+1[WQ$,F>M$-99A>(\J
M;%A3AX%#A.KH4!>J<YO(BXYF6ZN5F--YWU>B)3Y:?X7A&=U0]"V[G"^W/"^S
MIK)OOO>YP;F9A<M?=Z#L SGW5DZI FI:I:7C-#0+;P&CS<:;6@I0\4=V+LX+
M*(>13?TC3G%]F&671H--M@(Q<S0&B?MJ/)(P9H%LM]7QPMJJ"QX;X3<RM])U
MRE:?D^W'K]-GF+,B/%RBZY18$OE$[[2SBX;-<6<[3??>4E(6#A.&OPS"@E55
M%2H$U9%SR:1TB9)-*#.*DYG$2Y3RMFF0YH\PW&$8')5IP]MT,=8T,;9+P,)L
M)]'XHH7&94+NS9V0!ZAW\3JJD;>J&_=J(RC5HH-6I]L9G./--H-/Q%V29\C%
M( (MU_?1BV;*0S<9JROU+K+NS;O&+"!#5X$(:^@L8#A0&Q+".:B?+-> \!K9
M1<H*$64B[8<H3V)ZIY*@7:&7+#=(RAR; =+N-P+E; #([,OS@T DES L,(BE
M%"+Y&?K[/SU0Z?@='I<O#%=3A1IKZCUP6(7;5:50JN1MP-CQ6[TAG+SXWB^0
M-J:&J\4S6>(]PH\[6M!MN6;"22E/%BYIRL$<4C..[AVXE.,TXH)4[GJ4ZQ>V
MTUK:"':#S#SM =5- 0@9 !>"SK<\#DAR6,0$VL>*>?K9>^'GK+-5\U$8G2YX
M O#%+B,<23A*\(HG.GZ$7]BOE#98-M3U\33GY@;+%8YW]&2(7>NTO5-D^:*B
M7N:*24/G;B).Z?(I_,)_G[^9UK4=F 6V!Z0_[;'#F'^&.3V*6*[O#FWK#:K$
MJM,R-%0%VE[,4O"E766RBG-MI<A?_(5@@3I88EV]>K N;L6.S*LDYL6^./&I
M#(R'N_ MK(&GFHG)JC6R,1H"(R+V<MTTW,];G%Z^P"Q.<O+;7Z(LB])"W=[T
M"1O:GBXC+W98"D$-$0J6X(O@6+/'$ S1&'1LI7-W!LK-WH>%]E-V::)]G+S;
M:$N$!#LBRL%XR1^5]ANLR2J90:_-#H,PQG.8ZB4.V0@ZZLFA1-"F2JD" \>%
M2\N'5W2?:M@78LR3"CU0L9%N1S5.T4D'DRU6RAI@O21:-Y\#A!P88QMA]T=I
M94N?BDU@]M:+4YN==:LM:$R. L,1,"0F$&YCIXTU1GR!-U&2:ET<M1.PN%=H
M(^C?,<+PBWXXL)*6@E0]:M<Z^)4SF; ]TD^L%8]F2D'SRT[>YG-BWNHE##3C
M&#EQH$/][1419,T$IVITK&7P*V<PMEEW-(#1-_$!0LY;U/@R_4:+&MI)Z'P&
MG82ZG4)!?T&#@UIQD5L'3>0ZS2XO^C[31<%=YQE?7G+4<B8,YQB I*<)D!MW
M\*E^U*'YZ<R_[-UQ?FC=<5MV[C!<*&D0M4%)D8D/OZD:GDB\0<4\I"67/L#8
M6,>S 1/IX*C@FEIG#GZZMO"\B4]%E!7"2C]$B!XE.Y%ZG"K)QV,X2AEYX(,Z
M$57&? QNK#;<.J.=HENI5<5!IV4&1S.W#SK6-=J9J4H90>>U _T6#)R\1F!'
MUA7S,_:[Y9;5(BAOW+0R> V(6_;BTV'FX4Q5NH^M7=KB;4 %'<PA;_92U-?V
M[."M[BTHC)P]X/P!%T!45>=_(&0 E1!A>#./,K[<N9>Z<\![N(WOT(%-D.;H
M#WOVH-[GA_2P;XOI.0SG5LN79N%(*Q??CKZ[CC,J_#Q4S9 2K3X1C@3N\XY.
MKHU&KB<@A07]6E*2B'%>Y.2#?W__[BR,D&!E,SW=A]2QFJ-]H.8VM.Q2-+0*
M('+P7]MMR*=^KV+H'\U.QQT.XN3,8FH5&9B(F$Q4;,33Y>A_[WB%FOP>=UQU
M7:=Q!J,<T@_DTQ^:T5Y"7C^.U+M5]2.!S8V?#XD\W./&1 8J&U^)=C<7+S!S
MS@U;JX34H<NS]>%Q,'V=EE9=2E<B@GL,>NZH2T'Y9UQ4P&6E&;_2?8+R7= 8
M2^;*B^[Q7>4DR@__#(@Z6_QT,_'?1O,$S#_ZZ!M"]^)W"(O9@-ZUACG 3:+
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MH+P;89W!R/S!4]>C("LC:(..314_%X"K90^OSR9S!25;0/@"PA@0SH"R'KL
M.+T/H'?F<*55B[3^/9LN9P<Z'G+'6?I.KM4R,@QO:L4%]^DM) R$Y?/+)D'9
MOEQ",-UZ:X5!:JUZ-3,+NWKVOB)=H2,U*6?8L3X*7#O\W[\XTTX(W6V;Y64<
MM+9])9I!3:5HF<Q!)/!SOU*\S*B-JH'+AR)*4GJ)6!X97^%LJ->[P@1LQ<9\
MKK!@Z]YK[HZJ0@(L!*+K9%B>T=.D\$8='_R DL> VGVXL!KL$*896PB2C*-6
M/!.4LM!;]>H"AV:A&50_4@VH8W>:KO?^Z&PSW;F99#O0J%[M;'Y:0 T%E'P!
M8QS,[FN9/49I\D\6A\BLEF.4K-@_%NF*S&QYV3%\N19G.Q&JNAH;G8 Z8F@>
M'9P(X-1&9(E 321VJ"8+1:-))18XR!5<JVRW=H6]P#=&\^T/NYS$^SR_@'F<
M)5LAZ(<H3_+E6I;W'KX4'Y#FNSL3ZN:>H\_-0S5$V5?H1,'8T_65+$ 8/F"!
M/;;7^OQP%N&P9 \D_BP0<JB7=:C!KU0*P,08^Y9!5)PEL_HM"4.Q:>/5'BH6
MO2P[J;K>(0LVH.03W%RD !-65]P8L\:GY#%-UDE,RTP=B6,T4ZA2M#C#5>+@
MX\IYLXFR/3O[/(@ 6@PS#&O4Q!:;:7@>.):G]/VX31GBKZ(D8V=X%U4R@U&0
M[Z=CCE8?7:<844;\-!-(K(*+]4IX81W]C1'OVZ0P"O,#A-S:F<>@+EG;3S"B
MW#;A9/.KH35@9,[B]0C(#(2 Z:)S9T%.DQ"M0,SJQ64_<=<O+CO+A087LM5!
MQ-KZ'"-X=XIR<!*C6*Y'UX-IMO#QG'>F4-,V",OL0U;%2#LU.R<456+-@;G9
M-$&O;IC?G;T77E?E""AUHC%T00=,])&T9NH&UA6.=YOR=$VW[9"4\_UF6A]V
M9R?8&32CS$;\$I6*QP2.D-%^M9>,5<F7+K*N*[PP/BP<E9S"6_DH8(4UE#?;
MF-/6Y^Q2#C@>6WM-/WK4,?#>GF;64ZN;<',/-UN<1=F>SOG%_B"42=!1(&8>
M>@:).P6SX@8XNQI<@84A=0RQMCK'V8#5,D+-]EH=)&P6Y*TD?>R@6AF%85M#
MV&!%A06* VI ('* )PS(W!U-HF_SF^8JKU-RJFD134,+H1U:Q_TZ&>4JF1KD
M$T8K$C&X#!]Q 2V/IC2(6CX*4F'B,:2RQ:?\ B0,<],'M?EP2UVOLP&PO$R6
MN):++\HWD 7S08KEFA@67>JSDY8[7B2>90=_>HHR^!#E<%56*C6)Y[:<S(&W
MX^PV__H ^G(-9&& D$8D9!_D 55YV-!F&4>V@]TB-<8LIBSG!UE.H[G-FM4(
M?M/.VD-N%8VEIXQ;W7<N59YE!.<6 \9AXA=]2,S<$(PB*/C0"*'3S;1"NMLH
M*_;W642$CEEE(Y.Y=)B6Q7.U =INWZ0)R!@W(+,+;K93Q@_KZG*,&:M+$LN=
MEQ99]S8YRNY+MM%@TG9-\%0P3 _;KM&Q&PXM86R]KM,8;^!]]&)W2]%+QARV
M'K).8>)\ &$4\IV$"E980WECA/P6(8QB?#\=IQ;F,8H?["R4$*Z$3[]1.0O2
M_K'H=_?IHC"K;V"T"&]^TUS[=4I.]<U)!Q=/.[2.^W4R1M2\@7D.8;T>A]G)
MS1 E&WOIH^P^=G(&H5B.$CY83UMA8U'Y,F75K,TRZ:&&?/["JCT7"7\;8[>F
MU2)K4?U2G8W; ICRJ14O[UUR#GD1; (VMM#V&.&^(=3E9HOP'L(/,(7KI* Y
MY&;!7X^N,Q/NY>/C:*2R6\HJ2#-5@[3;3A54.B?XND)0R1H(W@Q0P[FEXYG$
M^?+GZXNS[V^C= 4W24RXGB_N+C\MXH(]K=[KOXG0H&B8C*S,P<MK!\;]].Q[
M4/+G"2!4 MK[+(0W#?J@8C/5S@/ 6K'E?O3L<\5''EL9.L 2_ RNP84\,AI"
MSL$"W(%+P$;'RR7LIUR<BA)!C;(1>X-@HTO1HMB1$@?WMAIRW2H]&+&9,N<!
M&9+16JZ/RI/L W"[6AD\"V?KIV.SYNJFZR-W,TGC9$L??^%UO9QB&.ZE!!?6
M45_(T%3+7[FLY?0^\YEVFK_,BV03%7H]GIO?-%=^G9)[3_C,NZ)7',(P_P[-
MXWZ]A*5E=%#P4DG!:ONU3_"1[D6NTS7.-OI508=I&"[I>VAZV84)?B Y, 0%
M#14/E&4(FS 5I+"J]D)%I98)*B"1N-EOI[R/ '4*/_49?@:?8)HGSY#?S]('
M"L;'GOVT[,[*^FC[Z)8D<03BZOK;&YSGOPEC\E*&#NNJ,7284 ]"['G-E [%
M6Y\V^X!;[(34"-IUT!UDX,&_RO:KS9ZV@7B7%H[82)VSP Q)<"U:X++:0'4L
M/NN-@TTO" :H&"YU>JEZ68+>U5L1A[#F5 ,(JZLL7##J5YZU3MSVJ\X1Y$>M
MHOOPVG-J-&DAFG8OU^<97"7%79+_G1:R6:\_1$0;,?ST!"'[U/CBSY:/Z6V2
M'5\_EX0UF>@12\RD AD1@-='6Z]/'[AD(*>BL5^%$$1<V0MVB<^<;:/1[%4V
M#/I<CAL&Y<[+.:W70(@%F%SL5PXN)D-0!;+3@H_P*%669ZWI$X*6:0A4HF5Z
MEC-,V\])FU1Y/R\9@RWC'$*XTL$/Z^HR=*QJYV\24!57!R=P8XT%]0PC@.N@
MJHBZU#;L.B6K-^8L0B4Z)PB*!!V4?>]CX+4P/Y9;T4FLPSA+T$.TK5C_L&)G
M@1XZ F[9 9SPP[$+XL L>2;3T3.T.;'KHV)1AZ&3JH]6J24O]?JFHU78&,8(
MJVLM7#Q0$XH0YJ;V,EJ';N3U H?7>;Z#^O.5!1/7!<(4F'K8NJ$HS]G*I.HL
M>6C^CE6:O]/J)X&XJ[W%#):+4P9IMM91KEB[RLE)%M$L_\EDF68VO=YLR41/
MI_-E=I'D6YQ':+F^P>GC#0EG*]:%W&:>-:-O\4[:@)^'M^R5%#064.ZGC#WO
MZAZ(UUM!CUVH?(XPHR.$EQDH1:!+92H$D-$.8$G WZ$2!;$'JI;E)A2(V;ZT
M[R'^VA]/JP)U]!)_4&?!@X)D/)@K\??4GIH"W<$<$FCH'?T%?(8(LQ9$K#:=
MT3VV C'S&]1!XEZ.>R7-KW$&,AA#%MCX_54.HAPD:8QV*_)9DH),R,F6PZN#
MI""FHH9P/JR%.=96?_#X-B[*.5KTBD7BR\LS.KDW'VE42&5 3F/';530$S!&
MV/1^J)>&H27UT/24]K+ES]%R4#Q!L.7LF;\'="ND@A96U6"HR-3>- D<''FR
M=]E1B]@^KG</K_&N<,;VWJS\K/S67OTH3)>B>;<M-0Z^VOF5[Q?I"B!G!9YY
MV?-8KE 0CK/K8XS--#T//!NMTF0PNZIU.^F1-N88T='PKLKA@99BY),<M-&F
M($G!R^&G1!-,3IC&YDU'32E;O1S0X.0E7^K ,8P-NR&LV$ZI\X*PRO.J6/,D
M=9EY(,4F?]Q%6906T+"B8.O7S<%J(>?>J0Y,PO"H/@BP@FX"5#=J:MKIHO9"
M7"8MU^2_Q*$,3["&R!@N=_K)^CZUPFL0'58%?)'*UCZK\@8."[G".:-2Q!-K
M*#A@[.HI+0*4DJ&K#>P8 T&]8YBTQ6.4I420_!9F+.O XCIWD)1%$\A^TNZM
M[2,L 'TJ#+8PX^D884R JG!A3=T%#HWPGY(7N"U1">#^]"/\(E6/RG!*?HRA
ME'IIX5+ZM,V!U.7EX]*!OO5 >[!8X2U]Z"87R*H)%(8S&B./;;4^-Y11&56_
M=&/JH@9:YVTN-RR62[5R[JWV/(SO!HUY>KKQ$0Z<,(%JR^LZUN$<";NP#>P*
MC[G:06L4Y]*8!O%9C!MI#CF<.H]$+K*T+?:T4'1!BU?_8Y>P"W&C=8H*-?,Y
M:YBZC\J/G">KI%WP(MLEVS!6'QH(8GU=AH\6&@9JTI<6\1-<[1"M%]C8(='Z
MK[3<\T6"=F25>T_3OHV\SIB%11Z]&4L/;UAWFTV4[>DA'N/,TLH$;W"\>P>+
MHLB2AUW!<NP+3"_]-C@%<D9^&&YM:S?8$5@SM1$1%4H96$G-XU,#;C(+R628
M+&'$BP59.:RH6,DS_ 3C7<8>[UV^\%S**V(M],9ZQQ?=QTJV#"7NN+NP(%?2
M> U MYBF)B41(BO "R$L.$@+2G$!]71P'J%XAZ+R,5AWS HM'CFWR]90Y1;Q
MUV>#+0%.%K#5[JZ8W1V$[(B*3HNE'-07QQG9%%V^T"0;2#,+EL43S,YW64:\
M1GJ>K+\0<L7)M'B'+6<_95A*R^#WFU0N (5@O* 4%0W$7#: #L*%<!SCSFZP
M6Y3F;2.UF4LR$"$4N)0-A,D%A&#J!01FI(ZV(-K4Q*)/$S;KQ:Z(R1Y]+]=\
M9\(V)O310O9,YAB<7>V*70;I^1*M=&4<*VUXF'J .4\_\9')PRKM\3T@RUMF
M[Y.H3"P#9,VD8L?83*P@(J,#^\"N,)FK+73%0?DX -S)IL"% I54#F+@U$HH
MHQ]WA&77Z*]:1A_2/KEL>OB)B)O0>H3\A*&>2KY +!RRE?D=C/%CFOP3KLB:
M-\$K_62X$81P<N[B5BB_KM?UTJ"<B4/;!OLRN_:#.Q](OEH3:SO\*SNC"D$/
M!X!-<SL(2[]W$!=P>:=/U3LH_Z#MVVA/ES:++U'&2]<LMZQ2*BW.QB$@D7O#
M/W-QT>"&LPL#="&)W\!6+V_()U<N6M7EB6S&4W!!?J!_\2--  >?<WIM_ %%
M)"@2:ICVGN/?.KW-DIC^\B>\@BBTL.C4)EMCH3O$7Y?]M40].<@)\0"3KV:&
M.:A$!)*,(:WQVN<56<N+N$B>DV+O-KKI<G-K47K<O=YMU,)6R1]\3E<PXTW&
MPXU#AA8S$'M,L)F_=0S$F-I"JAYB*IL)**I<KM>0BB4Z7-U'+W<1K09(#2U!
M">\>YR(MPX"/D\6Y-E^_*Z%*GK+)%Y$(4)% 7:;08HF%G;3OY@QQF;--M.W)
M%,TAI)!1/MTBHO+*?8MT975W:<W"A5%HL?0;(ZJW<=081'%$>AD57/UJ6YMH
MC0P&0,P4_Y9XT ;]H@[]]*& 51ZD9T#FKMY)PK+ZXC%)/]U4<<IRV&G56LJ6
MG8B%X9-#X#0+8G9I+% @A,\<M.[C^IGO^9;K7V#R^%3 U>(99M$C62%LHH1F
M"C'N]S#;Y"R#,V=/'/@: M&CK'N\W$+:J$G\J?$=M7=!3"\O/0OFY[;[L)7_
M(L0&$9<;9*7@ #'+*JCHO#ZG$!YD=%66<?%IVC0N!\"_$L;%^%B6BT<UA%=M
MI1VG3:7,IT)H4$DMIAPJMTCU%Q8J]@V5A5;" Y7:S:]'HZBNS.5!F:!/F;G(
M@F_3YOVQ-D-8A]&ZSW6%E@O%_4]109-?+0Z#C<C;+!NTV7EUP)(E_;F!?7@[
M,1M3P XPF"'LU4J2%4_O0GA_L /W"\UE]ABER3_YS5BZHD]Q\N7ZEI<*9I_>
M)"F\+N F5UXS:M$TG%@U>'A9R<G\V13X0"6@CKJ59 AA06:",#;5\EL_-LCL
MWJ']"7K>;(_1_Y?=::&J;G.2=N> H#RYU^"C:SW&FJX/9>8DPE/V/<$]R($B
MMV/T<X>P>\B354(66)\B=I%+KT<7+XG2[*9 Q.(<N(NHAR5F)"5[AK%Z',8%
M*ZLJ6 RJ76')!3 DEF5BQZ^4U>@><1CIQVA#?KS/HC2/8NJD%YCN4;5<0X&:
M!3Z#U+\.9U&'#.LK+WQXD(1,Y3R4(_V7Q!/\RKF.[5+7M\N?X.8!9CJ>(WW)
MHMM>2<1#I\3;91C6?ZQ=W*F 8#0I3/8:W((E^)53'MLLE\\PHWGUK+([SPC3
M-],>(N;*[B3JWHPO7V 6)SD+Z2QQ\DN6T-__1[3%^9]$HEP8ACZ,%U968;#8
ME)L&P@54;,H4UV%'"?:\R&371T4 3(8YCEAS^Z<TV)8XF)>!,(?QFT?\_'8%
M$QX#R0_-T$<^^MME6B3%GB:W95N<,>[TD<=R7?M()0;J4--W.'7J'J(BXTM;
M1!ZXG("5> M3^WC:V&@ *-97;?C@H1IN-0;\"1/QMVLUV-0.:7_,<)[?9CB&
M<)73$C;7:4*K+-WN'E 2ER7TE<]H5<D9'O"ID?=R0LM8TPJ[C#>O,I5P[F#+
MV%>=+$(XIM7$%1LHN/]2P-$I!GL^SRN^TI=YL"SXI'5XT4W$8E/<1=3#406O
M(5#6>R9S;X[1ZJ1I=L0XB1AAK'&'<</*J@P6(U2#1Y0E9GP.];[L%WQCQKQ:
M6RKU@#>O02)Y?"5/7KY-< 6<;=5!QFI\4LG>P^A$J0^/HR0;KP=<:[5B":7:
M>N+CCN[LR(:$3)LTD5EYY7#\1<,U0I.0E]4 9\+N9P6;$";]3N7C7MT$I>A:
M@Z C+=M'&C]2HYK =%,\*+"7]=(=S LR 15P=1[E3SJ+I.8WS6?=.B4?O0]*
M^H R"&/!TZ%XW*^6L)2,-/7K^35@=XU[U;0A?9HNWGOU\_#XP(^=Q?46ZE=(
M/QG_A9\BSJU/^E1T/1=,D6LXQ^UI\F%_3X:NFW.C1,Y#GXP#>?<.>8/3Q].;
MY)D]MDP?$YK<RUY<AN%Y.@BJ-#5IJG(&: E7ZW6O#WM F4Z3O=,=;XA(^ND[
M2N1\=*.IR/_+RWH05&H=U%#E#-!2\3+N8M/D\U12Z*=+''W5HK=KG92'2\"P
M6FIU:1T/J"0P#:.&<J?*_N$=)V!F8<R=),Q5WD'23\D$R@CD>%U\H<6RZ/T(
M#,ODAS#"BHH+% _4@&)RGUBNUTD,+3RB@X!%ME4;00\928P-6.^R-&$UQ:DS
MK),7^G,@[TG[L<%**@L2!U2#8'(?8(]-:=.]Z\TVP\^\-:J^)_22L:SDTD[6
MPTZA9 9D;F&X@PI,S<(Z?7H+&!+4A\94;M*Y&;K1>1^M0\W#QNW&7XYK_PGD
MC6IFZ^2[[F,X53;=-[W/H .$3F7+;9RBZ]';/N=PO4,WR5KK7D>)G ?0#N0]
M.EQM'W,"'FFZ2N!.UH*BBI<UU3D#Q%3\C/,$E&DH;E:U1"CU\0S=S&_MA#T
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MJV.']309-D[-8BF$I?"-@Z\H>TE@8T..AF5^N%9[+78KWM$Y.F,;I.WP4&:
MUY@G;K#G<6((<<3&#/H.X)0@F!OD1\=QEY]N;_T<QXTRGOY3N<;;SE*(24_G
M!K=H73NT&Y/"ZRZX>=R.#G+W]!QF8 <ZD'MT$UH5>(<VI7/ H8C>_.U'X_#"
MA>F$%7?X2\'\1Y8I?IWR<A$_9C@?)Q#UL9_ LKK%\5F.2;2Q?:1<0RFJ[].@
M7$2A(:1>H?$XBU-"4, E!==I626&"6N[<5NDZ2Y"UVF<0<+[.JWJ6O%&",]1
M@FAV[Q7.RA<,/T4OR6:W*?]0>F+)Z]4H[^M\L#;< [@7Q<NND(M)\RZ8G.0'
MJ4AZV0Z]%)8])JZ>'VVXO-+?UUX@\])R(6PA/1HD]HQV?_GV#@<DSDS3%:)'
M6-'EQ:>$>(M=@3<$_SA":'^=7D;QTU]AI'YZ8DS?T)4,^7GQEX,LLL&+-O2E
M$T6R0-2E(!$)[(E,(;B#K7E@%["\LJA:N]/IC(O"3!A?^U.94'51IIOPF:64
MCZXRI(*2HD]1-;/0F@75@\92@X>_K]4]N':DP$GC2NV-@UU0F;DFT)$2),!%
MV<)2"35!J$E14<!?>Y40UGZ[VTO9:GR43?>@#!-LG@9D&F'[75_FBIHY;$\^
M\QVYJLFYV)8KP?A:S<O9!GU@HORQWRC#"GCL?VB9X:H4KE:E'[=\)["\%CG\
ME'&FU7ZWC,',XU6?Q;B(49V(O";K<!:+^/^6!B9DG"+X/ RK]Z&IWLN7;9*Q
M/^:":T<>-TPM#<N%$!ZN6MEF#/-*D[!B%UX,<FHXS0#D#IM78R1RZ'E0BSP/
M+8'G()R(.I,5,*IR77C)_(Y@STMOD9^6ZSL8X\>4]E_FDI_CO,@MBADY%<!%
M[1F' ODM<G3($>*2]E2GJ:2EWSO(6]Z-,8E#K7CDPT);JQ\Y!_Y56B,*P!"]
MQ,3K-,8;R'I;TTA](P35?8K:2\;<(GK(NH\RG!FHN(&271BQ004IK*&Z@%%!
M X!,\]RU8]CZ[U8'"#D'QM=+TGDZ3/<+407U!8W-L-M,TQZ UC$GN#TMTM4%
M?(8(;ZE89#= 9DBHWS%*B9PY4 KD?;PLXDQ9C1^);1B>I ,@-M#D#,!"#9P6
M=9R 8#G5*X4?80JS"!&I%JM-DB9Y03?:S]#8R10)FB.GQ,"]HPFVS,_JC,-P
M-3T@L9$^9P$:JN.U.,)K:I=SLT>],7DEY)RU@W9_;D3QV*O1U3;])K371+X,
ML:U/I$N47YG1H2GMS4]ALK+W1+N"1?S5"5RJ%"VJ;2EQ\'1W)JHWQ#+*D',,
M(U1H(HK-]#H/],JLUJK!2J>C7@Y!&%9^SE649#]': <7>;[;\)=!=TG^]ZL,
MPNN4&"W,BSLRXE&2=M2%F2!70U4X#_M]PN5T3=B 1/ !9%4;2)08S_)<)/_H
M@?CJK<Q9FA 5&S"Y@20XH)(#*CHH90=WO98;?G"D\3TF,\!%\IRL8+J:-#BV
M"Q.(V;8)YV'+)KB E6 #]@E$(24@C6)YOH)C-XBOWLI\!\?*<DO1)XN-)LEC
M?5C<PVRCG^;M28H)$NL&I?(8!LF'&_!MDK*W8?EO HJ#?JW,16:F(FZOUZ(<
MY6X.!3PF\6M8!/Z,$2&#DF(?Q#*P*4Y@4W1=/(\Q\+EB%%#X&\GV?"\$VT#\
M"NQLM,7@0?A9;95%4:'EKLB+*%TEZ2-_Q3A*3.QF/ET=J"-AW-@A?U[SJ8BR
MXD8RR?P$2 S!!8S9-3?X[NR$=@'[?N9Q<-"Z'-84ZP#NU5F2LXA6UA.3#9 +
M:E6:HE+?H4+)Q2ZK'DIRLV>_7);A'V9QDEL7,OF>ZR>%C_2FI^%E%9.9!>8K
MG*UA0HL:5+7IQ@S-K>RG<ZD6<7P:S3FM:X/0:RGNV&=+#@-Q)TBOR6Y\!6-)
MTD.%1S?Q.,SIC"^,+M.F[_4LB]Z_FUD0%Y,/??HU_NJZA?ETCG@DC*=:XH<9
MGY5?B0H=&YI33.\V+8<1O0.U5V=&SJ.Y;(-#2^L@(Q<M( )7BW15'5IC^M&D
MQP7J,DUGH*HR^@M_7 +V! )6=TP8/--<CM<;#K7MU6&4U,/\:[%-YS%5&#9]
M*W*XF,+L8ZVCC"#CK32 7V#R^$2!>H99] C+ XS;+(G'N;'2%2F(D[8^$7V=
MY)8\@6!:'38!QO9K.^)5,EP_![_#Z'\E1NKUD'C WD,+N9WME5L[?XP6=EV*
M-45S:FTQW:]U!P/OC[/JS>/!4)VT1C=$^BLR2HUP.]!(O;/)SRL+NJ7TX<5=
M3<DFM'(M22>(O@IWKK.*OV8VZS($&R#^==FG^T!<#>+UQN*6V]%@HK&V;!/:
MNZ:L$T3DN24T^+)<ES'9"/6OS4K=Q^761 GSR/Q:#X*:Z14V9Y5SSKL(Y31=
M6:0@+M<#F[Z^NI2.L8_2M:#_2BS4:U+(S'82UC?+H81A6TE#OKT/*VC_*P_%
MPA-&S4X).>*'8/639;($.$D\#$/YH+W]N8.T<#GY_!RG11;%Q2Y"],GY>^V9
M86SQ)J@L8"ZN^SE $N+DV%HK08 D";A)UO#UU+MP8-LN"F'8&L57:,=R5']0
M"^H/IGDR[9[ !C.S(-Z] ^N":YRZ0C;B36?\!N+ZJ,)1"?%U!W$;VW88Q(V-
MXBNT8\=!O/>$ICN(SZ:_KNFF*HC8[E+JZ5S%W2C\M"7O.++YNF<&#P[C<,)P
M;5+_<@Y/TXOQN4]@4X^;._!K,I(DS9.8%=>:Z&534X@@GHG4A?+U>FGQ^)BQ
MZB>@XL?KG'UM[Y8Z#-'/2Z4V;%^MT7E]C=2PVM!2?/PY\2&IQ\R%ITGG<;.]
MK&MUJK.E(RF"V'HWI'*_/^@QMQEEZ/@U1#\'0:W0OEZC\WBLT[#<N:V?AW=(
ME9-.M[ZV$#+D3(,.H4>-L__*JC&S^E$3:GH-Y:NU\,G2:#K=:6:QO_=Q,_OE
M!1ED56A]S(BO+=IT7J IJK_$R=-(G.ZM:87Y9U9A'J\!%M;]R$L8T.@.1=?9
M_ 2LDHP8.LYR-@60T)OO4$$']#H"O:F).PSO1O;QE9FS\U ^7/6 _06@8Y$Z
M,LPL@!^]B[['182F6Z>KR3/Y<X]>^7RNOI-JN5!%YYS6KZ]B-)Q9H0.7]NG^
M]9$"SE^#+?IZ=U1[+\NDGW@]?"F6-9]@]IS$L!VACSA]YOL6.J:<R2W__ASG
MQ4=<_!46=S#&CVGR3[B2FTSHQ-.1!#(WXE$$=!]1/Z=9Q8E'T%-^7!?+=@UY
M(W:00=I0B>S;R,IW)X92C[MA1-MQS1=/8@5?A:F*@%M*#(3(H#,"5V+S0)N+
M:%K[&RHZ^<,"$.'!07K Q"]#\VL)N'Q2N<*9^(C^G=;=W-B2!6C7K9+ZB,5M
M$;5VF/Q 8W!EL)ALP$ $OC1/+;8*'4IF'XK[#7N,F-QC%E^7$8\:I<4JF0P$
MR"-1CM=HGT4L"I^]%S&8?O*W19KNZ*8ASB"1]SKEI<J7:S:&?/$<)8A>4A*V
MM'\:K=FTR(DH,5G3$Y=;IM*I-O_*<DV&L\$IGQ33JR2-T$6T7ZZO-QNX2L@F
M%NUOB3-#^I7S",%T%65_A9%2WX;@1-8W^,"&X,835CC>T6T>,^%O_L*'!Q(Q
M/O(#2-D(V7D%$QA$Y2#!FIAT(H8)HIR&<3%00/P!2]<FXJN$2,Q&6\X8*5C3
M 8-5M*>_3 YC!MMRT" 6HV9IX&^FG24",P)Y^@A,M-9Y12VTW1(K?HK$N_M*
M=DG.&_R%#HH>WOX497^'!3MRJ(FJ')3<,#,,)RZ8>PD$I6#$#>G$*'E_S<T1
M%8_^EMT[;9B$AP-.V==#\%NG=H6=0_BO*>GX_-S9?+1NFX\,)J-UDI/YB$U%
M5EG"KQ(Z5$.M'!<]*N8C \LU7V/GH!H<6QB7PP.+'!P&")9I+?E"?)40X:,L
M#T!2P 8*R$CI+Z6Q@FJPH!PM^*L3Z,*)W+*_. _;KTE1J*$C)I%LDC7;8V+1
MW[(K8BX9O]IH&N#8-\?Q$USM$-'0'3W=IC=,6;&_SR*R$8W9"<R'?>TWU,NT
MKH+-&%C<IYDP]-#U3HA!\17L .,'9%'H/5G]M[\R>?YO&,=7=M:!G8 R2TM
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MB+/6:M$#SJAM[]7M?HB"X45,)T4OUS&<&YNG4,4OA-NZ86BPFL+"A*'V+N2
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MR_VS0P7+-(E398(J&,!E7$M)VP!FR:./W2N?.#&,WZV&VMB[?Z9:!H5FZ01
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ME1X5S#9/[R%4QD*77249$^,HG V21XH9/J=+Q-SI@J<;Y% 5:=W]ZI8$KGB
M.8"88>P!4?)UK3N<"8D1-%&J'\V^ZLD^^9,>J6%"3]C7)5/BV*Z:,A50#FLH
M12-GM^LRT1?-G!43>Q*X5U'H9LW+G'AU5 R/HE2C;CFF!II&5ED4[5W.&E;5
MNH41&<0V8-:AY E03L#,C8+.(W:IRG_N1,]R[%?3,'\"I'DBI_/O$4KQE#\
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M<Z-\;X*XI;CFC4WP_"L*:+\^%=@3;X$#S.8YIM)/8B\WDC)4&0E159<E"KM
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M&$ M82G^?Z-W>RI_V%F:5P'8!4R89S%B&O@4W@_BM(Q)XLR][2()*4O9YLJ
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MC:(/;#[EX(VB3\R8SA$;]5XE;RP<T/$L:9V1R_)"E# ,Y5YX.9;C>0)R"N#
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M:N^@D$)VQK1XM&":YCD)Z*$>8_K7V>8D :;DE23<@O_)1UT# %%N,X(/VD8
MH=QF!*?:1@"AW&8$)]I& *'<G;1FR?3@GL3-M [@_#E;E1. NA]K9<.LVW++
MH;1P;E;3\VC6[M0%6LTD#L]16NFV(X8DTU >)4R<,HUS5CQ:A^*[+:RP$'G%
M:RA^W;)80M3PH?AZRV()N90-Q0-<%DO(%7TH'N&26$+L-4-Q"H= *6"FLSVQ
M]<%HM#=E*;*'>%JU,-*KFXW-6P6?"@-/Q*;?.J\<'*9N,M^0P_Z=%>51ES91
MFGY_7A+A0S!AYO'IV@D<MK2OZ:F8.3B=/SO!$_TWXS;+U8_<YP#_$U: %$S:
M7")%[/B%=&GYQ/"Y@HQ3F*01LUT4H;CMB&J(&)FC_8ZEC(_U=#H_LH2&281F
M92@Y$:&0"6_-H>1+!*\YJ PWFDO1M))3EK5N/T"Y?5K UOWT1^F1'TJ7"9IN
M$>B@J:=CZ+6.EU:A<TQE7J9(T@60BI? H]>0,%XGA:]D&/BVIZC/3I-QI:48
ME,SVFM*8_% ^\5Y CZ(DK79XS1;,$Y56$MD/Z^F,:1P!JG@2!CBF<IRNBBO\
MROXF,8PZ*E)>39M$//=D'O]P4KH220^%28U)&\>DC6/2QOW!]2MI8R4/,K8#
M 6*=7^;$!]PRDZ/=#XH&,SG:;5PPD\G1[K=%Y9D<+?=2 >(EK/(-Q3-%<KW5
M:?1#<431F];1;L\3Z02L=1?[X?F?:,Z):;G/B.*$CFOSGU$WCX-#3YW1F)=H
MMCT'B^)UFCY*Z"QPO9=;I0_O= I]D63)]_M5KFM/I*(X@%AJMMN-AJ:^&)JV
MY\6HAXII><.2AB7(NWQ=HB!"$45HRHB<)V&82NG<]Z3@.2S:1$Y$&>2H/U+-
MQ*!E7JLJ.BE07_<G_&@%H&BDV)O\<!I)&/*>8'!2,3>GU\E4"%TAJ6$T49)Z
M[7QXQJ$W<Z@ OJ,;BHKM9Y9""[T@GV29Y-?+ +J*P'1-YI*Y0^DEH=VJ$B!F
M1&%P5NP^SO9IND <7\J?M99,]TJ"P"!+XHAJIF8P[R9BR,GMV:$4MP8NOR9!
M;;3,]>' 5GE,#Z8(#&"O K0TG4;#SLTQ I&W"JTSBGKKS[6F[8#,6$1<A+R(
MQ4)>1U'B!"Z]7 DP#K24R'9BQ,$J33/,&&/'"G;1)OX3Y%%53:2#>AM%;B"C
MJ"73P3BHOC0-[V.F9Z;!+S(S(TRRLWF:)/$S/3/^5C!715(=C&?_70,^D!M1
MU_7:Q(GGNO(F0@@;<;WWG2B:SM-^X=Z[9:V-R%RV =.0M (#4!?=&B(28XC"
MN, __=<N[_2C/[_A "^2A?C**6FDC3?G58*W[4:Z>+MC@8<PSK:::.5+=-WM
M-.A OIZMBDL=[/8M0JV#414> B2,:P+$.K]\B@^XNL!-Z6P-)1<E8!^0O8UJ
M>R;(<D%&2L2H[:D9JXX:4GK8V>Z:WH3&MEHR%,=SF"@1T#6WQ<NIM< UZ^RD
M_F(Q%/_RFBL9D;Y+#L7!7&Y[5ML0AN);WFB)J49KWW2DL8 ?7>6/Q K8JBV)
M&A^%[(%OV[C,(5,NW@X8LII7!0[8*-<4/#3Q>H8&M%_S;O5K?B>!5RC:JM2S
M7KJ'_KS7R@RBLS?:G7?DP,L^0/1+10^TS3T8?-_XW0E#)XBGX1TK\WKYBD(7
M1RB5B?F7T?K;Z$3B"03:@9FT2ODBE'W1K21AYI6'=IMU>)&$K%P/O?80K\C(
M%0GI7>B%H@Q\^H%1[FREYG6(\_33YX[O(^]LM;NF6J]92%>&DH*5G[;%6?J^
M)$'VPP@8/B1%WE"4T9XTO0XPJRT[2QY][$[GE%NZ9MN*Z JB4J_F:0SL5B>R
M'(/(C?X]"B3I+?J1?J5.@A8H&AL=RZQ MVFFYM\AMF4S/>-^Z6/0BZ 0.=GT
M=9O3]#?"ZL]E\G0C>>EG8I, (&98SRAR(JEG;),P(W&+\E^%TY@H1?.C:^,R
MUD3)\%I3,5%"Y#K1U>6FJ):,:7^R?6,+T*7L9O3E&WWY.O#E X]A?4."IW#=
M:2BURF])L FJ8QG.4!"E)B;@DFZ@HLN#[@*'R*4LP9S[=EOIXNX!QRQ:_#KP
M\ OV$L?_'<?/:>0BA29ZQLL'<AG$S"5+>+M)D34V/H@O8T5C$_OM>C:%[[5"
M(R/!\?1 F/@^24MG;!?,$^>YAH@1V>RP&4Z%*:L..)T_4&D5.6D>-O@)(T+-
MR*B2QPA[V E7!8[ )TXU$</ZHDR>_+W&IE*=QRMVNI" +F?X JH@8%1+V>$A
MDM94R@F930F>+H&UCTR++. E9,RM)QFG[]V6G3]35PRE-']W"=I#\>,66;EE
M7I?E>\UVQVZ8["*-<M9V]V^Q<XK4GJ.V.X7+[L1J;6DP_L^-6B>!J<H:?=[Z
M!9SX)80(W9R&XOLF!USAFFS4JZW_PJS&Z+$MQ#Y:AU2SL:@*GR;3%E]C=DJQ
M-F9$4F[MY)"-\HLC)6+%YMFO[0XA$M9@=]X?<GQ^LGQE2=XCFZ+W/MF+F++H
MO4]VFRCT1N]]LEMN ?=EA:] CM;GX2RUF[K EEJO$(Z6W58P&;0$8O0^VYVC
M5ABU)N>P'+ O=HLP2< $5MH7.R](;?;GMJ]HCM17NRLP-2(%\ _FF(W27]S[
MFZ-F]ST)AII ., &N!/+G]S$@6L.T:8ZQK"Q H4$<=3LSGL/T#.$0[]R[$YL
M3SP!4#8DP@0YCJ.4*_Y0/N"4(SI>MYH/W)((9@[@P ^32IO(;BJ9D]/1>E2]
M>9LS'' <QX.X\B 629.1 _G!@.6D)[EEN"&X\"&K?!2^I(+M*F&EYS<H2A9+
MU-)W[_/12 [/K$_[N;/$L>-GDKF2.4F?=U'B]L9+*O*_7K^TIWW+1KC4$#$2
MI9/V>$VWWBOR'DBJ!&P,/P^4?7B0@BC%/HP.&KP@1L_XVFNYZL88W2'$Z(Y1
M+V/4RV'>,'1Y*UF,F#)O)<M#7>J]E6I/RS'2I73WB:E(0PEZ 2F@ !3W:P+8
M?00 KRE5>[<B#L;R@@J*O0HMKZ @8T$7M:@8K19MVI29+2XG0EXQ]&!=!5IA
MLNS6_?3'1"D_%)E$2;,D=)^=_,UB[:,8S5#HLD$_H1OR@SU(7CDX_.:$?Z$X
M=<7;,I2*W+<4=B:5$&H2! D#S0T19> ZR!]:,QY>*(!,]M']N=F91;ZFP32)
MH]@)/!P\94VVF)H&5YC.R86SFLZO%POD8:IK^ZM9B%S$FIP[/ETF3O@'<L2S
M3_6)9:/FJ^R!-N5Y;Q_<,I>"*$;>Y(<3>M$#*^A>_/Z<1/$MB?] \1URR5/
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M.'LKO* +Y 1B)RAO+V6P3$E=!Q2.G)2P9;*TK207=%NB[;/A<CW[Z3]8S4P
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M3_U___]02P$"% ,4    " !)@VE2B)'8$5L* 0#K;1$ $0
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M+3(P,C Q,C,Q7VQA8BYX;6Q02P$"% ,4    " !)@VE2E>(O+K,\  !KP 0
M%0              @ &8L0$ ;'ER82TR,#(P,3(S,5]P<F4N>&UL4$L%!@
0   &  8 B@$  '[N 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
